<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004310.pub3" GROUP_ID="SYMPT" ID="414502030415252593" MERGED_FROM="" MODIFIED="2017-07-07 11:30:54 +0100" MODIFIED_BY="Anna Erskine" REVIEW_NO="67" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.0">
<COVER_SHEET MODIFIED="2017-07-07 11:27:49 +0100" MODIFIED_BY="Anna Erskine">
<TITLE>Megestrol acetate for treatment of anorexia-cachexia syndrome</TITLE>
<CONTACT>
<PERSON ID="D1EA7F3482E26AA20024C3AAEF298BFE" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Vicente</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Ruiz Garcia</LAST_NAME>
<SUFFIX/>
<POSITION>MD</POSITION>
<EMAIL_1>vicenteruizgarcia@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>0034634552726</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Hospital at Home Unit, Tower C, Floor 1 Office 5 &amp; CASPe Spain</DEPARTMENT>
<ORGANISATION>La Fe University Hospital</ORGANISATION>
<ADDRESS_1>Av Fernando Abril Martorell nº 106</ADDRESS_1>
<ADDRESS_2/>
<CITY>Valencia</CITY>
<ZIP>46026</ZIP>
<REGION/>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1>+34 963862700 ext 2707</PHONE_1>
<PHONE_2>+34 634552726</PHONE_2>
<FAX_1>00341973172</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2017-07-07 11:27:17 +0100" MODIFIED_BY="Anna Erskine">
<PERSON ID="D1EA7F3482E26AA20024C3AAEF298BFE" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Vicente</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Ruiz Garcia</LAST_NAME>
<SUFFIX/>
<POSITION>MD</POSITION>
<EMAIL_1>vicenteruizgarcia@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>0034634552726</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Hospital at Home Unit, Tower C, Floor 1 Office 5 &amp; CASPe Spain</DEPARTMENT>
<ORGANISATION>La Fe University Hospital</ORGANISATION>
<ADDRESS_1>Av Fernando Abril Martorell nº 106</ADDRESS_1>
<ADDRESS_2/>
<CITY>Valencia</CITY>
<ZIP>46026</ZIP>
<REGION/>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1>+34 963862700 ext 2707</PHONE_1>
<PHONE_2>+34 634552726</PHONE_2>
<FAX_1>00341973172</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="1C971CEA82E26AA200CF0384847F5625" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Eduardo</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>López-Briz</LAST_NAME>
<SUFFIX/>
<POSITION>Pharmacist</POSITION>
<EMAIL_1>lopez_edubri@gva.es</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Pharmacy &amp; CASP Spain</DEPARTMENT>
<ORGANISATION>La Fe University Hospital</ORGANISATION>
<ADDRESS_1>Avda Fernando Abril Martorell 106</ADDRESS_1>
<ADDRESS_2/>
<CITY>Valencia</CITY>
<ZIP>46026</ZIP>
<REGION>Valencia</REGION>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1>+34 669856879</PHONE_1>
<PHONE_2/>
<FAX_1>+34 96 1973130</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="2B62B22E82E26AA200CF03843CB493E4" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Rafael</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Carbonell Sanchis</LAST_NAME>
<SUFFIX/>
<POSITION>Ear Nose and Throat Specialist</POSITION>
<EMAIL_1>carbonell_raf@gva.es</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>ENT Department</DEPARTMENT>
<ORGANISATION>Sagunt Hospital</ORGANISATION>
<ADDRESS_1>Ramón y Cajal 46</ADDRESS_1>
<ADDRESS_2/>
<CITY>Sagunt</CITY>
<ZIP>46520</ZIP>
<REGION>Valencia</REGION>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1>+34 962 339 406</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="40485845019743310210110726175720" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Jose Luis</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Gonzalvez Perales</LAST_NAME>
<SUFFIX/>
<POSITION>Family Physician &amp; CASP Spain</POSITION>
<EMAIL_1>jlgonzalvez@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL>www.netvibes.com/jlgonzalvez</URL>
<MOBILE_PHONE>+34 67650 0883</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>National Health Service</ORGANISATION>
<ADDRESS_1>Plaza de la Ribera s/n</ADDRESS_1>
<ADDRESS_2/>
<CITY>Algemesi</CITY>
<ZIP>46680</ZIP>
<REGION>Valencia</REGION>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1>+34 676500883</PHONE_1>
<PHONE_2>+34 961234940</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="2B5E30BD82E26AA200CF038492C0D51A" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Sylvia</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Bort-Marti</LAST_NAME>
<SUFFIX/>
<POSITION>European Patent Attorney</POSITION>
<EMAIL_1>silviabort@acellaincubator.com</EMAIL_1>
<EMAIL_2>silviabortmarti@gmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Acella Incubator</ORGANISATION>
<ADDRESS_1>Avda Benjamin Franklin, 19</ADDRESS_1>
<ADDRESS_2/>
<CITY>Paterna</CITY>
<ZIP>46980</ZIP>
<REGION/>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1>+34600379528</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2017-07-07 11:27:16 +0100" MODIFIED_BY="Anna Erskine">
<UP_TO_DATE>
<DATE DAY="31" MONTH="8" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="7" MONTH="5" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="3" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2005"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2013"/>
</DATES>
<WHATS_NEW MODIFIED="2017-07-07 11:27:49 +0100" MODIFIED_BY="Anna Erskine">
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2017-07-07 11:27:49 +0100" MODIFIED_BY="Anna Erskine">
<DATE DAY="7" MONTH="7" YEAR="2017"/>
<DESCRIPTION>
<P>See <LINK TAG="PUBLIC_NOTES" TYPE="SECTION">Published notes</LINK>.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2017-07-07 11:27:37 +0100" MODIFIED_BY="Anna Erskine">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2017-07-07 11:27:35 +0100" MODIFIED_BY="Anna Erskine">
<DATE DAY="24" MONTH="6" YEAR="2012"/>
<DESCRIPTION>
<P>The search was updated on 7 May 2012.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2017-07-07 11:27:37 +0100" MODIFIED_BY="Anna Erskine">
<DATE DAY="24" MONTH="6" YEAR="2012"/>
<DESCRIPTION>
<P>In the current update we decided not to include cross-over studies and to include only trials with patients who clearly had some previous weight loss or any definition of cachexia-anorexia syndrome.</P>
<P>None of the original authors remaining in this review.</P>
<P>Eleven studies were excluded: <LINK REF="STD-Bruera-1990" TYPE="STUDY">Bruera 1990</LINK>; <LINK REF="STD-Bruera-1998" TYPE="STUDY">Bruera 1998</LINK>; <LINK REF="STD-Chen-1997" TYPE="STUDY">Chen 1997</LINK>; <LINK REF="STD-Erkurt-2000" TYPE="STUDY">Erkurt 2000</LINK>; <LINK REF="STD-Lai-1994" TYPE="STUDY">Lai 1994</LINK>; <LINK REF="STD-Marchand-2000" TYPE="STUDY">Marchand 2000</LINK>; <LINK REF="STD-McQuellon-2002" TYPE="STUDY">McQuellon 2002</LINK>; <LINK REF="STD-Pardo-2003a" TYPE="STUDY">Pardo 2003a</LINK>; <LINK REF="STD-Rowland-1996" TYPE="STUDY">Rowland 1996</LINK>; <LINK REF="STD-Westman-1999" TYPE="STUDY">Westman 1999</LINK>; <LINK REF="STD-Zeca-1995" TYPE="STUDY">Zeca 1995</LINK>.</P>
<P>Thirteen new studies were included: <LINK REF="STD-Casado-2008" TYPE="STUDY">Casado 2008</LINK>; <LINK REF="STD-Giacosa-1997" TYPE="STUDY">Giacosa 1997</LINK>; <LINK REF="STD-Herrejon-2011" TYPE="STUDY">Herrejon 2011</LINK>; <LINK REF="STD-Lesser-2006" TYPE="STUDY">Lesser 2006</LINK>; ; <LINK REF="STD-Macbeth-1994" TYPE="STUDY">Macbeth 1994</LINK>; <LINK REF="STD-Madeddu-2012" TYPE="STUDY">Madeddu 2012</LINK>; <LINK REF="STD-Mwamburi-2004" TYPE="STUDY">Mwamburi 2004</LINK>; <LINK REF="STD-Schmoll-1991" TYPE="STUDY">Schmoll 1991</LINK>; <LINK REF="STD-Summerbell-1992" TYPE="STUDY">Summerbell 1992</LINK>; <LINK REF="STD-Timpone-1997" TYPE="STUDY">Timpone 1997</LINK>; <LINK REF="STD-Wanke-2007" TYPE="STUDY">Wanke 2007</LINK>. We included 35 trials which represent 3963 patients studied for effectiveness and 3240 for safety. We could not use the data from the included trials <LINK REF="STD-Lesser-2006" TYPE="STUDY">Lesser 2006</LINK> and <LINK REF="STD-Gambardella-1998" TYPE="STUDY">Gambardella 1998</LINK>, therefore 863 fewer patients were ultimately studied in this update.</P>
<P>There are changes to the previous conclusions of the review.</P>
<P>More than 40 side effects were studied. Oedema, thromboembolic phenomena and deaths were more frequent in the patients treated with megestrol acetate (MA). Despite MA being approved for use in AIDS patients by US Food and Drug Administration, this drug failed to show weight improvement and weight gain when compared with other drugs. MA compared with placebo was effective in one trial in AIDS patients.</P>
<P>MA could be prescribed to improve appetite in the context of palliative medicine, but it should be emphasised that this drug probably will not recover full weight loss, nor increase quality of life and it is related to adverse events, including increased mortality.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-05-16 17:34:27 +0100" MODIFIED_BY="Jessica Thomas">
<DATE DAY="11" MONTH="5" YEAR="2011"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-05-11 16:05:03 +0100" MODIFIED_BY="Jessica Thomas">
<DATE DAY="30" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-02-08 07:57:01 +0000" MODIFIED_BY="Jessica R Thomas">
<DATE DAY="20" MONTH="8" YEAR="2007"/>
<DESCRIPTION>
<P>For the update for Issue 4, 2007 the following changes were made:<BR/>Four new studies and three abstracts were identified, two of these studies were full text and were included in this updated review (<LINK REF="STD-Jatoi-2004" TYPE="STUDY">Jatoi 2004</LINK>; <LINK REF="STD-Ulutin-2002" TYPE="STUDY">Ulutin 2002</LINK>). These trials added 540 additional participants to the review. Two of these studies were excluded (<LINK REF="STD-Macbeth-1994" TYPE="STUDY">Macbeth 1994</LINK>; <LINK REF="STD-Yeh-2004" TYPE="STUDY">Yeh 2004</LINK>).<BR/>
<BR/>There was no change to the previous conclusions of the review. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2013-01-31 10:15:24 +0000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2013-01-31 10:15:24 +0000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2013-01-31 10:15:24 +0000" MODIFIED_BY="[Empty name]">
<NAME>Instituto de Investigaciones Epidemiológicas, Academia Nacional de Medicina de Buenos Aires</NAME>
<COUNTRY CODE="AR">Argentina</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2017-07-07 11:28:36 +0100" MODIFIED_BY="Anna Erskine">
<SUMMARY MODIFIED="2013-02-05 16:24:35 +0000" MODIFIED_BY="Laila Tyrrell">
<TITLE MODIFIED="2012-06-20 20:01:30 +0100" MODIFIED_BY="Laila Tyrrell">Megestrol acetate for treatment of anorexia-cachexia syndrome</TITLE>
<SUMMARY_BODY MODIFIED="2013-02-05 16:24:35 +0000" MODIFIED_BY="Laila Tyrrell" NOTES="&lt;p&gt;This is better but please turn into a paragraph and see my changes&lt;/p&gt;" NOTES_MODIFIED="2013-02-05 16:24:35 +0000" NOTES_MODIFIED_BY="Laila Tyrrell">
<P>
<B>Anorexia-cachexia syndrome (ACS)</B> is a common clinical problem characterised by loss of appetite and weight loss. It is common in patients who suffer from advanced cancer, AIDS and some other conditions. At present, there is no cure for ACS.</P>
<P>
<B>Megestrol acetate (MA) </B>is classified as a female hormone and is taken by mouth. It is currently used to improve appetite and to increase weight in ACS.</P>
<P>This updated review shows that:</P>
<P>- MA improves appetite and has a small effect on weight gain;</P>
<P>- MA does not improve quality of life;</P>
<P>- side effects are more frequent in patients treated with MA.</P>
<P>This review shows that MA is associated with an increased risk of blood clots (which may result in swelling, pain or redness of one extremity and not the other, sudden difficulty in breathing, severe headache or vision changes), fluid retention (resulting in swelling of the feet or hands) and death.</P>
<P>In patients who take MA, approximately one in four will have an increase in their appetite, one in 12 will have an increase in their weight and one in 23 will die.</P>
<P>Limited data are available regarding the safety of using MA, especially in the long term. </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-02-05 16:24:35 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2013-02-05 16:24:34 +0000" MODIFIED_BY="[Empty name]">
<P>This is an updated version of a previously published review in <I>The Cochrane Library</I> (2005, Issue 2) on 'Megestrol acetate for the treatment of anorexia-cachexia syndrome'. Megestrol acetate (MA) is currently used to improve appetite and to increase weight in cancer-associated anorexia. In 1993, MA was approved by the US Food and Drug Administration for the treatment of anorexia, cachexia or unexplained weight loss in patients with AIDS. The mechanism by which MA increases appetite is unknown and its effectiveness for anorexia and cachexia in neoplastic and AIDS (acquired immunodeficiency syndrome) patients is under investigation.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2012-06-26 17:33:16 +0100" MODIFIED_BY="[Empty name]">
<P>To evaluate the efficacy, effectiveness and safety of MA in palliating anorexia-cachexia syndrome in patients with cancer, AIDS and other underlying pathologies.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-02-05 16:24:34 +0000" MODIFIED_BY="[Empty name]">
<P>We sought studies through an extensive search of electronic databases, journals, reference lists, contact with investigators and other search strategies outlined in the methods. The most recent search for this update was carried out in May 2012.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2012-12-17 17:05:30 +0000" MODIFIED_BY="[Empty name]">
<P>Studies were included in the review if they assessed MA compared to placebo or other drug treatments in randomised controlled trials of patients with a clinical diagnosis of anorexia-cachexia syndrome related to cancer, AIDS or any other underlying pathology.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2013-02-05 16:24:34 +0000" MODIFIED_BY="[Empty name]">
<P>Two independent review authors conducted data extraction and evaluated methodological quality. We performed quantitative analyses using appetite and quality of life as a dichotomous variable, and analysed weight gain as continuous and dichotomous variables.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-02-05 16:24:34 +0000" MODIFIED_BY="Laila Tyrrell">
<P>We included 35 trials in this update, the same number but not the same trials as in the previous version of the review. The trials comprised 3963 patients for effectiveness and 3180 for safety. Sixteen trials compared MA at different doses with placebo, seven trials compared different doses of MA with other drug treatments and 10 trials compared different doses of MA. Meta-analysis showed a benefit of MA compared with placebo, particularly with regard to appetite improvement and weight gain in cancer, AIDS and other underlying conditions, and lack of benefit in the same patients when MA was compared to other drugs. There was insufficient information to define the optimal dose of MA, but higher doses were more related to weight improvement than lower doses. Quality of life improvement in patients was seen only when comparing MA versus placebo but not other drugs in both subcategories: cancer and AIDS. Oedema, thromboembolic phenomena and deaths were more frequent in the patients treated with MA. More than 40 side effects were studied.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-02-05 16:24:35 +0000" MODIFIED_BY="[Empty name]">
<P>This review shows that MA improves appetite and is associated with slight weight gain in cancer, AIDS and in patients with other underlying pathology. Despite the fact that these patients are receiving palliative care they should be informed of the risks involved in taking MA.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-02-11 09:19:15 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2013-02-05 16:24:35 +0000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2013-02-05 16:24:35 +0000" MODIFIED_BY="[Empty name]">
<P>This review is an update of a previously published review in <I>The Cochrane Library</I> (2005, Issue 2) on megestrol acetate for anorexia-cachexia syndrome. Anorexia-cachexia syndrome is a common clinical problem that substantially impacts upon the quality of life and survival of affected patients. It is characterised by loss of appetite, weight loss and tissue wasting, accompanied by a decrease in muscle mass and adipose tissue, impoverishing quality of life and often preceding the patient's death (<LINK REF="REF-Nelson-1994" TYPE="REFERENCE">Nelson 1994</LINK>; <LINK REF="REF-Splinter-1992" TYPE="REFERENCE">Splinter 1992</LINK>).</P>
<P>More than two-thirds of patients dying from advanced cancer suffer from anorexia-cachexia syndrome (<LINK REF="REF-Argil_x00e9_s-2001" TYPE="REFERENCE">Argilés 2001</LINK>). Anorexia-cachexia syndrome is also described in other pathologies such as in acquired immune deficiency syndrome (AIDS), anorexia nervosa, degenerative illnesses of the central nervous system and terminally ill patients (<LINK REF="REF-Von-Roenn-1996" TYPE="REFERENCE">Von Roenn 1996</LINK>). Incidence is variable and difficult to determine but in general the syndrome may occur in 15% to 40% of patients with cancer, and in more than 80% of patients with advanced illness (<LINK REF="REF-Bruera-1992" TYPE="REFERENCE">Bruera 1992</LINK>).<BR/>
</P>
<P>The mechanism that causes cachexia is poorly understood, but inflammatory cytokines probably have a role, such as tumour necrosis factor-alpha (which is also nicknamed 'cachexin' or 'cachectin'), angiotensin II and glucocorticoids, interferon gamma and interleukin 6, as well as the tumour-secreted proteolysis-inducing factor (<LINK REF="REF-Tisdale-2009" TYPE="REFERENCE">Tisdale 2009</LINK>). Ghrelin levels are also high in patients who have cancer-induced cachexia (<LINK REF="REF-Wolf-2006" TYPE="REFERENCE">Wolf 2006</LINK>). </P>
<P>An international consensus statement defines cachexia as weight loss greater than 5%, or weight loss greater than 2% in individuals already showing depletion according to current body weight and height (body mass index (BMI) &lt; 20 kg/m<SUP>2</SUP>) or skeletal muscle mass (sarcopaenia) (<LINK REF="REF-Fearon-2011" TYPE="REFERENCE">Fearon 2011</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2013-02-05 16:24:35 +0000" MODIFIED_BY="[Empty name]">
<P>Early intervention and attention to nutritional status are essential in patients with anorexia-cachexia syndrome. Pharmacological interventions for neoplastic cachexia include drugs that stimulate the appetite: megestrol acetate (MA) and dronabinol; cytokine inhibitors (such as cyproheptadine, thalidomide, pentoxifylline and an eicosapentaenoic acid (EPA)); and anabolic agents such as nandrolone decanoate, oxandrolone and corticosteroids (<LINK REF="REF-Balog-1998" TYPE="REFERENCE">Balog 1998</LINK>). EPA seems to suppress well-characterised mediators of cancer-associated wasting, including interleukin-6, an inflammatory cytokine. It also acts over the proteolysis-inducing factor, another well-described mediator (<LINK REF="REF-Barber-1999" TYPE="REFERENCE">Barber 1999</LINK>; <LINK REF="REF-Wigmore-1997" TYPE="REFERENCE">Wigmore 1997</LINK>).</P>
<P>MA is a synthetic progestogen agent. It was first synthesised in England in 1963. Developed as an oral contraceptive, the agent was first tested in the treatment of breast cancer in 1967 and, later on, for the treatment of endometrial cancer. MA is currently used to improve appetite and to increase weight in cancer-associated anorexia. From September 1993, MA was approved by the Food and Drug Administration (FDA) in the USA for the treatment of anorexia, cachexia or unexplained weight loss in patients with AIDS. In addition, there are recent reports of the drug being used to improve the quality of life of elderly patients with cachexia. A possible role in anorexia nervosa has also been proposed (<LINK REF="STD-Yeh-2000" TYPE="STUDY">Yeh 2000</LINK>).</P>
<P>MA is only available as a tablet of 20 to 40 mg or liquid form (200 mg or 625 mg/5ml MA). A great variability in dosage is observed in the scientific literature, ranging from 100 mg to 1600 mg per day (<LINK REF="STD-Tchekmedyian-1992" TYPE="STUDY">Tchekmedyian 1992</LINK>; <LINK REF="STD-Von-Roenn-1994" TYPE="STUDY">Von Roenn 1994</LINK>). The liquid form is usually dosed at 800 mg per day and the oral form at four tablets per day. The recommended duration of treatment is six weeks or more. MA is considered a relatively non toxic drug with a low incidence of adverse effects, such as fluid retention, venous thrombosis, diarrhoea, rash, impotence, pruritus, increased blood sugar level and headache (<LINK REF="REF-Loprinzi-1990a" TYPE="REFERENCE">Loprinzi 1990a</LINK>; <LINK REF="STD-Vadell-1998" TYPE="STUDY">Vadell 1998</LINK>; <LINK REF="STD-Von-Roenn-1994" TYPE="STUDY">Von Roenn 1994</LINK>). The recommended adult initial dosage of MA oral suspension in HIV patients is 800 mg/day (20 ml/day); clinically effective dosages are expected to range from 312.5 to 625 mg daily. In patients with neoplastic disease the most common dosages used range from 480 to 600 mg daily.<BR/>
</P>
</INTERVENTION>
<THEORY MODIFIED="2013-02-05 16:24:35 +0000" MODIFIED_BY="[Empty name]">
<P>Although the mechanism by which MA increases appetite is unknown, most hypotheses point to action on cytokines, which inhibit the action of tumour necrosis factor on fatty tissue and its products. Currently, interest is especially focused on its effectiveness in the treatment of anorexia and cachexia in neoplastic and AIDS patients. Studies at the Mayo Clinic and The North Central Cancer Treatment Group Study have reported and reviewed multiple placebo-controlled, randomised, double-blind clinical trials of MA and other drugs for the improvement of anorexia-cachexia syndrome in all types of cancer (<LINK REF="STD-Jatoi-2004" TYPE="STUDY">Jatoi 2004</LINK>; <LINK REF="REF-Loprinzi-1990a" TYPE="REFERENCE">Loprinzi 1990a</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2013-02-05 16:24:35 +0000" MODIFIED_BY="[Empty name]">
<P>This is an update of a previous systematic review. In this update we identified new trials and found that more diseases have begun to be treated with MA. We focused on the adverse events of MA as main outcomes.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2013-02-05 18:56:30 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>To evaluate the effectiveness and safety of MA in palliating anorexia-cachexia syndrome in subgroups of patients with cancer, AIDS and other underlying pathologies.</LI>
</OL>
</OBJECTIVES>
<METHODS MODIFIED="2013-02-08 08:02:35 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2013-02-05 16:24:35 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2013-02-05 16:24:35 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs) which may be double-blind, single-blind or unblinded.</P>
<P>In the previous version of the review we included some cross-over studies. However, in the current update we decided not to include these studies, because the time between the two phases is too short to be certain whether any adverse event or outcome, such as weight or appetite, is due to MA or placebo. Moreover, treating with MA or placebo in the first phase could result in groups in the second phase not having the same basal characteristics. Finally, due to the fact that these patients are very frail and have high mortality, the number of patients in such studies could be too low.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-02-05 16:24:35 +0000" MODIFIED_BY="[Empty name]">
<P>Patients with a clinical diagnosis of anorexia-cachexia related to cancer, AIDS or another underlying pathology (independent of gender, age or race) were included. We decided to include only trials with patients who clearly had some previous weight loss or definition of cachexia-anorexia syndrome.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2013-02-05 16:24:35 +0000" MODIFIED_BY="[Empty name]">
<P>The review focuses on the following treatment comparisons:</P>
<UL>
<LI>MA at any dose versus placebo;</LI>
<LI>MA at any dose versus other active drug treatments (stimulants of appetite such as dronabinol, cytokine inhibitors such as cyproheptadine, eicosapentaenoic acid (EPA) and anabolic agents such as nandrolone decanoate and corticosteroids);</LI>
<LI>MA at different doses.</LI>
</UL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-02-05 16:24:35 +0000" MODIFIED_BY="[Empty name]">
<P>We assessed the following outcome measures.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<UL>
<LI>Weight gain, measured as a dichotomous variable (number of patients who gained weight) and as a continuous variable in kg (difference between baseline and the end of treatment).</LI>
<LI>Improvement in quality of life by means of a validated instrument, or with scales of functional scores (e.g. Karnofsky Index and performance status) that measure the well-being status of the patient. The quality of life measures will depend on the instrument used, e.g. patient assessments using a Likert-type scale based on patients' statements and self report questionnaires, or the use of the Spitzer Index of quality of life, completed by the clinician.</LI>
<LI>Adverse effects: we analysed these as the number of patients who suffered an event described as a side effect by the authors of each study.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<UL>
<LI>Appetite increase, expressed as a dichotomous variable (number of patients who experienced appetite increase) or a continuous variable.</LI>
<LI>Measurements of the mid-arm circumference and triceps skin fold thickness by anthropometry, as a percentage of the differences in the total body muscle and fat mass.</LI>
<LI>Deaths.</LI>
</UL>
<P>Study withdrawals and drop-outs were analysed as:<BR/>
</P>
<UL>
<LI>total number of drop-outs and withdrawals;</LI>
<LI>number of withdrawals due to lack of effectiveness of treatment;</LI>
<LI>number of withdrawals due to adverse effects.</LI>
</UL>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-02-05 16:24:35 +0000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2013-02-05 16:24:35 +0000" MODIFIED_BY="[Empty name]">
<P>We searched the following electronic databases to identify relevant studies:<BR/>
</P>
<UL>
<LI>Cochrane Pain, Palliative and Supportive Care Group Trials Register (2011, Issue 3) (see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>);</LI>
<LI>Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2011, Issue 3);</LI>
<LI>MEDLINE from 1966 to May 2012 (see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>);</LI>
<LI>EMBASE from 1980 to May 2012 (see <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>).</LI>
</UL>
<P>We combined the general strategy for identifying RCTs in MEDLINE with a strategy designed to retrieve trials of MA for cachexia. For the identification of studies to include in or consider for this review, we developed detailed search strategies for each database searched.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-02-05 16:24:35 +0000" MODIFIED_BY="[Empty name]">
<P>We checked lists of references from systematic reviews of MA and from the included studies to identify further trials.</P>
<P>Studies were not excluded on the basis of language or publication status (published, unpublished, in press and in progress).</P>
<P>We sought additional data from published trials by contacting authors. We consulted the information made available by the main researchers/sponsors.</P>
<P>We also reviewed information on the clinical trial meta-register database (<A HREF="http://www.controlled-trials.com/mrct/">http://www.controlled-trials.com/mrct/</A>).</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-02-08 08:02:35 +0000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2013-02-05 16:24:35 +0000" MODIFIED_BY="[Empty name]">
<P>Two review authors independently reviewed the titles and abstracts of studies identified in the search to assess which studies might potentially meet the inclusion criteria. Where there was doubt, we acquired the full article for further inspection. We then obtained potential studies identified by this process and two authors independently screened them to see if they met the review criteria. We created an Excel spreadsheet. We did not need to resolve any disagreements through discussion.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-02-05 16:24:35 +0000" MODIFIED_BY="[Empty name]">
<P>Two authors independently extracted data using a data collection form (in Excel). We checked any disagreements in the data collection and we reviewed the studies again only if there was a mismatch between them. We collected, when possible, data for intention-to-treat populations as raw numbers, summary measures with standard deviations, confidence intervals and P values of outcomes reported and compiled these into the Excel spreadsheet.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2013-02-07 13:24:51 +0000" MODIFIED_BY="[Empty name]">
<P>According to the recommendations in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I>, we assessed the risk of bias by creating a summary of 'Risk of bias' table (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<P>The main criteria used to measure the risk of bias included: blinding of participants, allocation concealment, random sequence generation, incomplete outcome data, selective reporting of outcomes and other bias (early stopping of trials or imbalance in the baseline of people in the groups). We explicitly judged the risk of bias in each study on the basis of the following criteria: low risk of bias, high risk of bias, unclear risk of bias (either lack of information or uncertainty over the potential bias). These criteria were included in the tables. Disagreements were resolved by discussion between the two review authors. If needed, a third review author was available for discussion in case of unresolved disagreements.</P>
<P>We also evaluated the methodological quality of the studies using a validated scale called the Oxford Quality Scale (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>), according to the following domains: concealment of allocation, double-blinding, intention-to-treat analysis and loss to follow-up. We also assessed each study using the zero to five-point scale described by <LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>, as summarised below.</P>
<OL>
<LI>Was the study described as randomised? (1 = yes; 0 = no).</LI>
<LI>Was the study described as double-blind? (1 = yes; 0 = no).</LI>
<LI>Were withdrawals and drop-outs described? (1 = yes; 0 = no).</LI>
<LI>Was the method of randomisation well-described and appropriate? (1 = yes; 0 = no); deduct one point if inappropriate.</LI>
<LI>Was the double-blinding well-described and appropriate? (1= yes; 0 = no); deduct one point if inappropriate.</LI>
</OL>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-02-05 16:24:35 +0000" MODIFIED_BY="[Empty name]">
<P>We use the risk ratio (RR) because it is more intuitive (<LINK REF="REF-Boissel-1999" TYPE="REFERENCE">Boissel 1999</LINK>) than the odds ratio and because odds ratios tend to be interpreted as RR by clinicians (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We used the risk difference to quantify the number needed to treat for an additional beneficial outcome (NNTB) (<LINK REF="REF-Laupacis-1988" TYPE="REFERENCE">Laupacis 1988</LINK>). For continuous data we used mean differences (MD) when the results were measured in the same way in different studies. We used standardised mean differences (SMD) when the results obtained were conceptually the same but used different measurement scales. We recorded the central estimate (mean) and standard deviation. Where these were not directly stated we calculated them from the standard error.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2013-02-05 16:24:35 +0000" MODIFIED_BY="[Empty name]">
<P>Most of the studies used a simple parallel-group design, in which participants are individually randomised to one of two intervention groups. Unit of analysis was not an issue in this review.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2013-02-05 16:24:35 +0000" MODIFIED_BY="[Empty name]">
<P>We carried out an intention-to-treat analysis. Everyone allocated to the intervention was counted whether they completed the follow-up or not. We have assumed that those who dropped out had no change in their outcome. This rule is conservative concerning response to treatment, because it assumes that those discontinuing the studies would not have responded. It is not conservative concerning adverse effects, but we felt that assuming that all those leaving early would have developed side effects would overestimate risk.</P>
<P>When published data were missing, incomplete or inconsistent with RCT protocols or meeting abstracts, we asked for further information from the authors/manufacturers. We have only excluded abstracts of studies that are interim reports of studies that have not yet finished recruiting.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-02-05 16:24:35 +0000" MODIFIED_BY="[Empty name]">
<P>We explored heterogeneity between the trials using the Chi<SUP>2</SUP> test for heterogeneity with a 10% level of significance, and the I<SUP>2</SUP> statistic. We complied with the recommendations in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I>, which determine that an I<SUP>2</SUP> value of 0% to 40% might not be important; 30% to 60% may represent moderate heterogeneity; 50% to 90% may represent substantial heterogeneity; and 75% to 100% considerable heterogeneity (<LINK REF="REF-Deeks-2008" TYPE="REFERENCE">Deeks 2008</LINK>).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2013-02-05 17:10:08 +0000" MODIFIED_BY="[Empty name]">
<P>We planned to explore reporting bias using funnel plots if we had a meta-analysis of 10 or more studies. The items in the assessment biases were: 1) Allocation 2) Blinding 3) Incomplete outcome data 4) Selective reporting 5) Other potential source of bias</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2013-02-08 08:02:35 +0000" MODIFIED_BY="[Empty name]">
<P>We explored the need to analyse the results according to a fixed or random-effects analysis (<LINK REF="REF-Laird-1990" TYPE="REFERENCE">Laird 1990</LINK>). In the event of significant heterogeneity we may have made a decision not to present combined result (<LINK REF="REF-Schulz-1993" TYPE="REFERENCE">Schulz 1993</LINK>). We calculated the number needed to treat for an additional beneficial outcome (NNT or NNTB) and the number needed for an additional harmful outcome (NNTH). We used the mean difference to calculate the benefit (absolute change expressed as both a percentage and in its original units) for continuous outcomes such as Karnofsky Index score or weight gain.<BR/>
</P>
<P>For dichotomous variables, we computed treatment effects as risk ratios (RR) with 95% confidence intervals (CI). For continuous variables such as weight gain or appetite gain we calculated differences in means and their 95% CI (mean difference (MD)) and for quality of life (including different scales), we calculated differences in means and their 95% CI (standardised mean difference (SMD)). Only validated scales with a normal distribution were included in the analysis. We determined validity of the scale from the psychometric properties of the instrument as described in the trial by the review authors.</P>
<P>We used a random-effects model in the analysis. We analysed statistical heterogeneity between studies with the Chi<SUP>2</SUP> test, using P &lt; 0.1 as a cut-off value to represent the presence of significant heterogeneity. When a high level of heterogeneity was detected, we made attempts to identify the sources of the heterogeneity and performed subsequent meta-analysis using a random-effects model.</P>
<P>We used the 'Grades of Recommendation, Assessment, Development and Evaluation' approach developed by the GRADE Working Group for grading the quality of evidence. The GRADE approach specifies four levels of quality. The highest quality rating is for randomised trial evidence. Review authors can, however, downgrade randomised trial evidence to moderate, low or even very low-quality evidence, depending on the presence of five specific factors (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>, chapter 11).</P>
<P>We used GRADE software to provide an overall grading of the quality of the evidence by outcome.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2013-02-05 16:24:35 +0000" MODIFIED_BY="[Empty name]">
<P>If heterogeneity was detected we planned to carry out subgroup analysis (<LINK REF="REF-Yusuf-1991" TYPE="REFERENCE">Yusuf 1991</LINK>) and/or a meta-regression in order to explain it (<LINK REF="REF-Thompson-1999" TYPE="REFERENCE">Thompson 1999</LINK>).</P>
<P>Subgroup analyses were planned for:</P>
<UL>
<LI>patients with AIDS;</LI>
<LI>patients with cancer;</LI>
<LI>patients with other underlying disease (elderly, chronic obstructive pulmonary disease (COPD), cardiac heart failure);</LI>
<LI>high doses of MA (=&gt; 800 mg/d) versus low doses of MA (&lt; 800 mg/d);</LI>
<LI>duration of trial, size and methodological quality.</LI>
</UL>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2013-02-05 16:24:35 +0000" MODIFIED_BY="[Empty name]">
<P>In order to explore the impact of specific factors on the meta-analysis results, we undertook sensitivity analyses with:<BR/>
</P>
<UL>
<LI>studies of high methodological quality, defined as studies with appropriate concealment of allocation, appropriate blinding and analysis by intention-to-treat (ITT);</LI>
<LI>studies where patients received more than six weeks of treatment.</LI>
</UL>
<P>We carried out the statistical analyses using the statistical package in Review Manager 5.1.6 (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>).</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-02-11 09:16:06 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2013-02-05 16:24:36 +0000" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2013-02-05 16:24:35 +0000" MODIFIED_BY="[Empty name]">
<P>Searching the electronic databases identified:<BR/>
</P>
<UL>
<LI>385 references in MEDLINE;</LI>
<LI>401 references in EMBASE; and</LI>
<LI>164 references in the Cochrane Central Register of Controlled Trials (CENTRAL).</LI>
</UL>
<P>We located an additional reference through Google and one more through a researcher who was involved in one trial that was never published.</P>
<P>We updated the first search to May 2012 (see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>; <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>; <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>) and one trial was added (<LINK REF="STD-Madeddu-2012" TYPE="STUDY">Madeddu 2012</LINK>).</P>
<P>A flowchart of included studies, according to the PRISMA recommendations, is shown in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>
</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2013-02-05 16:24:35 +0000" MODIFIED_BY="[Empty name]">
<P>We included most of the trials that were in the previous version of the review: <LINK REF="STD-Batterham-2001" TYPE="STUDY">Batterham 2001</LINK>; <LINK REF="STD-Beller-1997" TYPE="STUDY">Beller 1997</LINK>; <LINK REF="STD-De-Conno-1998" TYPE="STUDY">De Conno 1998</LINK>; <LINK REF="STD-Eubanks-2002" TYPE="STUDY">Eubanks 2002</LINK>; <LINK REF="STD-Feliu-1992" TYPE="STUDY">Feliu 1992</LINK>; <LINK REF="STD-Fietkau-1996" TYPE="STUDY">Fietkau 1996</LINK>; <LINK REF="STD-Gambardella-1998" TYPE="STUDY">Gambardella 1998</LINK>; <LINK REF="STD-Gebbia-1996" TYPE="STUDY">Gebbia 1996</LINK>; <LINK REF="STD-Heckmayr-1992" TYPE="STUDY">Heckmayr 1992</LINK>; <LINK REF="STD-Jatoi-2002" TYPE="STUDY">Jatoi 2002</LINK>; <LINK REF="STD-Jatoi-2004" TYPE="STUDY">Jatoi 2004</LINK>; <LINK REF="STD-Loprinzi-1990b" TYPE="STUDY">Loprinzi 1990b</LINK>; <LINK REF="STD-Loprinzi-1994" TYPE="STUDY">Loprinzi 1994</LINK>; <LINK REF="STD-Loprinzi-1999a" TYPE="STUDY">Loprinzi 1999a</LINK>; <LINK REF="STD-McMillan-1994" TYPE="STUDY">McMillan 1994</LINK>; <LINK REF="STD-Oster-1994" TYPE="STUDY">Oster 1994</LINK>; <LINK REF="STD-Sancho_x002d_Cuesta-1993" TYPE="STUDY">Sancho-Cuesta 1993</LINK>; <LINK REF="STD-Schmoll-1992" TYPE="STUDY">Schmoll 1992</LINK>; <LINK REF="STD-Tchekmedyian-1992" TYPE="STUDY">Tchekmedyian 1992</LINK>; <LINK REF="STD-Ulutin-2002" TYPE="STUDY">Ulutin 2002</LINK>; <LINK REF="STD-Vadell-1998" TYPE="STUDY">Vadell 1998</LINK>; <LINK REF="STD-Von-Roenn-1994" TYPE="STUDY">Von Roenn 1994</LINK>; <LINK REF="STD-Weisberg-2002" TYPE="STUDY">Weisberg 2002</LINK>; <LINK REF="STD-Yeh-2000" TYPE="STUDY">Yeh 2000</LINK> and included the following new trials: <LINK REF="STD-Casado-2008" TYPE="STUDY">Casado 2008</LINK>; <LINK REF="STD-Giacosa-1997" TYPE="STUDY">Giacosa 1997</LINK>; <LINK REF="STD-Herrejon-2011" TYPE="STUDY">Herrejon 2011</LINK>; <LINK REF="STD-Lesser-2006" TYPE="STUDY">Lesser 2006</LINK>; <LINK REF="STD-Madeddu-2012" TYPE="STUDY">Madeddu 2012</LINK>; <LINK REF="STD-Macbeth-1994" TYPE="STUDY">Macbeth 1994</LINK>; <LINK REF="STD-Mwamburi-2004" TYPE="STUDY">Mwamburi 2004</LINK>; <LINK REF="STD-Schmoll-1991" TYPE="STUDY">Schmoll 1991</LINK>; <LINK REF="STD-Summerbell-1992" TYPE="STUDY">Summerbell 1992</LINK>;<LINK REF="STD-Timpone-1997" TYPE="STUDY">Timpone 1997</LINK>; <LINK REF="STD-Wanke-2007" TYPE="STUDY">Wanke 2007</LINK>. Ultimately we included 35 trials, representing 3963 patients studied for effectiveness and 3240 for safety. We could not use the data from the included trials <LINK REF="STD-Lesser-2006" TYPE="STUDY">Lesser 2006</LINK> and <LINK REF="STD-Gambardella-1998" TYPE="STUDY">Gambardella 1998</LINK>. See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
<P>Many of these citations were replicated across the three databases.</P>
<P>The designs of the 35 trials were as follows:</P>
<SUBSECTION>
<HEADING LEVEL="4">MA at different doses compared with placebo</HEADING>
<P>Seventeen trials compared MA at different doses with placebo: <LINK REF="STD-Beller-1997" TYPE="STUDY">Beller 1997</LINK>; <LINK REF="STD-Casado-2008" TYPE="STUDY">Casado 2008</LINK>; <LINK REF="STD-De-Conno-1998" TYPE="STUDY">De Conno 1998</LINK>; <LINK REF="STD-Eubanks-2002" TYPE="STUDY">Eubanks 2002</LINK>; <LINK REF="STD-Feliu-1992" TYPE="STUDY">Feliu 1992</LINK>; <LINK REF="STD-Fietkau-1996" TYPE="STUDY">Fietkau 1996</LINK>; <LINK REF="STD-Herrejon-2011" TYPE="STUDY">Herrejon 2011</LINK>; <LINK REF="STD-Loprinzi-1990b" TYPE="STUDY">Loprinzi 1990b</LINK>; <LINK REF="STD-McMillan-1994" TYPE="STUDY">McMillan 1994</LINK>; <LINK REF="STD-Oster-1994" TYPE="STUDY">Oster 1994</LINK>; <LINK REF="STD-Schmoll-1991" TYPE="STUDY">Schmoll 1991</LINK>; <LINK REF="STD-Schmoll-1992" TYPE="STUDY">Schmoll 1992</LINK>; <LINK REF="STD-Tchekmedyian-1992" TYPE="STUDY">Tchekmedyian 1992</LINK>; <LINK REF="STD-Vadell-1998" TYPE="STUDY">Vadell 1998</LINK>; <LINK REF="STD-Von-Roenn-1994" TYPE="STUDY">Von Roenn 1994</LINK>; <LINK REF="STD-Weisberg-2002" TYPE="STUDY">Weisberg 2002</LINK>; <LINK REF="STD-Yeh-2000" TYPE="STUDY">Yeh 2000</LINK>. In <LINK REF="STD-Madeddu-2012" TYPE="STUDY">Madeddu 2012</LINK> one arm was carnitine plus celecoxib and the second arm was carnitine plus celecoxib plus MA 300 mg/day. In this trial only few safety data were available for the meta-analysis and we decided include it in this comparison.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">MA at different doses compared with other treatment drugs</HEADING>
<P>Seven trials compared different doses of MA with other drug treatments. MA was compared with dronabinol in two studies (<LINK REF="STD-Jatoi-2002" TYPE="STUDY">Jatoi 2002</LINK>; <LINK REF="STD-Timpone-1997" TYPE="STUDY">Timpone 1997</LINK>); dexamethasone and fluoxymesterone in one study (<LINK REF="REF-Loprinzi-1999" TYPE="REFERENCE">Loprinzi 1999</LINK>); nandrolone decanoate in one study (<LINK REF="STD-Batterham-2001" TYPE="STUDY">Batterham 2001</LINK>); cyproheptadine in one study (<LINK REF="STD-Summerbell-1992" TYPE="STUDY">Summerbell 1992</LINK>); oxandrolone in two studies (<LINK REF="STD-Lesser-2006" TYPE="STUDY">Lesser 2006</LINK>; <LINK REF="STD-Mwamburi-2004" TYPE="STUDY">Mwamburi 2004</LINK>); prednisolone in one study (<LINK REF="STD-Macbeth-1994" TYPE="STUDY">Macbeth 1994</LINK>) and eicosapentaenoic acid (EPA) in one study (<LINK REF="STD-Jatoi-2004" TYPE="STUDY">Jatoi 2004</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">MA at different doses</HEADING>
<P>Ten trials compared different doses of MA.</P>
<UL>
<LI>
<LINK REF="STD-Beller-1997" TYPE="STUDY">Beller 1997</LINK>: MA 160 mg versus MA 480 mg</LI>
<LI>
<LINK REF="STD-Casado-2008" TYPE="STUDY">Casado 2008</LINK>: MA 160 mg versus MA 960 mg versus placebo</LI>
<LI>
<LINK REF="STD-Gebbia-1996" TYPE="STUDY">Gebbia 1996</LINK>: MA 160 mg versus MA 320 mg</LI>
<LI>
<LINK REF="STD-Heckmayr-1992" TYPE="STUDY">Heckmayr 1992</LINK>: MA 160 versus MA 480 mg</LI>
<LI>
<LINK REF="STD-Loprinzi-1994" TYPE="STUDY">Loprinzi 1994</LINK>: MA 160 versus MA 480 mg versus MA 800 mg versus MA 1280 mg</LI>
<LI>
<LINK REF="STD-Sancho_x002d_Cuesta-1993" TYPE="STUDY">Sancho-Cuesta 1993</LINK>: MA 160 versus MA 320 mg</LI>
<LI>
<LINK REF="STD-Schmoll-1991" TYPE="STUDY">Schmoll 1991</LINK>: MA 480 mg versus MA 960 mg versus placebo</LI>
<LI>
<LINK REF="STD-Schmoll-1992" TYPE="STUDY">Schmoll 1992</LINK>: MA 480 mg versus MA 960 mg versus placebo</LI>
<LI>
<LINK REF="STD-Ulutin-2002" TYPE="STUDY">Ulutin 2002</LINK>: MA 160 mg versus MA 320 mg</LI>
<LI>
<LINK REF="STD-Vadell-1998" TYPE="STUDY">Vadell 1998</LINK>: MA 160 mg versus MA 480 mg versus placebo</LI>
<LI>
<LINK REF="STD-Wanke-2007" TYPE="STUDY">Wanke 2007</LINK>: MA 575 mg versus MA 800 mg</LI>
</UL>
<P>We categorised the included studies according to the healthcare problem of the patient - see <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> for a summary.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Patient characteristics</HEADING>
<P>A total of 4234 patients were included in this update.</P>
<SUBSECTION>
<HEADING LEVEL="5">Patients with any cancer</HEADING>
<P>Twenty-three trials (3428 patients) (<LINK REF="STD-Beller-1997" TYPE="STUDY">Beller 1997</LINK>; <LINK REF="STD-Casado-2008" TYPE="STUDY">Casado 2008</LINK>; <LINK REF="STD-De-Conno-1998" TYPE="STUDY">De Conno 1998</LINK>; <LINK REF="STD-Feliu-1992" TYPE="STUDY">Feliu 1992</LINK>; <LINK REF="STD-Fietkau-1996" TYPE="STUDY">Fietkau 1996</LINK>; <LINK REF="STD-Gambardella-1998" TYPE="STUDY">Gambardella 1998</LINK>; <LINK REF="STD-Gebbia-1996" TYPE="STUDY">Gebbia 1996</LINK>; <LINK REF="STD-Giacosa-1997" TYPE="STUDY">Giacosa 1997</LINK>; <LINK REF="STD-Heckmayr-1992" TYPE="STUDY">Heckmayr 1992</LINK>; <LINK REF="STD-Jatoi-2002" TYPE="STUDY">Jatoi 2002</LINK>; <LINK REF="STD-Jatoi-2004" TYPE="STUDY">Jatoi 2004</LINK>; <LINK REF="STD-Lesser-2006" TYPE="STUDY">Lesser 2006</LINK> <LINK REF="STD-Loprinzi-1990b" TYPE="STUDY">Loprinzi 1990b</LINK>; <LINK REF="STD-Loprinzi-1994" TYPE="STUDY">Loprinzi 1994</LINK>; <LINK REF="REF-Loprinzi-1999" TYPE="REFERENCE">Loprinzi 1999</LINK>; <LINK REF="STD-McMillan-1994" TYPE="STUDY">McMillan 1994</LINK>; <LINK REF="STD-Macbeth-1994" TYPE="STUDY">Macbeth 1994</LINK>; <LINK REF="STD-Madeddu-2012" TYPE="STUDY">Madeddu 2012</LINK>; <LINK REF="STD-Sancho_x002d_Cuesta-1993" TYPE="STUDY">Sancho-Cuesta 1993</LINK> <LINK REF="STD-Schmoll-1991" TYPE="STUDY">Schmoll 1991</LINK>; <LINK REF="STD-Schmoll-1992" TYPE="STUDY">Schmoll 1992</LINK>; <LINK REF="STD-Tchekmedyian-1992" TYPE="STUDY">Tchekmedyian 1992</LINK>; <LINK REF="STD-Ulutin-2002" TYPE="STUDY">Ulutin 2002</LINK> <LINK REF="STD-Vadell-1998" TYPE="STUDY">Vadell 1998</LINK>) assessed the effectiveness/safety of MA for anorexia-cachexia syndrome in cancer patients where the primary site was:<BR/>
</P>
<UL>
<LI>lung cancer(1342 patients);</LI>
<LI>gastrointestinal and pancreatic cancer(928 patients);</LI>
<LI>head and neck cancer(284 patients);</LI>
<LI>gynaecological cancer (21 patients);</LI>
<LI>non-specified sites(907 patients).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Patients with AIDS</HEADING>
<P>Five trials (475 patients) assessed the effectiveness of MA for anorexia-cachexia syndrome in AIDS patients (<LINK REF="STD-Batterham-2001" TYPE="STUDY">Batterham 2001</LINK>; <LINK REF="STD-Mwamburi-2004" TYPE="STUDY">Mwamburi 2004</LINK>; <LINK REF="STD-Oster-1994" TYPE="STUDY">Oster 1994</LINK>; <LINK REF="STD-Timpone-1997" TYPE="STUDY">Timpone 1997</LINK>; <LINK REF="STD-Von-Roenn-1994" TYPE="STUDY">Von Roenn 1994</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Patients with other underlying conditions</HEADING>
<P>Four trials (271 patients) assessed the effectiveness of MA for anorexia-cachexia syndrome in patients with the following conditions:<BR/>
</P>
<UL>
<LI>COPD: two trials with 185 patients (<LINK REF="STD-Herrejon-2011" TYPE="STUDY">Herrejon 2011</LINK>; <LINK REF="STD-Weisberg-2002" TYPE="STUDY">Weisberg 2002</LINK>);</LI>
<LI>cystic fibrosis: one trial with 17 patients (<LINK REF="STD-Eubanks-2002" TYPE="STUDY">Eubanks 2002</LINK>);</LI>
<LI>elderly: one trial with 69 patients (<LINK REF="STD-Yeh-2000" TYPE="STUDY">Yeh 2000</LINK>).</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Dose</HEADING>
<P>Across the studies, the dose of MA ranged from 100 mg per day to 1600 mg per day in at least one of the study arms.</P>
<P>The doses of MA assessed were as follows: <B>
<BR/>
</B>
</P>
<UL>
<LI>
<I>400 mg per day or less</I>
</LI>
</UL>
<P>Seventeen trials: (<LINK REF="STD-Batterham-2001" TYPE="STUDY">Batterham 2001</LINK> 400 mg per day; <LINK REF="STD-Beller-1997" TYPE="STUDY">Beller 1997</LINK> 160 mg per day; <LINK REF="STD-De-Conno-1998" TYPE="STUDY">De Conno 1998</LINK> 320 mg per day; <LINK REF="STD-Feliu-1992" TYPE="STUDY">Feliu 1992</LINK> 240 mg per day; <LINK REF="STD-Fietkau-1996" TYPE="STUDY">Fietkau 1996</LINK> 160 mg per day; <LINK REF="STD-Gebbia-1996" TYPE="STUDY">Gebbia 1996</LINK> 160 mg and 320 mg per day; <LINK REF="STD-Giacosa-1997" TYPE="STUDY">Giacosa 1997</LINK> 320 mg per day; <LINK REF="STD-Heckmayr-1992" TYPE="STUDY">Heckmayr 1992</LINK> 160 mg per day; <LINK REF="STD-Herrejon-2011" TYPE="STUDY">Herrejon 2011</LINK> 320 mg per day; <LINK REF="STD-Loprinzi-1994" TYPE="STUDY">Loprinzi 1994</LINK> 160 mg per day; <LINK REF="STD-Madeddu-2012" TYPE="STUDY">Madeddu 2012</LINK> 320 mg/per day <LINK REF="STD-Sancho_x002d_Cuesta-1993" TYPE="STUDY">Sancho-Cuesta 1993</LINK> 160 mg per day; <LINK REF="STD-Summerbell-1992" TYPE="STUDY">Summerbell 1992</LINK> 40 mg daily on alternate weeks to a maximum of 160 mg daily; <LINK REF="STD-Timpone-1997" TYPE="STUDY">Timpone 1997</LINK> 250 mg per day; <LINK REF="STD-Ulutin-2002" TYPE="STUDY">Ulutin 2002</LINK> 160 mg and 320 mg per day; <LINK REF="STD-Vadell-1998" TYPE="STUDY">Vadell 1998</LINK> 160 mg per day; <LINK REF="STD-Von-Roenn-1994" TYPE="STUDY">Von Roenn 1994</LINK> 100 mg and 400 mg per day).<BR/>
</P>
<UL>
<LI>
<I>480 mg per day</I>
</LI>
</UL>
<P>Seven trials: <LINK REF="STD-Beller-1997" TYPE="STUDY">Beller 1997</LINK>; <LINK REF="STD-Heckmayr-1992" TYPE="STUDY">Heckmayr 1992</LINK>; <LINK REF="STD-Loprinzi-1994" TYPE="STUDY">Loprinzi 1994</LINK>; <LINK REF="STD-McMillan-1994" TYPE="STUDY">McMillan 1994</LINK>; <LINK REF="STD-Schmoll-1991" TYPE="STUDY">Schmoll 1991</LINK>; <LINK REF="STD-Schmoll-1992" TYPE="STUDY">Schmoll 1992</LINK>; <LINK REF="STD-Vadell-1998" TYPE="STUDY">Vadell 1998</LINK>.</P>
<UL>
<LI>
<I>575 to 600 mg per day</I>
</LI>
</UL>
<P>Two trials: (<LINK REF="STD-Wanke-2007" TYPE="STUDY">Wanke 2007</LINK> 575 mg per day; <LINK REF="STD-Jatoi-2004" TYPE="STUDY">Jatoi 2004</LINK> 600 mg per day).<BR/>
</P>
<UL>
<LI>
<I>750 to 800 mg per day</I>
</LI>
</UL>
<P>Ten trials: (<LINK REF="STD-Timpone-1997" TYPE="STUDY">Timpone 1997</LINK> 750 mg per day; <LINK REF="STD-Jatoi-2002" TYPE="STUDY">Jatoi 2002</LINK>; <LINK REF="STD-Loprinzi-1990b" TYPE="STUDY">Loprinzi 1990b</LINK>; <LINK REF="STD-Loprinzi-1994" TYPE="STUDY">Loprinzi 1994</LINK>; <LINK REF="REF-Loprinzi-1999" TYPE="REFERENCE">Loprinzi 1999</LINK>; <LINK REF="STD-Mwamburi-2004" TYPE="STUDY">Mwamburi 2004</LINK>; <LINK REF="STD-Oster-1994" TYPE="STUDY">Oster 1994</LINK>; <LINK REF="STD-Von-Roenn-1994" TYPE="STUDY">Von Roenn 1994</LINK>; <LINK REF="STD-Weisberg-2002" TYPE="STUDY">Weisberg 2002</LINK>; <LINK REF="STD-Yeh-2000" TYPE="STUDY">Yeh 2000</LINK> (all 800 mg per day)).<BR/>
</P>
<UL>
<LI>
<I>1280 mg per day</I>
</LI>
</UL>
<P>One trial: <LINK REF="STD-Loprinzi-1994" TYPE="STUDY">Loprinzi 1994</LINK>.<BR/>
</P>
<UL>
<LI>
<I>1600 mg per day</I>
</LI>
</UL>
<P>One trial: <LINK REF="STD-Tchekmedyian-1992" TYPE="STUDY">Tchekmedyian 1992</LINK>.<BR/>
</P>
<UL>
<LI>One trial in children with cystic fibrosis assessed MA at a dose of 10 mg/kg per day (<LINK REF="STD-Eubanks-2002" TYPE="STUDY">Eubanks 2002</LINK>).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Study duration</HEADING>
<P>The study duration ranged from two weeks to 24 weeks. The median trial duration time was eight weeks. Seventeen trials had a duration of 12 weeks or more. (See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table).<BR/>
</P>
<UL>
<LI>Final assessment at two weeks (<LINK REF="STD-Beller-1997" TYPE="STUDY">Beller 1997</LINK>; <LINK REF="STD-De-Conno-1998" TYPE="STUDY">De Conno 1998</LINK>).</LI>
<LI>Assessment at four weeks/one month (<LINK REF="STD-Gebbia-1996" TYPE="STUDY">Gebbia 1996</LINK>; <LINK REF="STD-Heckmayr-1992" TYPE="STUDY">Heckmayr 1992</LINK>; <LINK REF="STD-Loprinzi-1990b" TYPE="STUDY">Loprinzi 1990b</LINK>).</LI>
<LI>Assessment at six weeks (<LINK REF="STD-Fietkau-1996" TYPE="STUDY">Fietkau 1996</LINK>; <LINK REF="STD-Tchekmedyian-1992" TYPE="STUDY">Tchekmedyian 1992</LINK>).</LI>
<LI>Assessment at eight weeks/two months (<LINK REF="STD-Feliu-1992" TYPE="STUDY">Feliu 1992</LINK>; <LINK REF="STD-Jatoi-2002" TYPE="STUDY">Jatoi 2002</LINK>; <LINK REF="STD-Herrejon-2011" TYPE="STUDY">Herrejon 2011</LINK>; <LINK REF="STD-Macbeth-1994" TYPE="STUDY">Macbeth 1994</LINK>; <LINK REF="STD-Mwamburi-2004" TYPE="STUDY">Mwamburi 2004</LINK>; <LINK REF="STD-Loprinzi-1994" TYPE="STUDY">Loprinzi 1994</LINK>; <LINK REF="STD-Loprinzi-1999b" TYPE="STUDY">Loprinzi 1999b</LINK>; <LINK REF="STD-Schmoll-1991" TYPE="STUDY">Schmoll 1991</LINK>; <LINK REF="STD-Schmoll-1992" TYPE="STUDY">Schmoll 1992</LINK>; <LINK REF="STD-Weisberg-2002" TYPE="STUDY">Weisberg 2002</LINK>).</LI>
<LI>Assessment at 12 weeks/three months (<LINK REF="STD-Batterham-2001" TYPE="STUDY">Batterham 2001</LINK>; <LINK REF="STD-Casado-2008" TYPE="STUDY">Casado 2008</LINK>; <LINK REF="STD-Jatoi-2004" TYPE="STUDY">Jatoi 2004</LINK>; <LINK REF="STD-Lesser-2006" TYPE="STUDY">Lesser 2006</LINK>; <LINK REF="STD-McMillan-1994" TYPE="STUDY">McMillan 1994</LINK>; <LINK REF="STD-Oster-1994" TYPE="STUDY">Oster 1994</LINK>; <LINK REF="STD-Timpone-1997" TYPE="STUDY">Timpone 1997</LINK>; <LINK REF="STD-Ulutin-2002" TYPE="STUDY">Ulutin 2002</LINK>; <LINK REF="STD-Vadell-1998" TYPE="STUDY">Vadell 1998</LINK>; <LINK REF="STD-Von-Roenn-1994" TYPE="STUDY">Von Roenn 1994</LINK>; <LINK REF="STD-Wanke-2007" TYPE="STUDY">Wanke 2007</LINK>).</LI>
<LI>Assessment at 13 to 16 weeks (<LINK REF="STD-Madeddu-2012" TYPE="STUDY">Madeddu 2012</LINK>; <LINK REF="STD-Summerbell-1992" TYPE="STUDY">Summerbell 1992</LINK>; <LINK REF="STD-Yeh-2000" TYPE="STUDY">Yeh 2000</LINK>).</LI>
<LI>Assessment at six months or more (<LINK REF="STD-Eubanks-2002" TYPE="STUDY">Eubanks 2002</LINK>; <LINK REF="STD-Sancho_x002d_Cuesta-1993" TYPE="STUDY">Sancho-Cuesta 1993</LINK>).</LI>
</UL>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-02-05 16:24:36 +0000" MODIFIED_BY="[Empty name]">
<P>We excluded a total of 110 studies.</P>
<P>In the present update we excluded the following studies that had been included in the previous review: <LINK REF="STD-Bruera-1990" TYPE="STUDY">Bruera 1990</LINK>(cross-over study); <LINK REF="STD-Bruera-1998" TYPE="STUDY">Bruera 1998</LINK>(cross-over study); <LINK REF="STD-Chen-1997" TYPE="STUDY">Chen 1997</LINK> (a trial of patients with head and neck cancers but only 18% were underweight; moreover 11% were overweight); <LINK REF="STD-Erkurt-2000" TYPE="STUDY">Erkurt 2000</LINK> (this study included a proportion of patients without weight loss in the previous six months and in addition patients were not balanced in both arms, specifically while in the MA arm 27% of the patients received oral nutrition support, in the placebo group 72% of patients received it); <LINK REF="STD-Lai-1994" TYPE="STUDY">Lai 1994</LINK> (patients did not have cachexia or any weight loss); <LINK REF="STD-Marchand-2000" TYPE="STUDY">Marchand 2000</LINK> (cross-over study); <LINK REF="STD-McQuellon-2002" TYPE="STUDY">McQuellon 2002</LINK> (patients were not described as patients with cachexia); <LINK REF="STD-Rowland-1996" TYPE="STUDY">Rowland 1996</LINK> (patients were not described as patients with cachexia and anorexia); and <LINK REF="STD-Zeca-1995" TYPE="STUDY">Zeca 1995</LINK> (a trial that included patients with cancer and anorexia, but cachexia was not needed as a inclusion criterion).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-02-08 08:13:12 +0000" MODIFIED_BY="[Empty name]">
<P>We assessed the methodological quality of the included studies using the Oxford Quality Scale (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>). The review authors scored each report independently for quality using the three-item scale described in the <LINK TAG="METHODS" TYPE="SECTION">Methods</LINK> section above and agreed a 'consensus' score. The scores for methodological quality are shown in <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> .</P>
<P>Eighteen trials (51%) scored three or more out of a maximum of five: <LINK REF="STD-Beller-1997" TYPE="STUDY">Beller 1997</LINK>; <LINK REF="STD-De-Conno-1998" TYPE="STUDY">De Conno 1998</LINK>; <LINK REF="STD-Eubanks-2002" TYPE="STUDY">Eubanks 2002</LINK>; <LINK REF="STD-Feliu-1992" TYPE="STUDY">Feliu 1992</LINK>; <LINK REF="STD-Fietkau-1996" TYPE="STUDY">Fietkau 1996</LINK>; <LINK REF="STD-Herrejon-2011" TYPE="STUDY">Herrejon 2011</LINK>; <LINK REF="STD-Jatoi-2002" TYPE="STUDY">Jatoi 2002</LINK>; <LINK REF="STD-Jatoi-2004" TYPE="STUDY">Jatoi 2004</LINK>; <LINK REF="STD-Loprinzi-1990b" TYPE="STUDY">Loprinzi 1990b</LINK>; <LINK REF="STD-McMillan-1994" TYPE="STUDY">McMillan 1994</LINK>; <LINK REF="STD-Mwamburi-2004" TYPE="STUDY">Mwamburi 2004</LINK>; <LINK REF="STD-Oster-1994" TYPE="STUDY">Oster 1994</LINK>; <LINK REF="STD-Tchekmedyian-1992" TYPE="STUDY">Tchekmedyian 1992</LINK>; <LINK REF="STD-Timpone-1997" TYPE="STUDY">Timpone 1997</LINK>; <LINK REF="STD-Vadell-1998" TYPE="STUDY">Vadell 1998</LINK>; <LINK REF="STD-Wanke-2007" TYPE="STUDY">Wanke 2007</LINK>; <LINK REF="STD-Weisberg-2002" TYPE="STUDY">Weisberg 2002</LINK>; <LINK REF="STD-Yeh-2000" TYPE="STUDY">Yeh 2000</LINK>.</P>
<P>Seventeen trials 49% achieved a low score (two points or lower): <LINK REF="STD-Batterham-2001" TYPE="STUDY">Batterham 2001</LINK>; <LINK REF="STD-Casado-2008" TYPE="STUDY">Casado 2008</LINK>; <LINK REF="STD-Gambardella-1998" TYPE="STUDY">Gambardella 1998</LINK>; <LINK REF="STD-Gebbia-1996" TYPE="STUDY">Gebbia 1996</LINK>; <LINK REF="STD-Giacosa-1997" TYPE="STUDY">Giacosa 1997</LINK>; <LINK REF="STD-Heckmayr-1992" TYPE="STUDY">Heckmayr 1992</LINK>; <LINK REF="STD-Lesser-2006" TYPE="STUDY">Lesser 2006</LINK>; <LINK REF="STD-Loprinzi-1994" TYPE="STUDY">Loprinzi 1994</LINK>; <LINK REF="STD-Loprinzi-1999a" TYPE="STUDY">Loprinzi 1999a</LINK>; <LINK REF="STD-Macbeth-1994" TYPE="STUDY">Macbeth 1994</LINK>; <LINK REF="STD-Madeddu-2012" TYPE="STUDY">Madeddu 2012</LINK>; <LINK REF="STD-Sancho_x002d_Cuesta-1993" TYPE="STUDY">Sancho-Cuesta 1993</LINK>; <LINK REF="STD-Schmoll-1991" TYPE="STUDY">Schmoll 1991</LINK>; <LINK REF="STD-Schmoll-1992" TYPE="STUDY">Schmoll 1992</LINK>; <LINK REF="STD-Summerbell-1992" TYPE="STUDY">Summerbell 1992</LINK>; <LINK REF="STD-Ulutin-2002" TYPE="STUDY">Ulutin 2002</LINK>; <LINK REF="STD-Von-Roenn-1994" TYPE="STUDY">Von Roenn 1994</LINK>.</P>
<P>The scores of risk of bias are shown in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>
</P>
<ALLOCATION MODIFIED="2013-02-05 16:24:36 +0000" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-Beller-1997" TYPE="STUDY">Beller 1997</LINK>; <LINK REF="STD-Herrejon-2011" TYPE="STUDY">Herrejon 2011</LINK>; <LINK REF="STD-Tchekmedyian-1992" TYPE="STUDY">Tchekmedyian 1992</LINK>; <LINK REF="STD-Timpone-1997" TYPE="STUDY">Timpone 1997</LINK> and <LINK REF="STD-Wanke-2007" TYPE="STUDY">Wanke 2007</LINK> adequately described the methods used to ensure that allocation of participants to treatment groups was concealed. The remaining studies did not report the method used.</P>
</ALLOCATION>
<BLINDING MODIFIED="2013-02-05 16:24:36 +0000" MODIFIED_BY="[Empty name]">
<P>Eleven studies were not blinded: <LINK REF="STD-Batterham-2001" TYPE="STUDY">Batterham 2001</LINK>; <LINK REF="STD-Casado-2008" TYPE="STUDY">Casado 2008</LINK>; <LINK REF="STD-Gebbia-1996" TYPE="STUDY">Gebbia 1996</LINK>; <LINK REF="STD-Giacosa-1997" TYPE="STUDY">Giacosa 1997</LINK>; <LINK REF="STD-Heckmayr-1992" TYPE="STUDY">Heckmayr 1992</LINK>; <LINK REF="STD-Lesser-2006" TYPE="STUDY">Lesser 2006</LINK>; <LINK REF="STD-Loprinzi-1999a" TYPE="STUDY">Loprinzi 1999a</LINK>; <LINK REF="STD-Loprinzi-1999b" TYPE="STUDY">Loprinzi 1999b</LINK>; <LINK REF="STD-Macbeth-1994" TYPE="STUDY">Macbeth 1994</LINK>;<LINK REF="STD-Madeddu-2012" TYPE="STUDY">Madeddu 2012</LINK>; <LINK REF="STD-Ulutin-2002" TYPE="STUDY">Ulutin 2002</LINK>; <LINK REF="STD-Wanke-2007" TYPE="STUDY">Wanke 2007</LINK>.</P>
<P>Ten more studies were described as blinded but did not describe the methods used to ensure that participants and interacting investigators were unable to differentiate between the treatment and control tablets: <LINK REF="STD-Beller-1997" TYPE="STUDY">Beller 1997</LINK>; <LINK REF="STD-De-Conno-1998" TYPE="STUDY">De Conno 1998</LINK>; <LINK REF="STD-Fietkau-1996" TYPE="STUDY">Fietkau 1996</LINK>; <LINK REF="STD-Gambardella-1998" TYPE="STUDY">Gambardella 1998</LINK>; <LINK REF="STD-Loprinzi-1994" TYPE="STUDY">Loprinzi 1994</LINK>; <LINK REF="STD-McMillan-1994" TYPE="STUDY">McMillan 1994</LINK>; <LINK REF="STD-Tchekmedyian-1992" TYPE="STUDY">Tchekmedyian 1992</LINK>; <LINK REF="STD-Von-Roenn-1994" TYPE="STUDY">Von Roenn 1994</LINK>; <LINK REF="STD-Weisberg-2002" TYPE="STUDY">Weisberg 2002</LINK>; <LINK REF="STD-Yeh-2000" TYPE="STUDY">Yeh 2000</LINK>.</P>
<P>The remaining seven studies were blinded and provided adequate information: <LINK REF="STD-Eubanks-2002" TYPE="STUDY">Eubanks 2002</LINK>; <LINK REF="STD-Herrejon-2011" TYPE="STUDY">Herrejon 2011</LINK>; <LINK REF="STD-Jatoi-2002" TYPE="STUDY">Jatoi 2002</LINK>; <LINK REF="STD-Jatoi-2004" TYPE="STUDY">Jatoi 2004</LINK>; <LINK REF="STD-Loprinzi-1990b" TYPE="STUDY">Loprinzi 1990b</LINK>; <LINK REF="STD-Oster-1994" TYPE="STUDY">Oster 1994</LINK>; <LINK REF="STD-Vadell-1998" TYPE="STUDY">Vadell 1998</LINK>.</P>
<P>We have rated trials that were not blinded as follows: when the main outcome was weight, we decided that this outcome was not likely to the influenced for patients or researchers, so we rated the risk of bias as 'low'. When the main outcome was appetite, we decided that this could be influenced by patients and researchers, and we rated risk of bias as 'high'.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2013-02-05 16:24:36 +0000" MODIFIED_BY="[Empty name]">
<P>In <LINK REF="STD-Schmoll-1992" TYPE="STUDY">Schmoll 1992</LINK>, withdrawals were higher in the placebo group (44%) than in both MA groups (30%) and explanations were not provided. In <LINK REF="STD-Vadell-1998" TYPE="STUDY">Vadell 1998</LINK>, the rate of withdrawals was very high (only 64 out of 152 initial patients remained in the study after 12 weeks). In both cases we rated risk of bias as 'high'. We rated the remaining studies as low risk, either because of lack of drop-outs or losses in the follow-up or because the number of drop-outs was low and equitably balanced between intervention groups.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2013-02-05 16:24:36 +0000" MODIFIED_BY="[Empty name]">
<P>The protocols for the studies were not available (except for <LINK REF="STD-Herrejon-2011" TYPE="STUDY">Herrejon 2011</LINK>), which we rated low risk of bias. In view of the fact that the authors only reported data at 12 weeks and not at 24 weeks we rated this a high risk bias in <LINK REF="STD-Batterham-2001" TYPE="STUDY">Batterham 2001</LINK>. We rated the rest of the studies as unclear risk of bias because all the predefined outcomes were available.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2013-02-05 16:24:36 +0000" MODIFIED_BY="[Empty name]">
<P>Studies with small group sizes and poor quality (allocation sequence, concealment of allocation or adequate blinding) tend to overestimate efficacy (<LINK REF="REF-Kjaergard-2001" TYPE="REFERENCE">Kjaergard 2001</LINK>; <LINK REF="REF-N_x00fc_esch-2010" TYPE="REFERENCE">Nüesch 2010</LINK>). In this review, 18 out of 34 trials had a sample size of less than 100 and poor quality; in particular the following: <LINK REF="STD-Batterham-2001" TYPE="STUDY">Batterham 2001</LINK> (15 patients); <LINK REF="STD-De-Conno-1998" TYPE="STUDY">De Conno 1998</LINK> (48 patients); <LINK REF="STD-Eubanks-2002" TYPE="STUDY">Eubanks 2002</LINK> (17 patients); <LINK REF="STD-Fietkau-1996" TYPE="STUDY">Fietkau 1996</LINK> (61 patients); <LINK REF="STD-Gambardella-1998" TYPE="STUDY">Gambardella 1998</LINK> (30 patients); <LINK REF="STD-Giacosa-1997" TYPE="STUDY">Giacosa 1997</LINK> (28 patients); <LINK REF="STD-Heckmayr-1992" TYPE="STUDY">Heckmayr 1992</LINK> (66 patients); <LINK REF="STD-Lesser-2006" TYPE="STUDY">Lesser 2006</LINK> (74 patients); <LINK REF="STD-Madeddu-2012" TYPE="STUDY">Madeddu 2012</LINK> (60 patients); <LINK REF="STD-Macbeth-1994" TYPE="STUDY">Macbeth 1994</LINK> (75 patients); <LINK REF="STD-McMillan-1994" TYPE="STUDY">McMillan 1994</LINK> (38 patients); <LINK REF="STD-Mwamburi-2004" TYPE="STUDY">Mwamburi 2004</LINK> (40 patients); <LINK REF="STD-Schmoll-1991" TYPE="STUDY">Schmoll 1991</LINK> (55 patients); <LINK REF="STD-Schmoll-1992" TYPE="STUDY">Schmoll 1992</LINK> (91 patients); <LINK REF="STD-Summerbell-1992" TYPE="STUDY">Summerbell 1992</LINK> (14 patients); <LINK REF="STD-Timpone-1997" TYPE="STUDY">Timpone 1997</LINK> (50 patients); <LINK REF="STD-Wanke-2007" TYPE="STUDY">Wanke 2007</LINK> (63 patients); and <LINK REF="STD-Yeh-2000" TYPE="STUDY">Yeh 2000</LINK> (69 patients).</P>
<P>Additionally, we rated three trials as high risk of bias: <LINK REF="STD-Macbeth-1994" TYPE="STUDY">Macbeth 1994</LINK> (stopped early for safety); <LINK REF="STD-Summerbell-1992" TYPE="STUDY">Summerbell 1992</LINK> (discontinued because the recruitment was too slow) and <LINK REF="STD-Lesser-2006" TYPE="STUDY">Lesser 2006</LINK> (we only have a conference proceeding dated 2006; we have not found any paper with all the relevant data for this trial).</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-02-11 09:16:06 +0000" MODIFIED_BY="Jessica Thomas">
<P>We meta-analysed data from the included studies in three groups.<BR/>
</P>
<UL>
<LI>Megestrol acetate (MA) versus placebo</LI>
<LI>MA versus other active drug treatments</LI>
<LI>MA at different doses</LI>
</UL>
<P>We further categorised the studies as follows.<BR/>
</P>
<UL>
<LI>Patients with cancer</LI>
<LI>Patients with AIDS</LI>
<LI>Patients with other underlying pathologies</LI>
</UL>
<P>We used risk ratio (RR) to assess quality of life, weight and appetite and used mean difference (MD) for weight and appetite gain as continuous variables. When quality of life was described as a continuous variable we used standardised mean difference (SMD) because this item was reported using different scales (Karnofsky Index, linear analogue self assessment, etc.).</P>
<SUBSECTION>
<HEADING LEVEL="3">Megestrol acetate versus placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Weight gain</HEADING>
<P>The overall results show weight improvement for patients treated with MA (RR 1.51, 95% CI 1.08 to 2.11) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). Eight trials were studied. The result for the subcategory of cancer patients was RR 1.55 (95% CI 1.06 to 2.26) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). One trial was found for each of the subcategories AIDS and other underlying pathologies. No overall results for these subcategories could be achieved. The quality of the trials for this outcome is shown in <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P>
<P>For weight gain, the overall results show an improvement for patients treated with MA (MD 1.93, 95% CI 0.95 to 2.91) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). Both the subcategories cancer patients and patients with other underlying pathologies show improvement (MD 1.63, 95% CI 0.87 to 2.38 and MD 1.47, 95% CI 0.06 to 2.87, respectively) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
<P>We explored heterogeneity between the trials using the Chi<SUP>2</SUP> test, with a 10% level of significance, and the I<SUP>2</SUP> statistic. When we explored weight improvement in the MA versus placebo comparison, we obtained an I<SUP>2 </SUP>of 66 %. We applied the recommendations in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I>, which suggest that an I<SUP>2</SUP> value more than 60% may represent high heterogeneity (<LINK REF="REF-Deeks-2008" TYPE="REFERENCE">Deeks 2008</LINK>). When we analysed data without the trials of <LINK REF="STD-Weisberg-2002" TYPE="STUDY">Weisberg 2002</LINK>; <LINK REF="STD-Yeh-2000" TYPE="STUDY">Yeh 2000</LINK> the I<SUP>2</SUP> became 2%. Those two trials with patients with COPD and geriatric cachexia could be quite different from the overall and could explain heterogeneity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Quality of life</HEADING>
<P>The overall results show improvement in quality of life for patients treated with MA (RR 1.78, 95% CI 1.09 to 2.92) (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>). The overall results for the cancer and AIDS patients subcategories were RR 1.91 (95% CI 1.02 to 3.59) and RR 1.49 (95% CI 0.47 to 4.69), respectively (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>). However, quality of life as a continuous variable shows no improvement (SMD 0.50, 95% CI -0.13 to 1.13) (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Appetite</HEADING>
<P>The overall results show appetite improvement for patients treated with MA (RR 2.19, 95% confidence interval (CI) 1.41 to 3.40)) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). The only subcategory that could be analysed was cancer patients and appetite improvement was detected (RR 2.57, 95% CI 1.48 to 4.49). We could not analyse the subcategories of AIDS patients and patients with other underlying pathologies because there was only one trial including AIDS patients. The quality of trials for this outcome is shown in <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>.</P>
<P>For appetite gain, we did not find trials with patients with cancer or AIDS and only one subcategory could be analysed. There were patients with other underlying pathologies, namely chronic obstructive pulmonary disease (COPD) and geriatric cachexia (<LINK REF="STD-Herrejon-2011" TYPE="STUDY">Herrejon 2011</LINK>; <LINK REF="STD-Yeh-2000" TYPE="STUDY">Yeh 2000</LINK>). The overall results show an improvement for patients treated with MA (SMD 0.91, 95% CI 0.43 to 1.39) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Anthropometric values</HEADING>
<P>Seven studies showed results for triceps skinfold thickness (TST). Only four of them had results which were statistically significant (<LINK REF="STD-Herrejon-2011" TYPE="STUDY">Herrejon 2011</LINK>; <LINK REF="STD-Vadell-1998" TYPE="STUDY">Vadell 1998</LINK>; <LINK REF="STD-Von-Roenn-1994" TYPE="STUDY">Von Roenn 1994</LINK>; <LINK REF="STD-Weisberg-2002" TYPE="STUDY">Weisberg 2002</LINK>) and three did not show statistical significance (<LINK REF="STD-Beller-1997" TYPE="STUDY">Beller 1997</LINK>; <LINK REF="STD-Fietkau-1996" TYPE="STUDY">Fietkau 1996</LINK>; <LINK REF="STD-Tchekmedyian-1992" TYPE="STUDY">Tchekmedyian 1992</LINK>; )</P>
<P>Two studies showed results for mid-arm circumference (MAC). Only one had results which were statistically significant (<LINK REF="STD-Eubanks-2002" TYPE="STUDY">Eubanks 2002</LINK>) and (<LINK REF="STD-Tchekmedyian-1992" TYPE="STUDY">Tchekmedyian 1992</LINK>)did not show statistical significance.</P>
<P>In <LINK REF="STD-Beller-1997" TYPE="STUDY">Beller 1997</LINK> the average difference in TST in mm between baseline and subsequent weeks was -0.28, -0.70 and +0.15 (P = 0.72) for placebo, lower doses of MA and higher doses of MA, respectively.</P>
<P>In <LINK REF="STD-Eubanks-2002" TYPE="STUDY">Eubanks 2002</LINK> TST and MAC measurements were also increased compared with baseline for the entire MA-treated group at two, three and six months (P &lt; 0.001 at all time points).</P>
<P>In <LINK REF="STD-Fietkau-1996" TYPE="STUDY">Fietkau 1996</LINK>, &#8220;There was no decrease or even a slight increase in the thickness of the triceps skinfold in MA group compared with a continuous decrease in the control group" and "No differences in upper arm muscle circumferences were observed between the groups&#8221;.</P>
<P>In <LINK REF="STD-Herrejon-2011" TYPE="STUDY">Herrejon 2011</LINK> the mean differences in TST at eight weeks were 0.8 versus -0.1 (P = 0.003) for the MA and placebo group, respectively.</P>
<P>In <LINK REF="STD-Vadell-1998" TYPE="STUDY">Vadell 1998</LINK> a significant increase in TST was noted in patients receiving higher doses of MA after the second month of treatment.</P>
<P>In <LINK REF="STD-Von-Roenn-1994a" TYPE="STUDY">Von Roenn 1994a</LINK> &#8220;MA treatment presented the decrease of TST in patients receiving placebo and resulted in an increase in all doses tested&#8221;.</P>
<P>In <LINK REF="STD-Weisberg-2002" TYPE="STUDY">Weisberg 2002</LINK> the mean TST values in the MA group increased significantly when compared to the placebo group: 1.35 ± 2.38 (n = 72) versus 0.13 ± 2.24 (n = 73). Only Weisberg&#8217;s trial described mean difference and standard deviation (SD)</P>
<P>In <LINK REF="STD-Tchekmedyian-1992" TYPE="STUDY">Tchekmedyian 1992</LINK> there were no significant changes in MAC or TST in either group at one month.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Megestrol acetate versus other drugs</HEADING>
<P>We found seven trials in this group: <LINK REF="STD-Loprinzi-1999a" TYPE="STUDY">Loprinzi 1999a</LINK>; <LINK REF="STD-Loprinzi-1999b" TYPE="STUDY">Loprinzi 1999b</LINK>; <LINK REF="STD-Jatoi-2002" TYPE="STUDY">Jatoi 2002</LINK>; <LINK REF="STD-Jatoi-2004" TYPE="STUDY">Jatoi 2004</LINK> in the subcategory of cancer and <LINK REF="STD-Batterham-2001" TYPE="STUDY">Batterham 2001</LINK>; <LINK REF="STD-Mwamburi-2004" TYPE="STUDY">Mwamburi 2004</LINK>; <LINK REF="STD-Summerbell-1992" TYPE="STUDY">Summerbell 1992</LINK>; <LINK REF="STD-Timpone-1997" TYPE="STUDY">Timpone 1997</LINK> in the subcategory of AIDS. Loprinzi 1999 (<LINK REF="STD-Loprinzi-1999a" TYPE="STUDY">Loprinzi 1999a</LINK>; <LINK REF="STD-Loprinzi-1999b" TYPE="STUDY">Loprinzi 1999b</LINK>) compared MA to fluoxymesterone and dexamethasone, respectively. The analysis of Loprinzi 1999 was carried out by dividing the total number of placebo patients by two. In other words, the number of placebo patients in each comparison was taken to be 79 instead of 158</P>
<SUBSECTION>
<HEADING LEVEL="4">Weight gain</HEADING>
<P>The overall results show weight improvement (RR 1.66, 95% CI 1.09 to 2.52) (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>). Three studies in the subcategory of cancer patients (<LINK REF="STD-Jatoi-2002" TYPE="STUDY">Jatoi 2002</LINK>; <LINK REF="STD-Jatoi-2004" TYPE="STUDY">Jatoi 2004</LINK>; <LINK REF="STD-Loprinzi-1999a" TYPE="STUDY">Loprinzi 1999a</LINK>; <LINK REF="STD-Loprinzi-1999b" TYPE="STUDY">Loprinzi 1999b</LINK>) and two in the subcategory of AIDS patients (<LINK REF="STD-Mwamburi-2004" TYPE="STUDY">Mwamburi 2004</LINK>; <LINK REF="STD-Summerbell-1992" TYPE="STUDY">Summerbell 1992</LINK>) were considered.</P>
<P>The overall results for the outcome weight gain show improvement (MD 2.50, 95% CI 0.37 to 4.64) (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>). However, the overall results for each subcategory show no weight gain either in cancer or in AIDS patients (MD 0.61, 95% CI -0.15 to 1.38 and MD 4.85, 95% CI -0.79 to 10.49, respectively) (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Quality of life</HEADING>
<P>Two trials (<LINK REF="STD-Jatoi-2002" TYPE="STUDY">Jatoi 2002</LINK>; <LINK REF="STD-Loprinzi-1999a" TYPE="STUDY">Loprinzi 1999a</LINK>) included in the analysis measured health-related quality of life as an outcome using different instruments. Quality of life did not show any benefit (RR 1.05, 95% CI 0.77 to 1.44 and SMD 0.20, 95% CI -0.02 to 0.43, respectively).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Appetite</HEADING>
<P>When we looked at the overall results, MA did not show benefits in terms of appetite improvement in comparison with other drugs in any category (RR 1.03, 95% CI 0.64 to 1.67) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>). The only trial available in this analysis was Loprinzi 1999.</P>
<P>Appetite gain as a continuous variable could only be analysed in one trial (<LINK REF="STD-Batterham-2001" TYPE="STUDY">Batterham 2001</LINK>) and shows lack of efficacy (MD 1.60, 95% CI -1.28 to 4.48) (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>).</P>
<P>The quality of trials for the outcomes appetite and weight improvement is shown in <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> and <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Anthropometric values</HEADING>
<P>In <LINK REF="STD-Macbeth-1994" TYPE="STUDY">Macbeth 1994</LINK> there was no evidence of statistical significance in the median change in TST at 12 weeks in either group.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Different dose levels of megestrol acetate</HEADING>
<P>We analysed low doses versus high doses of megestrol. However, the definitions of low dose and high dose were according to those used in each trial. Accordingly, in some trials (such as <LINK REF="STD-Beller-1997" TYPE="STUDY">Beller 1997</LINK>) low doses of MA were described as 160 mg and high doses as 480 mg; while in <LINK REF="STD-Wanke-2007" TYPE="STUDY">Wanke 2007</LINK> low doses were defined as 575 mg and high doses as 800 mg.</P>
<SUBSECTION>
<HEADING LEVEL="4">Weight gain</HEADING>
<P>The overall results show weight improvement with high doses versus low doses (RR 0.77, 95% CI 0.64 to 0.93) (<LINK REF="STD-Gebbia-1996" TYPE="STUDY">Gebbia 1996</LINK>; <LINK REF="STD-Heckmayr-1992" TYPE="STUDY">Heckmayr 1992</LINK>; <LINK REF="STD-Loprinzi-1994" TYPE="STUDY">Loprinzi 1994</LINK>; <LINK REF="STD-Sancho_x002d_Cuesta-1993" TYPE="STUDY">Sancho-Cuesta 1993</LINK>; <LINK REF="STD-Schmoll-1992" TYPE="STUDY">Schmoll 1992</LINK>; <LINK REF="STD-Ulutin-2002" TYPE="STUDY">Ulutin 2002</LINK>) (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>). All these trials were in the subcategory of cancer patients. When we analysed 160 mg of MA versus higher doses, the results remained unchanged, i.e. higher doses showed weight improvement (RR 0.72, 95% CI 0.52 to 0.99) (<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>).</P>
<P>Only two trials were found for the outcome weight gain as a continuous variable and demonstrated no statistical significance (MD -0.94, 95% CI -3.33 to 1.45); both were in the subcategory of AIDS patients (<LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Quality of life</HEADING>
<P>Two studies included in this analysis (<LINK REF="STD-Von-Roenn-1994" TYPE="STUDY">Von Roenn 1994</LINK>; <LINK REF="STD-Wanke-2007" TYPE="STUDY">Wanke 2007</LINK>) measured health-related quality of life as an outcome using different instruments. Quality of life did not show any benefit related to dose (RR 0.81, 95% CI 0.58 to 1.11and SMD 0.26, 95% CI -0.23 to 0.76) (<LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>; <LINK REF="CMP-003.06" TYPE="ANALYSIS">Analysis 3.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Appetite</HEADING>
<P>The overall results show no differences in appetite improvement between doses (high and low doses) (<LINK REF="STD-Gebbia-1996" TYPE="STUDY">Gebbia 1996</LINK>; <LINK REF="STD-Schmoll-1992" TYPE="STUDY">Schmoll 1992</LINK>; <LINK REF="STD-Ulutin-2002" TYPE="STUDY">Ulutin 2002</LINK>). All trials were in the subcategory of cancer patients.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Anthropometric values</HEADING>
<P>In <LINK REF="STD-Wanke-2007" TYPE="STUDY">Wanke 2007</LINK> there were no significant changes in TST or MAC in either group.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Safety</HEADING>
<P>More than 40 adverse events were studied, categorised into more and less than 800 mg of MA.</P>
<P>Fifteen trials reported 'any adverse events' and show an increase in the risk of suffering some of them, independent of dose (RR 1.20, 95% CI 1.07 to 1.36) (<LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>). All studies except <LINK REF="STD-Jatoi-2002" TYPE="STUDY">Jatoi 2002</LINK> are shown in the forest plot because this study had more 'any adverse events' in both arms than there were patients: 186/159 and 155/152 in the MA and placebo arm respectively. Therefore, 458 'any adverse events' were detected in 830 patients in the MA arm and 358 in 722 patients in the control arm. However, the overall results were the same.</P>
<P>The numbers of serious adverse events (SAE) were reported in four trials, but without further information. In these cases, SAEs seemed not to be related to MA (RR 2.10, 95% CI 0.98 to 4.47) (<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>). Lower doses seemed to produce more SAEs (RR 4.65, 95% CI 1.33 to 16.29).</P>
<P>Dyspnoea was reported in eight trials and was related to MA (RR 2.23, 95% CI 1.01 to 4.93) (<LINK REF="CMP-004.11" TYPE="ANALYSIS">Analysis 4.11</LINK>). Lower doses seemed to produce more dyspnoea (RR 2.80, 95% CI 1.02 to 7.67).</P>
<P>Deaths were reported in 11 trials and MA seemed to produce more deaths (RR 1.42, 95% CI 1.04 to 1.94) (<LINK REF="CMP-004.13" TYPE="ANALYSIS">Analysis 4.13</LINK>). Higher doses seemed to produce more deaths (RR 1.66, 95% CI 1.08 to 2.57).</P>
<P>Oedema was reported in 15 trials and could be related to MA (RR 1.36, 95% CI 1.07 to 1.72) (<LINK REF="CMP-004.31" TYPE="ANALYSIS">Analysis 4.31</LINK>). Higher doses seemed to produce more oedema (RR 1.37, 95% CI 1.04 to 1.81).</P>
<P>Impotence was reported in 13 trials and MA produced more impotence than placebo or other drugs (RR 2.58, 95% CI 1.78 to 3.75) (<LINK REF="CMP-004.24" TYPE="ANALYSIS">Analysis 4.24</LINK>). Both lower and higher doses were related to this adverse event (RR 2.89, 95% CI 1.33 to 6.26 and RR 2.49, 95% CI 1.63 to 3.81, respectively).</P>
<P>Nausea and vomiting were reported in 12 trials and MA produced less nausea and vomiting (RR 0.58, 95% CI 0.45 to 0.74) (<LINK REF="CMP-004.29" TYPE="ANALYSIS">Analysis 4.29</LINK>). Both lower and higher doses were related to this adverse event (RR 0.51, 95% CI 0.37 to 0.72 and RR 0.68, 95% CI 0.46 to 1.00, respectively).</P>
<P>Thromboembolic phenomena including thrombophlebitis were reported in 11 trials and MA produced an overall increased risk (RR 1.84, 95% CI 1.07 to 3.18) (<LINK REF="CMP-004.42" TYPE="ANALYSIS">Analysis 4.42</LINK>). However, neither higher doses nor lower doses showed statistical significance (RR 2.35, 95% CI 0.93 to 5.94 and RR 1.62, 95% CI 0.82 to 3.18, respectively).</P>
<P>Sixteen trials described withdrawals (RR 0.94, 95% CI 0.83 to 1.06) (<LINK REF="CMP-004.44" TYPE="ANALYSIS">Analysis 4.44</LINK>). Neither higher doses nor low doses showed statistical significance in the MA group versus the placebo group (RR 0.92, 95% CI 0.80 to 1.06 and RR 0.98, 95% CI 0.75 to 1.28, respectively).</P>
<P>The quality of trials for the outcome of death is shown in <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analysis</HEADING>
<P>This 2013 update of the review does not show any change with regard to the sensitivity analyses from the previous review (2006).</P>
<P>We undertook sensitivity analysis with trials where patients received more than 12 weeks of MA versus any drugs or placebo for any condition (cancer patients, AIDS, other underlying pathology). We analysed three outcomes: appetite improvement, weight improvement and weight gain.</P>
<P>One trial studied appetite at six weeks and did not show an increase in appetite compared to more than six weeks (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>). Appetite did not change with treatment for less or more than 12 weeks (RR 1.80, 95% CI 1.06 to 3.04 and RR 1.56, 95% CI 1.13 to 2.16, respectively) (<LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>).</P>
<P>No differences were shown for weight improvement with less or more than 12 weeks of treatment (RR 1.40, 95% CI 0.90 to 2.18 and RR 1.46, 95% CI 0.92 to 2.31, respectively) (<LINK REF="CMP-005.06" TYPE="ANALYSIS">Analysis 5.6</LINK>).</P>
<P>Weight gain was related to treatment duration of less of 12 weeks, but not to more than 12 weeks (MD 1.96 , 95% CI 1.06 to 2.87 and MD 1.94, 95% CI -1.64 to 5.53, respectively) (<LINK REF="CMP-005.08" TYPE="ANALYSIS">Analysis 5.8</LINK>).</P>
<P>Although appetite is a subjective perception and could be related to blinding, we did not detect this association; on the contrary, we found that only blinded trials showed an increase in appetite (RR 1.96, 95% CI 1.17 to 3.27 and RR 1.53, 95% CI 0.82 to 2.87 for blinded and open-label trials, respectively) (<LINK REF="CMP-005.09" TYPE="ANALYSIS">Analysis 5.9</LINK>).</P>
<P>Weight improvement only showed benefit in blinded trials (RR 1.63, 95% CI 1.15 to 2.32 and RR 1.14, 95% CI 0.53 to 2.47 for blinded and open-label trials, respectively) (<LINK REF="CMP-005.11" TYPE="ANALYSIS">Analysis 5.11</LINK>).</P>
<P>We also analysed according to a more broad definition of quality, using the Jadad scale of high quality (3 to 5 points) or low quality (0 to 2 points). Appetite was not related to quality (high quality RR 2.31, 95% CI 0.93 to 5.72 and low quality RR 1.47, 95% CI 0.96 to 2.27) (<LINK REF="CMP-005.13" TYPE="ANALYSIS">Analysis 5.13</LINK>). Weight improvement was not related to quality (high quality RR 1.50, 95% CI 1.07 to 2.10 and low quality RR 1.60, 95% CI 1.17 to 2.20) (<LINK REF="CMP-005.14" TYPE="ANALYSIS">Analysis 5.14</LINK>). When we analysed weight gain according to quality, both the categories of high and low quality were favourable to MA (MD 1.90, 95% CI 0.89 to 2.91 and MD 2.30, 95% CI 0.25 to 4.35) (<LINK REF="CMP-005.15" TYPE="ANALYSIS">Analysis 5.15</LINK>).</P>
<P>We also analysed whether the number of patients in the trials could be related to results for the main outcomes. We analysed two groups with more and fewer than 100 patients. Neither appetite nor weight improvement were related (<LINK REF="CMP-005.19" TYPE="ANALYSIS">Analysis 5.19</LINK> and <LINK REF="CMP-005.12" TYPE="ANALYSIS">Analysis 5.12</LINK>, respectively). However, weight gain in studies with fewer than 100 patients showed a MD of 3.45 (95% CI 0.82 to 6.08) and a MD of 1.13 (95% CI 0.59 to 1.68) with more than 100 patients (<LINK REF="CMP-005.20" TYPE="ANALYSIS">Analysis 5.20</LINK>). Consequently, small trial size may be related to weight gain.</P>
<P>We explored the duration of trials with oedema as an adverse event. This seemed to be related to trials of shorter duration: one to four weeks (RR 1.81, 95% CI 1.07 to 3.08), five to eight weeks (RR 1.43, 95% CI 1.04 to 1.97) versus 9 to 12 weeks (RR 1.10, 95% CI 0.82 to 1.46) (<LINK REF="CMP-005.16" TYPE="ANALYSIS">Analysis 5.16</LINK>). When we explored trials with thromboembolic phenomena the shortest trials, with less than 12 weeks of follow-up, showed a RR of 2.59(95% CI 1.16 to 5.76) whereas trials with follow-up of 12 or more weeks did not show statistical significance (RR 1.45, 95% CI 0.71 to 2.94) (<LINK REF="CMP-005.17" TYPE="ANALYSIS">Analysis 5.17</LINK>).</P>
<P>We carried out two sensitivity analyses to study death. In the first one, we explored duration of exposure to MA and this suggested a link (<LINK REF="CMP-005.25" TYPE="ANALYSIS">Analysis 5.25</LINK>). When deaths and pathology were explored, the association was not significant, but cancer and AIDS patients were more likely to suffer death as an adverse event (<LINK REF="CMP-005.26" TYPE="ANALYSIS">Analysis 5.26</LINK>). The explanation could be thromboembolic phenomena, although pulmonary embolism was not detected in the trials (only two trials reported this). It is known that pulmonary embolism is frequently unreported in 'real life'. We need to emphasise that the mortality results are sensitive to the trial of <LINK REF="STD-Jatoi-2002" TYPE="STUDY">Jatoi 2002</LINK>, so this result needs to be interpreted with caution.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-02-11 09:19:15 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2013-02-05 16:24:36 +0000" MODIFIED_BY="[Empty name]">
<P>The aim of the present update of the review was to assess the efficacy, effectiveness and safety of megestrol acetate (MA) for the management of anorexia-cachexia syndrome, a common clinical problem that substantially impacts upon the quality of life and survival of affected patients.</P>
<P>Our search strategy allowed us to identify all relevant studies. We tried to include more data by requesting this from authors but unfortunately very few new data were introduced in this update.</P>
<P>Our systematic review suggests that patients with cachexia-anorexia syndrome treated with MA improve their weight and appetite (mean difference (MD) for weight gain 1.96 kg (95% confidence interval (CI) 1.11 kg to 2.81 kg) (<LINK REF="CMP-005.15" TYPE="ANALYSIS">Analysis 5.15</LINK>); risk ratio (RR) for appetite improvement for any condition at six or more weeks of follow-up 1.70 (95% CI 1.14 to 2.54) (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>)). This overall result was obtained from trials with a duration of 14 to 180 days. Most of the trials had a follow-up of around 56 to 84 days.</P>
<P>Appetite and weight improvement was seen in the subcategories of cancer and AIDS patients when comparing MA with placebo. When MA was compared with other drugs, weight improvement was only seen in cancer patients. Quality of life improvement was seen in both subcategories of cancer and AIDS, when comparing MA-treated patients with placebo, but not against other drugs. However, no clear benefits were detected for quality of life gain (standardised mean difference (SMD) 0.32, 95% CI -0.02 to 0.65).</P>
<P>More adverse events were related to MA than placebo ('any adverse event') (RR 1.20, 95% CI 1.07 to 1.36). Serious adverse events were related to lower doses (&lt; 800 mg/day RR 4.65, 95% CI 1.33 to 16.29). Dyspnoea seemed to be related to lower doses of MA (RR 2.23, 95% CI 1.01 to 4.93). Oedema and thromboembolic phenomena were common adverse events (RR 1.36, 95% CI 1.07 to 1.72 and RR 1.91, 95% CI 1.13 to 3.23, respectively). Deaths seemed to be increased (RR 1.43, 95% CI 1.05 to 1.96), especially with higher doses (RR 1.66, 95% CI 1.08 to 2.57). We could not pool data for anthropometrics values, but all results from the included trials are shown in <LINK TAG="INTERVENTION_EFFECTS" TYPE="SECTION">Effects of interventions</LINK>.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2013-02-05 16:24:36 +0000" MODIFIED_BY="[Empty name]">
<P>All the planned outcomes have been analysed. Unfortunately, a large proportion of data available in the included trials could not be pooled because the authors did not provide enough information or data were not complete. This review has focused on the patients that were selected in the initial design of the review. Cancer and AIDS patients were the most common disease categories; the elderly and patients with chronic obstructive pulmonary disease (COPD) were new subcategories included in this review.</P>
<P>The mortality associated with cachexia-anorexia syndrome was high and the review failed to show any improvement with MA; in fact mortality was increased. This conclusion should be taken with caution, however, because the severity of illness in these patients is high and they have a high risk of death. Increased death was related only to higher doses in all trials except <LINK REF="STD-Yeh-2000" TYPE="STUDY">Yeh 2000</LINK>. It must also be stressed that these results are sensitive to the removal of the trial with most weight (<LINK REF="STD-Jatoi-2002" TYPE="STUDY">Jatoi 2002</LINK>) (RR 2.69, 95% CI 0.93 to 7.78), so must be taken with caution. However, none of the trials included in the review were designed to investigate mortality as primary endpoint and duration of follow-up was very short in most, so this unexpected result requires serious additional research in the form of clinical trials with longer follow-up and survival as a main outcome.</P>
<P>Most trials defined weight loss as a loss of more than 5% of previous weight. Appetite and weight gain showed benefits, however, in most of the trials this weight gain did not result in the recovery of the initial weight. In particular, the benefits of weight gain compared with placebo were in the range of 2 kg. The likelihood of oedema and thromboembolic phenomena means that patients should be informed of these adverse events.</P>
<P>The included trials did not have long-term follow-up. Since MA can be prescribed for several months in the treatment of cachexia-anorexia syndrome, adverse events could be more relevant than those described in the present review.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2013-02-07 13:21:31 +0000" MODIFIED_BY="[Empty name]">
<P>The main results are shown in <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK> and we rated the quality from low to high using the GRADE system. We have calculated numbers needed to treat for an additional beneficial outcome (NNTB) from the risk ratio according to the formula NNT or NNH = 1/ACR*(1-RR), where ACR = assumed control risk and RR = risk ratio.</P>
<OL>
<LI>Appetite improvement versus placebo (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). There is an improvement in appetite but the quality of the evidence is downgraded to <B>very low</B> because the risk bias for sequence generation was low only in <LINK REF="STD-Feliu-1992" TYPE="STUDY">Feliu 1992</LINK>. Moreover, allocation concealment was unclear in all trials and in three out of five trials we rated the outcome appetite as high risk of bias because it could be sensitive to lack of blinding. The statistical test for heterogeneity was moderate (P &lt; 0.04 and I<SUP>2 </SUP>= 59%; NNTB = 4, 95% CI 2 to 11). Doses of MA compared with placebo were very different, ranging from 160 mg to 960 mg in each subgroup.</LI>
<LI>Weight improvement versus placebo (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). We rated eight out of 10 trials as unclear regarding adequate sequence generation; we rated only one trial as low risk for allocation concealment. We rated all studies as low risk of bias for blinding. We rated <LINK REF="STD-Schmoll-1991" TYPE="STUDY">Schmoll 1991</LINK>; <LINK REF="STD-Schmoll-1992" TYPE="STUDY">Schmoll 1992</LINK> and <LINK REF="STD-Von-Roenn-1994" TYPE="STUDY">Von Roenn 1994</LINK> as low risk because lack of blinding is not related to weight. We rated only one study as high risk of bias due to incomplete outcome data addressed. We rated all trials as unclear with respect to 'other bias'. The results were quite similar and CI values overlapped for most of the trials. However, two studies (<LINK REF="STD-Feliu-1992" TYPE="STUDY">Feliu 1992</LINK>; <LINK REF="STD-Schmoll-1991" TYPE="STUDY">Schmoll 1991</LINK>) showed higher effects and the CI was quite wide. The statistical test for heterogeneity was moderate (P = 0.02 and I<SUP>2 </SUP>= 53%). The quality of the evidence is <B>very low </B>and the NNTB = 12 (95% CI 6 to 69).</LI>
<LI>Appetite improvement versus other drugs (Figure not shown). Only one trial showed improvement but there was an unclear risk of bias for sequence generation and allocation concealment and a high risk of bias for blinding. The quality of the evidence was low and the NNTB was not statistically significant.</LI>
<LI>Weight improvement versus other drugs (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>). We rated all studies except <LINK REF="STD-Mwamburi-2004" TYPE="STUDY">Mwamburi 2004</LINK> as unclear risk of bias for adequate sequence generation and allocation concealment. The statistical test for heterogeneity was moderate (P = 0.05 and I<SUP>2 </SUP>= 51%). The CI values overlapped for most of the studies. Cancer patients showed a better response in terms of weight. The quality of the evidence was <B>very low</B> and the NNTB = 22 (95% CI 9 to 159).</LI>
<LI>Deaths (<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>). We rated only two trials out of 11 as low risk of bias for adequate sequence generation and blinding. Allocation concealment was unclear in all trials. The CI values did not overlap. There was no large variation in the effect. The statistical test for heterogeneity was low (P &lt; 0.05 and I<SUP>2 </SUP>= 0%). Follow-up for this outcome was very short (up to 15 weeks) and we cannot disregard the possibility that in 'real life' very sick patients taking MA for a longer time, the number of deaths could increase. The quality of the evidence was <B>very low</B> and the number needed to treat for an additional harmful outcome (NNTH) = 23 (95% CI 10 to 200).</LI>
<LI>Thromboembolic phenomena (Figure not shown). We rated adequate sequence generation as low risk in three out of 10 trials, and rated allocation concealment as low risk only in two out of 10 trials. The statistical test for heterogeneity was low (P &lt; 0.9 and I<SUP>2 </SUP>= 0%). Thrombosis is a common complication in cancer patients and venous thromboembolism (VTE) is found at autopsy in at least 50% of cancer patients (<LINK REF="REF-Thompson-1952" TYPE="REFERENCE">Thompson 1952</LINK>). However, assessment of the true incidence of VTE in cancer patients is difficult because most of these patients receive chemotherapy or hormonal therapy which could precipitate VTE. In addition, many cancer patients have indwelling central venous lines, which can also initiate thrombotic events in relation to the catheter (<LINK REF="REF-Verso-2003" TYPE="REFERENCE">Verso 2003</LINK>). Consequently, we have calculated the NNTH assuming different basal risks from those obtained in the trials, namely 0.02, 0.10 and 0.50 in cancer patients. The resulting NNTH values were NNTH = 55 (95% CI 22 to 385), NNTH = 11 (95% CI 4 to 77) and NNTH = 2 (95% CI 1 to 15), respectively. The quality of the evidence was <B>very low</B>.</LI>
<LI>Oedema (Figure not shown). We rated only three out of 11 trials as low risk regarding adequate sequence generation. We rated only two out of 11 trials as low risk for allocation concealment. We rated incomplete outcome data as low risk in eight out of 11 trials. The statistical test for heterogeneity was low (P = 0.76 and I<SUP>2 </SUP>= 0%). The quality of the evidence was rated as <B>very low</B> (NNTH = 28, 95% CI 4 to 143).</LI>
</OL>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2013-02-07 11:39:28 +0000" MODIFIED_BY="[Empty name]">
<P>We have estimated that the potential bias in this review is low. Objectivity during the review process cannot be assessed, but the evaluation of trials to be included was done in pairs. We detected one trial that was unpublished due to early stopping because of increased mortality. Despite the fact that this trial was removed, mortality remained unchanged. We created funnels plot for all outcomes with more than 10 trials and these did not suggest publication bias. (These figures are not shown). The authors of this review do not have any conflicts of interest regarding MA.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2013-02-11 09:19:15 +0000" MODIFIED_BY="[Empty name]">
<P>Previous systematic reviews have shown similar results despite the fact that they did not include the same trials. <LINK REF="STD-Ruiz_x002d_Garcia-2002" TYPE="STUDY">Ruiz-Garcia 2002</LINK> found weight gain (MD 0.448 kg, CI 95% 0.02 to 0.87) only with low MA doses (&#8804; 240 mg). <LINK REF="STD-Pascual-2004" TYPE="STUDY">Pascual 2004</LINK> concluded that MA improved appetite (RR 2.31, 95% CI 1.52 to 3.59), led to weight gain (RR 1.88, 95% CI 1.43 to 2.47) and improved health-related quality of life (RR 1.52, 95% CI 1.00 to 2.30). <LINK REF="STD-Lesniak-2008" TYPE="STUDY">Lesniak 2008</LINK> concluded, as in the present review, that MA increases appetite (RR 3.00, 95% CI 1.86 to 4.84, NNT = 3) and leads to weight gain (RR 1.71, 95% CI 1.24 to 2.36, NNT = 8). None of the reviews mentioned showed an increase in mortality in MA arm. Additionally, they either did not explicitly analyse adverse events or did not include them in their protocols.</P>
<P>In palliative medicine, quality of life means not only the control of physical symptoms, functioning in daily life and psychological and social well being; quality of life also implies care of the patient's spiritual and existential concerns and also the perception by members of the patient's family of the quality of their care. It is our opinion that improving appetite and slight weight gain is not enough to improve quality of life in these patients.</P>
<P>Prevalence of cachexia in AIDS patients is high (from 18% to 38% in cohort studies) despite antiretroviral therapy (<LINK REF="REF-Campa-2005" TYPE="REFERENCE">Campa 2005</LINK>; <LINK REF="REF-Tang-2005" TYPE="REFERENCE">Tang 2005</LINK>). The prevalence of weight loss and wasting has not changed over time; it is as frequent now as it was in 1997 (<LINK REF="REF-Tang-2005" TYPE="REFERENCE">Tang 2005</LINK>). The conclusion of the present review is in line with the statement of <LINK REF="REF-Mangili-2006" TYPE="REFERENCE">Mangili 2006</LINK>, "Although there has been the presumption that, if weight loss is associated with morbidity and mortality in HIV infection, then improvements in weight would lead to improved QoL, there has been little data that support this&#8221;. The conclusions of this review regarding geriatric patients are in line with the guidelines of the American Geriatrics Society (<LINK REF="REF-Fick-2012" TYPE="REFERENCE">Fick 2012</LINK>) which state &#8220;Rationale: minimal effect on weight; increases risk of thrombotic events and possibly risk of death in older.. Recomendation: Avoid; Quality of evidence: moderate; Strenght of recommendation: Strong".<BR/>
</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-02-05 16:24:36 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2013-02-05 16:24:36 +0000" MODIFIED_BY="[Empty name]">
<P>The new trials identified and included in the present review update have not led to significant changes to the conclusions of the previous review (megestrol acetate (MA) improves appetite and slightly increases weight, without clinical relevance), except for adverse events. MA may be prescribed in patients with cancer to increase appetite and improve weight gain. Currently, there is no evidence to recommend MA to improve quality of life. This update has followed The Cochrane Collaboration guidelines for an unbiased review. Quality is difficult to define, since it depends on the design, conduct and analysis of a trial, its clinical relevance or the quality of reporting. Studies of low methodological quality can alter the interpretation of the benefit of an intervention. In this update, we assessed 58% of the trials as high quality for some outcomes such as improvement of weight.</P>
<P>Many concerns remain unresolved. Health-related quality of life is an important goal in health care and cancer clinical trials, and is the cornerstone for delivery of good palliative medicine. The increasing recognition of patient autonomy means that subjective measures will become more important and, in the current climate of evidence-based medicine, such measures must be valid and reliable.</P>
<P>Despite MA being approved US Food and Drug Administration for use in AIDS patients, this drug failed to show weight improvement and weight gain when compared with other drugs. MA compared with placebo was effective in AIDS patients in one trial.</P>
<P>In summary, MA could be prescribed to improve appetite in the context of palliative medicine, but it should be emphasised that this drug will probably not lead to full weight loss recovery or improve quality of life, and it is related to adverse events, including an increased risk of death.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-02-05 16:24:36 +0000" MODIFIED_BY="[Empty name]">
<P>This update of the review shows that there is still a need for high-quality trials focused on the evaluation of the effectiveness of MA. Trials with long-term follow-up are needed to rule out an increase in mortality. Even though the US Food and Drug Administration has approved MA for use in AIDS patients, more research is needed in this respect.<BR/>
</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-02-12 09:46:11 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="2">Previous review</HEADING>
<P>We are grateful to Dr CL Loprinzi and Paul Novotny from the Mayo Clinic; Professor E Bruera, Department of Palliative Care and Rehabilitation Medicine at Cross Cancer Institute, University of Alberta, Edmonton, and MD Anderson for supplying additional data for this review. We would also like to thank Marcelo García Diéguez and NicolasGarrigue from Argentina who have helped us with the search strategy and comments. We would like to thank Sylvia Bickley (Trials Search Co-ordinator, Cochrane Pain, Palliative Care &amp; Supportive Care Group) for performing the bibliographic searches in the previous version of this review.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Present review</HEADING>
<P>We would like to thank Graciella Berenstein (deceased in 2011) and Zulma Ortiz for his inspiration, and for what they started in 2002. We would like to thank Dr Herrejon, Dr Casado, Dr McMillan and Dra Vadell who provided us with explanations of their work. We would like to thank Ms Jane Hayes for the electronic searches. We would like to thank Warren Anthony Stevens who reviewed the English draft. This update systematic review is dedicated to the memory of Graciella Bernstein, who was the first author of the previous version of this review.</P>
</SUBSECTION>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2013-02-05 16:24:36 +0000" MODIFIED_BY="[Empty name]">
<P>No one involved in this review has any conflict of interest.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-02-05 16:24:36 +0000" MODIFIED_BY="[Empty name]">
<P>VR put forward the idea of updating the review.<BR/>JH performed the search.<BR/>VR located trials.<BR/>EL and VR applied the inclusion/exclusion criteria.<BR/>RC and JLG extracted the data and appraised the quality of the trials.<BR/>Data entry into RevMan was carried out by SB.<BR/>VR and SB produced the first draft.<BR/>All of the team wrote and approved the final draft.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES MODIFIED="2017-07-07 11:28:36 +0100" MODIFIED_BY="Anna Erskine">
<P>We performed full searches in February 2015, and April and December 2016, intending to complete a full update, but we did not identify any potentially relevant studies likely to change the conclusions. Therefore, this review has now been stabilised following discussion with the authors and editors. If appropriate, we will update the review if new evidence likely to change the conclusions is published, or if standards change substantially which necessitate major revisions.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2017-07-07 11:30:54 +0100" MODIFIED_BY="Anna Erskine">
<STUDIES MODIFIED="2013-02-13 09:50:15 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2013-02-07 13:03:15 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Batterham-2001" MODIFIED="2013-02-07 09:43:26 +0000" MODIFIED_BY="[Empty name]" NAME="Batterham 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-02-07 09:43:26 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Batterham M, Garsia R</AU>
<TI>Randomised prospective medium term comparison of megestrol acetate, nandrolone decanoate and dietary therapy alone for HIV associated weight loss [abstract]</TI>
<SO>Australasian Society for HIV Medicine</SO>
<YR>1997</YR>
<VL>9</VL>
<PG>91</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241565"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-01-30 13:54:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Batterham MJ, Garsia R</AU>
<TI>A comparison of megestrol acetate, nandrolone decanoate and dietary counselling for HIV associated weight loss</TI>
<SO>International Journal of Andrology</SO>
<YR>2001</YR>
<VL>24</VL>
<NO>4</NO>
<PG>232-40</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2780245"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780243"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beller-1997" MODIFIED="2013-02-07 09:43:48 +0000" MODIFIED_BY="[Empty name]" NAME="Beller 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-02-07 09:43:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beller E, Tattersall M</AU>
<TI>Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: a randomised placebo-controlled trial</TI>
<SO>Annals of Oncology</SO>
<YR>1997</YR>
<VL>8</VL>
<PG>277-83</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241566"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780246"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Casado-2008" MODIFIED="2013-02-07 13:03:15 +0000" MODIFIED_BY="[Empty name]" NAME="Casado 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-02-07 13:03:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Casado Herráez A</AU>
<TI>Phase II randomized study of two dose levels of megestrol acetate versus placebo for the treatment of anorexia and cachexia in patients with locoregional advanced or metastatic cancer</TI>
<TO>Estudio de fase II randomizado de dos niveles posológicos de acetato de Megestrol versus placebo para el tratamiento de la anorexia y la caquexia en pacientes con cáncer locoregional avanzado o metastásico. (Tesis de Doctorado - Universidad Complutense Madrid)</TO>
<SO>Available from http://eprints.ucm.es/8119/1/T30450.pdf</SO>
<YR>2008 (accessed 24 December 2011)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241567"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780248"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Conno-1998" MODIFIED="2013-01-30 13:58:11 +0000" MODIFIED_BY="[Empty name]" NAME="De Conno 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-01-30 13:58:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Conno F, Martini C</AU>
<TI>Megestrol acetate for anorexia in patients with far-advanced cancer: a double-blind controlled clinical trial</TI>
<SO>European Journal of Cancer</SO>
<YR>1998</YR>
<VL>34</VL>
<PG>1705-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241568"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780250"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eubanks-2002" MODIFIED="2013-01-30 13:59:09 +0000" MODIFIED_BY="[Empty name]" NAME="Eubanks 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-01-30 13:59:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eubanks V, Koppersmith N</AU>
<TI>Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis</TI>
<SO>Journal of Pediatrics</SO>
<YR>2002</YR>
<VL>140</VL>
<PG>439-44</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241569"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780252"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Feliu-1992" MODIFIED="2013-01-30 13:59:53 +0000" MODIFIED_BY="[Empty name]" NAME="Feliu 1992" YEAR="1992">
<REFERENCE MODIFIED="2013-01-30 13:59:26 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feliu J, Gonzalez-Baron M</AU>
<TI>Usefulness of megestrol acetate in cancer cachexia and anorexia. A placebo controlled study</TI>
<SO>American Journal of Clinical Oncology</SO>
<YR>1992</YR>
<VL>15</VL>
<PG>436-40</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241570"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-01-30 13:59:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gonzalez Baron M, Feliu J, Zamora P, Artal A, Garrido P, Chacon I</AU>
<TI>Usefulness of megestrol acetate on cancer cachexia: a double blind randomized study</TI>
<SO>Annals of Oncology</SO>
<YR>1990</YR>
<VL>1</VL>
<PG>29-31</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2780256"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780254"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fietkau-1996" MODIFIED="2013-01-30 14:01:11 +0000" MODIFIED_BY="[Empty name]" NAME="Fietkau 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-01-30 14:00:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fietkau R, Riepl M, Kettner H, Hinke A, Sauer R</AU>
<TI>Supportive use of megestrol acetate in patients with head and neck cancer during radio(chemo)therapy</TI>
<SO>European Journal of Cancer</SO>
<YR>1997</YR>
<VL>33</VL>
<PG>75-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241571"/><IDENTIFIER TYPE="OTHER" VALUE="CN-00137738"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-01-30 14:01:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fietkau R, Riepl M</AU>
<TI>Supportive treatment with megestrol acetate during radio (chemo) therapy. A randomised trial</TI>
<SO>Strahlentherapie und Onkologie</SO>
<YR>1996</YR>
<VL>172</VL>
<PG>162-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241572"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780257"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gambardella-1998" MODIFIED="2013-02-07 09:45:09 +0000" MODIFIED_BY="[Empty name]" NAME="Gambardella 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-02-07 09:44:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gambardella A, Pesce L, Bolognino P, Lombardi G, Barbieri M, Rinaldi C</AU>
<TI>Megestrol acetate prevents cachexia in elderly cancer patient</TI>
<SO>Annals of Oncology</SO>
<YR>1998</YR>
<VL>9</VL>
<NO>Suppl 3</NO>
<PG>72</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2780261"/><IDENTIFIER TYPE="OTHER" VALUE="CN-00305911"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-02-07 09:45:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gambardella A, Pesce L, Lammardo AM, Lombardi G, Barbagallo M, Tirelli P, et al</AU>
<TI>New factors involvement in elderly cancer patients with anorexia/cachexia syndrome role of megestrol acetate</TI>
<SO>Annals of Oncology</SO>
<YR>2000</YR>
<VL>9 Suppl 2</VL>
<PG>22</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241573"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780260"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gebbia-1996" MODIFIED="2013-01-30 14:02:24 +0000" MODIFIED_BY="[Empty name]" NAME="Gebbia 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-01-30 14:02:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gebbia V, Testa A</AU>
<TI>Prospective randomised trial of two dose levels of megestrol acetate in the management of anorexia-cachexia syndrome in patients with metastatic cancer</TI>
<SO>British Journal of Cancer</SO>
<YR>1996</YR>
<VL>73</VL>
<PG>1576-80</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241574"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780263"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Giacosa-1997" MODIFIED="2011-12-17 18:53:14 +0000" MODIFIED_BY="[Empty name]" NAME="Giacosa 1997" YEAR="1997">
<REFERENCE MODIFIED="2011-12-17 18:53:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giacosa A, Frascio F, Sukkar SG, Costantini M, Baracco G, Capelli M</AU>
<TI>Changes of nutritional and psychological status after megestrol acetate treatment of cancer cachexia</TI>
<SO>Rivista Italiana Di Nutrizione Parenterale Ed Enterale.</SO>
<YR>1997</YR>
<VL>15</VL>
<PG>20-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241575"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780265"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heckmayr-1992" MODIFIED="2013-01-30 14:02:38 +0000" MODIFIED_BY="[Empty name]" NAME="Heckmayr 1992" YEAR="1992">
<REFERENCE MODIFIED="2013-01-30 14:02:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heckmayr M, Gatzemeier U</AU>
<TI>Treatment of cancer weight loss in patients with advanced lung cancer</TI>
<SO>Oncology</SO>
<YR>1992</YR>
<VL>49</VL>
<NO>Suppl 2</NO>
<PG>32-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2780268"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780267"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Herrejon-2011" MODIFIED="2013-02-07 09:45:48 +0000" MODIFIED_BY="[Empty name]" NAME="Herrejon 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-02-07 09:45:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Herrejon A, Catalan P, Palop J, Inchaurraga I, Blanquer R, Lopez A</AU>
<TI>Effect of 8-week 320 mg megestrol acetate daily administration in severe COPD and weight loss [Abstract]</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2010</YR>
<VL>181</VL>
<PG>A4484</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241576"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-02-07 09:45:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Herrejon A, Palop J, Inchaurraga I, Lopez A, Bañuls C, Hernandez A, et al</AU>
<TI>Low doses of megestrol acetate increase weight and improve nutrition status in patients with severe chronic obstructive pulmonary disease and weight loss</TI>
<SO>Medicina Clinica</SO>
<YR>2011</YR>
<VL>137</VL>
<PG>193-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241577"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780269"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jatoi-2002" MODIFIED="2013-01-30 14:04:02 +0000" MODIFIED_BY="[Empty name]" NAME="Jatoi 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-01-30 14:04:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jatoi A, Windschitl HE</AU>
<TI>Dronabinol versus megestrol acetate versus combination for cancer-associated anorexia: A North Central Cancer Treatment Group Study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2002</YR>
<VL>20</VL>
<PG>567-73</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241578"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780272"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jatoi-2004" MODIFIED="2013-02-07 09:46:11 +0000" MODIFIED_BY="[Empty name]" NAME="Jatoi 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-02-07 09:46:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jatoi A, Rowland K, Loprinzi CL, Sloan JA, Dakhil SR, MacDonald N, et al</AU>
<TI>An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2004</YR>
<VL>22</VL>
<PG>2469-76</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241579"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780274"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lesser-2006" MODIFIED="2013-02-07 09:46:37 +0000" MODIFIED_BY="[Empty name]" NAME="Lesser 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-02-07 09:46:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lesser GJ, Case D, Sharp S, Choksi J, Miller A, Atkins J, et al</AU>
<TI>A phase III randomized study comparing the effects of oxandrolone (Ox) and megestrol acetate (Meg) on weight (wt), lean body mass (LBM) and quality of life (QOL) in solid tumor patients (pts) receiving chemotherapy (chemo)</TI>
<SO>Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>18S (June 20 Suppl)</NO>
<PG>18546</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241580"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780442"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Loprinzi-1990b" MODIFIED="2013-01-30 14:06:11 +0000" MODIFIED_BY="[Empty name]" NAME="Loprinzi 1990b" YEAR="1990">
<REFERENCE MODIFIED="2013-01-30 14:06:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Loprinzi CL, Ellison NM</AU>
<TI>Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>1990</YR>
<VL>82</VL>
<PG>1127-32</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241582"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241581"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Loprinzi-1994" MODIFIED="2013-02-07 09:47:03 +0000" MODIFIED_BY="[Empty name]" NAME="Loprinzi 1994" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Loprinzi CL, Bernath AM</AU>
<TI>Phase III evaluation of 4 doses of megestrol acetate for patients with cancer anorexia and/or cachexia</TI>
<SO>Oncology</SO>
<YR>1994</YR>
<VL>51</VL>
<PG>2-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241583"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-02-07 09:47:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Loprinzi CL, Michalak JC, Schaid DJ, Mailliard JA, Athmann LM, Goldberg RM, et al</AU>
<TI>Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1993</YR>
<VL>11</VL>
<PG>762-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241584"/><IDENTIFIER TYPE="OTHER" VALUE="CN-00092689"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780280"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Loprinzi-1999a" MODIFIED="2013-02-07 09:47:17 +0000" MODIFIED_BY="[Empty name]" NAME="Loprinzi 1999a" YEAR="1999">
<REFERENCE MODIFIED="2013-02-07 09:47:17 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Loprinzi CL, Kugler J, Sloan J, Mailliard J, Krook J, Wilwerding M, et al</AU>
<TI>Phase III randomized comparison of megestrol acetate, dexamethasone, and fluoxymesterone for the treatment of cancer anorexia/cachexia [Meeting abstract no 167]</TI>
<SO>ASCO Annual Meeting</SO>
<YR>1997</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241586"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-01-30 14:07:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Loprinzi CL, Kugler JW</AU>
<TI>Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1999</YR>
<VL>17</VL>
<PG>3299-306</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241587"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241585"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Loprinzi-1999b" MODIFIED="2013-02-07 09:47:40 +0000" MODIFIED_BY="[Empty name]" NAME="Loprinzi 1999b" YEAR="1999">
<REFERENCE MODIFIED="2013-02-07 09:47:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Loprinzi CL, Kugler J, Sloan J, Mailliard J, Krook J, Wilwerding M, et al</AU>
<TI>Phase III randomized comparison of megestrol acetate, dexamethasone, and fluoxymesterone for the treatment of cancer anorexia/cachexia [Meeting abstract no 167]</TI>
<SO>ASCO Annual Meeting</SO>
<YR>1997</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241589"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Loprinzi CL, Kugler JW</AU>
<TI>Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1999</YR>
<VL>17</VL>
<PG>3299-306</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241590"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241588"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Macbeth-1994" MODIFIED="2013-01-30 14:08:27 +0000" MODIFIED_BY="[Empty name]" NAME="Macbeth 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-01-30 14:08:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Macbeth FR, Grgeor A, Cott</AU>
<TI>A randomised study of megestrol acetate (MA) and prednisolone (P) for anorexia and weight loss in patients with lung cancer</TI>
<SO>Lung Cancer</SO>
<YR>1994</YR>
<VL>1 Suppl 1</VL>
<PG>88</PG>
<IDENTIFIERS MODIFIED="2012-02-05 18:27:45 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241591"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780286"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Madeddu-2012" MODIFIED="2013-02-07 09:48:00 +0000" MODIFIED_BY="[Empty name]" NAME="Madeddu 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-02-07 09:48:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Madeddu C, Dessì M, Panzone F, Serpe R, Antoni G, Cau MC, et al</AU>
<TI>Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer-related anorexia/cachexia syndrome</TI>
<SO>Clinical Nutrition</SO>
<YR>2012</YR>
<VL>31</VL>
<PG>176-82</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241592"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780288"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McMillan-1994" MODIFIED="2013-02-07 09:48:21 +0000" MODIFIED_BY="[Empty name]" NAME="McMillan 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-02-07 09:48:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McMillan DC, Simpson JM</AU>
<TI>Effect of megestrol acetate on weight loss, body composition and blood screen of gastrointestinal cancer patients</TI>
<SO>Clinical Nutrition</SO>
<YR>1994</YR>
<VL>13</VL>
<PG>85-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241593"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780294"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mwamburi-2004" MODIFIED="2013-02-07 09:48:40 +0000" MODIFIED_BY="[Empty name]" NAME="Mwamburi 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-02-07 09:48:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mwamburi DM, Gerrior J, Wilson IB, Chang H, Scully E, Saboori S, et al</AU>
<TI>Comparing megestrol acetate therapy with oxandrolone therapy for HIV-related weight loss: similar results in 2 months</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2004</YR>
<VL>38</VL>
<PG>895-902</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241594"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780296"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oster-1994" MODIFIED="2013-01-30 14:09:39 +0000" MODIFIED_BY="[Empty name]" NAME="Oster 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-01-30 14:09:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oster MH, Enders SR</AU>
<TI>Megestrol acetate in patients with AIDS and cachexia</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1994</YR>
<VL>121</VL>
<PG>400-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241595"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780301"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sancho_x002d_Cuesta-1993" MODIFIED="2013-02-07 09:49:04 +0000" MODIFIED_BY="[Empty name]" NAME="Sancho-Cuesta 1993" YEAR="1993">
<REFERENCE MODIFIED="2013-02-07 09:49:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sancho-Cuesta JF</AU>
<TI>Megestrol acetate and weight loss in advanced cancer [Abstract no: 1141]</TI>
<SO>European Journal of Cancer</SO>
<YR>1993</YR>
<VL>29A</VL>
<PG>S204</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2780304"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780303"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmoll-1991" MODIFIED="2013-02-07 09:49:20 +0000" MODIFIED_BY="[Empty name]" NAME="Schmoll 1991" YEAR="1991">
<REFERENCE MODIFIED="2013-02-07 09:49:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schmoll E, Wilke H, Thole R, Preusser P, Wildfang I, Schmoll HJ</AU>
<TI>Megestrol acetate in cancer cachexia</TI>
<SO>Seminars in Oncology</SO>
<YR>1991</YR>
<VL>18</VL>
<NO>1 Suppl 2</NO>
<PG>32-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2780306"/><IDENTIFIER TYPE="OTHER" VALUE="CN-00072963"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780305"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmoll-1992" MODIFIED="2012-02-05 19:25:12 +0000" MODIFIED_BY="[Empty name]" NAME="Schmoll 1992" YEAR="1992">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schmoll E</AU>
<TI>Risks and benefits of various therapies for cancer anorexia</TI>
<SO>Oncology</SO>
<YR>1992</YR>
<VL>49</VL>
<PG>43-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241596"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780307"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Summerbell-1992" MODIFIED="2013-01-30 14:10:54 +0000" MODIFIED_BY="[Empty name]" NAME="Summerbell 1992" YEAR="1992">
<REFERENCE MODIFIED="2013-01-30 14:10:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Summerbell CD, Youle M, McDonald V, Catalan J, Gazzard BG</AU>
<TI>Megestrol acetate vs cyproheptadine in the treatment of weight loss associated with HIV infection</TI>
<SO>International Journal of STD and AIDS</SO>
<YR>1992</YR>
<VL>3</VL>
<PG>278-80</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241597"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780309"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tchekmedyian-1992" NAME="Tchekmedyian 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tchekmedyian NS, Hickman M</AU>
<TI>Megestrol acetate in cancer anorexia and weight loss</TI>
<SO>Cancer</SO>
<YR>1992</YR>
<VL>69</VL>
<PG>1268-74</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241598"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780311"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Timpone-1997" MODIFIED="2013-01-30 14:11:11 +0000" MODIFIED_BY="[Empty name]" NAME="Timpone 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-01-30 14:11:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Timpone JG, Wright DJ</AU>
<TI>The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome</TI>
<SO>AIDS Research and Human Retroviruses</SO>
<YR>1997</YR>
<VL>13</VL>
<PG>305-15</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241599"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780313"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ulutin-2002" NAME="Ulutin 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ulutin HC, Arpaci F, Pak Y</AU>
<TI>Megestrol acetate for cachexia and anorexia in advanced non-small cell lung cancer: a randomized study comparing two different doses</TI>
<SO>Tumori</SO>
<YR>2002</YR>
<VL>88</VL>
<PG>277-80</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241600"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780315"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vadell-1998" MODIFIED="2013-02-07 09:49:46 +0000" MODIFIED_BY="[Empty name]" NAME="Vadell 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-02-07 09:49:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Segui MA, Vadell C, Gimenez-Arnau JM, Morales S, Cirera L, Bestit I, et al</AU>
<TI>Double-blind randomized trial for the treatment of cancer related cachexia: comparison of placebo vs two different doses of megestrol acetate [Abstract 99]</TI>
<SO>Proceedings of the American Society of Clinical Oncology</SO>
<YR>1996</YR>
<VL>15</VL>
<PG>529</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2780318"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-01-30 14:11:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vadell C, Segui MA</AU>
<TI>Anticachectic efficacy of megestrol acetate at different doses and versus placebo in patients with neoplastic cachexia</TI>
<SO>American Journal of Clinical Oncology</SO>
<YR>1998</YR>
<VL>21</VL>
<PG>347-51</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241601"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780317"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Von-Roenn-1994" MODIFIED="2013-01-30 14:12:06 +0000" MODIFIED_BY="[Empty name]" NAME="Von Roenn 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-01-30 14:12:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Von Roenn JH, Armstrong D</AU>
<TI>Megestrol acetate in patients with AIDS-related cachexia</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1994</YR>
<VL>121</VL>
<PG>393-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241602"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780320"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wanke-2007" MODIFIED="2013-02-07 09:50:29 +0000" MODIFIED_BY="[Empty name]" NAME="Wanke 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-02-07 09:50:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cilla DD, Gutierrez JL, Kristensen A, Kramer LD</AU>
<TI>The safety of megestrol acetate concentrated suspension (MA-CS) and megestrol acetate oral suspension (MA-OS) in a pilot study in patients with HIV-associated unintended weight loss (UWL) [Abstract]</TI>
<SO>Blood</SO>
<YR>2006</YR>
<VL>108</VL>
<PG>43</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241603"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-02-07 09:50:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wanke C, Gutierrez J, Kristensen A, MacEarchern, L</AU>
<TI>Safety and efficacy of two preparations of megestrol acetate in HIV-infected individuals with weight loss in Africa, India, and the United States</TI>
<SO>Journal of Applied Research</SO>
<YR>2007</YR>
<VL>7</VL>
<PG>206-16</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241604"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780322"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weisberg-2002" NAME="Weisberg 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weisberg J, Wanger J</AU>
<TI>Megestrol acetate stimulates weight gain and ventilation in underweight COPD patients</TI>
<SO>Chest</SO>
<YR>2002</YR>
<VL>121</VL>
<NO>4</NO>
<PG>1070-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2780326"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780325"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yeh-2000" MODIFIED="2013-02-07 09:51:15 +0000" MODIFIED_BY="[Empty name]" NAME="Yeh 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-02-07 09:50:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yeh SS, Lovitt S, Schuster MW</AU>
<TI>Usage of megestrol acetate in the treatment of anorexia-cachexia syndrome in the elderly</TI>
<SO>Journal of Nutrition, Health and Aging</SO>
<YR>2009</YR>
<VL>13</VL>
<PG>448-54</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241605"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-02-07 09:51:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yeh SS, Wu SY, Levine DM, Parker TS, Olson JS, Stevens MR, et al</AU>
<TI>The correlation of cytokine levels with body weight after megestrol acetate treatment in geriatric patients</TI>
<SO>Journals of Gerontology. Series A, Biological Sciences and Medical Sciences</SO>
<YR>2001</YR>
<VL>56</VL>
<PG>M48-54</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241606"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-02-07 09:51:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yeh SS, Wu SY</AU>
<TI>Improvement in quality of life measures and stimulation of weight gain after treatment with megestrol acetate oral suspension in geriatric cachexia: results of a double-blind, placebo-controlled study</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>2000</YR>
<VL>48</VL>
<NO>5</NO>
<PG>485-92</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2780331"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780327"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-02-13 09:50:15 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Aguilera-2001" MODIFIED="2013-02-07 09:51:55 +0000" MODIFIED_BY="[Empty name]" NAME="Aguilera 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-02-07 09:51:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aguilera A, Selgas R, Diez JJ, Bajo MA, Codoceo R, Alvarez V</AU>
<TI>Anorexia in end-stage renal disease: pathophysiology and treatment</TI>
<SO>Expert Opinion on Pharmacotherapy</SO>
<YR>2001</YR>
<VL>2</VL>
<NO>11</NO>
<PG>1825-38</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241608"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241607"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aisner-1988" MODIFIED="2013-02-07 09:52:08 +0000" MODIFIED_BY="[Empty name]" NAME="Aisner 1988" YEAR="1988">
<REFERENCE MODIFIED="2013-02-07 09:52:08 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 19880616&lt;br&gt;IS - 0093-7754 (Print)&lt;br&gt;IS - 0093-7754 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;PT - Review&lt;br&gt;RN - 3562-63-8 (Megestrol)&lt;br&gt;RN - 51154-23-5 (Megestrol Acetate)&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2013-02-07 09:52:08 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aisner J, Tchekmedyian NS, Tait N, Parnes H, Novak M</AU>
<TI>Studies of high-dose megestrol acetate: potential applications in cachexia</TI>
<SO>Seminars in Oncology</SO>
<YR>1988</YR>
<VL>15</VL>
<NO>2 Suppl 1</NO>
<PG>68-75</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241610"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241609"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anonymous-1995" MODIFIED="2011-08-26 16:30:24 +0100" MODIFIED_BY="[Empty name]" NAME="Anonymous 1995" YEAR="1995">
<REFERENCE MODIFIED="2011-08-26 16:29:14 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Embase&lt;br&gt;UI - 1995096226&lt;/p&gt;" NOTES_MODIFIED="2011-08-26 16:29:14 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Megestrol found effective in two trials</TI>
<SO>AIDS Patient Care</SO>
<YR>1995</YR>
<VL>9</VL>
<NO>1</NO>
<PG>41</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241612"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241611"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ansfield-1982" MODIFIED="2013-02-07 09:52:21 +0000" MODIFIED_BY="[Empty name]" NAME="Ansfield 1982" YEAR="1982">
<REFERENCE MODIFIED="2013-02-07 09:52:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ansfield FJ, Kallas GJ, Singson JP</AU>
<TI>Clinical results with megestrol acetate in patients with advanced carcinoma of the breast</TI>
<SO>Surgery, Gynecology &amp; Obstetrics</SO>
<YR>1982</YR>
<VL>155</VL>
<NO>6</NO>
<PG>888-90</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2780333"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780332"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Argiles-2007" MODIFIED="2013-02-07 09:52:44 +0000" MODIFIED_BY="[Empty name]" NAME="Argiles 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-02-07 09:52:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Argiles JM, Lopez-Soriano FJ, Busquets S</AU>
<TI>Emerging drugs for cancer cachexia</TI>
<SO>Expert Opinion on Emerging Drugs</SO>
<YR>2007</YR>
<VL>12</VL>
<NO>4</NO>
<PG>555-70</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241614"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241613"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Argiles-2008" MODIFIED="2013-02-07 09:52:56 +0000" MODIFIED_BY="[Empty name]" NAME="Argiles 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-02-07 09:52:56 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Embase&lt;br&gt;UI - 2008010553&lt;/p&gt;" NOTES_MODIFIED="2013-02-07 09:52:56 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Argiles JM, Lopez-Soriano FJ, Busquets S</AU>
<TI>Novel approaches to the treatment of cachexia</TI>
<SO>Drug Discovery Today</SO>
<YR>2008</YR>
<VL>13</VL>
<NO>1-2</NO>
<PG>73-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241616"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241615"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Argiles-2010" MODIFIED="2013-02-07 09:53:11 +0000" MODIFIED_BY="[Empty name]" NAME="Argiles 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-02-07 09:53:11 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Embase&lt;br&gt;UI - 2010243964&lt;/p&gt;" NOTES_MODIFIED="2013-02-07 09:53:11 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Argiles JM, Olivan M, Busquets S, Lopez-Soriano FJ</AU>
<TI>Optimal management of cancer anorexia-cachexia syndrome</TI>
<SO>Cancer Management and Research</SO>
<YR>2010</YR>
<VL>2</VL>
<NO>1</NO>
<PG>27-38</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241618"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241617"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Behl-2007" MODIFIED="2013-02-07 09:53:29 +0000" MODIFIED_BY="[Empty name]" NAME="Behl 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-02-07 09:53:29 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Embase&lt;br&gt;UI - 2007292726&lt;/p&gt;" NOTES_MODIFIED="2013-02-07 09:53:29 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Behl D, Jatoi A</AU>
<TI>Pharmacological options for advanced cancer patients with loss of appetite and weight</TI>
<SO>Expert Opinion on Pharmacotherapy</SO>
<YR>2007</YR>
<VL>8</VL>
<NO>8</NO>
<PG>1085-90</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241620"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241619"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bossola-2006" MODIFIED="2013-01-30 14:22:03 +0000" MODIFIED_BY="[Empty name]" NAME="Bossola 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-01-30 14:22:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bossola M, Tazza L, Giungi S, Luciani G</AU>
<TI>Anorexia in hemodialysis patients: an update</TI>
<SO>Kidney International</SO>
<YR>2006</YR>
<VL>70</VL>
<NO>3</NO>
<PG>417-22</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241622"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241621"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bossola-2009" MODIFIED="2013-01-30 14:22:18 +0000" MODIFIED_BY="[Empty name]" NAME="Bossola 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-30 14:22:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bossola M, Tazza L, Luciani G</AU>
<TI>Mechanisms and treatment of anorexia in end-stage renal disease patients on hemodialysis</TI>
<SO>Journal of Renal Nutrition</SO>
<YR>2009</YR>
<VL>19</VL>
<NO>1</NO>
<PG>2-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241624"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241623"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bruera-1990" MODIFIED="2013-01-30 14:22:24 +0000" MODIFIED_BY="[Empty name]" NAME="Bruera 1990" YEAR="1990">
<REFERENCE MODIFIED="2013-01-30 14:22:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bruera E, McMillan K</AU>
<TI>A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer</TI>
<SO>Cancer</SO>
<YR>1990</YR>
<VL>66</VL>
<PG>1279-82</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241625"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780334"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bruera-1992a" MODIFIED="2013-02-07 09:53:51 +0000" MODIFIED_BY="[Empty name]" NAME="Bruera 1992a" YEAR="1992">
<REFERENCE MODIFIED="2013-02-07 09:53:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bruera E</AU>
<TI>Clinical management of anorexia and cachexia in patients with advanced cancer</TI>
<SO>Oncology</SO>
<YR>1992</YR>
<VL>49 Suppl 2</VL>
<PG>35-42</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241627"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241626"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bruera-1998" MODIFIED="2013-01-30 14:22:50 +0000" MODIFIED_BY="[Empty name]" NAME="Bruera 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-01-30 14:22:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bruera E, Scott E</AU>
<TI>Effectiveness of megestrol acetate in patients with advanced cancer: a randomized, double-blind, crossover study</TI>
<SO>Cancer Prevention and Control</SO>
<YR>1998</YR>
<VL>2</VL>
<NO>2</NO>
<PG>74-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2780337"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780336"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bruera-1998a" MODIFIED="2013-01-30 14:23:01 +0000" MODIFIED_BY="[Empty name]" NAME="Bruera 1998a" YEAR="1998">
<REFERENCE MODIFIED="2013-01-30 14:23:01 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 9540168&lt;br&gt;ST - MEDLINE&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Review&lt;br&gt;DC - 19980521&lt;/p&gt;" NOTES_MODIFIED="2013-01-30 14:23:01 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bruera E</AU>
<TI>Pharmacological treatment of cachexia: any progress? [Review]</TI>
<SO>Supportive Care in Cancer</SO>
<YR>1998</YR>
<VL>6</VL>
<NO>2</NO>
<PG>109-13</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241629"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241628"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cardona-2006" MODIFIED="2013-02-07 09:54:08 +0000" MODIFIED_BY="[Empty name]" NAME="Cardona 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-02-07 09:54:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cardona D</AU>
<TI>Pharmacological therapy of cancer anorexia-cachexia</TI>
<SO>Nutricion Hospitalaria</SO>
<YR>2006</YR>
<VL>21</VL>
<PG>Suppl 26</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241631"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241630"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carroll-2007" MODIFIED="2013-02-07 09:54:35 +0000" MODIFIED_BY="[Empty name]" NAME="Carroll 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-02-07 09:54:35 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Embase&lt;br&gt;UI - 2008581868&lt;/p&gt;" NOTES_MODIFIED="2013-02-07 09:54:35 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carroll JK, Kohli S, Mustian KM, Roscoe JA, Morrow GR</AU>
<TI>Pharmacologic treatment of cancer-related fatigue</TI>
<SO>Oncologist</SO>
<YR>2007</YR>
<VL>12</VL>
<NO>Suppl 1</NO>
<PG>43-51</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241633"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241632"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cat-1994" MODIFIED="2013-01-30 14:23:41 +0000" MODIFIED_BY="[Empty name]" NAME="Cat 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-01-30 14:23:41 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 8068997&lt;br&gt;ST - MEDLINE&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Review&lt;br&gt;DC - 19940923&lt;/p&gt;" NOTES_MODIFIED="2013-01-30 14:23:41 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cat LK, Coleman RL</AU>
<TI>Treatment for HIV wasting syndrome</TI>
<SO>Annals of Pharmacotherapy</SO>
<YR>1994</YR>
<VL>28</VL>
<NO>5</NO>
<PG>595-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241635"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241634"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Celik-2009" MODIFIED="2013-02-07 10:19:42 +0000" MODIFIED_BY="[Empty name]" NAME="Celik 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-02-07 10:19:42 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Celik T, Iyisoy A, Gundogdu F, Isik E</AU>
<TI>Chronic pulmonary cachexia syndrome: the role of anorexia</TI>
<SO>International Journal of Cardiology</SO>
<YR>2009</YR>
<VL>132</VL>
<NO>3</NO>
<PG>432-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241637"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241636"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-1997" MODIFIED="2013-02-07 09:54:58 +0000" MODIFIED_BY="[Empty name]" NAME="Chen 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-02-07 09:54:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen HC, Leung SW, Wang CJ, Sun LM, Fang FM, Hsu JH</AU>
<TI>Effect of megestrol acetate and prepulsid on nutritional improvement in patients with head and neck cancers undergoing radiotherapy</TI>
<SO>Radiotherapy and Oncology</SO>
<YR>1997</YR>
<VL>43</VL>
<PG>75-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241638"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780338"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chlebowski-1996" MODIFIED="2013-02-07 09:55:15 +0000" MODIFIED_BY="[Empty name]" NAME="Chlebowski 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-02-07 09:55:15 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 8850220&lt;br&gt;ST - MEDLINE&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Review&lt;br&gt;DC - 19961206&lt;/p&gt;" NOTES_MODIFIED="2013-02-07 09:55:15 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chlebowski RT, Palomares MR, Lillington L, Grosvenor M</AU>
<TI>Recent implications of weight loss in lung cancer management</TI>
<SO>Nutrition</SO>
<YR>1996</YR>
<VL>12</VL>
<NO>1 Suppl</NO>
<PG>S43-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241640"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241639"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Costero-2004" MODIFIED="2013-02-07 09:55:36 +0000" MODIFIED_BY="[Empty name]" NAME="Costero 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-02-07 09:55:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Costero O, Bajo MA, del Peso G, Gil F, Aguilera A, Ros S, et al</AU>
<TI>Treatment of anorexia and malnutrition in peritoneal dialysis patients with megestrol acetate</TI>
<SO>Advances in Peritoneal Dialysis</SO>
<YR>2004</YR>
<VL>20</VL>
<PG>209-21</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241641"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780342"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cruz-1990" MODIFIED="2013-01-30 14:25:49 +0000" MODIFIED_BY="[Empty name]" NAME="Cruz 1990" YEAR="1990">
<REFERENCE MODIFIED="2013-01-30 14:25:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cruz JM, Muss HB, Brockschmidt JK, Evans GW</AU>
<TI>Weight changes in women with metastatic breast cancer treated with megestrol acetate: a comparison of standard versus high-dose therapy</TI>
<SO>Seminars in Oncology</SO>
<YR>1990</YR>
<VL>17</VL>
<PG>63-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241643"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241642"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cuerda-1998" MODIFIED="2013-02-07 09:55:52 +0000" MODIFIED_BY="[Empty name]" NAME="Cuerda 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-02-07 09:55:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cuerda Compes M, Breton Lesmes I, Camblor Alvarez M, Garcia Peris P</AU>
<TI>Pharmacological modulation of the appetite</TI>
<SO>Nutricion Hospitalaria</SO>
<YR>1998</YR>
<VL>13</VL>
<NO>2</NO>
<PG>69-75</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241645"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241644"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Desport-2000" MODIFIED="2013-02-07 09:56:11 +0000" MODIFIED_BY="[Empty name]" NAME="Desport 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-02-07 09:56:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Desport JC, Blanc-Vincent MP, Gory-Delabaere G, Bachmann P, Beal J, Benamouzig R, et al</AU>
<TI>Standards, Options and Recommendations (SOR) for the use of appetite stimulants in oncology. Work group. Federation of the French Cancer Centres (FNCLCC)</TI>
<SO>Bulletin du Cancer</SO>
<YR>2000</YR>
<VL>87</VL>
<NO>4</NO>
<PG>315-28</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241647"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241646"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elovic-2000" MODIFIED="2013-02-07 09:56:32 +0000" MODIFIED_BY="[Empty name]" NAME="Elovic 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-02-07 09:56:32 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 20000727&lt;br&gt;IS - 0885-9701 (Print)&lt;br&gt;IS - 0885-9701 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Review&lt;br&gt;RN - 0 (Anabolic Agents)&lt;br&gt;RN - 0 (Psychotropic Drugs)&lt;br&gt;RN - 1972-08-3 (Tetrahydrocannabinol)&lt;br&gt;RN - 51154-23-5 (Megestrol Acetate)&lt;br&gt;RN - 57-83-0 (Progesterone)&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2013-02-07 09:56:32 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Elovic E</AU>
<TI>Pharmacological therapeutics in nutritional management</TI>
<SO>Journal of Head Trauma Rehabilitation</SO>
<YR>2000</YR>
<VL>15</VL>
<NO>3</NO>
<PG>962-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241649"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241648"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Erkurt-2000" MODIFIED="2013-02-07 09:56:48 +0000" MODIFIED_BY="[Empty name]" NAME="Erkurt 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-02-07 09:56:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Erkurt E, Erkisi M, Tunali C</AU>
<TI>Supportive treatment in weight-losing cancer patients due to the additive adverse effects of radiation treatment and/or chemotherapy</TI>
<SO>Journal of Experimental &amp; Clinical Cancer Research </SO>
<YR>2000</YR>
<VL>19</VL>
<PG>431-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241650"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780348"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Farmer-2005" MODIFIED="2013-02-07 09:57:10 +0000" MODIFIED_BY="[Empty name]" NAME="Farmer 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-02-07 09:57:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Farmer M, Case D, Lesser G, Monitto D, Smathers S, May B, et al</AU>
<TI>A phase III, double blind, placebo-controlled, prospective randomized trial on the effect of megestrol acetate on weight and health related quality of life in lung cancer and head and neck cancer patients receiving curative radiation therapy. Proceedings of the American Society for Therapeutic Radiology and Oncology, 47th.Annual Meeting; 2005 Oct 16-19; Denver, Colorado, USA</TI>
<SO>International Journal of Radiation Oncology Biology Physics</SO>
<YR>2005</YR>
<VL>63</VL>
<PG>S77-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241652"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241651"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Farrar-1999" MODIFIED="2013-02-07 10:20:17 +0000" MODIFIED_BY="[Empty name]" NAME="Farrar 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-02-07 10:20:17 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 10375262&lt;br&gt;ST - MEDLINE&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Review&lt;br&gt;DC - 19990616&lt;/p&gt;" NOTES_MODIFIED="2013-02-07 10:20:17 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Farrar DJ</AU>
<TI>Megestrol acetate: promises and pitfalls [Review]</TI>
<SO>Aids Patient Care and STDS</SO>
<YR>1999</YR>
<VL>13</VL>
<NO>3</NO>
<PG>149-52</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241654"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241653"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fearon-2002" MODIFIED="2013-01-30 14:29:09 +0000" MODIFIED_BY="[Empty name]" NAME="Fearon 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-01-30 14:29:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fearon KCH, Moses AGW</AU>
<TI>Cancer cachexia</TI>
<SO>International Journal of Cardiology</SO>
<YR>2002</YR>
<VL>85</VL>
<NO>1</NO>
<PG>73-81</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241656"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241655"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fossati-1998" MODIFIED="2013-02-07 09:57:25 +0000" MODIFIED_BY="[Empty name]" NAME="Fossati 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-02-07 09:57:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V, et al</AU>
<TI>Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1998</YR>
<VL>16</VL>
<NO>10</NO>
<PG>3439-60</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241658"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241657"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fox-2009" MODIFIED="2013-02-07 09:57:41 +0000" MODIFIED_BY="[Empty name]" NAME="Fox 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-02-07 09:57:41 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 20090327&lt;br&gt;IS - 1875-9114 (Electronic)&lt;br&gt;IS - 0277-0008 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Review&lt;br&gt;RN - 0 (Antidepressive Agents, Tricyclic)&lt;br&gt;RN - 0 (Appetite Stimulants)&lt;br&gt;RN - 24219-97-4 (Mianserin)&lt;br&gt;RN - 51154-23-5 (Megestrol Acetate)&lt;br&gt;RN - 61337-67-5 (mirtazapine)&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2013-02-07 09:57:41 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fox CB, Treadway AK, Blaszczyk AT, Sleeper RB</AU>
<TI>Megestrol acetate and mirtazepine for the treatment of unplanned weight loss in the elderly</TI>
<SO>Pharmacotherapy</SO>
<YR>2009</YR>
<VL>29</VL>
<NO>4</NO>
<PG>383-97</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241660"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241659"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Freyer-1996" MODIFIED="2013-02-07 09:57:54 +0000" MODIFIED_BY="[Empty name]" NAME="Freyer 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-02-07 09:57:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Freyer G, Catimel G, Merrouche Y</AU>
<TI>Synthetic progestational hormones in the treatment of neoplastic cachexia</TI>
<SO>Revue de Medecine Interne</SO>
<YR>1996</YR>
<VL>17</VL>
<NO>1</NO>
<PG>79-84</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241662"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241661"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Freyer-1996a" MODIFIED="2013-01-30 14:30:09 +0000" MODIFIED_BY="[Empty name]" NAME="Freyer 1996a" YEAR="1996">
<REFERENCE MODIFIED="2013-01-30 14:30:09 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Embase&lt;br&gt;UI - 1996037139&lt;br&gt;OT - UTILITE DES PROGESTATIFS DE SYNTHESE DANS LE TRAITEMENT DE LA CACHEXIE NEOPLASIQUE&lt;/p&gt;" NOTES_MODIFIED="2013-01-30 14:30:09 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Freyer G, Catimel G, Merrouche Y</AU>
<TI>Progesterone derivatives in cancer cachexia</TI>
<SO>Revue de Medecine Interne</SO>
<YR>1996</YR>
<VL>17</VL>
<NO>1</NO>
<PG>79-84</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241664"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241663"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gaducci-2001" MODIFIED="2013-02-07 09:58:08 +0000" MODIFIED_BY="[Empty name]" NAME="Gaducci 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-02-07 09:58:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gadducci A, Cosio S, Fanucchi A, Genazzani AR</AU>
<TI>Malnutrition and cachexia in ovarian cancer patients: pathophysiology and management</TI>
<SO>Anticancer Research</SO>
<YR>2011</YR>
<VL>21</VL>
<NO>4B</NO>
<PG>2941-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241666"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241665"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garg-2010" MODIFIED="2013-01-30 14:30:38 +0000" MODIFIED_BY="[Empty name]" NAME="Garg 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-30 14:30:38 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 19582484&lt;br&gt;ST - MEDLINE&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;PT - Review&lt;br&gt;DC - 20100521&lt;/p&gt;" NOTES_MODIFIED="2013-01-30 14:30:38 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garg S, Yoo J, Winquist E</AU>
<TI>Nutritional support for head and neck cancer patients receiving radiotherapy: a systematic review [Review]</TI>
<SO>Supportive Care in Cancer</SO>
<YR>2010</YR>
<VL>18</VL>
<NO>6</NO>
<PG>667-77</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241668"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241667"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gullett" MODIFIED="2013-02-07 09:58:23 +0000" MODIFIED_BY="[Empty name]" NAME="Gullett" YEAR="">
<REFERENCE MODIFIED="2013-02-07 09:58:23 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Embase&lt;br&gt;UI - 2011153407&lt;/p&gt;" NOTES_MODIFIED="2013-02-07 09:58:23 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gullett NP, Mazurak VC, Hebbar G, Ziegler TR</AU>
<TI>Nutritional Interventions for cancer-induced cachexia</TI>
<SO>Current Problems in Cancer</SO>
<YR>2011</YR>
<VL>35</VL>
<PG>58-90</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241670"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241669"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hanson-2011" MODIFIED="2013-02-07 09:58:35 +0000" MODIFIED_BY="[Empty name]" NAME="Hanson 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-02-07 09:58:35 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Embase&lt;br&gt;UI - 2011144498&lt;/p&gt;" NOTES_MODIFIED="2013-02-07 09:58:35 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hanson LC, Ersek M, Gilliam R, Carey TS</AU>
<TI>Oral feeding options for people with dementia: a systematic review</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>2011</YR>
<VL>59</VL>
<NO>3</NO>
<PG>463-72</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241672"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241671"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haren-2006" MODIFIED="2013-02-07 09:58:53 +0000" MODIFIED_BY="[Empty name]" NAME="Haren 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-02-07 09:58:53 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 16420220&lt;br&gt;ST - MEDLINE&lt;br&gt;CM - Comment on: J Am Geriatr Soc. 2005 Jun;53(6):970-5; PMID: 15935019&lt;br&gt;PT - Comment&lt;br&gt;PT - Letter&lt;br&gt;DC - 20060119&lt;/p&gt;" NOTES_MODIFIED="2013-02-07 09:58:53 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haren MT, Kim MJ, Kevorkian RT</AU>
<TI>Megestrol acetate for geriatric anorexia/cachexia</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>2006</YR>
<VL>54</VL>
<NO>1</NO>
<PG>172-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241674"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241673"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hellerstein-1990" MODIFIED="2013-02-07 09:59:13 +0000" MODIFIED_BY="[Empty name]" NAME="Hellerstein 1990" YEAR="1990">
<REFERENCE MODIFIED="2013-02-07 09:59:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hellerstein MK, Kahn J, Mudie H, Viteri F</AU>
<TI>Current approach to the treatment of human immunodeficiency virus-associated weight loss: pathophysiologic considerations and emerging management strategies</TI>
<SO>Seminars in Oncology</SO>
<YR>1990</YR>
<VL>17</VL>
<NO>6 Suppl 9</NO>
<PG>33</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241676"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241675"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoffman-1998" MODIFIED="2013-01-31 11:32:56 +0000" MODIFIED_BY="[Empty name]" NAME="Hoffman 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-01-31 08:47:35 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Para revisar si es un eca y si vale que figure aqui pues no aporta datos de ningun tipo&lt;/p&gt;" NOTES_MODIFIED="2013-01-31 08:47:35 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hoffman KR, Green NJ</AU>
<TI>Megestrol acetate (Megace) to prevent cachexia and marasmus in elderly cancer patients (Meeting abstract no 233)</TI>
<SO>ASCO Annual Meeting</SO>
<YR>1998</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241677"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780354"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Inui-2002" MODIFIED="2013-01-31 08:47:57 +0000" MODIFIED_BY="[Empty name]" NAME="Inui 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-01-31 08:47:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Inui A</AU>
<TI>Cancer anorexia-cachexia syndrome: current issues in research and management</TI>
<SO>CA: A Cancer Journal for Clinicians</SO>
<YR>2002</YR>
<VL>52</VL>
<PG>72-91</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241679"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241678"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jatoi-2001" MODIFIED="2013-02-07 09:59:40 +0000" MODIFIED_BY="[Empty name]" NAME="Jatoi 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-02-07 09:59:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jatoi A, Loprinzi CL</AU>
<TI>An update: cancer-associated anorexia as a treatment target</TI>
<SO>Current Opinion in Clinical Nutrition and Metabolic Care</SO>
<YR>2001</YR>
<VL>4</VL>
<NO>3</NO>
<PG>179-82</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241681"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241680"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kalantar_x002d_Zadeh-2008" MODIFIED="2013-01-31 08:49:44 +0000" MODIFIED_BY="[Empty name]" NAME="Kalantar-Zadeh 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-01-31 08:49:44 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 20080602&lt;br&gt;IS - 0002-9149 (Print)&lt;br&gt;IS - 0002-9149 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Research Support, N.I.H., Extramural&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;PT - Review&lt;br&gt;RN - 0 (Amino Acids)&lt;br&gt;RN - 0 (Antioxidants)&lt;br&gt;RN - 0 (Appetite Stimulants)&lt;br&gt;RN - 0 (Free Radical Scavengers)&lt;br&gt;RN - 51154-23-5 (Megestrol Acetate)&lt;br&gt;RN - 6493-05-6 (Pentoxifylline)&lt;br&gt;SB - AIM&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2013-01-31 08:49:44 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kalantar-Zadeh K, Anker SD, Horwich TB, Fonarow GC</AU>
<TI>Nutritional and anti-inflammatory interventions in chronic heart failure</TI>
<SO>American Journal of Cardiology</SO>
<YR>2008</YR>
<VL>101</VL>
<PG>89E-103E</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241683"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241682"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karcic-2002" MODIFIED="2013-02-07 09:59:53 +0000" MODIFIED_BY="[Empty name]" NAME="Karcic 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-02-07 09:59:53 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 20020801&lt;br&gt;IS - 1279-7707 (Print)&lt;br&gt;IS - 1279-7707 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Review&lt;br&gt;RN - 0 (Appetite Stimulants)&lt;br&gt;RN - 51154-23-5 (Megestrol Acetate)&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2013-02-07 09:59:53 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karcic E, Philpot C, Morley JE</AU>
<TI>Treating malnutrition with megestrol acetate: literature review and review of our experience</TI>
<SO>Journal of Nutrition, Health, and Aging</SO>
<YR>2002</YR>
<VL>6</VL>
<PG>191-200</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241685"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241684"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Khojasteh-1996" MODIFIED="2012-01-15 21:17:36 +0000" MODIFIED_BY="[Empty name]" NAME="Khojasteh 1996" YEAR="1996">
<REFERENCE MODIFIED="2012-01-15 21:17:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Khojasteh A, Khojasteh S, Reynolds R</AU>
<TI>Combined nortriptyline + megestrol acetate regimen for cancer anorexia-cachexia syndrome [abstract]</TI>
<SO>Proceedings of the American Society of Clinical Oncology</SO>
<YR>1996</YR>
<VL>15</VL>
<PG>451</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241686"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780356"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Krznaric-2007" MODIFIED="2013-02-07 10:00:21 +0000" MODIFIED_BY="[Empty name]" NAME="Krznaric 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-02-07 10:00:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Krznaric Z, Juretic A, Samija M, Dintinjana RD, Vrdoljak E, Samarzija M, et al</AU>
<TI>Croatian guidelines for use of eicosapentaenoic acid and megestrol acetate in cancer cachexia syndrome [Croatian]</TI>
<SO>Lijecnicki Vjesnik</SO>
<YR>2007</YR>
<VL>129</VL>
<PG>381-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241688"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241687"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kumar-2010" MODIFIED="2013-02-07 10:00:38 +0000" MODIFIED_BY="[Empty name]" NAME="Kumar 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-02-07 10:00:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kumar NB, Kazi A, Smith T, Crocker T, Yu D, Reich RR, et al</AU>
<TI>Cancer cachexia: traditional therapies and novel molecular mechanism-based approaches to treatment</TI>
<SO>Current Treatment Options in Oncology</SO>
<YR>2010</YR>
<VL>11</VL>
<PG>107-17</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241690"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241689"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lai-1994" MODIFIED="2013-02-07 10:01:01 +0000" MODIFIED_BY="[Empty name]" NAME="Lai 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-02-07 10:01:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lai YL, Fang FM, Yeh CY</AU>
<TI>Management of anorexic patients in radiotherapy: a prospective randomized comparison of megestrol and prednisolone</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>1994</YR>
<VL>9</VL>
<PG>265-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241691"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780360"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lelli-2003" MODIFIED="2013-01-31 08:56:31 +0000" MODIFIED_BY="[Empty name]" NAME="Lelli 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-01-31 08:56:31 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 20030718&lt;br&gt;IS - 1120-009X (Print)&lt;br&gt;IS - 1120-009X (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Review&lt;br&gt;RN - 364-62-5 (Metoclopramide)&lt;br&gt;RN - 51154-23-5 (Megestrol Acetate)&lt;br&gt;RN - 71-58-9 (Medroxyprogesterone Acetate)&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2013-01-31 08:56:31 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lelli G, Montanari M, Gilli G, Scapoli D, Antonietti C, Scapoli D</AU>
<TI>Treatment of the cancer anorexia-cachexia syndrome: a critical reappraisal</TI>
<SO>Journal of Chemotherapy</SO>
<YR>2003</YR>
<VL>15</VL>
<PG>220-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241693"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241692"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lesniak-2008" MODIFIED="2013-02-07 10:01:17 +0000" MODIFIED_BY="[Empty name]" NAME="Lesniak 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-02-07 10:01:17 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lesniak W, Bala M, Jaeschke R, Krzakowski M</AU>
<TI>Effects of megestrol acetate in patients with cancer anorexia-cachexia syndrome--a systematic review and meta-analysis</TI>
<SO>Polskie Archiwum Medycyny Wewn&#281;trznej</SO>
<YR>2008</YR>
<VL>118</VL>
<PG>636-44</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241695"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241694"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Loprinzi-1992" MODIFIED="2012-01-15 21:32:50 +0000" MODIFIED_BY="[Empty name]" NAME="Loprinzi 1992" YEAR="1992">
<REFERENCE MODIFIED="2012-01-15 21:32:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Loprinzi CL, Goldberg RM, Burnham NL</AU>
<TI>Cancer-associated anorexia and cachexia. Implications for drug therapy</TI>
<SO>Drugs</SO>
<YR>1992</YR>
<VL>43</VL>
<PG>499-506</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241697"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241696"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Loprinzi-1992a" MODIFIED="2012-01-15 21:33:05 +0000" MODIFIED_BY="[Empty name]" NAME="Loprinzi 1992a" YEAR="1992">
<REFERENCE MODIFIED="2012-01-15 21:33:05 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 19930108&lt;br&gt;IS - 0030-2414 (Print)&lt;br&gt;IS - 0030-2414 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Clinical Trial&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;RN - 3562-63-8 (Megestrol)&lt;br&gt;RN - 51154-23-5 (Megestrol Acetate)&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2012-01-15 21:33:05 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Loprinzi CL, Johnson PA, Jensen M</AU>
<TI>Megestrol acetate for anorexia and cachexia</TI>
<SO>Oncology</SO>
<YR>1992</YR>
<VL>49 Suppl 2</VL>
<PG>46-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241699"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241698"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Loprinzi-1993" MODIFIED="2013-01-31 08:57:34 +0000" MODIFIED_BY="[Empty name]" NAME="Loprinzi 1993" YEAR="1993">
<REFERENCE MODIFIED="2013-01-31 08:57:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Loprinzi CL, Schaid DJ, Dose AM, Burnham NL, Jensen MD</AU>
<TI>Body-composition changes in patients who gain weight while receiving megestrol acetate</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1993</YR>
<VL>11</VL>
<PG>152-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241700"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780364"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Loprinzi-1995" MODIFIED="2013-01-31 08:57:44 +0000" MODIFIED_BY="[Empty name]" NAME="Loprinzi 1995" YEAR="1995">
<REFERENCE MODIFIED="2013-01-31 08:57:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Loprinzi CL</AU>
<TI>Management of cancer anorexia/cachexia</TI>
<SO>Supportive Care in Cancer</SO>
<YR>1995</YR>
<VL>3</VL>
<PG>120-2</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241702"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241701"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mak-2007" MODIFIED="2013-01-31 08:57:56 +0000" MODIFIED_BY="[Empty name]" NAME="Mak 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-01-31 08:57:56 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Embase&lt;br&gt;UI - 2007617937&lt;/p&gt;" NOTES_MODIFIED="2013-01-31 08:57:56 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mak RH, Cheung W</AU>
<TI>Therapeutic strategy for cachexia in chronic kidney disease</TI>
<SO>Current Opinion in Nephrology and Hypertension</SO>
<YR>2007</YR>
<VL>16</VL>
<PG>542-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241704"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241703"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malone-2005" MODIFIED="2013-01-31 08:58:04 +0000" MODIFIED_BY="[Empty name]" NAME="Malone 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-01-31 08:58:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malone M</AU>
<TI>Medications associated with weight gain</TI>
<SO>Annals of Pharmacotherapy</SO>
<YR>2005</YR>
<VL>39</VL>
<PG>2046-55</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241706"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241705"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maltoni-2001a" MODIFIED="2013-01-31 08:58:34 +0000" MODIFIED_BY="[Empty name]" NAME="Maltoni 2001a" YEAR="2001">
<REFERENCE MODIFIED="2013-01-31 08:58:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maltoni M, Nanni O, Scarpi E, Rossi D, Serra P, Amadori D</AU>
<TI>High-dose progestins for the treatment of cancer anorexia-cachexia syndrome: a systematic review of randomised clinical trials</TI>
<SO>Annals of Oncology</SO>
<YR>2001</YR>
<VL>12</VL>
<PG>289-300</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241708"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241707"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mantovani-1998a" MODIFIED="2013-01-31 08:58:57 +0000" MODIFIED_BY="[Empty name]" NAME="Mantovani 1998a" YEAR="1998">
<REFERENCE MODIFIED="2013-01-31 08:58:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mantovani G, Maccio A, Lai P, Massa E, Ghiani M, Santona MC</AU>
<TI>Cytokine involvement in cancer anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate on cytokine downregulation and improvement of clinical symptoms</TI>
<SO>Critical Reviews in Oncogenesis</SO>
<YR>1998</YR>
<VL>9</VL>
<PG>99-106</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241710"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241709"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mantovani-2001" MODIFIED="2012-01-15 21:42:10 +0000" MODIFIED_BY="[Empty name]" NAME="Mantovani 2001" YEAR="2001">
<REFERENCE MODIFIED="2012-01-15 21:42:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mantovani G, Maccio A, Massa E, Madeddu C</AU>
<TI>Managing cancer-related anorexia/cachexia</TI>
<SO>Drugs</SO>
<YR>2001</YR>
<VL>61</VL>
<PG>499-514</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241712"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241711"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mantovani-2008" MODIFIED="2013-02-07 10:01:52 +0000" MODIFIED_BY="[Empty name]" NAME="Mantovani 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-02-07 10:01:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mantovani G, Macciò A, Madeddu C, Gramignano G, Serpe R, Massa E, et al</AU>
<TI>Randomized phase III clinical trial of five different arms of treatment for patients with cancer cachexia: interim results</TI>
<SO>Nutrition</SO>
<YR>2008</YR>
<VL>24</VL>
<PG>305-13</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241713"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780368"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mantovani-2010" MODIFIED="2011-12-17 18:05:45 +0000" MODIFIED_BY="[Empty name]" NAME="Mantovani 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-12-17 18:05:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mantovani G, Maccio A, Madeddu C, Serpe R, Massa E, Dessi M, et al</AU>
<TI>Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia</TI>
<SO>Oncologist</SO>
<YR>2010</YR>
<VL>15</VL>
<PG>200-11</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241714"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780370"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marchand-2000" MODIFIED="2013-01-31 09:00:23 +0000" MODIFIED_BY="[Empty name]" NAME="Marchand 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-01-31 09:00:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marchand V, Baker SS</AU>
<TI>Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis</TI>
<SO>Journal of Pediatric Gastroenterology and Nutrition</SO>
<YR>2000</YR>
<VL>31</VL>
<PG>264-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241715"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780372"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mateen-2006" MODIFIED="2013-01-31 09:00:33 +0000" MODIFIED_BY="[Empty name]" NAME="Mateen 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-01-31 09:00:33 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 20060929&lt;br&gt;IS - 0261-5614 (Print)&lt;br&gt;IS - 0261-5614 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Review&lt;br&gt;RN - 0 (Antineoplastic Agents, Hormonal)&lt;br&gt;RN - 51154-23-5 (Megestrol Acetate)&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2013-01-31 09:00:33 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mateen F, Jatoi A</AU>
<TI>Megestrol acetate for the palliation of anorexia in advanced, incurable cancer patients</TI>
<SO>Clinical Nutrition</SO>
<YR>2006</YR>
<VL>25</VL>
<PG>711-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241717"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241716"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McHugh-2011" MODIFIED="2013-02-07 10:02:20 +0000" MODIFIED_BY="[Empty name]" NAME="McHugh 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-02-07 10:02:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McHugh ME, Miller-Saultz D</AU>
<TI>Assessment and management of gastrointestinal symptoms in advanced illness</TI>
<SO>Primary Care</SO>
<YR>2011</YR>
<VL>38</VL>
<PG>225-46</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241719"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241718"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McMillan-1999" MODIFIED="2013-02-07 10:02:36 +0000" MODIFIED_BY="[Empty name]" NAME="McMillan 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-02-07 10:02:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McMillan DC, Wigmore SJ</AU>
<TI>A prospective randomised study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss</TI>
<SO>British Journal of Cancer</SO>
<YR>1999</YR>
<VL>79</VL>
<PG>495-500</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241720"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780374"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McQuellon-2002" MODIFIED="2013-02-07 10:02:50 +0000" MODIFIED_BY="[Empty name]" NAME="McQuellon 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-02-07 10:02:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McQuellon RP, Moose DB, Russell GB, Case LD, Greven K, Stevens M, et al</AU>
<TI>Supportive use of megestrol acetate (Megace) with head/neck and lung cancer patients receiving radiation therapy</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2002</YR>
<VL>52</VL>
<PG>1180-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241721"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780376"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Monfared-2009" MODIFIED="2013-01-31 09:01:57 +0000" MODIFIED_BY="[Empty name]" NAME="Monfared 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-31 09:01:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Monfared A, Heidarzadeh A, Ghaffari M, Akbarpour M</AU>
<TI>Effect of megestrol acetate on serum albumin level in malnourished dialysis patients</TI>
<SO>Journal of Renal Nutrition</SO>
<YR>2009</YR>
<VL>19</VL>
<PG>167-71</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241722"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780378"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mor_x00e1_n-1998" MODIFIED="2013-02-07 10:03:17 +0000" MODIFIED_BY="[Empty name]" NAME="Morán 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-02-07 10:03:17 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morán S, Ortega R, Garcia G, Uribe M</AU>
<TI>Megestrol acetate improve appetite and induce anti-catabolic effect in post-hepatitis C cirrhotic patients. A double-blind placebo-controlled clinical trial [Abstract 80]</TI>
<SO>Hepatology</SO>
<YR>1998</YR>
<VL>28</VL>
<PG>609A</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241723"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780380"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morley-2002" MODIFIED="2013-02-07 10:03:27 +0000" MODIFIED_BY="[Empty name]" NAME="Morley 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-02-07 10:03:27 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 20030228&lt;br&gt;IS - 0749-0690 (Print)&lt;br&gt;IS - 0749-0690 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Review&lt;br&gt;RN - 0 (Analgesics, Non-Narcotic)&lt;br&gt;RN - 0 (Appetite Stimulants)&lt;br&gt;RN - 1972-08-3 (Tetrahydrocannabinol)&lt;br&gt;RN - 51154-23-5 (Megestrol Acetate)&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2013-02-07 10:03:27 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morley JE</AU>
<TI>Orexigenic and anabolic agents</TI>
<SO>Clinics in Geriatric Medicine</SO>
<YR>2002</YR>
<VL>18</VL>
<PG>853-66</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241725"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241724"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mulligan-2007" MODIFIED="2013-02-07 10:03:43 +0000" MODIFIED_BY="[Empty name]" NAME="Mulligan 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-02-07 10:03:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mulligan K, Zackin R, Von-Roenn JH, Chesney MA, Egorin MJ, Sattler FR, et al</AU>
<TI>Testosterone supplementation of megestrol therapy does not enhance lean tissue accrual in men with human immunodeficiency virus-associated weight loss: a randomized, double-blind, placebo-controlled, multicenter trial</TI>
<SO>Journal of Clinical Endocrinology and Metabolism</SO>
<YR>2007</YR>
<VL>92</VL>
<PG>563-70</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241726"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780382"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muss-1990" MODIFIED="2013-02-07 10:03:58 +0000" MODIFIED_BY="[Empty name]" NAME="Muss 1990" YEAR="1990">
<REFERENCE MODIFIED="2013-02-07 10:03:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Muss HB, Case LD, Capizzi RL, Cooper MR, Cruz J, Jackson D, et al</AU>
<TI>High- versus standard-dose megestrol acetate in women with advanced breast cancer: a phase III trial of the Piedmont Oncology Association</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1990</YR>
<VL>8</VL>
<PG>1797-805</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241727"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780384"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Navari-2010" MODIFIED="2013-01-31 09:07:50 +0000" MODIFIED_BY="[Empty name]" NAME="Navari 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-31 09:07:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Navari RM, Brenner MC</AU>
<TI>Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial</TI>
<SO>Supportive Care in Cancer</SO>
<YR>2010</YR>
<VL>18</VL>
<PG>951-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241728"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780386"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nelson-2002" MODIFIED="2013-01-31 09:08:10 +0000" MODIFIED_BY="[Empty name]" NAME="Nelson 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-01-31 09:08:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nelson KA, Walsh D, Hussein M</AU>
<TI>A phase II study of low-dose megestrol acetate using twice-daily dosing for anorexia in nonhormonally dependent cancer</TI>
<SO>American Journal of Hospice and Palliative Care</SO>
<YR>2002</YR>
<VL>19</VL>
<PG>206-10</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241729"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780402"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Osoba-1994" MODIFIED="2013-02-07 10:04:23 +0000" MODIFIED_BY="[Empty name]" NAME="Osoba 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-02-07 10:04:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Osoba D, Murray N, Gelmon K, Karsai H, Knowling MA, Shah A, et al</AU>
<TI>Phase II trial of megestrol in the supportive care of patients receiving dose-intensive chemotherapy</TI>
<SO>Oncology</SO>
<YR>1994</YR>
<VL>8</VL>
<PG>43-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241730"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780404"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pardo-2003a" MODIFIED="2013-02-07 10:04:40 +0000" MODIFIED_BY="[Empty name]" NAME="Pardo 2003a" YEAR="2003">
<REFERENCE MODIFIED="2013-02-07 10:04:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pardo J, Mena AM, Montsech L</AU>
<TI>Megestrol acetate for anorexia in lung cancer patients undergoing radiation therapy. A randomized trial comparing the efficacy of two different doses in 130 patients [Abstract 3076]</TI>
<SO>Proceedings of the American Society of Clinical Oncology</SO>
<YR>2003</YR>
<VL>22</VL>
<PG>765</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241732"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241731"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pardo-2006" MODIFIED="2013-02-07 10:04:55 +0000" MODIFIED_BY="[Empty name]" NAME="Pardo 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-02-07 10:04:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pardo J, Mena A, Monleon A, Macias V, Sole J, Hernandez M, et al</AU>
<TI>Reversal of anorexia with megestrol acetate (MA): impact on quality of life (QoL) in non-metastatic lung cancer patients (pts) undergoing radiation therapy</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2006</YR>
<VL>24</VL>
<PG>18613</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241733"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780408"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pascual-2004" MODIFIED="2013-01-31 09:10:09 +0000" MODIFIED_BY="[Empty name]" NAME="Pascual 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-01-31 09:10:09 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 20040330&lt;br&gt;IS - 0885-3924 (Print)&lt;br&gt;IS - 0885-3924 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;PT - Review&lt;br&gt;RN - 51154-23-5 (Megestrol Acetate)&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2013-01-31 09:10:09 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pascual Lopez A, Figuls M, Urrutia Cuchi G, Berenstein EG, Almenar Pasies B, Balcells Alegre M, et al</AU>
<TI>Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>2004</YR>
<VL>27</VL>
<PG>360-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241735"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241734"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pruthi-2007" MODIFIED="2013-02-07 10:05:20 +0000" MODIFIED_BY="[Empty name]" NAME="Pruthi 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-02-07 10:05:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pruthi S, Boughey JC, Brandt KR, Degnim AC, Dy GK, Goetz MP, et al</AU>
<TI>A multidisciplinary approach to the management of breast cancer, part 2: Therapeutic considerations</TI>
<SO>Mayo Clinic Proceedings</SO>
<YR>2007</YR>
<VL>82</VL>
<PG>1131-40</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241737"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241736"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reuben-2005" MODIFIED="2013-01-31 09:10:38 +0000" MODIFIED_BY="[Empty name]" NAME="Reuben 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-01-31 09:10:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reuben DB, Hirsch SH, Zhou K, Greendale GA</AU>
<TI>The effects of megestrol acetate suspension for elderly patients with reduced appetite after hospitalization: a phase II randomized clinical trial</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>2005</YR>
<VL>53</VL>
<PG>970-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241738"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780410"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ross-2001" MODIFIED="2013-01-31 09:13:06 +0000" MODIFIED_BY="[Empty name]" NAME="Ross 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-01-31 09:13:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ross DD, Alexander CS</AU>
<TI>Management of common symptoms in terminally ill patients: Part I. Fatigue, anorexia, cachexia, nausea and vomiting</TI>
<SO>American Family Physician</SO>
<YR>2001</YR>
<VL>64</VL>
<PG>807-14</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241740"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241739"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rowland-1996" MODIFIED="2013-02-07 10:05:42 +0000" MODIFIED_BY="[Empty name]" NAME="Rowland 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-02-07 10:05:42 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rowland KM, Loprinzi CL</AU>
<TI>Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group Study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1996</YR>
<VL>14</VL>
<PG>135-41</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241741"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780412"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ruiz_x002d_Garcia-2002" MODIFIED="2013-02-07 10:06:01 +0000" MODIFIED_BY="[Empty name]" NAME="Ruiz-Garcia 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-02-07 10:06:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ruiz-Garcia V, Juan O, Perez Hoyos S, Peiro R, Ramon N, Rosero MA, et al</AU>
<TI>Megestrol acetate: a systematic review usefulness about the weight gain in neoplastic patients with cachexia</TI>
<SO>Medicina Clinica</SO>
<YR>2002</YR>
<VL>119</VL>
<PG>166-70</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241742"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780414"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sanz_x002d_Ortiz-2004" MODIFIED="2013-01-31 09:13:56 +0000" MODIFIED_BY="[Empty name]" NAME="Sanz-Ortiz 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-01-31 09:13:56 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sanz-Ortiz J</AU>
<TI>Anorexia treatment in the oncological patient</TI>
<SO>Revista Clinica Espanola</SO>
<YR>2004</YR>
<VL>204</VL>
<PG>542-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241744"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241743"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schacter-1989" MODIFIED="2013-02-13 09:50:15 +0000" MODIFIED_BY="[Empty name]" NAME="Schacter 1989" YEAR="1989">
<REFERENCE MODIFIED="2013-02-13 09:50:15 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 2471590&lt;br&gt;ST - MEDLINE&lt;br&gt;PT - Comparative Study&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Review&lt;br&gt;DC - 19890720&lt;/p&gt;" NOTES_MODIFIED="2013-02-13 09:50:15 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schacter L, Rozencweig M, Canetta R, Kelley S, Nicaise C, Smaldone L</AU>
<TI>Megestrol acetate: clinical experience [Review]</TI>
<SO>Cancer Treatment Reviews</SO>
<YR>1989</YR>
<VL>16</VL>
<PG>49-63</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241746"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241745"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmoll-1992a" MODIFIED="2012-01-15 22:00:13 +0000" MODIFIED_BY="[Empty name]" NAME="Schmoll 1992a" YEAR="1992">
<REFERENCE MODIFIED="2012-01-15 22:00:13 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 19930108&lt;br&gt;IS - 0030-2414 (Print)&lt;br&gt;IS - 0030-2414 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Clinical Trial&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;RN - 3562-63-8 (Megestrol)&lt;br&gt;RN - 51154-23-5 (Megestrol Acetate)&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2012-01-15 22:00:13 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schmoll E</AU>
<TI>Risks and benefits of various therapies for cancer anorexia</TI>
<SO>Oncology</SO>
<YR>1992</YR>
<VL>49 Suppl 2</VL>
<PG>43-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241748"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241747"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simmons-2004" MODIFIED="2013-02-07 10:06:20 +0000" MODIFIED_BY="[Empty name]" NAME="Simmons 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-02-07 10:06:20 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 20040106&lt;br&gt;IS - 1525-8610 (Print)&lt;br&gt;IS - 1525-8610 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Clinical Trial&lt;br&gt;PT - Controlled Clinical Trial&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Multicenter Study&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;PT - Research Support, U.S. Gov't, P.H.S&lt;br&gt;RN - 51154-23-5 (Megestrol Acetate)&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2013-02-07 10:06:20 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simmons SF, Walker KA, Osterweil D</AU>
<TI>The effect of megestrol acetate on oral food and fluid intake in nursing home residents: a pilot study</TI>
<SO>Journal of the American Medical Directors Association</SO>
<YR>2004</YR>
<VL>5</VL>
<PG>24-30</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241749"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780416"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Skarlos-1993" MODIFIED="2013-01-31 09:15:25 +0000" MODIFIED_BY="[Empty name]" NAME="Skarlos 1993" YEAR="1993">
<REFERENCE MODIFIED="2013-01-31 09:15:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Skarlos DV, Fountzilas G, Pavlidis N, Beer M, Makrantonakis P, Aravantinos G, et al</AU>
<TI>Megestrol acetate in cancer patients with anorexia and weight loss. A Hellenic Co-operative Oncology Group (HeCOG) study</TI>
<SO>Acta Oncologica</SO>
<YR>1993</YR>
<VL>32</VL>
<PG>37-41</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241750"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780418"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spaulding-1989" MODIFIED="2013-02-07 10:21:17 +0000" MODIFIED_BY="[Empty name]" NAME="Spaulding 1989" YEAR="1989">
<REFERENCE MODIFIED="2013-02-07 10:21:17 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 2701575&lt;br&gt;ST - MEDLINE&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Review&lt;br&gt;DC - 19900928&lt;/p&gt;" NOTES_MODIFIED="2013-02-07 10:21:17 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spaulding M</AU>
<TI>Recent studies of anorexia and appetite stimulation in the cancer patient</TI>
<SO>Oncology</SO>
<YR>1989</YR>
<VL>3</VL>
<NO>8 Suppl</NO>
<PG>18-23</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241752"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241751"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sullivan-2007" MODIFIED="2013-01-31 09:15:46 +0000" MODIFIED_BY="[Empty name]" NAME="Sullivan 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-01-31 09:15:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sullivan DH, Roberson PK, Smith ES, Price JA, Bopp MM</AU>
<TI>Effects of muscle strength training and megestrol acetate on strength, muscle mass, and function in frail older people</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>2007</YR>
<VL>55</VL>
<PG>20-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241753"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780420"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tchekmedyian-1986" MODIFIED="2013-02-07 10:06:43 +0000" MODIFIED_BY="[Empty name]" NAME="Tchekmedyian 1986" YEAR="1986">
<REFERENCE MODIFIED="2013-02-07 10:06:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tchekmedyian NS, Tait N, Aisner J</AU>
<TI>High dose megestrol acetate in the treatment of postmenopausal women with advanced breast cancer</TI>
<SO>Seminars in Oncology</SO>
<YR>1986</YR>
<VL>13</VL>
<PG>20-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241754"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780422"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tchekmedyian-1990" MODIFIED="2013-02-07 10:06:57 +0000" MODIFIED_BY="[Empty name]" NAME="Tchekmedyian 1990" YEAR="">
<REFERENCE MODIFIED="2013-02-07 10:06:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tchekmedyian NS, Hickman M, Siau J, Greco A, Aisner J</AU>
<TI>Treatment of cancer anorexia with megestrol acetate: impact on quality of life</TI>
<SO>Oncology</SO>
<YR>1990</YR>
<VL>4</VL>
<PG>185-92</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241755"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780424"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tchekmedyian-1991" MODIFIED="2013-01-31 09:16:13 +0000" MODIFIED_BY="[Empty name]" NAME="Tchekmedyian 1991" YEAR="1991">
<REFERENCE MODIFIED="2013-01-31 09:16:13 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 19910311&lt;br&gt;IS - 0093-7754 (Print)&lt;br&gt;IS - 0093-7754 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Clinical Trial&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;RN - 3562-63-8 (Megestrol)&lt;br&gt;RN - 51154-23-5 (Megestrol Acetate)&lt;br&gt;SB - IM&lt;br&gt;SB - X&lt;/p&gt;" NOTES_MODIFIED="2013-01-31 09:16:13 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tchekmedyian NS, Hickman M, Heber D</AU>
<TI>Treatment of anorexia and weight loss with megestrol acetate in patients with cancer or acquired immunodeficiency syndrome</TI>
<SO>Seminars in Oncology</SO>
<YR>1991</YR>
<VL>18 Suppl 2</VL>
<PG>35-42</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241757"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241756"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tchekmedyian-1993" MODIFIED="2013-01-31 09:16:26 +0000" MODIFIED_BY="[Empty name]" NAME="Tchekmedyian 1993" YEAR="1993">
<REFERENCE MODIFIED="2013-01-31 09:16:26 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tchekmedyian NS</AU>
<TI>Clinical approaches to nutritional support in cancer</TI>
<SO>Current Opinion in Oncology</SO>
<YR>1993</YR>
<VL>5</VL>
<PG>633-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241759"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241758"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tchekmedyian-1993a" MODIFIED="2013-01-31 09:16:39 +0000" MODIFIED_BY="[Empty name]" NAME="Tchekmedyian 1993a" YEAR="1993">
<REFERENCE MODIFIED="2013-01-31 09:16:39 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 19940224&lt;br&gt;IS - 0884-5336 (Print)&lt;br&gt;IS - 0884-5336 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Review&lt;br&gt;RN - 3562-63-8 (Megestrol)&lt;br&gt;RN - 51154-23-5 (Megestrol Acetate)&lt;br&gt;SB - N&lt;br&gt;SB - X&lt;/p&gt;" NOTES_MODIFIED="2013-01-31 09:16:39 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tchekmedyian NS</AU>
<TI>Treatment of anorexia with megestrol acetate</TI>
<SO>Nutrition in Clinical Practice</SO>
<YR>1993</YR>
<VL>8</VL>
<PG>115-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241761"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241760"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tchekmedyian-2006" MODIFIED="2013-02-07 10:07:18 +0000" MODIFIED_BY="[Empty name]" NAME="Tchekmedyian 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-02-07 10:07:18 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Embase&lt;br&gt;UI - 2007040440&lt;/p&gt;" NOTES_MODIFIED="2013-02-07 10:07:18 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tchekmedyian NS</AU>
<TI>Treating the anorexia/cachexia syndrome</TI>
<SO>Journal of Supportive Oncology</SO>
<YR>2006</YR>
<VL>4</VL>
<PG>506-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241763"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241762"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thomas-2006" MODIFIED="2013-02-07 10:07:31 +0000" MODIFIED_BY="[Empty name]" NAME="Thomas 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-02-07 10:07:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thomas DR</AU>
<TI>Guidelines for the use of orexigenic drugs in long-term care</TI>
<SO>Nutrition in Clinical Practice</SO>
<YR>2006</YR>
<VL>21</VL>
<PG>82-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241765"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241764"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tisdale-1993" MODIFIED="2012-01-15 22:20:09 +0000" MODIFIED_BY="[Empty name]" NAME="Tisdale 1993" YEAR="1993">
<REFERENCE MODIFIED="2012-01-15 22:20:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tisdale MJ</AU>
<TI>Cancer cachexia</TI>
<SO>Anti-Cancer Drugs</SO>
<YR>1993</YR>
<VL>4</VL>
<PG>115-25</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241767"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241766"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tisdale-2006" MODIFIED="2013-01-31 09:17:56 +0000" MODIFIED_BY="[Empty name]" NAME="Tisdale 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-01-31 09:17:56 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tisdale MJ</AU>
<TI>Clinical anticachexia treatments</TI>
<SO>Nutrition in Clinical Practice</SO>
<YR>2006</YR>
<VL>21</VL>
<PG>168-74</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241769"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241768"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tomiska-2003" MODIFIED="2013-02-13 09:49:02 +0000" MODIFIED_BY="[Empty name]" NAME="Tomiska 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-02-13 09:49:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tomíska M, Tomisková M, Salajka F, Adam Z, Vorlícek J</AU>
<TI>Palliative treatment of cancer anorexia with oral suspension of megestrol acetate</TI>
<SO>Neoplasma</SO>
<YR>2003</YR>
<VL>50</VL>
<PG>227-33</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241770"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780426"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vigano-1994" MODIFIED="2013-01-31 09:18:32 +0000" MODIFIED_BY="[Empty name]" NAME="Vigano 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-01-31 09:18:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vigano A, Watanabe S, Bruera E</AU>
<TI>Anorexia and cachexia in advanced cancer patients</TI>
<SO>Cancer Surveys</SO>
<YR>1994</YR>
<VL>21</VL>
<PG>99-115</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241772"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241771"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-von-Haehling-2009" MODIFIED="2013-02-07 10:07:53 +0000" MODIFIED_BY="[Empty name]" NAME="von Haehling 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-02-07 10:07:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>von Haehling S, Lainscak M, Springer J, Anker SD</AU>
<TI>Cardiac cachexia: a systematic overview</TI>
<SO>Pharmacology &amp; Therapeutics</SO>
<YR>2009</YR>
<VL>121</VL>
<PG>227-52</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241774"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241773"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Von-Roenn-1994a" MODIFIED="2012-01-10 17:48:34 +0000" MODIFIED_BY="[Empty name]" NAME="Von Roenn 1994a" YEAR="1994">
<REFERENCE MODIFIED="2012-01-10 17:48:34 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 19941219&lt;br&gt;IS - 0030-2414 (Print)&lt;br&gt;IS - 0030-2414 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Clinical Trial&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;RN - 3562-63-8 (Megestrol)&lt;br&gt;RN - 51154-23-5 (Megestrol Acetate)&lt;br&gt;SB - IM&lt;br&gt;SB - X&lt;/p&gt;" NOTES_MODIFIED="2012-01-10 17:48:34 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Von Roenn JH</AU>
<TI>Randomized trials of megestrol acetate for AIDS-associated anorexia and cachexia</TI>
<SO>Oncology</SO>
<YR>1994</YR>
<VL>51 Suppl 1</VL>
<PG>19-24</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241776"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241775"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vyzula-1997" MODIFIED="2013-02-07 10:08:10 +0000" MODIFIED_BY="[Empty name]" NAME="Vyzula 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-02-07 10:08:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vyzula R</AU>
<TI>Current views on use of megestrol acetate in oncology practice</TI>
<SO>Vnitrni Lekarstvi</SO>
<YR>1997</YR>
<VL>43</VL>
<PG>250-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241778"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241777"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Westman-1999" MODIFIED="2013-02-07 10:08:58 +0000" MODIFIED_BY="[Empty name]" NAME="Westman 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-02-07 10:08:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Westman G, Bergman B, Albertsson M, Kadar L, Gustavsson G, Thaning L, et al</AU>
<TI>Megestrol acetate in advanced, progressive, hormone-insensitive cancer. Effects on the quality of life: a placebo-controlled, randomised, multicentre trial</TI>
<SO>European Journal of Cancer</SO>
<YR>1999</YR>
<VL>35</VL>
<PG>586-95</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241779"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780430"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yavuzsen-2005" MODIFIED="2013-01-31 09:20:09 +0000" MODIFIED_BY="[Empty name]" NAME="Yavuzsen 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-01-31 09:20:09 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Embase&lt;br&gt;UI - 2007090195&lt;/p&gt;" NOTES_MODIFIED="2013-01-31 09:20:09 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yavuzsen T, Davis MP, Walsh D, LeGrand S, Lagman R</AU>
<TI>Systematic review of the treatment of cancer-associated anorexia and weight loss</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<PG>8500-11</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241781"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241780"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yeh-2004" MODIFIED="2013-02-07 10:09:24 +0000" MODIFIED_BY="[Empty name]" NAME="Yeh 2004" YEAR="">
<REFERENCE MODIFIED="2013-02-07 10:09:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Yeh S, Hafner A, Chang C, Levine DM, Parker TS, Schuster MW</AU>
<TI>Risk factors relating blood markers of inflammation and nutritional status to survival in cachectic geriatric patients in a randomized clinical trial</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>2004</YR>
<VL>52</VL>
<PG>1708-12</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241783"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241782"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yeh-2006" MODIFIED="2013-02-07 10:09:41 +0000" MODIFIED_BY="[Empty name]" NAME="Yeh 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-02-07 10:09:41 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 20070827&lt;br&gt;IS - 1176-9114 (Print)&lt;br&gt;IS - 1176-9114 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Review&lt;br&gt;RN - 0 (Drug Carriers)&lt;br&gt;RN - 51154-23-5 (Megestrol Acetate)&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2013-02-07 10:09:41 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yeh SS, Schuster MW</AU>
<TI>Megestrol acetate in cachexia and anorexia</TI>
<SO>International Journal of Nanomedicine</SO>
<YR>2006</YR>
<VL>1</VL>
<PG>411-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241785"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241784"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yeh-2007" MODIFIED="2013-02-07 10:09:55 +0000" MODIFIED_BY="[Empty name]" NAME="Yeh 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-02-07 10:09:55 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 20070709&lt;br&gt;IS - 1538-9375 (Electronic)&lt;br&gt;IS - 1525-8610 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Review&lt;br&gt;RN - 0 (Anabolic Agents)&lt;br&gt;RN - 0 (Appetite Stimulants)&lt;br&gt;RN - 1972-08-3 (Tetrahydrocannabinol)&lt;br&gt;RN - 51154-23-5 (Megestrol Acetate)&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2013-02-07 10:09:55 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yeh SS, Lovitt S, Schuster MW</AU>
<TI>Pharmacological treatment of geriatric cachexia: evidence and safety in perspective</TI>
<SO>Journal of the American Medical Directors Association</SO>
<YR>2007</YR>
<VL>8</VL>
<PG>363-77</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241787"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6241786"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yeh-2010" MODIFIED="2013-01-31 09:22:36 +0000" MODIFIED_BY="[Empty name]" NAME="Yeh 2010" YEAR="">
<REFERENCE MODIFIED="2013-01-31 09:22:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Yeh SS, Marandi M, Thode HC, Levine DM, Parker T, Dixon T, et al</AU>
<TI>Report of a pilot, double-blind, placebo-controlled study of megestrol acetate in elderly dialysis patients with cachexia</TI>
<SO>Journal of Renal Nutrition</SO>
<YR>2010</YR>
<VL>20</VL>
<PG>52-62</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241788"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780432"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zeca-1995" MODIFIED="2013-02-07 10:10:18 +0000" MODIFIED_BY="[Empty name]" NAME="Zeca 1995" YEAR="1995">
<REFERENCE MODIFIED="2013-02-07 10:10:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zeca E, Martini C, Venturino P, Tedeschi M, Ventafrida V, De Conno F</AU>
<TI>Efficacy of megestrol acetate on anorexia in patients with advanced non hormone-related tumors: a double-blind placebo controlled clinical trial</TI>
<SO>European Journal of Cancer</SO>
<YR>1995</YR>
<VL>31A</VL>
<PG>S261-2</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6241789"/><IDENTIFIER TYPE="OTHER" VALUE="CN-00519065"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2780434"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2012-02-01 18:11:31 +0000" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-02-11 09:22:35 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2013-02-08 09:31:39 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Argil_x00e9_s-2001" NAME="Argilés 2001" TYPE="JOURNAL_ARTICLE">
<AU>Argilés JM, Meijsing SH, Pallares-Trujillo J</AU>
<TI>Cancer cachexia. A therapeutic approach</TI>
<SO>Medical Research Review (US)</SO>
<YR>2001</YR>
<VL>21</VL>
<PG>83-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Balog-1998" MODIFIED="2013-02-07 10:11:55 +0000" MODIFIED_BY="[Empty name]" NAME="Balog 1998" TYPE="JOURNAL_ARTICLE">
<AU>Balog DL, Epstein ME, Amidio-Groton MI</AU>
<TI>HIV wasting syndrome: treatment update</TI>
<SO>Annals of Pharmacotherapy</SO>
<YR>1998</YR>
<VL>32</VL>
<NO>4</NO>
<PG>446-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barber-1999" MODIFIED="2013-02-07 10:12:06 +0000" MODIFIED_BY="[Empty name]" NAME="Barber 1999" TYPE="JOURNAL_ARTICLE">
<AU>Barber MD, Ross JA, Voss AC, Tisdale MJ, Fearon KC</AU>
<TI>The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer</TI>
<SO>British Journal of Cancer</SO>
<YR>1999</YR>
<VL>81</VL>
<PG>80-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boissel-1999" MODIFIED="2013-02-07 10:12:17 +0000" MODIFIED_BY="[Empty name]" NAME="Boissel 1999" TYPE="JOURNAL_ARTICLE">
<AU>Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al</AU>
<TI>The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use</TI>
<SO>Therapie</SO>
<YR>1999</YR>
<VL>54</VL>
<PG>405-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bruera-1992" NAME="Bruera 1992" TYPE="JOURNAL_ARTICLE">
<AU>Bruera E</AU>
<TI>Clinical management of anorexia and cachexia in patients with advanced cancer</TI>
<SO>Oncology</SO>
<YR>1992</YR>
<VL>49</VL>
<NO>2</NO>
<PG>35-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Campa-2005" MODIFIED="2013-02-07 10:12:28 +0000" MODIFIED_BY="[Empty name]" NAME="Campa 2005" TYPE="JOURNAL_ARTICLE">
<AU>Campa A, Yang Z, Lai S, Xue L, Phillips JC, Sales S, et al</AU>
<TI>HIV-related wasting in HIV-infected drug users in the era of highly active antiretroviral therapy</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2005</YR>
<VL>41</VL>
<PG>1179-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2008" MODIFIED="2013-02-07 10:12:39 +0000" MODIFIED_BY="[Empty name]" NAME="Deeks 2008" TYPE="OTHER">
<AU>Deeks J, Higgins J, Altman D</AU>
<TI>Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008</TI>
<SO>Available from: www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fearon-2011" MODIFIED="2013-02-07 10:12:58 +0000" MODIFIED_BY="[Empty name]" NAME="Fearon 2011" TYPE="JOURNAL_ARTICLE">
<AU>Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al</AU>
<TI>Definition and classification of cancer cachexia: an international consensus</TI>
<SO>Lancet Oncology</SO>
<YR>2011</YR>
<VL>12</VL>
<PG>489-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fick-2012" MODIFIED="2013-02-07 10:13:10 +0000" MODIFIED_BY="[Empty name]" NAME="Fick 2012" TYPE="JOURNAL_ARTICLE">
<AU>Fick D, Semla T, Beizer J, Brandt N, Dombrowski R, DuBeau CE, et al</AU>
<TI>American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>2012</YR>
<VL>60</VL>
<NO>4</NO>
<PG>616-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2013-02-07 10:13:25 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="BOOK">
<AU>Higgins JPT, Green S</AU>
<SO>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]</SO>
<YR>2011</YR>
<PG>649</PG>
<PB>Wiley-Blackwell</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" MODIFIED="2013-02-07 10:13:42 +0000" MODIFIED_BY="[Empty name]" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad A, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al</AU>
<TI>Assessing the quality of reports on randomized clinical trials: is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>170</VL>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kjaergard-2001" MODIFIED="2013-02-07 10:13:53 +0000" MODIFIED_BY="[Empty name]" NAME="Kjaergard 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kjaergard LL, Villumsen J, Gluud C</AU>
<TI>Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2001</YR>
<VL>135</VL>
<PG>982-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Laird-1990" MODIFIED="2011-07-27 17:09:36 +0100" MODIFIED_BY="[Empty name]" NAME="Laird 1990" TYPE="JOURNAL_ARTICLE">
<AU>Laird NM, Wang F</AU>
<TI>Estimating rates of change in randomized clinical trials</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1990</YR>
<VL>11</VL>
<PG>405-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Laupacis-1988" MODIFIED="2011-07-27 17:03:42 +0100" MODIFIED_BY="[Empty name]" NAME="Laupacis 1988" TYPE="JOURNAL_ARTICLE">
<AU>Laupacis A, Sackett DL, Roberts RS</AU>
<TI>An assessment of clinically useful measures of the consequences of treatment</TI>
<SO>New England Journal of Medicine</SO>
<YR>1988</YR>
<VL>318</VL>
<PG>1728-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Loprinzi-1990a" MODIFIED="2013-02-07 10:14:12 +0000" MODIFIED_BY="[Empty name]" NAME="Loprinzi 1990a" TYPE="JOURNAL_ARTICLE">
<AU>Loprinzi C, Ellison NM, Goldberg RM, Michalak JC, Burch PA</AU>
<TI>Alleviation of cancer anorexia and cachexia: studies of the Mayo Clinic and the North Central Cancer Treatment Group</TI>
<SO>Seminars in Oncology</SO>
<YR>1990</YR>
<VL>17</VL>
<NO>6 Suppl 9</NO>
<PG>8-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Loprinzi-1999" MODIFIED="2013-02-07 10:14:21 +0000" MODIFIED_BY="[Empty name]" NAME="Loprinzi 1999" TYPE="JOURNAL_ARTICLE">
<AU>Loprinzi CL, Kugler JW, Sloan JA</AU>
<TI>Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1999</YR>
<VL>17</VL>
<PG>3299-306</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mangili-2006" MODIFIED="2013-01-31 11:34:19 +0000" MODIFIED_BY="[Empty name]" NAME="Mangili 2006" TYPE="JOURNAL_ARTICLE">
<AU>Mangili A, Murman DH, Zampini AM, Wanke CA</AU>
<TI>Nutrition and HIV infection: review of weight loss and wasting in the era of highly active antiretroviral therapy from the nutrition for healthy living cohort</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2006</YR>
<VL>42</VL>
<PG>836-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nelson-1994" MODIFIED="2013-02-07 10:14:33 +0000" MODIFIED_BY="[Empty name]" NAME="Nelson 1994" TYPE="JOURNAL_ARTICLE">
<AU>Nelson KA, Walsh D, Sheehan FA</AU>
<TI>The cancer anorexia-cachexia syndrome</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1994</YR>
<VL>12</VL>
<PG>213-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-N_x00fc_esch-2010" MODIFIED="2013-02-07 12:09:09 +0000" MODIFIED_BY="[Empty name]" NAME="Nüesch 2010" TYPE="JOURNAL_ARTICLE">
<AU>Nüesch E, Trelle S, Reichenbach S, Rutjes AW, TschannenB, Altman DG, et al</AU>
<TI>Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study</TI>
<SO>BMJ</SO>
<YR>2010</YR>
<VL>341</VL>
<PG>c3515</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2011" MODIFIED="2013-02-07 10:14:51 +0000" MODIFIED_BY="[Empty name]" NAME="RevMan 2011" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2011</YR>
<EN>5.1</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1993" MODIFIED="2013-02-07 10:15:01 +0000" MODIFIED_BY="[Empty name]" NAME="Schulz 1993" TYPE="BOOK">
<AU>Schulz KF, Altman DG</AU>
<SO>Statistical Methods for Data Synthesis. Cochrane Workshop Report</SO>
<YR>1993</YR>
<PB>UK Cochrane Centre</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Splinter-1992" MODIFIED="2013-02-08 09:31:27 +0000" MODIFIED_BY="[Empty name]" NAME="Splinter 1992" TYPE="JOURNAL_ARTICLE">
<AU>Splinter TA</AU>
<TI>Cachexia and cancer: a clinician's view</TI>
<SO>Annals of Oncology</SO>
<YR>1992</YR>
<VL>3</VL>
<NO>3</NO>
<PG>25-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tang-2005" MODIFIED="2013-02-08 09:31:39 +0000" MODIFIED_BY="[Empty name]" NAME="Tang 2005" TYPE="JOURNAL_ARTICLE">
<AU>Tang AM, Jacobson DL, Spiegelman D, Knox TA, Wanke CA</AU>
<TI>Increasing risk of 5% or greater unintentional weight loss in a cohort of HIV-infected patients, 1995 to 2003</TI>
<SO>Journal of Acquired Immune Deficiency Syndromes</SO>
<YR>2005</YR>
<VL>40</VL>
<PG>70-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thompson-1952" MODIFIED="2013-02-07 10:15:14 +0000" MODIFIED_BY="[Empty name]" NAME="Thompson 1952" TYPE="JOURNAL_ARTICLE">
<AU>Thompson CM, Rodgers RL</AU>
<TI>Analysis of the autopsy records of 157 cases of carcinoma of the pancreas with particular reference to the incidence of thromboembolism</TI>
<SO>American Journal of the Medical Sciences</SO>
<YR>1952</YR>
<VL>223</VL>
<PG>469-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thompson-1999" MODIFIED="2011-07-27 17:17:52 +0100" MODIFIED_BY="[Empty name]" NAME="Thompson 1999" TYPE="JOURNAL_ARTICLE">
<AU>Thompson SG, Sharp SJ</AU>
<TI>Explaining heterogeneity in meta-analysis: a comparison of methods</TI>
<SO>Statistics in Medicine</SO>
<YR>1999</YR>
<VL>18</VL>
<PG>2693-708</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tisdale-2009" MODIFIED="2013-02-07 10:15:28 +0000" MODIFIED_BY="[Empty name]" NAME="Tisdale 2009" TYPE="JOURNAL_ARTICLE">
<AU>Tisdale M</AU>
<TI>Mechanisms of cancer cachexia</TI>
<SO>Physiological Reviews</SO>
<YR>209</YR>
<VL>89</VL>
<PG>381-410</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Verso-2003" MODIFIED="2013-02-07 10:15:38 +0000" MODIFIED_BY="[Empty name]" NAME="Verso 2003" TYPE="JOURNAL_ARTICLE">
<AU>Verso M, Agnelli G</AU>
<TI>Venous thromboembolism associated with long-term use of central venous catheters in cancer patients</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2003</YR>
<VL>21</VL>
<PG>3665-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Von-Roenn-1996" NAME="Von Roenn 1996" TYPE="JOURNAL_ARTICLE">
<AU>Von Roenn JH, Knopf K</AU>
<TI>Anorexia/cachexia in patients with HIV: lessons for the oncologist</TI>
<SO>Oncology</SO>
<YR>1996</YR>
<VL>10</VL>
<NO>7</NO>
<PG>1049-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wigmore-1997" MODIFIED="2013-02-07 10:15:51 +0000" MODIFIED_BY="[Empty name]" NAME="Wigmore 1997" TYPE="JOURNAL_ARTICLE">
<AU>Wigmore SJ, Fearon KCH, Maingay JP, Ross JA</AU>
<TI>Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6</TI>
<SO>Clinical Science</SO>
<YR>1997</YR>
<VL>92</VL>
<PG>215-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wolf-2006" MODIFIED="2013-02-07 10:15:58 +0000" MODIFIED_BY="[Empty name]" NAME="Wolf 2006" TYPE="JOURNAL_ARTICLE">
<AU>Wolf I, Sadetzki S, Kanety H, Kundel Y, Pariente C, Epstein N, et al</AU>
<TI>Adiponectin, ghrelin and leptin in cancer cachexia in breast and colon cancer patients</TI>
<SO>Cancer</SO>
<YR>2006</YR>
<VL>106</VL>
<PG>966-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yusuf-1991" MODIFIED="2013-01-31 09:34:45 +0000" MODIFIED_BY="[Empty name]" NAME="Yusuf 1991" TYPE="JOURNAL_ARTICLE">
<AU>Yusuf S, Wittes J, Probstfield J, Tyroler HA</AU>
<TI>Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials</TI>
<SO>JAMA</SO>
<YR>1991</YR>
<VL>266</VL>
<PG>93-8</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2013-02-11 09:22:35 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Berenstein-G-2005" MODIFIED="2013-02-11 09:22:35 +0000" MODIFIED_BY="[Empty name]" NAME="Berenstein G 2005" TYPE="COCHRANE_REVIEW">
<AU>Berenstein EG, Ortiz Z</AU>
<TI>Megestrol acetate for the treatment of anorexia-cachexia syndrome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2013-02-11 09:22:35 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2013-02-11 09:22:35 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Berenstein-G-2011" MODIFIED="2013-02-11 09:21:54 +0000" MODIFIED_BY="[Empty name]" NAME="Berenstein G 2011" TYPE="COCHRANE_REVIEW">
<AU>Berenstein EG, Ortiz Z</AU>
<TI>Megestrol acetate for the treatment of anorexia-cachexia syndrome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>7</NO>
<IDENTIFIERS MODIFIED="2013-02-11 09:21:54 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2013-02-11 09:21:54 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2011-08-26 16:15:17 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-_x002d_Wake_x002d_Forest_x002d_University_x002d_Baptist_x002d_Medical_x002d_Center_x002d_and_x002d_National_x002d_Cancer_x002d_Institute_x002d_-2010" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="-Wake-Forest-University-Baptist-Medical-Center-and-National-Cancer-Institute- 2010" TYPE="JOURNAL_ARTICLE">
<AU>-Wake-Forest-University-Baptist-Medical-Center-and-National-Cancer-Institute-</AU>
<TI>Megestrol to limit weight loss and improve quality of life in treating patients with head and neck cancer</TI>
<SO>ClinicalTrials.gov.[accessed.17 Jul 2010]</SO>
<YR>2010</YR>
<PG>ClinicalTrials</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Abrams-1999" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="Abrams 1999" TYPE="JOURNAL_ARTICLE">
<AU>Abrams J, Aisner J, Cirrincione C, Berry DA, Muss HB, Cooper MR, et al</AU>
<TI>Dose-response trial of megestrol acetate in advanced breast cancer: cancer and leukemia group B phase III study 8741</TI>
<SO>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</SO>
<YR>1999</YR>
<VL>17</VL>
<PG>64-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Aisner-1988" MODIFIED="2011-08-23 18:56:26 +0100" MODIFIED_BY="[Empty name]" NAME="Aisner 1988" TYPE="JOURNAL_ARTICLE">
<AU>Aisner J, Tchekmedyian NS, Tait N, Parnes H, Novak M</AU>
<TI>Studies of high-dose megestrol acetate: potential applications in cachexia</TI>
<SO>Semin.Oncol.</SO>
<YR>1988</YR>
<VL>15</VL>
<NO>0093-7754 (Print), 0093-7754 (Linking), 2 Suppl 1</NO>
<PG>68-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Argiles-2008" MODIFIED="2011-08-23 18:56:59 +0100" MODIFIED_BY="[Empty name]" NAME="Argiles 2008" TYPE="JOURNAL_ARTICLE">
<AU>Argiles JM, Lopez-Soriano FJ, Busquets S</AU>
<TI>Novel approaches to the treatment of cachexia</TI>
<SO>Drug Discovery Today.</SO>
<YR>2008</YR>
<VL>13</VL>
<NO>1-2</NO>
<PG>73-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Argiles-2010" MODIFIED="2011-08-23 18:57:09 +0100" MODIFIED_BY="[Empty name]" NAME="Argiles 2010" TYPE="JOURNAL_ARTICLE">
<AU>Argiles JM, Olivan M, Busquets S, Lopez-Soriano FJ</AU>
<TI>Optimal management of cancer anorexia-cachexia syndrome</TI>
<SO>Cancer Management and Research</SO>
<YR>2010</YR>
<VL>2</VL>
<NO>1</NO>
<PG>27-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Batterham-1997" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="Batterham 1997" TYPE="JOURNAL_ARTICLE">
<AU>Batterham M, Garsia R</AU>
<TI>Randomised prospective medium term comparison of megestrol acetate, nandrolone decanoate and dietary therapy alone for HIV associated weight loss [abstract]</TI>
<SO>Australasian.Society for HIV Medicine</SO>
<YR>1997</YR>
<VL>9</VL>
<PG>91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Batterham-2001" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="Batterham 2001" TYPE="JOURNAL_ARTICLE">
<AU>Batterham MJ, Garsia R</AU>
<TI>A comparison of megestrol acetate, nandrolone decanoate and dietary counselling for HIV associated weight loss</TI>
<SO>International journal of andrology</SO>
<YR>2001</YR>
<VL>24</VL>
<PG>232-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Behl-2007" MODIFIED="2011-08-23 18:57:19 +0100" MODIFIED_BY="[Empty name]" NAME="Behl 2007" TYPE="JOURNAL_ARTICLE">
<AU>Behl D, Jatoi A</AU>
<TI>Pharmacological options for advanced cancer patients with loss of appetite and weight</TI>
<SO>Expert Opinion on Pharmacotherapy</SO>
<YR>2007</YR>
<VL>8</VL>
<NO>8</NO>
<PG>1085-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bell-1996" MODIFIED="2011-08-23 18:57:28 +0100" MODIFIED_BY="[Empty name]" NAME="Bell 1996" TYPE="JOURNAL_ARTICLE">
<AU>Bell SJ, Hestnes JC, Wanke C, Forse RA</AU>
<TI>Megestrol acetate in patients with AIDS-related cachexia</TI>
<SO>Jpen: Journal of Parenteral &amp; Enteral Nutrition</SO>
<YR>1996</YR>
<VL>20</VL>
<NO>2</NO>
<PG>165-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Beller-1997" MODIFIED="2011-08-23 18:57:36 +0100" MODIFIED_BY="[Empty name]" NAME="Beller 1997" TYPE="JOURNAL_ARTICLE">
<AU>Beller E, Tattersall M, Lumley T, Levi J, Dalley D, Olver I, et al</AU>
<TI>Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: a randomised placebo-controlled trial. Australasian Megestrol Acetate Cooperative Study Group</TI>
<SO>Annals of Oncology</SO>
<YR>1997</YR>
<VL>8</VL>
<NO>3</NO>
<PG>277-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Berenstein-2005" MODIFIED="2011-08-23 18:58:09 +0100" MODIFIED_BY="[Empty name]" NAME="Berenstein 2005" TYPE="JOURNAL_ARTICLE">
<AU>Berenstein EG, Ortiz Z</AU>
<TI>Megestrol acetate for the treatment of anorexia-cachexia syndrome</TI>
<SO>Cochrane.Database.Syst Rev</SO>
<YR>2005</YR>
<NO>1469-493X (Electronic), 1361-6137 (Linking), 2</NO>
<PG>CD004310</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bruera-1989" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="Bruera 1989" TYPE="JOURNAL_ARTICLE">
<AU>Bruera E, Macmillan K, Kuehn N, Hanson J, MacDonald RN</AU>
<TI>A double-blind trial of megestrol acetate on appetite, caloric intake, nutritional status and other symptoms in patients with advanced cancer [abstract]</TI>
<SO>Proceedings of the American Society of Clinical Oncology</SO>
<YR>1989</YR>
<VL>8</VL>
<PG>327, Abstract</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bruera-1990" MODIFIED="2011-08-23 18:58:26 +0100" MODIFIED_BY="[Empty name]" NAME="Bruera 1990" TYPE="JOURNAL_ARTICLE">
<AU>Bruera E, Macmillan K, Kuehn N, Hanson J, MacDonald RN</AU>
<TI>A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer</TI>
<SO>Cancer</SO>
<YR>1990</YR>
<VL>66</VL>
<NO>0008-543X (Print), 0008-543X (Linking), 6</NO>
<PG>1279-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bruera-1998" MODIFIED="2011-08-23 18:58:39 +0100" MODIFIED_BY="[Empty name]" NAME="Bruera 1998" TYPE="JOURNAL_ARTICLE">
<AU>Bruera E, Ernst S, Hagen N, Spachynski K, Belzile M, Hanson J, et al</AU>
<TI>Effectiveness of megestrol acetate in patients with advanced cancer: a randomized, double-blind, crossover study</TI>
<SO>Cancer Prevention &amp; Control</SO>
<YR>1998</YR>
<VL>2</VL>
<NO>2</NO>
<PG>74-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bruera-1998a" MODIFIED="2011-08-23 18:58:45 +0100" MODIFIED_BY="[Empty name]" NAME="Bruera 1998a" TYPE="JOURNAL_ARTICLE">
<AU>Bruera E</AU>
<TI>Pharmacological treatment of cachexia: any progress?</TI>
<SO>Supportive Care in Cancer</SO>
<YR>1998</YR>
<VL>6</VL>
<NO>2</NO>
<PG>109-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Castle-1995" MODIFIED="2011-08-23 18:59:07 +0100" MODIFIED_BY="[Empty name]" NAME="Castle 1995" TYPE="JOURNAL_ARTICLE">
<AU>Castle S, Nguyen C, Joaquin A, Coyne B, Heuston C, Chan A, et al</AU>
<TI>Megestrol acetate suspension therapy in the treatment of geriatric anorexia/cachexia in nursing home patients</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>1995</YR>
<VL>43</VL>
<NO>7</NO>
<PG>835-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cat-1994" MODIFIED="2011-08-23 18:59:14 +0100" MODIFIED_BY="[Empty name]" NAME="Cat 1994" TYPE="JOURNAL_ARTICLE">
<AU>Cat LK, Coleman RL</AU>
<TI>Treatment for HIV wasting syndrome</TI>
<SO>Annals of Pharmacotherapy</SO>
<YR>1994</YR>
<VL>28</VL>
<NO>5</NO>
<PG>595-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cat-1994a" MODIFIED="2011-08-23 18:59:19 +0100" MODIFIED_BY="[Empty name]" NAME="Cat 1994a" TYPE="JOURNAL_ARTICLE">
<AU>Cat LK, Coleman RL</AU>
<TI>Treatment for HIV wasting syndrome</TI>
<SO>Annals of Pharmacotherapy</SO>
<YR>1994</YR>
<VL>28</VL>
<NO>5</NO>
<PG>595-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chen-1997" MODIFIED="2011-08-23 18:59:30 +0100" MODIFIED_BY="[Empty name]" NAME="Chen 1997" TYPE="JOURNAL_ARTICLE">
<AU>Chen HC, Leung SW, Wang CJ, Sun LM, Fang FM, Hsu JH</AU>
<TI>Effect of megestrol acetate and prepulsid on nutritional improvement in patients with head and neck cancers undergoing radiotherapy</TI>
<SO>Radiotherapy &amp; Oncology</SO>
<YR>1997</YR>
<VL>43</VL>
<NO>1</NO>
<PG>75-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chidakel-2006" MODIFIED="2011-08-23 18:59:36 +0100" MODIFIED_BY="[Empty name]" NAME="Chidakel 2006" TYPE="JOURNAL_ARTICLE">
<AU>Chidakel AR, Zweig SB, Schlosser JR, Homel P, Schappert JW, Fleckman AM</AU>
<TI>High prevalence of adrenal suppression during acute illness in hospitalized patients receiving megestrol acetate</TI>
<SO>Journal of Endocrinological Investigation</SO>
<YR>2006</YR>
<VL>29</VL>
<NO>2</NO>
<PG>136-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cilla-2005" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="Cilla 2005" TYPE="JOURNAL_ARTICLE">
<AU>Cilla DD, Gutierrez JL, Femia RA, Kramer LD, Wanke C</AU>
<TI>A pilot study comparing megestrol acetate concentrated suspension (MA-CS) to megestrol acetate oral suspension (MA-OS) on weight gain and body composition in patients with HIV-associated unintended weight loss (UWL)</TI>
<SO>Blood</SO>
<YR>2005</YR>
<VL>106</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cilla-2006" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="Cilla 2006" TYPE="JOURNAL_ARTICLE">
<AU>Cilla DD, Gutierrez JL, Kristensen A, Kramer LD</AU>
<TI>The Safety of Megestrol Acetate Concentrated Suspension (MA-CS) and Megestrol Acetate Oral Suspension (MA-OS) in a Pilot Study in Patients with HIV-Associated Unintended Weight Loss (UWL) [abstract]</TI>
<SO>Blood</SO>
<YR>2006</YR>
<VL>108</VL>
<PG>43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Collichio-1998" MODIFIED="2011-08-23 18:59:52 +0100" MODIFIED_BY="[Empty name]" NAME="Collichio 1998" TYPE="JOURNAL_ARTICLE">
<AU>Collichio FA, Pandya K</AU>
<TI>Interferon alpha-2b and megestrol acetate in the treatment of advanced renal cell carcinoma: a phase II study</TI>
<SO>American journal of clinical oncology</SO>
<YR>1998</YR>
<VL>21</VL>
<NO>2</NO>
<PG>209-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Costero-2004" MODIFIED="2011-08-23 18:59:57 +0100" MODIFIED_BY="[Empty name]" NAME="Costero 2004" TYPE="JOURNAL_ARTICLE">
<AU>Costero O, Bajo MA, del Peso G, Gil F, Aguilera A, Ros S, et al</AU>
<TI>Treatment of anorexia and malnutrition in peritoneal dialysis patients with megestrol acetate</TI>
<SO>Adv.Perit.Dial.</SO>
<YR>2004</YR>
<VL>20</VL>
<NO>1197-8554 (Print), 1197-8554 (Linking)</NO>
<PG>209-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cruz-1990" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="Cruz 1990" TYPE="JOURNAL_ARTICLE">
<AU>Cruz JM, Muss HB, Brockschmidt JK, Evans GW</AU>
<TI>Weight changes in women with metastatic breast cancer treated with megestrol acetate: a comparison of standard versus high-dose therapy</TI>
<SO>Seminars in oncology</SO>
<YR>1990</YR>
<VL>17</VL>
<PG>63-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-D_x0027_Olimpio-2001" MODIFIED="2011-08-23 19:00:31 +0100" MODIFIED_BY="[Empty name]" NAME="D'Olimpio 2001" TYPE="JOURNAL_ARTICLE">
<AU>D'Olimpio J</AU>
<TI>Contemporary drug therapy in palliative care: new directions</TI>
<SO>Cancer Investigation</SO>
<YR>2001</YR>
<VL>19</VL>
<NO>4</NO>
<PG>413-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elovic-2000" MODIFIED="2011-08-23 19:01:00 +0100" MODIFIED_BY="[Empty name]" NAME="Elovic 2000" TYPE="JOURNAL_ARTICLE">
<AU>Elovic E</AU>
<TI>Pharmacological therapeutics in nutritional management</TI>
<SO>J Head Trauma Rehabil.</SO>
<YR>2000</YR>
<VL>15</VL>
<NO>0885-9701 (Print), 0885-9701 (Linking), 3</NO>
<PG>962-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Eubanks-2002" MODIFIED="2011-08-23 19:01:12 +0100" MODIFIED_BY="[Empty name]" NAME="Eubanks 2002" TYPE="JOURNAL_ARTICLE">
<AU>Eubanks V, Koppersmith N, Wooldridge N, Clancy JP, Lyrene R, Arani RB, et al</AU>
<TI>Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis</TI>
<SO>Journal of Pediatrics</SO>
<YR>2002</YR>
<VL>140</VL>
<NO>4</NO>
<PG>439-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Farmer-2005" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="Farmer 2005" TYPE="JOURNAL_ARTICLE">
<AU>Farmer M, Case D, Lesser G, Monitto D, Smathers S, May B, et al</AU>
<TI>A phase III, double blind, placebo-controlled, prospective randomized trial on the effect of megestrol acetate on weight and health related quality of life in lung cancer and head and neck cancer patients receiving curative radiation therapy</TI>
<SO>Proceedings of the American Society for Therapeutic Radiology and Oncology , 47th.Annual Meeting; 2005 Oct 16 19; Denver., Colorado., USA.International Journal of Radiation Oncology Biology Physics</SO>
<YR>2005</YR>
<VL>63</VL>
<PG>S77-8, Abstract</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Farrar-1999" MODIFIED="2011-08-23 19:01:21 +0100" MODIFIED_BY="[Empty name]" NAME="Farrar 1999" TYPE="JOURNAL_ARTICLE">
<AU>Farrar DJ</AU>
<TI>Megestrol acetate: promises and pitfalls</TI>
<SO>AIDS Patient Care &amp; Stds</SO>
<YR>1999</YR>
<VL>13</VL>
<NO>3</NO>
<PG>149-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Feliu-1992" MODIFIED="2011-08-23 19:01:32 +0100" MODIFIED_BY="[Empty name]" NAME="Feliu 1992" TYPE="JOURNAL_ARTICLE">
<AU>Feliu J, Gonzalez-Baron M, Berrocal A, Artal A, Ordonez A, Garrido P, et al</AU>
<TI>Usefulness of megestrol acetate in cancer cachexia and anorexia. A placebo-controlled study</TI>
<SO>Am J Clin Oncol.</SO>
<YR>1992</YR>
<VL>15</VL>
<NO>0277-3732 (Print), 0277-3732 (Linking), 5</NO>
<PG>436-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fietkau-1996" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="Fietkau 1996" TYPE="JOURNAL_ARTICLE">
<AU>Fietkau R, Riepl M, Kettner H, Hinke A, Sauer R</AU>
<TI>Supportive treatment with megestrol acetate during radio-(chemo-) therapy. A randomized trial</TI>
<SO>Strahlentherapie Und Onkologie.</SO>
<YR>1996</YR>
<VL>172</VL>
<PG>162-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fietkau-1996a" MODIFIED="2011-08-23 19:01:42 +0100" MODIFIED_BY="[Empty name]" NAME="Fietkau 1996a" TYPE="JOURNAL_ARTICLE">
<AU>Fietkau R, Riepl M, Kettner H, Hinke A, Sauer R</AU>
<TI>Supportive treatment with megestrol acetate during radio(chemo)therapy in patients with tumors in the head-neck area. A randomized study</TI>
<SO>Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft</SO>
<YR>1996</YR>
<VL>172</VL>
<NO>3</NO>
<PG>162-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fietkau-1997" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="Fietkau 1997" TYPE="JOURNAL_ARTICLE">
<AU>Fietkau R, Riepl M, Kettner H, Hinke A, Sauer R</AU>
<TI>Supportive use of megestrol acetate in patients with head and neck cancer during radio(chemo)therapy</TI>
<SO>European journal of cancer</SO>
<YR>1997</YR>
<VL>33</VL>
<PG>75-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fox-2009" MODIFIED="2011-08-23 23:12:16 +0100" MODIFIED_BY="[Empty name]" NAME="Fox 2009" TYPE="JOURNAL_ARTICLE">
<AU>Fox CB, Treadway AK, Blaszczyk AT, Sleeper RB</AU>
<TI>Megestrol acetate and mirtazapine for the treatment of unplanned weight loss in the elderly</TI>
<SO>Pharmacotherapy</SO>
<YR>2009</YR>
<VL>29</VL>
<NO>1875-9114 (Electronic), 0277-0008 (Linking), 4</NO>
<PG>383-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Garg-2010" MODIFIED="2011-08-23 23:12:48 +0100" MODIFIED_BY="[Empty name]" NAME="Garg 2010" TYPE="JOURNAL_ARTICLE">
<AU>Garg S, Yoo J, Winquist E</AU>
<TI>Nutritional support for head and neck cancer patients receiving radiotherapy: a systematic review</TI>
<SO>Supportive Care in Cancer</SO>
<YR>2010</YR>
<VL>18</VL>
<NO>6</NO>
<PG>667-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gebbia-1996" MODIFIED="2011-08-23 23:12:58 +0100" MODIFIED_BY="[Empty name]" NAME="Gebbia 1996" TYPE="JOURNAL_ARTICLE">
<AU>Gebbia V, Testa A, Gebbia N</AU>
<TI>Prospective randomised trial of two dose levels of megestrol acetate in the management of anorexia-cachexia syndrome in patients with metastatic cancer</TI>
<SO>Br.J Cancer</SO>
<YR>1996</YR>
<VL>73</VL>
<NO>0007-0920 (Print), 0007-0920 (Linking), 12</NO>
<PG>1576-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Giacosa-1997" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="Giacosa 1997" TYPE="JOURNAL_ARTICLE">
<AU>Giacosa A, Frascio F, Sukkar SG, Costantini M, Baracco G, Capelli M</AU>
<TI>Changes of nutritional and psychological status after megestrol acetate treatment of cancer cachexia</TI>
<SO>Rivista Italiana Di Nutrizione Parenterale Ed Enterale.</SO>
<YR>1997</YR>
<VL>15</VL>
<PG>20-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gonzalez-1990" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="Gonzalez 1990" TYPE="JOURNAL_ARTICLE">
<AU>Gonzalez Baron M, Felio J, Zamora P, Artal A, Garrido P, Chacon I</AU>
<TI>Usefulnes of megestrol acetate on cancer cachexia: a double blind randomized study</TI>
<SO>Ann.Oncol.</SO>
<YR>1990</YR>
<VL>1</VL>
<PG>29</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goodwin-2008" MODIFIED="2011-08-23 23:13:07 +0100" MODIFIED_BY="[Empty name]" NAME="Goodwin 2008" TYPE="JOURNAL_ARTICLE">
<AU>Goodwin JW, Green SJ, Moinpour CM, Bearden III JD, Giguere JK, Jiang CS, et al</AU>
<TI>Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest oncology group study 9626</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2008</YR>
<VL>26</VL>
<NO>10</NO>
<PG>1650-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gullett-2011" MODIFIED="2011-08-23 23:13:25 +0100" MODIFIED_BY="[Empty name]" NAME="Gullett 2011" TYPE="JOURNAL_ARTICLE">
<AU>Gullett NP, Mazurak VC, Hebbar G, Ziegler TR</AU>
<TI>Nutritional Interventions for Cancer-Induced Cachexia</TI>
<SO>Current Problems in Cancer</SO>
<YR>2011</YR>
<VL>35</VL>
<NO>2</NO>
<PG>58-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hanson-2011" MODIFIED="2011-08-23 23:13:40 +0100" MODIFIED_BY="[Empty name]" NAME="Hanson 2011" TYPE="JOURNAL_ARTICLE">
<AU>Hanson LC, Ersek M, Gilliam R, Carey TS</AU>
<TI>Oral feeding options for people with dementia: A systematic review</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>2011</YR>
<VL>59</VL>
<NO>3</NO>
<PG>436-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haren-2005" MODIFIED="2011-08-23 23:13:50 +0100" MODIFIED_BY="[Empty name]" NAME="Haren 2005" TYPE="JOURNAL_ARTICLE">
<AU>Haren MT, Kim MJ, Kevorkian RT</AU>
<TI>Megestrol acetate for geriatric anorexia/cachexia REVISAR LA fecha pues no se grab¢</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>2005</YR>
<VL>54</VL>
<NO>1</NO>
<PG>172-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heckmayr-1992" MODIFIED="2011-08-23 23:13:56 +0100" MODIFIED_BY="[Empty name]" NAME="Heckmayr 1992" TYPE="JOURNAL_ARTICLE">
<AU>Heckmayr M, Gatzemeier U</AU>
<TI>Treatment of cancer weight loss in patients with advanced lung cancer</TI>
<SO>Oncology</SO>
<YR>1992</YR>
<VL>49 Suppl 2</VL>
<NO>0030-2414 (Print), 0030-2414 (Linking)</NO>
<PG>32-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Herrejon-2010" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="Herrejon 2010" TYPE="JOURNAL_ARTICLE">
<AU>Herrejon A, Catalan P, Palop J, Inchaurraga I, Blanquer R, Lopez Aet-al</AU>
<TI>Effect Of 8-week 320 Mg Megestrol acetate Daily Administration In Severe COPD And Weight Loss [Abstract]</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2010</YR>
<VL>181</VL>
<PG>A4484</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Herrejon-2011" MODIFIED="2011-08-23 23:14:17 +0100" MODIFIED_BY="[Empty name]" NAME="Herrejon 2011" TYPE="JOURNAL_ARTICLE">
<AU>Herrejon A, Palop J, Inchaurraga I, Lopez A, Banuls C, Hernandez A, et al</AU>
<TI>Low doses of megestrol acetate increase weight and improve nutrition status in patients with severe chronic obstructive pulmonary disease and weight loss</TI>
<SO>Med Clin (Barc)</SO>
<YR>2011</YR>
<VL>137</VL>
<NO>5</NO>
<PG>193-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Horton-1987" MODIFIED="2011-08-23 23:14:22 +0100" MODIFIED_BY="[Empty name]" NAME="Horton 1987" TYPE="JOURNAL_ARTICLE">
<AU>Horton J, Knuiman M, Keller AM, Vogel H, Gale KE, Hahn RG, et al</AU>
<TI>Combination hormone therapy for metastatic breast cancer. An ECOG study of megestrol and aminoglutethimide</TI>
<SO>Cancer</SO>
<YR>1987</YR>
<VL>60</VL>
<NO>9</NO>
<PG>2137-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jatoi-2001a" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="Jatoi 2001a" TYPE="JOURNAL_ARTICLE">
<AU>Jatoi A, Windschitl HE, Loprinzi CL, Sloan JA, Johnson DB, Mailliard JA, et al</AU>
<TI>Dronabinol versus megestrol acetate versus both for cancer-associated anorexia: a North Central Cancer Treatment Group study [abstract]</TI>
<SO>Proceedings of the American Society of Clinical Oncology</SO>
<YR>2001</YR>
<VL>20 (Pt 1)</VL>
<PG>388a, Abstract</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jatoi-2002" MODIFIED="2011-08-23 23:26:03 +0100" MODIFIED_BY="[Empty name]" NAME="Jatoi 2002" TYPE="JOURNAL_ARTICLE">
<AU>Jatoi A, Yamashita J, Sloan JA, Novotny PJ, Windschitl HE, Loprinzi CL</AU>
<TI>Does megestrol acetate down-regulate interleukin-6 in patients with cancer-associated anorexia and weight loss? A North Central Cancer Treatment Group investigation</TI>
<SO>Supportive Care in Cancer</SO>
<YR>2002</YR>
<VL>10</VL>
<NO>1</NO>
<PG>71-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jatoi-2002a" MODIFIED="2011-08-23 23:14:44 +0100" MODIFIED_BY="[Empty name]" NAME="Jatoi 2002a" TYPE="JOURNAL_ARTICLE">
<AU>Jatoi A, Windschitl HE, Loprinzi CL, Sloan JA, Dakhil SR, Mailliard JA, et al</AU>
<TI>Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2002</YR>
<VL>20</VL>
<NO>2</NO>
<PG>567-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jatoi-2003" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="Jatoi 2003" TYPE="JOURNAL_ARTICLE">
<AU>Jatoi A, Rowland KM, Loprinzi CL, Sloan JA, Dakhil SR, MacDonald N, et al</AU>
<TI>An eicosapentanoic acid (EPA)-enriched supplement versus megestrol acetate (MA) versus both for patients with cancer-associated wasting. A collaborative effort from the North Central Cancer Treatment Group (NCCTG) and the National Cancer Institute of Canada [abstract]</TI>
<SO>Proceedings of the American Society of Clinical Oncology</SO>
<YR>2003</YR>
<PG>743</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jeanfaivre-2000" MODIFIED="2011-08-23 23:14:57 +0100" MODIFIED_BY="[Empty name]" NAME="Jeanfaivre 2000" TYPE="JOURNAL_ARTICLE">
<AU>Jeanfaivre T, Souday V, Chaleil D, Maillet F, Tuchais E</AU>
<TI>[Phase II trial evaluating the effect of megestrol acetate-prednisolone combination in the treatment of anorexia during the palliative-care phase of lung cancer]</TI>
<SO>Rev Pneumol.Clin</SO>
<YR>2000</YR>
<VL>56</VL>
<NO>0761-8417 (Print), 0761-8417 (Linking), 4</NO>
<PG>255-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kalantar_x002d_Zadeh-2008" MODIFIED="2011-08-23 23:15:02 +0100" MODIFIED_BY="[Empty name]" NAME="Kalantar-Zadeh 2008" TYPE="JOURNAL_ARTICLE">
<AU>Kalantar-Zadeh K, Anker SD, Horwich TB, Fonarow GC</AU>
<TI>Nutritional and anti-inflammatory interventions in chronic heart failure</TI>
<SO>Am J Cardiol</SO>
<YR>2008</YR>
<VL>101</VL>
<NO>0002-9149 (Print), 0002-9149 (Linking), 11A</NO>
<PG>89E-103E</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Karcic-2002" MODIFIED="2011-08-23 23:15:07 +0100" MODIFIED_BY="[Empty name]" NAME="Karcic 2002" TYPE="JOURNAL_ARTICLE">
<AU>Karcic E, Philpot C, Morley JE</AU>
<TI>Treating malnutrition with megestrol acetate: literature review and review of our experience</TI>
<SO>J Nutr.Health Aging</SO>
<YR>2002</YR>
<VL>6</VL>
<NO>1279-7707 (Print), 1279-7707 (Linking), 3</NO>
<PG>191-200</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kornblith-1993" MODIFIED="2011-08-23 23:15:13 +0100" MODIFIED_BY="[Empty name]" NAME="Kornblith 1993" TYPE="JOURNAL_ARTICLE">
<AU>Kornblith AB, Hollis DR, Zuckerman E, Lyss AP, Canellos GP, Cooper MR, et al</AU>
<TI>Effect of megestrol acetate on quality of life in a dose-response trial in women with advanced breast cancer. The Cancer and Leukemia Group B</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1993</YR>
<VL>11</VL>
<NO>11</NO>
<PG>2081-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lai-1994" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="Lai 1994" TYPE="JOURNAL_ARTICLE">
<AU>Lai YL, Fang FM, Yeh CY</AU>
<TI>Management of anorexic patients in radiotherapy: a prospective randomized comparison of megestrol and prednisolone</TI>
<SO>Journal of pain and symptom management</SO>
<YR>1994</YR>
<VL>9</VL>
<PG>265-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lambert-2002" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="Lambert 2002" TYPE="JOURNAL_ARTICLE">
<AU>Lambert CP, Sullivan DH, Freeling SA, Lindquist DM, Evans WJ</AU>
<TI>Effects of testosterone replacement and/or resistance exercise on the composition of megestrol acetate stimulated weight gain in elderly men: a randomized controlled trial</TI>
<SO>J Clin Endocrinol.Metab</SO>
<YR>2002</YR>
<VL>87</VL>
<PG>2100-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lambert-2003" MODIFIED="2011-08-23 23:15:36 +0100" MODIFIED_BY="[Empty name]" NAME="Lambert 2003" TYPE="JOURNAL_ARTICLE">
<AU>Lambert CP, Sullivan DH, Evans WJ</AU>
<TI>Megestrol acetate-induced weight gain does not negatively affect blood lipids in elderly men: effects of resistance training and testosterone replacement</TI>
<SO>Journals of Gerontology Series A-Biological Sciences &amp; Medical Sciences</SO>
<YR>2003</YR>
<VL>58</VL>
<NO>7</NO>
<PG>644-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Latifzadeh-2004" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="Latifzadeh 2004" TYPE="JOURNAL_ARTICLE">
<AU>Latifzadeh SZ, Entezari V</AU>
<TI>Effect of megestrol acetate, cyproheptadine, and their combination on appetite, body weight and quality of life (QOL) in cancer patients: A double-blind placebo-controlled clinical trial [abstract]</TI>
<SO>Journal of Clinical Oncology : ASCO annual meeting proceedings</SO>
<YR>2004</YR>
<VL>22</VL>
<PG>760</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lelli-2003" MODIFIED="2011-08-23 23:15:43 +0100" MODIFIED_BY="[Empty name]" NAME="Lelli 2003" TYPE="JOURNAL_ARTICLE">
<AU>Lelli G, Montanari M, Gilli G, Scapoli D, Antonietti C, Scapoli D</AU>
<TI>Treatment of the cancer anorexia-cachexia syndrome: a critical reappraisal</TI>
<SO>J Chemother.</SO>
<YR>2003</YR>
<VL>15</VL>
<NO>1120-009X (Print), 1120-009X (Linking), 3</NO>
<PG>220-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lesser-2006" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="Lesser 2006" TYPE="JOURNAL_ARTICLE">
<AU>Lesser GJ, Case D, Sharp S, Choksi J, Miller A, Atkins J, et al</AU>
<TI>A Phase III randomized study comparing the effects of Oxandrolone (Ox) and Megestrol Acetate (Meg) on weight (wt), lean body mass (LBM) and quality of life (QOL) in solid tumor patients (pts) receiving chemotherapy (chemo) [abstract]</TI>
<SO>Journal of Clinical Oncology : ASCO annual meeting proceedings</SO>
<YR>2006</YR>
<VL>24</VL>
<PG>691</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Loprinzi-1990" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="Loprinzi 1990" TYPE="JOURNAL_ARTICLE">
<AU>Loprinzi CL, Ellison NM, Schaid DJ, Krook JE, Athmann LM, Dose AM, et al</AU>
<TI>Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>1990</YR>
<VL>82</VL>
<PG>1127-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Loprinzi-1992a" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="Loprinzi 1992a" TYPE="JOURNAL_ARTICLE">
<AU>Loprinzi CL, Mailliard J, Schaid D, Krook J, Goldberg RM, Keppen M, et al</AU>
<TI>Dose/response evaluation of Megestrol acetate for the treatment of cancer anorexia/cachexia: a Mayo Clinic and North Central Cancer Treatment Group trial [abstract]</TI>
<SO>Proceedings of the American Society of Clinical Oncology</SO>
<YR>1992</YR>
<VL>11</VL>
<PG>378, Abstract</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Loprinzi-1992b" MODIFIED="2011-08-26 16:15:17 +0100" MODIFIED_BY="[Empty name]" NAME="Loprinzi 1992b" TYPE="JOURNAL_ARTICLE">
<AU>Loprinzi CL, Johnson PA, Jensen M</AU>
<TI>Megestrol acetate for anorexia and cachexia</TI>
<SO>Oncology</SO>
<YR>1992</YR>
<VL>49 Suppl 2</VL>
<PG>46-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Loprinzi-1993" MODIFIED="2011-08-23 23:16:13 +0100" MODIFIED_BY="[Empty name]" NAME="Loprinzi 1993" TYPE="JOURNAL_ARTICLE">
<AU>Loprinzi CL, Schaid DJ, Dose AM, Burnham NL, Jensen MD</AU>
<TI>Body-composition changes in patients who gain weight while receiving megestrol acetate</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1993</YR>
<VL>11</VL>
<NO>1</NO>
<PG>152-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Loprinzi-1997" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="Loprinzi 1997" TYPE="JOURNAL_ARTICLE">
<AU>Loprinzi CL, Kugler J, Sloan J, Mailliard J, Krook J, Wilwerding M, et al</AU>
<TI>Phase III randomized comparison of megestrol acetate, dexamethasone, and fluoxymesterone for the treatment of cancer anorexia/cachexia</TI>
<SO>Proc.Annu.Meet.Am Soc.Clin Oncol.</SO>
<YR>1997</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Madeddu-2009" MODIFIED="2011-08-23 23:16:25 +0100" MODIFIED_BY="[Empty name]" NAME="Madeddu 2009" TYPE="JOURNAL_ARTICLE">
<AU>Madeddu C, Maccio' A, Panzone F, Dessi' M, Serpe R, Antoni G, et al</AU>
<TI>Randomised phase III clinical trial of 5 different arms of treatment for patients with cancer-related anorexia/cachexia syndrome (CACS)</TI>
<SO>European Journal of Cancer, Supplement.Conference: Joint ECCO 15 - 34th ESMO Multidisciplinary Congress Berlin Germany.Conference Start: 20090920 Conference End: 20090924.</SO>
<YR>2009</YR>
<VL>7</VL>
<NO>2-3</NO>
<PG>182-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Madeddu-2010" MODIFIED="2011-08-23 23:16:31 +0100" MODIFIED_BY="[Empty name]" NAME="Madeddu 2010" TYPE="JOURNAL_ARTICLE">
<AU>Madeddu C, Maccio' A, Panzone F, Serpe R, Dessi' M, Massa E, et al</AU>
<TI>Randomised phase III clinical trial of 5 different arms of treatment for patients with cancerrelated anorexia/cachexia syndrome (CACS)</TI>
<SO>Annals of Oncology.Conference: 35th ESMO Congress Milan Italy.Conference Start: 20101008 Conference End: 20101012.Conference Publication: (var.pagings).21 (pp viii376), 2010.Date of Publication: October 2010.</SO>
<YR>2010</YR>
<NO>var.pagings</NO>
<PG>October</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mak" MODIFIED="2011-08-23 23:16:37 +0100" MODIFIED_BY="[Empty name]" NAME="Mak" TYPE="JOURNAL_ARTICLE">
<AU>Mak RH, Cheung W</AU>
<TI>Therapeutic strategy for cachexia in chronic kidney disease</TI>
<SO>Current Opinion in Nephrology and Hypertension.16 (6) (pp 542-546), 2007.Date of Publication: Nov 2007.</SO>
<NO>6</NO>
<PG>Nov</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mantovani-2002" MODIFIED="2011-08-23 23:17:07 +0100" MODIFIED_BY="[Empty name]" NAME="Mantovani 2002" TYPE="JOURNAL_ARTICLE">
<AU>Mantovani G</AU>
<TI>Does megestrol acetate down-regulate interleukin-6 in patients? CORROBORAR el a¤o lo puse segun el comenatrio</TI>
<SO>Supportive Care in Cancer</SO>
<YR>2002</YR>
<VL>10</VL>
<NO>7</NO>
<PG>566-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mantovani-2007" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="Mantovani 2007" TYPE="JOURNAL_ARTICLE">
<AU>Mantovani G, Madeddu C, Gramignano G, Serpe R, Massa E, Deiana L, et al</AU>
<TI>An innovative treatment approach for cancer-related anorexia/cachexia and oxidative stress: Background and design of an ongoing, phase III, randomized clinical trial</TI>
<SO>Supportive Cancer Therapy</SO>
<YR>2007</YR>
<VL>4</VL>
<PG>163-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mantovani-2010" MODIFIED="2011-08-23 23:17:16 +0100" MODIFIED_BY="[Empty name]" NAME="Mantovani 2010" TYPE="JOURNAL_ARTICLE">
<AU>Mantovani G, Macci A, Madeddu C, Dess M, Serpe R, Antoni G, et al</AU>
<TI>Focus on the assessment of physical activity level of patients with cancer cachexia enrolled in a randomized phase III clinical trial</TI>
<SO>Journal of Clinical Oncology.Conference: 2010 Annual Meeting of the American Society of Clinical Oncology, ASCO Chicago, IL United States.Conference Start: 20100604 Conference End: 20100608.Conference Publication: (var.pagings).28 (15 SUPPL</SO>
<YR>2010</YR>
<VL>1)</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mantovani-2010a" MODIFIED="2011-08-23 23:17:22 +0100" MODIFIED_BY="[Empty name]" NAME="Mantovani 2010a" TYPE="JOURNAL_ARTICLE">
<AU>Mantovani G, Madeddu C, Maccio' A, Panzone F, Serpe R, Dessi' M, et al</AU>
<TI>Randomised phase III clinical trial of 5 different arms of treatment for patients with cancer-related anorexia/cachexia syndrome (CACS)</TI>
<SO>Palliative Medicine.Conference: EAPC 2010 Glasgow United Kingdom.Conference Start: 20100610 Conference End: 20100612.Conference Publication: (var.pagings).24 (4 SUPPL</SO>
<YR>2010</YR>
<VL>1)</VL>
<NO>pp S125</NO>
<PG>June</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mantovani-2010b" MODIFIED="2011-08-23 23:17:27 +0100" MODIFIED_BY="[Empty name]" NAME="Mantovani 2010b" TYPE="JOURNAL_ARTICLE">
<AU>Mantovani G</AU>
<TI>Randomised phase III clinical trial of 5 different arms of treatment on 332 patients with cancer cachexia</TI>
<SO>European Review for Medical &amp; Pharmacological Sciences</SO>
<YR>2010</YR>
<VL>14</VL>
<NO>4</NO>
<PG>292-301</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mateen-2006" MODIFIED="2011-08-23 23:17:33 +0100" MODIFIED_BY="[Empty name]" NAME="Mateen 2006" TYPE="JOURNAL_ARTICLE">
<AU>Mateen F, Jatoi A</AU>
<TI>Megestrol acetate for the palliation of anorexia in advanced, incurable cancer patients</TI>
<SO>Clin Nutr.</SO>
<YR>2006</YR>
<VL>25</VL>
<NO>0261-5614 (Print), 0261-5614 (Linking), 5</NO>
<PG>711-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McMillan-1994" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="McMillan 1994" TYPE="JOURNAL_ARTICLE">
<AU>McMillan DC, Simpson JM, Preston T, Watson WS, Fearon KCH, Shenkin A, et al</AU>
<TI>Effect of megestrol acetate on weight loss, body composition and blood screen of gastrointestinal cancer patients</TI>
<SO>Clin Nutr.</SO>
<YR>1994</YR>
<VL>13</VL>
<PG>85-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McMillan-1997" MODIFIED="2011-08-23 23:17:49 +0100" MODIFIED_BY="[Empty name]" NAME="McMillan 1997" TYPE="JOURNAL_ARTICLE">
<AU>McMillan DC, O'Gorman P, Fearon KC, McArdle CS</AU>
<TI>A pilot study of megestrol acetate and ibuprofen in the treatment of cachexia in gastrointestinal cancer patients</TI>
<SO>British journal of cancer</SO>
<YR>1997</YR>
<VL>76</VL>
<NO>6</NO>
<PG>788-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McMillan-1999" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="McMillan 1999" TYPE="JOURNAL_ARTICLE">
<AU>McMillan DC, Wigmore SJ, Fearon KC, O'Gorman P, Wright CE, McArdle CS</AU>
<TI>A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss</TI>
<SO>British journal of cancer</SO>
<YR>1999</YR>
<VL>79</VL>
<PG>495-500</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McQuellon-2000" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="McQuellon 2000" TYPE="JOURNAL_ARTICLE">
<AU>McQuellon R, Moose BD, Russell G, Case LD, Greven K, Stevens M, et al</AU>
<TI>Prophylactic megestrol acetate (MEGACE) in head and neck and lung cancer patients receiving radiation therapy: effect on weight, quality of life (QOL), and toxicity in a phase III placebo controlled trial [abstract]</TI>
<SO>International Journal of Radiation Oncology Biology Physics</SO>
<YR>2000</YR>
<VL>48</VL>
<PG>184</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McQuellon-2002" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="McQuellon 2002" TYPE="JOURNAL_ARTICLE">
<AU>McQuellon RP, Moose DB, Russell GB, Case LD, Greven K, Stevens M, et al</AU>
<TI>Supportive use of megestrol acetate (Megace) with head/neck and lung cancer patients receiving radiation therapy</TI>
<SO>International journal of radiation oncology, biology, physics</SO>
<YR>2002</YR>
<VL>52</VL>
<PG>1180-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Megestrol-found-effective-in-two-trials" MODIFIED="2011-08-23 23:17:56 +0100" MODIFIED_BY="[Empty name]" NAME="Megestrol found effective in two trials" TYPE="JOURNAL_ARTICLE">
<TI>Megestrol found effective in two trials</TI>
<SO>AIDS Patient Care</SO>
<YR>1995</YR>
<VL>9</VL>
<NO>1</NO>
<PG>41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Monfared-2009" MODIFIED="2011-08-23 23:18:02 +0100" MODIFIED_BY="[Empty name]" NAME="Monfared 2009" TYPE="JOURNAL_ARTICLE">
<AU>Monfared A, Heidarzadeh A, Ghaffari M, Akbarpour M</AU>
<TI>Effect of megestrol acetate on serum albumin level in malnourished dialysis patients</TI>
<SO>Journal of Renal Nutrition</SO>
<YR>2009</YR>
<VL>19</VL>
<NO>2</NO>
<PG>167-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Morley-2002" MODIFIED="2011-08-23 23:18:07 +0100" MODIFIED_BY="[Empty name]" NAME="Morley 2002" TYPE="JOURNAL_ARTICLE">
<AU>Morley JE</AU>
<TI>Orexigenic and anabolic agents</TI>
<SO>Clin Geriatr Med</SO>
<YR>2002</YR>
<VL>18</VL>
<NO>0749-0690 (Print), 0749-0690 (Linking), 4</NO>
<PG>853-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mor_x00a0_n-1998" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="Mor n 1998" TYPE="JOURNAL_ARTICLE">
<AU>Mor n S, Ortega R, Garcia G, Uribe M</AU>
<TI>Megestrol acetate improve appetite and induce anti-catabolic effect in post-hepatitis C cirrhotic patients A double-blind placebo-controlled clinical trial [abstract]</TI>
<SO>Hepatology</SO>
<YR>1998</YR>
<VL>28</VL>
<PG>609A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mwamburi-2004" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="Mwamburi 2004" TYPE="JOURNAL_ARTICLE">
<AU>Mwamburi DM, Gerrior J, Wilson IB, Chang H, Scully E, Saboori S, et al</AU>
<TI>Comparing megestrol acetate therapy with oxandrolone therapy for HIV-related weight loss: similar results in 2 months</TI>
<SO>Clinical infectious diseases : an.official publication of the Infectious Diseases Society of America.</SO>
<YR>2004</YR>
<VL>38</VL>
<PG>895-902</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nathanson-1994" MODIFIED="2011-08-23 23:18:15 +0100" MODIFIED_BY="[Empty name]" NAME="Nathanson 1994" TYPE="JOURNAL_ARTICLE">
<AU>Nathanson L, Meelu MA, Losada R</AU>
<TI>Chemohormone therapy of metastatic melanoma with megestrol acetate plus dacarbazine, carmustine, and cisplatin</TI>
<SO>Cancer</SO>
<YR>1994</YR>
<VL>73</VL>
<NO>0008-543X (Print), 0008-543X (Linking), 1</NO>
<PG>98-102</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Navari" MODIFIED="2011-08-23 23:18:26 +0100" MODIFIED_BY="[Empty name]" NAME="Navari" TYPE="JOURNAL_ARTICLE">
<AU>Navari R</AU>
<TI>Treatment of cancer related anorexia with megestrol acetate and olanzapine</TI>
<SO>Psycho-Oncology.Conference: 6th Annual Conference of the American Psychosocial Oncology Society, APOS Charlotte, NC United States.Conference Start: 20090205 Conference End: 20090208.Conference Publication: (var.pagings).18 (pp S47-S48), 2009.Date of</SO>
<NO>var.pagings</NO>
<PG>February</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Navari-2008" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="Navari 2008" TYPE="JOURNAL_ARTICLE">
<AU>Navari RM</AU>
<TI>Treatment of cancer-related anorexia with olanzapine and megestrol acetate [abstract no. 9576]</TI>
<SO>Journal of Clinical Oncology: ASCO annual meeting proceedings</SO>
<YR>2008</YR>
<VL>26</VL>
<PG>520</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Navari-2010" MODIFIED="2011-08-23 23:18:36 +0100" MODIFIED_BY="[Empty name]" NAME="Navari 2010" TYPE="JOURNAL_ARTICLE">
<AU>Navari RM, Brenner MC</AU>
<TI>Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial</TI>
<SO>Support.Care Cancer</SO>
<YR>2010</YR>
<VL>18</VL>
<NO>1433-7339 (Electronic), 0941-4355 (Linking), 8</NO>
<PG>951-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nelson-2002" MODIFIED="2011-08-23 23:18:42 +0100" MODIFIED_BY="[Empty name]" NAME="Nelson 2002" TYPE="JOURNAL_ARTICLE">
<AU>Nelson KA, Walsh D, Hussein M</AU>
<TI>A phase II study of low-dose megestrol acetate using twice-daily dosing for anorexia in nonhormonally dependent cancer</TI>
<SO>Am J Hosp.Palliat.Care</SO>
<YR>2002</YR>
<VL>19</VL>
<NO>1049-9091 (Print), 1049-9091 (Linking), 3</NO>
<PG>206-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-New-Reference" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="New Reference" TYPE="OTHER">
<VL>22</VL>
<NO>12</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-New-Referencea" MODIFIED="2011-08-23 23:18:49 +0100" MODIFIED_BY="[Empty name]" NAME="New Referencea" TYPE="JOURNAL_ARTICLE">
<TI>Cancer-related anorexia/cachexia an ongoing challenge despite an increasing range of drug choices</TI>
<SO>Drugs and Therapy Perspectives.17 (22) (pp 12-15), 2001.Date of Publication: 05 Nov 2001.</SO>
<NO>22</NO>
<PG>05</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-New-Referenceb" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="New Referenceb" TYPE="OTHER">
<VL>21</VL>
<NO>4B</NO>
<PG>2941-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-New-Referencec" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="New Referencec" TYPE="OTHER">
<VL>25</VL>
<NO>3</NO>
<PG>135-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-New-Referenced" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="New Referenced" TYPE="OTHER">
<VL>51 Suppl 1</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-New-Referencee" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="New Referencee" TYPE="OTHER">
<VL>11</VL>
<NO>4</NO>
<PG>762-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-New-Referencef" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="New Referencef" TYPE="OTHER">
<VL>17</VL>
<NO>10</NO>
<PG>3299-306</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-New-Referenceg" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="New Referenceg" TYPE="OTHER">
<VL>24</VL>
<NO>4</NO>
<PG>305-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-New-Referenceh" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="New Referenceh" TYPE="OTHER">
<VL>15</VL>
<NO>2</NO>
<PG>200-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-New-Referencei" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="New Referencei" TYPE="OTHER">
<VL>7</VL>
<PG>206-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-New-Referencej" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="New Referencej" TYPE="OTHER">
<VL>56</VL>
<NO>1</NO>
<PG>M54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Oster-1994" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="Oster 1994" TYPE="JOURNAL_ARTICLE">
<AU>Oster MH, Enders SR, Samuels SJ, Cone LA, Hooton TM, Browder HP, et al</AU>
<TI>Megestrol acetate in patients with AIDS and cachexia</TI>
<SO>Annals of internal medicine</SO>
<YR>1994</YR>
<VL>121</VL>
<PG>400-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pardo-2003" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="Pardo 2003" TYPE="JOURNAL_ARTICLE">
<AU>Pardo J, Mena AM, Montsech L</AU>
<TI>Megestrol acetate for anorexia in lung cancer patients undergoing radiation therapy. A randomized trial comparing the efficacy of two different doses in 130 patients [abstract]</TI>
<SO>Proceedings of the American Society of Clinical Oncology</SO>
<YR>2003</YR>
<PG>765</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Parnes-1991" MODIFIED="2011-08-23 23:18:58 +0100" MODIFIED_BY="[Empty name]" NAME="Parnes 1991" TYPE="JOURNAL_ARTICLE">
<AU>Parnes HL, Abrams JS, Tchekmedyian NS, Tait N, Aisner J</AU>
<TI>A phase I/II study of high-dose megestrol acetate in the treatment of metastatic breast cancer</TI>
<SO>Breast Cancer Research &amp; Treatment</SO>
<YR>1991</YR>
<VL>18</VL>
<NO>3</NO>
<PG>171-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pascual-2004" MODIFIED="2011-08-23 23:19:04 +0100" MODIFIED_BY="[Empty name]" NAME="Pascual 2004" TYPE="JOURNAL_ARTICLE">
<AU>Pascual Lopez A, Figuls M, Urrutia Cuchi G, Berenstein EG, Almenar Pasies B, Balcells Alegre M, et al</AU>
<TI>Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome</TI>
<SO>J Pain Symptom.Manage</SO>
<YR>2004</YR>
<VL>27</VL>
<NO>0885-3924 (Print), 0885-3924 (Linking), 4</NO>
<PG>360-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reuben-2005" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="Reuben 2005" TYPE="JOURNAL_ARTICLE">
<AU>Reuben DB, Hirsch SH, Zhou K, Greendale GA</AU>
<TI>The effects of megestrol acetate suspension for elderly patients with reduced appetite after hospitalization: a phase II randomized clinical trial</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>2005</YR>
<VL>53</VL>
<PG>970-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sanchetee" MODIFIED="2011-08-23 23:19:29 +0100" MODIFIED_BY="[Empty name]" NAME="Sanchetee" TYPE="JOURNAL_ARTICLE">
<AU>Sanchetee SC, Sanchetee S</AU>
<TI>Thalidomide versus thalidomide with Olanzapine &amp; Megastrol acetate in treatment of cachexia in gastro intestinal cancer; a randomized trial</TI>
<SO>Supportive Care in Cancer.Conference: 2010 International Multinational Association of Supportive Care in Cancer, MASCC/International Society for Oral Oncology, ISOO Symposium Vancouver, BC Canada.Conference Start: 20100624 Conference End: 20100626.Conf</SO>
<NO>var.pagings</NO>
<PG>June</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schacter-1989" MODIFIED="2011-08-23 23:20:13 +0100" MODIFIED_BY="[Empty name]" NAME="Schacter 1989" TYPE="JOURNAL_ARTICLE">
<AU>Schacter L, Rozencweig M, Canetta R, Kelley S, Nicaise C, Smaldone L</AU>
<TI>Megestrol acetate: clinical experience</TI>
<SO>Cancer Treatment Reviews</SO>
<YR>1989</YR>
<VL>16</VL>
<NO>1</NO>
<PG>49-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schmoll-1990" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="Schmoll 1990" TYPE="JOURNAL_ARTICLE">
<AU>Schmoll E, Preusser P, Wilke H, Thole R, Wildfang I, Achterrath W, et al</AU>
<TI>Placebo-controlled randomized study with two dose levels of megestrol acetate in cancer cachexia</TI>
<SO>Journal of Cancer Research &amp; Clinical Oncology</SO>
<YR>1990</YR>
<VL>116</VL>
<PG>1098</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schmoll-1991" MODIFIED="2011-08-23 23:20:20 +0100" MODIFIED_BY="[Empty name]" NAME="Schmoll 1991" TYPE="JOURNAL_ARTICLE">
<AU>Schmoll E, Wilke H, Thole R, Preusser P, Wildfang I, Schmoll HJ</AU>
<TI>Megestrol acetate in cancer cachexia</TI>
<SO>Semin.Oncol.</SO>
<YR>1991</YR>
<VL>18 Suppl 2</VL>
<NO>0093-7754 (Print), 0093-7754 (Linking)</NO>
<PG>32-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schmoll-1992" MODIFIED="2011-08-23 23:20:26 +0100" MODIFIED_BY="[Empty name]" NAME="Schmoll 1992" TYPE="JOURNAL_ARTICLE">
<AU>Schmoll E</AU>
<TI>Risks and benefits of various therapies for cancer anorexia</TI>
<SO>Oncology</SO>
<YR>1992</YR>
<VL>49 Suppl 2</VL>
<NO>0030-2414 (Print), 0030-2414 (Linking)</NO>
<PG>43-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Segui-1996" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="Segui 1996" TYPE="JOURNAL_ARTICLE">
<AU>Segui MA, Vadell C, Gimenez-Arnau JM, Morales S, Cirera L I, Bestit I, et al</AU>
<TI>Double-blind randomized trial for the treatment of cancer related cachexia: comparison of placebo vs two different doses of megestrol acetate [abstract]</TI>
<SO>Proceedings of the American Society of Clinical Oncology</SO>
<YR>1996</YR>
<VL>15</VL>
<PG>529, Abstract</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simmons-2004" MODIFIED="2011-08-23 23:20:34 +0100" MODIFIED_BY="[Empty name]" NAME="Simmons 2004" TYPE="JOURNAL_ARTICLE">
<AU>Simmons SF, Walker KA, Osterweil D</AU>
<TI>The effect of megestrol acetate on oral food and fluid intake in nursing home residents: a pilot study</TI>
<SO>J Am Med Dir.Assoc.</SO>
<YR>2004</YR>
<VL>5</VL>
<NO>1525-8610 (Print), 1525-8610 (Linking), 1</NO>
<PG>24-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Skarlos-1993" MODIFIED="2011-08-23 23:20:39 +0100" MODIFIED_BY="[Empty name]" NAME="Skarlos 1993" TYPE="JOURNAL_ARTICLE">
<AU>Skarlos DV, Fountzilas G, Pavlidis N, Beer M, Makrantonakis P, Aravantinos G, et al</AU>
<TI>Megestrol acetate in cancer patients with anorexia and weight loss. A Hellenic Co-operative Oncology Group (HeCOG) study</TI>
<SO>Acta Oncol.</SO>
<YR>1993</YR>
<VL>32</VL>
<NO>0284-186X (Print), 0284-186X (Linking), 1</NO>
<PG>37-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spaulding-1989" MODIFIED="2011-08-23 23:20:45 +0100" MODIFIED_BY="[Empty name]" NAME="Spaulding 1989" TYPE="JOURNAL_ARTICLE">
<AU>Spaulding M</AU>
<TI>Recent studies of anorexia and appetite stimulation in the cancer patient</TI>
<SO>Oncology (Williston Park)</SO>
<YR>1989</YR>
<VL>3</VL>
<NO>8:Suppl</NO>
<PG>Suppl-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Strang-1997" MODIFIED="2011-08-23 23:20:55 +0100" MODIFIED_BY="[Empty name]" NAME="Strang 1997" TYPE="JOURNAL_ARTICLE">
<AU>Strang P</AU>
<TI>The effect of megestrol acetate on anorexia, weight loss and cachexia in cancer and AIDS patients (review)</TI>
<SO>Anticancer Res</SO>
<YR>1997</YR>
<VL>17</VL>
<NO>0250-7005 (Print), 0250-7005 (Linking), 1B</NO>
<PG>657-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sullivan-2007" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="Sullivan 2007" TYPE="JOURNAL_ARTICLE">
<AU>Sullivan DH, Roberson PK, Smith ES, Price JA, Bopp MM</AU>
<TI>Effects of muscle strength training and megestrol acetate on strength, muscle mass, and function in frail older people</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>2007</YR>
<VL>55</VL>
<PG>20-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Summerbell-1992" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="Summerbell 1992" TYPE="JOURNAL_ARTICLE">
<AU>Summerbell CD, Youle M, McDonald V, Catalan J, Gazzard BG</AU>
<TI>Megestrol acetate vs cyproheptadine in the treatment of weight loss associated with HIV infection</TI>
<SO>International journal of STD &amp; AIDS</SO>
<YR>1992</YR>
<VL>3</VL>
<PG>278-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tanca-2009" MODIFIED="2011-08-23 23:21:02 +0100" MODIFIED_BY="[Empty name]" NAME="Tanca 2009" TYPE="JOURNAL_ARTICLE">
<AU>Tanca FM, Madeddu C, Maccio A, Serpe R, Panzone F, Antoni G, et al</AU>
<TI>New perspective on the nutritional approach to cancer-related anorexia/cachexia: Preliminary results of a randomised phase III clinical trial with five different arms of treatment</TI>
<SO>Mediterranean Journal of Nutrition and Metabolism</SO>
<YR>2009</YR>
<VL>2</VL>
<NO>1</NO>
<PG>29-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tchekmedyian" MODIFIED="2011-08-23 23:21:10 +0100" MODIFIED_BY="[Empty name]" NAME="Tchekmedyian" TYPE="JOURNAL_ARTICLE">
<AU>Tchekmedyian NS</AU>
<TI>Treating the anorexia/cachexia syndrome</TI>
<SO>Journal of Supportive Oncology.4 (10) (pp 506-507), 2006.Date of Publication: Nov 2006.</SO>
<NO>10</NO>
<PG>Nov</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tchekmedyian-1986a" MODIFIED="2011-08-23 23:21:22 +0100" MODIFIED_BY="[Empty name]" NAME="Tchekmedyian 1986a" TYPE="JOURNAL_ARTICLE">
<AU>Tchekmedyian NS, Tait N, Moody M, Greco FA, Aisner J</AU>
<TI>Appetite stimulation with megestrol acetate in cachectic cancer patients</TI>
<SO>Seminars in oncology</SO>
<YR>1986</YR>
<VL>13 Suppl 4</VL>
<PG>43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tchekmedyian-1987" MODIFIED="2011-08-23 23:21:34 +0100" MODIFIED_BY="[Empty name]" NAME="Tchekmedyian 1987" TYPE="JOURNAL_ARTICLE">
<AU>Tchekmedyian NS, Tait N, Moody M, Aisner J</AU>
<TI>High-dose megestrol acetate. A possible treatment for cachexia</TI>
<SO>JAMA</SO>
<YR>1987</YR>
<VL>257</VL>
<NO>9</NO>
<PG>1195-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tchekmedyian-1990" MODIFIED="2011-08-23 23:21:41 +0100" MODIFIED_BY="[Empty name]" NAME="Tchekmedyian 1990" TYPE="JOURNAL_ARTICLE">
<AU>Tchekmedyian NS, Hickman M, Siau J, Greco A, Aisner J</AU>
<TI>Treatment of cancer anorexia with megestrol acetate: impact on quality of life</TI>
<SO>Oncology</SO>
<YR>1990</YR>
<VL>4</VL>
<NO>5</NO>
<PG>185-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tchekmedyian-1992" MODIFIED="2011-08-23 23:21:47 +0100" MODIFIED_BY="[Empty name]" NAME="Tchekmedyian 1992" TYPE="JOURNAL_ARTICLE">
<AU>Tchekmedyian NS, Hickman M, Siau J, Greco FA, Keller J, Browder H, et al</AU>
<TI>Megestrol acetate in cancer anorexia and weight loss</TI>
<SO>Cancer</SO>
<YR>1992</YR>
<VL>69</VL>
<NO>0008-543X (Print), 0008-543X (Linking), 5</NO>
<PG>1268-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tchekmedyian-1993a" MODIFIED="2011-08-23 23:21:57 +0100" MODIFIED_BY="[Empty name]" NAME="Tchekmedyian 1993a" TYPE="JOURNAL_ARTICLE">
<AU>Tchekmedyian NS</AU>
<TI>Treatment of anorexia with megestrol acetate</TI>
<SO>Nutr.Clin Pract.</SO>
<YR>1993</YR>
<VL>8</VL>
<NO>0884-5336 (Print), 0884-5336 (Linking), 3</NO>
<PG>115-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ulutin-2002" MODIFIED="2011-08-23 23:22:42 +0100" MODIFIED_BY="[Empty name]" NAME="Ulutin 2002" TYPE="JOURNAL_ARTICLE">
<AU>Ulutin HC, Arpaci F, Pak Y</AU>
<TI>Megestrol acetate for cachexia and anorexia in advanced non-small cell lung cancer: a randomized study comparing two different doses</TI>
<SO>Tumori</SO>
<YR>2002</YR>
<VL>88</VL>
<NO>0300-8916 (Print), 0300-8916 (Linking), 4</NO>
<PG>277-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Von-Roenn-1994" MODIFIED="2011-08-23 23:23:04 +0100" MODIFIED_BY="[Empty name]" NAME="Von Roenn 1994" TYPE="JOURNAL_ARTICLE">
<AU>Von Roenn JH</AU>
<TI>Randomized trials of megestrol acetate for AIDS-associated anorexia and cachexia</TI>
<SO>Oncology</SO>
<YR>1994</YR>
<VL>51 Suppl 1</VL>
<NO>0030-2414 (Print), 0030-2414 (Linking)</NO>
<PG>19-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Von_x002d_Roenn-1994" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="Von-Roenn 1994" TYPE="JOURNAL_ARTICLE">
<AU>Von-Roenn JH, Armstrong D, Kotler DP, Cohn DL, Klimas NG, Tchekmedyian NS, et al</AU>
<TI>Megestrol acetate in patients with AIDS-related cachexia</TI>
<SO>Annals of internal medicine</SO>
<YR>1994</YR>
<VL>121</VL>
<PG>393-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weisberg-2001" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="Weisberg 2001" TYPE="JOURNAL_ARTICLE">
<AU>Weisberg J, Casaburi R, Olson J, Wagner J</AU>
<TI>Megestrol acetate induces weight gain and stimulates ventilation in underweight COPD patients: A randomized, double-blind, placebo-controlled, multi-centre trial</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2001</YR>
<VL>163</VL>
<PG>A503</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weisberg-2002" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="Weisberg 2002" TYPE="JOURNAL_ARTICLE">
<AU>Weisberg J, Wanger J, Olson J, Streit B, Fogarty C, Martin T, et al</AU>
<TI>Megestrol acetate stimulates weight gain and ventilation in underweight COPD patients</TI>
<SO>Chest</SO>
<YR>2002</YR>
<VL>121</VL>
<PG>1070-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Westman-1999" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="Westman 1999" TYPE="JOURNAL_ARTICLE">
<AU>Westman G, Bergman B, Albertsson M, Kadar L, Gustavsson G, Thaning L, et al</AU>
<TI>Megestrol acetate in advanced, progressive, hormone-insensitive cancer. Effects on the quality of life: a placebo-controlled, randomised, multicentre trial</TI>
<SO>European journal of cancer</SO>
<YR>1999</YR>
<VL>35</VL>
<PG>586-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yavuzsen-2005" MODIFIED="2011-08-23 23:23:26 +0100" MODIFIED_BY="[Empty name]" NAME="Yavuzsen 2005" TYPE="JOURNAL_ARTICLE">
<AU>Yavuzsen T, Davis MP, Walsh D, LeGrand S, Lagman R</AU>
<TI>Systematic review of the treatment of cancer-associated anorexia and weight loss</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>33</NO>
<PG>8500-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yeh" MODIFIED="2011-08-23 23:23:33 +0100" MODIFIED_BY="[Empty name]" NAME="Yeh" TYPE="JOURNAL_ARTICLE">
<AU>Yeh S-S, Lovitt S, Schuster MW</AU>
<TI>Usage of megestrol acetate in the treatment of anorexia-cachexia syndrome in the elderly</TI>
<SO>Journal of Nutrition, Health and Aging.13 (5) (pp 448-454), 2009.Date of Publication: May 2009.</SO>
<NO>5</NO>
<PG>May</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yeh-2000" MODIFIED="2011-08-23 23:23:40 +0100" MODIFIED_BY="[Empty name]" NAME="Yeh 2000" TYPE="JOURNAL_ARTICLE">
<AU>Yeh S, Wu SY, Levine DM, Parker TS, Olson JS, Stevens MR, et al</AU>
<TI>Quality of life and stimulation of weight gain after treatment with megestrol acetate: correlation between cytokine levels and nutritional status, appetite in geriatric patients with wasting syndrome</TI>
<SO>Journal of Nutrition, Health &amp; Aging</SO>
<YR>2000</YR>
<VL>4</VL>
<NO>4</NO>
<PG>246-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yeh-2007" MODIFIED="2011-08-23 23:23:49 +0100" MODIFIED_BY="[Empty name]" NAME="Yeh 2007" TYPE="JOURNAL_ARTICLE">
<AU>Yeh SS, Lovitt S, Schuster MW</AU>
<TI>Pharmacological treatment of geriatric cachexia: evidence and safety in perspective</TI>
<SO>J Am Med Dir.Assoc.</SO>
<YR>2007</YR>
<VL>8</VL>
<NO>1538-9375 (Electronic), 1525-8610 (Linking), 6</NO>
<PG>363-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yeh-2009" MODIFIED="2011-08-23 23:24:06 +0100" MODIFIED_BY="[Empty name]" NAME="Yeh 2009" TYPE="JOURNAL_ARTICLE">
<AU>Yeh SS, Lovitt S, Schuster MW</AU>
<TI>Usage of megestrol acetate in the treatment of anorexia-cachexia syndrome in the elderly</TI>
<SO>Journal of Nutrition, Health &amp; Aging</SO>
<YR>2009</YR>
<VL>13</VL>
<NO>5</NO>
<PG>448-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yeh-2010" MODIFIED="2011-08-23 23:24:17 +0100" MODIFIED_BY="[Empty name]" NAME="Yeh 2010" TYPE="JOURNAL_ARTICLE">
<AU>Yeh SS, Marandi M, Thode HC Jr, Levine DM, Parker T, Dixon T, et al</AU>
<TI>Report of a pilot, double-blind, placebo-controlled study of megestrol acetate in elderly dialysis patients with cachexia</TI>
<SO>Journal of Renal Nutrition</SO>
<YR>2010</YR>
<VL>20</VL>
<NO>1</NO>
<PG>52-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zecca-1995" MODIFIED="2011-08-23 18:54:11 +0100" MODIFIED_BY="[Empty name]" NAME="Zecca 1995" TYPE="JOURNAL_ARTICLE">
<AU>Zecca E</AU>
<TI>Efficacy of megestrol acetate on anorexia in patients with advanced non hormone-related tumors: a double-blind placebo controlled clinical trial [abstract no: 1253]</TI>
<SO>European journal of cancer</SO>
<YR>1995</YR>
<VL>31A</VL>
<PG>S261</PG>
<IDENTIFIERS/>
</REFERENCE>
</PENDING_REFERENCES>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-02-11 09:25:53 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-02-11 09:25:53 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-02-05 16:24:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Batterham-2001">
<CHAR_METHODS MODIFIED="2013-01-30 11:16:09 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled in a tertiary referral hospital, Sydney</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-05 16:24:36 +0000" MODIFIED_BY="[Empty name]">
<P>15 HIV pts<BR/>a) 4 M <BR/>Mean age 46 yrs<BR/>b) 8 M <BR/>Mean age 44 yrs<BR/>c) 5 M <BR/>Mean age 42 yrs<BR/>5 completed and then randomised 3 to nandrolone and 2 to megestrol</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-05 16:24:36 +0000" MODIFIED_BY="[Empty name]">
<P>a) MA 400 mg/d orally<BR/>b) Nandrolone decanoate 100 mg/fortnight as an intramuscular injection<BR/>c) Dietary counselling<BR/>Duration 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-05 16:24:37 +0000" MODIFIED_BY="[Empty name]">
<P>Weight and height<BR/>Appetite VAS 10-point score<BR/>0 = poor appetite<BR/>10 = good appetite<BR/>Dietary intake %</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-05 16:24:37 +0000" MODIFIED_BY="[Empty name]">
<P>12 weeks of treatment<BR/>QS = 2</P>
<P>Cachexia was defined as unintentional weight loss of at least 5% of their usual body weight despite an adequate nutritional intake (&gt; 85% estimated requirements calculated using the Harris Benedict equation)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-05 16:24:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Beller-1997">
<CHAR_METHODS MODIFIED="2013-02-05 16:24:37 +0000" MODIFIED_BY="[Empty name]">
<P>Double-blind, randomised, controlled, multicentre (15), stratified by institution and whether receiving any antitumour treatment<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-05 16:24:37 +0000" MODIFIED_BY="[Empty name]">
<P>240 cancer pts<BR/>a) 81 pts = 53 M + 28 F<BR/>(9 pts = 50 yrs, 49 pts = 51 to 70 yrs, 23 pts = &gt; 71 yrs)</P>
<P>b) 80 pts = 52 M + 28 F<BR/>(7 pts = less than 50 yrs, 52 pts = 51 to 70 yrs, 21 pts = &gt; 70 yrs)</P>
<P>c) 79 pts = 54 M + 25 F<BR/>(12 pts = 50 yrs, 51 pts = 51 to 70 yrs, 16 pts = &gt; 70 yrs)</P>
<P>Patients were excluded if they were under 18 years of age, had physical or functional obstruction to food intake or impaired digestive/absorptive function, were pregnant, were receiving concurrent corticosteroid treatment, were unable to complete quality of life forms, had endocrine-sensitive malignant disease (i.e. of breast, prostate, uterus), had a life expectancy of less than 2 months, or were diabetic</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-05 16:24:37 +0000" MODIFIED_BY="[Empty name]">
<P>a) MA 480 mg/d orally<BR/>b) MA 160 mg/d<BR/>c) Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-05 16:24:37 +0000" MODIFIED_BY="[Empty name]">
<P>QoL 5 linear analogue self assessment scales (LASA) asked patients about 5 factors: physical well being, mood, pain, nausea and vomiting, and appetite, LASA uni scale of overall QoL and the Spitzer QoL Index, completed by the clinician<BR/>Appetite (LASA score)<BR/>Nutritional status<BR/>Weight<BR/>Triceps skinfold<BR/>Mid-arm circumference</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-05 16:24:37 +0000" MODIFIED_BY="[Empty name]">
<P>2 weeks of treatment<BR/>QS = 3</P>
<P>Cachexia was defined as a body weight at least 5% below ideal, or unintentional loss of at least 5% of usual body weight, and eligible for the study. Withdrawals from randomised treatment (other than death whilst still on treatment) included drug intolerance or toxicity in 28 cases, deterioration in patient's condition not attributed to study treatment in 36 cases, and refusal by patient to continue in the study in 18 cases. &#8220;The proportion of incomplete data and withdrawals from treatment was very similar for the three treatment groups&#8221;.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-05 16:24:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Casado-2008">
<CHAR_METHODS MODIFIED="2013-02-05 16:24:37 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial, not blinded</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-05 16:24:37 +0000" MODIFIED_BY="[Empty name]">
<P>94 patients with non hormone-sensitive cancer</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-05 16:24:37 +0000" MODIFIED_BY="[Empty name]">
<P>MA tablets 160 mg</P>
<P>MA tablets 960 mg</P>
<P>Placebo</P>
<P>At least 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-05 16:24:37 +0000" MODIFIED_BY="[Empty name]">
<P>Weight QoL, appetite</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-05 16:24:37 +0000" MODIFIED_BY="[Empty name]">
<P>Cachexia was defined as weight loss of &lt; 5% of ideal weight</P>
<P>QS: 2</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-11 09:25:20 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-Conno-1998">
<CHAR_METHODS MODIFIED="2013-02-05 16:24:39 +0000" MODIFIED_BY="[Empty name]">
<P>Double-blind, randomised, controlled</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-05 16:24:39 +0000" MODIFIED_BY="[Empty name]">
<P>42 patients with advanced non hormone-responsive tumours<BR/>a) 21 pts = 15 M + 6 F<BR/>Mean age 63 yrs<BR/>b) 21 pts = 16 M + 5 F<BR/>Mean age 58 yrs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-05 16:24:39 +0000" MODIFIED_BY="[Empty name]">
<P>Phase A is a double-blind, placebo-controlled trial comparing MA 320 mg/day versus placebo for 2 weeks. In phase B all patients were treated with MA and the dosage was titrated according to clinical response for 76 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-11 09:25:20 +0000" MODIFIED_BY="[Empty name]">
<P>Appetite score (numeric scale ranging from 0 to 10), Karnofsky, weight, subjective food intake, pain intensity, patient's preference and quality of life (TIQ sub scales)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-05 16:24:39 +0000" MODIFIED_BY="[Empty name]">
<P>14 days of treatment<BR/>QS = 3</P>
<P>Withdrawals in the Phase A were 4 in MA and 5 in placebo group. Cachexia was not defined but patients had a weight loss of &gt; 10%</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-05 16:24:40 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Eubanks-2002">
<CHAR_METHODS MODIFIED="2013-01-30 11:32:30 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-05 16:24:39 +0000" MODIFIED_BY="[Empty name]">
<P>17 cystic fibrosis patients with growth failure, most &lt; 18 years old<BR/>a) 10 pts = 5 M + 4 F<BR/>Ranging from age 6 to 18 yrs, 1 F 35 yrs<BR/>b) 7 pts = 3 F + 4 M<BR/>Ranging from age 6 to 15 yrs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-05 16:24:39 +0000" MODIFIED_BY="[Empty name]">
<P>a) MA 10 mg/kg per day<BR/>b) Placebo</P>
<P>On day 0 of the study, patients were randomly assigned to receive either MA (n = 10) or placebo (n = 7) at a starting dose of 10 mg/kg per day. Medication doses were increased by 2.5 mg/kg per day for weight gain &lt; 2% above baseline at day 30 or &lt; 5% above baseline at days 60 or 90 (maximum dose, 15 mg/kg per day). Doses were decreased for weight gain &gt; 5% above baseline at day 30 or &gt; 10% above baseline at days 60 or 90. Medication doses were decreased by 2.5 mg/kg per day for side effects. At the conclusion of this study, the mean dose of MA was 7.5 mg/kg per day and the mean dose of placebo was 13.9 mg/kg per day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-05 16:24:40 +0000" MODIFIED_BY="[Empty name]">
<P>Weight for age (WAZ) gain included both fat and fat-free mass</P>
<P>Improved pulmonary function (forced vital capacity and forced expiratory volume in 1 second) and side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-05 16:24:40 +0000" MODIFIED_BY="[Empty name]">
<P>Growth failure defined as no weight gain in the preceding 6 months, per cent ideal body weight of &lt; 85%, weight &lt; 5th percentile for age, or weight for height &lt; 5th percentile</P>
<P>Follow-up was 180 days</P>
<P>QS = 4</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-05 16:24:41 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Feliu-1992">
<CHAR_METHODS MODIFIED="2013-02-05 16:24:40 +0000" MODIFIED_BY="[Empty name]">
<P>Double-blind randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-05 16:24:40 +0000" MODIFIED_BY="[Empty name]">
<P>150 cancer patients with cancer non hormone-dependent<BR/>a) 76 pts = 58 M + 8 F<BR/>Mean age 57 yrs<BR/>b) 74 pts = 55 M + 7 F<BR/>Mean age 58 yrs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-05 16:24:40 +0000" MODIFIED_BY="[Empty name]">
<P>a) MA 240 mg/day<BR/>b) Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-05 16:24:41 +0000" MODIFIED_BY="[Empty name]">
<P>Body weight, appetite (described as changes in SSA score in 2 ranges: 0 to 5 and 6 to 10)<BR/>Functional status (PS score described as 2 ranges: less than 60% and more than 60%)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-05 16:24:41 +0000" MODIFIED_BY="[Empty name]">
<P>2 months of treatment<BR/>QS = 4</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-05 16:24:42 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fietkau-1996">
<CHAR_METHODS MODIFIED="2013-02-05 16:24:42 +0000" MODIFIED_BY="[Empty name]">
<P>Double-blind randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-05 16:24:42 +0000" MODIFIED_BY="[Empty name]">
<P>64 cancer patients with head and neck cancer<BR/>61 pts:<BR/>a) 31 pts = 25 M + 6 F<BR/>Mean age 52 yrs<BR/>b) 30 pts = 24 M + 6 F<BR/>Mean age 48 yrs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-05 16:24:42 +0000" MODIFIED_BY="[Empty name]">
<P>a) MA 160 mg/day<BR/>b) Placebo</P>
<P>During 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-24 21:48:29 +0000" MODIFIED_BY="[Empty name]">
<P>Weight, anthropometric and biochemical parameters, and QoL (Padilla Index)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-05 16:24:42 +0000" MODIFIED_BY="[Empty name]">
<P>6 weeks of treatment during and up 6 weeks following radiotherapy</P>
<P>Pts were stratified according oral feeding versus gastrostomy</P>
<P>Definition of cachexia was weight loss of 5% over 6 weeks or 10% over the 6 months prior to radiotherapy</P>
<P>Withdrawals were 1 in MA group and 2 more in placebo group</P>
<P>QS = 3</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-05 16:24:44 +0000" MODIFIED_BY="Jessica Thomas" STUDY_ID="STD-Gambardella-1998">
<CHAR_METHODS MODIFIED="2013-02-05 16:24:42 +0000" MODIFIED_BY="Jessica Thomas">
<P>Double-blind randomised controlled</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-05 16:24:44 +0000" MODIFIED_BY="Jessica Thomas">
<P>30 elderly cancer patients, 15 in each arm</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-02-13 19:45:03 +0000" MODIFIED_BY="Jessica Thomas">
<P>MA 320 mg daily versus placebo for 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-09 22:06:56 +0100" MODIFIED_BY="Jessica Thomas">
<P>Weight, serum levels of interleukins and QoL</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-05 16:24:44 +0000" MODIFIED_BY="Jessica Thomas">
<P>We found just 2 proceedings reporting this trial</P>
<P>Cachexia was defined as weight loss &lt; 6 kg in last 3 months</P>
<P>Follow-up was 12 weeks<BR/>No data about weight in placebo group</P>
<P>QS: 1</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-05 16:24:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gebbia-1996">
<CHAR_METHODS MODIFIED="2012-01-02 16:54:25 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-05 16:24:44 +0000" MODIFIED_BY="[Empty name]">
<P>122 cancer pts<BR/>a) 62 pts = 46 M + 16 F<BR/>Mean age 63 yrs<BR/>b) 60 pts = 42 M + 18 F<BR/>Mean age 65 yrs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>a) MA 160 mg/d<BR/>b) MA 320 mg/d</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-05 16:24:44 +0000" MODIFIED_BY="[Empty name]">
<P>Appetite, body weight, pain, survival, Karnofsky Index</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-05 16:24:44 +0000" MODIFIED_BY="[Empty name]">
<P>30 days of treatment<BR/>QS = 2</P>
<P>Definition of cachexia was weight loss &gt; 5%</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-05 16:24:45 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Giacosa-1997">
<CHAR_METHODS MODIFIED="2013-02-05 16:24:45 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-05 16:24:45 +0000" MODIFIED_BY="[Empty name]">
<P>28 patients with non hormone-sensitive cancer</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-05 16:24:45 +0000" MODIFIED_BY="[Empty name]">
<P>MA 320 mg/day plus standardised dietary counselling versus standardised dietary counselling (35 Kcal/day)<BR/>30 days of intervention</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-05 16:24:45 +0000" MODIFIED_BY="[Empty name]">
<P>Body weight, appetite, daily food intake, body composition, psychological distress</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-05 16:24:45 +0000" MODIFIED_BY="[Empty name]">
<P>Withdrawal: 10 patients were unevaluated due to early death (5 in each group)</P>
<P>Cachexia was defined as weight loss &gt; 10% of usual weight</P>
<P>QS: 2</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-05 16:24:47 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Heckmayr-1992">
<CHAR_METHODS MODIFIED="2013-02-05 16:24:46 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-05 16:24:46 +0000" MODIFIED_BY="[Empty name]">
<P>66 patients with advanced bronchogenic carcinomas<BR/>a) 33 pts = 24 M + 9 F<BR/>Mean age 65 yrs<BR/>b) 33 pts = 27 M + 6 F<BR/>Mean age 68 yrs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-25 15:28:12 +0000" MODIFIED_BY="[Empty name]">
<P>a) MA 160 mg/daily<BR/>b) MA 480 mg/daily </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-05 16:24:47 +0000" MODIFIED_BY="[Empty name]">
<P>Weight</P>
<P>Well being</P>
<P>Appetite (subjective 10-point scale)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-05 16:24:47 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment for 4 to 16 weeks</P>
<P>Cachexia was defined as body weight loss &gt; 10%<BR/>QS = 1</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-05 16:24:50 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Herrejon-2011">
<CHAR_METHODS MODIFIED="2013-02-05 16:24:50 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial, double-blinded</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-28 08:45:22 +0000" MODIFIED_BY="[Empty name]">
<P>40 patients with stable COPD (without any exacerbation during the study)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-05 16:24:50 +0000" MODIFIED_BY="[Empty name]">
<P>320 mg MA daily during 8 weeks versus placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-09 22:09:43 +0100" MODIFIED_BY="[Empty name]">
<P>Body weight, triceps skin fold thickness and analytic values</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-05 16:24:50 +0000" MODIFIED_BY="[Empty name]">
<P>Cachexia was defined as body weight less &gt; 5%</P>
<P>QS: 5</P>
<P>NCT00507949</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-05 16:24:51 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jatoi-2002">
<CHAR_METHODS MODIFIED="2013-02-05 16:24:50 +0000" MODIFIED_BY="[Empty name]">
<P>Double-blind randomised controlled, multicentre (20)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-05 16:24:50 +0000" MODIFIED_BY="[Empty name]">
<P>469 cancer patients with cancer-associated anorexia other than brain, breast, ovarian or endometrial cancer<BR/>a) 159 pts = 103 M + 56 F<BR/>Mean age 65 yrs</P>
<P>b)152 pts = 100 M + 52 F<BR/>Mean age 67 yrs<BR/>c) 158 pts = 104 M + 54 F <BR/>Mean age 67 yrs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-05 16:24:50 +0000" MODIFIED_BY="[Empty name]">
<P>a) MA 800 mg/d liquid suspension +2 capsules placebo<BR/>b) Dronabinol capsules 2.5 mg orally x + liquid placebo<BR/>c) MA suspension 800 mg/d + dronabinol capsules 2.5 mg x 2</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-05 16:24:51 +0000" MODIFIED_BY="[Empty name]">
<P>Appetite (validated questionnaires)<BR/>Weight<BR/>QoL Functional Assessment of Anorexia/Cachexia Therapy (FAACT) instrument uni scale and 13-item</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-05 16:24:51 +0000" MODIFIED_BY="[Empty name]">
<P>Cachexia was defined as body weight loss &gt; 5 pounds (2.3 kg) during the preceding 2 months<BR/>QS = 4</P>
<P>Follow-up: as long as patients and healthcare providers thought it beneficial or until toxic side effects were shown. Follow-up median: 80 days (MA), 57 (DRO), 74 (MA+ DRO) (duration more than 4 weeks of treatment)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-05 16:24:52 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jatoi-2004">
<CHAR_METHODS MODIFIED="2013-02-05 16:24:52 +0000" MODIFIED_BY="[Empty name]">
<P>Double-blind randomised controlled, multicentre (26)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-05 16:24:52 +0000" MODIFIED_BY="[Empty name]">
<P>421 cancer pts<BR/>a) 140 pts = 97 M + 43 F<BR/>Mean age 65 yrs<BR/>b) 141 pts = 104 M + 37 F<BR/>Mean age 66 yrs<BR/>c) 140 pts = 92 M + 48 F<BR/>Mean age 66 yrs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-05 16:24:52 +0000" MODIFIED_BY="[Empty name]">
<P>a) MA 600 mg/d liquid suspension + isocaloric, isonitrogenous placebo cans<BR/>b) EPA supplement, 2 cans/d + placebo liquid suspension<BR/>c) EPA supplement 2 cans/d plus MA liquid suspension 600 mg/d orally in combination</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-05 16:24:52 +0000" MODIFIED_BY="[Empty name]">
<P>Weight<BR/>Appetite (NCCTG questionnaire and FAACT)<BR/>QoL (single-item uniscale)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-05 16:24:52 +0000" MODIFIED_BY="[Empty name]">
<P>Duration more than 3 months (patients continued treatment as long as both the patient and treating oncologist considered it beneficial or until concerning or intolerable side effects occurred)</P>
<P>Cachexia was defined as a self reported, 2-month weight loss of at least 5 lb (2.3 kg)<BR/>QS = 4</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-05 16:24:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lesser-2006">
<CHAR_METHODS MODIFIED="2012-02-01 18:28:02 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised clinical trial </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-05 16:24:53 +0000" MODIFIED_BY="[Empty name]">
<P>Cancer patients with solid tumours and cachexia that were receiving chemotherapy</P>
<P>74 pts accrued (72 eligible)<BR/>Median age 64 yrs<BR/>42% females and 62% stage 4 disease<BR/>25 pts (arm 1: 8, arm 2: 17) completed 12 weeks of therapy and 20 remained in study</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-05 16:24:54 +0000" MODIFIED_BY="[Empty name]">
<P>The effects of oxandrolone and megestrol (no more details about doses) on weight, body composition and QoL in pts with solid tumours and weight loss receiving chemotherapy</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-05 16:24:54 +0000" MODIFIED_BY="[Empty name]">
<P>Weight, body composition (main outcome) and QoL</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-02-19 16:34:28 +0000" MODIFIED_BY="[Empty name]">
<P>Cachexia was defined as progressive weight loss on chemotherapy</P>
<P>12 weeks of follow-up</P>
<P>QS: 1</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-05 16:24:55 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Loprinzi-1990b">
<CHAR_METHODS MODIFIED="2013-02-05 16:24:54 +0000" MODIFIED_BY="[Empty name]">
<P>Double-blind randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-05 16:24:54 +0000" MODIFIED_BY="[Empty name]">
<P>133 cancer pts (adults with advanced, incurable cancer - other than  breast or endometrial cancer - who were experiencing anorexia, cachexia or both)<BR/>a) 66 pts = 44 M + 23 F<BR/>Mean age 69 yrs<BR/>b) 67 pts = 44 M + 22 F<BR/>Mean age 67 yrs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-05 16:24:55 +0000" MODIFIED_BY="[Empty name]">
<P>a) MA 800 mg/d (5 tablets per day of 160 mg of MA)<BR/>b) Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Weight<BR/>Appetite</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-05 16:24:55 +0000" MODIFIED_BY="[Empty name]">
<P>1 month of treatment<BR/>QS = 4</P>
<P>Cachexia defined as loss of body weight in the preceding 2 months of at least 5 lb</P>
<P>Follow-up: median 1.6 months</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-05 16:24:55 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Loprinzi-1994">
<CHAR_METHODS MODIFIED="2012-02-19 17:08:00 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-05 16:24:55 +0000" MODIFIED_BY="[Empty name]">
<P>342 cancer pts<BR/>a) 88 pts = 56 M + 32 F<BR/>Mean age 67 yrs<BR/>b) 86 pts = 54 M + 32 F<BR/>Mean age 67 yrs<BR/>c) 85 pts = 55 M + 30 F<BR/>Mean age 67 yrs<BR/>d) 83 pts = 54 M + 29 F<BR/>Mean age 66 yrs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>a) MA 160 mg/d<BR/>b) MA 480 mg/d<BR/>c) MA 800 mg/d<BR/>d) MA 1280 mg/d</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-02-20 22:23:20 +0000" MODIFIED_BY="[Empty name]">
<P>Weight (primary outcome)<BR/>Appetite, perceived food intake<BR/>Serum albumin<BR/>Toxicity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-05 16:24:55 +0000" MODIFIED_BY="[Empty name]">
<P>Median 66 days of treatment (9 weeks)<BR/>QS = 1</P>
<P>Cachexia: the study required each patient to have lost at least 2.27 kg within the preceding 2 months or have an estimated daily caloric intake less than 20 kcal/kg</P>
<P>Withdrawals low doses (160 + 480 mg/d of MA): 28 patients versus high doses (800 mg + 1280 mg/d of MA): 39 patients<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-05 16:24:57 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Loprinzi-1999a">
<CHAR_METHODS MODIFIED="2013-02-05 16:24:57 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, controlled, multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-05 16:24:57 +0000" MODIFIED_BY="[Empty name]">
<P>475 cancer pts<BR/>a) 79 pts = 55 M + 30 F<BR/>Mean age 66 yrs<BR/>b) 159 pts = 99 M + 60 F <BR/>Mean age 66 yrs<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-05 16:24:57 +0000" MODIFIED_BY="[Empty name]">
<P>a) MA 800 mg/d<BR/>b) Dexamethasone 3 mg/d</P>
<P>1 month of treatment</P>
<P>The median durations of study for patients receiving MA, fluoxymesterone and dexamethasone were 64, 54 and 57 days<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-24 17:21:42 +0100" MODIFIED_BY="[Empty name]">
<P>Appetite<BR/>Weight<BR/>QoL (uni scale)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-05 16:24:57 +0000" MODIFIED_BY="[Empty name]">
<P>QS = 2</P>
<P>Cachexia was defined as a history of losing at least 5 pounds within the previous 2 months (excluding perioperative weight loss)</P>
<P>Quality of life, weight and body composition are assessed at baseline and monthly intervals</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-05 16:24:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Loprinzi-1999b">
<CHAR_METHODS MODIFIED="2013-02-05 16:24:58 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, controlled, multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-05 16:24:58 +0000" MODIFIED_BY="[Empty name]">
<P>475 cancer adult patients with advanced incurable cancer (other than breast, prostate, ovarian or endometrial cancer)<BR/>a) 79 pts = 54 M + 29 F<BR/>Mean age 66 yrs<BR/>b) 158 pts = 100 M + 58 F <BR/>Mean age 67 yrs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-05 16:24:58 +0000" MODIFIED_BY="[Empty name]">
<P>a) MA 800 mg/d<BR/>b) Fluoxymesterone 20 mg/d</P>
<P>1 month of treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-12-17 17:49:23 +0000" MODIFIED_BY="[Empty name]">
<P>Appetite<BR/>Weight<BR/>QoL (uni scale)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-05 16:24:58 +0000" MODIFIED_BY="[Empty name]">
<P>The median durations of study for patients receiving MA, fluoxymesterone and dexamethasone were 64, 54 and 57 days</P>
<P>1 month of treatment<BR/>QS = 2</P>
<P>Cachexia was defined as a history of losing at least 5 pounds within the previous 2 months (excluding perioperative weight loss)</P>
<P>Quality of life, weight and body composition are assessed at baseline and monthly intervals</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-05 16:25:00 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Macbeth-1994">
<CHAR_METHODS MODIFIED="2013-02-05 16:25:00 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial, single-blinded</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-02-05 19:15:23 +0000" MODIFIED_BY="[Empty name]">
<P>75 patients with advanced lung cancer</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-05 16:25:00 +0000" MODIFIED_BY="[Empty name]">
<P>38 patients received MA (460 mg/daily) and 37 patients received prednisolone (15 mg/day) for a minimum of 8 weeks<BR/>Medication was suspended if the patient achieved their ideal weight</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-02-05 19:15:23 +0000" MODIFIED_BY="[Empty name]">
<P>Weight, anorexia, quality of life</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-05 16:25:00 +0000" MODIFIED_BY="[Empty name]">
<P>Withdrawals were 28 in the MA and 20 in the placebo group; the major cause was deaths: 14 in the MA group and 7 in the placebo</P>
<P>Cachexia was defined as loss of &gt; 5% of ideal body weight</P>
<P>Trial was stopped at 12 weeks</P>
<P>QS: 2</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-08 09:36:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Madeddu-2012">
<CHAR_METHODS MODIFIED="2013-02-05 16:25:00 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised</P>
<P>Non-inferiority</P>
<P>Open-label</P>
<P>Single-centre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-05 16:25:00 +0000" MODIFIED_BY="[Empty name]">
<P>60 patients (56 evaluable) with cancer and a life expectancy &#8805; 4 months</P>
<P>33 M/23 F</P>
<P>Age (years) 62.6 ± 8.1 versus 66.3 ± 10.7 (MA group)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-08 09:36:04 +0000" MODIFIED_BY="[Empty name]">
<P>a) Polyphenols  + L-carnitine 4 G/day + celecoxib 300 mg/day</P>
<P>b) Polyphenols + L-carnitine 4 G/day + celecoxib 300 mg/day + MA 320 mg/day</P>
<P>Follow-up 16 weeks (4 months)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-05 16:25:00 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: lean body weight, physical activity</P>
<P>Secondary: grip strength, 6-minute walk test, fatigue, resting energy expenditure (REE), body weight, appetite by visual analogue scale, serum levels of IL-6 and TNF-a, plasma levels of C-reactive protein, quality of life (EORTC QLQ-C30) and Glasgow Prognostic Score</P>
<P>Clinical: objective clinical response, progression-free survival (PFS) and overall survival (OS)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-05 16:25:00 +0000" MODIFIED_BY="[Empty name]">
<P>Cachexia  loss &gt; 5% ideal or pre illness weight</P>
<P>56 patients evaluable: 4 deaths, 2 in each group</P>
<P>QS = 2</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-05 16:25:00 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McMillan-1994">
<CHAR_METHODS MODIFIED="2013-02-05 16:25:00 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial, double-blinded</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-05 16:25:00 +0000" MODIFIED_BY="[Empty name]">
<P>38 cancer pts<BR/>a) 20 pts<BR/>Mean age 73 yrs<BR/>b) 18 pts<BR/>Mean age 70 yrs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-05 16:25:00 +0000" MODIFIED_BY="[Empty name]">
<P>a) MA 480 mg/d<BR/>b) Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Weight</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-02-19 17:15:29 +0000" MODIFIED_BY="[Empty name]">
<P>12 weeks of treatment<BR/>QS = 3</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-05 16:25:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mwamburi-2004">
<CHAR_METHODS MODIFIED="2012-02-19 17:23:09 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-10 17:15:57 +0000" MODIFIED_BY="[Empty name]">
<P>40 patients with HIV that were receiving HAART (highly active antiretroviral therapy)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-05 16:25:01 +0000" MODIFIED_BY="[Empty name]">
<P>20 patients MA (800 mg/day) versus 20 patients oxandrolone (20 mg/day) for 2 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-05 16:25:01 +0000" MODIFIED_BY="[Empty name]">
<P>Weight, side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-05 16:25:01 +0000" MODIFIED_BY="[Empty name]">
<P>2 patients dropped out at 2 months in the MA group and 4 in the oxandrolone group. Finally 18 patients and 15 patients were used for analysis in the MA and oxandrolone groups, respectively.</P>
<P>Cachexia was defined as weight loss &gt; 5% during HAART </P>
<P>QS: 3</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-05 16:25:02 +0000" MODIFIED_BY="Jessica Thomas" STUDY_ID="STD-Oster-1994">
<CHAR_METHODS MODIFIED="2013-02-05 16:25:01 +0000" MODIFIED_BY="[Empty name]">
<P>Double-blind, randomised, controlled, multicentre (13)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-05 16:25:01 +0000" MODIFIED_BY="[Empty name]">
<P>100 AIDS pts<BR/>a) 52 pts = 50 M + 2 F<BR/>Mean age 40 yrs<BR/>b) 48 pts = 47 M + 1 F <BR/>Mean age 40 yrs</P>
<P>Mean age 40.00 ± 14 in placebo group and 40 ± 7.2 in MA group</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-05 16:25:02 +0000" MODIFIED_BY="[Empty name]">
<P>a) MA 800 mg/d suspension<BR/>b) Placebo, suspension</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-05 16:25:02 +0000" MODIFIED_BY="Jessica Thomas">
<P>Weight</P>
<P>Appetite<BR/>Triceps skinfold<BR/>Mid-arm circumference<BR/>Performance status KI</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-15 16:39:43 +0000" MODIFIED_BY="[Empty name]">
<P>12 weeks of treatment<BR/>QS = 4</P>
<P>Cachexia was defined as loss of 10% or more of ideal body weight</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-05 16:25:02 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sancho_x002d_Cuesta-1993">
<CHAR_METHODS MODIFIED="2013-02-05 16:25:02 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-10 18:11:28 +0000" MODIFIED_BY="[Empty name]">
<P>Patients with advanced cancer, anorexia and weight loss</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-10 18:11:42 +0000" MODIFIED_BY="[Empty name]">
<P>50 patients MA 160 mg daily versus 50 patients 320 mg daily for 24 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-05 16:25:02 +0000" MODIFIED_BY="[Empty name]">
<P>Weight gain, side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-05 16:25:02 +0000" MODIFIED_BY="[Empty name]">
<P>Loss to follow-up not described</P>
<P>Cachexia was not defined</P>
<P>QS: 1</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-07 12:00:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schmoll-1991">
<CHAR_METHODS MODIFIED="2013-02-05 16:25:03 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial, not blinded</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-07 12:00:04 +0000" MODIFIED_BY="[Empty name]">
<P>55 patients with advanced cancer</P>
<P>Placebo 61 years mean ages</P>
<P>MA low-dose 50 years mean ages</P>
<P>MA high-dose 58 years mean ages</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-05 16:25:03 +0000" MODIFIED_BY="[Empty name]">
<P>18 patients received high-dose MA (960 mg/daily) versus 20 patients low-dose MA (480 mg/daily) versus 17 patients placebo for 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-02-05 19:35:06 +0000" MODIFIED_BY="[Empty name]">
<P>Weight, appetite improvement, adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-05 16:25:03 +0000" MODIFIED_BY="[Empty name]">
<P>Losses to follow-up were 9 in the placebo group, 5 in the low-dose group and 7 in the high-dose group</P>
<P>Deaths: 8, 4 and 4 placebo, high-dose and low-dose</P>
<P>Not evaluable: 1, 1 and 3 respectively</P>
<P>Cachexia was defined as loss of &gt; 5% of ideal body weight</P>
<P>QS = 2</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-05 16:25:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schmoll-1992">
<CHAR_METHODS MODIFIED="2013-02-05 16:25:03 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial, not blinded</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-05 16:25:03 +0000" MODIFIED_BY="[Empty name]">
<P>91 cancer pts<BR/>a) 29 pts = 18 M + 11 F<BR/>Mean age 60 yrs (35 to 79)<BR/>b) 28 pts = 16 M + 12 F <BR/>Mean age 58 yrs (29 to 78)<BR/>c) 34 pts = 25 M + 9 F <BR/>Mean age 60 yrs (41 to 80)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-05 16:25:03 +0000" MODIFIED_BY="[Empty name]">
<P>a) MA 960 mg/d (high-dose)<BR/>b) Placebo<BR/>c) MA 480 mg/d (low-dose)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-10 18:52:39 +0000" MODIFIED_BY="[Empty name]">
<P>Weight, appetite improvement, adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-05 16:25:03 +0000" MODIFIED_BY="[Empty name]">
<P>a) Median duration 8 weeks of treatment<BR/>b) Median duration 6 weeks<BR/>c) Median duration 7 weeks<BR/>QS = 2</P>
<P>Withdrawals were deaths, stopped treatment due to size of capsules, and increased appetite after 14 days with lack of motivation to continue the study, but there was no description of which groups they were from</P>
<P>Cachexia was defined as loss of &gt; 5% of ideal body weight</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-05 16:25:05 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Summerbell-1992">
<CHAR_METHODS MODIFIED="2013-02-05 16:25:05 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-02-22 23:51:18 +0000" MODIFIED_BY="[Empty name]">
<P>14 patients with HIV infection</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-05 16:25:05 +0000" MODIFIED_BY="[Empty name]">
<P>MA 40 mg daily which was increased by 40 mg daily on alternate weeks to a maximum of 160 mg daily if there was no response in weight, or cyproheptadine 12 mg daily for a period of 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-12-26 10:11:51 +0000" MODIFIED_BY="[Empty name]">
<P>Weight, sexual thoughts, arousal and orgasms</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-05 16:25:05 +0000" MODIFIED_BY="[Empty name]">
<P>The study was discontinued after 14 patients were enrolled</P>
<P>Cachexia was defined as weight loss &lt; 5 kg</P>
<P>QS: 2</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-05 16:25:05 +0000" MODIFIED_BY="Jessica Thomas" STUDY_ID="STD-Tchekmedyian-1992">
<CHAR_METHODS MODIFIED="2013-02-05 16:25:05 +0000" MODIFIED_BY="[Empty name]">
<P>Double-blind, randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-05 16:25:05 +0000" MODIFIED_BY="[Empty name]">
<P>89 cancer pts<BR/>a) 49 pts = 28 M + 9 F<BR/>Mean age 63 yrs<BR/>b) 40 pts = 18 M + 12 F<BR/>Mean age 64 yrs<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-05 16:25:05 +0000" MODIFIED_BY="[Empty name]">
<P>a) MA 1600 mg/d, 10 tablets a day, in divided doses<BR/>b) Placebo 10 tablets</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-05 16:25:05 +0000" MODIFIED_BY="Jessica Thomas">
<P>Appetite, categorical scale of 5 levels<BR/>QoL LAS, 29 items<BR/>Weight<BR/>Triceps skinfold<BR/>Mid-arm circumference</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-05 16:25:05 +0000" MODIFIED_BY="[Empty name]">
<P>6 weeks of treatment<BR/>QS = 4</P>
<P>Cachexia was defined as weight loss of &lt; 5%</P>
<P>Patients were considered valuable for analysis if they had at least baseline and 1 follow-up evaluation a month, so 30/40 patients in  placebo group and 37/49 patients in MA group. The withdrawals were balanced and included 1 lost to follow-up in the placebo group and 0 in the MA group, cancer progression in 4 and 6 in the placebo and MA group, deep vein thrombosis 0 in the placebo and 2 in the MA group.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-05 16:25:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Timpone-1997">
<CHAR_METHODS MODIFIED="2013-02-05 16:25:06 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, controlled, multicentre (9)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-05 16:25:06 +0000" MODIFIED_BY="[Empty name]">
<P>50 HIV pts<BR/>a) 12 pts = 10 M + 2 F<BR/>Mean age 46 yrs<BR/>b) 12 pts = 10 M + 2 F<BR/>Mean age 39 yrs<BR/>c) 13 pts = 12 M + 1 F <BR/>Mean age 38 yrs<BR/>d) 13 pts = 12 M + 1 F <BR/>Mean age 40 yrs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-05 16:25:06 +0000" MODIFIED_BY="[Empty name]">
<P>a) MA 750 mg/d, tablets x 1<BR/>b) Dronabinol 5 mg/d, tablets x 2<BR/>c) MA 750 mg/d, tablets x 1 plus dronabinol 5 mg/d, tablets x 2<BR/>d) MA 250 mg/d plus dronabinol 5 mg/d, 2 tablets</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-05 16:25:06 +0000" MODIFIED_BY="[Empty name]">
<P>Height, weight and vital signs, Karnofsky performance status, complete blood count (CBC), CD4+ T lymphocyte count, chemistry panel, visual analogue scale for hunger (VASH) 3 times per day before meals, visual analogue scale for mood (VASM) at noon, visual analogue scale for nausea (VASN) at noon, and functional assessment for HIV (FAHI) questionnaire<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-05 16:25:06 +0000" MODIFIED_BY="[Empty name]">
<P>12 weeks of treatment<BR/>QS = 3</P>
<P>Losses to follow-up were 6, 2, 5, 7 in Arm 1, Arm 2, Arm 3, and Arm 4 respectively</P>
<P>Cachexia was defined as loss of weight of at least 10% or BMI of &lt; 20.5 kg/m<SUP>2</SUP> for age 18 to 34 years or &lt; 22.5 for age &gt; 35 years (the suggested BMI ranges are 19 to 24, 20 to 25, 21 to 26 and 22 to 27 kg/m<SUP>2</SUP> for age categories 18 to 24, 25 to 34, 35 to 44 and 45 to 54 years, respectively)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-05 16:25:07 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;We do not have included this trial in safety because the comparator was also MA ( 160 mg versus 320 mg.&lt;/p&gt;&lt;p&gt;The side events were 1 nausea/vomiting, and 1 DVT in MA 160 versus 3 events of DVT and 1 event of erithema in 320 mg.&lt;/p&gt;&lt;p&gt;One patient discontinued treatment due to gastrointestinal intolerance&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2013-02-05 16:25:07 +0000" NOTES_MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ulutin-2002">
<CHAR_METHODS MODIFIED="2013-02-05 16:25:07 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-05 16:25:07 +0000" MODIFIED_BY="[Empty name]">
<P>119 cancer pts<BR/>a) 59 pts = 48 M + 11 F<BR/>Mean age 56 (range 38 to 72)<BR/>b) 60 pts = 47 M + 13 F<BR/>Mean age 58 (range 40 to 74)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-05 16:25:07 +0000" MODIFIED_BY="[Empty name]">
<P>a) MA 160 mg/d orally<BR/>b) MA 320 mg/d orally in 2 divided doses 12 hrs apart</P>
<P>3 months duration treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-05 16:25:07 +0000" MODIFIED_BY="[Empty name]">
<P>Weight<BR/>Appetite (Symptom Distress Scale)<BR/>QoL (10-point scale) based on patient statements</P>
<P>Biochemical levels and side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-05 16:25:07 +0000" MODIFIED_BY="[Empty name]">
<P>QS = 2</P>
<P>Cachexia was defined as weight loss &gt; 10% in the last 6 months</P>
<P>Only 1 withdrawal was described</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-05 16:25:08 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vadell-1998">
<CHAR_METHODS MODIFIED="2013-02-05 16:25:08 +0000" MODIFIED_BY="[Empty name]">
<P>Double-blind, randomised, controlled, multicentre (9)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-05 16:25:08 +0000" MODIFIED_BY="[Empty name]">
<P>150 cancer pts<BR/>a) 49 pts = 38 M + 11 F <BR/>Mean age 66 yrs<BR/>b) 51 pts = 42 M + 9 F <BR/>Mean age 63 yrs<BR/>c) 50 pts = 31 M + 19 F <BR/>Mean age 65 yrs<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-05 16:25:08 +0000" MODIFIED_BY="[Empty name]">
<P>a) MA 480 mg/d, 3 tablets<BR/>b) Placebo, 3 tablets<BR/>c) MA 160 mg/d, 1 tablet + placebo 2 tablets<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-05 16:25:08 +0000" MODIFIED_BY="[Empty name]">
<P>Weight<BR/>Mid-arm circumference<BR/>Triceps skinfold<BR/>QoL</P>
<P>Performance status Karnofsky Index</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-05 16:25:08 +0000" MODIFIED_BY="[Empty name]">
<P>12 weeks of treatment<BR/>QS = 4</P>
<P>Follow-up 12 weeks; 64 patients remain at 12 weeks. Losses were homogeneously distributed among the 3 groups (16 in the placebo group, 13 in MA 160 mg and 14 in 480 mg/daily)</P>
<P>Cachexia was defined as weight loss &lt; 5%</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-07 12:07:52 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Von-Roenn-1994">
<CHAR_METHODS MODIFIED="2013-02-05 16:25:08 +0000" MODIFIED_BY="[Empty name]">
<P>Double-blind, randomised, controlled, multicentre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-01-30 12:33:01 +0000" MODIFIED_BY="[Empty name]">
<P>271 patients with AIDS who had substantial weight loss and anorexia</P>
<P>270 M and 1 F</P>
<P>a) 75 pts = 75 M<BR/>Mean age 38 yrs<BR/>b) 75 pts = 75 M <BR/>Mean age 39 yrs<BR/>c) 82 pts = 81 M + 1 F <BR/>Mean age 39 yrs<BR/>d) 38 pts = 38 M<BR/>Mean age 38 yrs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-05 16:25:08 +0000" MODIFIED_BY="[Empty name]">
<P>a) MA 800 mg/d, suspension<BR/>b) MA 400 mg/d, suspension<BR/>c) MA 100 mg/ d, suspension<BR/>d) Placebo, suspension</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-05 16:25:08 +0000" MODIFIED_BY="[Empty name]">
<P>Weight<BR/>Appetite<BR/>Mid-arm circumference<BR/>Triceps skinfold<BR/>QoL by linear analogue self assessment questionnaire</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-07 12:07:52 +0000" MODIFIED_BY="[Empty name]">
<P>12 weeks of treatment<BR/>QS = 2</P>
<P>Clinically significant weight loss was defined as a decrease of 20% from usual body weight, or as 10% below ideal body weight for patients whose premorbid weight was greater than ideal body weight, or as a loss of 10% or more of usual body weight for those whose premorbid weight was below ideal body weight.</P>
<P>Patients with stable weight or excessive weight gain could be removed from the study after completing the 12-week trial period. Patients otherwise continued on their assigned treatment as long as they did not have additional weight loss of more than 10% of their baseline body weight.</P>
<P>75 were not evaluable for the efficacy analysis (27 patients did not meet the premorbid weight loss requirement, 46 patients had no follow-up visits and 7 patients had only 1 follow-up visit. Authors do not describe how many patients were in each arm.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-05 16:25:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wanke-2007">
<CHAR_METHODS MODIFIED="2013-02-05 16:25:10 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial, open-label</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-05 16:25:10 +0000" MODIFIED_BY="[Empty name]">
<P>63 HIV-infected adults with weight loss in South Africa, India and the United States </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-05 16:25:10 +0000" MODIFIED_BY="[Empty name]">
<P>MA concentrated suspension (575 mg/5 ml; MA-CS) was compared with traditional MA oral suspension (800 mg/20 ml; MA-OS)</P>
<P>12-week trial</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-05 16:25:10 +0000" MODIFIED_BY="[Empty name]">
<P>Body weight, quality of life including appetite, safety</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-05 16:25:10 +0000" MODIFIED_BY="[Empty name]">
<P>Cachexia was defined as &#8220;body weight of less than 90% of the ideal body weight from the Metropolitan Height and Weight Table (1999 version)&#8221;</P>
<P>QS: 3</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-05 16:25:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weisberg-2002">
<CHAR_METHODS MODIFIED="2013-02-05 16:25:10 +0000" MODIFIED_BY="[Empty name]">
<P>Double-blind, randomised, controlled, multicentre (18)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-05 16:25:10 +0000" MODIFIED_BY="[Empty name]">
<P>145 COPD pts<BR/>a) 72 pts = 46 M + 26 F<BR/>Mean age 68 yrs<BR/>b) 73 pts = 45 M + 28 F <BR/>Mean age 66 yrs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-05 16:25:10 +0000" MODIFIED_BY="[Empty name]">
<P>a) MA 800 mg/d, suspension<BR/>b) Placebo, suspension</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-05 16:25:10 +0000" MODIFIED_BY="[Empty name]">
<P>Weight<BR/>Triceps skinfold<BR/>Mid-arm circumference<BR/>Appetite</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-05 16:25:10 +0000" MODIFIED_BY="[Empty name]">
<P>8 weeks of treatment<BR/>QS = 3</P>
<P>Cachexia was defined as "Underweight COPD patients (&lt; 95% of ideal body weight) &gt; 40 years of age in a stable phase of their disease were recruited at 18 study centres"</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-05 16:25:11 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yeh-2000">
<CHAR_METHODS MODIFIED="2013-02-05 16:25:11 +0000" MODIFIED_BY="[Empty name]">
<P>Double-blind randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-05 16:25:11 +0000" MODIFIED_BY="[Empty name]">
<P>69 patients with geriatric cachexia<BR/>a) 36 pts = 35 M + 1 F <BR/>Mean age 76 yrs<BR/>b) 33 pts = 31 M + 2 F <BR/>Mean age 76 yrs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-05 16:25:11 +0000" MODIFIED_BY="[Empty name]">
<P>a) MA 800 mg/d, suspension<BR/>b) Placebo, suspension</P>
<P>12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-05 16:25:11 +0000" MODIFIED_BY="[Empty name]">
<P>Weight<BR/>Appetite<BR/>
</P>
<P>Sense of well being (SOWB), enjoyment of life, laboratory nutrition parameter and adverse events were measured</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-05 16:25:11 +0000" MODIFIED_BY="[Empty name]">
<P>Follow_up 13 weeks<BR/>QS = 3</P>
<P>Cachexia was defined as experienced weight loss &gt; 5% of their usual body weight during the previous 3 months, or had a body weight of 20% below their ideal body weight (based on the tables of the Metropolitan Life Insurance Company and the Gerontology Research Center)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>BMI: body mass index<BR/>COPD: chronic obstructive pulmonary disease<BR/>d: day<BR/>DRO: dronabinol<BR/>EPA: eicosapentaenoic acid<BR/>F: female<BR/>FAACT: functional assessment of anorexia/cachexia therapy<BR/>HAART: highly active antiretroviral therapy<BR/>KI: Karnofsky Index<BR/>LASA: linear analogue self assessment<BR/>M: male<BR/>MA: megestrol acetate</P>
<P>NCCTG: The North Central Cancer Treatment Group <BR/>pts: patientsPS: Performance Status<BR/>QoL: quality of life<BR/>QS: quality score (Oxford Quality Scale)<BR/>SD: standard deviation<BR/>SSA: subjective sense of appetiteTIQ: Therapy Impact Questionnaire </P>
<P>VAS: visual analogue scale<BR/>yrs: years</P>
<P>
<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-01-30 12:54:14 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2011-08-24 09:57:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aguilera-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-24 09:57:21 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-26 17:08:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aisner-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-26 17:08:00 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-26 16:29:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anonymous-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-26 16:29:00 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-24 10:25:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ansfield-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-24 10:25:09 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-30 12:43:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Argiles-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-30 12:43:54 +0000" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-26 16:36:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Argiles-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-26 16:36:01 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-26 16:39:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Argiles-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-26 16:39:44 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-26 16:48:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Behl-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-26 16:48:58 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-24 10:01:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bossola-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-24 10:01:55 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-24 11:04:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bossola-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-24 11:04:00 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-30 12:44:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bruera-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-30 12:44:04 +0000" MODIFIED_BY="[Empty name]">
<P>This is a cross-over study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-24 10:20:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bruera-1992a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-24 10:20:43 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-30 12:44:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bruera-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-30 12:44:09 +0000" MODIFIED_BY="[Empty name]">
<P>This is a cross-over study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-26 16:49:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bruera-1998a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-26 16:49:25 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-23 23:36:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cardona-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-23 23:36:46 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-26 16:49:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carroll-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-26 16:49:09 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a systematic review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-26 17:21:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cat-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-26 17:21:41 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-24 10:17:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Celik-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-24 10:17:40 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-30 12:44:41 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-30 12:44:41 +0000" MODIFIED_BY="[Empty name]">
<P>This is a RCT of patients with head and neck cancers but only 18% of them were underweight; moreover 11% were overweight</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-26 17:03:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chlebowski-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-26 17:03:39 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-30 12:44:46 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Costero-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-30 12:44:46 +0000" MODIFIED_BY="[Empty name]">
<P>This is just a cohort study without any comparison group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-30 12:45:02 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cruz-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-30 12:45:02 +0000" MODIFIED_BY="[Empty name]">
<P>Patients not described as 'patients with cachexia'</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-23 23:33:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cuerda-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-23 23:33:54 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-23 23:45:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Desport-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-23 23:45:09 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a clinical guideline</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-26 16:49:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Elovic-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-26 16:49:16 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-30 12:45:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Erkurt-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-30 12:45:33 +0000" MODIFIED_BY="[Empty name]">
<P>This study included a small proportion of patients without weight loss in the previous 6 months. In addition, these patients were not balanced in both groups. 33 patients received oral nutrition support: 27% in the MA and 72% in the placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-30 12:45:43 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Farmer-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-30 12:45:43 +0000" MODIFIED_BY="[Empty name]">
<P>Patients not described as 'patients with cachexia'</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-26 16:28:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Farrar-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-26 16:28:40 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-24 10:14:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fearon-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-24 10:14:14 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-30 12:45:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fossati-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-30 12:45:48 +0000" MODIFIED_BY="[Empty name]">
<P>This study is a systematic review of treatment for metastatic breast cancer</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-26 16:05:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fox-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-26 16:05:33 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-23 23:41:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Freyer-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-23 23:41:54 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-26 17:03:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Freyer-1996a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-26 17:03:31 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-24 11:01:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gaducci-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-24 11:01:38 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-26 16:35:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garg-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-26 16:35:38 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a systematic review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-26 16:36:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gullett">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-26 16:36:28 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-26 16:40:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hanson-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-26 16:40:05 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a systematic review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-26 16:20:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Haren-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-26 16:20:52 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-24 10:43:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hellerstein-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-24 10:43:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-30 12:46:02 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hoffman-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-30 12:46:02 +0000" MODIFIED_BY="[Empty name]">
<P>This is not a trial: cohort study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-24 10:05:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Inui-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-24 10:05:23 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-23 23:47:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jatoi-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-23 23:47:38 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-26 16:36:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kalantar_x002d_Zadeh-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-26 16:36:19 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-26 17:13:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Karcic-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-26 17:13:27 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-30 12:46:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Khojasteh-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-30 12:46:18 +0000" MODIFIED_BY="[Empty name]">
<P>This is a small clinical trial that compared combined nortriptyline (25 to 50 mg Q HS PO) + MA (400 mg BID PO) versus MA (400 mg BID PO)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-30 12:46:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Krznaric-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-30 12:46:34 +0000" MODIFIED_BY="[Empty name]">
<P>This is a clinical guideline</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-24 10:13:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kumar-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-24 10:13:27 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-30 12:46:45 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lai-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-30 12:46:45 +0000" MODIFIED_BY="[Empty name]">
<P>Patients did not have cachexia or any weight loss</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-26 17:21:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lelli-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-26 17:21:47 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-24 10:45:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lesniak-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-24 10:45:12 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a systematic review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-24 10:07:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Loprinzi-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-24 10:07:16 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-26 16:16:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Loprinzi-1992a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-26 16:16:06 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-01 18:36:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Loprinzi-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-01 18:36:14 +0000" MODIFIED_BY="[Empty name]">
<P>This study Is not a trial, is a cohort study without any control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-24 11:06:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Loprinzi-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-24 11:06:49 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-26 17:13:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mak-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-26 17:13:32 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-24 11:05:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Malone-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-24 11:05:05 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-24 10:56:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Maltoni-2001a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-24 10:56:13 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a systematic review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-24 10:36:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mantovani-1998a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-24 10:36:02 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-24 11:02:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mantovani-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-24 11:02:38 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-30 12:47:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mantovani-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-30 12:47:06 +0000" MODIFIED_BY="[Empty name]">
<P>This is a RCT with 5 arms; in one of them patients received medroxyprogesterone acetate or megestrol acetate</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-30 12:47:23 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mantovani-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-30 12:47:23 +0000" MODIFIED_BY="[Empty name]">
<P>This is a clinical abstract in proceedings</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-30 12:47:29 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Marchand-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-30 12:47:29 +0000" MODIFIED_BY="[Empty name]">
<P>This is a RCT cross-over study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-26 16:20:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mateen-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-26 16:20:59 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-24 10:04:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McHugh-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-24 10:04:15 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-30 12:47:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McMillan-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-30 12:47:34 +0000" MODIFIED_BY="[Empty name]">
<P>This is a trial that compared MA plus placebo versus MA plus ibuprofen in patients with gastrointestinal cancer with weight loss</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-30 12:47:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McQuellon-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-30 12:47:54 +0000" MODIFIED_BY="[Empty name]">
<P>Patients not described as 'patients with cachexia'</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-30 12:48:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Monfared-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-30 12:48:03 +0000" MODIFIED_BY="[Empty name]">
<P>Patients not described as 'patients with cachexia' and the outcome was levels of albumin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-26 16:40:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Morley-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-26 16:40:18 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-30 12:48:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mor_x00e1_n-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-30 12:48:34 +0000" MODIFIED_BY="[Empty name]">
<P>This is a trial with malnourished post necrotic (VHC) patients, but cachexia was not described. This is an abstract without any data on the placebo group for appetite.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-17 19:13:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mulligan-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-17 19:13:35 +0000" MODIFIED_BY="[Empty name]">
<P>This study compared patients allocated to receive megestrol acetate plus testosterone versus placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-30 12:49:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Muss-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-30 12:49:01 +0000" MODIFIED_BY="[Empty name]">
<P>Patients were not described as having cachexia-anorexia related to cancer. This is a trial in breast cancer.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-30 12:49:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Navari-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-30 12:49:04 +0000" MODIFIED_BY="[Empty name]">
<P>This is a RCT that compared MA plus olanzapine versus MA</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-30 12:49:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nelson-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-30 12:49:13 +0000" MODIFIED_BY="[Empty name]">
<P>This is not a trial: cohort study without comparison group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-30 12:49:19 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Osoba-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-30 12:49:19 +0000" MODIFIED_BY="[Empty name]">
<P>All patients received MA, without a control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-30 12:49:28 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pardo-2003a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-30 12:49:28 +0000" MODIFIED_BY="[Empty name]">
<P>Patients were not described as 'patients with cachexia'</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-30 12:49:30 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pardo-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-30 12:49:30 +0000" MODIFIED_BY="[Empty name]">
<P>Patients were not described as 'patients with cachexia'</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-26 17:08:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pascual-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-26 17:08:36 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a systematic review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-23 23:44:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pruthi-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-23 23:44:52 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a clinical guideline</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-30 12:49:39 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Reuben-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-30 12:49:39 +0000" MODIFIED_BY="[Empty name]">
<P>Patients were older persons (mean age 83) discharged from an acute hospital with fair or poor appetite</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-24 11:07:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ross-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-24 11:07:34 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-30 12:50:15 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rowland-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-30 12:50:15 +0000" MODIFIED_BY="[Empty name]">
<P>This is a trial that compared chemotherapy in cancer patients in both groups with MA versus placebo in patients who started chemotherapy for small cell lung cancer. Patients were not described as 'patients with cachexia/anorexia'. Moreover most of them (85%) had weight loss &lt; 10%. This study was included in the previous review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-20 23:05:16 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ruiz_x002d_Garcia-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-20 23:05:16 +0000" MODIFIED_BY="[Empty name]">
<P>This study is a systematic review about megestrol and weight gain in cancer patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-24 10:01:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sanz_x002d_Ortiz-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-24 10:01:01 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-26 16:28:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schacter-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-26 16:28:30 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-26 17:08:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schmoll-1992a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-26 17:08:09 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-30 12:50:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Simmons-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-30 12:50:37 +0000" MODIFIED_BY="[Empty name]">
<P>Patients not described as 'patients with cachexia'</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-30 12:50:41 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Skarlos-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-30 12:50:41 +0000" MODIFIED_BY="[Empty name]">
<P>This is a cohort study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-26 17:03:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Spaulding-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-26 17:03:48 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-30 12:51:02 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sullivan-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-30 12:51:02 +0000" MODIFIED_BY="[Empty name]">
<P>Patients were older than 65 with functional decline without any criteria for cachexia</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-30 12:51:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tchekmedyian-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-30 12:51:06 +0000" MODIFIED_BY="[Empty name]">
<P>This is not a trial and patients were women with advanced breast cancer</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-30 12:51:11 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tchekmedyian-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-30 12:51:11 +0000" MODIFIED_BY="[Empty name]">
<P>This is not a trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-26 17:21:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tchekmedyian-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-26 17:21:29 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-24 10:19:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tchekmedyian-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-24 10:19:40 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-26 17:21:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tchekmedyian-1993a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-26 17:21:32 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-26 17:13:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tchekmedyian-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-26 17:13:44 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-24 10:54:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Thomas-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-24 10:54:38 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a clinical guideline</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-24 10:12:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tisdale-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-24 10:12:38 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-24 10:18:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tisdale-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-24 10:18:13 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-30 12:51:47 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tomiska-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-30 12:51:47 +0000" MODIFIED_BY="[Empty name]">
<P>This is a RCT that compared 2 doses of MA in cancer anorexia/cachexia syndrome, but results were described as improvement of appetite, gain of weight etc. in all evaluated patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-23 23:52:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vigano-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-23 23:52:37 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-12-01 20:00:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-von-Haehling-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-12-01 20:00:24 +0000" MODIFIED_BY="[Empty name]">
<P>This study is a review of cardiac cachexia</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-26 17:03:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Von-Roenn-1994a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-26 17:03:14 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-23 23:28:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vyzula-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-23 23:28:46 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-30 12:52:16 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Westman-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-30 12:52:16 +0000" MODIFIED_BY="[Empty name]">
<P>This is a trial in malnourished cancer patients but 1/3 of patients in the MA and placebo group had not developed cachexia</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-26 17:08:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yavuzsen-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-26 17:08:20 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a systematic review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-30 12:52:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yeh-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-30 12:52:33 +0000" MODIFIED_BY="[Empty name]">
<P>This study involved the same participants as <LINK REF="STD-Yeh-2000" TYPE="STUDY">Yeh 2000</LINK>, in which they measured different outcomes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-26 16:28:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yeh-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-26 16:28:21 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-26 16:55:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yeh-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-26 16:55:45 +0100" MODIFIED_BY="[Empty name]">
<P>This study is a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-30 12:52:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yeh-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-30 12:52:49 +0000" MODIFIED_BY="[Empty name]">
<P>Patients not described as 'patients with cachexia'</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-30 12:53:17 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zeca-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-30 12:53:17 +0000" MODIFIED_BY="[Empty name]">
<P>This is a trial that included patients with cancer and anorexia. Cachexia was not needed. This is a small trial, published in proceedings, with two phases. In first phase patients received 320 mg/d of MA. In the second phase all patients received different dosages of MA according to the response to treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>BID: twice a day<BR/>d: day<BR/>MA: megestrol acetate<BR/>PO: orally<BR/>RCT: randomised controlled trial</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2012-02-01 18:11:31 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-02-11 09:25:53 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-02-05 16:25:11 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:37 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Batterham-2001">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process to permit judgement of low or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:37 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Beller-1997">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-28 09:45:12 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Casado-2008">
<DESCRIPTION>
<P>Random tables</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:39 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Conno-1998">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-09 22:01:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Eubanks-2002">
<DESCRIPTION>
<P>&#8220;Through the use of a computer-generated randomisation schedule&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Feliu-1992">
<DESCRIPTION>
<P>They used computer random generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fietkau-1996">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:44 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gambardella-1998">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:44 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gebbia-1996">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Giacosa-1997">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:47 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Heckmayr-1992">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-28 08:48:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Herrejon-2011">
<DESCRIPTION>
<P>Random number table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:51 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jatoi-2002">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jatoi-2004">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lesser-2006">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Loprinzi-1990b">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Loprinzi-1994">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Loprinzi-1999a">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Loprinzi-1999b">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:25:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Macbeth-1994">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-11 23:23:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Madeddu-2012">
<DESCRIPTION>
<P>Random number table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:25:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McMillan-1994">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-29 17:27:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mwamburi-2004">
<DESCRIPTION>
<P>&#8220;Computed generated random numbers&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:25:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Oster-1994">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:25:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sancho_x002d_Cuesta-1993">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:25:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schmoll-1991">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:25:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schmoll-1992">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:25:05 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Summerbell-1992">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-09 22:16:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tchekmedyian-1992">
<DESCRIPTION>
<P>6 tables of randomisation were generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:25:06 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Timpone-1997">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:25:07 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ulutin-2002">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:25:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vadell-1998">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:25:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Von-Roenn-1994">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:25:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wanke-2007">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:25:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Weisberg-2002">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:25:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yeh-2000">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-02-05 16:25:11 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:37 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Batterham-2001">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process to permit judgement of low or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-02 17:56:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Beller-1997">
<DESCRIPTION>
<P>By telephone through a central office</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:37 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Casado-2008">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:39 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Conno-1998">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:40 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Eubanks-2002">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:41 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Feliu-1992">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fietkau-1996">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:44 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gambardella-1998">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:44 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gebbia-1996">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Giacosa-1997">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Heckmayr-1992">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Herrejon-2011">
<DESCRIPTION>
<P>Was external and warranted for the promotor Madaus</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:51 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jatoi-2002">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jatoi-2004">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lesser-2006">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Loprinzi-1990b">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Loprinzi-1994">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Loprinzi-1999a">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Loprinzi-1999b">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:25:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Macbeth-1994">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:25:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Madeddu-2012">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:25:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McMillan-1994">
<DESCRIPTION>
<P>&#8220; ...the randomisation code was not known to any of the investigators and was only broken at the end of the study&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:25:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mwamburi-2004">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:25:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Oster-1994">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:25:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sancho_x002d_Cuesta-1993">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:25:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schmoll-1991">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:25:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schmoll-1992">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:25:05 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Summerbell-1992">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:25:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tchekmedyian-1992">
<DESCRIPTION>
<P>Central randomisation office</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:25:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Timpone-1997">
<DESCRIPTION>
<P>Patients were sequentially enrolled and the study was performed in an outpatient setting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:25:07 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ulutin-2002">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:25:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vadell-1998">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:25:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Von-Roenn-1994">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:25:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wanke-2007">
<DESCRIPTION>
<P>Central allocation. This was a multicentre study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:25:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Weisberg-2002">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:25:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yeh-2000">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2013-02-05 16:25:05 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-12-29 08:44:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Batterham-2001">
<DESCRIPTION>
<P>No blinding but the review authors judge that the outcome is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-05 16:24:37 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Beller-1997">
<DESCRIPTION>
<P>No data about blinding but unlikely the outcome could be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-01-28 10:05:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Casado-2008">
<DESCRIPTION>
<P>See below</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-12-30 09:31:14 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Conno-1998">
<DESCRIPTION>
<P>See below</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-02-06 00:27:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Eubanks-2002">
<DESCRIPTION>
<P>See below</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-01-02 16:44:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Feliu-1992">
<DESCRIPTION>
<P>See below</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-01-02 16:52:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fietkau-1996">
<DESCRIPTION>
<P>See below</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-02-13 19:51:35 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gambardella-1998">
<DESCRIPTION>
<P>See below</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-01-03 17:40:17 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gebbia-1996">
<DESCRIPTION>
<P>See below</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-01-25 15:23:15 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giacosa-1997">
<DESCRIPTION>
<P>See below</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-01-25 15:31:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Heckmayr-1992">
<DESCRIPTION>
<P>See below</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-01-28 08:47:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Herrejon-2011">
<DESCRIPTION>
<P>See below</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-02-01 17:03:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jatoi-2002">
<DESCRIPTION>
<P>See below</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-02-01 17:53:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jatoi-2004">
<DESCRIPTION>
<P>See below</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-05 16:24:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lesser-2006">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-05 16:24:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Loprinzi-1990b">
<DESCRIPTION>
<P>See below</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-05 16:24:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Loprinzi-1994">
<DESCRIPTION>
<P>See below</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-02-19 09:19:31 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Loprinzi-1999a">
<DESCRIPTION>
<P>See below</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-02-19 09:22:09 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Loprinzi-1999b">
<DESCRIPTION>
<P>See below</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-02-05 19:17:15 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Macbeth-1994">
<DESCRIPTION>
<P>See below</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-06-11 23:35:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Madeddu-2012">
<DESCRIPTION>
<P>No blinding or incomplete blinding, but the outcome is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-01-29 11:12:47 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McMillan-1994">
<DESCRIPTION>
<P>See below</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-01-29 17:28:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mwamburi-2004">
<DESCRIPTION>
<P>See below</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-02-19 09:55:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oster-1994">
<DESCRIPTION>
<P>See below</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-01-10 18:27:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sancho_x002d_Cuesta-1993">
<DESCRIPTION>
<P>This study was not blinded </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-02-05 19:28:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schmoll-1991">
<DESCRIPTION>
<P>This study was not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-02-04 00:26:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schmoll-1992">
<DESCRIPTION>
<P>This study was not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-05 16:25:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Summerbell-1992">
<DESCRIPTION>
<P>See below</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-01-28 12:25:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tchekmedyian-1992">
<DESCRIPTION>
<P>See below</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-01-28 18:39:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Timpone-1997">
<DESCRIPTION>
<P>See below</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-01-29 18:29:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ulutin-2002">
<DESCRIPTION>
<P>See below</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-01-29 19:14:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vadell-1998">
<DESCRIPTION>
<P>See below</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-01-30 23:32:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Von-Roenn-1994">
<DESCRIPTION>
<P>See below</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-01-31 00:13:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wanke-2007">
<DESCRIPTION>
<P>See below</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-01-31 00:28:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Weisberg-2002">
<DESCRIPTION>
<P>See below</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-01-29 23:32:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yeh-2000">
<DESCRIPTION>
<P>See below</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2013-02-05 16:25:11 +0000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-12-29 08:45:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Batterham-2001">
<DESCRIPTION>
<P>No blinding but the review authors judge that the outcome measurement is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-05 16:24:37 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Beller-1997">
<DESCRIPTION>
<P>No data about blinding but unlikely the outcome could be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-28 09:53:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Casado-2008">
<DESCRIPTION>
<P>No blinding but the review authors judge that the outcome is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-05 16:24:39 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Conno-1998">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-01-30 11:34:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Eubanks-2002">
<DESCRIPTION>
<P>&#8220;Each subject received MA or a placebo of similar physical characteristics (provided by Bristol Meyers-Squibb, New York City, NY). Participants, treating physicians, and ancillary staff were blinded to the treatment group&#8221;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-05 16:24:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Feliu-1992">
<DESCRIPTION>
<P>Study medication was provided in blinded packages</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-02-19 16:48:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fietkau-1996">
<DESCRIPTION>
<P>The main outcome is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-05 16:24:44 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gambardella-1998">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-05 16:24:44 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gebbia-1996">
<DESCRIPTION>
<P>It was a not blinded trial. One arm received 1 tablet and the other 2 tablets of MA</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-05 16:24:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giacosa-1997">
<DESCRIPTION>
<P>Not a blinded study but the outcome is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-01-31 10:30:23 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Heckmayr-1992">
<DESCRIPTION>
<P>This study was not blinded but the main outcome is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-05 16:24:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Herrejon-2011">
<DESCRIPTION>
<P>The pills were similar and it was double-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-05 16:24:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jatoi-2002">
<DESCRIPTION>
<P>Authors used capsules and liquid placebo to assure the blinding in all groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-05 16:24:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jatoi-2004">
<DESCRIPTION>
<P>This double-dummy study design used an active EPA supplement and an identical placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-05 16:24:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lesser-2006">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-05 16:24:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Loprinzi-1990b">
<DESCRIPTION>
<P>Authors declared that placebo tablets were identical to MA and weight is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-01-31 10:30:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Loprinzi-1994">
<DESCRIPTION>
<P>This study was not blinded but the main outcome is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-05 16:24:57 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Loprinzi-1999a">
<DESCRIPTION>
<P>Not a blinded study and the outcome was appetite</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-05 16:24:58 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Loprinzi-1999b">
<DESCRIPTION>
<P>Not a blinded study and the outcome was appetite</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-02-05 19:17:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Macbeth-1994">
<DESCRIPTION>
<P>Patients were not blinded but: &#8220; an attempt was made to keep the clinicians unaware of which tablets the patients were taking&#8230;&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-06-11 23:35:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Madeddu-2012">
<DESCRIPTION>
<P>No blinding or incomplete blinding, but the outcome is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-05 16:25:01 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McMillan-1994">
<DESCRIPTION>
<P>No data about blinding but unlikely could be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-01-31 10:30:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mwamburi-2004">
<DESCRIPTION>
<P>This study was not blinded but the main outcome is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-05-09 22:15:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oster-1994">
<DESCRIPTION>
<P>"All patients received bottles containing 20-mL portions of a liquid, lemon-lime flavoured suspension of either placebo or 800 mg of megestrol acetate (Megace; Bristol-Myers Squibb, Princeton, New Jersey). Patients were instructed to take the drug orally once daily, 1 hour before or 2 hours after breakfast. Patients and clinicians were blinded to treatment groups throughout the study".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-05 16:25:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sancho_x002d_Cuesta-1993">
<DESCRIPTION>
<P>The main outcome was weight. This is not a blinded study but the main outcome is not likely to be influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-05 16:25:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schmoll-1991">
<DESCRIPTION>
<P>The main outcome was weight. This is not a blinded study but the main outcome is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-05 16:25:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schmoll-1992">
<DESCRIPTION>
<P>The main outcome was weight. This is not a blinded study but the main outcome is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-05 16:25:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Summerbell-1992">
<DESCRIPTION>
<P>The main outcome was weight. This is not a blinded study but the main outcome is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-05 16:25:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tchekmedyian-1992">
<DESCRIPTION>
<P>The main outcome was weight. This is a blinded study and the main outcome is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-05 16:25:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Timpone-1997">
<DESCRIPTION>
<P>This is an open-label study but weight was the main outcome and is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-05 16:25:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ulutin-2002">
<DESCRIPTION>
<P>The main outcome was weight. This is not a blinded study but the main outcome is not likely to be influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-05 16:25:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vadell-1998">
<DESCRIPTION>
<P>All participants received 3 tablets to assure the blinding and the main outcome was weight</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-05 16:25:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Von-Roenn-1994">
<DESCRIPTION>
<P>The main outcome was weight. This is a blinded study and the main outcome is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-05 16:25:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wanke-2007">
<DESCRIPTION>
<P>Weight was the main outcome. This is not a blinded study but the main outcome is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-05 16:25:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Weisberg-2002">
<DESCRIPTION>
<P>The main outcome was a functional test (spirometry)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-05 16:25:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yeh-2000">
<DESCRIPTION>
<P>The main outcome was weight. This is a blinded study and the main outcome is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2013-02-05 16:25:11 +0000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-12-29 21:52:31 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Batterham-2001">
<DESCRIPTION>
<P>No blinding but the review authors judge that the outcome measurement is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-05 16:24:37 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Beller-1997">
<DESCRIPTION>
<P>No data about blinding but unlikely the outcome could be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-28 09:53:37 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Casado-2008">
<DESCRIPTION>
<P>Main outcome was weight</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-05 16:24:39 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-De-Conno-1998">
<DESCRIPTION>
<P>Appetite is the main outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-05-09 22:05:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Eubanks-2002">
<DESCRIPTION>
<P>The main outcome is not likely to be influenced by blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-02 16:44:18 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Feliu-1992">
<DESCRIPTION>
<P>The main outcome was body weight</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-02-19 16:49:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fietkau-1996">
<DESCRIPTION>
<P>The main outcome is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-02-13 19:51:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gambardella-1998">
<DESCRIPTION>
<P>The main outcome was body weight</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-05 16:24:44 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gebbia-1996">
<DESCRIPTION>
<P>The main outcome was appetite</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-05 16:24:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giacosa-1997">
<DESCRIPTION>
<P>Not a blinded study but the outcome is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-01-31 10:30:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Heckmayr-1992">
<DESCRIPTION>
<P>This study was not blinded but the main outcome is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-05-09 22:09:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Herrejon-2011">
<DESCRIPTION>
<P>Body weight</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-05 16:24:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jatoi-2002">
<DESCRIPTION>
<P>The main outcome was appetite, without more details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-05 16:24:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jatoi-2004">
<DESCRIPTION>
<P>No data about blinding but weight is unlikely to have been influenced by blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-05 16:24:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lesser-2006">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-02-16 16:54:15 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Loprinzi-1990b">
<DESCRIPTION>
<P>Weight is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-01-31 10:30:34 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Loprinzi-1994">
<DESCRIPTION>
<P>This study was not blinded but the main outcome is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-05 16:24:57 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Loprinzi-1999a">
<DESCRIPTION>
<P>Not a blinded study and the outcome was appetite</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-05 16:24:58 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Loprinzi-1999b">
<DESCRIPTION>
<P>Not a blinded study and the outcome was appetite</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-01-31 10:30:37 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Macbeth-1994">
<DESCRIPTION>
<P>This study was not blinded but the main outcome is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-11 23:35:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Madeddu-2012">
<DESCRIPTION>
<P>No blinding or incomplete blinding, but the outcome is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-05 16:25:01 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McMillan-1994">
<DESCRIPTION>
<P>No data about blinding but unlikely could be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-01-31 10:30:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mwamburi-2004">
<DESCRIPTION>
<P>This study was not blinded but the man outcome is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-15 16:19:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Oster-1994">
<DESCRIPTION>
<P>Main outcome was weight and well being</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-05 16:25:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sancho_x002d_Cuesta-1993">
<DESCRIPTION>
<P>This is not a blinded study but the main outcome is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-05 16:25:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schmoll-1991">
<DESCRIPTION>
<P>This is not a blinded study but the main outcome is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-05 16:25:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schmoll-1992">
<DESCRIPTION>
<P>This is not a blinded study but the main outcome is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-05 16:25:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Summerbell-1992">
<DESCRIPTION>
<P>The main outcome was weight. This is not a blinded study but the main outcome is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-05 16:25:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tchekmedyian-1992">
<DESCRIPTION>
<P>The main outcome was weight. This is a blinded study and the main outcome is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-05 16:25:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Timpone-1997">
<DESCRIPTION>
<P>This is an open-label study but weight was the main outcome and is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-05 16:25:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ulutin-2002">
<DESCRIPTION>
<P>The main outcome was weight. This is not a blinded study but the main outcome is not likely to be influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-29 19:17:00 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vadell-1998">
<DESCRIPTION>
<P>The main outcome was weight</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-05 16:25:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Von-Roenn-1994">
<DESCRIPTION>
<P>The main outcome was weight. This is a blinded study and the main outcome is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-05 16:25:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wanke-2007">
<DESCRIPTION>
<P>Weight was the main outcome. This is not a blinded study but the main outcome is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-05 16:25:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Weisberg-2002">
<DESCRIPTION>
<P>The main outcome was a functional test (spirometry)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-05 16:25:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yeh-2000">
<DESCRIPTION>
<P>The main outcome was weight. This is a blinded study and the main outcome is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-02-07 11:57:18 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-12-29 08:47:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Batterham-2001">
<DESCRIPTION>
<P>Withdrawals were similar in all groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-05 16:24:37 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Beller-1997">
<DESCRIPTION>
<P>Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-05 16:24:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Casado-2008">
<DESCRIPTION>
<P>Withdrawals were balanced, most for progression of cancer (no data between groups); patients deciding stop treatment = 5 (no data between groups) and related to adverse effects of treatments</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-12-30 09:35:25 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Conno-1998">
<DESCRIPTION>
<P>Missing data have been imputed using appropriate methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-05 16:24:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Eubanks-2002">
<DESCRIPTION>
<P>All patients in the treatment group completed the study. 3 patients in the placebo group withdrew when they failed to observe a treatment effect</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-05 16:24:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Feliu-1992">
<DESCRIPTION>
<P>No withdrawals; authors reported data for all patients that were alive</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-05 16:24:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fietkau-1996">
<DESCRIPTION>
<P>1 patient was withdrawn in each arm because of suspected side effects (diarrhoea, impotence respectively) and 1 patient in the placebo arm refused further participation following randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-05 16:24:44 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gambardella-1998">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-05 16:24:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gebbia-1996">
<DESCRIPTION>
<P>Withdrawals were quite similar and related to cancer: 1 patient died in the 160 mg/day arm and 2 patients died in the 320 mg/day arm at 30 days</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-05 16:24:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giacosa-1997">
<DESCRIPTION>
<P>Withdrawals were balanced but no data about 2 patients in the dietary counselling arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-05 16:24:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Heckmayr-1992">
<DESCRIPTION>
<P>No mention of any withdrawals</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-05 16:24:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Herrejon-2011">
<DESCRIPTION>
<P>5 patients in each group were withdrawals</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-05 16:24:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jatoi-2002">
<DESCRIPTION>
<P>Withdrawals were quite similar in all groups, but the number in each group was uncertain and only 45% of patients remained at the end of the first month</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-05 16:24:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jatoi-2004">
<DESCRIPTION>
<P>The withdrawals were balanced and well described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-05 16:24:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lesser-2006">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-07 11:57:18 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Loprinzi-1990b">
<DESCRIPTION>
<P>3 patients were moved from the study after randomisation but before the initiation of study (1 for additional treatment with prednisone and another due to a decline in physical condition), so all analyses were based on 133 eligible for treatment. 9 patients in each group had no weight recorded beyond their initial study weight and hence could not be included in analyses of weight. Withdrawals were balanced (nausea: 1 in MA and 1 in placebo group; refusal: 2 in MA and 4 in placebo group; physical deterioration: 1 in MA; inability to take oral medication: 2 in placebo). </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-02-20 22:27:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Loprinzi-1994">
<DESCRIPTION>
<P>Withdrawals were balanced</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-05 16:24:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Loprinzi-1999a">
<DESCRIPTION>
<P>After randomisation, 10 patients cancelled (before taking any study medication) and 11% were found to be ineligible, resulting in 475 assessable patients. For the effect of the study medications on patients&#8217; appetites, 311 (66%) of the patients completed a baseline questionnaire and at least 1 follow-up questionnaire. For the weight gain analyses, all patients with clinically apparent oedema or ascites were censored. Drop-out rates were quite similar: 71 patients in the MA group, 70 in the dexamethasone group and 70 patients in the fluoxymesterone group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-05 16:24:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Loprinzi-1999b">
<DESCRIPTION>
<P>After randomisation, 10 patients cancelled (before taking any study medication) and 11% were found to be ineligible, resulting in 475 assessable patients. For the effect of the study medications on patients&#8217; appetites, 311 (66%) of the patients completed a baseline questionnaire and at least 1 follow-up questionnaire. For the weight gain analyses, all patients with clinically apparent oedema or ascites were censored. Drop-out rates were quite similar: 71 patients in the MA group, 70 in the dexamethasone group and 70 patients in the fluoxymesterone group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-02-05 19:17:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Macbeth-1994">
<DESCRIPTION>
<P>Withdrawals were not balanced</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-11 23:36:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Madeddu-2012">
<DESCRIPTION>
<P>Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-05 16:25:01 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McMillan-1994">
<DESCRIPTION>
<P>The withdrawals were unbalanced but the authors explain all withdrawals</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-02-19 17:23:44 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mwamburi-2004">
<DESCRIPTION>
<P>Authors describe drop-outs but not the number in each arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-04-03 16:58:08 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Oster-1994">
<DESCRIPTION>
<P>Withdrawals were balanced (27 in MA and 22 in placebo group)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-05 16:25:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sancho_x002d_Cuesta-1993">
<DESCRIPTION>
<P>Loss to follow-up not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-05 16:25:03 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Schmoll-1991">
<DESCRIPTION>
<P>Reasons for missing outcome data are likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-05 16:25:05 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Schmoll-1992">
<DESCRIPTION>
<P>Withdrawals were high: 44% in the placebo group and 30% in each of the MA groups, but the causes in each group were not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-02-22 23:56:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Summerbell-1992">
<DESCRIPTION>
<P>All patients were studied</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-05 16:25:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tchekmedyian-1992">
<DESCRIPTION>
<P>The withdrawals were balanced across groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-05 16:25:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Timpone-1997">
<DESCRIPTION>
<P>Missing outcome data balanced</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-05 16:25:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ulutin-2002">
<DESCRIPTION>
<P>1 patient discontinued treatment due to gastrointestinal intolerance on MA 320 mg</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-05 16:25:08 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Vadell-1998">
<DESCRIPTION>
<P>Only 64 patients remained at 12 weeks but the losses were described as balanced in all groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-05 16:25:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Von-Roenn-1994">
<DESCRIPTION>
<P>No data on balance of withdrawals in each arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-05 16:25:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wanke-2007">
<DESCRIPTION>
<P>2 participants in 575 mg MA group withdrew because of an adverse event and 3 participants in the MA 800 mg because an adverse event</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-05 16:25:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Weisberg-2002">
<DESCRIPTION>
<P>17 withdrawals but balanced in 2 arms   </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-05 16:25:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yeh-2000">
<DESCRIPTION>
<P>The withdrawals were balanced</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-02-11 09:25:53 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:37 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Batterham-2001">
<DESCRIPTION>
<P>Yes. Authors reported only data at 12 weeks and not at 24 weeks</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-11 09:25:16 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Beller-1997">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk. No information in the meta register of clinical trials or <A HREF="http://apps.who.int/trialsearch">http://apps.who.int/trialsearch</A>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:38 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Casado-2008">
<DESCRIPTION>
<P>All outcomes were reported but data were shown in graphical manner or before/after, but not as mean change with SD in each group or as number of patients that gained appetite, weight or QoL, so only adverse events were included in the review</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-11 09:25:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Conno-1998">
<DESCRIPTION>
<P>All outcomes in the paper have been reported but we did not find this trial in the meta register of clinical trial or <A HREF="http://apps.who.int/trialsearch">http://apps.who.int/trialsearch</A>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-06 00:27:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Eubanks-2002">
<DESCRIPTION>
<P>All outcomes in the paper have been reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-11 09:25:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Feliu-1992">
<DESCRIPTION>
<P>All outcomes in the paper have been reported but we did not find this trial in the meta register of clinical trials or <A HREF="http://apps.who.int/trialsearch">http://apps.who.int/trialsearch</A>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-11 09:25:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fietkau-1996">
<DESCRIPTION>
<P>All outcomes in the paper have been reported and we did not find this trial in the meta register of clinical trials or <A HREF="http://apps.who.int/trialsearch">http://apps.who.int/trialsearch</A>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:44 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gambardella-1998">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-11 09:25:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gebbia-1996">
<DESCRIPTION>
<P>All outcomes in the paper have been reported but we did not find this trial in the meta register of clinical trials or <A HREF="http://apps.who.int/trialsearch">http://apps.who.int/trialsearch</A>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-11 09:25:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giacosa-1997">
<DESCRIPTION>
<P>All outcomes in the paper have been reported but we did not find this trial in the meta register of clinical trial neither <A HREF="http://apps.who.int/trialsearch">http://apps.who.int/trialsearch</A>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-11 09:25:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Heckmayr-1992">
<DESCRIPTION>
<P>All outcomes in the paper have been reported but we did not find this trial in the meta register of clinical trials or <A HREF="http://apps.who.int/trialsearch">http://apps.who.int/trialsearch</A>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Herrejon-2011">
<DESCRIPTION>
<P>NCT00507949; all outcomes that were planned were shown</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-01 17:05:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jatoi-2002">
<DESCRIPTION>
<P>All results were available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jatoi-2004">
<DESCRIPTION>
<P>All the outcomes were available and was registered</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lesser-2006">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-20 14:05:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Loprinzi-1990b">
<DESCRIPTION>
<P>All the outcomes were available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-19 08:51:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Loprinzi-1994">
<DESCRIPTION>
<P>All outcomes in the paper have been reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-02 19:29:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Loprinzi-1999a">
<DESCRIPTION>
<P>All outcomes in the paper have been reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-02 19:29:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Loprinzi-1999b">
<DESCRIPTION>
<P>All outcomes in the paper have been reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:25:00 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Macbeth-1994">
<DESCRIPTION>
<P>All the pre-specified outcomes were reported in private files</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-11 23:37:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Madeddu-2012">
<DESCRIPTION>
<P>The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-11 09:25:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McMillan-1994">
<DESCRIPTION>
<P>All outcomes in the paper have been reported but we did not find this trial in the meta register of clinical trials or <A HREF="http://apps.who.int/trialsearch">http://apps.who.int/trialsearch</A>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-29 17:30:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mwamburi-2004">
<DESCRIPTION>
<P>All outcomes in the paper have been reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-19 10:02:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oster-1994">
<DESCRIPTION>
<P>All outcomes were available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-10 18:27:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sancho_x002d_Cuesta-1993">
<DESCRIPTION>
<P>All the outcomes described in the study were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-05 19:29:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schmoll-1991">
<DESCRIPTION>
<P>All the pre-specified outcome were published</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:25:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schmoll-1992">
<DESCRIPTION>
<P>All the pre-specified outcomes were published</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-22 23:56:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Summerbell-1992">
<DESCRIPTION>
<P>All outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-28 12:27:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tchekmedyian-1992">
<DESCRIPTION>
<P>All the results were available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-28 18:39:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Timpone-1997">
<DESCRIPTION>
<P>All the results were available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-29 18:30:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ulutin-2002">
<DESCRIPTION>
<P>All the results were available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-29 19:18:14 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vadell-1998">
<DESCRIPTION>
<P>All the outcomes were described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-20 14:07:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Von-Roenn-1994">
<DESCRIPTION>
<P>All the results were available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-31 00:14:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wanke-2007">
<DESCRIPTION>
<P>All the results were available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-31 00:29:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Weisberg-2002">
<DESCRIPTION>
<P>All the results were available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-29 23:34:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yeh-2000">
<DESCRIPTION>
<P>All the results were available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-02-05 16:25:12 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:37 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Batterham-2001">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:37 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Beller-1997">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:39 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Casado-2008">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:39 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Conno-1998">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:40 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Eubanks-2002">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Feliu-1992">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fietkau-1996">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:44 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gambardella-1998">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gebbia-1996">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Giacosa-1997">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Heckmayr-1992">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Herrejon-2011">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jatoi-2002">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jatoi-2004">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:54 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lesser-2006">
<DESCRIPTION>
<P>We have just a proceeding dated 2006. We have not found any paper with all the relevant data from this trial. There is a suspicion of publication bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Loprinzi-1990b">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Loprinzi-1994">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Loprinzi-1999a">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:24:59 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Loprinzi-1999b">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-05 19:18:21 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Macbeth-1994">
<DESCRIPTION>
<P>The trial was stopped early for safety at 12 weeks</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:25:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Madeddu-2012">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:25:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McMillan-1994">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:25:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mwamburi-2004">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:25:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Oster-1994">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:25:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sancho_x002d_Cuesta-1993">
<DESCRIPTION>
<P>Report only from old conference proceeding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:25:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schmoll-1991">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:25:05 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schmoll-1992">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:25:05 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Summerbell-1992">
<DESCRIPTION>
<P>The study was discontinued after 14 patients were enrolled, because recruitment was too slow and the majority of patients had diarrhoea or overt infections</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:25:06 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tchekmedyian-1992">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:25:06 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Timpone-1997">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:25:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ulutin-2002">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:25:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vadell-1998">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:25:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Von-Roenn-1994">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:25:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wanke-2007">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:25:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Weisberg-2002">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-05 16:25:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yeh-2000">
<DESCRIPTION>
<P>Insufficient information to permit judgement of low risk or high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2013-02-08 09:27:03 +0000" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2013-02-08 09:27:03 +0000" MODIFIED_BY="Grade Profiler" NO="1" READONLY="YES">
<TITLE MODIFIED="2012-12-15 19:41:08 +0000" MODIFIED_BY="Grade Profiler">Megestrol acetate for cachexia anorexia syndrome</TITLE>
<TABLE COLS="7" ROWS="35">
<TR>
<TD COLSPAN="7">
<P>
<B>Megestrol acetate for cachexia anorexia syndrome</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> cachexia anorexia syndrome<BR/>
<B>Settings:</B> cancer patients, AIDS patients and patients with other underlying conditions<BR/>
<B>Intervention:</B> megestrol acetate<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Megestrol acetate </B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Appetite improvement compared with placebo</B>
<BR/>Subjective sense of appetite, responses to follow-up questionnaire<BR/>Follow-up: mean 4 to 12 weeks</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 2.19 </B>
<BR/>(1.41 to 3.4)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>699<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>NNTB = 4 (95% CI 2 to 11)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>214 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>469 per 1000</B>
<BR/>(302 to 728)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Weight improvement compared with placebo</B>
<BR/>% of patients that improved their weight in kg<BR/>Follow-up: mean 4 to 12 weeks</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.51 </B>
<BR/>(1.08 to 2.11)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>1106<BR/>(10 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>3,4,5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>NNTB = 12 (95% CI 6 to 69)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>246 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>329 per 1000</B>
<BR/>(260 to 408)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>233 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>312 per 1000</B>
<BR/>(247 to 387)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Appetite improvement compared to other drugs</B>
<BR/>Questionnaire of appetite rating<BR/>Follow-up: median 8 weeks</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.03 </B>
<BR/>(0.64 to 1.67)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>475<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>6,7</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>NNTB = NS</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>325 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>335 per 1000</B>
<BR/>(208 to 543)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>325 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>335 per 1000</B>
<BR/>(208 to 543)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Weight improvement compared to other drugs</B>
<BR/>% of patients that improved their weight in kg<BR/>Follow-up: mean 8 to 15 weeks</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.66 </B>
<BR/>(1.09 to 2.52)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>1131<BR/>(7 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>3,8,9,10</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>NNTB = 22 (95% CI 9 to 159)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>72 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>119 per 1000</B>
<BR/>(78 to 180)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>57 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>95 per 1000</B>
<BR/>(62 to 144)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>Deaths</B>
<BR/>Follow-up: mean 2 to 15 weeks</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>RR 1.42 </B>
<BR/>(1.04 to 1.94)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>1307<BR/>(10 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>11,12,13,14</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>NNTH = 23 (95% CI 10 to 200)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>102 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>146 per 1000</B>
<BR/>(107 to 200)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>48 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>69 per 1000</B>
<BR/>(50 to 94)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Thromboembolic phenomena including thrombophlebitis</B>
<BR/>Follow-up: mean 4 to 16 weeks</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.84 </B>
<BR/>(1.07 to 3.18)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>1544<BR/>(11 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>13,15,16</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>NNTH = 55 (95% CI 22 to 385)<BR/>NNTH = 11 (95% CI 4 to 77)<BR/>NNTH = 2 (95% CI 1 to 15) <SUP>17</SUP>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>100 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>191 per 1000</B>
<BR/>(113 to 323)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>500 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>955 per 1000</B>
<BR/>(565 to 1000)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Oedema</B>
<BR/>Follow-up: mean 2 to 12 weeks</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.36 </B>
<BR/>(1.07 to 1.72)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>2182<BR/>(12 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>18,19</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>NNTH = 28 (95% CI 4 to 143)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>104 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>141 per 1000</B>
<BR/>(111 to 179)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>109 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>148 per 1000</B>
<BR/>(117 to 187)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval;<B> NNTB:</B> number needed to treat for an additional beneficial outcome; <B>RR:</B> risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Adequate sequence generation was low risk only in <LINK REF="STD-Feliu-1992" TYPE="STUDY">Feliu 1992</LINK>. Allocation concealment was unclear in all studies. In three out of five studies appetite was rated as high risk of bias because it could be sensitive to lack of blinding.<BR/>
<SUP>2</SUP> The two different subcategories (cancer and AIDS patients) showed similar effects. Heterogeneity was moderate (I<SUP>2 </SUP>= 59%) and is due to the study of <LINK REF="STD-Schmoll-1991" TYPE="STUDY">Schmoll 1991</LINK>. Heterogeneity without this study became low (I<SUP>2 </SUP>= 39%). The confidence intervals of the studies overlap.<BR/>
<SUP>3</SUP> Doses of MA were very different (960 mg, 800 mg, 480 and 160 mg) compared with placebo.<BR/>
<SUP>4</SUP> Eight out of 10 studies were rated as unclear for adequate sequence generation; only one study was rated as low risk for allocation concealment. All studies were rated as low risk of bias for blinding. <LINK REF="STD-Schmoll-1991" TYPE="STUDY">Schmoll 1991</LINK>, <LINK REF="STD-Schmoll-1992" TYPE="STUDY">Schmoll 1992</LINK> and <LINK REF="STD-Von-Roenn-1994" TYPE="STUDY">Von Roenn 1994</LINK> were rated low risk because lack of blinding is not related to weight. Only one study was rated as high risk of bias for incomplete outcome data. All trials were rated unclear with respect to freedom from 'other bias'.<BR/>
<SUP>5</SUP> The effect is quite similar and CI values overlap for most of the studies. However, two studies (Feliu and Schmoll) showed greater effects and the CI was quite wide. The study of <LINK REF="STD-Yeh-2000" TYPE="STUDY">Yeh 2000</LINK> showed different results in patients with geriatric cachexia to patients with neoplasia and AIDS. Heterogeneity was moderate (I<SUP>2 </SUP>= 53%).<BR/>
<SUP>6</SUP> The only study found was rated as unclear risk of bias for adequate sequence generation and allocation concealment. It was not a blinded study and was rated as high risk of bias for the blinding item.<BR/>
<SUP>7</SUP> We pooled the results of two comparisons: MA versus dexamethasone and fluoxymesterone.<BR/>
<SUP>8</SUP> All studies except <LINK REF="STD-Mwamburi-2004" TYPE="STUDY">Mwamburi 2004</LINK> were rated as unclear risk of bias for adequate sequence generation and allocation concealment study.<BR/>
<SUP>9</SUP> Heterogeneity was moderate (I<SUP>2 </SUP>= 51%) but heterogeneity between subgroups was high. The effect seemed to be different in cancer and AIDS patients. The CI values overlapped for most of the studies. Cancer patients showed a better response for weight.<BR/>
<SUP>10</SUP> The CI interval (9 to 159) is too wide to establish a true effect.<BR/>
<SUP>11</SUP> Only one study out of seven was rated as low risk of bias for adequate sequence generation and allocation concealment.<BR/>
<SUP>12</SUP> Although the I<SUP>2</SUP> in both subgroups was 0% and the overall I<SUP>2</SUP> was low (6.4%), patients with cancer, AIDS and other pathologies were quite different. Moreover the comparator included placebo and other drugs.<BR/>
<SUP>13</SUP> Different doses of MA in each subgroup.<BR/>
<SUP>14</SUP> The CI interval for the NNT (10 to 200) is too wide to establish a true effect.<BR/>
<SUP>15</SUP> Adequate sequence generation was rated as low risk in three out of 10 trials and allocation concealment was rated low risk only in two out of 10.<BR/>
<SUP>16</SUP> Although the I<SUP>2</SUP> in both subgroups was 0% and the overall I<SUP>2</SUP> was low (0%), patients with cancer, AIDS and other pathologies were quite different. Moreover the comparator included placebo and other drugs.<BR/>
<SUP>17</SUP> The first NNTH was calculated with data of this Systematic Review. The second NNTH was calculated with an expected value of 0.10% and the last was calculated with an expected rate of 50%.<BR/>
<SUP>18</SUP> Only three out of 11 trials were rated as low risk for adequate sequence generation. Only two out of 11 trials were rated as low risk for allocation concealment.<BR/>
<SUP>19</SUP> Although the I<SUP>2</SUP> in both subgroups was 0% and the overall I<SUP>2</SUP> was low (0%), patients with cancer, AIDS and other pathologies such as COPD were quite different. Moreover the comparator included placebo and other drugs.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2013-02-07 10:23:26 +0000" MODIFIED_BY="Jessica R Thomas">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2013-02-07 10:23:26 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE>Patient condition and numbers recruited to each trial</TITLE>
<TABLE COLS="10" ROWS="35">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Study</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Lung cancer</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Gastrointestinal and pancreas</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Head and neck cancer</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Gynaecological cancer</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Other cancer</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>AIDS</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>COPD</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Cystic fibrosis</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Elderly</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Batterham-2001" TYPE="STUDY">Batterham 2001</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>15</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Beller-1997" TYPE="STUDY">Beller 1997</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>48</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>106</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>18</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>68</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Casado-2008" TYPE="STUDY">Casado 2008</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>35</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>21</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>21</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> ­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> ­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> ­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> ­</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-De-Conno-1998" TYPE="STUDY">De Conno 1998</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>21</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Eubanks-2002" TYPE="STUDY">Eubanks 2002</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>17</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Feliu-1992" TYPE="STUDY">Feliu 1992</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>75</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>36</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>9</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>30</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Fietkau-1996" TYPE="STUDY">Fietkau 1996</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>64</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Gambardella-1998" TYPE="STUDY">Gambardella 1998</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No data</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No data</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No data</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No data</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No data</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Gebbia-1996" TYPE="STUDY">Gebbia 1996</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>50</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>22</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>40</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Giacosa-1997" TYPE="STUDY">Giacosa 1997</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> ­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> ­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Heckmayr-1992" TYPE="STUDY">Heckmayr 1992</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>66</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Herrejon-2011" TYPE="STUDY">Herrejon 2011</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> ­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> ­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> ­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>40</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> ­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> ­</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Jatoi-2001" TYPE="STUDY">Jatoi 2001</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>208</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>139</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> ­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> ­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>121</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Jatoi-2004" TYPE="STUDY">Jatoi 2004</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>166</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>141</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> ­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> ­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>114</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Lesser-2006" TYPE="STUDY">Lesser 2006</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No data</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No data</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No data</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No data</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>74</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Loprinzi-1990b" TYPE="STUDY">Loprinzi 1990b</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>42</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>53</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>38</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Loprinzi-1994" TYPE="STUDY">Loprinzi 1994</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>130</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>111</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>101</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="REF-Loprinzi-1999" TYPE="REFERENCE">Loprinzi 1999</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>192</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>171</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>114</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> ­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Mwamburi-2004" TYPE="STUDY">Mwamburi 2004</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> ­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> ­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>40</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> ­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> ­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> ­</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-McMillan-1994" TYPE="STUDY">McMillan 1994</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>26</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Macbeth-1994" TYPE="STUDY">Macbeth 1994</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>75</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> ­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> ­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> ­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> ­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Madeddu-2012" TYPE="STUDY">Madeddu 2012</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>24</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>13</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Oster-1994" TYPE="STUDY">Oster 1994</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>100</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Sancho_x002d_Cuesta-1993" TYPE="STUDY">Sancho-Cuesta 1993</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Schmoll-1991" TYPE="STUDY">Schmoll 1991</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Schmoll-1992" TYPE="STUDY">Schmoll 1992</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Tchekmedyian-1992" TYPE="STUDY">Tchekmedyian 1992</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>27</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>23</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>35</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Von-Roenn-1994" TYPE="STUDY">Von Roenn 1994</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>270</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Ulutin-2002" TYPE="STUDY">Ulutin 2002</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>119</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Timpone-1997" TYPE="STUDY">Timpone 1997</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>50</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Vadell-1998" TYPE="STUDY">Vadell 1998</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>75</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>35</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>27</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Weisberg-2002" TYPE="STUDY">Weisberg 2002</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>145</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>­</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Yeh-2000" TYPE="STUDY">Yeh 2000</LINK>
</P>
</TD>
<TD>
<P>­</P>
</TD>
<TD>
<P>­</P>
</TD>
<TD>
<P>­</P>
</TD>
<TD>
<P>­</P>
</TD>
<TD>
<P>­</P>
</TD>
<TD>
<P>­</P>
</TD>
<TD>
<P>­</P>
</TD>
<TD>
<P>­</P>
</TD>
<TD>
<P>69</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Total</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>1342</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>928</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>284</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>21</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>907</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>475</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>185</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>17</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>69</B>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-02-08 09:23:44 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2013-02-05 20:21:39 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Megestrol acetate versus placebo (ITT)</NAME>
<DICH_OUTCOME CHI2="9.767225710383759" CI_END="3.3950853562895578" CI_START="1.411404241513742" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="2.189026695170316" ESTIMABLE="YES" EVENTS_1="294" EVENTS_2="52" I2="59.04671276565761" I2_Q="56.864255202396855" ID="CMP-001.01" LOG_CI_END="0.5308506974087323" LOG_CI_START="0.14965141823007289" LOG_EFFECT_SIZE="0.34025105781940257" METHOD="MH" MODIFIED="2013-01-31 09:36:57 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.04453674894399384" P_Q="0.12786287634218652" P_Z="4.672668898164228E-4" Q="2.3182629735317923" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.1323739423330451" TOTALS="YES" TOTAL_1="476" TOTAL_2="223" WEIGHT="100.0" Z="3.4988514168471623">
<NAME>Appetite improvement</NAME>
<GROUP_LABEL_1>Megestrol acetate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.320884551383262" CI_END="4.4920973476756085" CI_START="1.475629656183723" DF="3" EFFECT_SIZE="2.5746207613344483" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="33" I2="52.53828834219919" ID="CMP-001.01.01" LOG_CI_END="0.6524491592323952" LOG_CI_START="0.16897737479244712" LOG_EFFECT_SIZE="0.4107132670124212" MODIFIED="2012-04-20 23:21:49 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.09700054026529015" P_Z="8.684251307288816E-4" STUDIES="4" TAU2="0.1579378302263176" TOTAL_1="244" TOTAL_2="185" WEIGHT="68.64409486348417" Z="3.3300111287760785">
<NAME>Cancer</NAME>
<DICH_DATA CI_END="6.869043147371471" CI_START="1.9929995643190366" EFFECT_SIZE="3.7" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="10" LOG_CI_END="0.8368962443727193" LOG_CI_START="0.2995072037612709" LOG_EFFECT_SIZE="0.568201724066995" MODIFIED="2012-01-09 12:57:43 +0000" MODIFIED_BY="[Empty name]" ORDER="51920" O_E="0.0" SE="0.31566498257381764" STUDY_ID="STD-Feliu-1992" TOTAL_1="76" TOTAL_2="74" VAR="0.0996443812233286" WEIGHT="21.61011415499846"/>
<DICH_DATA CI_END="2.5191420940586524" CI_START="0.8666986476316989" EFFECT_SIZE="1.4776119402985075" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="16" LOG_CI_END="0.4012526648880033" LOG_CI_START="-0.062131881094556314" LOG_EFFECT_SIZE="0.1695603918967235" ORDER="51923" O_E="0.0" SE="0.2721943761006519" STUDY_ID="STD-Loprinzi-1990b" TOTAL_1="67" TOTAL_2="66" VAR="0.07408977838082315" WEIGHT="24.284859542240223"/>
<DICH_DATA CI_END="43.86715397607745" CI_START="0.8942259357832195" EFFECT_SIZE="6.2631578947368425" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="1" LOG_CI_END="1.6421394590555214" LOG_CI_START="-0.04855273817611772" LOG_EFFECT_SIZE="0.7967933604397018" MODIFIED="2012-04-20 23:21:49 +0100" MODIFIED_BY="[Empty name]" ORDER="219" O_E="0.0" SE="0.9931209657152156" STUDY_ID="STD-Schmoll-1991" TOTAL_1="38" TOTAL_2="17" VAR="0.9862892525431224" WEIGHT="4.482084045555492"/>
<DICH_DATA CI_END="5.737800103182554" CI_START="1.309153277018078" EFFECT_SIZE="2.740740740740741" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="6" LOG_CI_END="0.7587454139697585" LOG_CI_START="0.11699049717421948" LOG_EFFECT_SIZE="0.43786795557198893" MODIFIED="2012-02-11 19:35:18 +0000" MODIFIED_BY="[Empty name]" ORDER="51924" O_E="0.0" SE="0.37697001486377146" STUDY_ID="STD-Schmoll-1992" TOTAL_1="63" TOTAL_2="28" VAR="0.1421063921063921" WEIGHT="18.26703712069"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1600019935455093" CI_START="1.1271637657049847" DF="0" EFFECT_SIZE="1.5603448275862069" ESTIMABLE="YES" EVENTS_1="181" EVENTS_2="19" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.3344541519775117" LOG_CI_START="0.05198701930702044" LOG_EFFECT_SIZE="0.19322058564226602" MODIFIED="2012-01-30 23:40:14 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.007331217912929622" STUDIES="1" TAU2="0.0" TOTAL_1="232" TOTAL_2="38" WEIGHT="31.355905136515826" Z="2.681412066248096">
<NAME>AIDS</NAME>
<DICH_DATA CI_END="2.160001993545509" CI_START="1.1271637657049847" EFFECT_SIZE="1.5603448275862069" ESTIMABLE="YES" EVENTS_1="181" EVENTS_2="19" LOG_CI_END="0.3344541519775116" LOG_CI_START="0.05198701930702044" LOG_EFFECT_SIZE="0.19322058564226602" MODIFIED="2012-01-30 23:40:14 +0000" MODIFIED_BY="[Empty name]" ORDER="51926" O_E="0.0" SE="0.1659225919655037" STUDY_ID="STD-Von-Roenn-1994" TOTAL_1="232" TOTAL_2="38" VAR="0.02753030652455104" WEIGHT="31.355905136515826"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-02-01 22:37:03 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Other underlying pathology</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.3930816043231128" CI_END="1.385027323162599" CI_START="0.42706838631094196" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.9060478547367704" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2013-02-05 19:00:44 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5306843937933667" P_Q="1.0" P_Z="2.0930716333393188E-4" Q="0.0" RANDOM="YES" SCALE="374.9789014284296" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="38" UNITS="" WEIGHT="100.0" Z="3.7075099886642437">
<NAME>Appetite gain</NAME>
<GROUP_LABEL_1>Megestrol acetate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.02.01" MODIFIED="2012-01-24 21:59:43 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Cancer</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.02.02" MODIFIED="2012-01-30 23:39:27 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>AIDS</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.3930816043231128" CI_END="1.385027323162599" CI_START="0.42706838631094196" DF="1" EFFECT_SIZE="0.9060478547367704" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.03" MODIFIED="2012-02-13 16:59:17 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5306843937933667" P_Z="2.0930716333393188E-4" STUDIES="2" TAU2="0.0" TOTAL_1="37" TOTAL_2="38" WEIGHT="100.0" Z="3.7075099886642437">
<NAME>Other underlying pathology</NAME>
<CONT_DATA CI_END="1.9405294398384951" CI_START="0.29826659572185454" EFFECT_SIZE="1.1193980177801748" ESTIMABLE="YES" MEAN_1="3.46" MEAN_2="0.93" MODIFIED="2012-01-25 16:25:07 +0000" MODIFIED_BY="[Empty name]" ORDER="127" SD_1="1.9" SD_2="2.43" SE="0.4189523014378326" STUDY_ID="STD-Herrejon-2011" TOTAL_1="13" TOTAL_2="14" WEIGHT="34.02580841471683"/>
<CONT_DATA CI_END="1.3857120171474409" CI_START="0.2063154626584609" EFFECT_SIZE="0.7960137399029509" ESTIMABLE="YES" MEAN_1="1.16" MEAN_2="0.25" MODIFIED="2012-02-13 16:59:17 +0000" MODIFIED_BY="[Empty name]" ORDER="184" SD_1="1.02" SD_2="1.22" SE="0.3008719965754242" STUDY_ID="STD-Yeh-2000" TOTAL_1="24" TOTAL_2="24" WEIGHT="65.97419158528317"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="19.979450646375557" CI_END="2.1053278789380414" CI_START="1.0784987323588398" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5068488473083166" ESTIMABLE="YES" EVENTS_1="277" EVENTS_2="100" I2="54.95371639944126" I2_Q="51.13844987669444" ID="CMP-001.03" LOG_CI_END="0.3233197414660974" LOG_CI_START="0.03281963897970018" LOG_EFFECT_SIZE="0.17806969022289879" METHOD="MH" MODIFIED="2013-01-31 09:35:55 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0180396595561656" P_Q="0.12917374336845067" P_Z="0.016269055051061024" Q="4.093198015521119" RANDOM="YES" SCALE="17.78" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.13965201472951366" TOTALS="YES" TOTAL_1="711" TOTAL_2="395" WEIGHT="100.0" Z="2.4028231080670848">
<NAME>Weight improvement</NAME>
<GROUP_LABEL_1>Megestrol acetate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="15.757065311104423" CI_END="2.2593239716542284" CI_START="1.0644257429532278" DF="7" EFFECT_SIZE="1.5507683892509834" ESTIMABLE="YES" EVENTS_1="165" EVENTS_2="83" I2="55.57548400166296" ID="CMP-001.03.01" LOG_CI_END="0.3539785102535176" LOG_CI_START="0.027115369343594146" LOG_EFFECT_SIZE="0.1905469397985559" MODIFIED="2012-04-20 23:42:27 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.02743096671833689" P_Z="0.02230421814352865" STUDIES="8" TAU2="0.14081356409488194" TOTAL_1="443" TOTAL_2="324" WEIGHT="79.36606637501434" Z="2.2851468558359747">
<NAME>Cancer</NAME>
<DICH_DATA CI_END="10.274845018517457" CI_START="1.6276445030275961" EFFECT_SIZE="4.089473684210526" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="5" LOG_CI_END="1.0117752798804394" LOG_CI_START="0.2115595558157313" LOG_EFFECT_SIZE="0.6116674178480853" MODIFIED="2012-04-20 23:42:27 +0100" MODIFIED_BY="[Empty name]" ORDER="51938" O_E="0.0" SE="0.47005067744732804" STUDY_ID="STD-Feliu-1992" TOTAL_1="76" TOTAL_2="74" VAR="0.22094763936869202" WEIGHT="8.074999016757667"/>
<DICH_DATA CI_END="5.09648598079" CI_START="1.0004649042928742" EFFECT_SIZE="2.2580645161290325" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" LOG_CI_END="0.7072708339097552" LOG_CI_START="2.0185845021324637E-4" LOG_EFFECT_SIZE="0.3537363461799842" MODIFIED="2012-01-24 22:14:01 +0000" MODIFIED_BY="[Empty name]" ORDER="130" O_E="0.0" SE="0.41533581623281146" STUDY_ID="STD-Fietkau-1996" TOTAL_1="31" TOTAL_2="30" VAR="0.17250384024577572" WEIGHT="9.32816670222851"/>
<DICH_DATA CI_END="1.4019742832668287" CI_START="0.6921468047426783" EFFECT_SIZE="0.9850746268656716" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="32" LOG_CI_END="0.1467400473412371" LOG_CI_START="-0.15980178165915268" LOG_EFFECT_SIZE="-0.00653086715895778" MODIFIED="2012-02-16 17:29:25 +0000" MODIFIED_BY="[Empty name]" ORDER="51940" O_E="0.0" SE="0.18006418776135494" STUDY_ID="STD-Loprinzi-1990b" TOTAL_1="67" TOTAL_2="66" VAR="0.03242311171415649" WEIGHT="16.921921909726887"/>
<DICH_DATA CI_END="1.7903122675350842" CI_START="0.20108223941047487" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.2529287875383019" LOG_CI_START="-0.6966262867710147" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2012-01-29 11:17:14 +0000" MODIFIED_BY="[Empty name]" ORDER="162" O_E="0.0" SE="0.5577733510227171" STUDY_ID="STD-McMillan-1994" TOTAL_1="20" TOTAL_2="18" VAR="0.3111111111111111" WEIGHT="6.459804907191319"/>
<DICH_DATA CI_END="38.04338372729278" CI_START="0.7575547118765404" EFFECT_SIZE="5.368421052631579" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="1" LOG_CI_END="1.5802791378325827" LOG_CI_START="-0.12058599621440545" LOG_EFFECT_SIZE="0.7298465708090885" MODIFIED="2012-04-20 23:42:26 +0100" MODIFIED_BY="[Empty name]" ORDER="218" O_E="0.0" SE="0.9990965991574009" STUDY_ID="STD-Schmoll-1991" TOTAL_1="38" TOTAL_2="17" VAR="0.9981940144478842" WEIGHT="2.559082492374889"/>
<DICH_DATA CI_END="5.104141833207412" CI_START="0.6990207856990239" EFFECT_SIZE="1.8888888888888888" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="4" LOG_CI_END="0.7079227339974891" LOG_CI_START="-0.15550991011959098" LOG_EFFECT_SIZE="0.27620641193894907" MODIFIED="2012-02-11 19:35:46 +0000" MODIFIED_BY="[Empty name]" ORDER="51942" O_E="0.0" SE="0.5071846092148924" STUDY_ID="STD-Schmoll-1992" TOTAL_1="63" TOTAL_2="28" VAR="0.25723622782446315" WEIGHT="7.336679548752708"/>
<DICH_DATA CI_END="2.1734264488318" CI_START="0.873112966324461" EFFECT_SIZE="1.3775510204081634" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="16" LOG_CI_END="0.33714494776726445" LOG_CI_START="-0.05892956216224188" LOG_EFFECT_SIZE="0.13910769280251128" MODIFIED="2012-03-05 17:27:38 +0000" MODIFIED_BY="[Empty name]" ORDER="51943" O_E="0.0" SE="0.23265612773303632" STUDY_ID="STD-Tchekmedyian-1992" TOTAL_1="49" TOTAL_2="40" VAR="0.054128873771730916" WEIGHT="15.02646558598819">
<FOOTNOTE>Data at one month</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.5620676643452334" CI_START="0.8850337986238072" EFFECT_SIZE="1.505827505827506" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="13" LOG_CI_END="0.4085905953008247" LOG_CI_START="-0.05304014368010501" LOG_EFFECT_SIZE="0.17777522581035987" MODIFIED="2012-01-29 19:35:19 +0000" MODIFIED_BY="[Empty name]" ORDER="51944" O_E="0.0" SE="0.2711641811864099" STUDY_ID="STD-Vadell-1998" TOTAL_1="99" TOTAL_2="51" VAR="0.07353001315849614" WEIGHT="13.658946211994165">
<FOOTNOTE>Esta bien. Ha sumado los dos</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.04356192770385" CI_START="1.1429460967682334" DF="0" EFFECT_SIZE="2.1497844827586206" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="8" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.606764098776945" LOG_CI_START="0.058025748830864796" LOG_EFFECT_SIZE="0.33239492380390495" MODIFIED="2012-01-30 23:36:15 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.01757404205564924" STUDIES="1" TAU2="0.0" TOTAL_1="232" TOTAL_2="38" WEIGHT="11.955842985714398" Z="2.3744725673487364">
<NAME>AIDS</NAME>
<DICH_DATA CI_END="4.04356192770385" CI_START="1.1429460967682334" EFFECT_SIZE="2.1497844827586206" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="8" LOG_CI_END="0.606764098776945" LOG_CI_START="0.058025748830864796" LOG_EFFECT_SIZE="0.33239492380390495" MODIFIED="2012-01-30 23:36:15 +0000" MODIFIED_BY="[Empty name]" ORDER="51945" O_E="0.0" SE="0.32233162305696766" STUDY_ID="STD-Von-Roenn-1994" TOTAL_1="232" TOTAL_2="38" VAR="0.1038976752225391" WEIGHT="11.955842985714398"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6974685611582485" CI_START="0.2994554351039547" DF="0" EFFECT_SIZE="0.7129629629629629" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" I2="0.0" ID="CMP-001.03.03" LOG_CI_END="0.22980173945213891" LOG_CI_START="-0.5236678000810746" LOG_EFFECT_SIZE="-0.14693303031446786" MODIFIED="2012-03-15 16:43:35 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.444617229849409" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="33" WEIGHT="8.678090639271266" Z="0.7644196147175356">
<NAME>Other underlying pathology</NAME>
<DICH_DATA CI_END="1.6974685611582485" CI_START="0.2994554351039547" EFFECT_SIZE="0.7129629629629629" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.22980173945213891" LOG_CI_START="-0.5236678000810746" LOG_EFFECT_SIZE="-0.14693303031446786" MODIFIED="2012-03-15 16:43:35 +0000" MODIFIED_BY="[Empty name]" ORDER="51947" O_E="0.0" SE="0.44259173725618267" STUDY_ID="STD-Yeh-2000" TOTAL_1="36" TOTAL_2="33" VAR="0.19588744588744586" WEIGHT="8.678090639271266"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="30.47678692475521" CI_END="2.907031833150734" CI_START="0.9468098533127028" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="MD" EFFECT_SIZE="1.9269208432317184" ESTIMABLE="YES" I2="77.03169951188605" I2_Q="78.96141141299614" ID="CMP-001.04" MODIFIED="2013-02-05 20:21:39 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="7.761953813734124E-5" P_Q="0.008624343230461462" P_Z="1.1652005089134161E-4" Q="9.506341129915235" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="1.344161888003373" TOTALS="YES" TOTAL_1="290" TOTAL_2="262" UNITS="" WEIGHT="100.0" Z="3.8533344617488474">
<NAME>Weight gain</NAME>
<GROUP_LABEL_1>Megestrol acetate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.7800430904069605" CI_END="2.3813944145080743" CI_START="0.8738260110936996" DF="2" EFFECT_SIZE="1.627610212800887" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.01" MODIFIED="2012-03-15 16:45:20 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6770424811423871" P_Z="2.315641240381226E-5" STUDIES="3" TAU2="0.0" TOTAL_1="115" TOTAL_2="112" WEIGHT="40.708821810829704" Z="4.232056589584126">
<NAME>Cancer</NAME>
<CONT_DATA CI_END="2.450790635597685" CI_START="0.3492093644023153" EFFECT_SIZE="1.4000000000000001" ESTIMABLE="YES" MEAN_1="1.06" MEAN_2="-0.34" MODIFIED="2012-01-09 10:59:32 +0000" MODIFIED_BY="[Empty name]" ORDER="51929" SD_1="1.95" SD_2="1.01" SE="0.5361275226923491" STUDY_ID="STD-De-Conno-1998" TOTAL_1="17" TOTAL_2="16" WEIGHT="15.326467699232742"/>
<CONT_DATA CI_END="4.007979966871202" CI_START="0.5920200331287977" EFFECT_SIZE="2.3000000000000003" ESTIMABLE="YES" MEAN_1="-0.9" MEAN_2="-3.2" MODIFIED="2012-01-24 22:11:05 +0000" MODIFIED_BY="[Empty name]" ORDER="51931" SD_1="3.6" SD_2="3.2" SE="0.8714343632554121" STUDY_ID="STD-Fietkau-1996" TOTAL_1="31" TOTAL_2="30" WEIGHT="11.887745150013291"/>
<CONT_DATA CI_END="2.9782080386276055" CI_START="0.1817919613723944" EFFECT_SIZE="1.58" ESTIMABLE="YES" MEAN_1="1.36" MEAN_2="-0.22" ORDER="51932" SD_1="4.99" SD_2="3.01" SE="0.7133845568880307" STUDY_ID="STD-Loprinzi-1990b" TOTAL_1="67" TOTAL_2="66" WEIGHT="13.494608961583666"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.824705003771884" CI_START="2.695294996228116" DF="0" EFFECT_SIZE="4.26" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.02" MODIFIED="2012-02-11 12:37:55 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="9.495894260591631E-8" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="28" WEIGHT="12.62003682641779" Z="5.336115468419558">
<NAME>AIDS</NAME>
<CONT_DATA CI_END="5.824705003771884" CI_START="2.695294996228116" EFFECT_SIZE="4.26" ESTIMABLE="YES" MEAN_1="3.54" MEAN_2="-0.72" MODIFIED="2012-02-11 12:37:55 +0000" MODIFIED_BY="[Empty name]" ORDER="51934" SD_1="4.29" SD_2="2.85" SE="0.7983335490417564" STUDY_ID="STD-Von-Roenn-1994" TOTAL_1="53" TOTAL_2="28" WEIGHT="12.62003682641779">
<FOOTNOTE>MA 800 mg/d versus placebo</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="8.853556728189577" CI_END="2.8720520781084424" CI_START="0.05881154068282268" DF="3" EFFECT_SIZE="1.4654318093956327" ESTIMABLE="YES" I2="66.11531283864653" ID="CMP-001.04.03" MODIFIED="2013-02-05 20:21:39 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.03130266785178204" P_Z="0.041160348539344464" STUDIES="4" TAU2="1.269633032100904" TOTAL_1="122" TOTAL_2="122" WEIGHT="46.67114136275251" Z="2.041911119937958">
<NAME>Other underlying pathology</NAME>
<CONT_DATA CI_END="6.3265405202233715" CI_START="1.2734594797766285" EFFECT_SIZE="3.8" ESTIMABLE="YES" MEAN_1="5.3" MEAN_2="1.5" ORDER="51935" SD_1="3.6" SD_2="1.6" SE="1.2890749728833797" STUDY_ID="STD-Eubanks-2002" TOTAL_1="10" TOTAL_2="7" WEIGHT="8.319232270933338"/>
<CONT_DATA CI_END="4.000770353465514" CI_START="0.3992296465344851" EFFECT_SIZE="2.1999999999999997" ESTIMABLE="YES" MEAN_1="2.3" MEAN_2="0.1" MODIFIED="2012-01-25 16:29:33 +0000" MODIFIED_BY="[Empty name]" ORDER="129" SD_1="3.37" SD_2="1.18" SE="0.9187772671690712" STUDY_ID="STD-Herrejon-2011" TOTAL_1="15" TOTAL_2="16" WEIGHT="11.42733042687392"/>
<CONT_DATA CI_END="1.0101786698446733" CI_START="0.18982133015532654" EFFECT_SIZE="0.6" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="0.6" MODIFIED="2013-02-05 20:21:39 +0000" MODIFIED_BY="[Empty name]" ORDER="51936" SD_1="1.4" SD_2="1.1" SE="0.20927867709820713" STUDY_ID="STD-Weisberg-2002" TOTAL_1="72" TOTAL_2="73" WEIGHT="18.016795820895265">
<FOOTNOTE>Values at 2 weeks. Values at 8 weeks were written without SD</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="2.5107557286828244" CI_START="-2.230755728682824" EFFECT_SIZE="0.14" ESTIMABLE="YES" MEAN_1="1.05" MEAN_2="0.91" MODIFIED="2013-02-05 20:21:38 +0000" MODIFIED_BY="[Empty name]" ORDER="51937" SD_1="5.0" SD_2="3.47" SE="1.2095914758551907" STUDY_ID="STD-Yeh-2000" TOTAL_1="25" TOTAL_2="26" WEIGHT="8.907782844049988"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="4.500928595768254" CI_END="2.918951812225103" CI_START="1.0893654834393536" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7832008726054327" ESTIMABLE="YES" EVENTS_1="140" EVENTS_2="29" I2="33.34708746944838" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.4652269254582181" LOG_CI_START="0.037173610528351324" LOG_EFFECT_SIZE="0.2512002679932847" METHOD="MH" MODIFIED="2013-01-31 09:37:51 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.2122077807268934" P_Q="0.7084115985678541" P_Z="0.02142647983372599" Q="0.1398687932085015" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.08417218348253735" TOTALS="YES" TOTAL_1="459" TOTAL_2="211" WEIGHT="100.0" Z="2.3003839054689457">
<NAME>Quality of life improvement</NAME>
<GROUP_LABEL_1>Megestrol acetate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.4955189745711888" CI_END="3.5886781013456437" CI_START="1.0203037920166338" DF="1" EFFECT_SIZE="1.9135155800593875" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="17" I2="33.13357991417456" ID="CMP-001.05.01" LOG_CI_END="0.5549345045636673" LOG_CI_START="0.00872950073533961" LOG_EFFECT_SIZE="0.2818320026495035" MODIFIED="2012-03-15 16:49:11 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.22136249411960285" P_Z="0.04311309904456149" STUDIES="2" TAU2="0.06949504352823842" TOTAL_1="175" TOTAL_2="125" WEIGHT="57.263865665782994" Z="2.022612649141666">
<NAME>Cancer</NAME>
<DICH_DATA CI_END="4.875183598535852" CI_START="1.3145949967266393" EFFECT_SIZE="2.531578947368421" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="10" LOG_CI_END="0.6879909757944671" LOG_CI_START="0.11879197504753854" LOG_EFFECT_SIZE="0.40339147542100284" ORDER="51948" O_E="0.0" SE="0.33435031061924086" STUDY_ID="STD-Feliu-1992" TOTAL_1="76" TOTAL_2="74" VAR="0.11179013021118286" WEIGHT="32.26252654635126"/>
<DICH_DATA CI_END="2.962977402442392" CI_START="0.5922302054538852" EFFECT_SIZE="1.3246753246753247" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="7" LOG_CI_END="0.4717283392856544" LOG_CI_START="-0.227509446106783" LOG_EFFECT_SIZE="0.12210944658943569" MODIFIED="2012-03-15 16:49:11 +0000" MODIFIED_BY="[Empty name]" ORDER="51951" O_E="0.0" SE="0.41073573642237826" STUDY_ID="STD-Vadell-1998" TOTAL_1="99" TOTAL_2="51" VAR="0.16870384517443338" WEIGHT="25.001339119431734">
<FOOTNOTE>Data from previous review of Benrstein</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.9401219910181178" CI_END="4.693409127358417" CI_START="0.47359617911123325" DF="1" EFFECT_SIZE="1.4908992688048157" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="12" I2="65.9878058442835" ID="CMP-001.05.02" LOG_CI_END="0.6714884135795557" LOG_CI_START="-0.3245918100807472" LOG_EFFECT_SIZE="0.17344830174940426" NO="2" P_CHI2="0.08640436694033538" P_Z="0.49487201980929796" STUDIES="2" TAU2="0.4594520336647631" TOTAL_1="284" TOTAL_2="86" WEIGHT="42.736134334217006" Z="0.6825804117649129">
<NAME>AIDS</NAME>
<DICH_DATA CI_END="2.3578225471960006" CI_START="0.2509586554912917" EFFECT_SIZE="0.7692307692307693" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.37251111641913165" LOG_CI_START="-0.6003978210328051" LOG_EFFECT_SIZE="-0.11394335230683675" ORDER="51952" O_E="0.0" SE="0.5714915258361791" STUDY_ID="STD-Oster-1994" TOTAL_1="52" TOTAL_2="48" VAR="0.32660256410256416" WEIGHT="15.391012677375606"/>
<DICH_DATA CI_END="5.267131328919774" CI_START="1.171648552394913" EFFECT_SIZE="2.4841954022988504" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="6" LOG_CI_END="0.7215741470482185" LOG_CI_START="0.06879736027850236" LOG_EFFECT_SIZE="0.3951857536633604" ORDER="51953" O_E="0.0" SE="0.38344431584573946" STUDY_ID="STD-Von-Roenn-1994" TOTAL_1="232" TOTAL_2="38" VAR="0.1470295433544072" WEIGHT="27.3451216568414"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.05.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Other underlying pathology</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.7097143553937184" CI_END="1.1306484389063214" CI_START="-0.12710594632846428" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.5017712462889286" ESTIMABLE="YES" I2="41.510697570898216" I2_Q="41.510697570898216" ID="CMP-001.06" MODIFIED="2013-01-31 09:38:12 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.19102252766129546" P_Q="0.19102252766129546" P_Z="0.11785878526793667" Q="1.7097143553937184" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.08547647893126735" TOTALS="YES" TOTAL_1="34" TOTAL_2="36" UNITS="" WEIGHT="99.99999999999999" Z="1.5638245157388109">
<NAME>Quality of life gain</NAME>
<GROUP_LABEL_1>Megestrol acetate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.8628948000283901" CI_START="-0.5055630229376596" DF="0" EFFECT_SIZE="0.17866588854536525" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.01" MODIFIED="2012-02-11 09:28:21 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6088008640507712" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="16" WEIGHT="49.65157776672142" Z="0.5117858964126086">
<NAME>Cancer</NAME>
<CONT_DATA CI_END="0.8628948000283901" CI_START="-0.5055630229376596" EFFECT_SIZE="0.17866588854536525" ESTIMABLE="YES" MEAN_1="-0.59" MEAN_2="-1.88" MODIFIED="2012-01-09 11:26:26 +0000" MODIFIED_BY="[Empty name]" ORDER="51929" SD_1="8.27" SD_2="5.44" SE="0.34910279825554713" STUDY_ID="STD-De-Conno-1998" TOTAL_1="17" TOTAL_2="16" WEIGHT="49.65157776672142"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.06.02" MODIFIED="2012-02-11 09:29:18 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>AIDS</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.4965296446992846" CI_START="0.14427972081129448" DF="0" EFFECT_SIZE="0.8204046827552895" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.03" MODIFIED="2012-02-11 09:27:10 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.017397160401223428" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="20" WEIGHT="50.34842223327857" Z="2.378204801557922">
<NAME>Other underlying pathology</NAME>
<CONT_DATA CI_END="1.4965296446992846" CI_START="0.14427972081129448" EFFECT_SIZE="0.8204046827552895" ESTIMABLE="YES" MEAN_1="7.76" MEAN_2="4.65" MODIFIED="2012-02-08 20:04:53 +0000" MODIFIED_BY="[Empty name]" ORDER="185" SD_1="4.18" SD_2="3.26" SE="0.3449680541464958" STUDY_ID="STD-Yeh-2000" TOTAL_1="17" TOTAL_2="20" WEIGHT="50.34842223327857">
<FOOTNOTE>Sense of well being</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2013-01-31 09:40:03 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Megestrol acetate versus other drugs (ITT)</NAME>
<DICH_OUTCOME CHI2="2.97970856169791" CI_END="1.6682627757622985" CI_START="0.6402915833654829" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.033525333101486" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="103" I2="66.43967088411574" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.22226445941630385" LOG_CI_START="-0.19362220694039797" LOG_EFFECT_SIZE="0.014321126237952914" METHOD="MH" MODIFIED="2012-01-10 19:31:30 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0843146361092203" P_Q="1.0" P_Z="0.892625023734617" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.07943998794257037" TOTALS="YES" TOTAL_1="158" TOTAL_2="317" WEIGHT="100.0" Z="0.13498336886023143">
<NAME>Appetite improvement</NAME>
<GROUP_LABEL_1>Megestrol acetate</GROUP_LABEL_1>
<GROUP_LABEL_2>Other drugs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other drugs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.97970856169791" CI_END="1.6682627757622985" CI_START="0.6402915833654829" DF="1" EFFECT_SIZE="1.033525333101486" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="103" I2="66.43967088411574" ID="CMP-002.01.01" LOG_CI_END="0.22226445941630385" LOG_CI_START="-0.19362220694039797" LOG_EFFECT_SIZE="0.014321126237952914" MODIFIED="2012-01-10 19:31:30 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0843146361092203" P_Z="0.892625023734617" STUDIES="2" TAU2="0.07943998794257037" TOTAL_1="158" TOTAL_2="317" WEIGHT="100.0" Z="0.13498336886023143">
<NAME>Cancer</NAME>
<DICH_DATA CI_END="1.1806591625625122" CI_START="0.5662422515797703" EFFECT_SIZE="0.8176424050632911" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="64" LOG_CI_END="0.0721245418283099" LOG_CI_START="-0.24699772779442827" LOG_EFFECT_SIZE="-0.08743659298305917" ORDER="51966" O_E="0.0" SE="0.1874540008571078" STUDY_ID="STD-Loprinzi-1999a" TOTAL_1="79" TOTAL_2="159" VAR="0.03513900243733657" WEIGHT="52.08590403753171"/>
<DICH_DATA CI_END="2.0217938657680343" CI_START="0.879307138021432" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="39" LOG_CI_END="0.3057368745373635" LOG_CI_START="-0.05585940132076362" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="51967" O_E="0.0" SE="0.21240344236949693" STUDY_ID="STD-Loprinzi-1999b" TOTAL_1="79" TOTAL_2="158" VAR="0.0451152223304122" WEIGHT="47.91409596246828"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-01-04 17:12:19 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>AIDS</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Other underlying pathology</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.480547005813186" CI_START="-1.280547005813186" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.5999999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.02" MODIFIED="2013-01-31 09:38:41 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.27630293419524765" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="4" TOTAL_2="5" UNITS="" WEIGHT="100.0" Z="1.0886621079036347">
<NAME>Appetite gain</NAME>
<GROUP_LABEL_1>Megestrol acetate</GROUP_LABEL_1>
<GROUP_LABEL_2>Other drugs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.02.01" MODIFIED="2012-01-09 08:19:37 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Cancer</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.480547005813186" CI_START="-1.280547005813186" DF="0" EFFECT_SIZE="1.5999999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.02" MODIFIED="2012-03-15 16:58:18 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.27630293419524765" STUDIES="1" TAU2="0.0" TOTAL_1="4" TOTAL_2="5" WEIGHT="100.0" Z="1.0886621079036347">
<NAME>AIDS</NAME>
<CONT_DATA CI_END="4.480547005813186" CI_START="-1.280547005813186" EFFECT_SIZE="1.5999999999999999" ESTIMABLE="YES" MEAN_1="3.3" MEAN_2="1.7" MODIFIED="2012-03-15 16:58:18 +0000" MODIFIED_BY="[Empty name]" ORDER="104" SD_1="2.8" SD_2="1.0" SE="1.4696938456699067" STUDY_ID="STD-Batterham-2001" TOTAL_1="4" TOTAL_2="5" WEIGHT="100.0">
<FOOTNOTE>MA compared to Nandrolone</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.02.03" MODIFIED="2012-02-19 19:13:52 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Other underlying pathology</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="12.351352000718508" CI_END="2.5225605828652773" CI_START="1.0937090434155805" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6610079235342112" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="46" I2="51.422322028787086" I2_Q="85.03931060951177" ID="CMP-002.03" LOG_CI_END="0.4018416052313028" LOG_CI_START="0.03890180312600433" LOG_EFFECT_SIZE="0.2203717041786536" METHOD="MH" MODIFIED="2013-01-31 09:40:03 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.054574227891058924" P_Q="0.009727246720573679" P_Z="0.01730688131173775" Q="6.684183956360893" RANDOM="YES" SCALE="13.52" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.1510399965611462" TOTALS="YES" TOTAL_1="488" TOTAL_2="643" WEIGHT="100.0" Z="2.3801225486785516">
<NAME>Weight improvement</NAME>
<GROUP_LABEL_1>Megestrol acetate</GROUP_LABEL_1>
<GROUP_LABEL_2>Other drugs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other drugs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.5895529652744864" CI_END="4.00177516108382" CI_START="1.5435042889920185" DF="3" EFFECT_SIZE="2.485308255471462" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="26" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="0.6022526842393028" LOG_CI_START="0.18850784060980746" LOG_EFFECT_SIZE="0.3953802624245551" MODIFIED="2012-02-01 17:58:08 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6617609765821151" P_Z="1.7972164033976665E-4" STUDIES="4" TAU2="0.0" TOTAL_1="457" TOTAL_2="610" WEIGHT="45.67177178316934" Z="3.745937074416169">
<NAME>Cancer</NAME>
<DICH_DATA CI_END="8.144860274151203" CI_START="1.1489714717071373" EFFECT_SIZE="3.059119496855346" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="5" LOG_CI_END="0.9108836383454965" LOG_CI_START="0.0603092455429576" LOG_EFFECT_SIZE="0.4855964419442271" MODIFIED="2012-02-01 17:08:59 +0000" MODIFIED_BY="[Empty name]" ORDER="198" O_E="0.0" SE="0.4996316087433604" STUDY_ID="STD-Jatoi-2002" TOTAL_1="159" TOTAL_2="152" VAR="0.24963174445547834" WEIGHT="11.343724933850682"/>
<DICH_DATA CI_END="6.736736556469645" CI_START="1.4703903131304714" EFFECT_SIZE="3.1473214285714284" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="8" LOG_CI_END="0.8284495643767887" LOG_CI_START="0.16743263293768296" LOG_EFFECT_SIZE="0.49794109865723585" MODIFIED="2012-02-01 17:58:08 +0000" MODIFIED_BY="[Empty name]" ORDER="208" O_E="0.0" SE="0.3882846176139129" STUDY_ID="STD-Jatoi-2004" TOTAL_1="140" TOTAL_2="141" VAR="0.15076494427558257" WEIGHT="15.059760142622954"/>
<DICH_DATA CI_END="4.200975696245815" CI_START="0.5423909365820319" EFFECT_SIZE="1.509493670886076" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.6233501690369533" LOG_CI_START="-0.26568757619353306" LOG_EFFECT_SIZE="0.1788312964217101" ORDER="51974" O_E="0.0" SE="0.5222251723562018" STUDY_ID="STD-Loprinzi-1999a" TOTAL_1="79" TOTAL_2="159" VAR="0.2727191306424647" WEIGHT="10.725692326329005"/>
<DICH_DATA CI_END="6.705706743584816" CI_START="0.5965068490098677" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.8264445567832687" LOG_CI_START="-0.22438456545530627" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="51975" O_E="0.0" SE="0.6172622280909857" STUDY_ID="STD-Loprinzi-1999b" TOTAL_1="79" TOTAL_2="158" VAR="0.38101265822784813" WEIGHT="8.5425943803667"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.624824169808396" CI_END="1.6064770295518818" CI_START="0.843179424524563" DF="2" EFFECT_SIZE="1.1638506679507836" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="20" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="0.2058745201083987" LOG_CI_START="-0.07407999976491447" LOG_EFFECT_SIZE="0.06589726017174215" MODIFIED="2012-02-22 23:58:07 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7316799957061513" P_Z="0.3561664110429169" STUDIES="3" TAU2="0.0" TOTAL_1="31" TOTAL_2="33" WEIGHT="54.32822821683067" Z="0.9226945624948432">
<NAME>AIDS</NAME>
<DICH_DATA CI_END="1.8600503184319712" CI_START="0.7053928072271484" EFFECT_SIZE="1.1454545454545455" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.26952469299305315" LOG_CI_START="-0.1515689730743774" LOG_EFFECT_SIZE="0.05897785995933788" ORDER="51976" O_E="0.0" SE="0.24735250389527325" STUDY_ID="STD-Batterham-2001" TOTAL_1="4" TOTAL_2="6" VAR="0.06118326118326117" WEIGHT="21.416644279080774"/>
<DICH_DATA CI_END="1.7527020355825875" CI_START="0.6696010430095779" EFFECT_SIZE="1.0833333333333333" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.24370809105031782" LOG_CI_START="-0.174183878531894" LOG_EFFECT_SIZE="0.03476210625921191" MODIFIED="2012-01-29 17:40:05 +0000" MODIFIED_BY="[Empty name]" ORDER="167" O_E="0.0" SE="0.24547181153120257" STUDY_ID="STD-Mwamburi-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.06025641025641024" WEIGHT="21.510588312010977"/>
<DICH_DATA CI_END="4.4199565732614685" CI_START="0.6284626854892529" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.6454180023614081" LOG_CI_START="-0.20172050312869536" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2012-02-22 23:58:07 +0000" MODIFIED_BY="[Empty name]" ORDER="449" O_E="0.0" SE="0.4976133515281193" STUDY_ID="STD-Summerbell-1992" TOTAL_1="7" TOTAL_2="7" VAR="0.24761904761904763" WEIGHT="11.400995625738913"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.03.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Other underlying pathology</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="25.57147078648886" CI_END="4.643572992106845" CI_START="0.36593922567482196" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="2.5047561088908337" ESTIMABLE="YES" I2="84.3575677230366" I2_Q="53.07467185414934" ID="CMP-002.04" MODIFIED="2013-01-31 09:39:14 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="3.86063561153005E-5" P_Q="0.14434235552328334" P_Z="0.021715793795597696" Q="2.13104530008156" RANDOM="YES" SCALE="41.6" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="4.359843925960055" TOTALS="YES" TOTAL_1="192" TOTAL_2="349" UNITS="" WEIGHT="100.0" Z="2.2953025114057453">
<NAME>Weight gain</NAME>
<GROUP_LABEL_1>Megestrol acetate</GROUP_LABEL_1>
<GROUP_LABEL_2>Other drugs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other drugs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.09450665787216106" CI_END="1.379180884603668" CI_START="-0.14977214528337246" DF="1" EFFECT_SIZE="0.6147043696601477" ESTIMABLE="YES" I2="0.0" ID="CMP-002.04.01" MODIFIED="2012-03-15 17:00:18 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7585242201943108" P_Z="0.11503079604945714" STUDIES="2" TAU2="0.0" TOTAL_1="158" TOTAL_2="317" WEIGHT="51.05883693728808" Z="1.575978335661883">
<NAME>Cancer</NAME>
<CONT_DATA CI_END="1.592969098374519" CI_START="-0.6129690983745186" EFFECT_SIZE="0.4900000000000002" ESTIMABLE="YES" MEAN_1="2.5" MEAN_2="2.01" MODIFIED="2012-03-15 17:00:14 +0000" MODIFIED_BY="[Empty name]" ORDER="51969" SD_1="4.45" SD_2="3.24" SE="0.5627496765627319" STUDY_ID="STD-Loprinzi-1999a" TOTAL_1="79" TOTAL_2="159" WEIGHT="25.46403345068117"/>
<CONT_DATA CI_END="1.7905445910798514" CI_START="-0.33054459107985146" EFFECT_SIZE="0.73" ESTIMABLE="YES" MEAN_1="2.5" MEAN_2="1.77" MODIFIED="2012-03-15 17:00:18 +0000" MODIFIED_BY="[Empty name]" ORDER="51970" SD_1="4.45" SD_2="2.58" SE="0.5411041220375945" STUDY_ID="STD-Loprinzi-1999b" TOTAL_1="79" TOTAL_2="158" WEIGHT="25.594803486606903">
<FOOTNOTE>SD were available from the previous review of Bernstein</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="17.162561662718666" CI_END="10.493979980705719" CI_START="-0.7861430194660866" DF="2" EFFECT_SIZE="4.853918480619816" ESTIMABLE="YES" I2="88.3467279576073" ID="CMP-002.04.02" MODIFIED="2012-03-15 17:00:43 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.8758527704343386E-4" P_Z="0.09164694256358999" STUDIES="3" TAU2="21.643840013530014" TOTAL_1="34" TOTAL_2="32" WEIGHT="48.94116306271192" Z="1.686773345603292">
<NAME>AIDS</NAME>
<CONT_DATA CI_END="10.848577123414998" CI_START="1.5314228765850002" EFFECT_SIZE="6.1899999999999995" ESTIMABLE="YES" MEAN_1="10.2" MEAN_2="4.01" MODIFIED="2012-01-04 16:59:36 +0000" MODIFIED_BY="[Empty name]" ORDER="51971" SD_1="4.51" SD_2="1.68" SE="2.3768687384876768" STUDY_ID="STD-Batterham-2001" TOTAL_1="4" TOTAL_2="5" WEIGHT="11.897211883264799"/>
<CONT_DATA CI_END="2.628336756896459" CI_START="-2.028336756896459" EFFECT_SIZE="0.2999999999999998" ESTIMABLE="YES" MEAN_1="2.8" MEAN_2="2.5" MODIFIED="2012-01-29 17:38:33 +0000" MODIFIED_BY="[Empty name]" ORDER="168" SD_1="4.3" SD_2="2.4" SE="1.18794874562088" STUDY_ID="STD-Mwamburi-2004" TOTAL_1="18" TOTAL_2="15" WEIGHT="20.63454861337599"/>
<CONT_DATA CI_END="11.836072310194206" CI_START="5.163927689805794" EFFECT_SIZE="8.5" ESTIMABLE="YES" MEAN_1="6.5" MEAN_2="-2.0" MODIFIED="2012-03-15 17:00:43 +0000" MODIFIED_BY="[Empty name]" ORDER="51972" SD_1="3.81" SD_2="4.5" SE="1.702108985934802" STUDY_ID="STD-Timpone-1997" TOTAL_1="12" TOTAL_2="12" WEIGHT="16.409402566071133"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.04.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Other underlying pathology</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.19567064721491412" CI_END="1.4426413804692129" CI_START="0.766918499226389" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0518499714461824" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="82" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.15915838525852002" LOG_CI_START="-0.1152507862686496" LOG_EFFECT_SIZE="0.02195379949493521" METHOD="MH" MODIFIED="2013-01-31 09:39:22 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.6582383150095501" P_Q="1.0" P_Z="0.753817672641648" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="158" TOTAL_2="317" WEIGHT="100.0" Z="0.31360946206294243">
<NAME>Quality of life improvement</NAME>
<GROUP_LABEL_1>Megestrol acetate</GROUP_LABEL_1>
<GROUP_LABEL_2>Other drugs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other drugs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.19567064721491412" CI_END="1.4426413804692129" CI_START="0.766918499226389" DF="1" EFFECT_SIZE="1.0518499714461824" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="82" I2="0.0" ID="CMP-002.05.01" LOG_CI_END="0.15915838525852002" LOG_CI_START="-0.1152507862686496" LOG_EFFECT_SIZE="0.02195379949493521" MODIFIED="2012-03-15 17:01:05 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6582383150095501" P_Z="0.753817672641648" STUDIES="2" TAU2="0.0" TOTAL_1="158" TOTAL_2="317" WEIGHT="100.0" Z="0.31360946206294243">
<NAME>Cancer</NAME>
<DICH_DATA CI_END="1.5166325580101394" CI_START="0.6383811066471903" EFFECT_SIZE="0.9839662447257383" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="45" LOG_CI_END="0.1808803748817009" LOG_CI_START="-0.1949199747279556" LOG_EFFECT_SIZE="-0.00701979992312741" ORDER="51978" O_E="0.0" SE="0.22074698560244438" STUDY_ID="STD-Loprinzi-1999a" TOTAL_1="79" TOTAL_2="159" VAR="0.04872923165256579" WEIGHT="53.319109273176124"/>
<DICH_DATA CI_END="1.8024528462108282" CI_START="0.7148768289428777" EFFECT_SIZE="1.135135135135135" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="37" LOG_CI_END="0.25586391200544417" LOG_CI_START="-0.1457687793436333" LOG_EFFECT_SIZE="0.05504756633090545" ORDER="51979" O_E="0.0" SE="0.2359210310123342" STUDY_ID="STD-Loprinzi-1999b" TOTAL_1="79" TOTAL_2="158" VAR="0.05565873287392275" WEIGHT="46.68089072682388"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.05.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>AIDS</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.05.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Other underlying pathology</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.42661033323225606" CI_START="-0.019225541326092777" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.20369239595308164" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.06" MODIFIED="2013-01-31 09:39:36 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.07330500498875335" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="159" TOTAL_2="152" UNITS="" WEIGHT="100.00000000000001" Z="1.7909270329050788">
<NAME>Quality of life gain</NAME>
<GROUP_LABEL_1>Megestrol acetate</GROUP_LABEL_1>
<GROUP_LABEL_2>Other drugs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.42661033323225606" CI_START="-0.019225541326092777" DF="0" EFFECT_SIZE="0.20369239595308164" ESTIMABLE="YES" I2="0.0" ID="CMP-002.06.01" MODIFIED="2012-02-01 17:18:30 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.07330500498875335" STUDIES="1" TAU2="0.0" TOTAL_1="159" TOTAL_2="152" WEIGHT="100.00000000000001" Z="1.7909270329050788">
<NAME>Cancer</NAME>
<CONT_DATA CI_END="0.42661033323225606" CI_START="-0.01922554132609275" EFFECT_SIZE="0.20369239595308164" ESTIMABLE="YES" MEAN_1="15.0" MEAN_2="12.0" MODIFIED="2012-02-01 17:18:30 +0000" MODIFIED_BY="[Empty name]" ORDER="208" SD_1="19.0" SD_2="8.0" SE="0.11373573138972075" STUDY_ID="STD-Jatoi-2002" TOTAL_1="159" TOTAL_2="152" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.06.02" MODIFIED="2012-02-01 17:13:28 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>AIDS</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.06.03" MODIFIED="2012-02-01 17:13:41 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Other underlying pathology</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2013-01-31 09:42:19 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Megestrol acetate versus megestrol acetate (ITT)</NAME>
<DICH_OUTCOME CHI2="2.9220171364438903" CI_END="1.18436745788356" CI_START="0.7613758414473886" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9496045333869252" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="95" I2="31.554131731273483" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.07348646604607154" LOG_CI_START="-0.11840090752236505" LOG_EFFECT_SIZE="-0.02245722073814677" METHOD="MH" MODIFIED="2013-01-31 09:41:13 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.23200221823641254" P_Q="1.0" P_Z="0.6464048910125451" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.012177821261786506" TOTALS="YES" TOTAL_1="155" TOTAL_2="149" WEIGHT="100.0" Z="0.4587622731094975">
<NAME>Appetite improvement</NAME>
<GROUP_LABEL_1>MA (low doses)</GROUP_LABEL_1>
<GROUP_LABEL_2>MA (high doses)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours low doses of MA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours high doses of MA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.9220171364438903" CI_END="1.18436745788356" CI_START="0.7613758414473886" DF="2" EFFECT_SIZE="0.9496045333869252" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="95" I2="31.554131731273483" ID="CMP-003.01.01" LOG_CI_END="0.07348646604607154" LOG_CI_START="-0.11840090752236505" LOG_EFFECT_SIZE="-0.02245722073814677" MODIFIED="2012-02-09 15:43:22 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.23200221823641254" P_Z="0.6464048910125451" STUDIES="3" TAU2="0.012177821261786506" TOTAL_1="155" TOTAL_2="149" WEIGHT="100.0" Z="0.4587622731094975">
<NAME>Cancer</NAME>
<DICH_DATA CI_END="1.0661639000571246" CI_START="0.6040672198205792" EFFECT_SIZE="0.8025177025963808" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="41" LOG_CI_END="0.027823973376141963" LOG_CI_START="-0.21891473096032318" LOG_EFFECT_SIZE="-0.09554537879209063" MODIFIED="2012-01-24 22:30:31 +0000" MODIFIED_BY="[Empty name]" ORDER="134" O_E="0.0" SE="0.14493553630352424" STUDY_ID="STD-Gebbia-1996" TOTAL_1="62" TOTAL_2="60" VAR="0.021006309683590196" WEIGHT="38.285784693219114">
<FOOTNOTE>Megestrol acetate 160 mg versus MA 320 mg/daily</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.923885681589991" CI_START="0.8134329167976274" EFFECT_SIZE="1.2509803921568627" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="15" LOG_CI_END="0.28417926243689295" LOG_CI_START="-0.08967825719044112" LOG_EFFECT_SIZE="0.09725050262322596" MODIFIED="2012-02-09 15:43:22 +0000" MODIFIED_BY="[Empty name]" ORDER="214" O_E="0.0" SE="0.2196057576536647" STUDY_ID="STD-Schmoll-1992" TOTAL_1="34" TOTAL_2="29" VAR="0.04822668879464011" WEIGHT="21.032874721100598"/>
<DICH_DATA CI_END="1.2645254036410951" CI_START="0.7361141279430927" EFFECT_SIZE="0.9647979139504563" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="39" LOG_CI_END="0.10192755851263154" LOG_CI_START="-0.13305484694864111" LOG_EFFECT_SIZE="-0.015563644218004763" MODIFIED="2012-01-29 18:55:23 +0000" MODIFIED_BY="[Empty name]" ORDER="347" O_E="0.0" SE="0.13802982814961814" STUDY_ID="STD-Ulutin-2002" TOTAL_1="59" TOTAL_2="60" VAR="0.019052233459013117" WEIGHT="40.68134058568029"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.4822086695018255" CI_END="0.9285781348714586" CI_START="0.6445324121589077" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7736269806222639" ESTIMABLE="YES" EVENTS_1="150" EVENTS_2="194" I2="22.865796907703327" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-0.03218154683446922" LOG_CI_START="-0.19075523801916214" LOG_EFFECT_SIZE="-0.1114683924268157" METHOD="MH" MODIFIED="2013-01-31 09:41:24 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.26208248226415853" P_Q="1.0" P_Z="0.005860446672274589" Q="0.0" RANDOM="YES" SCALE="3.58" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.011739681712831547" TOTALS="YES" TOTAL_1="412" TOTAL_2="400" WEIGHT="100.00000000000001" Z="2.755489046624718">
<NAME>Weight improvement</NAME>
<GROUP_LABEL_1>MA (low doses)</GROUP_LABEL_1>
<GROUP_LABEL_2>MA (high doses)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MA high doses</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MA low doses</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.4822086695018255" CI_END="0.9285781348714586" CI_START="0.6445324121589077" DF="5" EFFECT_SIZE="0.7736269806222639" ESTIMABLE="YES" EVENTS_1="150" EVENTS_2="194" I2="22.865796907703327" ID="CMP-003.02.01" LOG_CI_END="-0.03218154683446922" LOG_CI_START="-0.19075523801916214" LOG_EFFECT_SIZE="-0.1114683924268157" MODIFIED="2012-02-20 22:28:03 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.26208248226415853" P_Z="0.005860446672274589" STUDIES="6" TAU2="0.011739681712831547" TOTAL_1="412" TOTAL_2="400" WEIGHT="100.00000000000001" Z="2.755489046624718">
<NAME>Cancer</NAME>
<DICH_DATA CI_END="1.135170824914332" CI_START="0.4405735362073235" EFFECT_SIZE="0.707196029776675" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="26" LOG_CI_END="0.05506122076730264" LOG_CI_START="-0.35598159303250115" LOG_EFFECT_SIZE="-0.15046018613259923" MODIFIED="2012-01-24 22:31:36 +0000" MODIFIED_BY="[Empty name]" ORDER="135" O_E="0.0" SE="0.24144858352074816" STUDY_ID="STD-Gebbia-1996" TOTAL_1="62" TOTAL_2="60" VAR="0.0582974184841757" WEIGHT="12.388231681234556"/>
<DICH_DATA CI_END="1.168397491034979" CI_START="0.334325435476569" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="16" LOG_CI_END="0.067590615717779" LOG_CI_START="-0.47583058102962855" LOG_EFFECT_SIZE="-0.2041199826559248" MODIFIED="2012-01-25 15:53:44 +0000" MODIFIED_BY="[Empty name]" ORDER="125" O_E="0.0" SE="0.31920830094773445" STUDY_ID="STD-Heckmayr-1992" TOTAL_1="33" TOTAL_2="33" VAR="0.1018939393939394" WEIGHT="7.635379521234543"/>
<DICH_DATA CI_END="1.0536854290221418" CI_START="0.6109369864095179" EFFECT_SIZE="0.8023312287518213" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="71" LOG_CI_END="0.02271097441466878" LOG_CI_START="-0.21400358168200476" LOG_EFFECT_SIZE="-0.09564630363366795" MODIFIED="2012-02-20 22:28:03 +0000" MODIFIED_BY="[Empty name]" ORDER="254" O_E="0.0" SE="0.13904730200713655" STUDY_ID="STD-Loprinzi-1994" TOTAL_1="174" TOTAL_2="168" VAR="0.01933415219546384" WEIGHT="27.92175005127843"/>
<DICH_DATA CI_END="1.1955573901528527" CI_START="0.7507016665197557" EFFECT_SIZE="0.9473684210526315" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="38" LOG_CI_END="0.07757042832169996" LOG_CI_START="-0.12453262002074575" LOG_EFFECT_SIZE="-0.023481095849522914" MODIFIED="2012-01-10 18:44:53 +0000" MODIFIED_BY="[Empty name]" ORDER="483" O_E="0.0" SE="0.11871633102257659" STUDY_ID="STD-Sancho_x002d_Cuesta-1993" TOTAL_1="50" TOTAL_2="50" VAR="0.014093567251461981" WEIGHT="33.58601253452874"/>
<DICH_DATA CI_END="1.7100411908311002" CI_START="0.33614491444702843" EFFECT_SIZE="0.7581699346405228" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.23300657164080818" LOG_CI_START="-0.4734734548221688" LOG_EFFECT_SIZE="-0.12023344159068035" MODIFIED="2012-02-09 15:41:29 +0000" MODIFIED_BY="[Empty name]" ORDER="215" O_E="0.0" SE="0.4149898646768847" STUDY_ID="STD-Schmoll-1992" TOTAL_1="34" TOTAL_2="29" VAR="0.17221658778453908" WEIGHT="4.716533042842368"/>
<DICH_DATA CI_END="0.8394261579620788" CI_START="0.3453052291443708" EFFECT_SIZE="0.5383848454636092" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="34" LOG_CI_END="-0.07601750155104267" LOG_CI_START="-0.46179684484385647" LOG_EFFECT_SIZE="-0.26890717319744956" MODIFIED="2012-01-30 23:21:30 +0000" MODIFIED_BY="[Empty name]" ORDER="346" O_E="0.0" SE="0.22660869588874644" STUDY_ID="STD-Ulutin-2002" TOTAL_1="59" TOTAL_2="60" VAR="0.05135150105239837" WEIGHT="13.752093168881366"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.005448430304763" CI_END="0.9939329985741425" CI_START="0.5240516607527645" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7217147903290846" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="114" I2="57.17618893570973" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="-0.0026428905828408894" LOG_CI_START="-0.2806258983713184" LOG_EFFECT_SIZE="-0.14163439447707965" METHOD="MH" MODIFIED="2013-01-31 09:41:34 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.07172439831367095" P_Q="1.0" P_Z="0.04579996071684036" Q="0.0" RANDOM="YES" SCALE="4.88" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.05894415736656607" TOTALS="YES" TOTAL_1="204" TOTAL_2="203" WEIGHT="100.0" Z="1.9972322362843462">
<NAME>Weight improvement 160 mg versus other higher doses</NAME>
<GROUP_LABEL_1>MA (low doses)</GROUP_LABEL_1>
<GROUP_LABEL_2>MA (high doses)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MA high doses</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MA low doses</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.005448430304763" CI_END="0.9939329985741425" CI_START="0.5240516607527645" DF="3" EFFECT_SIZE="0.7217147903290846" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="114" I2="57.17618893570973" ID="CMP-003.03.01" LOG_CI_END="-0.0026428905828408894" LOG_CI_START="-0.2806258983713184" LOG_EFFECT_SIZE="-0.14163439447707965" MODIFIED="2012-04-12 23:57:28 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.07172439831367095" P_Z="0.04579996071684036" STUDIES="4" TAU2="0.05894415736656607" TOTAL_1="204" TOTAL_2="203" WEIGHT="100.0" Z="1.9972322362843462">
<NAME>Cancer</NAME>
<DICH_DATA CI_END="1.135170824914332" CI_START="0.4405735362073235" EFFECT_SIZE="0.707196029776675" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="26" LOG_CI_END="0.05506122076730264" LOG_CI_START="-0.35598159303250115" LOG_EFFECT_SIZE="-0.15046018613259923" MODIFIED="2012-04-12 23:55:38 +0100" MODIFIED_BY="[Empty name]" ORDER="135" O_E="0.0" SE="0.24144858352074816" STUDY_ID="STD-Gebbia-1996" TOTAL_1="62" TOTAL_2="60" VAR="0.0582974184841757" WEIGHT="22.742073366498573"/>
<DICH_DATA CI_END="1.168397491034979" CI_START="0.334325435476569" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="16" LOG_CI_END="0.067590615717779" LOG_CI_START="-0.47583058102962855" LOG_EFFECT_SIZE="-0.2041199826559248" MODIFIED="2012-04-12 23:55:38 +0100" MODIFIED_BY="[Empty name]" ORDER="125" O_E="0.0" SE="0.31920830094773445" STUDY_ID="STD-Heckmayr-1992" TOTAL_1="33" TOTAL_2="33" VAR="0.1018939393939394" WEIGHT="16.577642817868774"/>
<DICH_DATA CI_END="1.1955573901528527" CI_START="0.7507016665197557" EFFECT_SIZE="0.9473684210526315" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="38" LOG_CI_END="0.07757042832169996" LOG_CI_START="-0.12453262002074575" LOG_EFFECT_SIZE="-0.023481095849522914" MODIFIED="2012-04-12 23:55:38 +0100" MODIFIED_BY="[Empty name]" ORDER="483" O_E="0.0" SE="0.11871633102257659" STUDY_ID="STD-Sancho_x002d_Cuesta-1993" TOTAL_1="50" TOTAL_2="50" VAR="0.014093567251461981" WEIGHT="36.50601841097531"/>
<DICH_DATA CI_END="0.8394261579620788" CI_START="0.3453052291443708" EFFECT_SIZE="0.5383848454636092" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="34" LOG_CI_END="-0.07601750155104267" LOG_CI_START="-0.46179684484385647" LOG_EFFECT_SIZE="-0.26890717319744956" MODIFIED="2012-04-12 23:55:38 +0100" MODIFIED_BY="[Empty name]" ORDER="346" O_E="0.0" SE="0.22660869588874644" STUDY_ID="STD-Ulutin-2002" TOTAL_1="59" TOTAL_2="60" VAR="0.05135150105239837" WEIGHT="24.174265404657355"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="10.161122903325552" CI_END="1.4515839499744616" CI_START="-3.3305275640309806" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.9394718070282594" ESTIMABLE="YES" I2="80.31713601903746" I2_Q="0.0" ID="CMP-003.04" MODIFIED="2013-01-31 09:41:56 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.006216441797970873" P_Q="1.0" P_Z="0.44124582473021645" Q="0.0" RANDOM="YES" SCALE="23.73" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="3.556469404436402" TOTALS="YES" TOTAL_1="146" TOTAL_2="137" UNITS="" WEIGHT="100.0" Z="0.7700911619787278">
<NAME>Weight gain</NAME>
<GROUP_LABEL_1>MA (low doses)</GROUP_LABEL_1>
<GROUP_LABEL_2>MA (high doses)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MA low doses</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MA high doses</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.04.01" MODIFIED="2012-03-15 17:06:05 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Cancer</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="10.161122903325552" CI_END="1.4515839499744616" CI_START="-3.3305275640309806" DF="2" EFFECT_SIZE="-0.9394718070282594" ESTIMABLE="YES" I2="80.31713601903746" ID="CMP-003.04.02" MODIFIED="2012-02-11 12:39:35 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.006216441797970873" P_Z="0.44124582473021645" STUDIES="2" TAU2="3.556469404436402" TOTAL_1="146" TOTAL_2="137" WEIGHT="100.0" Z="0.7700911619787278">
<NAME>AIDS</NAME>
<CONT_DATA CI_END="0.0033619950474963467" CI_START="-3.2633619950474966" EFFECT_SIZE="-1.6300000000000001" ESTIMABLE="YES" MEAN_1="1.91" MEAN_2="3.54" MODIFIED="2012-02-11 12:39:35 +0000" MODIFIED_BY="[Empty name]" ORDER="481" SD_1="4.29" SD_2="4.29" SE="0.8333632699025326" STUDY_ID="STD-Von-Roenn-1994" TOTAL_1="53" TOTAL_2="53" WEIGHT="35.01029934659098">
<FOOTNOTE>MA 400 mg versus MA 800 mg daily</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="-1.0470636598231173" CI_START="-4.312936340176883" EFFECT_SIZE="-2.68" ESTIMABLE="YES" MEAN_1="0.86" MEAN_2="3.54" MODIFIED="2012-02-11 12:38:57 +0000" MODIFIED_BY="[Empty name]" ORDER="482" SD_1="4.6" SD_2="4.29" SE="0.83314609505954" STUDY_ID="STD-Von-Roenn-1994" TOTAL_1="61" TOTAL_2="53" WEIGHT="35.0132803513886">
<FOOTNOTE>MA 100 mg versus MA 800 mg daily</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="4.225966149823461" CI_START="-0.42596614982346015" EFFECT_SIZE="1.9000000000000004" ESTIMABLE="YES" MEAN_1="5.4" MEAN_2="3.5" MODIFIED="2012-01-31 00:21:23 +0000" MODIFIED_BY="[Empty name]" ORDER="196" SD_1="5.32" SD_2="4.03" SE="1.1867392299911552" STUDY_ID="STD-Wanke-2007" TOTAL_1="32" TOTAL_2="31" WEIGHT="29.97642030202042"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.04.03" MODIFIED="2012-01-10 18:38:01 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Other underlying pathology</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1136466408282968" CI_START="0.583334679139923" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8059954751131222" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="34" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="0.046747411409972246" LOG_CI_START="-0.23408220407502278" LOG_EFFECT_SIZE="-0.09366739633252526" METHOD="MH" MODIFIED="2013-01-31 09:42:06 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.19106141716797975" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="156" TOTAL_2="75" WEIGHT="100.0" Z="1.3074456055522237">
<NAME>Quality of life improvement</NAME>
<GROUP_LABEL_1>MA (low doses)</GROUP_LABEL_1>
<GROUP_LABEL_2>MA (high doses)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher doses MA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower doses MA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1136466408282968" CI_START="0.583334679139923" DF="0" EFFECT_SIZE="0.8059954751131222" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="34" I2="0.0" ID="CMP-003.05.01" LOG_CI_END="0.046747411409972246" LOG_CI_START="-0.23408220407502278" LOG_EFFECT_SIZE="-0.09366739633252526" MODIFIED="2012-05-10 12:00:15 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.19106141716797975" STUDIES="1" TAU2="0.0" TOTAL_1="156" TOTAL_2="75" WEIGHT="100.0" Z="1.3074456055522237">
<NAME>AIDS</NAME>
<DICH_DATA CI_END="1.1136466408282968" CI_START="0.583334679139923" EFFECT_SIZE="0.8059954751131222" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="34" LOG_CI_END="0.046747411409972246" LOG_CI_START="-0.23408220407502278" LOG_EFFECT_SIZE="-0.09366739633252526" MODIFIED="2012-02-11 12:49:46 +0000" MODIFIED_BY="[Empty name]" ORDER="483" O_E="0.0" SE="0.16496070626490242" STUDY_ID="STD-Von-Roenn-1994" TOTAL_1="156" TOTAL_2="75" VAR="0.027212034611415414" WEIGHT="100.0">
<FOOTNOTE>MA low doses (100 and 400 mg) versus MA 800 mg/daily57</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.7592366676304618" CI_START="-0.23316193132262103" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.2630373681539204" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.06" MODIFIED="2013-01-31 09:42:19 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.2988115970563433" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="31" UNITS="" WEIGHT="100.0" Z="1.0389852801359307">
<NAME>Quality of life gain</NAME>
<GROUP_LABEL_1>MA (low doses)</GROUP_LABEL_1>
<GROUP_LABEL_2>MA (high doses)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher doses MA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower doses MA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7592366676304618" CI_START="-0.23316193132262103" DF="0" EFFECT_SIZE="0.2630373681539204" ESTIMABLE="YES" I2="0.0" ID="CMP-003.06.01" MODIFIED="2012-05-10 12:00:19 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.2988115970563433" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="1.0389852801359307">
<NAME>AIDS</NAME>
<CONT_DATA CI_END="0.7592366676304618" CI_START="-0.23316193132262103" EFFECT_SIZE="0.2630373681539204" ESTIMABLE="YES" MEAN_1="56.2" MEAN_2="53.2" MODIFIED="2012-01-31 00:22:37 +0000" MODIFIED_BY="[Empty name]" ORDER="198" SD_1="9.52" SD_2="12.82" SE="0.25316755990951784" STUDY_ID="STD-Wanke-2007" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2013-02-08 09:23:44 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Safety</NAME>
<DICH_OUTCOME CHI2="7.16610019797033" CI_END="2.5054467926795727" CI_START="0.7202445719126768" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.343329614295571" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="9" I2="58.13622588127227" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.39888518421239244" LOG_CI_START="-0.14252000607393597" LOG_EFFECT_SIZE="0.1281825890692282" METHOD="MH" MODIFIED="2013-01-31 10:03:25 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.06678798422304089" P_Q="0.776707463102744" P_Z="0.35336686300540887" Q="0.0804359785824122" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="138" TOTAL_2="133" WEIGHT="99.99999999999999" Z="0.9280784984270923">
<NAME>Acute decompensation of COPD or pulmonary exacerbation</NAME>
<GROUP_LABEL_1>Megestrol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours megestrol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.78496886198786" CI_END="5.825673731548857" CI_START="0.4107855564217944" DF="1" EFFECT_SIZE="1.5469656186697003" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="0.7653461581914504" LOG_CI_START="-0.3863848349788254" LOG_EFFECT_SIZE="0.18948066160631247" MODIFIED="2013-01-31 09:42:47 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3756258253420057" P_Z="0.5189924302993197" STUDIES="2" TAU2="0.0" TOTAL_1="108" TOTAL_2="106" WEIGHT="31.651637672552287" Z="0.6448993293007416">
<NAME>High doses (=&gt; 800 mg/d)</NAME>
<DICH_DATA CI_END="4.858044935353795" CI_START="0.21160172305764852" EFFECT_SIZE="1.0138888888888888" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6864615275720225" LOG_CI_START="-0.6744808001936476" LOG_EFFECT_SIZE="0.00599036368918742" MODIFIED="2012-02-11 09:57:43 +0000" MODIFIED_BY="[Empty name]" ORDER="243" O_E="0.0" SE="0.7994242601027264" STUDY_ID="STD-Weisberg-2002" TOTAL_1="72" TOTAL_2="73" VAR="0.6390791476407915" WEIGHT="26.939507469892714"/>
<DICH_DATA CI_END="92.32633958063262" CI_START="0.22864872131361072" EFFECT_SIZE="4.594594594594595" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.965325617630964" LOG_CI_START="-0.6408312230084063" LOG_EFFECT_SIZE="0.6622471973112789" MODIFIED="2012-01-30 00:24:51 +0000" MODIFIED_BY="[Empty name]" ORDER="189" O_E="0.0" SE="1.530869428875987" STUDY_ID="STD-Yeh-2000" TOTAL_1="36" TOTAL_2="33" VAR="2.3435612082670905" WEIGHT="4.712130202659572"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.539422104205288" CI_END="2.401715799581391" CI_START="0.649564382232191" DF="1" EFFECT_SIZE="1.2490272373540856" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" I2="81.94757537540164" ID="CMP-004.01.02" LOG_CI_END="0.38052161506690974" LOG_CI_START="-0.1873777969197547" LOG_EFFECT_SIZE="0.09657190907357754" MODIFIED="2013-01-31 09:42:58 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.018592825858306794" P_Z="0.50503534707938" STUDIES="2" TAU2="0.0" TOTAL_1="30" TOTAL_2="27" WEIGHT="68.3483623274477" Z="0.6665879897298908">
<NAME>Low doses (&lt; 800 mg/d)</NAME>
<DICH_DATA CI_END="1.2622145104320057" CI_START="0.3882065971752238" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.1011331685216337" LOG_CI_START="-0.41093708849312005" LOG_EFFECT_SIZE="-0.1549019599857432" MODIFIED="2012-02-06 00:37:46 +0000" MODIFIED_BY="[Empty name]" ORDER="233" O_E="0.0" SE="0.30079260375911915" STUDY_ID="STD-Eubanks-2002" TOTAL_1="10" TOTAL_2="7" VAR="0.09047619047619046" WEIGHT="63.82726443030136">
<FOOTNOTE>Pulmonary exacerbation in cystic fibrosis</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="156.90994575594544" CI_START="0.5162196673369944" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.195650472267817" LOG_CI_START="-0.2871654533891674" LOG_EFFECT_SIZE="0.9542425094393249" MODIFIED="2012-01-25 16:46:17 +0000" MODIFIED_BY="[Empty name]" ORDER="133" O_E="0.0" SE="1.4584183648679576" STUDY_ID="STD-Herrejon-2011" TOTAL_1="20" TOTAL_2="20" VAR="2.1269841269841274" WEIGHT="4.521097897146347"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.526005875359868" CI_END="4.466862831917916" CI_START="0.983491249305095" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="2.095977220066441" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="10" I2="33.716391833860214" I2_Q="75.40886502871092" ID="CMP-004.02" LOG_CI_END="0.6500026163948766" LOG_CI_START="-0.007229499898601863" LOG_EFFECT_SIZE="0.3213865582481374" METHOD="MH" MODIFIED="2013-01-31 10:03:22 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.20998236991806118" P_Q="0.04374175715971562" P_Z="0.055257614014748276" Q="4.066506085089326" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="274" TOTAL_2="193" WEIGHT="100.0" Z="1.9168450952581177">
<NAME>Serious adverse events (SAE)</NAME>
<GROUP_LABEL_1>Megestrol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours megestrol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.4604343876726618" CI_START="0.30695545792900614" DF="0" EFFECT_SIZE="0.8690476190476191" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" I2="0.0" ID="CMP-004.02.01" LOG_CI_END="0.39101178820706645" LOG_CI_START="-0.5129246400899179" LOG_EFFECT_SIZE="-0.060956425941425744" MODIFIED="2013-01-31 09:43:18 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7915194380141772" STUDIES="1" TAU2="0.0" TOTAL_1="72" TOTAL_2="73" WEIGHT="67.53580302057452" Z="0.2643380568179191">
<NAME>High doses (=&gt; 800 mg/d)</NAME>
<DICH_DATA CI_END="2.4604343876726618" CI_START="0.30695545792900614" EFFECT_SIZE="0.8690476190476191" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.39101178820706645" LOG_CI_START="-0.5129246400899179" LOG_EFFECT_SIZE="-0.060956425941425744" MODIFIED="2012-01-31 00:31:34 +0000" MODIFIED_BY="[Empty name]" ORDER="199" O_E="0.0" SE="0.5309767325391334" STUDY_ID="STD-Weisberg-2002" TOTAL_1="72" TOTAL_2="73" VAR="0.28193629049793434" WEIGHT="67.53580302057452"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9250252519857447" CI_END="16.294233886257516" CI_START="1.3260781676103985" DF="2" EFFECT_SIZE="4.6483790523690764" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="3" I2="0.0" ID="CMP-004.02.02" LOG_CI_END="1.2120339458510216" LOG_CI_START="0.12256912494453852" LOG_EFFECT_SIZE="0.6673015353977801" MODIFIED="2013-01-31 09:43:25 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6296994913464165" P_Z="0.016351611317413455" STUDIES="3" TAU2="0.0" TOTAL_1="202" TOTAL_2="120" WEIGHT="32.46419697942547" Z="2.4009714698629905">
<NAME>Low doses (&lt; 800 mg/d)</NAME>
<DICH_DATA CI_END="58.142501131580985" CI_START="1.0601045190286011" EFFECT_SIZE="7.850931677018633" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="1" LOG_CI_END="1.7644937099985736" LOG_CI_START="0.025348685830459083" LOG_EFFECT_SIZE="0.8949211979145165" MODIFIED="2012-01-04 17:43:46 +0000" MODIFIED_BY="[Empty name]" ORDER="106" O_E="0.0" SE="1.0215823961030628" STUDY_ID="STD-Beller-1997" TOTAL_1="161" TOTAL_2="79" VAR="1.0436305920276752" WEIGHT="13.034253650093518"/>
<DICH_DATA CI_END="20.412520736125575" CI_START="0.19595815978380854" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3098966389244104" LOG_CI_START="-0.707836647596448" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2012-01-09 11:40:18 +0000" MODIFIED_BY="[Empty name]" ORDER="130" O_E="0.0" SE="1.185226520443204" STUDY_ID="STD-De-Conno-1998" TOTAL_1="21" TOTAL_2="21" VAR="1.4047619047619047" WEIGHT="9.714971664665978"/>
<DICH_DATA CI_END="26.450125630660757" CI_START="0.34026303412212444" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4224277391527982" LOG_CI_START="-0.4681852297134733" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2012-01-25 16:32:53 +0000" MODIFIED_BY="[Empty name]" ORDER="131" O_E="0.0" SE="1.1105554165971787" STUDY_ID="STD-Herrejon-2011" TOTAL_1="20" TOTAL_2="20" VAR="1.2333333333333332" WEIGHT="9.714971664665978"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="29.74267948376471" CI_END="1.3624761538202637" CI_START="1.0654667384610297" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2048539429498517" ESTIMABLE="YES" EVENTS_1="272" EVENTS_2="203" I2="56.29176582057391" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.1343289099542569" LOG_CI_START="0.027539896538904554" LOG_EFFECT_SIZE="0.08093440324658072" METHOD="MH" MODIFIED="2013-01-31 10:03:18 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.005128600033068809" P_Q="0.321085727781955" P_Z="0.002969506212007571" Q="0.984519724170273" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="671" TOTAL_2="570" WEIGHT="100.0" Z="2.970877066848807">
<NAME>Any adverse event</NAME>
<GROUP_LABEL_1>Megestrol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours megestrol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.7622927406218896" CI_END="1.8330916296125677" CI_START="1.0113535368089661" DF="4" EFFECT_SIZE="1.3615813243811703" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="46" I2="0.0" ID="CMP-004.03.01" LOG_CI_END="0.26318417431328905" LOG_CI_START="0.004902997575157791" LOG_EFFECT_SIZE="0.13404358594422341" MODIFIED="2013-01-31 09:43:33 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.43913083854405566" P_Z="0.0419136317308395" STUDIES="5" TAU2="0.0" TOTAL_1="189" TOTAL_2="158" WEIGHT="24.02255190311295" Z="2.0343766752746926">
<NAME>High doses (=&gt; 800 mg/d)</NAME>
<DICH_DATA CI_END="2.241201286382377" CI_START="0.5782337825112127" EFFECT_SIZE="1.1383928571428572" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="7" LOG_CI_END="0.35048086306762055" LOG_CI_START="-0.23789653886803583" LOG_EFFECT_SIZE="0.05629216209979239" MODIFIED="2012-03-15 17:07:47 +0000" MODIFIED_BY="[Empty name]" ORDER="151" O_E="0.0" SE="0.3456157984121166" STUDY_ID="STD-Casado-2008" TOTAL_1="32" TOTAL_2="17" VAR="0.1194502801120448" WEIGHT="4.371250725831389"/>
<DICH_DATA CI_END="2.9965801800903877" CI_START="0.6810484632081674" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.47662590269158706" LOG_CI_START="-0.1668219827201008" LOG_EFFECT_SIZE="0.1549019599857432" MODIFIED="2012-03-15 17:08:03 +0000" MODIFIED_BY="[Empty name]" ORDER="336" O_E="0.0" SE="0.3779644730092272" STUDY_ID="STD-Mwamburi-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.14285714285714285" WEIGHT="3.346738836964657"/>
<DICH_DATA CI_END="3.7874040444516104" CI_START="1.1620606517621452" EFFECT_SIZE="2.097902097902098" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="11" LOG_CI_END="0.5783416386079006" LOG_CI_START="0.06522879590130068" LOG_EFFECT_SIZE="0.32178521725460063" MODIFIED="2012-03-15 17:09:46 +0000" MODIFIED_BY="[Empty name]" ORDER="455" O_E="0.0" SE="0.3014050237553919" STUDY_ID="STD-Oster-1994" TOTAL_1="52" TOTAL_2="48" VAR="0.09084498834498836" WEIGHT="5.469527470696525"/>
<DICH_DATA CI_END="1.7407115055331515" CI_START="0.5096791129490592" EFFECT_SIZE="0.9419152276295133" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="13" LOG_CI_END="0.24072679987267204" LOG_CI_START="-0.2927031637760856" LOG_EFFECT_SIZE="-0.02598818195170682" MODIFIED="2012-03-15 17:08:10 +0000" MODIFIED_BY="[Empty name]" ORDER="466" O_E="0.0" SE="0.3133394011681861" STUDY_ID="STD-Tchekmedyian-1992" TOTAL_1="49" TOTAL_2="40" VAR="0.09818158032443747" WEIGHT="6.843892902556939"/>
<DICH_DATA CI_END="2.745845825360946" CI_START="0.5785649576309626" EFFECT_SIZE="1.2604166666666667" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.4386761486783319" LOG_CI_START="-0.2376478741245685" LOG_EFFECT_SIZE="0.10051413727688169" MODIFIED="2012-01-30 00:21:54 +0000" MODIFIED_BY="[Empty name]" ORDER="187" O_E="0.0" SE="0.39727607885233013" STUDY_ID="STD-Yeh-2000" TOTAL_1="36" TOTAL_2="33" VAR="0.15782828282828285" WEIGHT="3.9911419670634416"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="20.386924811093618" CI_END="1.3156404220395774" CI_START="1.0145004500629822" DF="8" EFFECT_SIZE="1.1552998746127359" ESTIMABLE="YES" EVENTS_1="196" EVENTS_2="157" I2="60.75916267839095" ID="CMP-004.03.02" LOG_CI_END="0.11913720837936898" LOG_CI_START="0.006252244035531683" LOG_EFFECT_SIZE="0.06269472620745035" MODIFIED="2013-01-31 09:43:38 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.008967238025265889" P_Z="0.02947511936061892" STUDIES="9" TAU2="0.0" TOTAL_1="482" TOTAL_2="412" WEIGHT="75.97744809688704" Z="2.177073024763913">
<NAME>Low doses (&lt; 800 mg/d)</NAME>
<DICH_DATA CI_END="116.40042449559729" CI_START="0.42096066412415317" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.065954564126235" LOG_CI_START="-0.3757584840977216" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2012-01-04 17:32:55 +0000" MODIFIED_BY="[Empty name]" ORDER="105" O_E="0.0" SE="1.4342743312012722" STUDY_ID="STD-Batterham-2001" TOTAL_1="4" TOTAL_2="6" VAR="2.057142857142857" WEIGHT="0.19921064505742006"/>
<DICH_DATA CI_END="183.04267615724405" CI_START="0.8418925162722024" EFFECT_SIZE="12.413793103448276" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="0" LOG_CI_END="2.2625523567186314" LOG_CI_START="-0.07474335098196877" LOG_EFFECT_SIZE="1.0939045028683312" MODIFIED="2012-03-15 17:10:30 +0000" MODIFIED_BY="[Empty name]" ORDER="152" O_E="0.0" SE="1.3729390685036809" STUDY_ID="STD-Casado-2008" TOTAL_1="28" TOTAL_2="7" VAR="1.8849616858237548" WEIGHT="0.37473137556747127"/>
<DICH_DATA CI_END="6.451402929711635" CI_START="0.15500504477786478" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8096541670972182" LOG_CI_START="-0.8096541670972182" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-01-09 11:41:27 +0000" MODIFIED_BY="[Empty name]" ORDER="131" O_E="0.0" SE="0.9511897312113418" STUDY_ID="STD-De-Conno-1998" TOTAL_1="21" TOTAL_2="21" VAR="0.9047619047619047" WEIGHT="0.9562110962756163"/>
<DICH_DATA CI_END="2.3372792322844136" CI_START="0.7211126728379914" EFFECT_SIZE="1.2982456140350878" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="15" LOG_CI_END="0.3687106001954188" LOG_CI_START="-0.14199687207844916" LOG_EFFECT_SIZE="0.1133568640584848" MODIFIED="2012-01-09 13:15:01 +0000" MODIFIED_BY="[Empty name]" ORDER="278" O_E="0.0" SE="0.2999920972564295" STUDY_ID="STD-Feliu-1992" TOTAL_1="76" TOTAL_2="74" VAR="0.08999525841631105" WEIGHT="7.267204331694684"/>
<DICH_DATA CI_END="15.304614839074713" CI_START="0.06533976911636269" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1848224044743985" LOG_CI_START="-1.1848224044743985" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-01-24 22:15:13 +0000" MODIFIED_BY="[Empty name]" ORDER="131" O_E="0.0" SE="1.3919410907075054" STUDY_ID="STD-Fietkau-1996" TOTAL_1="32" TOTAL_2="32" VAR="1.9375" WEIGHT="0.47810554813780815"/>
<DICH_DATA CI_END="1.7128062692168" CI_START="0.5467778058299058" EFFECT_SIZE="0.967741935483871" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="17" LOG_CI_END="0.2337082438947888" LOG_CI_START="-0.26218912212400924" LOG_EFFECT_SIZE="-0.01424043911461023" MODIFIED="2012-01-24 22:32:41 +0000" MODIFIED_BY="[Empty name]" ORDER="136" O_E="0.0" SE="0.2912925675309932" STUDY_ID="STD-Gebbia-1996" TOTAL_1="62" TOTAL_2="60" VAR="0.08485135989879823" WEIGHT="8.261036848151635"/>
<DICH_DATA CI_END="12.051964846872265" CI_START="1.327584356848861" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" LOG_CI_END="1.0810578562545836" LOG_CI_START="0.12306212640134116" LOG_EFFECT_SIZE="0.6020599913279624" MODIFIED="2012-03-15 17:10:41 +0000" MODIFIED_BY="[Empty name]" ORDER="130" O_E="0.0" SE="0.5627314338711378" STUDY_ID="STD-Herrejon-2011" TOTAL_1="20" TOTAL_2="20" VAR="0.31666666666666665" WEIGHT="1.4343166444134243"/>
<DICH_DATA CI_END="1.0888169111409507" CI_START="0.8852161977064964" EFFECT_SIZE="0.9817527010804322" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="119" LOG_CI_END="0.036954857564640675" LOG_CI_START="-0.05295064794158143" LOG_EFFECT_SIZE="-0.007997895188470385" MODIFIED="2012-03-15 17:11:45 +0000" MODIFIED_BY="[Empty name]" ORDER="456" O_E="0.0" SE="0.05281093897378464" STUDY_ID="STD-Jatoi-2004" TOTAL_1="140" TOTAL_2="141" VAR="0.002788995275292805" WEIGHT="56.69208848381412"/>
<DICH_DATA CI_END="85.26467400193184" CI_START="0.25687543236843613" EFFECT_SIZE="4.68" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.930769135930272" LOG_CI_START="-0.5902774297820242" LOG_EFFECT_SIZE="0.670245853074124" MODIFIED="2012-01-29 19:38:11 +0000" MODIFIED_BY="[Empty name]" ORDER="348" O_E="0.0" SE="1.480875232081168" STUDY_ID="STD-Vadell-1998" TOTAL_1="99" TOTAL_2="51" VAR="2.1929914529914534" WEIGHT="0.3145431237748738"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.264905944097287" CI_END="3.061202225137543" CI_START="0.8860908628366929" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6469679174136118" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="20" I2="11.696112361207541" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="0.48589202033904466" LOG_CI_START="-0.05252174176388504" LOG_EFFECT_SIZE="0.21668513928757982" METHOD="MH" MODIFIED="2013-01-31 10:03:31 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.32224217897623786" P_Q="0.748003477554376" P_Z="0.11466240536682318" Q="0.10321639783654468" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="187" TOTAL_2="348" WEIGHT="99.99999999999999" Z="1.5775788023319943">
<NAME>Abdominal pain</NAME>
<GROUP_LABEL_1>Megestrol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours megestrol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.1667122238907504" CI_END="3.1987373792717686" CI_START="0.8941685180664616" DF="1" EFFECT_SIZE="1.6912156166814551" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="19" I2="53.847124275492995" ID="CMP-004.04.01" LOG_CI_END="0.5049785853748225" LOG_CI_START="-0.04858062486242045" LOG_EFFECT_SIZE="0.22819898025620106" MODIFIED="2013-01-31 09:43:50 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.14102753418796554" P_Z="0.10610529606118332" STUDIES="2" TAU2="0.0" TOTAL_1="158" TOTAL_2="317" WEIGHT="92.8890812058272" Z="1.6159492041302488">
<NAME>High doses (=&gt; 800 mg/d)</NAME>
<DICH_DATA CI_END="2.6262158039950805" CI_START="0.5036554736907968" EFFECT_SIZE="1.1500904159132008" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="14" LOG_CI_END="0.419330410494284" LOG_CI_START="-0.2978664418068528" LOG_EFFECT_SIZE="0.060731984343715656" MODIFIED="2012-02-19 11:48:51 +0000" MODIFIED_BY="[Empty name]" ORDER="266" O_E="0.0" SE="0.4212849812233632" STUDY_ID="STD-Loprinzi-1999a" TOTAL_1="79" TOTAL_2="159" VAR="0.17748103540436952" WEIGHT="68.36867157074859"/>
<DICH_DATA CI_END="9.462832339322611" CI_START="1.0821284402818683" EFFECT_SIZE="3.2" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.9760211454116298" LOG_CI_START="0.034278811228182174" LOG_EFFECT_SIZE="0.505149978319906" MODIFIED="2012-02-19 11:48:58 +0000" MODIFIED_BY="[Empty name]" ORDER="267" O_E="0.0" SE="0.5531841087990942" STUDY_ID="STD-Loprinzi-1999b" TOTAL_1="79" TOTAL_2="158" VAR="0.3060126582278481" WEIGHT="24.520409635078607"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="16.31130518173396" CI_START="0.07005492597433315" DF="0" EFFECT_SIZE="1.0689655172413792" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-004.04.02" LOG_CI_END="1.2124887133729667" LOG_CI_START="-1.1545613215023336" LOG_EFFECT_SIZE="0.028963695935316558" MODIFIED="2013-01-31 09:43:58 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.9617441206590881" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="31" WEIGHT="7.110918794172796" Z="0.04796501979763198">
<NAME>Low doses (&lt; 800 mg/d)</NAME>
<DICH_DATA CI_END="16.31130518173396" CI_START="0.07005492597433315" EFFECT_SIZE="1.0689655172413792" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2124887133729667" LOG_CI_START="-1.1545613215023336" LOG_EFFECT_SIZE="0.028963695935316558" MODIFIED="2012-06-11 23:50:24 +0100" MODIFIED_BY="[Empty name]" ORDER="518" O_E="0.0" SE="1.3904169075723947" STUDY_ID="STD-Madeddu-2012" TOTAL_1="29" TOTAL_2="31" VAR="1.9332591768631813" WEIGHT="7.110918794172796"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.7338482924506207" CI_START="0.11903120042211038" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="0.5721566684362998" LOG_CI_START="-0.9243391865476622" LOG_EFFECT_SIZE="-0.17609125905568127" METHOD="MH" MODIFIED="2013-01-31 10:03:36 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.6446162159946162" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="33" TOTAL_2="33" WEIGHT="100.0" Z="0.4612542354755092">
<NAME>Abnormal appetite</NAME>
<GROUP_LABEL_1>Megestrol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours megestrol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.05.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-01-31 09:44:07 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>High doses (=&gt; 800 mg/d)</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.7338482924506207" CI_START="0.11903120042211038" DF="0" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-004.05.02" LOG_CI_END="0.5721566684362998" LOG_CI_START="-0.9243391865476622" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2013-01-31 09:44:13 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.6446162159946162" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="33" WEIGHT="100.0" Z="0.4612542354755092">
<NAME>Low doses (&lt; 800 mg/d)</NAME>
<DICH_DATA CI_END="3.7338482924506207" CI_START="0.11903120042211038" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5721566684362998" LOG_CI_START="-0.9243391865476622" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2012-01-25 15:57:40 +0000" MODIFIED_BY="[Empty name]" ORDER="127" O_E="0.0" SE="0.8790490729915326" STUDY_ID="STD-Heckmayr-1992" TOTAL_1="33" TOTAL_2="33" VAR="0.7727272727272727" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.093827538334796" CI_END="2.091299236936926" CI_START="0.4544834334259728" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9749158207374682" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" I2="0.0" I2_Q="39.560214413517556" ID="CMP-004.06" LOG_CI_END="0.32041617899294433" LOG_CI_START="-0.34248194281123784" LOG_EFFECT_SIZE="-0.011032881909146716" METHOD="MH" MODIFIED="2013-01-31 10:03:48 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.5422483050145812" P_Q="0.19834230272843867" P_Z="0.9479821581890352" Q="1.6545392911249066" RANDOM="NO" SCALE="946.23" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="253" TOTAL_2="251" WEIGHT="100.00000000000001" Z="0.06524094872605099">
<NAME>Amenorrhoea/irregular menses</NAME>
<GROUP_LABEL_1>Megestrol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours megestrol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.20290520492861164" CI_END="5.754634944064847" CI_START="0.5321797177001762" DF="1" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" I2="0.0" ID="CMP-004.06.01" LOG_CI_END="0.7600177785641056" LOG_CI_START="-0.27394168119151674" LOG_EFFECT_SIZE="0.24303804868629444" MODIFIED="2013-01-31 09:44:33 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6523860081420144" P_Z="0.3568409336363154" STUDIES="2" TAU2="0.0" TOTAL_1="83" TOTAL_2="83" WEIGHT="31.616655497919307" Z="0.9214013524487977">
<NAME>High doses (=&gt; 800 mg/d)</NAME>
<DICH_DATA CI_END="7.647146737244775" CI_START="0.5230709096398454" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8834994237268242" LOG_CI_START="-0.2814394323988618" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2012-02-16 22:54:24 +0000" MODIFIED_BY="[Empty name]" ORDER="249" O_E="0.0" SE="0.6842908506285673" STUDY_ID="STD-Loprinzi-1990b" TOTAL_1="63" TOTAL_2="63" VAR="0.46825396825396826" WEIGHT="23.71249162343948"/>
<DICH_DATA CI_END="14.903914722906746" CI_START="0.06709646549862758" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1733003569528007" LOG_CI_START="-1.1733003569528007" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-01-29 17:50:03 +0000" MODIFIED_BY="[Empty name]" ORDER="341" O_E="0.0" SE="1.378404875209022" STUDY_ID="STD-Mwamburi-2004" TOTAL_1="20" TOTAL_2="20" VAR="1.9" WEIGHT="7.904163874479827"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2579532115720524" CI_END="1.7679967919079378" CI_START="0.21501522883604662" DF="2" EFFECT_SIZE="0.6165600009678551" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" I2="0.0" ID="CMP-004.06.02" LOG_CI_END="0.24748147263523068" LOG_CI_START="-0.6675307793158446" LOG_EFFECT_SIZE="-0.21002465334030695" MODIFIED="2013-01-31 09:44:38 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5331374794033534" P_Z="0.3682537609289389" STUDIES="3" TAU2="0.0" TOTAL_1="170" TOTAL_2="168" WEIGHT="68.3833445020807" Z="0.8997491684614548">
<NAME>Low doses (&lt; 800 mg/d)</NAME>
<DICH_DATA CI_END="9.40648846996848" CI_START="0.05209170261191442" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.9734275274935905" LOG_CI_START="-1.283231447465077" LOG_EFFECT_SIZE="-0.1549019599857432" MODIFIED="2012-03-15 19:34:01 +0000" MODIFIED_BY="[Empty name]" ORDER="454" O_E="0.0" SE="1.325572652532805" STUDY_ID="STD-Eubanks-2002" TOTAL_1="10" TOTAL_2="7" VAR="1.7571428571428571" WEIGHT="9.299016322917444"/>
<DICH_DATA CI_END="69.5152908317231" CI_START="0.12946791838627933" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.84208034406391" LOG_CI_START="-0.8878378346245852" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2012-01-25 16:37:43 +0000" MODIFIED_BY="[Empty name]" ORDER="133" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Herrejon-2011" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="3.9520819372399134"/>
<DICH_DATA CI_END="1.6355093043938742" CI_START="0.11391359663203954" EFFECT_SIZE="0.4316326530612245" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.21365301916440785" LOG_CI_START="-0.943424435799313" LOG_EFFECT_SIZE="-0.3648857083174525" MODIFIED="2012-02-01 18:00:43 +0000" MODIFIED_BY="[Empty name]" ORDER="210" O_E="0.0" SE="0.6796730246714656" STUDY_ID="STD-Jatoi-2004" TOTAL_1="140" TOTAL_2="141" VAR="0.46195542046605875" WEIGHT="55.13224624192335"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="69.69936418378434" CI_START="0.12912599857107263" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.07" LOG_CI_END="1.8432288163658224" LOG_CI_START="-0.8889863069264972" LOG_EFFECT_SIZE="0.47712125471966244" METHOD="MH" MODIFIED="2013-01-31 10:03:57 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.49364108067680157" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="21" TOTAL_2="21" WEIGHT="100.0" Z="0.6845291701498639">
<NAME>Bowel obstruction</NAME>
<GROUP_LABEL_1>Megestrol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours megestrol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.07.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-01-31 09:44:49 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>High doses (=&gt; 800 mg/d)</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="69.69936418378434" CI_START="0.12912599857107263" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-004.07.02" LOG_CI_END="1.8432288163658224" LOG_CI_START="-0.8889863069264972" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-01-31 09:44:54 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.49364108067680157" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="100.0" Z="0.6845291701498639">
<NAME>Low doses (&lt; 800 mg/d)</NAME>
<DICH_DATA CI_END="69.69936418378434" CI_START="0.12912599857107263" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8432288163658224" LOG_CI_START="-0.8889863069264972" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2012-01-09 11:49:52 +0000" MODIFIED_BY="[Empty name]" ORDER="136" O_E="0.0" SE="1.6049166881048922" STUDY_ID="STD-De-Conno-1998" TOTAL_1="21" TOTAL_2="21" VAR="2.5757575757575757" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.022124495104108115" CI_END="16.733044833095267" CI_START="0.2047706999009315" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8510638297872342" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.08" LOG_CI_END="1.2235749746678948" LOG_CI_START="-0.6887321853020925" LOG_EFFECT_SIZE="0.2674213946829011" METHOD="MH" MODIFIED="2013-01-31 10:04:07 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.8817564017375468" P_Q="1.0" P_Z="0.5835740368698992" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="109" TOTAL_2="58" WEIGHT="100.0" Z="0.5481716674450807">
<NAME>Constipation</NAME>
<GROUP_LABEL_1>Megestrol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours megestrol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.08.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-01-31 09:45:07 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>High doses (=&gt; 800 mg/d)</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.022124495104108115" CI_END="16.733044833095267" CI_START="0.2047706999009315" DF="1" EFFECT_SIZE="1.8510638297872342" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-004.08.02" LOG_CI_END="1.2235749746678948" LOG_CI_START="-0.6887321853020925" LOG_EFFECT_SIZE="0.2674213946829011" MODIFIED="2013-01-31 09:45:13 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8817564017375468" P_Z="0.5835740368698992" STUDIES="2" TAU2="0.0" TOTAL_1="109" TOTAL_2="58" WEIGHT="100.0" Z="0.5481716674450807">
<NAME>Low doses (&lt; 800 mg/d)</NAME>
<DICH_DATA CI_END="46.920830390765005" CI_START="0.10145452539666325" EFFECT_SIZE="2.1818181818181817" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6713656895248183" LOG_CI_START="-0.9937285764180563" LOG_EFFECT_SIZE="0.33881855655338095" MODIFIED="2012-03-15 19:34:52 +0000" MODIFIED_BY="[Empty name]" ORDER="237" O_E="0.0" SE="1.5654895642442257" STUDY_ID="STD-Eubanks-2002" TOTAL_1="10" TOTAL_2="7" VAR="2.4507575757575757" WEIGHT="46.808510638297875"/>
<DICH_DATA CI_END="37.62630761264252" CI_START="0.06467815085799983" EFFECT_SIZE="1.56" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.575491601733785" LOG_CI_START="-1.1892424050248618" LOG_EFFECT_SIZE="0.1931245983544616" MODIFIED="2012-01-29 19:40:02 +0000" MODIFIED_BY="[Empty name]" ORDER="351" O_E="0.0" SE="1.6240184412240821" STUDY_ID="STD-Vadell-1998" TOTAL_1="99" TOTAL_2="51" VAR="2.6374358974358976" WEIGHT="53.19148936170213"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="69.5152908317231" CI_START="0.12946791838627933" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.09" LOG_CI_END="1.84208034406391" LOG_CI_START="-0.8878378346245852" LOG_EFFECT_SIZE="0.47712125471966244" METHOD="MH" MODIFIED="2013-01-31 10:04:16 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.49327758741034344" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.6851051308492764">
<NAME>Chest pain</NAME>
<GROUP_LABEL_1>Megestrol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours megestrol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.09.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-01-31 09:45:21 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>High doses (=&gt; 800 mg/d)</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="69.5152908317231" CI_START="0.12946791838627933" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-004.09.02" LOG_CI_END="1.84208034406391" LOG_CI_START="-0.8878378346245852" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2012-01-25 16:40:38 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.49327758741034344" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.6851051308492764">
<NAME>Low doses (&lt;800 mg/d)</NAME>
<DICH_DATA CI_END="69.5152908317231" CI_START="0.12946791838627933" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.84208034406391" LOG_CI_START="-0.8878378346245852" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2012-01-25 16:40:38 +0000" MODIFIED_BY="[Empty name]" ORDER="135" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Herrejon-2011" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.023699370220930396" CI_END="1.2807561936796683" CI_START="0.621936128224521" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.892495685309855" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="50" I2="0.0" I2_Q="0.0" ID="CMP-004.10" LOG_CI_END="0.10746646478214684" LOG_CI_START="-0.20625421431878455" LOG_EFFECT_SIZE="-0.049393874768318836" METHOD="MH" MODIFIED="2013-01-31 10:04:26 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.8776523308432801" P_Q="0.8779267458894965" P_Z="0.5371195780406527" Q="0.02359233909487369" RANDOM="NO" SCALE="94.46" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="293" WEIGHT="100.0" Z="0.617174589065839">
<NAME>Confusion</NAME>
<GROUP_LABEL_1>Megestrol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours megestrol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3293855682709104" CI_START="0.5776500904490278" DF="0" EFFECT_SIZE="0.8763102725366876" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="36" I2="0.0" ID="CMP-004.10.01" LOG_CI_END="0.12365095978916128" LOG_CI_START="-0.23833515431931881" LOG_EFFECT_SIZE="-0.057342097265078745" MODIFIED="2012-02-01 18:03:04 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5346295926422937" STUDIES="1" TAU2="0.0" TOTAL_1="159" TOTAL_2="152" WEIGHT="72.51763297090537" Z="0.6209544568544776">
<NAME>High doses(=&gt; 800 mg /d)</NAME>
<DICH_DATA CI_END="1.3293855682709104" CI_START="0.5776500904490278" EFFECT_SIZE="0.8763102725366876" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="36" LOG_CI_END="0.12365095978916128" LOG_CI_START="-0.23833515431931881" LOG_EFFECT_SIZE="-0.057342097265078745" MODIFIED="2012-02-01 18:03:04 +0000" MODIFIED_BY="[Empty name]" ORDER="213" O_E="0.0" SE="0.21263243528748477" STUDY_ID="STD-Jatoi-2002" TOTAL_1="159" TOTAL_2="152" VAR="0.0452125525362864" WEIGHT="72.51763297090537"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9170473798376564" CI_START="0.45622590422175124" DF="0" EFFECT_SIZE="0.935204081632653" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" I2="0.0" ID="CMP-004.10.02" LOG_CI_END="0.28263284660146776" LOG_CI_START="-0.3408200593899866" LOG_EFFECT_SIZE="-0.029093606394259407" MODIFIED="2013-01-31 09:45:27 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.8548572209379026" STUDIES="1" TAU2="0.0" TOTAL_1="140" TOTAL_2="141" WEIGHT="27.482367029094625" Z="0.18292454863916946">
<NAME>Low doses (&lt; 800 mg/d)</NAME>
<DICH_DATA CI_END="1.9170473798376562" CI_START="0.4562259042217513" EFFECT_SIZE="0.935204081632653" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" LOG_CI_END="0.2826328466014677" LOG_CI_START="-0.34082005938998655" LOG_EFFECT_SIZE="-0.029093606394259407" MODIFIED="2012-02-01 18:03:29 +0000" MODIFIED_BY="[Empty name]" ORDER="212" O_E="0.0" SE="0.36621932312103755" STUDY_ID="STD-Jatoi-2004" TOTAL_1="140" TOTAL_2="141" VAR="0.1341165926272309" WEIGHT="27.482367029094625"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.730634992323816" CI_END="4.932265387474647" CI_START="1.0100531770473802" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="2.2320058970933734" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-004.11" LOG_CI_END="0.6930464363776652" LOG_CI_START="0.004344239020556965" LOG_EFFECT_SIZE="0.34869533769911104" METHOD="MH" MODIFIED="2013-01-31 10:04:34 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.9427318016292677" P_Q="0.40472567186798447" P_Z="0.0471789328217268" Q="0.6942419773903166" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="490" TOTAL_2="368" WEIGHT="100.0" Z="1.9846903526370336">
<NAME>Dyspnoea</NAME>
<GROUP_LABEL_1>Megestrol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours megestrol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.25211550945130623" CI_END="5.1644337503506765" CI_START="0.3713554892404952" DF="2" EFFECT_SIZE="1.3848613006404653" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" ID="CMP-004.11.01" LOG_CI_END="0.7130227106418202" LOG_CI_START="-0.4302101521193612" LOG_EFFECT_SIZE="0.14140627926122953" MODIFIED="2013-01-31 09:45:54 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8815639358329368" P_Z="0.6277790458619139" STUDIES="4" TAU2="0.0" TOTAL_1="201" TOTAL_2="178" WEIGHT="40.18915503199775" Z="0.48485522690528055">
<NAME>High doses (=&gt; 800 mg/d)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-01-28 10:12:39 +0000" MODIFIED_BY="[Empty name]" ORDER="138" O_E="0.0" SE="0.0" STUDY_ID="STD-Casado-2008" TOTAL_1="28" TOTAL_2="17" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="66.49261543937459" CI_START="0.11569364775432935" EFFECT_SIZE="2.7735849056603774" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8227734159495634" LOG_CI_START="-0.9366904856547894" LOG_EFFECT_SIZE="0.44304146514738707" MODIFIED="2012-02-19 10:30:30 +0000" MODIFIED_BY="[Empty name]" ORDER="257" O_E="0.0" SE="1.6209227553690084" STUDY_ID="STD-Oster-1994" TOTAL_1="52" TOTAL_2="48" VAR="2.6273905788730585" WEIGHT="5.621220334623304"/>
<DICH_DATA CI_END="6.974699315923134" CI_START="0.21497346228032424" EFFECT_SIZE="1.2244897959183674" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8435254896158642" LOG_CI_START="-0.6676151489056041" LOG_EFFECT_SIZE="0.08795517035512998" MODIFIED="2012-01-28 18:10:19 +0000" MODIFIED_BY="[Empty name]" ORDER="459" O_E="0.0" SE="0.8876514913343114" STUDY_ID="STD-Tchekmedyian-1992" TOTAL_1="49" TOTAL_2="40" VAR="0.7879251700680271" WEIGHT="23.824345331733962"/>
<DICH_DATA CI_END="15.901568703064594" CI_START="0.06464586596504984" EFFECT_SIZE="1.0138888888888888" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2014399699480751" LOG_CI_START="-1.1894592425697006" LOG_EFFECT_SIZE="0.00599036368918742" MODIFIED="2012-02-11 09:39:15 +0000" MODIFIED_BY="[Empty name]" ORDER="238" O_E="0.0" SE="1.404426032574918" STUDY_ID="STD-Weisberg-2002" TOTAL_1="72" TOTAL_2="73" VAR="1.9724124809741248" WEIGHT="10.74358936564048"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9242703750229652" CI_END="7.666377661156209" CI_START="1.0235489779097764" DF="3" EFFECT_SIZE="2.8012341957335125" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="4" I2="0.0" ID="CMP-004.11.02" LOG_CI_END="0.8845902096634706" LOG_CI_START="0.01010862894969871" LOG_EFFECT_SIZE="0.4473494193065846" MODIFIED="2013-01-31 09:46:00 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8195673534936939" P_Z="0.04493347891371765" STUDIES="4" TAU2="0.0" TOTAL_1="289" TOTAL_2="190" WEIGHT="59.81084496800226" Z="2.005276656896897">
<NAME>Low doses (&lt; 800 mg/d)</NAME>
<DICH_DATA CI_END="37.65812587988567" CI_START="0.6393574464866614" EFFECT_SIZE="4.906832298136646" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" LOG_CI_END="1.5758587028214641" LOG_CI_START="-0.19425627230428058" LOG_EFFECT_SIZE="0.6908012152585917" MODIFIED="2012-01-04 17:47:08 +0000" MODIFIED_BY="[Empty name]" ORDER="107" O_E="0.0" SE="1.0397742985993044" STUDY_ID="STD-Beller-1997" TOTAL_1="161" TOTAL_2="79" VAR="1.0811305920276753" WEIGHT="14.514415147041491"/>
<DICH_DATA CI_END="69.87971393943685" CI_START="0.20862295471514214" EFFECT_SIZE="3.8181818181818183" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8443511184806365" LOG_CI_START="-0.6806379080012854" LOG_EFFECT_SIZE="0.5818566052396754" MODIFIED="2012-01-28 10:13:06 +0000" MODIFIED_BY="[Empty name]" ORDER="139" O_E="0.0" SE="1.4831910530527415" STUDY_ID="STD-Casado-2008" TOTAL_1="32" TOTAL_2="17" VAR="2.1998556998557" WEIGHT="7.000010228021473"/>
<DICH_DATA CI_END="6.548679574237269" CI_START="0.4021425367260122" EFFECT_SIZE="1.6228070175438596" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8161537409945255" LOG_CI_START="-0.39561998686144306" LOG_EFFECT_SIZE="0.21026687706654118" MODIFIED="2012-01-09 13:09:25 +0000" MODIFIED_BY="[Empty name]" ORDER="280" O_E="0.0" SE="0.7118018861192893" STUDY_ID="STD-Feliu-1992" TOTAL_1="76" TOTAL_2="74" VAR="0.5066619250829777" WEIGHT="32.887320780377244"/>
<DICH_DATA CI_END="69.5152908317231" CI_START="0.12946791838627933" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.84208034406391" LOG_CI_START="-0.8878378346245852" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2012-01-25 16:39:36 +0000" MODIFIED_BY="[Empty name]" ORDER="134" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Herrejon-2011" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="5.409098812562047"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.010824762750385096" CI_END="22.178036013858115" CI_START="0.27157450502730884" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.454177897574124" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.12" LOG_CI_END="1.345923084369072" LOG_CI_START="-0.5661110033372861" LOG_EFFECT_SIZE="0.38990604051589295" METHOD="MH" MODIFIED="2013-01-31 10:04:44 +0000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.917135923938814" P_Q="0.9171935667564122" P_Z="0.4240816968346196" Q="0.010809653543584586" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="46" TOTAL_2="40" WEIGHT="100.0" Z="0.7993600131705687">
<NAME>Depression</NAME>
<GROUP_LABEL_1>Megestrol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours megestrol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="65.40585934911009" CI_START="0.11619307339667935" DF="0" EFFECT_SIZE="2.7567567567567566" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-004.12.01" LOG_CI_END="1.8156166561071514" LOG_CI_START="-0.934819760717306" LOG_EFFECT_SIZE="0.44039844769492253" MODIFIED="2013-01-31 09:46:07 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5302287772345889" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="33" WEIGHT="47.37196765498652" Z="0.6276568264217288">
<NAME>High doses (=&gt; 800 mg/d)</NAME>
<DICH_DATA CI_END="65.40585934911009" CI_START="0.11619307339667935" EFFECT_SIZE="2.7567567567567566" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8156166561071514" LOG_CI_START="-0.934819760717306" LOG_EFFECT_SIZE="0.44039844769492253" MODIFIED="2012-02-08 20:16:58 +0000" MODIFIED_BY="[Empty name]" ORDER="237" O_E="0.0" SE="1.6156199661225275" STUDY_ID="STD-Yeh-2000" TOTAL_1="36" TOTAL_2="33" VAR="2.610227874933757" WEIGHT="47.37196765498652"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="46.920830390765005" CI_START="0.10145452539666325" DF="0" EFFECT_SIZE="2.1818181818181817" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-004.12.02" LOG_CI_END="1.6713656895248183" LOG_CI_START="-0.9937285764180563" LOG_EFFECT_SIZE="0.33881855655338095" MODIFIED="2013-01-31 09:46:12 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.6182387992738754" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="7" WEIGHT="52.62803234501348" Z="0.49834797712382933">
<NAME>Low doses (&lt; 800 mg/d)</NAME>
<DICH_DATA CI_END="46.920830390765005" CI_START="0.10145452539666325" EFFECT_SIZE="2.1818181818181817" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6713656895248183" LOG_CI_START="-0.9937285764180563" LOG_EFFECT_SIZE="0.33881855655338095" MODIFIED="2012-02-06 00:40:54 +0000" MODIFIED_BY="[Empty name]" ORDER="238" O_E="0.0" SE="1.5654895642442257" STUDY_ID="STD-Eubanks-2002" TOTAL_1="10" TOTAL_2="7" VAR="2.4507575757575757" WEIGHT="52.62803234501348"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.347749819102358" CI_END="1.9376922984568723" CI_START="1.0447045744986698" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4227845965460606" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="56" I2="0.0" I2_Q="6.397938228379596" ID="CMP-004.13" LOG_CI_END="0.28728481312134047" LOG_CI_START="0.018993496376119766" LOG_EFFECT_SIZE="0.15313915474873013" METHOD="MH" MODIFIED="2013-01-31 10:04:55 +0000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.8491834087420442" P_Q="0.3013182697974287" P_Z="0.02525547163406264" Q="1.0683525352677585" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="807" TOTAL_2="560" WEIGHT="100.00000000000001" Z="2.237472547167435">
<NAME>Deaths</NAME>
<GROUP_LABEL_1>Megestrol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours megestrol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.7188841106660913" CI_END="2.569125173685708" CI_START="1.0763970401561884" DF="4" EFFECT_SIZE="1.6629488064116855" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="27" I2="0.0" ID="CMP-004.13.01" LOG_CI_END="0.4097852646075818" LOG_CI_START="0.03197249488361398" LOG_EFFECT_SIZE="0.22087887974559786" MODIFIED="2013-01-31 09:46:20 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7872845385709889" P_Z="0.02192360630660071" STUDIES="5" TAU2="0.0" TOTAL_1="389" TOTAL_2="337" WEIGHT="48.18674754422351" Z="2.291688814876297">
<NAME>High doses (=&gt; 800 mg/d)</NAME>
<DICH_DATA CI_END="2.343475769883212" CI_START="0.9030522444829295" EFFECT_SIZE="1.4547443259502324" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="23" LOG_CI_END="0.3698604675381503" LOG_CI_START="-0.04428712362414266" LOG_EFFECT_SIZE="0.1627866719570038" MODIFIED="2012-12-26 09:31:16 +0000" MODIFIED_BY="[Empty name]" ORDER="455" O_E="0.0" SE="0.24327234511237011" STUDY_ID="STD-Jatoi-2002" TOTAL_1="159" TOTAL_2="152" VAR="0.0591814338964721" WEIGHT="40.07631385330546"/>
<DICH_DATA CI_END="12.249197952852823" CI_START="0.49512018267925834" EFFECT_SIZE="2.462686567164179" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0881076531043297" LOG_CI_START="-0.30528937007817014" LOG_EFFECT_SIZE="0.3914091415130798" MODIFIED="2012-04-19 19:33:36 +0100" MODIFIED_BY="[Empty name]" ORDER="246" O_E="0.0" SE="0.8184883088439054" STUDY_ID="STD-Loprinzi-1990b" TOTAL_1="67" TOTAL_2="66" VAR="0.6699231117141564" WEIGHT="3.4338107440929058"/>
<DICH_DATA CI_END="31.88561370954489" CI_START="0.4275638605818494" EFFECT_SIZE="3.6923076923076925" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5035947803668315" LOG_CI_START="-0.3689990102293305" LOG_EFFECT_SIZE="0.5672978850687505" MODIFIED="2012-04-19 19:33:15 +0100" MODIFIED_BY="[Empty name]" ORDER="256" O_E="0.0" SE="1.0999708620849453" STUDY_ID="STD-Oster-1994" TOTAL_1="52" TOTAL_2="48" VAR="1.2099358974358976" WEIGHT="1.7722563512049654"/>
<DICH_DATA CI_END="83.61109906920848" CI_START="0.25510743497983424" EFFECT_SIZE="4.618421052631579" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.9222639322782635" LOG_CI_START="-0.5932768839081981" LOG_EFFECT_SIZE="0.6644935241850327" MODIFIED="2012-04-21 10:30:50 +0100" MODIFIED_BY="[Empty name]" ORDER="724" O_E="0.0" SE="1.4776411275557928" STUDY_ID="STD-Von-Roenn-1994" TOTAL_1="75" TOTAL_2="38" VAR="2.1834233018443547" WEIGHT="1.12618296564864"/>
<DICH_DATA CI_END="14.072922267905014" CI_START="0.05970883387128004" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1483842888383442" LOG_CI_START="-1.2239614106171437" LOG_EFFECT_SIZE="-0.0377885608893998" MODIFIED="2012-01-30 00:19:28 +0000" MODIFIED_BY="[Empty name]" ORDER="186" O_E="0.0" SE="1.3935276071607594" STUDY_ID="STD-Yeh-2000" TOTAL_1="36" TOTAL_2="33" VAR="1.941919191919192" WEIGHT="1.778183629971537"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.7646756615266757" CI_END="1.8646567493057153" CI_START="0.7715265224216369" DF="6" EFFECT_SIZE="1.1994299217969646" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="29" I2="0.0" ID="CMP-004.13.02" LOG_CI_END="0.27059889748392435" LOG_CI_START="-0.11264913979736245" LOG_EFFECT_SIZE="0.07897487884328096" MODIFIED="2013-01-31 09:46:25 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7084863848162686" P_Z="0.41922365258585015" STUDIES="7" TAU2="0.0" TOTAL_1="418" TOTAL_2="223" WEIGHT="51.81325245577651" Z="0.8077688763354977">
<NAME>Low doses (&lt; 800 mg/d)</NAME>
<DICH_DATA CI_END="14.954425656523698" CI_START="0.06686983659340748" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1747697380632693" LOG_CI_START="-1.1747697380632693" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-03-15 19:38:48 +0000" MODIFIED_BY="[Empty name]" ORDER="456" O_E="0.0" SE="1.3801311186847085" STUDY_ID="STD-De-Conno-1998" TOTAL_1="21" TOTAL_2="21" VAR="1.9047619047619047" WEIGHT="1.7040926453893896"/>
<DICH_DATA CI_END="1.7625727840986332" CI_START="0.37353104506494894" EFFECT_SIZE="0.8114035087719298" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.24614705989308047" LOG_CI_START="-0.42767329708796054" LOG_EFFECT_SIZE="-0.09076311859744" MODIFIED="2012-01-09 13:07:16 +0000" MODIFIED_BY="[Empty name]" ORDER="277" O_E="0.0" SE="0.3958054131552242" STUDY_ID="STD-Feliu-1992" TOTAL_1="76" TOTAL_2="74" VAR="0.15666192508297774" WEIGHT="20.721766567934978"/>
<DICH_DATA CI_END="2.7514307510854565" CI_START="0.363447271789593" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.4395585868182921" LOG_CI_START="-0.4395585868182921" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-01-24 23:05:36 +0000" MODIFIED_BY="[Empty name]" ORDER="143" O_E="0.0" SE="0.5163977794943223" STUDY_ID="STD-Giacosa-1997" TOTAL_1="15" TOTAL_2="15" VAR="0.2666666666666667" WEIGHT="8.520463226946948"/>
<DICH_DATA CI_END="4.2749448044003024" CI_START="0.8870860188439328" EFFECT_SIZE="1.9473684210526316" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="7" LOG_CI_END="0.6309305117427589" LOG_CI_START="-0.05203426551442686" LOG_EFFECT_SIZE="0.28944812311416607" MODIFIED="2012-04-19 19:44:57 +0100" MODIFIED_BY="[Empty name]" ORDER="216" O_E="0.0" SE="0.401176890891042" STUDY_ID="STD-Macbeth-1994" TOTAL_1="38" TOTAL_2="37" VAR="0.16094289778500304" WEIGHT="12.087697164628738">
<FOOTNOTE>The most of patients were looked after their General Practitioner or in Hospices during the terminal phase of their illnes, very few died in hospital under the care of the clinicians involved and non had a post portem examination. Authors do not have evidence for an increase in thrombo-embolic events in patients treated with MA, but is the most likely explanation of death. The study failed to shown any significant improvement in any of the measures of lean body weight, anorexia or general well being with either medications and authors in your own discussion explained that &#8220; is not surprising in view of the early closure before enough patients had been recruited&#8221;.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="7.1001879173392695" CI_START="0.1609376104343082" EFFECT_SIZE="1.0689655172413792" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.851269843139287" LOG_CI_START="-0.7933424512686539" LOG_EFFECT_SIZE="0.028963695935316558" MODIFIED="2012-06-11 23:42:54 +0100" MODIFIED_BY="[Empty name]" ORDER="516" O_E="0.0" SE="0.9660534026973775" STUDY_ID="STD-Madeddu-2012" TOTAL_1="29" TOTAL_2="31" VAR="0.9332591768631814" WEIGHT="3.2945791144194865"/>
<DICH_DATA CI_END="7.016577384170804" CI_START="0.015835514243992307" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8461253193035242" LOG_CI_START="-1.8003678287428493" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2012-02-23 00:09:31 +0000" MODIFIED_BY="[Empty name]" ORDER="451" O_E="0.0" SE="1.5545631755148024" STUDY_ID="STD-Summerbell-1992" TOTAL_1="7" TOTAL_2="7" VAR="2.4166666666666665" WEIGHT="2.5561389680840847"/>
<DICH_DATA CI_END="18.063068247507584" CI_START="0.3341813574062578" EFFECT_SIZE="2.456896551724138" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="1" LOG_CI_END="1.2567915228203472" LOG_CI_START="-0.47601778125716376" LOG_EFFECT_SIZE="0.39038687078159173" MODIFIED="2012-04-21 10:37:00 +0100" MODIFIED_BY="[Empty name]" ORDER="188" O_E="0.0" SE="1.017860762759522" STUDY_ID="STD-Von-Roenn-1994" TOTAL_1="232" TOTAL_2="38" VAR="1.036040532365396" WEIGHT="2.928514768372877">
<FOOTNOTE>In this 4 arm trial, 4 patients were death in arm of 800 mg of MA but only one patient was death at the placebo group.</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.613613260284581" CI_END="3.0233355983637686" CI_START="0.3473938198650204" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.024835646457268" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-004.14" LOG_CI_END="0.4804863577064254" LOG_CI_START="-0.45917791191768553" LOG_EFFECT_SIZE="0.010654222894369928" METHOD="MH" MODIFIED="2013-01-31 10:05:02 +0000" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.8933089869512625" P_Q="0.71598498897429" P_Z="0.964549346282365" Q="0.13237232672038513" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="212" TOTAL_2="162" WEIGHT="100.0" Z="0.0444454340369469">
<NAME>Diarrhoea</NAME>
<GROUP_LABEL_1>Megestrol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours megestrol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.218792697554555" CI_START="0.2902573424918933" DF="0" EFFECT_SIZE="1.2307692307692308" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-004.14.01" LOG_CI_END="0.717570046022691" LOG_CI_START="-0.537216785324515" LOG_EFFECT_SIZE="0.09017663034908803" MODIFIED="2013-01-31 09:46:44 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7781659491975801" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="48" WEIGHT="49.96347699050401" Z="0.2817099180768952">
<NAME>High doses (=&gt; 800 mg/d)</NAME>
<DICH_DATA CI_END="5.218792697554555" CI_START="0.2902573424918933" EFFECT_SIZE="1.2307692307692308" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.717570046022691" LOG_CI_START="-0.537216785324515" LOG_EFFECT_SIZE="0.09017663034908803" MODIFIED="2012-03-15 19:40:01 +0000" MODIFIED_BY="[Empty name]" ORDER="457" O_E="0.0" SE="0.7370679960283384" STUDY_ID="STD-Oster-1994" TOTAL_1="52" TOTAL_2="48" VAR="0.5432692307692306" WEIGHT="49.96347699050401"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5041879652414828" CI_END="4.264532283889987" CI_START="0.15736615671055426" DF="2" EFFECT_SIZE="0.8192026951151038" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-004.14.02" LOG_CI_END="0.6298714065083945" LOG_CI_START="-0.8030886616479784" LOG_EFFECT_SIZE="-0.08660862756979197" MODIFIED="2013-01-31 09:46:49 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7771717043049863" P_Z="0.8127174019398616" STUDIES="3" TAU2="0.0" TOTAL_1="160" TOTAL_2="114" WEIGHT="50.03652300949598" Z="0.2369218718085185">
<NAME>Low doses (&lt; 800 mg/d)</NAME>
<DICH_DATA CI_END="7.888578229356675" CI_START="0.014085061703212953" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8969987366967316" LOG_CI_START="-1.8512412461360563" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2012-03-15 19:40:10 +0000" MODIFIED_BY="[Empty name]" ORDER="458" O_E="0.0" SE="1.6143297699232972" STUDY_ID="STD-Fietkau-1996" TOTAL_1="32" TOTAL_2="32" VAR="2.606060606060606" WEIGHT="24.020902399280775"/>
<DICH_DATA CI_END="16.31130518173396" CI_START="0.07005492597433315" EFFECT_SIZE="1.0689655172413792" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2124887133729667" LOG_CI_START="-1.1545613215023336" LOG_EFFECT_SIZE="0.028963695935316558" MODIFIED="2012-06-11 23:49:20 +0100" MODIFIED_BY="[Empty name]" ORDER="517" O_E="0.0" SE="1.3904169075723947" STUDY_ID="STD-Madeddu-2012" TOTAL_1="29" TOTAL_2="31" VAR="1.9332591768631813" WEIGHT="15.480137101758721"/>
<DICH_DATA CI_END="37.62630761264252" CI_START="0.06467815085799983" EFFECT_SIZE="1.56" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.575491601733785" LOG_CI_START="-1.1892424050248618" LOG_EFFECT_SIZE="0.1931245983544616" MODIFIED="2012-01-29 19:39:29 +0000" MODIFIED_BY="[Empty name]" ORDER="350" O_E="0.0" SE="1.6240184412240821" STUDY_ID="STD-Vadell-1998" TOTAL_1="99" TOTAL_2="51" VAR="2.6374358974358976" WEIGHT="10.535483508456482"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2286882931731764" CI_START="0.6648635362170976" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.903830760434534" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="55" I2="0.0" I2_Q="100.0" ID="CMP-004.15" LOG_CI_END="0.08944172037645398" LOG_CI_START="-0.17726748484670124" LOG_EFFECT_SIZE="-0.043912882235123615" METHOD="MH" MODIFIED="2013-01-31 10:05:11 +0000" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="1.0" P_Q="0.0" P_Z="0.5186650578058292" Q="7.846740154671047E-33" RANDOM="NO" SCALE="115.78" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="159" TOTAL_2="152" WEIGHT="100.0" Z="0.6454045526188595">
<NAME>Drowsiness</NAME>
<GROUP_LABEL_1>Megestrol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours megestrol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2286882931731764" CI_START="0.6648635362170976" DF="0" EFFECT_SIZE="0.903830760434534" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="55" I2="0.0" ID="CMP-004.15.01" LOG_CI_END="0.08944172037645398" LOG_CI_START="-0.17726748484670124" LOG_EFFECT_SIZE="-0.043912882235123615" MODIFIED="2013-01-31 09:47:04 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5186650578058292" STUDIES="1" TAU2="0.0" TOTAL_1="159" TOTAL_2="152" WEIGHT="100.0" Z="0.6454045526188595">
<NAME>High doses (=&gt; 800 mg/d)</NAME>
<DICH_DATA CI_END="1.2286882931731764" CI_START="0.6648635362170976" EFFECT_SIZE="0.903830760434534" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="55" LOG_CI_END="0.08944172037645398" LOG_CI_START="-0.17726748484670124" LOG_EFFECT_SIZE="-0.043912882235123615" MODIFIED="2012-03-15 19:40:49 +0000" MODIFIED_BY="[Empty name]" ORDER="211" O_E="0.0" SE="0.15666630737993964" STUDY_ID="STD-Jatoi-2002" TOTAL_1="159" TOTAL_2="152" VAR="0.024544331868065733" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.15.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-01-31 09:47:09 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Low doses (&lt; 800 mg/d)</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.7303102550217595" CI_END="1.5896275901247519" CI_START="0.06989757336961626" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="63.37412577340848" I2_Q="62.378830332388425" ID="CMP-004.16" LOG_CI_END="0.2012953919319992" LOG_CI_START="-1.155537901371324" LOG_EFFECT_SIZE="-0.47712125471966244" METHOD="MH" MODIFIED="2013-02-08 09:23:24 +0000" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.0984602310398186" P_Q="0.10302521966364009" P_Z="0.1680748338868528" Q="2.658077908887851" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="1.378416169656956">
<NAME>Elevated transaminase levels</NAME>
<GROUP_LABEL_1>Megestrol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours megestrol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5422965811171738" CI_START="0.005358543169388946" DF="0" EFFECT_SIZE="0.09090909090909091" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" I2="0.0" ID="CMP-004.16.01" LOG_CI_END="0.1881678958663492" LOG_CI_START="-2.2709532661827994" LOG_EFFECT_SIZE="-1.041392685158225" MODIFIED="2013-01-31 09:47:48 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.09691091981099019" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="91.66666666666667" Z="1.6600175608856702">
<NAME>High doses (=&gt; 800 mg/d)</NAME>
<DICH_DATA CI_END="1.5422965811171738" CI_START="0.005358543169388946" EFFECT_SIZE="0.09090909090909091" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.1881678958663492" LOG_CI_START="-2.2709532661827994" LOG_EFFECT_SIZE="-1.041392685158225" MODIFIED="2012-01-29 17:46:25 +0000" MODIFIED_BY="[Empty name]" ORDER="337" O_E="0.0" SE="1.444499943433743" STUDY_ID="STD-Mwamburi-2004" TOTAL_1="20" TOTAL_2="20" VAR="2.0865800865800868" WEIGHT="91.66666666666667"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="67.05568402675195" CI_START="0.13421680996363317" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-004.16.02" LOG_CI_END="1.8264355970545303" LOG_CI_START="-0.8721930876152056" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-01-31 09:47:54 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.4882790296766242" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="8.333333333333334" Z="0.6930486441661347">
<NAME>Low doses (&lt; 800 mg/d)</NAME>
<DICH_DATA CI_END="67.05568402675195" CI_START="0.13421680996363317" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8264355970545303" LOG_CI_START="-0.8721930876152056" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2012-03-15 19:43:05 +0000" MODIFIED_BY="[Empty name]" ORDER="459" O_E="0.0" SE="1.585187847802434" STUDY_ID="STD-Timpone-1997" TOTAL_1="12" TOTAL_2="12" VAR="2.5128205128205123" WEIGHT="8.333333333333334"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.991693162189227" CI_END="4.80128870373863" CI_START="0.16413748559162322" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8877338877338877" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="100.0" ID="CMP-004.17" LOG_CI_END="0.6813578210849466" LOG_CI_START="-0.7847922237825624" LOG_EFFECT_SIZE="-0.051717201348807904" METHOD="MH" MODIFIED="2013-02-08 09:23:25 +0000" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.3193291417459211" P_Q="0.0" P_Z="0.890025343192613" Q="2.5966202855092086E-34" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="69" TOTAL_2="60" WEIGHT="100.0" Z="0.13827213985323">
<NAME>Glucose intolerance</NAME>
<GROUP_LABEL_1>Megestrol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours megestrol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.991693162189227" CI_END="4.80128870373863" CI_START="0.16413748559162322" DF="1" EFFECT_SIZE="0.8877338877338877" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-004.17.01" LOG_CI_END="0.6813578210849466" LOG_CI_START="-0.7847922237825624" LOG_EFFECT_SIZE="-0.051717201348807904" MODIFIED="2013-01-31 09:48:03 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3193291417459211" P_Z="0.890025343192613" STUDIES="2" TAU2="0.0" TOTAL_1="69" TOTAL_2="60" WEIGHT="100.0" Z="0.13827213985323">
<NAME>High doses (=&gt; 800 mg/d)</NAME>
<DICH_DATA CI_END="69.5152908317231" CI_START="0.12946791838627933" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.84208034406391" LOG_CI_START="-0.8878378346245852" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2012-01-29 17:51:02 +0000" MODIFIED_BY="[Empty name]" ORDER="342" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Mwamburi-2004" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="18.503118503118504"/>
<DICH_DATA CI_END="4.339482791646798" CI_START="0.03839103855096377" EFFECT_SIZE="0.40816326530612246" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6374379704988811" LOG_CI_START="-1.415770139227946" LOG_EFFECT_SIZE="-0.3891660843645325" MODIFIED="2012-01-28 18:11:17 +0000" MODIFIED_BY="[Empty name]" ORDER="460" O_E="0.0" SE="1.206064607197597" STUDY_ID="STD-Tchekmedyian-1992" TOTAL_1="49" TOTAL_2="40" VAR="1.454591836734694" WEIGHT="81.4968814968815"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.17.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-01-31 09:48:18 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Low doses (&lt; 800 mg/d)</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.38190843595683516" CI_END="3.828246756967245" CI_START="0.07836350524001585" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5477178423236515" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-004.18" LOG_CI_END="0.582999923288558" LOG_CI_START="-1.105886146026595" LOG_EFFECT_SIZE="-0.2614431113690185" METHOD="MH" MODIFIED="2013-02-08 09:23:27 +0000" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.5365839673364987" P_Q="1.0" P_Z="0.5439749671987475" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="61" TOTAL_2="52" WEIGHT="100.0" Z="0.606813084197157">
<NAME>Hallucinations/psychosis</NAME>
<GROUP_LABEL_1>Megestrol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours megestrol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.38190843595683516" CI_END="3.828246756967245" CI_START="0.07836350524001585" DF="1" EFFECT_SIZE="0.5477178423236515" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-004.18.01" LOG_CI_END="0.582999923288558" LOG_CI_START="-1.105886146026595" LOG_EFFECT_SIZE="-0.2614431113690185" MODIFIED="2013-01-31 09:48:52 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5365839673364987" P_Z="0.5439749671987475" STUDIES="2" TAU2="0.0" TOTAL_1="61" TOTAL_2="52" WEIGHT="100.0" Z="0.606813084197157">
<NAME>High doses (=&gt; 800 mg/d)</NAME>
<DICH_DATA CI_END="6.532525082510129" CI_START="0.011436789016109412" EFFECT_SIZE="0.2733333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8150810859347369" LOG_CI_START="-1.9416958906066286" LOG_EFFECT_SIZE="-0.5633074023359458" MODIFIED="2012-01-28 18:21:27 +0000" MODIFIED_BY="[Empty name]" ORDER="463" O_E="0.0" SE="1.619344442286516" STUDY_ID="STD-Tchekmedyian-1992" TOTAL_1="49" TOTAL_2="40" VAR="2.6222764227642275" WEIGHT="62.24066390041494"/>
<DICH_DATA CI_END="14.207980025005401" CI_START="0.07038298183415555" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.152532337860481" LOG_CI_START="-1.152532337860481" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-03-15 19:44:17 +0000" MODIFIED_BY="[Empty name]" ORDER="460" O_E="0.0" SE="1.3540064007726602" STUDY_ID="STD-Timpone-1997" TOTAL_1="12" TOTAL_2="12" VAR="1.8333333333333335" WEIGHT="37.75933609958506"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.18.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-01-31 09:49:02 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Low doses (&lt; 800 mg/d)</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="69.5152908317231" CI_START="0.12946791838627933" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.19" LOG_CI_END="1.84208034406391" LOG_CI_START="-0.8878378346245852" LOG_EFFECT_SIZE="0.47712125471966244" METHOD="MH" MODIFIED="2013-02-08 09:23:28 +0000" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="1.0" P_Q="1.0" P_Z="0.49327758741034344" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.6851051308492764">
<NAME>Headaches</NAME>
<GROUP_LABEL_1>Megestrol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours megestrol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="69.5152908317231" CI_START="0.12946791838627933" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-004.19.01" LOG_CI_END="1.84208034406391" LOG_CI_START="-0.8878378346245852" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-01-31 09:49:11 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.49327758741034344" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.6851051308492764">
<NAME>High doses (=&gt; 800 mg/d)</NAME>
<DICH_DATA CI_END="69.5152908317231" CI_START="0.12946791838627933" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.84208034406391" LOG_CI_START="-0.8878378346245852" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2012-01-29 17:54:15 +0000" MODIFIED_BY="[Empty name]" ORDER="344" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Mwamburi-2004" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.19.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-01-31 09:49:16 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Low doses (&lt; 800 mg/d)</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="116.40042449559739" CI_START="0.420960664124153" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.20" LOG_CI_END="2.0659545641262356" LOG_CI_START="-0.3757584840977218" LOG_EFFECT_SIZE="0.8450980400142568" METHOD="MH" MODIFIED="2013-02-08 09:23:28 +0000" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="1.0" P_Q="1.0" P_Z="0.17486986751087724" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4" TOTAL_2="6" WEIGHT="100.0" Z="1.356721030784621">
<NAME>Hyperphagia</NAME>
<GROUP_LABEL_1>Megestrol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours megestrol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.20.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-01-31 09:49:32 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>High doses (=&gt; 800 mg/d)</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="116.40042449559739" CI_START="0.420960664124153" DF="0" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-004.20.02" LOG_CI_END="2.0659545641262356" LOG_CI_START="-0.3757584840977218" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2013-01-31 09:49:37 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.17486986751087724" STUDIES="1" TAU2="0.0" TOTAL_1="4" TOTAL_2="6" WEIGHT="100.0" Z="1.356721030784621">
<NAME>Low doses (&lt; 800 mg/d)</NAME>
<DICH_DATA CI_END="116.40042449559729" CI_START="0.42096066412415317" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.065954564126235" LOG_CI_START="-0.3757584840977216" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2012-01-09 08:35:43 +0000" MODIFIED_BY="[Empty name]" ORDER="124" O_E="0.0" SE="1.4342743312012722" STUDY_ID="STD-Batterham-2001" TOTAL_1="4" TOTAL_2="6" VAR="2.057142857142857" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.1297582867485647" CI_END="1.3548379298467297" CI_START="0.37009304323253545" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7081074018422944" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="31" I2="36.097301556224814" I2_Q="0.0" ID="CMP-004.21" LOG_CI_END="0.13188734658829093" LOG_CI_START="-0.4316890784123663" LOG_EFFECT_SIZE="-0.1499008659120377" METHOD="MH" MODIFIED="2013-02-08 09:23:29 +0000" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="0.20911339126714423" P_Q="0.6290219875449099" P_Z="0.29712060137693663" Q="0.2333893792522557" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="179" TOTAL_2="338" WEIGHT="100.0" Z="1.042628063935141">
<NAME>Heart burn</NAME>
<GROUP_LABEL_1>Megestrol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours megestrol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.857372931513596" CI_END="1.432278174917168" CI_START="0.37851664137133456" DF="1" EFFECT_SIZE="0.7363023321157629" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="30" I2="65.00281818410437" ID="CMP-004.21.01" LOG_CI_END="0.15602737418623502" LOG_CI_START="-0.42191502211670234" LOG_EFFECT_SIZE="-0.1329438239652337" MODIFIED="2013-01-31 09:49:46 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.09095605503433013" P_Z="0.36721667210692266" STUDIES="2" TAU2="0.0" TOTAL_1="158" TOTAL_2="317" WEIGHT="93.00320114980074" Z="0.901699230254469">
<NAME>High doses (=&gt; 800 mg/d)</NAME>
<DICH_DATA CI_END="1.1625927239754525" CI_START="0.17997289906091168" EFFECT_SIZE="0.4574223245109321" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="22" LOG_CI_END="0.06542760062002588" LOG_CI_START="-0.7447928875323806" LOG_EFFECT_SIZE="-0.3396826434561774" MODIFIED="2012-02-19 11:47:37 +0000" MODIFIED_BY="[Empty name]" ORDER="264" O_E="0.0" SE="0.475927525396823" STUDY_ID="STD-Loprinzi-1999a" TOTAL_1="79" TOTAL_2="159" VAR="0.22650700943034358" WEIGHT="68.12569412687006"/>
<DICH_DATA CI_END="4.174242636926308" CI_START="0.5390199362384889" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.6205776897738868" LOG_CI_START="-0.26839517166252436" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2012-02-19 11:47:48 +0000" MODIFIED_BY="[Empty name]" ORDER="265" O_E="0.0" SE="0.5221870592943822" STUDY_ID="STD-Loprinzi-1999b" TOTAL_1="79" TOTAL_2="158" VAR="0.27267932489451474" WEIGHT="24.877507022930686"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.7443737981982546" CI_START="0.014347333174563614" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-004.21.02" LOG_CI_END="0.8889863069264973" LOG_CI_START="-1.8432288163658224" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-01-31 09:49:51 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.49364108067680157" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="6.996798850199255" Z="0.6845291701498639">
<NAME>Low doses (&lt; 800 mg/d)</NAME>
<DICH_DATA CI_END="7.7443737981982546" CI_START="0.014347333174563614" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8889863069264973" LOG_CI_START="-1.8432288163658224" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2012-01-09 11:52:21 +0000" MODIFIED_BY="[Empty name]" ORDER="138" O_E="0.0" SE="1.6049166881048922" STUDY_ID="STD-De-Conno-1998" TOTAL_1="21" TOTAL_2="21" VAR="2.5757575757575757" WEIGHT="6.996798850199255"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.532525082510132" CI_START="0.011436789016109412" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2733333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-004.22" LOG_CI_END="0.815081085934737" LOG_CI_START="-1.9416958906066286" LOG_EFFECT_SIZE="-0.5633074023359458" METHOD="MH" MODIFIED="2013-02-08 09:23:30 +0000" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="1.0" P_Q="1.0" P_Z="0.4231429755920685" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="49" TOTAL_2="40" WEIGHT="100.0" Z="0.8009804421599727">
<NAME>Heart failure</NAME>
<GROUP_LABEL_1>Megestrol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours megestrol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.532525082510132" CI_START="0.011436789016109412" DF="0" EFFECT_SIZE="0.2733333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-004.22.01" LOG_CI_END="0.815081085934737" LOG_CI_START="-1.9416958906066286" LOG_EFFECT_SIZE="-0.5633074023359458" MODIFIED="2013-01-31 09:50:07 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4231429755920685" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="40" WEIGHT="100.0" Z="0.8009804421599727">
<NAME>High doses (=&gt; 800 mg/d)</NAME>
<DICH_DATA CI_END="6.532525082510129" CI_START="0.011436789016109412" EFFECT_SIZE="0.2733333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8150810859347369" LOG_CI_START="-1.9416958906066286" LOG_EFFECT_SIZE="-0.5633074023359458" MODIFIED="2012-01-28 18:20:26 +0000" MODIFIED_BY="[Empty name]" ORDER="463" O_E="0.0" SE="1.619344442286516" STUDY_ID="STD-Tchekmedyian-1992" TOTAL_1="49" TOTAL_2="40" VAR="2.6222764227642275" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.22.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-01-28 18:19:18 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Low doses (&lt;800 mg/d)</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6913685138357629" CI_END="2.91066418804237" CI_START="0.13575618420148258" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6286021505376344" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-004.23" LOG_CI_END="0.4639921024869376" LOG_CI_START="-0.8672403775519727" LOG_EFFECT_SIZE="-0.20162413753251754" METHOD="MH" MODIFIED="2013-02-08 09:23:31 +0000" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="0.7077360011043453" P_Q="1.0" P_Z="0.5527131014294548" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="159" TOTAL_2="130" WEIGHT="100.0" Z="0.5936995286745624">
<NAME>Hypertension</NAME>
<GROUP_LABEL_1>Megestrol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours megestrol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.6913685138357629" CI_END="2.91066418804237" CI_START="0.13575618420148258" DF="2" EFFECT_SIZE="0.6286021505376344" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-004.23.01" LOG_CI_END="0.4639921024869376" LOG_CI_START="-0.8672403775519727" LOG_EFFECT_SIZE="-0.20162413753251754" MODIFIED="2012-02-16 22:55:11 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7077360011043453" P_Z="0.5527131014294548" STUDIES="3" TAU2="0.0" TOTAL_1="127" TOTAL_2="113" WEIGHT="100.0" Z="0.5936995286745624">
<NAME>High doses(=&gt; 800 mg /d)</NAME>
<DICH_DATA CI_END="43.28468102978302" CI_START="0.08010457163717327" EFFECT_SIZE="1.8620689655172413" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6363342214948577" LOG_CI_START="-1.096342697646833" LOG_EFFECT_SIZE="0.2699957619240124" MODIFIED="2012-01-28 10:13:37 +0000" MODIFIED_BY="[Empty name]" ORDER="136" O_E="0.0" SE="1.605187949272739" STUDY_ID="STD-Casado-2008" TOTAL_1="28" TOTAL_2="17" VAR="2.5766283524904217" WEIGHT="14.759856630824373"/>
<DICH_DATA CI_END="5.375067687491468" CI_START="0.04651104219241459" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7303839376330282" LOG_CI_START="-1.3324439289609906" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2012-02-16 22:55:11 +0000" MODIFIED_BY="[Empty name]" ORDER="251" O_E="0.0" SE="1.2117152999999499" STUDY_ID="STD-Loprinzi-1990b" TOTAL_1="63" TOTAL_2="63" VAR="1.4682539682539684" WEIGHT="47.842293906810035"/>
<DICH_DATA CI_END="7.267317705456675" CI_START="0.01291034148851992" EFFECT_SIZE="0.3063063063063063" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8613741466678263" LOG_CI_START="-1.889062270156631" LOG_EFFECT_SIZE="-0.5138440617444023" MODIFIED="2012-02-08 20:17:34 +0000" MODIFIED_BY="[Empty name]" ORDER="238" O_E="0.0" SE="1.6156199661225275" STUDY_ID="STD-Yeh-2000" TOTAL_1="36" TOTAL_2="33" VAR="2.610227874933757" WEIGHT="37.39784946236559"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.23.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-01-31 09:50:13 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>Low doses (&lt; 800 mg/d)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-01-28 10:11:12 +0000" MODIFIED_BY="[Empty name]" ORDER="137" O_E="0.0" SE="0.0" STUDY_ID="STD-Casado-2008" TOTAL_1="32" TOTAL_2="17" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.852779672697705" CI_END="3.749879901650158" CI_START="1.7809569852580311" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="RR" EFFECT_SIZE="2.5842551740728985" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="39" I2="0.0" I2_Q="0.0" ID="CMP-004.24" LOG_CI_END="0.5740173586914915" LOG_CI_START="0.2506534302489404" LOG_EFFECT_SIZE="0.4123353944702159" METHOD="MH" MODIFIED="2013-02-08 09:23:32 +0000" MODIFIED_BY="[Empty name]" NO="24" NOTES="&lt;p&gt;Data could be underestimated because is calculated from the whole population, but not only men&lt;/p&gt;" NOTES_MODIFIED="2013-02-08 09:23:32 +0000" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="0.9513470711191255" P_Q="0.7461483977473578" P_Z="5.778685593272641E-7" Q="0.10479605920294958" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1098" TOTAL_2="973" WEIGHT="100.0" Z="4.998470463945503">
<NAME>Impotence</NAME>
<GROUP_LABEL_1>Megestrol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours megestrol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.061037504243343" CI_END="3.812668721626881" CI_START="1.6311565204025722" DF="7" EFFECT_SIZE="2.4938042115243584" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="33" I2="0.0" ID="CMP-004.24.01" LOG_CI_END="0.5812290715680083" LOG_CI_START="0.21249563650665482" LOG_EFFECT_SIZE="0.3968623540373316" MODIFIED="2013-01-31 09:50:21 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6525147786696022" P_Z="2.4543113303085835E-5" STUDIES="8" TAU2="0.0" TOTAL_1="668" TOTAL_2="678" WEIGHT="76.91085412997384" Z="4.218960619090753">
<NAME>High doses (=&gt; 800 mg/d)</NAME>
<DICH_DATA CI_END="10.81536775995558" CI_START="1.9739908294325155" EFFECT_SIZE="4.620545073375262" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="6" LOG_CI_END="1.0340412915424604" LOG_CI_START="0.2953451307368065" LOG_EFFECT_SIZE="0.6646932111396335" MODIFIED="2012-02-01 17:31:04 +0000" MODIFIED_BY="[Empty name]" ORDER="214" O_E="0.0" SE="0.4339137814622101" STUDY_ID="STD-Jatoi-2002" TOTAL_1="159" TOTAL_2="152" VAR="0.18828116974283463" WEIGHT="17.167681054213464"/>
<DICH_DATA CI_END="7.647146737244775" CI_START="0.5230709096398454" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8834994237268242" LOG_CI_START="-0.2814394323988618" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2012-02-16 22:53:58 +0000" MODIFIED_BY="[Empty name]" ORDER="248" O_E="0.0" SE="0.6842908506285673" STUDY_ID="STD-Loprinzi-1990b" TOTAL_1="63" TOTAL_2="63" VAR="0.46825396825396826" WEIGHT="8.394888062673566"/>
<DICH_DATA CI_END="4.124351872099115" CI_START="0.8117064283537686" EFFECT_SIZE="1.8296892980437285" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.6153557103437745" LOG_CI_START="-0.09060101460020444" LOG_EFFECT_SIZE="0.262377347871785" MODIFIED="2012-02-19 11:53:10 +0000" MODIFIED_BY="[Empty name]" ORDER="272" O_E="0.0" SE="0.414682474774241" STUDY_ID="STD-Loprinzi-1999a" TOTAL_1="79" TOTAL_2="159" VAR="0.171961554884889" WEIGHT="20.434615480289434">
<FOOTNOTE>We have split events and total patients</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="3.0995830674633513" CI_START="0.6185218210275557" EFFECT_SIZE="1.3846153846153846" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" LOG_CI_END="0.4913032797447138" LOG_CI_START="-0.20864497415177521" LOG_EFFECT_SIZE="0.1413291527964693" MODIFIED="2012-02-19 11:53:17 +0000" MODIFIED_BY="[Empty name]" ORDER="273" O_E="0.0" SE="0.411153069138534" STUDY_ID="STD-Loprinzi-1999b" TOTAL_1="79" TOTAL_2="158" VAR="0.16904684626203612" WEIGHT="24.25189884772363">
<FOOTNOTE>We have split events and total patients</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="69.5152908317231" CI_START="0.12946791838627933" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.84208034406391" LOG_CI_START="-0.8878378346245852" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2012-01-29 17:52:33 +0000" MODIFIED_BY="[Empty name]" ORDER="343" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Mwamburi-2004" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="1.3991480104455942">
<FOOTNOTE>Is described as decreased libido.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="93.91422450702834" CI_START="0.2275354413765373" EFFECT_SIZE="4.622641509433962" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9727313766862018" LOG_CI_START="-0.6429509471587148" LOG_EFFECT_SIZE="0.6648902147637434" MODIFIED="2012-02-19 10:32:41 +0000" MODIFIED_BY="[Empty name]" ORDER="258" O_E="0.0" SE="1.536464744862827" STUDY_ID="STD-Oster-1994" TOTAL_1="52" TOTAL_2="48" VAR="2.360723912206392" WEIGHT="1.4540165598748334"/>
<DICH_DATA CI_END="58.79272574259117" CI_START="0.10293110114498476" EFFECT_SIZE="2.46" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7693235953740618" LOG_CI_START="-0.9874533811673035" LOG_EFFECT_SIZE="0.39093510710337914" MODIFIED="2012-01-28 18:20:42 +0000" MODIFIED_BY="[Empty name]" ORDER="464" O_E="0.0" SE="1.619344442286516" STUDY_ID="STD-Tchekmedyian-1992" TOTAL_1="49" TOTAL_2="40" VAR="2.6222764227642275" WEIGHT="1.53752528620395"/>
<DICH_DATA CI_END="74.17537724149487" CI_START="0.26227572051121284" EFFECT_SIZE="4.410714285714286" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" LOG_CI_END="1.8702597637314875" LOG_CI_START="-0.5812419112245568" LOG_EFFECT_SIZE="0.6445089262534653" MODIFIED="2012-01-31 00:04:11 +0000" MODIFIED_BY="[Empty name]" ORDER="193" O_E="0.0" SE="1.4400242189981842" STUDY_ID="STD-Von-Roenn-1994" TOTAL_1="167" TOTAL_2="38" VAR="2.0736697513013302" WEIGHT="2.2710808285493704"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5420768019062864" CI_END="6.261444797689078" CI_START="1.329789564655766" DF="5" EFFECT_SIZE="2.885550892227526" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="6" I2="0.0" ID="CMP-004.24.02" LOG_CI_END="0.7966745560963276" LOG_CI_START="0.123782920561379" LOG_EFFECT_SIZE="0.4602287383288533" MODIFIED="2013-01-31 09:50:26 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9905014923312646" P_Z="0.0073389142456951805" STUDIES="6" TAU2="0.0" TOTAL_1="430" TOTAL_2="295" WEIGHT="23.089145870026165" Z="2.681060973681881">
<NAME>Low doses (&lt; 800 mg/d)</NAME>
<DICH_DATA CI_END="38.135201620572175" CI_START="0.07021559705006873" EFFECT_SIZE="1.6363636363636365" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.581326046843009" LOG_CI_START="-1.1535664069528468" LOG_EFFECT_SIZE="0.21387981994508107" MODIFIED="2012-01-28 10:15:22 +0000" MODIFIED_BY="[Empty name]" ORDER="140" O_E="0.0" SE="1.6064893652956689" STUDY_ID="STD-Casado-2008" TOTAL_1="32" TOTAL_2="17" VAR="2.580808080808081" WEIGHT="1.8106621311648867"/>
<DICH_DATA CI_END="70.99720406421005" CI_START="0.12676555532891653" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8512412461360563" LOG_CI_START="-0.8969987366967316" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2012-01-24 22:17:54 +0000" MODIFIED_BY="[Empty name]" ORDER="133" O_E="0.0" SE="1.6143297699232972" STUDY_ID="STD-Fietkau-1996" TOTAL_1="32" TOTAL_2="32" VAR="2.606060606060606" WEIGHT="1.3991480104455942"/>
<DICH_DATA CI_END="69.93293609783412" CI_START="0.12065333152253178" EFFECT_SIZE="2.9047619047619047" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8446817622502414" LOG_CI_START="-0.9184606816965457" LOG_EFFECT_SIZE="0.4631105402768477" MODIFIED="2012-01-24 22:39:13 +0000" MODIFIED_BY="[Empty name]" ORDER="142" O_E="0.0" SE="1.6230835493500326" STUDY_ID="STD-Gebbia-1996" TOTAL_1="62" TOTAL_2="60" VAR="2.6344002081707" WEIGHT="1.421714913839878"/>
<DICH_DATA CI_END="9.793855506507258" CI_START="1.0939442340236183" EFFECT_SIZE="3.273214285714286" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="4" LOG_CI_END="0.9909536923726754" LOG_CI_START="0.038995183539357006" LOG_EFFECT_SIZE="0.5149744379560163" MODIFIED="2012-02-01 18:00:09 +0000" MODIFIED_BY="[Empty name]" ORDER="209" O_E="0.0" SE="0.5591851403593084" STUDY_ID="STD-Jatoi-2004" TOTAL_1="140" TOTAL_2="141" VAR="0.3126880211986595" WEIGHT="11.153350688249576"/>
<DICH_DATA CI_END="27.410901151648815" CI_START="0.5837093757509528" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.4379233134948128" LOG_CI_START="-0.23380333083888805" LOG_EFFECT_SIZE="0.6020599913279624" MODIFIED="2012-03-15 19:45:41 +0000" MODIFIED_BY="[Empty name]" ORDER="450" O_E="0.0" SE="0.9819805060619657" STUDY_ID="STD-Summerbell-1992" TOTAL_1="7" TOTAL_2="7" VAR="0.9642857142857144" WEIGHT="2.7982960208911885">
<FOOTNOTE>Eight of the patients in this trial were sexually active before the start of therapy</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="13.36127512506557" CI_START="0.2148404541216815" EFFECT_SIZE="1.694267515923567" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.1258479067438725" LOG_CI_START="-0.6678839383002059" LOG_EFFECT_SIZE="0.22898198422183327" MODIFIED="2012-03-15 19:45:45 +0000" MODIFIED_BY="[Empty name]" ORDER="192" O_E="0.0" SE="1.053646964894725" STUDY_ID="STD-Von-Roenn-1994" TOTAL_1="157" TOTAL_2="38" VAR="1.1101719266318661" WEIGHT="4.505974105435042"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.5620444330143715" CI_END="1.389076145458918" CI_START="0.637493553095276" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9410244882512335" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="53" I2="0.0" I2_Q="0.0" ID="CMP-004.25" LOG_CI_END="0.14272605325829307" LOG_CI_START="-0.19552420284585703" LOG_EFFECT_SIZE="-0.026399074793782007" METHOD="MH" MODIFIED="2013-02-08 09:23:32 +0000" MODIFIED_BY="[Empty name]" NO="25" P_CHI2="0.9058007992163037" P_Q="0.7796923725128408" P_Z="0.7596544082223681" Q="0.07824325571710057" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="462" TOTAL_2="423" WEIGHT="100.0" Z="0.30593464387539343">
<NAME>Infections</NAME>
<GROUP_LABEL_1>Megestrol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours megestrol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.4788305567856137" CI_END="1.4016126207032824" CI_START="0.6027467278089641" DF="3" EFFECT_SIZE="0.9191395001764695" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="49" I2="0.0" ID="CMP-004.25.01" LOG_CI_END="0.14662799940984753" LOG_CI_START="-0.21986513864170415" LOG_EFFECT_SIZE="-0.03661856961592832" MODIFIED="2013-01-31 09:50:34 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6871648002102269" P_Z="0.6953065204555466" STUDIES="4" TAU2="0.0" TOTAL_1="285" TOTAL_2="384" WEIGHT="85.97068197392748" Z="0.3916639639921267">
<NAME>High doses (=&gt; 800 mg/d)</NAME>
<DICH_DATA CI_END="1.4774778177585282" CI_START="0.3553236366118876" EFFECT_SIZE="0.7245569620253165" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="25" LOG_CI_END="0.16952096928433547" LOG_CI_START="-0.44937590168974073" LOG_EFFECT_SIZE="-0.13992746620270266" MODIFIED="2012-02-19 11:42:55 +0000" MODIFIED_BY="[Empty name]" ORDER="260" O_E="0.0" SE="0.36354308559909265" STUDY_ID="STD-Loprinzi-1999a" TOTAL_1="79" TOTAL_2="159" VAR="0.1321635750869092" WEIGHT="36.65452222503275">
<FOOTNOTE>We have split events and total patients</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.8460592296068064" CI_START="0.5322422258996903" EFFECT_SIZE="1.2307692307692308" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.45424393398569934" LOG_CI_START="-0.2738906732875232" LOG_EFFECT_SIZE="0.09017663034908803" MODIFIED="2012-02-19 11:43:39 +0000" MODIFIED_BY="[Empty name]" ORDER="261" O_E="0.0" SE="0.4277098726367267" STUDY_ID="STD-Loprinzi-1999b" TOTAL_1="79" TOTAL_2="158" VAR="0.182935735150925" WEIGHT="19.14077498130824">
<FOOTNOTE>We have split events and total patients</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.9380632823276134" CI_START="0.47940612745338834" EFFECT_SIZE="1.1868131868131868" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.4680611457325581" LOG_CI_START="-0.31929641940084585" LOG_EFFECT_SIZE="0.0743823631658561" MODIFIED="2012-02-19 10:33:58 +0000" MODIFIED_BY="[Empty name]" ORDER="259" O_E="0.0" SE="0.46249773124216664" STUDY_ID="STD-Oster-1994" TOTAL_1="52" TOTAL_2="48" VAR="0.2139041514041514" WEIGHT="16.078250984298922"/>
<DICH_DATA CI_END="1.946944538248011" CI_START="0.24928519272623417" EFFECT_SIZE="0.6966666666666667" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" LOG_CI_END="0.2893535801405164" LOG_CI_START="-0.6033035173577332" LOG_EFFECT_SIZE="-0.15697496860860843" MODIFIED="2012-01-31 00:00:02 +0000" MODIFIED_BY="[Empty name]" ORDER="189" O_E="0.0" SE="0.5243511977943688" STUDY_ID="STD-Von-Roenn-1994" TOTAL_1="75" TOTAL_2="19" VAR="0.2749441786283892" WEIGHT="14.097133783287575"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.003302739116882978" CI_END="2.964148273499009" CI_START="0.3899647969280112" DF="1" EFFECT_SIZE="1.075134168157424" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="4" I2="0.0" ID="CMP-004.25.02" LOG_CI_END="0.4718999242573001" LOG_CI_START="-0.4089745960246676" LOG_EFFECT_SIZE="0.03146266411631624" MODIFIED="2013-01-31 09:50:43 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9541712646134279" P_Z="0.8886519678862507" STUDIES="2" TAU2="0.0" TOTAL_1="177" TOTAL_2="39" WEIGHT="14.029318026072517" Z="0.14001015378653797">
<NAME>Low doses (&lt; 800 mg/d)</NAME>
<DICH_DATA CI_END="14.903914722906746" CI_START="0.06709646549862758" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1733003569528007" LOG_CI_START="-1.1733003569528007" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-01-25 16:42:27 +0000" MODIFIED_BY="[Empty name]" ORDER="137" O_E="0.0" SE="1.378404875209022" STUDY_ID="STD-Herrejon-2011" TOTAL_1="20" TOTAL_2="20" VAR="1.9" WEIGHT="2.20855095938172"/>
<DICH_DATA CI_END="3.2514045627589683" CI_START="0.36485634659937954" EFFECT_SIZE="1.089171974522293" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="3" LOG_CI_END="0.5120710108503164" LOG_CI_START="-0.4378780948844762" LOG_EFFECT_SIZE="0.03709645798292009" MODIFIED="2012-03-15 19:46:21 +0000" MODIFIED_BY="[Empty name]" ORDER="190" O_E="0.0" SE="0.5580048070325286" STUDY_ID="STD-Von-Roenn-1994" TOTAL_1="157" TOTAL_2="19" VAR="0.3113693646714096" WEIGHT="11.820767066690797"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="40.44343256901176" CI_START="0.5649173685026102" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="4.779874213836478" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-004.26" LOG_CI_END="1.6068480085044354" LOG_CI_START="-0.24801507258375577" LOG_EFFECT_SIZE="0.6794164679603398" METHOD="MH" MODIFIED="2013-02-08 09:23:34 +0000" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="1.0" P_Q="1.0" P_Z="0.1510514026606233" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="159" TOTAL_2="152" WEIGHT="100.0" Z="1.4358276050482932">
<NAME>Inappropriate behaviour</NAME>
<GROUP_LABEL_1>Megestrol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours megestrol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="40.44343256901176" CI_START="0.5649173685026102" DF="0" EFFECT_SIZE="4.779874213836478" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" I2="0.0" ID="CMP-004.26.01" LOG_CI_END="1.6068480085044354" LOG_CI_START="-0.24801507258375577" LOG_EFFECT_SIZE="0.6794164679603398" MODIFIED="2013-01-31 09:51:03 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.1510514026606233" STUDIES="1" TAU2="0.0" TOTAL_1="159" TOTAL_2="152" WEIGHT="100.0" Z="1.4358276050482932">
<NAME>High doses (=&gt; 800 mg/d)</NAME>
<DICH_DATA CI_END="40.44343256901176" CI_START="0.5649173685026102" EFFECT_SIZE="4.779874213836478" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.6068480085044354" LOG_CI_START="-0.24801507258375577" LOG_EFFECT_SIZE="0.6794164679603398" MODIFIED="2012-02-01 17:34:40 +0000" MODIFIED_BY="[Empty name]" ORDER="211" O_E="0.0" SE="1.0895557555515358" STUDY_ID="STD-Jatoi-2002" TOTAL_1="159" TOTAL_2="152" VAR="1.1871317444554783" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.26.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-01-31 09:51:08 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Low doses (&lt; 800 mg/d)</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.28909272913028533" CI_END="15.765332065582541" CI_START="0.8721032413326519" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="3.707964022894522" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-004.27" LOG_CI_END="1.1977031227357675" LOG_CI_START="-0.05943209937131472" LOG_EFFECT_SIZE="0.5691355116822264" METHOD="MH" MODIFIED="2013-02-08 09:23:36 +0000" MODIFIED_BY="[Empty name]" NO="27" P_CHI2="0.8654147980863283" P_Q="0.7427647311174068" P_Z="0.0759563282754027" Q="0.1077115522945997" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="327" TOTAL_2="165" WEIGHT="100.0" Z="1.7746461726691203">
<NAME>Insomnia</NAME>
<GROUP_LABEL_1>Megestrol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours megestrol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.2056676437689181" CI_END="35.30605237616348" CI_START="0.5760946461735936" DF="1" EFFECT_SIZE="4.509947643979058" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" I2="0.0" ID="CMP-004.27.01" LOG_CI_END="1.5478491611458824" LOG_CI_START="-0.23950616078817466" LOG_EFFECT_SIZE="0.6541715001788538" MODIFIED="2013-01-31 09:51:16 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6501844739178435" P_Z="0.15137476071772016" STUDIES="2" TAU2="0.0" TOTAL_1="317" TOTAL_2="158" WEIGHT="53.098937040065415" Z="1.434692435610064">
<NAME>High doses (=&gt; 800 mg/d)</NAME>
<DICH_DATA CI_END="113.94265815026971" CI_START="0.3708005472742256" EFFECT_SIZE="6.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.0566863468261944" LOG_CI_START="-0.4308596335404831" LOG_EFFECT_SIZE="0.8129133566428556" MODIFIED="2012-03-15 19:47:47 +0000" MODIFIED_BY="[Empty name]" ORDER="461" O_E="0.0" SE="1.4611968224185794" STUDY_ID="STD-Loprinzi-1999a" TOTAL_1="159" TOTAL_2="79" VAR="2.1350961538461535" WEIGHT="26.5772690106296"/>
<DICH_DATA CI_END="51.780543992275085" CI_START="0.12222474090613596" EFFECT_SIZE="2.5157232704402515" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7141666087022187" LOG_CI_START="-0.9128408746871967" LOG_EFFECT_SIZE="0.4006628670075109" MODIFIED="2012-03-15 19:47:50 +0000" MODIFIED_BY="[Empty name]" ORDER="462" O_E="0.0" SE="1.5431171996397095" STUDY_ID="STD-Loprinzi-1999b" TOTAL_1="158" TOTAL_2="79" VAR="2.381210691823899" WEIGHT="26.521668029435816"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="20.016777917809875" CI_START="0.3916714284482508" DF="0" EFFECT_SIZE="2.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" ID="CMP-004.27.02" LOG_CI_END="1.3013941707889545" LOG_CI_START="-0.40707810810451606" LOG_EFFECT_SIZE="0.4471580313422192" MODIFIED="2013-01-31 09:51:21 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.3049096105552892" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="7" WEIGHT="46.90106295993459" Z="1.0259617877981735">
<NAME>Low doses (&lt; 800 mg/d)</NAME>
<DICH_DATA CI_END="20.016777917809875" CI_START="0.3916714284482508" EFFECT_SIZE="2.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.3013941707889545" LOG_CI_START="-0.40707810810451606" LOG_EFFECT_SIZE="0.4471580313422192" MODIFIED="2012-02-06 00:42:17 +0000" MODIFIED_BY="[Empty name]" ORDER="239" O_E="0.0" SE="1.003565073696199" STUDY_ID="STD-Eubanks-2002" TOTAL_1="10" TOTAL_2="7" VAR="1.0071428571428571" WEIGHT="46.90106295993459"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.7492204026535152" CI_START="0.6172665433902699" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0391030899644518" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="23" I2="0.0" I2_Q="100.0" ID="CMP-004.28" LOG_CI_END="0.24284453425031902" LOG_CI_START="-0.20952726169278746" LOG_EFFECT_SIZE="0.01665863627876581" METHOD="MH" MODIFIED="2013-02-08 09:23:37 +0000" MODIFIED_BY="[Empty name]" NO="28" P_CHI2="1.0" P_Q="0.0" P_Z="0.8852227263095717" Q="6.81889887814581E-34" RANDOM="NO" SCALE="481.97" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="159" TOTAL_2="152" WEIGHT="100.0" Z="0.14435173647315397">
<NAME>Loss of co-ordination</NAME>
<GROUP_LABEL_1>Megestrol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours megestrol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7492204026535152" CI_START="0.6172665433902699" DF="0" EFFECT_SIZE="1.0391030899644518" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="23" I2="0.0" ID="CMP-004.28.01" LOG_CI_END="0.24284453425031902" LOG_CI_START="-0.20952726169278746" LOG_EFFECT_SIZE="0.01665863627876581" MODIFIED="2013-01-31 09:51:37 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.8852227263095717" STUDIES="1" TAU2="0.0" TOTAL_1="159" TOTAL_2="152" WEIGHT="100.0" Z="0.14435173647315397">
<NAME>High doses (=&gt; 800 mg/d)</NAME>
<DICH_DATA CI_END="1.7492204026535154" CI_START="0.6172665433902699" EFFECT_SIZE="1.0391030899644518" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="23" LOG_CI_END="0.24284453425031904" LOG_CI_START="-0.20952726169278746" LOG_EFFECT_SIZE="0.01665863627876581" MODIFIED="2012-03-15 19:48:28 +0000" MODIFIED_BY="[Empty name]" ORDER="211" O_E="0.0" SE="0.26572543221348527" STUDY_ID="STD-Jatoi-2002" TOTAL_1="159" TOTAL_2="152" VAR="0.07061000532504355" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.28.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-01-31 09:51:42 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Low doses (&lt; 800 mg/d)</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.813330621787756" CI_END="0.7410002135771014" CI_START="0.44738172903481815" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5757690133771469" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="147" I2="0.0" I2_Q="14.718752466829184" ID="CMP-004.29" LOG_CI_END="-0.13018166684477" LOG_CI_START="-0.34932175636229185" LOG_EFFECT_SIZE="-0.2397517116035309" METHOD="MH" MODIFIED="2013-02-08 09:23:43 +0000" MODIFIED_BY="[Empty name]" NO="29" P_CHI2="0.5449805514626208" P_Q="0.278869607890431" P_Z="1.7978344768291478E-5" Q="1.1725907264795137" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="776" TOTAL_2="869" WEIGHT="100.0" Z="4.288623966608194">
<NAME>Nausea/vomiting</NAME>
<GROUP_LABEL_1>Megestrol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours megestrol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.045520473151802" CI_END="0.7181333381201138" CI_START="0.36706611612792495" DF="5" EFFECT_SIZE="0.5134222582687004" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="98" I2="29.032922137500254" ID="CMP-004.29.01" LOG_CI_END="-0.14379491142138062" LOG_CI_START="-0.4352557033681035" LOG_EFFECT_SIZE="-0.2895253073947421" MODIFIED="2013-01-31 09:51:49 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.21727693818188742" P_Z="9.864648338209797E-5" STUDIES="6" TAU2="0.0" TOTAL_1="428" TOTAL_2="569" WEIGHT="62.654356099254365" Z="3.8938971606878123">
<NAME>High doses (=&gt; 800 mg/d)</NAME>
<DICH_DATA CI_END="43.28468102978302" CI_START="0.08010457163717327" EFFECT_SIZE="1.8620689655172413" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6363342214948577" LOG_CI_START="-1.096342697646833" LOG_EFFECT_SIZE="0.2699957619240124" MODIFIED="2012-03-15 19:48:49 +0000" MODIFIED_BY="[Empty name]" ORDER="141" O_E="0.0" SE="1.605187949272739" STUDY_ID="STD-Casado-2008" TOTAL_1="28" TOTAL_2="17" VAR="2.5766283524904217" WEIGHT="0.4506928992691982"/>
<DICH_DATA CI_END="1.4531858332315526" CI_START="0.3677567339012895" EFFECT_SIZE="0.731039585645579" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="17" LOG_CI_END="0.16232115537609346" LOG_CI_START="-0.4344393662703257" LOG_EFFECT_SIZE="-0.13605910544711608" MODIFIED="2012-02-01 17:32:11 +0000" MODIFIED_BY="[Empty name]" ORDER="215" O_E="0.0" SE="0.3505400844273305" STUDY_ID="STD-Jatoi-2002" TOTAL_1="159" TOTAL_2="152" VAR="0.12287835079031997" WEIGHT="12.696856994358178"/>
<DICH_DATA CI_END="0.5462289820329627" CI_START="0.1933712847071633" EFFECT_SIZE="0.325" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="40" LOG_CI_END="-0.26262526061688585" LOG_CI_START="-0.7136080174253654" LOG_EFFECT_SIZE="-0.4881166390211256" MODIFIED="2012-02-16 22:52:14 +0000" MODIFIED_BY="[Empty name]" ORDER="247" O_E="0.0" SE="0.26490950374995076" STUDY_ID="STD-Loprinzi-1990b" TOTAL_1="63" TOTAL_2="63" VAR="0.07017704517704518" WEIGHT="29.21733278021009"/>
<DICH_DATA CI_END="1.443388783423768" CI_START="0.2525801689593593" EFFECT_SIZE="0.6037974683544304" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="20" LOG_CI_END="0.15938332607184824" LOG_CI_START="-0.5976007505725032" LOG_EFFECT_SIZE="-0.21910871225032752" MODIFIED="2012-03-15 19:49:36 +0000" MODIFIED_BY="[Empty name]" ORDER="274" O_E="0.0" SE="0.4446561937525044" STUDY_ID="STD-Loprinzi-1999a" TOTAL_1="79" TOTAL_2="159" VAR="0.19771913064246477" WEIGHT="9.698190292590745"/>
<DICH_DATA CI_END="1.2155883682440471" CI_START="0.18654124664097446" EFFECT_SIZE="0.47619047619047616" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="21" LOG_CI_END="0.08478653573861102" LOG_CI_START="-0.7292251252064496" LOG_EFFECT_SIZE="-0.3222192947339193" MODIFIED="2012-03-15 19:49:46 +0000" MODIFIED_BY="[Empty name]" ORDER="275" O_E="0.0" SE="0.47815447906183595" STUDY_ID="STD-Loprinzi-1999b" TOTAL_1="79" TOTAL_2="158" VAR="0.2286317058468957" WEIGHT="10.226066473073532"/>
<DICH_DATA CI_END="97.99788802329087" CI_START="0.2551075385834674" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.991216716205615" LOG_CI_START="-0.5932767075335774" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2012-01-29 17:48:02 +0000" MODIFIED_BY="[Empty name]" ORDER="339" O_E="0.0" SE="1.5181442305531794" STUDY_ID="STD-Mwamburi-2004" TOTAL_1="20" TOTAL_2="20" VAR="2.304761904761905" WEIGHT="0.3652166597526261"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.228679252507782" CI_END="0.9983712736079979" CI_START="0.4636550279882051" DF="6" EFFECT_SIZE="0.6803674454346976" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="49" I2="0.0" ID="CMP-004.29.02" LOG_CI_END="-7.079235480827362E-4" LOG_CI_START="-0.33380502626019504" LOG_EFFECT_SIZE="-0.16725647490413892" MODIFIED="2013-01-31 09:51:55 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8975116537795159" P_Z="0.049034114520865806" STUDIES="8" TAU2="0.0" TOTAL_1="348" TOTAL_2="300" WEIGHT="37.34564390074564" Z="1.9682949165520878">
<NAME>Low doses (&lt; 800 mg/d)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-04-13 17:47:36 +0100" MODIFIED_BY="[Empty name]" ORDER="142" O_E="0.0" SE="0.0" STUDY_ID="STD-Casado-2008" TOTAL_1="32" TOTAL_2="17" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.634450118448915" CI_START="0.008030907340103696" EFFECT_SIZE="0.14545454545454545" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.4206899799110945" LOG_CI_START="-2.095235384915695" LOG_EFFECT_SIZE="-0.8372727025023002" MODIFIED="2012-02-06 00:39:16 +0000" MODIFIED_BY="[Empty name]" ORDER="235" O_E="0.0" SE="1.4778670133306682" STUDY_ID="STD-Eubanks-2002" TOTAL_1="10" TOTAL_2="7" VAR="2.184090909090909" WEIGHT="2.1144122406730985"/>
<DICH_DATA CI_END="3.72616335125094" CI_START="0.11170554033573438" EFFECT_SIZE="0.6451612903225806" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5712618900105318" LOG_CI_START="-0.951925286351115" LOG_EFFECT_SIZE="-0.1903316981702915" MODIFIED="2012-03-15 19:49:59 +0000" MODIFIED_BY="[Empty name]" ORDER="141" O_E="0.0" SE="0.8947276872929563" STUDY_ID="STD-Gebbia-1996" TOTAL_1="62" TOTAL_2="60" VAR="0.800537634408602" WEIGHT="2.227222908655359"/>
<DICH_DATA CI_END="1.0189323097114102" CI_START="0.4424399169934024" EFFECT_SIZE="0.6714285714285714" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="42" LOG_CI_END="0.008145333667596502" LOG_CI_START="-0.3541456978246753" LOG_EFFECT_SIZE="-0.1730001820785394" MODIFIED="2012-02-01 18:01:28 +0000" MODIFIED_BY="[Empty name]" ORDER="211" O_E="0.0" SE="0.21281154526808949" STUDY_ID="STD-Jatoi-2004" TOTAL_1="140" TOTAL_2="141" VAR="0.045288753799392095" WEIGHT="30.569024332319454"/>
<DICH_DATA CI_END="13.360609146112969" CI_START="0.06062597828749859" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1258262592446688" LOG_CI_START="-1.217341240366019" LOG_EFFECT_SIZE="-0.045757490560675115" MODIFIED="2012-01-29 11:18:55 +0000" MODIFIED_BY="[Empty name]" ORDER="163" O_E="0.0" SE="1.3763881881375053" STUDY_ID="STD-McMillan-1994" TOTAL_1="20" TOTAL_2="18" VAR="1.8944444444444444" WEIGHT="0.7688771784265813"/>
<DICH_DATA CI_END="32.36010399225211" CI_START="0.059244548898008155" EFFECT_SIZE="1.3846153846153846" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5100099085888343" LOG_CI_START="-1.2273516029958957" LOG_EFFECT_SIZE="0.1413291527964693" MODIFIED="2012-02-13 17:09:32 +0000" MODIFIED_BY="[Empty name]" ORDER="222" O_E="0.0" SE="1.607939702062887" STUDY_ID="STD-Schmoll-1991" TOTAL_1="38" TOTAL_2="17" VAR="2.5854700854700856" WEIGHT="0.49977016597727786"/>
<DICH_DATA CI_END="12.580511634505648" CI_START="0.05390883230705526" EFFECT_SIZE="0.8235294117647058" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0996983037105368" LOG_CI_START="-1.2683400751106084" LOG_EFFECT_SIZE="-0.08432088570003593" MODIFIED="2012-02-09 15:44:18 +0000" MODIFIED_BY="[Empty name]" ORDER="225" O_E="0.0" SE="1.3909974656985655" STUDY_ID="STD-Schmoll-1992" TOTAL_1="34" TOTAL_2="28" VAR="1.934873949579832" WEIGHT="0.8011204149412443"/>
<DICH_DATA CI_END="67.05568402675195" CI_START="0.13421680996363317" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8264355970545303" LOG_CI_START="-0.8721930876152056" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2012-03-15 19:50:43 +0000" MODIFIED_BY="[Empty name]" ORDER="463" O_E="0.0" SE="1.585187847802434" STUDY_ID="STD-Timpone-1997" TOTAL_1="12" TOTAL_2="12" VAR="2.5128205128205123" WEIGHT="0.3652166597526261"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="14.072922267905014" CI_START="0.05970883387128004" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-004.30" LOG_CI_END="1.1483842888383442" LOG_CI_START="-1.2239614106171437" LOG_EFFECT_SIZE="-0.0377885608893998" METHOD="MH" MODIFIED="2013-02-08 09:23:44 +0000" MODIFIED_BY="[Empty name]" NO="30" P_CHI2="1.0" P_Q="1.0" P_Z="0.950212719875196" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="36" TOTAL_2="33" WEIGHT="100.00000000000001" Z="0.06243965066964909">
<NAME>Neoplasma</NAME>
<GROUP_LABEL_1>Megestrol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours megestrol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="14.072922267905014" CI_START="0.05970883387128004" DF="0" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-004.30.01" LOG_CI_END="1.1483842888383442" LOG_CI_START="-1.2239614106171437" LOG_EFFECT_SIZE="-0.0377885608893998" MODIFIED="2013-01-31 09:52:05 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.950212719875196" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="33" WEIGHT="100.00000000000001" Z="0.06243965066964909">
<NAME>High doses (=&gt; 800 mg/d)</NAME>
<DICH_DATA CI_END="14.072922267905014" CI_START="0.05970883387128004" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1483842888383442" LOG_CI_START="-1.2239614106171437" LOG_EFFECT_SIZE="-0.0377885608893998" MODIFIED="2012-02-08 20:14:55 +0000" MODIFIED_BY="[Empty name]" ORDER="190" O_E="0.0" SE="1.3935276071607594" STUDY_ID="STD-Yeh-2000" TOTAL_1="36" TOTAL_2="33" VAR="1.941919191919192" WEIGHT="100.00000000000001">
<FOOTNOTE>A new colon cancer in MA Group and a new prostate cancer in Placebo group</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.30.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-01-31 09:52:10 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Low doses (&lt; 800 mg/d)</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="13.059187031600048" CI_END="1.7213203443091065" CI_START="1.0741890275382053" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3597880080126932" ESTIMABLE="YES" EVENTS_1="149" EVENTS_2="102" I2="0.45322141000684246" I2_Q="0.0" ID="CMP-004.31" LOG_CI_END="0.2358617017158334" LOG_CI_START="0.03108071189728391" LOG_EFFECT_SIZE="0.1334712068065587" METHOD="MH" MODIFIED="2013-02-08 09:23:44 +0000" MODIFIED_BY="[Empty name]" NO="31" P_CHI2="0.44325041888818395" P_Q="0.8972445930256706" P_Z="0.010621448554810864" Q="0.016677884838350247" RANDOM="NO" SCALE="909.59" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1201" TOTAL_2="981" WEIGHT="100.00000000000003" Z="2.554912529192748">
<NAME>Oedema</NAME>
<GROUP_LABEL_1>Megestrol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours megestrol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="10.351716459687442" CI_END="1.8078674593533248" CI_START="1.0417631876000168" DF="7" EFFECT_SIZE="1.3723591975916012" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="81" I2="32.37836423302346" ID="CMP-004.31.01" LOG_CI_END="0.25716658776465195" LOG_CI_START="0.017769006864536138" LOG_EFFECT_SIZE="0.13746779731459405" MODIFIED="2013-01-31 09:47:34 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.16950267639585725" P_Z="0.024390853304415986" STUDIES="8" TAU2="0.0" TOTAL_1="604" TOTAL_2="681" WEIGHT="73.40864225964319" Z="2.2509160765753244">
<NAME>High doses (=&gt; 800 mg/d)</NAME>
<DICH_DATA CI_END="2.119453164930638" CI_START="0.5111217570160983" EFFECT_SIZE="1.0408163265306123" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.3262238240951255" LOG_CI_START="-0.29147563195628007" LOG_EFFECT_SIZE="0.017374096069422723" MODIFIED="2012-03-15 19:40:59 +0000" MODIFIED_BY="[Empty name]" ORDER="149" O_E="0.0" SE="0.3628397181462164" STUDY_ID="STD-Casado-2008" TOTAL_1="28" TOTAL_2="17" VAR="0.13165266106442575" WEIGHT="8.824689768680052"/>
<DICH_DATA CI_END="2.8432163806372266" CI_START="0.9353651130956683" EFFECT_SIZE="1.6307806141324455" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="17" LOG_CI_END="0.4538099125714769" LOG_CI_START="-0.029018832281470428" LOG_EFFECT_SIZE="0.21239554014500323" MODIFIED="2012-02-01 17:30:27 +0000" MODIFIED_BY="[Empty name]" ORDER="213" O_E="0.0" SE="0.28361599476745436" STUDY_ID="STD-Jatoi-2002" TOTAL_1="159" TOTAL_2="152" VAR="0.08043803248793269" WEIGHT="17.609277839973064"/>
<DICH_DATA CI_END="4.792262977570249" CI_START="1.0563902740092879" EFFECT_SIZE="2.25" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="8" LOG_CI_END="0.6805406421387491" LOG_CI_START="0.02382439408397598" LOG_EFFECT_SIZE="0.3521825181113625" MODIFIED="2012-02-16 22:53:12 +0000" MODIFIED_BY="[Empty name]" ORDER="250" O_E="0.0" SE="0.3857583749052298" STUDY_ID="STD-Loprinzi-1990b" TOTAL_1="63" TOTAL_2="63" VAR="0.1488095238095238" WEIGHT="8.104306930420456"/>
<DICH_DATA CI_END="1.666271152948541" CI_START="0.4220577767556478" EFFECT_SIZE="0.8386075949367089" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="24" LOG_CI_END="0.22174567573055243" LOG_CI_START="-0.37462809309374434" LOG_EFFECT_SIZE="-0.07644120868159596" MODIFIED="2012-02-19 11:50:26 +0000" MODIFIED_BY="[Empty name]" ORDER="268" O_E="0.0" SE="0.3503129039051584" STUDY_ID="STD-Loprinzi-1999a" TOTAL_1="79" TOTAL_2="159" VAR="0.12271913064246476" WEIGHT="16.140510441257547">
<FOOTNOTE>We have split events and total patients</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="3.0995830674633513" CI_START="0.6185218210275557" EFFECT_SIZE="1.3846153846153846" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" LOG_CI_END="0.4913032797447138" LOG_CI_START="-0.20864497415177521" LOG_EFFECT_SIZE="0.1413291527964693" MODIFIED="2012-02-19 11:50:31 +0000" MODIFIED_BY="[Empty name]" ORDER="269" O_E="0.0" SE="0.411153069138534" STUDY_ID="STD-Loprinzi-1999b" TOTAL_1="79" TOTAL_2="158" VAR="0.16904684626203612" WEIGHT="8.779665841288827">
<FOOTNOTE>We have split events and total patients</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.8787678644278736" CI_START="0.41152729900149687" EFFECT_SIZE="1.08843537414966" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.4592066460303423" LOG_CI_START="-0.3856013502148449" LOG_EFFECT_SIZE="0.036802647907748724" MODIFIED="2012-01-28 18:09:08 +0000" MODIFIED_BY="[Empty name]" ORDER="458" O_E="0.0" SE="0.4962443988614486" STUDY_ID="STD-Tchekmedyian-1992" TOTAL_1="49" TOTAL_2="40" VAR="0.2462585034013605" WEIGHT="6.692882689729253"/>
<DICH_DATA CI_END="1.3243001827858807" CI_START="0.01211541359957555" EFFECT_SIZE="0.12666666666666668" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.12198643899412455" LOG_CI_START="-1.916661755199829" LOG_EFFECT_SIZE="-0.8973376581028523" MODIFIED="2012-01-31 00:06:26 +0000" MODIFIED_BY="[Empty name]" ORDER="194" O_E="0.0" SE="1.1975120407408428" STUDY_ID="STD-Von-Roenn-1994" TOTAL_1="75" TOTAL_2="19" VAR="1.4340350877192982" WEIGHT="3.233101169050714"/>
<DICH_DATA CI_END="8.351880446698283" CI_START="0.930811726729654" EFFECT_SIZE="2.7881944444444446" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" LOG_CI_END="0.9217842689782489" LOG_CI_START="-0.031138153939348854" LOG_EFFECT_SIZE="0.4453230575194501" MODIFIED="2012-02-11 09:38:30 +0000" MODIFIED_BY="[Empty name]" ORDER="237" O_E="0.0" SE="0.559751348263866" STUDY_ID="STD-Weisberg-2002" TOTAL_1="72" TOTAL_2="73" VAR="0.31332157188321574" WEIGHT="4.024207579243261"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.6281374410110585" CI_END="2.088712705821512" CI_START="0.8406358988310039" DF="5" EFFECT_SIZE="1.3250837267350335" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="21" I2="0.0" ID="CMP-004.31.02" LOG_CI_END="0.3198787085983861" LOG_CI_START="-0.07539206765997479" LOG_EFFECT_SIZE="0.12224332046920565" MODIFIED="2013-01-31 09:47:40 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.757085670718358" P_Z="0.22539928152924127" STUDIES="6" TAU2="0.0" TOTAL_1="597" TOTAL_2="300" WEIGHT="26.59135774035684" Z="1.212295569827941">
<NAME>Low doses (&lt; 800 mg/d)</NAME>
<DICH_DATA CI_END="81.5401396001865" CI_START="0.2422498479473772" EFFECT_SIZE="4.444444444444445" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.911371450647396" LOG_CI_START="-0.6157364868701207" LOG_EFFECT_SIZE="0.6478174818886375" MODIFIED="2012-01-04 17:48:10 +0000" MODIFIED_BY="[Empty name]" ORDER="109" O_E="0.0" SE="1.4844357118838287" STUDY_ID="STD-Beller-1997" TOTAL_1="161" TOTAL_2="79" VAR="2.2035493827160493" WEIGHT="0.6781496501694804"/>
<DICH_DATA CI_END="2.1199434429073345" CI_START="0.5325171545387053" EFFECT_SIZE="1.0625" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="7" LOG_CI_END="0.3263242747207799" LOG_CI_START="-0.2736663972760816" LOG_EFFECT_SIZE="0.02632893872234915" MODIFIED="2012-03-15 19:41:28 +0000" MODIFIED_BY="[Empty name]" ORDER="150" O_E="0.0" SE="0.3524374907326824" STUDY_ID="STD-Casado-2008" TOTAL_1="32" TOTAL_2="17" VAR="0.12421218487394957" WEIGHT="9.262065063337664"/>
<DICH_DATA CI_END="8.454599871089044" CI_START="0.610515601735595" EFFECT_SIZE="2.2719298245614037" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.9270930586646785" LOG_CI_START="-0.2143032331751198" LOG_EFFECT_SIZE="0.35639491274477925" MODIFIED="2012-01-09 13:08:54 +0000" MODIFIED_BY="[Empty name]" ORDER="279" O_E="0.0" SE="0.6704618318294641" STUDY_ID="STD-Feliu-1992" TOTAL_1="76" TOTAL_2="74" VAR="0.44951906794012053" WEIGHT="3.0796366335597734"/>
<DICH_DATA CI_END="2.648913122911793" CI_START="0.5281432800850032" EFFECT_SIZE="1.1827956989247312" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.42306771486245204" LOG_CI_START="-0.2772482416538721" LOG_EFFECT_SIZE="0.07290973660428994" MODIFIED="2012-01-24 22:34:02 +0000" MODIFIED_BY="[Empty name]" ORDER="138" O_E="0.0" SE="0.4113690594775825" STUDY_ID="STD-Gebbia-1996" TOTAL_1="62" TOTAL_2="60" VAR="0.16922450309547082" WEIGHT="9.266809973718473"/>
<DICH_DATA CI_END="53.16111846915853" CI_START="0.12716060524425982" EFFECT_SIZE="2.6" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7255941095896155" LOG_CI_START="-0.8956474136479796" LOG_EFFECT_SIZE="0.414973347970818" MODIFIED="2012-01-29 19:38:51 +0000" MODIFIED_BY="[Empty name]" ORDER="349" O_E="0.0" SE="1.5397302461045672" STUDY_ID="STD-Vadell-1998" TOTAL_1="99" TOTAL_2="51" VAR="2.370769230769231" WEIGHT="0.6664726094095771"/>
<DICH_DATA CI_END="3.0322048441667704" CI_START="0.18036091740217222" EFFECT_SIZE="0.7395209580838323" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="2" LOG_CI_END="0.48175853722592" LOG_CI_START="-0.7438575643297174" LOG_EFFECT_SIZE="-0.13104951355189876" MODIFIED="2012-01-31 00:06:38 +0000" MODIFIED_BY="[Empty name]" ORDER="195" O_E="0.0" SE="0.7199329649513297" STUDY_ID="STD-Von-Roenn-1994" TOTAL_1="167" TOTAL_2="19" VAR="0.5183034740236125" WEIGHT="3.6382238101618714"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.95308850216311" CI_END="6.417615505060714" CI_START="0.5084874664608775" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8064542753383954" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-004.32" LOG_CI_END="0.8073736939011865" LOG_CI_START="-0.2937197473901323" LOG_EFFECT_SIZE="0.2568269732555271" METHOD="MH" MODIFIED="2013-01-31 10:07:21 +0000" MODIFIED_BY="[Empty name]" NO="32" P_CHI2="0.5822005171923146" P_Q="0.5642564299266208" P_Z="0.3605527994072063" Q="0.33238807696381195" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="149" TOTAL_2="147" WEIGHT="100.0" Z="0.914312262634006">
<NAME>Pneumonia</NAME>
<GROUP_LABEL_1>Megestrol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours megestrol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.5453630892412198" CI_END="6.538323625061589" CI_START="0.2764648061190432" DF="1" EFFECT_SIZE="1.3444762449914138" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="35.29028828487133" ID="CMP-004.32.01" LOG_CI_END="0.8154664128947104" LOG_CI_START="-0.5583601463886193" LOG_EFFECT_SIZE="0.12855313325304557" MODIFIED="2013-01-31 09:52:22 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.21382175234315604" P_Z="0.7137685121356404" STUDIES="2" TAU2="0.0" TOTAL_1="108" TOTAL_2="106" WEIGHT="72.09475074281941" Z="0.3667995928207778">
<NAME>High doses (=&gt; 800 mg/d)</NAME>
<DICH_DATA CI_END="103.7665745189153" CI_START="0.24757127174760102" EFFECT_SIZE="5.068493150684931" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0160574802968294" LOG_CI_START="-0.606299752403751" LOG_EFFECT_SIZE="0.7048788639465391" MODIFIED="2012-02-11 09:42:23 +0000" MODIFIED_BY="[Empty name]" ORDER="239" O_E="0.0" SE="1.5403856193659755" STUDY_ID="STD-Weisberg-2002" TOTAL_1="72" TOTAL_2="73" VAR="2.3727878563495" WEIGHT="13.85770881479036"/>
<DICH_DATA CI_END="4.822849873001808" CI_START="0.043557118711160366" EFFECT_SIZE="0.4583333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6833037432941281" LOG_CI_START="-1.36094085640089" LOG_EFFECT_SIZE="-0.338818556553381" MODIFIED="2012-01-30 00:24:02 +0000" MODIFIED_BY="[Empty name]" ORDER="188" O_E="0.0" SE="1.200799397034822" STUDY_ID="STD-Yeh-2000" TOTAL_1="36" TOTAL_2="33" VAR="1.441919191919192" WEIGHT="58.23704192802906"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="27.714000118626288" CI_START="0.3247456145441523" DF="1" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-004.32.02" LOG_CI_END="1.4426992144891333" LOG_CI_START="-0.48845670504980815" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-01-31 09:52:40 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.332805990380166" STUDIES="2" TAU2="0.0" TOTAL_1="41" TOTAL_2="41" WEIGHT="27.90524925718059" Z="0.9684774450862179">
<NAME>Low doses (&lt; 800 mg/d)</NAME>
<DICH_DATA CI_END="69.69936418378434" CI_START="0.12912599857107263" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8432288163658224" LOG_CI_START="-0.8889863069264972" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2012-01-09 11:48:28 +0000" MODIFIED_BY="[Empty name]" ORDER="135" O_E="0.0" SE="1.6049166881048922" STUDY_ID="STD-De-Conno-1998" TOTAL_1="21" TOTAL_2="21" VAR="2.5757575757575757" WEIGHT="13.952624628590295"/>
<DICH_DATA CI_END="69.5152908317231" CI_START="0.12946791838627933" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.84208034406391" LOG_CI_START="-0.8878378346245852" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2012-01-25 16:41:20 +0000" MODIFIED_BY="[Empty name]" ORDER="136" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Herrejon-2011" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="13.952624628590295"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9202254885620109" CI_END="6.810412573531982" CI_START="0.1384858314960757" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9711568606959976" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-004.33" LOG_CI_END="0.8331734221889837" LOG_CI_START="-0.8585946570532008" LOG_EFFECT_SIZE="-0.012710617432108565" METHOD="MH" MODIFIED="2013-01-31 10:07:29 +0000" MODIFIED_BY="[Empty name]" NO="33" P_CHI2="0.3374159140629339" P_Q="1.0" P_Z="0.9765046894285668" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="138" TOTAL_2="134" WEIGHT="100.00000000000001" Z="0.029451261900341665">
<NAME>Pruritus</NAME>
<GROUP_LABEL_1>Megestrol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours megestrol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.33.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-01-31 09:52:48 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>High doses (=&gt; 800 mg/d)</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9202254885620109" CI_END="6.810412573531982" CI_START="0.1384858314960757" DF="1" EFFECT_SIZE="0.9711568606959976" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-004.33.02" LOG_CI_END="0.8331734221889837" LOG_CI_START="-0.8585946570532008" LOG_EFFECT_SIZE="-0.012710617432108565" MODIFIED="2013-01-31 09:52:53 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.3374159140629339" P_Z="0.9765046894285668" STUDIES="2" TAU2="0.0" TOTAL_1="138" TOTAL_2="134" WEIGHT="100.00000000000001" Z="0.029451261900341665">
<NAME>Low doses (&lt; 800 mg/d)</NAME>
<DICH_DATA CI_END="70.6027000861454" CI_START="0.12093785892433276" EFFECT_SIZE="2.9220779220779223" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.848821310259886" LOG_CI_START="-0.9174377243821247" LOG_EFFECT_SIZE="0.46569179293888063" MODIFIED="2012-01-09 13:10:15 +0000" MODIFIED_BY="[Empty name]" ORDER="281" O_E="0.0" SE="1.6249142501517797" STUDY_ID="STD-Feliu-1992" TOTAL_1="76" TOTAL_2="74" VAR="2.64034632034632" WEIGHT="24.94513533284565"/>
<DICH_DATA CI_END="7.770326233092679" CI_START="0.013405925724725758" EFFECT_SIZE="0.32275132275132273" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8904392528109164" LOG_CI_START="-1.8727031911358705" LOG_EFFECT_SIZE="-0.49113196916247714" MODIFIED="2012-01-24 22:37:06 +0000" MODIFIED_BY="[Empty name]" ORDER="140" O_E="0.0" SE="1.6230835493500326" STUDY_ID="STD-Gebbia-1996" TOTAL_1="62" TOTAL_2="60" VAR="2.6344002081707" WEIGHT="75.05486466715436"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.473746856867961E-32" CI_END="6.548679574237269" CI_START="0.40214253672601225" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6228070175438598" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="100.0" I2_Q="0.0" ID="CMP-004.34" LOG_CI_END="0.8161537409945255" LOG_CI_START="-0.395619986861443" LOG_EFFECT_SIZE="0.21026687706654126" METHOD="MH" MODIFIED="2013-01-31 10:07:37 +0000" MODIFIED_BY="[Empty name]" NO="34" P_CHI2="0.0" P_Q="1.0" P_Z="0.4963869680829336" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="76" TOTAL_2="74" WEIGHT="99.99999999999999" Z="0.6801855770900425">
<NAME>Pyrosis</NAME>
<GROUP_LABEL_1>Megestrol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours megestrol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.34.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-01-31 09:53:02 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>High doses (=&gt; 800 mg/d)</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.473746856867961E-32" CI_END="6.548679574237269" CI_START="0.40214253672601225" DF="0" EFFECT_SIZE="1.6228070175438598" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="100.0" ID="CMP-004.34.02" LOG_CI_END="0.8161537409945255" LOG_CI_START="-0.395619986861443" LOG_EFFECT_SIZE="0.21026687706654126" MODIFIED="2013-01-31 09:53:10 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.4963869680829336" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="74" WEIGHT="99.99999999999999" Z="0.6801855770900425">
<NAME>Low doses (&lt; 800 mg/d)</NAME>
<DICH_DATA CI_END="6.548679574237269" CI_START="0.4021425367260122" EFFECT_SIZE="1.6228070175438596" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8161537409945255" LOG_CI_START="-0.39561998686144306" LOG_EFFECT_SIZE="0.21026687706654118" MODIFIED="2012-01-09 13:16:41 +0000" MODIFIED_BY="[Empty name]" ORDER="284" O_E="0.0" SE="0.7118018861192893" STUDY_ID="STD-Feliu-1992" TOTAL_1="76" TOTAL_2="74" VAR="0.5066619250829777" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="50.8254041631223" CI_START="0.11995244723422141" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.4691358024691357" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.35" LOG_CI_END="1.7060808408293269" LOG_CI_START="-0.9209908872586638" LOG_EFFECT_SIZE="0.3925449767853314" METHOD="MH" MODIFIED="2013-01-31 10:07:44 +0000" MODIFIED_BY="[Empty name]" NO="35" P_CHI2="1.0" P_Q="1.0" P_Z="0.5580586850123226" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="161" TOTAL_2="79" WEIGHT="100.0" Z="0.5857274535639112">
<NAME>Pulmonary embolism</NAME>
<GROUP_LABEL_1>Megestrol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours megestrol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.35.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-01-31 09:53:17 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>High doses (=&gt; 800 mg/d)</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="50.8254041631223" CI_START="0.11995244723422141" DF="0" EFFECT_SIZE="2.4691358024691357" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-004.35.02" LOG_CI_END="1.7060808408293269" LOG_CI_START="-0.9209908872586638" LOG_EFFECT_SIZE="0.3925449767853314" MODIFIED="2013-01-31 09:53:23 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5580586850123226" STUDIES="1" TAU2="0.0" TOTAL_1="161" TOTAL_2="79" WEIGHT="100.0" Z="0.5857274535639112">
<NAME>Low doses (&lt; 800 mg/d)</NAME>
<DICH_DATA CI_END="50.82540416312226" CI_START="0.11995244723422141" EFFECT_SIZE="2.4691358024691357" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7060808408293264" LOG_CI_START="-0.9209908872586638" LOG_EFFECT_SIZE="0.3925449767853314" MODIFIED="2012-01-04 17:47:33 +0000" MODIFIED_BY="[Empty name]" ORDER="108" O_E="0.0" SE="1.5431549372936688" STUDY_ID="STD-Beller-1997" TOTAL_1="161" TOTAL_2="79" VAR="2.381327160493827" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.7443737981982546" CI_START="0.014347333174563614" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-004.36" LOG_CI_END="0.8889863069264973" LOG_CI_START="-1.8432288163658224" LOG_EFFECT_SIZE="-0.47712125471966244" METHOD="MH" MODIFIED="2013-01-31 10:07:51 +0000" MODIFIED_BY="[Empty name]" NO="36" P_CHI2="1.0" P_Q="1.0" P_Z="0.49364108067680157" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="21" TOTAL_2="21" WEIGHT="100.0" Z="0.6845291701498639">
<NAME>Respiratory failure</NAME>
<GROUP_LABEL_1>Megestrol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours megestrol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.36.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-01-31 09:53:30 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>High doses (=&gt; 800 mg/d)</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.7443737981982546" CI_START="0.014347333174563614" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-004.36.02" LOG_CI_END="0.8889863069264973" LOG_CI_START="-1.8432288163658224" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-01-31 09:53:35 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.49364108067680157" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="100.0" Z="0.6845291701498639">
<NAME>Low doses (&lt; 800 mg/d)</NAME>
<DICH_DATA CI_END="7.7443737981982546" CI_START="0.014347333174563614" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8889863069264973" LOG_CI_START="-1.8432288163658224" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2012-01-09 11:52:08 +0000" MODIFIED_BY="[Empty name]" ORDER="137" O_E="0.0" SE="1.6049166881048922" STUDY_ID="STD-De-Conno-1998" TOTAL_1="21" TOTAL_2="21" VAR="2.5757575757575757" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.800503372463156" CI_END="3.7566225614673043" CI_START="0.6033458479689592" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5055041098741027" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" I2="47.375392046981034" I2_Q="0.0" ID="CMP-004.37" LOG_CI_END="0.574797562455863" LOG_CI_START="-0.21943367159496188" LOG_EFFECT_SIZE="0.17768194543045052" METHOD="MH" MODIFIED="2013-01-31 10:08:03 +0000" MODIFIED_BY="[Empty name]" NO="37" P_CHI2="0.14953109645631601" P_Q="1.0" P_Z="0.38051425261416105" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="128" TOTAL_2="126" WEIGHT="100.0" Z="0.8769491775600677">
<NAME>Other adverse events</NAME>
<GROUP_LABEL_1>Megestrol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours megestrol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.800503372463156" CI_END="3.7566225614673043" CI_START="0.6033458479689592" DF="2" EFFECT_SIZE="1.5055041098741027" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" I2="47.375392046981034" ID="CMP-004.37.01" LOG_CI_END="0.574797562455863" LOG_CI_START="-0.21943367159496188" LOG_EFFECT_SIZE="0.17768194543045052" MODIFIED="2013-01-31 09:53:43 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.14953109645631601" P_Z="0.38051425261416105" STUDIES="3" TAU2="0.0" TOTAL_1="128" TOTAL_2="126" WEIGHT="100.0" Z="0.8769491775600677">
<NAME>High doses (=&gt; 800 mg/d)</NAME>
<DICH_DATA CI_END="127.32047017394626" CI_START="0.38485563187958544" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1048982337313515" LOG_CI_START="-0.4147021537028377" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2012-01-29 17:56:53 +0000" MODIFIED_BY="[Empty name]" ORDER="345" O_E="0.0" SE="1.4800257398019099" STUDY_ID="STD-Mwamburi-2004" TOTAL_1="20" TOTAL_2="20" VAR="2.1904761904761907" WEIGHT="7.035688273852877">
<FOOTNOTE>Bloated and swollen</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.754375871678735" CI_START="0.0076137468686924385" EFFECT_SIZE="0.14481409001956946" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4400232052954118" LOG_CI_START="-2.118401566102885" LOG_EFFECT_SIZE="-0.8391891804037366" MODIFIED="2012-02-11 09:49:17 +0000" MODIFIED_BY="[Empty name]" ORDER="242" O_E="0.0" SE="1.5028313751262268" STUDY_ID="STD-Weisberg-2002" TOTAL_1="72" TOTAL_2="73" VAR="2.2585021420637856" WEIGHT="48.91478514202476">
<FOOTNOTE>1 pneumoyhorax 1 metabolic disorder and 1 alcohol related problem in placebo group</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="7.596036818401551" CI_START="0.6022674439820632" EFFECT_SIZE="2.138888888888889" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.880587061118939" LOG_CI_START="-0.22021061230854985" LOG_EFFECT_SIZE="0.3301882244051946" MODIFIED="2012-01-30 00:35:42 +0000" MODIFIED_BY="[Empty name]" ORDER="191" O_E="0.0" SE="0.6466140024076714" STUDY_ID="STD-Yeh-2000" TOTAL_1="36" TOTAL_2="33" VAR="0.4181096681096681" WEIGHT="44.04952658412236">
<FOOTNOTE>2 Gastrointestinall problems (disphagia, gastritis), 1 worsening of dementia, 1 parkinson's disease, 1 progression of paget's disease, 1 depression, 1 hip fracture in MA group and 1 chest pain, 1 hypertension and 1 worsening of dementia in placebo group</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.37.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-01-31 09:53:47 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Low doses (&lt; 800 mg/d)</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.169831726198176" CI_END="3.3642345013480583" CI_START="0.21125549555887008" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8430379746835442" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" I2_Q="0.9653148852929107" ID="CMP-004.38" LOG_CI_END="0.5268862603398897" LOG_CI_START="-0.6751919845801705" LOG_EFFECT_SIZE="-0.0741528621201404" METHOD="MH" MODIFIED="2013-01-31 10:08:15 +0000" MODIFIED_BY="[Empty name]" NO="38" P_CHI2="0.5571529393308092" P_Q="0.3149636715310966" P_Z="0.8089278170295195" Q="1.0097472404155658" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="82" TOTAL_2="75" WEIGHT="100.0" Z="0.2418094491273398">
<NAME>Skin disorder (includes vesiculobullous rash)</NAME>
<GROUP_LABEL_1>Megestrol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours megestrol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.23177598124404733" CI_END="11.88485789624461" CI_START="0.21714073547440765" DF="1" EFFECT_SIZE="1.606451612903226" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-004.38.01" LOG_CI_END="1.074993993363671" LOG_CI_START="-0.6632586955127813" LOG_EFFECT_SIZE="0.2058676489254449" MODIFIED="2013-01-31 09:54:03 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6302101030480556" P_Z="0.6424675951905423" STUDIES="2" TAU2="0.0" TOTAL_1="72" TOTAL_2="68" WEIGHT="39.24050632911393" Z="0.46425146361961034">
<NAME>High doses (=&gt; 800 mg/d)</NAME>
<DICH_DATA CI_END="14.903914722906746" CI_START="0.06709646549862758" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1733003569528007" LOG_CI_START="-1.1733003569528007" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-01-29 17:49:04 +0000" MODIFIED_BY="[Empty name]" ORDER="340" O_E="0.0" SE="1.378404875209022" STUDY_ID="STD-Mwamburi-2004" TOTAL_1="20" TOTAL_2="20" VAR="1.9" WEIGHT="25.82278481012658"/>
<DICH_DATA CI_END="66.49261543937459" CI_START="0.11569364775432935" EFFECT_SIZE="2.7735849056603774" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8227734159495634" LOG_CI_START="-0.9366904856547894" LOG_EFFECT_SIZE="0.44304146514738707" MODIFIED="2012-03-15 19:52:15 +0000" MODIFIED_BY="[Empty name]" ORDER="464" O_E="0.0" SE="1.6209227553690084" STUDY_ID="STD-Oster-1994" TOTAL_1="52" TOTAL_2="48" VAR="2.6273905788730585" WEIGHT="13.417721518987342"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.1510514273033343" CI_START="0.03887591263619436" DF="0" EFFECT_SIZE="0.35" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-004.38.02" LOG_CI_END="0.49845549121328825" LOG_CI_START="-1.410319402512737" LOG_EFFECT_SIZE="-0.4559319556497244" MODIFIED="2013-01-31 09:54:09 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.3491094582311065" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="7" WEIGHT="60.75949367088607" Z="0.9363180702047068">
<NAME>Low doses (&lt; 800 mg/d)</NAME>
<DICH_DATA CI_END="3.1510514273033343" CI_START="0.03887591263619436" EFFECT_SIZE="0.35" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.49845549121328825" LOG_CI_START="-1.410319402512737" LOG_EFFECT_SIZE="-0.4559319556497244" MODIFIED="2012-02-06 00:39:55 +0000" MODIFIED_BY="[Empty name]" ORDER="236" O_E="0.0" SE="1.121223821162776" STUDY_ID="STD-Eubanks-2002" TOTAL_1="10" TOTAL_2="7" VAR="1.2571428571428571" WEIGHT="60.75949367088607"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.016196852378226812" CI_END="18.352150966703217" CI_START="0.53989041235755" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="3.147721454173067" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.39" LOG_CI_END="1.263686973123479" LOG_CI_START="-0.2676943848776781" LOG_EFFECT_SIZE="0.49799629412290036" METHOD="MH" MODIFIED="2013-01-31 10:08:25 +0000" MODIFIED_BY="[Empty name]" NO="39" P_CHI2="0.9919342778993725" P_Q="0.8990827809661879" P_Z="0.20240211178783796" Q="0.016083340874846072" RANDOM="NO" SCALE="976.6" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="57" TOTAL_2="52" WEIGHT="100.0" Z="1.2747377337664616">
<NAME>Sweating</NAME>
<GROUP_LABEL_1>Megestrol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours megestrol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.885472758238589E-5" CI_END="26.578905140086924" CI_START="0.3101001957827788" DF="1" EFFECT_SIZE="2.870909905871806" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-004.39.01" LOG_CI_END="1.4245370871630718" LOG_CI_START="-0.5084979595693371" LOG_EFFECT_SIZE="0.45801956379686737" MODIFIED="2013-01-31 09:54:18 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9929148635022859" P_Z="0.3529925550837171" STUDIES="2" TAU2="0.0" TOTAL_1="47" TOTAL_2="45" WEIGHT="63.83693262251137" Z="0.9288003864948808">
<NAME>High doses (=&gt; 800 mg/d)</NAME>
<DICH_DATA CI_END="65.33683949785127" CI_START="0.12362952338910503" EFFECT_SIZE="2.8421052631578947" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8151581227650624" LOG_CI_START="-0.9078778050247834" LOG_EFFECT_SIZE="0.45364015887013953" MODIFIED="2012-03-15 19:52:53 +0000" MODIFIED_BY="[Empty name]" ORDER="229" O_E="0.0" SE="1.5995247832289885" STUDY_ID="STD-Schmoll-1991" TOTAL_1="18" TOTAL_2="17" VAR="2.5584795321637426" WEIGHT="32.07584108912382"/>
<DICH_DATA CI_END="68.33069297388181" CI_START="0.12307792638974949" EFFECT_SIZE="2.9" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8346158251308082" LOG_CI_START="-0.9098198293328961" LOG_EFFECT_SIZE="0.4623979978989561" MODIFIED="2012-02-09 15:49:42 +0000" MODIFIED_BY="[Empty name]" ORDER="230" O_E="0.0" SE="1.6120950886075684" STUDY_ID="STD-Schmoll-1992" TOTAL_1="29" TOTAL_2="28" VAR="2.598850574712644" WEIGHT="31.761091533387546"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.2574063364805228E-32" CI_END="65.86125296122286" CI_START="0.20077268350259225" DF="0" EFFECT_SIZE="3.636363636363636" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="100.0" ID="CMP-004.39.02" LOG_CI_END="1.818629988583132" LOG_CI_START="-0.6972953762436576" LOG_EFFECT_SIZE="0.5606673061697373" MODIFIED="2013-01-31 09:54:22 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.3823657887871018" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="7" WEIGHT="36.16306737748863" Z="0.8735455691686866">
<NAME>Low doses (&lt; 800 mg/d)</NAME>
<DICH_DATA CI_END="65.86125296122286" CI_START="0.2007726835025923" EFFECT_SIZE="3.6363636363636362" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.818629988583132" LOG_CI_START="-0.6972953762436574" LOG_EFFECT_SIZE="0.5606673061697374" MODIFIED="2012-02-06 00:38:46 +0000" MODIFIED_BY="[Empty name]" ORDER="234" O_E="0.0" SE="1.4778670133306682" STUDY_ID="STD-Eubanks-2002" TOTAL_1="10" TOTAL_2="7" VAR="2.184090909090909" WEIGHT="36.16306737748863"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.139014903563041" CI_END="1.3867733377054297" CI_START="0.7303855682457918" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0064190142719351" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="60" I2="6.499015192997405" I2_Q="10.30185713046336" ID="CMP-004.40" LOG_CI_END="0.1420054832592952" LOG_CI_START="-0.13644781665275219" LOG_EFFECT_SIZE="0.002778833303271522" METHOD="MH" MODIFIED="2013-01-31 10:08:32 +0000" MODIFIED_BY="[Empty name]" NO="40" P_CHI2="0.3431777121994437" P_Q="0.2910300650385882" P_Z="0.9687954791149113" Q="1.1148502834160916" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="298" TOTAL_2="458" WEIGHT="100.0" Z="0.039119042188926936">
<NAME>Swelling legs or abdominal</NAME>
<GROUP_LABEL_1>Megestrol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours megestrol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.354523155387576" CI_END="1.681116606005727" CI_START="0.2335595316753549" DF="1" EFFECT_SIZE="0.6266105706021562" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="16" I2="26.173281274481766" ID="CMP-004.40.01" LOG_CI_END="0.22559783812031867" LOG_CI_START="-0.6316024042505715" LOG_EFFECT_SIZE="-0.20300228306512635" MODIFIED="2013-01-31 09:54:50 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2444890934658881" P_Z="0.3532427035461907" STUDIES="2" TAU2="0.0" TOTAL_1="158" TOTAL_2="317" WEIGHT="19.547574001492258" Z="0.9283178980131485">
<NAME>High doses (=&gt; 800 mg/d)</NAME>
<DICH_DATA CI_END="4.925030666471963" CI_START="0.29609674130405317" EFFECT_SIZE="1.2075949367088608" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.69240893904441" LOG_CI_START="-0.5285663722171026" LOG_EFFECT_SIZE="0.08192128341365369" MODIFIED="2012-03-15 19:53:31 +0000" MODIFIED_BY="[Empty name]" ORDER="270" O_E="0.0" SE="0.7172069417602784" STUDY_ID="STD-Loprinzi-1999a" TOTAL_1="79" TOTAL_2="159" VAR="0.5143857973091315" WEIGHT="6.090947986265666"/>
<DICH_DATA CI_END="1.6010054086096641" CI_START="0.08259272844899963" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="0.20439279908067653" LOG_CI_START="-1.083058186741202" LOG_EFFECT_SIZE="-0.43933269383026263" MODIFIED="2012-03-15 19:53:56 +0000" MODIFIED_BY="[Empty name]" ORDER="271" O_E="0.0" SE="0.7562550820569334" STUDY_ID="STD-Loprinzi-1999b" TOTAL_1="79" TOTAL_2="158" VAR="0.571921749136939" WEIGHT="13.456626015226593"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5368992074202648" CI_START="0.7854415812954655" DF="0" EFFECT_SIZE="1.0987012987012987" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="44" I2="0.0" ID="CMP-004.40.02" LOG_CI_END="0.18664538663016697" LOG_CI_START="-0.10488611089708365" LOG_EFFECT_SIZE="0.040879637866541675" MODIFIED="2013-01-31 09:54:55 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5825478159356381" STUDIES="1" TAU2="0.0" TOTAL_1="140" TOTAL_2="141" WEIGHT="80.45242599850774" Z="0.5496669732022498">
<NAME>Low doses (&lt; 800 mg/d)</NAME>
<DICH_DATA CI_END="1.5368992074202648" CI_START="0.7854415812954655" EFFECT_SIZE="1.0987012987012987" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="44" LOG_CI_END="0.18664538663016697" LOG_CI_START="-0.10488611089708365" LOG_EFFECT_SIZE="0.040879637866541675" MODIFIED="2012-02-01 18:06:55 +0000" MODIFIED_BY="[Empty name]" ORDER="216" O_E="0.0" SE="0.17124704475169383" STUDY_ID="STD-Jatoi-2004" TOTAL_1="140" TOTAL_2="141" VAR="0.029325550336188635" WEIGHT="80.45242599850774"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.1995702654966691" CI_END="5.6423326841847645" CI_START="0.2364782573585224" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1551142803173404" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-004.41" LOG_CI_END="0.7514586895198195" LOG_CI_START="-0.6262087836504839" LOG_EFFECT_SIZE="0.06262495293466777" METHOD="MH" MODIFIED="2013-01-31 10:08:41 +0000" MODIFIED_BY="[Empty name]" NO="41" P_CHI2="0.5489298145848954" P_Q="0.4606986888024809" P_Z="0.8585744826237874" Q="0.5441968545057174" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="109" TOTAL_2="74" WEIGHT="100.0" Z="0.17818908361537794">
<NAME>Stroke</NAME>
<GROUP_LABEL_1>Megestrol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours megestrol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.7084222818757797" CI_END="5.218645922468989" CI_START="0.09552640575461485" DF="1" EFFECT_SIZE="0.7060584167612756" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-004.41.01" LOG_CI_END="0.7175578316064789" LOG_CI_START="-1.0198765625693624" LOG_EFFECT_SIZE="-0.15115936548144165" MODIFIED="2013-01-31 09:55:04 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.39996853664590026" P_Z="0.7330738170022212" STUDIES="2" TAU2="0.0" TOTAL_1="77" TOTAL_2="57" WEIGHT="77.78286739705327" Z="0.34103953883114885">
<NAME>High doses (=&gt; 800 mg/d)</NAME>
<DICH_DATA CI_END="43.28468102978302" CI_START="0.08010457163717327" EFFECT_SIZE="1.8620689655172413" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6363342214948577" LOG_CI_START="-1.096342697646833" LOG_EFFECT_SIZE="0.2699957619240124" MODIFIED="2012-01-28 10:19:38 +0000" MODIFIED_BY="[Empty name]" ORDER="143" O_E="0.0" SE="1.605187949272739" STUDY_ID="STD-Casado-2008" TOTAL_1="28" TOTAL_2="17" VAR="2.5766283524904217" WEIGHT="21.185776350585567"/>
<DICH_DATA CI_END="6.532525082510129" CI_START="0.011436789016109412" EFFECT_SIZE="0.2733333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8150810859347369" LOG_CI_START="-1.9416958906066286" LOG_EFFECT_SIZE="-0.5633074023359458" MODIFIED="2012-01-28 18:19:02 +0000" MODIFIED_BY="[Empty name]" ORDER="462" O_E="0.0" SE="1.619344442286516" STUDY_ID="STD-Tchekmedyian-1992" TOTAL_1="49" TOTAL_2="40" VAR="2.6222764227642275" WEIGHT="56.597091046467696"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="53.777683313296116" CI_START="0.138310467663575" DF="0" EFFECT_SIZE="2.727272727272727" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-004.41.02" LOG_CI_END="1.7306020893353513" LOG_CI_START="-0.8591449502124765" LOG_EFFECT_SIZE="0.43572856956143735" MODIFIED="2013-01-31 09:55:08 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5095533254114084" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="17" WEIGHT="22.217132602946734" Z="0.6595333755258848">
<NAME>Low doses (&lt; 800 mg/d)</NAME>
<DICH_DATA CI_END="53.777683313296116" CI_START="0.138310467663575" EFFECT_SIZE="2.727272727272727" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7306020893353513" LOG_CI_START="-0.8591449502124765" LOG_EFFECT_SIZE="0.43572856956143735" MODIFIED="2012-01-28 10:19:44 +0000" MODIFIED_BY="[Empty name]" ORDER="144" O_E="0.0" SE="1.5212302304849894" STUDY_ID="STD-Casado-2008" TOTAL_1="32" TOTAL_2="17" VAR="2.3141414141414143" WEIGHT="22.217132602946734"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.380725818441791" CI_END="3.176803621249199" CI_START="1.0668139096973954" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8409395132718787" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-004.42" LOG_CI_END="0.5019903691098584" LOG_CI_START="0.02808866962136431" LOG_EFFECT_SIZE="0.2650395193656113" METHOD="MH" MODIFIED="2013-01-31 10:08:49 +0000" MODIFIED_BY="[Empty name]" NO="42" P_CHI2="0.9285418558557613" P_Q="0.5258602456400292" P_Z="0.028357679843260188" Q="0.40238475641347393" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="761" TOTAL_2="843" WEIGHT="100.0" Z="2.1923023825282426">
<NAME>Thromboembolic phenomena including thrombophlebitis</NAME>
<GROUP_LABEL_1>Megestrol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours megestrol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.420672699425859" CI_END="5.935992938236429" CI_START="0.9280329596365909" DF="4" EFFECT_SIZE="2.3470826774644" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" I2="0.0" ID="CMP-004.42.01" LOG_CI_END="0.7734933756121473" LOG_CI_START="-0.03243659928317936" LOG_EFFECT_SIZE="0.37052838816448397" MODIFIED="2013-01-31 09:55:18 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6588946975689345" P_Z="0.0715144147623838" STUDIES="6" TAU2="0.0" TOTAL_1="327" TOTAL_2="465" WEIGHT="34.5765704606" Z="1.80219701133808">
<NAME>High doses (=&gt; 800 mg/d)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-03-15 19:54:25 +0000" MODIFIED_BY="[Empty name]" ORDER="143" O_E="0.0" SE="0.0" STUDY_ID="STD-Casado-2008" TOTAL_1="28" TOTAL_2="17" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.030017184192781" CI_START="0.013836970527265503" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9047164746674874" LOG_CI_START="-1.8589589841068126" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2012-02-19 11:46:17 +0000" MODIFIED_BY="[Empty name]" ORDER="252" O_E="0.0" SE="1.6233966448981796" STUDY_ID="STD-Loprinzi-1990b" TOTAL_1="63" TOTAL_2="63" VAR="2.6354166666666665" WEIGHT="2.9403731490643246"/>
<DICH_DATA CI_END="21.507553852360854" CI_START="0.7533712424818613" EFFECT_SIZE="4.025316455696203" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.3325910189959207" LOG_CI_START="-0.12299096160793822" LOG_EFFECT_SIZE="0.6048000286939913" MODIFIED="2012-02-19 11:45:28 +0000" MODIFIED_BY="[Empty name]" ORDER="262" O_E="0.0" SE="0.8550160606537155" STUDY_ID="STD-Loprinzi-1999a" TOTAL_1="79" TOTAL_2="159" VAR="0.7310524639757982" WEIGHT="10.599934731250436"/>
<DICH_DATA CI_END="11.62563201676808" CI_START="0.6116752277084367" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="1.0654165722229592" LOG_CI_START="-0.213479107678397" LOG_EFFECT_SIZE="0.4259687322722811" MODIFIED="2012-02-19 11:45:33 +0000" MODIFIED_BY="[Empty name]" ORDER="263" O_E="0.0" SE="0.7512296530097713" STUDY_ID="STD-Loprinzi-1999b" TOTAL_1="79" TOTAL_2="158" VAR="0.5643459915611814" WEIGHT="13.731130404287068"/>
<DICH_DATA CI_END="14.696930580691841" CI_START="0.06342981197893298" EFFECT_SIZE="0.9655172413793104" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.167226642839416" LOG_CI_START="-1.1977065759528895" LOG_EFFECT_SIZE="-0.015239966556736846" MODIFIED="2012-02-09 15:46:42 +0000" MODIFIED_BY="[Empty name]" ORDER="228" O_E="0.0" SE="1.389173479326835" STUDY_ID="STD-Schmoll-1992" TOTAL_1="29" TOTAL_2="28" VAR="1.9298029556650245" WEIGHT="4.015492037938594"/>
<DICH_DATA CI_END="83.0247600695134" CI_START="0.20246972091127569" EFFECT_SIZE="4.1" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9192076292190898" LOG_CI_START="-0.6936399157796186" LOG_EFFECT_SIZE="0.6127838567197355" MODIFIED="2012-01-28 18:11:57 +0000" MODIFIED_BY="[Empty name]" ORDER="461" O_E="0.0" SE="1.5347995817361826" STUDY_ID="STD-Tchekmedyian-1992" TOTAL_1="49" TOTAL_2="40" VAR="2.355609756097561" WEIGHT="3.289640138059579"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.5939107287881402" CI_END="3.1786075921307075" CI_START="0.8247825414427714" DF="5" EFFECT_SIZE="1.6191541149893216" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="11" I2="0.0" ID="CMP-004.42.02" LOG_CI_END="0.5022369163729985" LOG_CI_START="-0.08366054054136007" LOG_EFFECT_SIZE="0.20928818791581918" MODIFIED="2013-01-31 09:55:26 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9019847857527188" P_Z="0.161442704802018" STUDIES="7" TAU2="0.0" TOTAL_1="434" TOTAL_2="378" WEIGHT="65.4234295394" Z="1.4002358462689681">
<NAME>Low doses (&lt; 800 mg/d)</NAME>
<DICH_DATA CI_END="69.87971393943685" CI_START="0.20862295471514214" EFFECT_SIZE="3.8181818181818183" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8443511184806365" LOG_CI_START="-0.6806379080012854" LOG_EFFECT_SIZE="0.5818566052396754" MODIFIED="2012-03-10 16:28:57 +0000" MODIFIED_BY="[Empty name]" ORDER="144" O_E="0.0" SE="1.4831910530527415" STUDY_ID="STD-Casado-2008" TOTAL_1="32" TOTAL_2="17" VAR="2.1998556998557" WEIGHT="3.5225530491711687"/>
<DICH_DATA CI_END="129.75780650166408" CI_START="0.3582644047330511" EFFECT_SIZE="6.818181818181818" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.113133495372975" LOG_CI_START="-0.44579633890602527" LOG_EFFECT_SIZE="0.8336685782334751" MODIFIED="2012-01-09 13:11:42 +0000" MODIFIED_BY="[Empty name]" ORDER="282" O_E="0.0" SE="1.5031280515624539" STUDY_ID="STD-Feliu-1992" TOTAL_1="76" TOTAL_2="74" VAR="2.2593939393939393" WEIGHT="3.4297287729035406"/>
<DICH_DATA CI_END="5.524267745677316" CI_START="0.3013851679121783" EFFECT_SIZE="1.2903225806451613" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7422747194453831" LOG_CI_START="-0.5208781244580037" LOG_EFFECT_SIZE="0.1106982974936897" MODIFIED="2012-01-24 22:36:16 +0000" MODIFIED_BY="[Empty name]" ORDER="139" O_E="0.0" SE="0.7419822332162692" STUDY_ID="STD-Gebbia-1996" TOTAL_1="62" TOTAL_2="60" VAR="0.550537634408602" WEIGHT="14.07552893561493">
<FOOTNOTE>Both arms were MA. First MA 160 mg and second MA 320 mg daily</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="3.3392773430618368" CI_START="0.5742950321317771" EFFECT_SIZE="1.3848214285714286" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.5236524908001913" LOG_CI_START="-0.2408649405133445" LOG_EFFECT_SIZE="0.14139377514342336" MODIFIED="2012-02-01 18:04:15 +0000" MODIFIED_BY="[Empty name]" ORDER="214" O_E="0.0" SE="0.4490813235758903" STUDY_ID="STD-Jatoi-2004" TOTAL_1="140" TOTAL_2="141" VAR="0.20167403518467347" WEIGHT="38.423926987762165"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-06-11 23:51:26 +0100" MODIFIED_BY="[Empty name]" ORDER="519" O_E="0.0" SE="0.0" STUDY_ID="STD-Madeddu-2012" TOTAL_1="29" TOTAL_2="31" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="59.29601510215695" CI_START="0.11151246650499884" EFFECT_SIZE="2.5714285714285716" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.773025508249681" LOG_CI_START="-0.9526765780715827" LOG_EFFECT_SIZE="0.41017446508904926" MODIFIED="2012-02-05 19:56:01 +0000" MODIFIED_BY="[Empty name]" ORDER="224" O_E="0.0" SE="1.601090897948041" STUDY_ID="STD-Schmoll-1991" TOTAL_1="20" TOTAL_2="17" VAR="2.5634920634920637" WEIGHT="3.022872008703319"/>
<DICH_DATA CI_END="36.917263636388" CI_START="0.06419704471381053" EFFECT_SIZE="1.5394736842105263" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.567229502980672" LOG_CI_START="-1.1924849640499313" LOG_EFFECT_SIZE="0.1873722694653703" MODIFIED="2012-01-31 00:01:48 +0000" MODIFIED_BY="[Empty name]" ORDER="191" O_E="0.0" SE="1.6210699387407068" STUDY_ID="STD-Von-Roenn-1994" TOTAL_1="75" TOTAL_2="38" VAR="2.627867746288799" WEIGHT="2.948819785244875"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="83.33450830148686" CI_START="0.21167701543497636" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="4.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.43" LOG_CI_END="1.9208248772954328" LOG_CI_START="-0.6743262964996318" LOG_EFFECT_SIZE="0.6232492903979004" METHOD="MH" MODIFIED="2013-01-31 10:08:58 +0000" MODIFIED_BY="[Empty name]" NO="43" P_CHI2="1.0" P_Q="1.0" P_Z="0.3464965672717294" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4" TOTAL_2="6" WEIGHT="100.0" Z="0.9414065545813125">
<NAME>Testicular shrinkage</NAME>
<GROUP_LABEL_1>Megestrol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours megestrol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.43.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-01-31 09:55:36 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>High doses (=&gt; 800 mg/d)</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="83.33450830148686" CI_START="0.21167701543497636" DF="0" EFFECT_SIZE="4.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-004.43.02" LOG_CI_END="1.9208248772954328" LOG_CI_START="-0.6743262964996318" LOG_EFFECT_SIZE="0.6232492903979004" MODIFIED="2013-01-31 09:56:10 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.3464965672717294" STUDIES="1" TAU2="0.0" TOTAL_1="4" TOTAL_2="6" WEIGHT="100.0" Z="0.9414065545813125">
<NAME>Low doses (&lt; 800 mg/d)</NAME>
<DICH_DATA CI_END="83.33450830148686" CI_START="0.21167701543497636" EFFECT_SIZE="4.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9208248772954328" LOG_CI_START="-0.6743262964996318" LOG_EFFECT_SIZE="0.6232492903979004" MODIFIED="2012-01-09 08:52:26 +0000" MODIFIED_BY="[Empty name]" ORDER="125" O_E="0.0" SE="1.5244046456927123" STUDY_ID="STD-Batterham-2001" TOTAL_1="4" TOTAL_2="6" VAR="2.3238095238095235" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.352115835620753" CI_END="1.0627069642425844" CI_START="0.8250864188095929" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="RR" EFFECT_SIZE="0.93638938661805" ESTIMABLE="YES" EVENTS_1="228" EVENTS_2="231" I2="0.0" I2_Q="0.0" ID="CMP-004.44" LOG_CI_END="0.02641352665218577" LOG_CI_START="-0.0835005614542234" LOG_EFFECT_SIZE="-0.028543517401018813" METHOD="MH" MODIFIED="2013-01-31 10:09:04 +0000" MODIFIED_BY="[Empty name]" NO="44" P_CHI2="0.6522048539649129" P_Q="0.6491429051632369" P_Z="0.3086953061704847" Q="0.20698243347433154" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="685" TOTAL_2="654" WEIGHT="100.0" Z="1.017963521544734">
<NAME>Withdrawals</NAME>
<GROUP_LABEL_1>Megestrol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours megestrol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.367590873857246" CI_END="1.0583447930499092" CI_START="0.7965247729265598" DF="5" EFFECT_SIZE="0.9181491414591019" ESTIMABLE="YES" EVENTS_1="163" EVENTS_2="168" I2="0.0" ID="CMP-004.44.01" LOG_CI_END="0.024627177457681518" LOG_CI_START="-0.09880071254583968" LOG_EFFECT_SIZE="-0.03708676754407907" MODIFIED="2013-01-31 09:56:30 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6435105874198246" P_Z="0.2388631608565358" STUDIES="6" TAU2="0.0" TOTAL_1="419" TOTAL_2="399" WEIGHT="72.58092378388072" Z="1.1778331248687848">
<NAME>High doses (=&gt; 800 mg/d)</NAME>
<DICH_DATA CI_END="1.065508238630954" CI_START="0.7969988834379971" EFFECT_SIZE="0.9215252988837894" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="111" LOG_CI_END="0.027556812077559126" LOG_CI_START="-0.09854228703181268" LOG_EFFECT_SIZE="-0.035492737477126744" MODIFIED="2012-03-15 19:55:58 +0000" MODIFIED_BY="[Empty name]" ORDER="465" O_E="0.0" SE="0.07407123501745257" STUDY_ID="STD-Jatoi-2002" TOTAL_1="159" TOTAL_2="152" VAR="0.005486547857010691" WEIGHT="47.78831399993671"/>
<DICH_DATA CI_END="2.325884247913399" CI_START="0.4172056375398233" EFFECT_SIZE="0.9850746268656716" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.3665880974331164" LOG_CI_START="-0.37964983175103195" LOG_EFFECT_SIZE="-0.00653086715895778" MODIFIED="2012-02-16 18:12:44 +0000" MODIFIED_BY="[Empty name]" ORDER="505" O_E="0.0" SE="0.43834385354009325" STUDY_ID="STD-Loprinzi-1990b" TOTAL_1="67" TOTAL_2="66" VAR="0.19214533393637873" WEIGHT="3.817927399388379"/>
<DICH_DATA CI_END="1.8255673991975914" CI_START="0.08764398404042836" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.2613978715554003" LOG_CI_START="-1.0572778888994754" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2012-01-29 17:43:52 +0000" MODIFIED_BY="[Empty name]" ORDER="335" O_E="0.0" SE="0.7745966692414833" STUDY_ID="STD-Mwamburi-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.5999999999999999" WEIGHT="2.1052418910391975"/>
<DICH_DATA CI_END="1.6963243312138672" CI_START="0.7565699065415296" EFFECT_SIZE="1.132867132867133" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="22" LOG_CI_END="0.22950889142902034" LOG_CI_START="-0.12115093727388206" LOG_EFFECT_SIZE="0.054178977077569156" MODIFIED="2012-02-19 10:28:34 +0000" MODIFIED_BY="[Empty name]" ORDER="255" O_E="0.0" SE="0.20597931917423148" STUDY_ID="STD-Oster-1994" TOTAL_1="52" TOTAL_2="48" VAR="0.04242747992747993" WEIGHT="9.633586893395366"/>
<DICH_DATA CI_END="2.0284614274032147" CI_START="0.473067988197196" EFFECT_SIZE="0.9795918367346939" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.30716675370896235" LOG_CI_START="-0.3250764390148152" LOG_EFFECT_SIZE="-0.008954842652926454" MODIFIED="2012-01-28 12:46:30 +0000" MODIFIED_BY="[Empty name]" ORDER="303" O_E="0.0" SE="0.3713827810602253" STUDY_ID="STD-Tchekmedyian-1992" TOTAL_1="49" TOTAL_2="40" VAR="0.13792517006802724" WEIGHT="4.636263040940254"/>
<DICH_DATA CI_END="1.415664724886406" CI_START="0.21604163096903453" EFFECT_SIZE="0.553030303030303" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" LOG_CI_END="0.15096041057638743" LOG_CI_START="-0.6654625527471755" LOG_EFFECT_SIZE="-0.257251071085394" MODIFIED="2012-02-11 09:37:47 +0000" MODIFIED_BY="[Empty name]" ORDER="236" O_E="0.0" SE="0.47957089001510755" STUDY_ID="STD-Weisberg-2002" TOTAL_1="72" TOTAL_2="73" VAR="0.22998823854988237" WEIGHT="4.599590559180812"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.163488808408772" CI_END="1.2844031845624881" CI_START="0.7548883836430897" DF="9" EFFECT_SIZE="0.9846730644942076" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="63" I2="0.0" ID="CMP-004.44.02" LOG_CI_END="0.10870137369001247" LOG_CI_START="-0.12211725757794216" LOG_EFFECT_SIZE="-0.00670794194396483" MODIFIED="2013-01-31 09:56:34 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5177584277418166" P_Z="0.9093019296763407" STUDIES="10" TAU2="0.0" TOTAL_1="266" TOTAL_2="255" WEIGHT="27.41907621611928" Z="0.11391909351801056">
<NAME>Low doses (&lt; 800 mg/d)</NAME>
<DICH_DATA CI_END="2.5708795860891116" CI_START="0.2489420365944033" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4100817357942751" LOG_CI_START="-0.6039017618103879" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2012-01-09 11:45:46 +0000" MODIFIED_BY="[Empty name]" ORDER="134" O_E="0.0" SE="0.5956189257922424" STUDY_ID="STD-De-Conno-1998" TOTAL_1="21" TOTAL_2="21" VAR="0.3547619047619048" WEIGHT="2.1052418910391975"/>
<DICH_DATA CI_END="1.742638853130925" CI_START="0.0061942842519528245" EFFECT_SIZE="0.1038961038961039" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.241207392650116" LOG_CI_START="-2.2080088690111923" LOG_EFFECT_SIZE="-0.9834007381805383" MODIFIED="2012-02-13 16:54:07 +0000" MODIFIED_BY="[Empty name]" ORDER="240" O_E="0.0" SE="1.4386817559158782" STUDY_ID="STD-Eubanks-2002" TOTAL_1="10" TOTAL_2="7" VAR="2.0698051948051948" WEIGHT="1.706353953789665"/>
<DICH_DATA CI_END="5.242335393587904" CI_START="0.04768866950134176" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7195248027465787" LOG_CI_START="-1.321584794074541" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2012-01-24 22:15:54 +0000" MODIFIED_BY="[Empty name]" ORDER="132" O_E="0.0" SE="1.1989578808281798" STUDY_ID="STD-Fietkau-1996" TOTAL_1="32" TOTAL_2="32" VAR="1.4375" WEIGHT="0.8420967564156789"/>
<DICH_DATA CI_END="5.197263659443108" CI_START="0.045048919732620325" EFFECT_SIZE="0.4838709677419355" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7157747493294457" LOG_CI_START="-1.3463156188866288" LOG_EFFECT_SIZE="-0.3152704347785914" MODIFIED="2012-01-24 22:33:16 +0000" MODIFIED_BY="[Empty name]" ORDER="137" O_E="0.0" SE="1.2112820898020695" STUDY_ID="STD-Gebbia-1996" TOTAL_1="62" TOTAL_2="60" VAR="1.467204301075269" WEIGHT="0.8559016212749524"/>
<DICH_DATA CI_END="2.7514307510854565" CI_START="0.363447271789593" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.4395585868182921" LOG_CI_START="-0.4395585868182921" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-01-24 23:06:00 +0000" MODIFIED_BY="[Empty name]" ORDER="144" O_E="0.0" SE="0.5163977794943223" STUDY_ID="STD-Giacosa-1997" TOTAL_1="15" TOTAL_2="15" VAR="0.2666666666666667" WEIGHT="2.1052418910391975"/>
<DICH_DATA CI_END="2.925649438310225" CI_START="0.3418044509726267" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.4662222862019852" LOG_CI_START="-0.46622228620198514" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-01-25 16:33:41 +0000" MODIFIED_BY="[Empty name]" ORDER="132" O_E="0.0" SE="0.5477225575051662" STUDY_ID="STD-Herrejon-2011" TOTAL_1="20" TOTAL_2="20" VAR="0.30000000000000004" WEIGHT="2.1052418910391975"/>
<DICH_DATA CI_END="1.939523144619324" CI_START="0.9580702613105935" EFFECT_SIZE="1.3631578947368421" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="20" LOG_CI_END="0.2876949664679053" LOG_CI_START="-0.018602640211059566" LOG_EFFECT_SIZE="0.13454616312842288" MODIFIED="2012-02-05 19:21:49 +0000" MODIFIED_BY="[Empty name]" ORDER="217" O_E="0.0" SE="0.17992073036082995" STUDY_ID="STD-Macbeth-1994" TOTAL_1="38" TOTAL_2="37" VAR="0.03237146921357448" WEIGHT="8.533247131678879"/>
<DICH_DATA CI_END="2.0556785006489684" CI_START="0.49869483466230874" EFFECT_SIZE="1.0125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.31295519382910997" LOG_CI_START="-0.3021651300556977" LOG_EFFECT_SIZE="0.005395031886706144" MODIFIED="2012-01-29 11:19:37 +0000" MODIFIED_BY="[Empty name]" ORDER="164" O_E="0.0" SE="0.36132472314464664" STUDY_ID="STD-McMillan-1994" TOTAL_1="20" TOTAL_2="18" VAR="0.13055555555555556" WEIGHT="3.5456705533291744"/>
<DICH_DATA CI_END="1.6737465940499652" CI_START="0.09559392118782327" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.22368970626394244" LOG_CI_START="-1.0195697236080177" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2012-03-15 19:56:07 +0000" MODIFIED_BY="[Empty name]" ORDER="466" O_E="0.0" SE="0.7302967433402214" STUDY_ID="STD-Timpone-1997" TOTAL_1="12" TOTAL_2="12" VAR="0.5333333333333332" WEIGHT="2.1052418910391975"/>
<DICH_DATA CI_END="2.5520324136165327" CI_START="0.5144660470503956" EFFECT_SIZE="1.1458333333333333" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.40688618610139793" LOG_CI_START="-0.2886432818640847" LOG_EFFECT_SIZE="0.059121452118656596" MODIFIED="2012-03-15 19:56:21 +0000" MODIFIED_BY="[Empty name]" ORDER="467" O_E="0.0" SE="0.40855745240931773" STUDY_ID="STD-Yeh-2000" TOTAL_1="36" TOTAL_2="33" VAR="0.16691919191919194" WEIGHT="3.514838635474138"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2013-01-31 10:12:50 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Sensitivity analyses</NAME>
<DICH_OUTCOME CHI2="24.082929744996765" CI_END="2.5393122612422356" CI_START="1.142607460008368" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7033605411028212" ESTIMABLE="YES" EVENTS_1="346" EVENTS_2="155" I2="75.08608768313789" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.4047161096944523" LOG_CI_START="0.057897055213671465" LOG_EFFECT_SIZE="0.23130658245406188" METHOD="MH" MODIFIED="2013-01-31 10:09:23 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="5.042299425692676E-4" P_Q="0.6097449386236822" P_Z="0.008939835084533622" Q="0.2605465785829601" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.19317462033056854" TOTALS="YES" TOTAL_1="634" TOTAL_2="540" WEIGHT="100.00000000000001" Z="2.614346386911844">
<NAME>Appetite improvement treatment duration 6 weeks</NAME>
<GROUP_LABEL_1>Megestrol acetate</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.5191420940586524" CI_START="0.8666986476316989" DF="0" EFFECT_SIZE="1.4776119402985075" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="16" I2="0.0" ID="CMP-005.01.01" LOG_CI_END="0.4012526648880033" LOG_CI_START="-0.062131881094556314" LOG_EFFECT_SIZE="0.1695603918967235" MODIFIED="2012-04-14 09:56:11 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.1514669308920707" STUDIES="1" TAU2="0.0" TOTAL_1="67" TOTAL_2="66" WEIGHT="15.528874923394103" Z="1.434369204598305">
<NAME>&lt; 6 weeks</NAME>
<DICH_DATA CI_END="2.5191420940586524" CI_START="0.8666986476316989" EFFECT_SIZE="1.4776119402985075" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="16" LOG_CI_END="0.4012526648880033" LOG_CI_START="-0.062131881094556314" LOG_EFFECT_SIZE="0.1695603918967235" MODIFIED="2012-04-14 00:03:10 +0100" MODIFIED_BY="[Empty name]" ORDER="51923" O_E="0.0" SE="0.2721943761006519" STUDY_ID="STD-Loprinzi-1990b" TOTAL_1="67" TOTAL_2="66" VAR="0.07408977838082315" WEIGHT="15.528874923394103"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="24.15050395123151" CI_END="2.860055043973001" CI_START="1.1072618464293618" DF="5" EFFECT_SIZE="1.7795588860386595" ESTIMABLE="YES" EVENTS_1="322" EVENTS_2="139" I2="79.29649828385865" ID="CMP-005.01.02" LOG_CI_END="0.45637439154292303" LOG_CI_START="0.04425033543354508" LOG_EFFECT_SIZE="0.2503123634882341" MODIFIED="2012-04-14 00:03:10 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="2.0312155355550754E-4" P_Z="0.017272644124580072" STUDIES="6" TAU2="0.24350881409044356" TOTAL_1="567" TOTAL_2="474" WEIGHT="84.47112507660592" Z="2.3808521247390195">
<NAME>6 or more weeks</NAME>
<DICH_DATA CI_END="6.869043147371471" CI_START="1.9929995643190366" EFFECT_SIZE="3.7" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="10" LOG_CI_END="0.8368962443727193" LOG_CI_START="0.2995072037612709" LOG_EFFECT_SIZE="0.568201724066995" MODIFIED="2012-04-14 00:00:55 +0100" MODIFIED_BY="[Empty name]" ORDER="51920" O_E="0.0" SE="0.31566498257381764" STUDY_ID="STD-Feliu-1992" TOTAL_1="76" TOTAL_2="74" VAR="0.0996443812233286" WEIGHT="14.173654704923289"/>
<DICH_DATA CI_END="1.1806591625625122" CI_START="0.5662422515797703" EFFECT_SIZE="0.8176424050632911" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="64" LOG_CI_END="0.0721245418283099" LOG_CI_START="-0.24699772779442827" LOG_EFFECT_SIZE="-0.08743659298305917" MODIFIED="2012-04-14 00:01:17 +0100" MODIFIED_BY="[Empty name]" ORDER="51966" O_E="0.0" SE="0.1874540008571078" STUDY_ID="STD-Loprinzi-1999a" TOTAL_1="79" TOTAL_2="159" VAR="0.03513900243733657" WEIGHT="18.178133081810827"/>
<DICH_DATA CI_END="2.0217938657680343" CI_START="0.879307138021432" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="39" LOG_CI_END="0.3057368745373635" LOG_CI_START="-0.05585940132076362" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2012-04-14 00:01:17 +0100" MODIFIED_BY="[Empty name]" ORDER="51967" O_E="0.0" SE="0.21240344236949693" STUDY_ID="STD-Loprinzi-1999b" TOTAL_1="79" TOTAL_2="158" VAR="0.0451152223304122" WEIGHT="17.41708909082651"/>
<DICH_DATA CI_END="43.86715397607745" CI_START="0.8942259357832195" EFFECT_SIZE="6.2631578947368425" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="1" LOG_CI_END="1.6421394590555214" LOG_CI_START="-0.04855273817611772" LOG_EFFECT_SIZE="0.7967933604397018" MODIFIED="2012-04-14 00:00:50 +0100" MODIFIED_BY="[Empty name]" ORDER="219" O_E="0.0" SE="0.9931209657152156" STUDY_ID="STD-Schmoll-1991" TOTAL_1="38" TOTAL_2="17" VAR="0.9862892525431224" WEIGHT="3.518815213011439"/>
<DICH_DATA CI_END="5.737800103182554" CI_START="1.309153277018078" EFFECT_SIZE="2.740740740740741" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="6" LOG_CI_END="0.7587454139697585" LOG_CI_START="0.11699049717421948" LOG_EFFECT_SIZE="0.43786795557198893" MODIFIED="2012-04-14 00:00:50 +0100" MODIFIED_BY="[Empty name]" ORDER="51924" O_E="0.0" SE="0.37697001486377146" STUDY_ID="STD-Schmoll-1992" TOTAL_1="63" TOTAL_2="28" VAR="0.1421063921063921" WEIGHT="12.378617533093001"/>
<DICH_DATA CI_END="2.160001993545509" CI_START="1.1271637657049847" EFFECT_SIZE="1.5603448275862069" ESTIMABLE="YES" EVENTS_1="181" EVENTS_2="19" LOG_CI_END="0.3344541519775116" LOG_CI_START="0.05198701930702044" LOG_EFFECT_SIZE="0.19322058564226602" MODIFIED="2012-04-14 00:01:01 +0100" MODIFIED_BY="[Empty name]" ORDER="51926" O_E="0.0" SE="0.1659225919655037" STUDY_ID="STD-Von-Roenn-1994" TOTAL_1="232" TOTAL_2="38" VAR="0.02753030652455104" WEIGHT="18.80481545294085"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="24.082929744996754" CI_END="2.5393122612422347" CI_START="1.142607460008368" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.703360541102821" ESTIMABLE="YES" EVENTS_1="346" EVENTS_2="155" I2="75.08608768313788" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="0.4047161096944522" LOG_CI_START="0.057897055213671465" LOG_EFFECT_SIZE="0.23130658245406183" METHOD="MH" MODIFIED="2013-01-31 10:09:34 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="5.042299425689345E-4" P_Q="0.6519941887765833" P_Z="0.008939835084533622" Q="0.2033952071396308" RANDOM="YES" SCALE="94.46" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.19317462033056843" TOTALS="YES" TOTAL_1="634" TOTAL_2="540" WEIGHT="100.0" Z="2.614346386911844">
<NAME>Appetite improvement treatment duration 12 weeks</NAME>
<GROUP_LABEL_1>Megestrol acetate</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="24.063000925053394" CI_END="3.044014835633744" CI_START="1.0631368627296254" DF="5" EFFECT_SIZE="1.7989453528270656" ESTIMABLE="YES" EVENTS_1="165" EVENTS_2="136" I2="79.22121178662215" ID="CMP-005.02.01" LOG_CI_END="0.48344676472736897" LOG_CI_START="0.026589176943027166" LOG_EFFECT_SIZE="0.25501797083519806" MODIFIED="2013-01-31 09:56:59 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="2.1114434832103512E-4" P_Z="0.02866200191684754" STUDIES="6" TAU2="0.30587187299563984" TOTAL_1="402" TOTAL_2="502" WEIGHT="81.19518454705914" Z="2.1881043529189035">
<NAME>0 to 11 weeks</NAME>
<DICH_DATA CI_END="6.869043147371471" CI_START="1.9929995643190366" EFFECT_SIZE="3.7" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="10" LOG_CI_END="0.8368962443727193" LOG_CI_START="0.2995072037612709" LOG_EFFECT_SIZE="0.568201724066995" MODIFIED="2012-02-19 21:51:28 +0000" MODIFIED_BY="[Empty name]" ORDER="51920" O_E="0.0" SE="0.31566498257381764" STUDY_ID="STD-Feliu-1992" TOTAL_1="76" TOTAL_2="74" VAR="0.0996443812233286" WEIGHT="14.173654704923283"/>
<DICH_DATA CI_END="2.5191420940586524" CI_START="0.8666986476316989" EFFECT_SIZE="1.4776119402985075" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="16" LOG_CI_END="0.4012526648880033" LOG_CI_START="-0.062131881094556314" LOG_EFFECT_SIZE="0.1695603918967235" MODIFIED="2012-04-14 12:05:18 +0100" MODIFIED_BY="[Empty name]" ORDER="51923" O_E="0.0" SE="0.2721943761006519" STUDY_ID="STD-Loprinzi-1990b" TOTAL_1="67" TOTAL_2="66" VAR="0.07408977838082315" WEIGHT="15.528874923394099"/>
<DICH_DATA CI_END="1.1806591625625122" CI_START="0.5662422515797703" EFFECT_SIZE="0.8176424050632911" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="64" LOG_CI_END="0.0721245418283099" LOG_CI_START="-0.24699772779442827" LOG_EFFECT_SIZE="-0.08743659298305917" MODIFIED="2012-02-19 21:53:53 +0000" MODIFIED_BY="[Empty name]" ORDER="369" O_E="0.0" SE="0.1874540008571078" STUDY_ID="STD-Loprinzi-1999a" TOTAL_1="79" TOTAL_2="159" VAR="0.03513900243733657" WEIGHT="18.178133081810824"/>
<DICH_DATA CI_END="2.0217938657680343" CI_START="0.879307138021432" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="39" LOG_CI_END="0.3057368745373635" LOG_CI_START="-0.05585940132076362" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2012-02-19 21:54:02 +0000" MODIFIED_BY="[Empty name]" ORDER="370" O_E="0.0" SE="0.21240344236949693" STUDY_ID="STD-Loprinzi-1999b" TOTAL_1="79" TOTAL_2="158" VAR="0.0451152223304122" WEIGHT="17.417089090826508"/>
<DICH_DATA CI_END="43.86715397607745" CI_START="0.8942259357832195" EFFECT_SIZE="6.2631578947368425" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="1" LOG_CI_END="1.6421394590555214" LOG_CI_START="-0.04855273817611772" LOG_EFFECT_SIZE="0.7967933604397018" MODIFIED="2012-02-19 21:54:18 +0000" MODIFIED_BY="[Empty name]" ORDER="219" O_E="0.0" SE="0.9931209657152156" STUDY_ID="STD-Schmoll-1991" TOTAL_1="38" TOTAL_2="17" VAR="0.9862892525431224" WEIGHT="3.518815213011437"/>
<DICH_DATA CI_END="5.737800103182554" CI_START="1.309153277018078" EFFECT_SIZE="2.740740740740741" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="6" LOG_CI_END="0.7587454139697585" LOG_CI_START="0.11699049717421948" LOG_EFFECT_SIZE="0.43786795557198893" MODIFIED="2012-02-19 21:54:18 +0000" MODIFIED_BY="[Empty name]" ORDER="51924" O_E="0.0" SE="0.37697001486377146" STUDY_ID="STD-Schmoll-1992" TOTAL_1="63" TOTAL_2="28" VAR="0.1421063921063921" WEIGHT="12.378617533092998"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1600019935455093" CI_START="1.1271637657049847" DF="0" EFFECT_SIZE="1.5603448275862069" ESTIMABLE="YES" EVENTS_1="181" EVENTS_2="19" I2="0.0" ID="CMP-005.02.02" LOG_CI_END="0.3344541519775117" LOG_CI_START="0.05198701930702044" LOG_EFFECT_SIZE="0.19322058564226602" MODIFIED="2012-02-19 21:54:18 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.007331217912929622" STUDIES="1" TAU2="0.0" TOTAL_1="232" TOTAL_2="38" WEIGHT="18.80481545294085" Z="2.681412066248096">
<NAME>12 or more weeks</NAME>
<DICH_DATA CI_END="2.160001993545509" CI_START="1.1271637657049847" EFFECT_SIZE="1.5603448275862069" ESTIMABLE="YES" EVENTS_1="181" EVENTS_2="19" LOG_CI_END="0.3344541519775116" LOG_CI_START="0.05198701930702044" LOG_EFFECT_SIZE="0.19322058564226602" MODIFIED="2012-02-19 21:53:43 +0000" MODIFIED_BY="[Empty name]" ORDER="51926" O_E="0.0" SE="0.1659225919655037" STUDY_ID="STD-Von-Roenn-1994" TOTAL_1="232" TOTAL_2="38" VAR="0.02753030652455104" WEIGHT="18.80481545294085"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="3.3622236950219375" CI_END="2.542626525281144" CI_START="0.3517666653001592" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="1.4471965952906518" ESTIMABLE="YES" I2="40.51555811229417" I2_Q="68.27470593824687" ID="CMP-005.03" MODIFIED="2013-01-31 10:09:45 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.18616709884865634" P_Q="0.0758315419554827" P_Z="0.009615686783642389" Q="3.152059041764923" RANDOM="YES" SCALE="7.94" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.4163050503943871" TOTALS="YES" TOTAL_1="41" TOTAL_2="43" UNITS="" WEIGHT="100.0" Z="2.589351566597495">
<NAME>Appetite gain 12 weeks</NAME>
<GROUP_LABEL_1>Megestrol acetate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.169203641533771" CI_START="0.8907963584662286" DF="0" EFFECT_SIZE="2.53" ESTIMABLE="YES" I2="0.0" ID="CMP-005.03.01" MODIFIED="2012-02-19 21:59:45 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.0024857402389420516" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="14" WEIGHT="27.996003257685178" Z="3.0250719039683007">
<NAME>&lt; 12 weeks</NAME>
<CONT_DATA CI_END="4.169203641533771" CI_START="0.8907963584662286" EFFECT_SIZE="2.53" ESTIMABLE="YES" MEAN_1="3.46" MEAN_2="0.93" MODIFIED="2012-02-19 21:57:01 +0000" MODIFIED_BY="[Empty name]" ORDER="127" SD_1="1.9" SD_2="2.43" SE="0.8363437565504266" STUDY_ID="STD-Herrejon-2011" TOTAL_1="13" TOTAL_2="14" WEIGHT="27.996003257685178"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.21016465325701503" CI_END="1.563330288586464" CI_START="0.320856230152224" DF="1" EFFECT_SIZE="0.942093259369344" ESTIMABLE="YES" I2="0.0" ID="CMP-005.03.02" MODIFIED="2013-01-31 09:57:05 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6466383942933859" P_Z="0.002956303554074715" STUDIES="2" TAU2="0.0" TOTAL_1="28" TOTAL_2="29" WEIGHT="72.00399674231483" Z="2.9722453292405597">
<NAME>&gt; 12 weeks</NAME>
<CONT_DATA CI_END="4.480547005813186" CI_START="-1.280547005813186" EFFECT_SIZE="1.5999999999999999" ESTIMABLE="YES" MEAN_1="3.3" MEAN_2="1.7" MODIFIED="2012-02-19 21:57:01 +0000" MODIFIED_BY="[Empty name]" ORDER="373" SD_1="2.8" SD_2="1.0" SE="1.4696938456699067" STUDY_ID="STD-Batterham-2001" TOTAL_1="4" TOTAL_2="5" WEIGHT="12.124832248717686"/>
<CONT_DATA CI_END="1.5462088580598388" CI_START="0.27379114194016096" EFFECT_SIZE="0.9099999999999999" ESTIMABLE="YES" MEAN_1="1.16" MEAN_2="0.25" MODIFIED="2012-02-19 21:59:45 +0000" MODIFIED_BY="[Empty name]" ORDER="184" SD_1="1.02" SD_2="1.22" SE="0.3246023207967969" STUDY_ID="STD-Yeh-2000" TOTAL_1="24" TOTAL_2="24" WEIGHT="59.87916449359714"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="31.026641394512136" CI_END="1.9798538243061832" CI_START="1.2145531232665754" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5506894098826973" ESTIMABLE="YES" EVENTS_1="351" EVENTS_2="146" I2="48.43141480717919" I2_Q="80.84086182216566" ID="CMP-005.04" LOG_CI_END="0.2966331268066368" LOG_CI_START="0.08441651513701051" LOG_EFFECT_SIZE="0.19052482097182363" METHOD="MH" MODIFIED="2013-01-31 10:09:52 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.013351250734806364" P_Q="0.022335772176690916" P_Z="4.3276666379008996E-4" Q="5.219441452522764" RANDOM="YES" SCALE="317.94" SORT_BY="STUDY" STUDIES="17" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.11168924968808429" TOTALS="YES" TOTAL_1="1199" TOTAL_2="1038" WEIGHT="100.0" Z="3.5192512436024557">
<NAME>Weight improvement treatment duration 6 weeks</NAME>
<GROUP_LABEL_1>Megestrol acetate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4019742832668287" CI_START="0.6921468047426783" DF="0" EFFECT_SIZE="0.9850746268656716" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="32" I2="0.0" ID="CMP-005.04.01" LOG_CI_END="0.1467400473412371" LOG_CI_START="-0.15980178165915268" LOG_EFFECT_SIZE="-0.00653086715895778" MODIFIED="2012-04-14 09:56:58 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9334428600764844" STUDIES="1" TAU2="0.0" TOTAL_1="67" TOTAL_2="66" WEIGHT="10.782829094804551" Z="0.08351398216102116">
<NAME>&lt; 6 weeks</NAME>
<DICH_DATA CI_END="1.4019742832668287" CI_START="0.6921468047426783" EFFECT_SIZE="0.9850746268656716" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="32" LOG_CI_END="0.1467400473412371" LOG_CI_START="-0.15980178165915268" LOG_EFFECT_SIZE="-0.00653086715895778" MODIFIED="2012-04-14 00:11:39 +0100" MODIFIED_BY="[Empty name]" ORDER="51940" O_E="0.0" SE="0.18006418776135494" STUDY_ID="STD-Loprinzi-1990b" TOTAL_1="67" TOTAL_2="66" VAR="0.03242311171415649" WEIGHT="10.782829094804551"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="25.63098337996244" CI_END="2.099252876719305" CI_START="1.2694870734189174" DF="15" EFFECT_SIZE="1.6324749280869935" ESTIMABLE="YES" EVENTS_1="319" EVENTS_2="114" I2="41.47707960465315" ID="CMP-005.04.02" LOG_CI_END="0.3220647569953945" LOG_CI_START="0.10362828301878711" LOG_EFFECT_SIZE="0.21284652000709084" MODIFIED="2012-04-14 09:56:58 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0420850603151296" P_Z="1.3366064326067855E-4" STUDIES="16" TAU2="0.09872359632864308" TOTAL_1="1132" TOTAL_2="972" WEIGHT="89.21717090519545" Z="3.819614058531795">
<NAME>6 or more weeks</NAME>
<DICH_DATA CI_END="1.8600503184319712" CI_START="0.7053928072271484" EFFECT_SIZE="1.1454545454545455" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.26952469299305315" LOG_CI_START="-0.1515689730743774" LOG_EFFECT_SIZE="0.05897785995933788" MODIFIED="2012-04-14 00:08:45 +0100" MODIFIED_BY="[Empty name]" ORDER="51976" O_E="0.0" SE="0.24735250389527325" STUDY_ID="STD-Batterham-2001" TOTAL_1="4" TOTAL_2="6" VAR="0.06118326118326117" WEIGHT="8.988930371963745"/>
<DICH_DATA CI_END="10.274845018517457" CI_START="1.6276445030275961" EFFECT_SIZE="4.089473684210526" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="5" LOG_CI_END="1.0117752798804394" LOG_CI_START="0.2115595558157313" LOG_EFFECT_SIZE="0.6116674178480853" MODIFIED="2012-04-14 00:11:18 +0100" MODIFIED_BY="[Empty name]" ORDER="51938" O_E="0.0" SE="0.47005067744732804" STUDY_ID="STD-Feliu-1992" TOTAL_1="76" TOTAL_2="74" VAR="0.22094763936869202" WEIGHT="4.671577370313354"/>
<DICH_DATA CI_END="5.09648598079" CI_START="1.0004649042928742" EFFECT_SIZE="2.2580645161290325" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" LOG_CI_END="0.7072708339097552" LOG_CI_START="2.0185845021324637E-4" LOG_EFFECT_SIZE="0.3537363461799842" MODIFIED="2012-04-14 00:11:18 +0100" MODIFIED_BY="[Empty name]" ORDER="130" O_E="0.0" SE="0.41533581623281146" STUDY_ID="STD-Fietkau-1996" TOTAL_1="31" TOTAL_2="30" VAR="0.17250384024577572" WEIGHT="5.4678984763870115"/>
<DICH_DATA CI_END="8.144860274151203" CI_START="1.1489714717071373" EFFECT_SIZE="3.059119496855346" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="5" LOG_CI_END="0.9108836383454965" LOG_CI_START="0.0603092455429576" LOG_EFFECT_SIZE="0.4855964419442271" MODIFIED="2012-04-14 00:11:18 +0100" MODIFIED_BY="[Empty name]" ORDER="198" O_E="0.0" SE="0.4996316087433604" STUDY_ID="STD-Jatoi-2002" TOTAL_1="159" TOTAL_2="152" VAR="0.24963174445547834" WEIGHT="4.300715952396744"/>
<DICH_DATA CI_END="6.736736556469645" CI_START="1.4703903131304714" EFFECT_SIZE="3.1473214285714284" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="8" LOG_CI_END="0.8284495643767887" LOG_CI_START="0.16743263293768296" LOG_EFFECT_SIZE="0.49794109865723585" MODIFIED="2012-04-14 00:11:18 +0100" MODIFIED_BY="[Empty name]" ORDER="208" O_E="0.0" SE="0.3882846176139129" STUDY_ID="STD-Jatoi-2004" TOTAL_1="140" TOTAL_2="141" VAR="0.15076494427558257" WEIGHT="5.920800654700878"/>
<DICH_DATA CI_END="4.200975696245815" CI_START="0.5423909365820319" EFFECT_SIZE="1.509493670886076" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.6233501690369533" LOG_CI_START="-0.26568757619353306" LOG_EFFECT_SIZE="0.1788312964217101" MODIFIED="2012-04-14 00:11:18 +0100" MODIFIED_BY="[Empty name]" ORDER="51974" O_E="0.0" SE="0.5222251723562018" STUDY_ID="STD-Loprinzi-1999a" TOTAL_1="79" TOTAL_2="159" VAR="0.2727191306424647" WEIGHT="4.042416978820423"/>
<DICH_DATA CI_END="6.705706743584816" CI_START="0.5965068490098677" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.8264445567832687" LOG_CI_START="-0.22438456545530627" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2012-04-14 00:11:18 +0100" MODIFIED_BY="[Empty name]" ORDER="51975" O_E="0.0" SE="0.6172622280909857" STUDY_ID="STD-Loprinzi-1999b" TOTAL_1="79" TOTAL_2="158" VAR="0.38101265822784813" WEIGHT="3.153913022220754"/>
<DICH_DATA CI_END="1.7903122675350842" CI_START="0.20108223941047487" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.2529287875383019" LOG_CI_START="-0.6966262867710147" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2012-04-14 00:11:18 +0100" MODIFIED_BY="[Empty name]" ORDER="162" O_E="0.0" SE="0.5577733510227171" STUDY_ID="STD-McMillan-1994" TOTAL_1="20" TOTAL_2="18" VAR="0.3111111111111111" WEIGHT="3.675349189654777"/>
<DICH_DATA CI_END="1.7527020355825875" CI_START="0.6696010430095779" EFFECT_SIZE="1.0833333333333333" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.24370809105031782" LOG_CI_START="-0.174183878531894" LOG_EFFECT_SIZE="0.03476210625921191" MODIFIED="2012-04-14 00:08:45 +0100" MODIFIED_BY="[Empty name]" ORDER="167" O_E="0.0" SE="0.24547181153120257" STUDY_ID="STD-Mwamburi-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.06025641025641024" WEIGHT="9.037384043020886"/>
<DICH_DATA CI_END="38.04338372729278" CI_START="0.7575547118765404" EFFECT_SIZE="5.368421052631579" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="1" LOG_CI_END="1.5802791378325827" LOG_CI_START="-0.12058599621440545" LOG_EFFECT_SIZE="0.7298465708090885" MODIFIED="2012-04-14 00:11:18 +0100" MODIFIED_BY="[Empty name]" ORDER="218" O_E="0.0" SE="0.9990965991574009" STUDY_ID="STD-Schmoll-1991" TOTAL_1="38" TOTAL_2="17" VAR="0.9981940144478842" WEIGHT="1.4000922562417353"/>
<DICH_DATA CI_END="5.104141833207412" CI_START="0.6990207856990239" EFFECT_SIZE="1.8888888888888888" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="4" LOG_CI_END="0.7079227339974891" LOG_CI_START="-0.15550991011959098" LOG_EFFECT_SIZE="0.27620641193894907" MODIFIED="2012-04-14 00:11:18 +0100" MODIFIED_BY="[Empty name]" ORDER="51942" O_E="0.0" SE="0.5071846092148924" STUDY_ID="STD-Schmoll-1992" TOTAL_1="63" TOTAL_2="28" VAR="0.25723622782446315" WEIGHT="4.212067363648583"/>
<DICH_DATA CI_END="4.4199565732614685" CI_START="0.6284626854892529" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.6454180023614081" LOG_CI_START="-0.20172050312869536" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2012-04-14 00:08:45 +0100" MODIFIED_BY="[Empty name]" ORDER="449" O_E="0.0" SE="0.4976133515281193" STUDY_ID="STD-Summerbell-1992" TOTAL_1="7" TOTAL_2="7" VAR="0.24761904761904763" WEIGHT="4.324806788752735"/>
<DICH_DATA CI_END="2.1734264488318" CI_START="0.873112966324461" EFFECT_SIZE="1.3775510204081634" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="16" LOG_CI_END="0.33714494776726445" LOG_CI_START="-0.05892956216224188" LOG_EFFECT_SIZE="0.13910769280251128" MODIFIED="2012-04-14 00:11:18 +0100" MODIFIED_BY="[Empty name]" ORDER="51943" O_E="0.0" SE="0.23265612773303632" STUDY_ID="STD-Tchekmedyian-1992" TOTAL_1="49" TOTAL_2="40" VAR="0.054128873771730916" WEIGHT="9.371345731250274">
<FOOTNOTE>Data at one month</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.5620676643452334" CI_START="0.8850337986238072" EFFECT_SIZE="1.505827505827506" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="13" LOG_CI_END="0.4085905953008247" LOG_CI_START="-0.05304014368010501" LOG_EFFECT_SIZE="0.17777522581035987" MODIFIED="2012-04-14 00:11:18 +0100" MODIFIED_BY="[Empty name]" ORDER="51944" O_E="0.0" SE="0.2711641811864099" STUDY_ID="STD-Vadell-1998" TOTAL_1="99" TOTAL_2="51" VAR="0.07353001315849614" WEIGHT="8.389726530421507">
<FOOTNOTE>Esta bien. Ha sumado los dos</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="4.04356192770385" CI_START="1.1429460967682334" EFFECT_SIZE="2.1497844827586206" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="8" LOG_CI_END="0.606764098776945" LOG_CI_START="0.058025748830864796" LOG_EFFECT_SIZE="0.33239492380390495" MODIFIED="2012-04-14 00:06:44 +0100" MODIFIED_BY="[Empty name]" ORDER="51945" O_E="0.0" SE="0.32233162305696766" STUDY_ID="STD-Von-Roenn-1994" TOTAL_1="232" TOTAL_2="38" VAR="0.1038976752225391" WEIGHT="7.207946233721234"/>
<DICH_DATA CI_END="1.6974685611582485" CI_START="0.2994554351039547" EFFECT_SIZE="0.7129629629629629" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.22980173945213891" LOG_CI_START="-0.5236678000810746" LOG_EFFECT_SIZE="-0.14693303031446786" MODIFIED="2012-04-14 09:56:58 +0100" MODIFIED_BY="[Empty name]" ORDER="51947" O_E="0.0" SE="0.44259173725618267" STUDY_ID="STD-Yeh-2000" TOTAL_1="36" TOTAL_2="33" VAR="0.19588744588744586" WEIGHT="5.052199941680812"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="2.937386588704055" CI_END="0.6461020694808284" CI_START="-0.01585333121222937" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.3151243691342995" ESTIMABLE="YES" I2="31.912264878884066" I2_Q="65.9022002309962" ID="CMP-005.05" MODIFIED="2013-01-31 10:10:01 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.23022618102068182" P_Q="0.0868001885617834" P_Z="0.06202951981038503" Q="2.932740548582369" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.03253585119539195" TOTALS="YES" TOTAL_1="193" TOTAL_2="188" UNITS="" WEIGHT="100.00000000000001" Z="1.8660846743073032">
<NAME>Quality of life gain</NAME>
<GROUP_LABEL_1>Megestrol acetate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.004646040121685288" CI_END="0.41324393423620065" CI_START="-0.010662075630068019" DF="1" EFFECT_SIZE="0.20129092930306633" ESTIMABLE="YES" I2="0.0" ID="CMP-005.05.01" MODIFIED="2012-04-16 23:34:47 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9456567820687672" P_Z="0.06269193939517875" STUDIES="2" TAU2="0.0" TOTAL_1="176" TOTAL_2="168" WEIGHT="81.18182881411272" Z="1.8613700332914362">
<NAME>Cancer</NAME>
<CONT_DATA CI_END="0.8628948000283901" CI_START="-0.5055630229376596" EFFECT_SIZE="0.17866588854536525" ESTIMABLE="YES" MEAN_1="-0.59" MEAN_2="-1.88" MODIFIED="2012-04-16 23:32:54 +0100" MODIFIED_BY="[Empty name]" ORDER="51929" SD_1="8.27" SD_2="5.44" SE="0.34910279825554713" STUDY_ID="STD-De-Conno-1998" TOTAL_1="17" TOTAL_2="16" WEIGHT="18.468420696196354"/>
<CONT_DATA CI_END="0.42661033323225606" CI_START="-0.01922554132609275" EFFECT_SIZE="0.20369239595308164" ESTIMABLE="YES" MEAN_1="15.0" MEAN_2="12.0" MODIFIED="2012-04-16 23:34:47 +0100" MODIFIED_BY="[Empty name]" ORDER="208" SD_1="19.0" SD_2="8.0" SE="0.11373573138972075" STUDY_ID="STD-Jatoi-2002" TOTAL_1="159" TOTAL_2="152" WEIGHT="62.71340811791637"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.4965296446992846" CI_START="0.14427972081129448" DF="0" EFFECT_SIZE="0.8204046827552895" ESTIMABLE="YES" I2="0.0" ID="CMP-005.05.02" MODIFIED="2012-05-10 12:02:58 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.017397160401223428" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="20" WEIGHT="18.81817118588729" Z="2.378204801557922">
<NAME>Other underlying pathology</NAME>
<CONT_DATA CI_END="1.4965296446992846" CI_START="0.14427972081129448" EFFECT_SIZE="0.8204046827552895" ESTIMABLE="YES" MEAN_1="7.76" MEAN_2="4.65" MODIFIED="2012-04-16 23:32:54 +0100" MODIFIED_BY="[Empty name]" ORDER="185" SD_1="4.18" SD_2="3.26" SE="0.3449680541464958" STUDY_ID="STD-Yeh-2000" TOTAL_1="17" TOTAL_2="20" WEIGHT="18.81817118588729">
<FOOTNOTE>Sense of well being</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="58.32253192052497" CI_END="1.9445561481394842" CI_START="1.008118760831346" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4001226854920077" ESTIMABLE="YES" EVENTS_1="351" EVENTS_2="219" I2="72.56634876242529" I2_Q="0.0" ID="CMP-005.06" LOG_CI_END="0.2888204877123773" LOG_CI_START="0.003511696926561406" LOG_EFFECT_SIZE="0.14616609231946928" METHOD="MH" MODIFIED="2013-01-31 10:10:07 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0007180043514197E-6" P_Q="0.9068335940974357" P_Z="0.04462076240052439" Q="0.013696814985696875" RANDOM="YES" SCALE="15.8" SORT_BY="STUDY" STUDIES="17" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.30844196169465593" TOTALS="YES" TOTAL_1="1199" TOTAL_2="1038" WEIGHT="99.99999999999999" Z="2.0082120562641905">
<NAME>Weight improvement 12 weeks</NAME>
<GROUP_LABEL_1>Megestrol acetate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="50.476027380573385" CI_END="2.183667257629233" CI_START="0.899225349338732" DF="11" EFFECT_SIZE="1.401288318862752" ESTIMABLE="YES" EVENTS_1="275" EVENTS_2="184" I2="78.20747675512683" ID="CMP-005.06.01" LOG_CI_END="0.33918646224475185" LOG_CI_START="-0.04613145875593527" LOG_EFFECT_SIZE="0.1465275017444083" MODIFIED="2013-01-31 09:57:39 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="5.13897574161426E-7" P_Z="0.13605130088080297" STUDIES="12" TAU2="0.4290651453826978" TOTAL_1="929" TOTAL_2="815" WEIGHT="69.34714510676163" Z="1.4906580281437682">
<NAME>&lt; 12 weeks</NAME>
<DICH_DATA CI_END="10.274845018517457" CI_START="1.6276445030275961" EFFECT_SIZE="4.089473684210526" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="5" LOG_CI_END="1.0117752798804394" LOG_CI_START="0.2115595558157313" LOG_EFFECT_SIZE="0.6116674178480853" MODIFIED="2012-02-19 22:00:31 +0000" MODIFIED_BY="[Empty name]" ORDER="51938" O_E="0.0" SE="0.47005067744732804" STUDY_ID="STD-Feliu-1992" TOTAL_1="76" TOTAL_2="74" VAR="0.22094763936869202" WEIGHT="5.305546242892872"/>
<DICH_DATA CI_END="5.09648598079" CI_START="1.0004649042928742" EFFECT_SIZE="2.2580645161290325" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" LOG_CI_END="0.7072708339097552" LOG_CI_START="2.0185845021324637E-4" LOG_EFFECT_SIZE="0.3537363461799842" MODIFIED="2012-02-19 22:00:31 +0000" MODIFIED_BY="[Empty name]" ORDER="130" O_E="0.0" SE="0.41533581623281146" STUDY_ID="STD-Fietkau-1996" TOTAL_1="31" TOTAL_2="30" VAR="0.17250384024577572" WEIGHT="5.839953270443721"/>
<DICH_DATA CI_END="8.144860274151203" CI_START="1.1489714717071373" EFFECT_SIZE="3.059119496855346" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="5" LOG_CI_END="0.9108836383454965" LOG_CI_START="0.0603092455429576" LOG_EFFECT_SIZE="0.4855964419442271" MODIFIED="2012-02-19 22:00:31 +0000" MODIFIED_BY="[Empty name]" ORDER="332" O_E="0.0" SE="0.4996316087433604" STUDY_ID="STD-Jatoi-2002" TOTAL_1="159" TOTAL_2="152" VAR="0.24963174445547834" WEIGHT="5.032849564484944"/>
<DICH_DATA CI_END="1.4019742832668287" CI_START="0.6921468047426783" EFFECT_SIZE="0.9850746268656716" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="32" LOG_CI_END="0.1467400473412371" LOG_CI_START="-0.15980178165915268" LOG_EFFECT_SIZE="-0.00653086715895778" MODIFIED="2012-02-19 22:00:31 +0000" MODIFIED_BY="[Empty name]" ORDER="51940" O_E="0.0" SE="0.18006418776135494" STUDY_ID="STD-Loprinzi-1990b" TOTAL_1="67" TOTAL_2="66" VAR="0.03242311171415649" WEIGHT="8.23992021493977"/>
<DICH_DATA CI_END="0.3265771783915999" CI_START="0.06805917755032036" EFFECT_SIZE="0.1490857946554149" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="81" LOG_CI_END="-0.4860141675628994" LOG_CI_START="-1.1671133033670926" LOG_EFFECT_SIZE="-0.8265637354649961" MODIFIED="2012-02-19 22:02:51 +0000" MODIFIED_BY="[Empty name]" ORDER="334" O_E="0.0" SE="0.40008100386648004" STUDY_ID="STD-Loprinzi-1999a" TOTAL_1="79" TOTAL_2="159" VAR="0.16006480965481043" WEIGHT="5.995006221272199"/>
<DICH_DATA CI_END="6.705706743584816" CI_START="0.5965068490098677" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.8264445567832687" LOG_CI_START="-0.22438456545530627" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2012-02-19 22:03:06 +0000" MODIFIED_BY="[Empty name]" ORDER="335" O_E="0.0" SE="0.6172622280909857" STUDY_ID="STD-Loprinzi-1999b" TOTAL_1="79" TOTAL_2="158" VAR="0.38101265822784813" WEIGHT="4.073801128874741"/>
<DICH_DATA CI_END="1.7527020355825875" CI_START="0.6696010430095779" EFFECT_SIZE="1.0833333333333333" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.24370809105031782" LOG_CI_START="-0.174183878531894" LOG_EFFECT_SIZE="0.03476210625921191" MODIFIED="2012-02-19 22:03:26 +0000" MODIFIED_BY="[Empty name]" ORDER="337" O_E="0.0" SE="0.24547181153120257" STUDY_ID="STD-Mwamburi-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.06025641025641024" WEIGHT="7.617882862040342"/>
<DICH_DATA CI_END="38.04338372729278" CI_START="0.7575547118765404" EFFECT_SIZE="5.368421052631579" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="1" LOG_CI_END="1.5802791378325827" LOG_CI_START="-0.12058599621440545" LOG_EFFECT_SIZE="0.7298465708090885" MODIFIED="2012-02-19 22:03:36 +0000" MODIFIED_BY="[Empty name]" ORDER="218" O_E="0.0" SE="0.9990965991574009" STUDY_ID="STD-Schmoll-1991" TOTAL_1="38" TOTAL_2="17" VAR="0.9981940144478842" WEIGHT="2.1495665665352863"/>
<DICH_DATA CI_END="5.104141833207412" CI_START="0.6990207856990239" EFFECT_SIZE="1.8888888888888888" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="4" LOG_CI_END="0.7079227339974891" LOG_CI_START="-0.15550991011959098" LOG_EFFECT_SIZE="0.27620641193894907" MODIFIED="2012-02-19 22:03:39 +0000" MODIFIED_BY="[Empty name]" ORDER="51942" O_E="0.0" SE="0.5071846092148924" STUDY_ID="STD-Schmoll-1992" TOTAL_1="63" TOTAL_2="28" VAR="0.25723622782446315" WEIGHT="4.965192331943837"/>
<DICH_DATA CI_END="2.1734264488318" CI_START="0.873112966324461" EFFECT_SIZE="1.3775510204081634" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="16" LOG_CI_END="0.33714494776726445" LOG_CI_START="-0.05892956216224188" LOG_EFFECT_SIZE="0.13910769280251128" MODIFIED="2012-02-19 22:00:31 +0000" MODIFIED_BY="[Empty name]" ORDER="51943" O_E="0.0" SE="0.23265612773303632" STUDY_ID="STD-Tchekmedyian-1992" TOTAL_1="49" TOTAL_2="40" VAR="0.054128873771730916" WEIGHT="7.746626960040174"/>
<DICH_DATA CI_END="4.04356192770385" CI_START="1.1429460967682334" EFFECT_SIZE="2.1497844827586206" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="8" LOG_CI_END="0.606764098776945" LOG_CI_START="0.058025748830864796" LOG_EFFECT_SIZE="0.33239492380390495" MODIFIED="2012-02-19 22:00:31 +0000" MODIFIED_BY="[Empty name]" ORDER="51945" O_E="0.0" SE="0.32233162305696766" STUDY_ID="STD-Von-Roenn-1994" TOTAL_1="232" TOTAL_2="38" VAR="0.1038976752225391" WEIGHT="6.811620221492892"/>
<DICH_DATA CI_END="1.6974685611582485" CI_START="0.2994554351039547" EFFECT_SIZE="0.7129629629629629" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.22980173945213891" LOG_CI_START="-0.5236678000810746" LOG_EFFECT_SIZE="-0.14693303031446786" MODIFIED="2012-04-14 10:22:36 +0100" MODIFIED_BY="[Empty name]" ORDER="51947" O_E="0.0" SE="0.44259173725618267" STUDY_ID="STD-Yeh-2000" TOTAL_1="36" TOTAL_2="33" VAR="0.19588744588744586" WEIGHT="5.569179521800863"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.457755920753003" CI_END="2.3136581231452698" CI_START="0.9162587572801847" DF="4" EFFECT_SIZE="1.4559909054263662" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="35" I2="52.70613106503698" ID="CMP-005.06.02" LOG_CI_END="0.3642991859896919" LOG_CI_START="-0.037981861496479356" LOG_EFFECT_SIZE="0.1631586622466063" MODIFIED="2013-01-31 09:57:43 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.07617822089624027" P_Z="0.11186655774554617" STUDIES="5" TAU2="0.13972638407305166" TOTAL_1="270" TOTAL_2="223" WEIGHT="30.652854893238352" Z="1.589859148311362">
<NAME>&gt; 12 weeks</NAME>
<DICH_DATA CI_END="1.8600503184319712" CI_START="0.7053928072271484" EFFECT_SIZE="1.1454545454545455" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.26952469299305315" LOG_CI_START="-0.1515689730743774" LOG_EFFECT_SIZE="0.05897785995933788" MODIFIED="2012-02-19 22:00:31 +0000" MODIFIED_BY="[Empty name]" ORDER="336" O_E="0.0" SE="0.24735250389527325" STUDY_ID="STD-Batterham-2001" TOTAL_1="4" TOTAL_2="6" VAR="0.06118326118326117" WEIGHT="7.598780697592933"/>
<DICH_DATA CI_END="6.736736556469645" CI_START="1.4703903131304714" EFFECT_SIZE="3.1473214285714284" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="8" LOG_CI_END="0.8284495643767887" LOG_CI_START="0.16743263293768296" LOG_EFFECT_SIZE="0.49794109865723585" MODIFIED="2012-02-19 22:01:52 +0000" MODIFIED_BY="[Empty name]" ORDER="333" O_E="0.0" SE="0.3882846176139129" STUDY_ID="STD-Jatoi-2004" TOTAL_1="140" TOTAL_2="141" VAR="0.15076494427558257" WEIGHT="6.116417180211649"/>
<DICH_DATA CI_END="1.7903122675350842" CI_START="0.20108223941047487" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.2529287875383019" LOG_CI_START="-0.6966262867710147" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2012-02-19 22:02:03 +0000" MODIFIED_BY="[Empty name]" ORDER="162" O_E="0.0" SE="0.5577733510227171" STUDY_ID="STD-McMillan-1994" TOTAL_1="20" TOTAL_2="18" VAR="0.3111111111111111" WEIGHT="4.5334308427015815"/>
<DICH_DATA CI_END="4.4199565732614685" CI_START="0.6284626854892529" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.6454180023614081" LOG_CI_START="-0.20172050312869536" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2012-02-24 14:46:30 +0000" MODIFIED_BY="[Empty name]" ORDER="449" O_E="0.0" SE="0.4976133515281193" STUDY_ID="STD-Summerbell-1992" TOTAL_1="7" TOTAL_2="7" VAR="0.24761904761904763" WEIGHT="5.0510662713336645"/>
<DICH_DATA CI_END="2.5620676643452334" CI_START="0.8850337986238072" EFFECT_SIZE="1.505827505827506" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="13" LOG_CI_END="0.4085905953008247" LOG_CI_START="-0.05304014368010501" LOG_EFFECT_SIZE="0.17777522581035987" MODIFIED="2012-02-19 22:02:34 +0000" MODIFIED_BY="[Empty name]" ORDER="51944" O_E="0.0" SE="0.2711641811864099" STUDY_ID="STD-Vadell-1998" TOTAL_1="99" TOTAL_2="51" VAR="0.07353001315849614" WEIGHT="7.353159901398522">
<FOOTNOTE>Esta bien. Ha sumado los dos</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="56.05085164983189" CI_END="2.8103781913621932" CI_START="1.107856212525368" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="MD" EFFECT_SIZE="1.9591172019437806" ESTIMABLE="YES" I2="78.59086945731362" I2_Q="0.0" ID="CMP-005.07" MODIFIED="2013-01-31 10:10:21 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.1720042025764599E-7" P_Q="0.3189932257201078" P_Z="6.4608246493105816E-6" Q="0.9930708667964839" RANDOM="YES" SCALE="14.47" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="1.585910705201146" TOTALS="YES" TOTAL_1="482" TOTAL_2="611" UNITS="" WEIGHT="100.00000000000001" Z="4.510719045079314">
<NAME>Weight gain 6 weeks</NAME>
<GROUP_LABEL_1>Megestrol acetate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0406856155800191" CI_END="2.3049853031640266" CI_START="0.6249522210023291" DF="1" EFFECT_SIZE="1.4649687620831777" ESTIMABLE="YES" I2="0.0" ID="CMP-005.07.01" MODIFIED="2012-04-14 10:48:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8401460819276885" P_Z="6.3052907540073E-4" STUDIES="2" TAU2="0.0" TOTAL_1="84" TOTAL_2="82" WEIGHT="19.074532962918482" Z="3.4181303245109604">
<NAME>&lt; 6 weeks</NAME>
<CONT_DATA CI_END="2.450790635597685" CI_START="0.3492093644023153" EFFECT_SIZE="1.4000000000000001" ESTIMABLE="YES" MEAN_1="1.06" MEAN_2="-0.34" MODIFIED="2012-04-14 10:45:40 +0100" MODIFIED_BY="[Empty name]" ORDER="51929" SD_1="1.95" SD_2="1.01" SE="0.5361275226923491" STUDY_ID="STD-De-Conno-1998" TOTAL_1="17" TOTAL_2="16" WEIGHT="10.069592145129038"/>
<CONT_DATA CI_END="2.9782080386276055" CI_START="0.1817919613723944" EFFECT_SIZE="1.58" ESTIMABLE="YES" MEAN_1="1.36" MEAN_2="-0.22" MODIFIED="2012-04-14 10:45:40 +0100" MODIFIED_BY="[Empty name]" ORDER="51932" SD_1="4.99" SD_2="3.01" SE="0.7133845568880307" STUDY_ID="STD-Loprinzi-1990b" TOTAL_1="67" TOTAL_2="66" WEIGHT="9.004940817789443"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="55.07057264063246" CI_END="3.2118171661271884" CI_START="1.0929827743912846" DF="10" EFFECT_SIZE="2.1523999702592365" ESTIMABLE="YES" I2="81.84148171972748" ID="CMP-005.07.02" MODIFIED="2012-04-14 10:48:32 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="3.063656894841671E-8" P_Z="6.833041041165965E-5" STUDIES="11" TAU2="2.176290665022876" TOTAL_1="398" TOTAL_2="529" WEIGHT="80.92546703708153" Z="3.9820256254921187">
<NAME>6 or more weeks</NAME>
<CONT_DATA CI_END="10.848577123414998" CI_START="1.5314228765850002" EFFECT_SIZE="6.1899999999999995" ESTIMABLE="YES" MEAN_1="10.2" MEAN_2="4.01" MODIFIED="2012-04-14 10:48:05 +0100" MODIFIED_BY="[Empty name]" ORDER="51971" SD_1="4.51" SD_2="1.68" SE="2.3768687384876768" STUDY_ID="STD-Batterham-2001" TOTAL_1="4" TOTAL_2="5" WEIGHT="2.6071486441197456"/>
<CONT_DATA CI_END="6.3265405202233715" CI_START="1.2734594797766285" EFFECT_SIZE="3.8" ESTIMABLE="YES" MEAN_1="5.3" MEAN_2="1.5" MODIFIED="2012-04-14 10:48:18 +0100" MODIFIED_BY="[Empty name]" ORDER="51935" SD_1="3.6" SD_2="1.6" SE="1.2890749728833797" STUDY_ID="STD-Eubanks-2002" TOTAL_1="10" TOTAL_2="7" WEIGHT="5.808492143712873"/>
<CONT_DATA CI_END="4.007979966871202" CI_START="0.5920200331287977" EFFECT_SIZE="2.3000000000000003" ESTIMABLE="YES" MEAN_1="-0.9" MEAN_2="-3.2" MODIFIED="2012-04-14 10:48:18 +0100" MODIFIED_BY="[Empty name]" ORDER="51931" SD_1="3.6" SD_2="3.2" SE="0.8714343632554121" STUDY_ID="STD-Fietkau-1996" TOTAL_1="31" TOTAL_2="30" WEIGHT="8.043207878958308"/>
<CONT_DATA CI_END="4.000770353465514" CI_START="0.3992296465344851" EFFECT_SIZE="2.1999999999999997" ESTIMABLE="YES" MEAN_1="2.3" MEAN_2="0.1" MODIFIED="2012-04-14 10:48:32 +0100" MODIFIED_BY="[Empty name]" ORDER="129" SD_1="3.37" SD_2="1.18" SE="0.9187772671690712" STUDY_ID="STD-Herrejon-2011" TOTAL_1="15" TOTAL_2="16" WEIGHT="7.762683157370417"/>
<CONT_DATA CI_END="1.592969098374519" CI_START="-0.6129690983745186" EFFECT_SIZE="0.4900000000000002" ESTIMABLE="YES" MEAN_1="2.5" MEAN_2="2.01" MODIFIED="2012-04-14 10:48:32 +0100" MODIFIED_BY="[Empty name]" ORDER="51969" SD_1="4.45" SD_2="3.24" SE="0.5627496765627319" STUDY_ID="STD-Loprinzi-1999a" TOTAL_1="79" TOTAL_2="159" WEIGHT="9.91476139495627"/>
<CONT_DATA CI_END="1.7905445910798514" CI_START="-0.33054459107985146" EFFECT_SIZE="0.73" ESTIMABLE="YES" MEAN_1="2.5" MEAN_2="1.77" MODIFIED="2012-04-14 10:48:32 +0100" MODIFIED_BY="[Empty name]" ORDER="51970" SD_1="4.45" SD_2="2.58" SE="0.5411041220375945" STUDY_ID="STD-Loprinzi-1999b" TOTAL_1="79" TOTAL_2="158" WEIGHT="10.04085820289913">
<FOOTNOTE>SD were available from the previous review of Bernstein</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="2.628336756896459" CI_START="-2.028336756896459" EFFECT_SIZE="0.2999999999999998" ESTIMABLE="YES" MEAN_1="2.8" MEAN_2="2.5" MODIFIED="2012-04-14 10:48:32 +0100" MODIFIED_BY="[Empty name]" ORDER="168" SD_1="4.3" SD_2="2.4" SE="1.18794874562088" STUDY_ID="STD-Mwamburi-2004" TOTAL_1="18" TOTAL_2="15" WEIGHT="6.2939498187940135"/>
<CONT_DATA CI_END="11.836072310194206" CI_START="5.163927689805794" EFFECT_SIZE="8.5" ESTIMABLE="YES" MEAN_1="6.5" MEAN_2="-2.0" MODIFIED="2012-04-14 10:48:32 +0100" MODIFIED_BY="[Empty name]" ORDER="51972" SD_1="3.81" SD_2="4.5" SE="1.702108985934802" STUDY_ID="STD-Timpone-1997" TOTAL_1="12" TOTAL_2="12" WEIGHT="4.207772388462848"/>
<CONT_DATA CI_END="5.824705003771884" CI_START="2.695294996228116" EFFECT_SIZE="4.26" ESTIMABLE="YES" MEAN_1="3.54" MEAN_2="-0.72" MODIFIED="2012-04-14 10:48:32 +0100" MODIFIED_BY="[Empty name]" ORDER="51934" SD_1="4.29" SD_2="2.85" SE="0.7983335490417564" STUDY_ID="STD-Von-Roenn-1994" TOTAL_1="53" TOTAL_2="28" WEIGHT="8.484798531932693">
<FOOTNOTE>MA 800 mg/d versus placebo</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="1.0101786698446733" CI_START="0.18982133015532654" EFFECT_SIZE="0.6" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="0.6" MODIFIED="2012-04-14 10:48:32 +0100" MODIFIED_BY="[Empty name]" ORDER="51936" SD_1="1.4" SD_2="1.1" SE="0.20927867709820713" STUDY_ID="STD-Weisberg-2002" TOTAL_1="72" TOTAL_2="73" WEIGHT="11.574957674321238">
<FOOTNOTE>Values at 2 weeks. Values at 8 weeks were written without SD</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="2.5107557286828244" CI_START="-2.230755728682824" EFFECT_SIZE="0.14" ESTIMABLE="YES" MEAN_1="1.05" MEAN_2="0.91" MODIFIED="2012-04-14 10:48:32 +0100" MODIFIED_BY="[Empty name]" ORDER="51937" SD_1="5.0" SD_2="3.47" SE="1.2095914758551907" STUDY_ID="STD-Yeh-2000" TOTAL_1="25" TOTAL_2="26" WEIGHT="6.186837201553979"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="56.0508516498319" CI_END="2.8103781913621932" CI_START="1.107856212525368" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="MD" EFFECT_SIZE="1.9591172019437806" ESTIMABLE="YES" I2="78.59086945731362" I2_Q="0.0" ID="CMP-005.08" MODIFIED="2013-01-31 10:10:33 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.172004209237798E-7" P_Q="0.9914231022603216" P_Z="6.460824649310606E-6" Q="1.1555721606361922E-4" RANDOM="YES" SCALE="14.34" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="1.5859107052011465" TOTALS="YES" TOTAL_1="482" TOTAL_2="611" UNITS="" WEIGHT="100.00000000000001" Z="4.5107190450793135">
<NAME>Weight gain 12 weeks</NAME>
<GROUP_LABEL_1>Megestrol acetate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="50.96547123466215" CI_END="2.8674252136544505" CI_START="1.0588827851106732" DF="10" EFFECT_SIZE="1.9631539993825617" ESTIMABLE="YES" I2="80.37887268037483" ID="CMP-005.08.01" MODIFIED="2013-01-31 09:57:51 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.7722446932211255E-7" P_Z="2.0901066802264667E-5" STUDIES="11" TAU2="1.5710926047743297" TOTAL_1="447" TOTAL_2="578" WEIGHT="88.00467065473316" Z="4.255041047606202">
<NAME>&lt; 12 weeks</NAME>
<CONT_DATA CI_END="10.848577123414998" CI_START="1.5314228765850002" EFFECT_SIZE="6.1899999999999995" ESTIMABLE="YES" MEAN_1="10.2" MEAN_2="4.01" MODIFIED="2012-04-14 10:47:26 +0100" MODIFIED_BY="[Empty name]" ORDER="51971" SD_1="4.51" SD_2="1.68" SE="2.3768687384876768" STUDY_ID="STD-Batterham-2001" TOTAL_1="4" TOTAL_2="5" WEIGHT="2.607148644119746"/>
<CONT_DATA CI_END="2.450790635597685" CI_START="0.3492093644023153" EFFECT_SIZE="1.4000000000000001" ESTIMABLE="YES" MEAN_1="1.06" MEAN_2="-0.34" MODIFIED="2012-04-14 10:47:26 +0100" MODIFIED_BY="[Empty name]" ORDER="51929" SD_1="1.95" SD_2="1.01" SE="0.5361275226923491" STUDY_ID="STD-De-Conno-1998" TOTAL_1="17" TOTAL_2="16" WEIGHT="10.06959214512904"/>
<CONT_DATA CI_END="4.007979966871202" CI_START="0.5920200331287977" EFFECT_SIZE="2.3000000000000003" ESTIMABLE="YES" MEAN_1="-0.9" MEAN_2="-3.2" MODIFIED="2012-04-14 10:47:26 +0100" MODIFIED_BY="[Empty name]" ORDER="51931" SD_1="3.6" SD_2="3.2" SE="0.8714343632554121" STUDY_ID="STD-Fietkau-1996" TOTAL_1="31" TOTAL_2="30" WEIGHT="8.04320787895831"/>
<CONT_DATA CI_END="4.000770353465514" CI_START="0.3992296465344851" EFFECT_SIZE="2.1999999999999997" ESTIMABLE="YES" MEAN_1="2.3" MEAN_2="0.1" MODIFIED="2012-04-14 10:47:26 +0100" MODIFIED_BY="[Empty name]" ORDER="129" SD_1="3.37" SD_2="1.18" SE="0.9187772671690712" STUDY_ID="STD-Herrejon-2011" TOTAL_1="15" TOTAL_2="16" WEIGHT="7.762683157370418"/>
<CONT_DATA CI_END="2.9782080386276055" CI_START="0.1817919613723944" EFFECT_SIZE="1.58" ESTIMABLE="YES" MEAN_1="1.36" MEAN_2="-0.22" MODIFIED="2012-04-14 10:47:26 +0100" MODIFIED_BY="[Empty name]" ORDER="51932" SD_1="4.99" SD_2="3.01" SE="0.7133845568880307" STUDY_ID="STD-Loprinzi-1990b" TOTAL_1="67" TOTAL_2="66" WEIGHT="9.004940817789443"/>
<CONT_DATA CI_END="1.592969098374519" CI_START="-0.6129690983745186" EFFECT_SIZE="0.4900000000000002" ESTIMABLE="YES" MEAN_1="2.5" MEAN_2="2.01" MODIFIED="2012-04-14 10:47:26 +0100" MODIFIED_BY="[Empty name]" ORDER="51969" SD_1="4.45" SD_2="3.24" SE="0.5627496765627319" STUDY_ID="STD-Loprinzi-1999a" TOTAL_1="79" TOTAL_2="159" WEIGHT="9.914761394956273"/>
<CONT_DATA CI_END="1.7905445910798514" CI_START="-0.33054459107985146" EFFECT_SIZE="0.73" ESTIMABLE="YES" MEAN_1="2.5" MEAN_2="1.77" MODIFIED="2012-04-14 10:47:26 +0100" MODIFIED_BY="[Empty name]" ORDER="51970" SD_1="4.45" SD_2="2.58" SE="0.5411041220375945" STUDY_ID="STD-Loprinzi-1999b" TOTAL_1="79" TOTAL_2="158" WEIGHT="10.040858202899132">
<FOOTNOTE>SD were available from the previous review of Bernstein</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="2.628336756896459" CI_START="-2.028336756896459" EFFECT_SIZE="0.2999999999999998" ESTIMABLE="YES" MEAN_1="2.8" MEAN_2="2.5" MODIFIED="2012-04-14 10:47:26 +0100" MODIFIED_BY="[Empty name]" ORDER="168" SD_1="4.3" SD_2="2.4" SE="1.18794874562088" STUDY_ID="STD-Mwamburi-2004" TOTAL_1="18" TOTAL_2="15" WEIGHT="6.293949818794014"/>
<CONT_DATA CI_END="11.836072310194206" CI_START="5.163927689805794" EFFECT_SIZE="8.5" ESTIMABLE="YES" MEAN_1="6.5" MEAN_2="-2.0" MODIFIED="2012-04-14 10:47:26 +0100" MODIFIED_BY="[Empty name]" ORDER="51972" SD_1="3.81" SD_2="4.5" SE="1.702108985934802" STUDY_ID="STD-Timpone-1997" TOTAL_1="12" TOTAL_2="12" WEIGHT="4.20777238846285"/>
<CONT_DATA CI_END="5.824705003771884" CI_START="2.695294996228116" EFFECT_SIZE="4.26" ESTIMABLE="YES" MEAN_1="3.54" MEAN_2="-0.72" MODIFIED="2012-04-14 10:47:26 +0100" MODIFIED_BY="[Empty name]" ORDER="51934" SD_1="4.29" SD_2="2.85" SE="0.7983335490417564" STUDY_ID="STD-Von-Roenn-1994" TOTAL_1="53" TOTAL_2="28" WEIGHT="8.484798531932695">
<FOOTNOTE>MA 800 mg/d versus placebo</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="1.0101786698446733" CI_START="0.18982133015532654" EFFECT_SIZE="0.6" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="0.6" MODIFIED="2012-04-14 10:47:26 +0100" MODIFIED_BY="[Empty name]" ORDER="51936" SD_1="1.4" SD_2="1.1" SE="0.20927867709820713" STUDY_ID="STD-Weisberg-2002" TOTAL_1="72" TOTAL_2="73" WEIGHT="11.574957674321242">
<FOOTNOTE>Values at 2 weeks. Values at 8 weeks were written without SD</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.286830931939415" CI_END="5.529208348350439" CI_START="-1.6434713940479115" DF="1" EFFECT_SIZE="1.9428684771512637" ESTIMABLE="YES" I2="76.67274460139282" ID="CMP-005.08.02" MODIFIED="2013-01-31 09:57:55 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.038408868973994315" P_Z="0.2883294725147525" STUDIES="2" TAU2="5.135387087912086" TOTAL_1="35" TOTAL_2="33" WEIGHT="11.995329345266855" Z="1.0617934659498354">
<NAME>&gt; 12 weeks</NAME>
<CONT_DATA CI_END="6.3265405202233715" CI_START="1.2734594797766285" EFFECT_SIZE="3.8" ESTIMABLE="YES" MEAN_1="5.3" MEAN_2="1.5" MODIFIED="2012-04-14 10:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="51935" SD_1="3.6" SD_2="1.6" SE="1.2890749728833797" STUDY_ID="STD-Eubanks-2002" TOTAL_1="10" TOTAL_2="7" WEIGHT="5.808492143712875"/>
<CONT_DATA CI_END="2.5107557286828244" CI_START="-2.230755728682824" EFFECT_SIZE="0.14" ESTIMABLE="YES" MEAN_1="1.05" MEAN_2="0.91" MODIFIED="2012-04-14 10:51:39 +0100" MODIFIED_BY="[Empty name]" ORDER="51937" SD_1="5.0" SD_2="3.47" SE="1.2095914758551907" STUDY_ID="STD-Yeh-2000" TOTAL_1="25" TOTAL_2="26" WEIGHT="6.18683720155398"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="24.082929744996765" CI_END="2.539312261242235" CI_START="1.1426074600083678" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.703360541102821" ESTIMABLE="YES" EVENTS_1="346" EVENTS_2="155" I2="75.08608768313789" I2_Q="0.0" ID="CMP-005.09" LOG_CI_END="0.40471610969445226" LOG_CI_START="0.05789705521367138" LOG_EFFECT_SIZE="0.23130658245406183" METHOD="MH" MODIFIED="2013-01-31 10:10:41 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="5.042299425692676E-4" P_Q="0.5559063808243974" P_Z="0.008939835084533642" Q="0.3468421394391574" RANDOM="YES" SCALE="226.78" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.19317462033056854" TOTALS="YES" TOTAL_1="634" TOTAL_2="540" WEIGHT="100.00000000000001" Z="2.6143463869118433">
<NAME>Blinded versus open-label appetite improvement</NAME>
<GROUP_LABEL_1>Megestrol acetate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.743949938417393" CI_END="3.2714062321175557" CI_START="1.1712570233535726" DF="2" EFFECT_SIZE="1.9574620112815306" ESTIMABLE="YES" EVENTS_1="243" EVENTS_2="45" I2="70.34378934803686" ID="CMP-005.09.01" LOG_CI_END="0.5147344766877097" LOG_CI_START="0.06865220811744055" LOG_EFFECT_SIZE="0.2916933424025751" MODIFIED="2012-04-14 09:47:19 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.03432189744213221" P_Z="0.010369968342203873" STUDIES="3" TAU2="0.14337584354226368" TOTAL_1="375" TOTAL_2="178" WEIGHT="48.50734508125824" Z="2.563242190600988">
<NAME>Blinded studies</NAME>
<DICH_DATA CI_END="6.869043147371471" CI_START="1.9929995643190366" EFFECT_SIZE="3.7" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="10" LOG_CI_END="0.8368962443727193" LOG_CI_START="0.2995072037612709" LOG_EFFECT_SIZE="0.568201724066995" MODIFIED="2012-04-14 09:43:55 +0100" MODIFIED_BY="[Empty name]" ORDER="51920" O_E="0.0" SE="0.31566498257381764" STUDY_ID="STD-Feliu-1992" TOTAL_1="76" TOTAL_2="74" VAR="0.0996443812233286" WEIGHT="14.173654704923285"/>
<DICH_DATA CI_END="2.5191420940586524" CI_START="0.8666986476316989" EFFECT_SIZE="1.4776119402985075" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="16" LOG_CI_END="0.4012526648880033" LOG_CI_START="-0.062131881094556314" LOG_EFFECT_SIZE="0.1695603918967235" MODIFIED="2012-04-14 09:44:05 +0100" MODIFIED_BY="[Empty name]" ORDER="51923" O_E="0.0" SE="0.2721943761006519" STUDY_ID="STD-Loprinzi-1990b" TOTAL_1="67" TOTAL_2="66" VAR="0.07408977838082315" WEIGHT="15.5288749233941"/>
<DICH_DATA CI_END="2.160001993545509" CI_START="1.1271637657049847" EFFECT_SIZE="1.5603448275862069" ESTIMABLE="YES" EVENTS_1="181" EVENTS_2="19" LOG_CI_END="0.3344541519775116" LOG_CI_START="0.05198701930702044" LOG_EFFECT_SIZE="0.19322058564226602" MODIFIED="2012-04-14 09:47:19 +0100" MODIFIED_BY="[Empty name]" ORDER="51926" O_E="0.0" SE="0.1659225919655037" STUDY_ID="STD-Von-Roenn-1994" TOTAL_1="232" TOTAL_2="38" VAR="0.02753030652455104" WEIGHT="18.804815452940847"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="12.466558317923278" CI_END="2.870713353860748" CI_START="0.8203703166575631" DF="3" EFFECT_SIZE="1.5346165720269793" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="110" I2="75.93561973165542" ID="CMP-005.09.02" LOG_CI_END="0.4579898295388078" LOG_CI_START="-0.085990062034832" LOG_EFFECT_SIZE="0.1859998837519879" MODIFIED="2013-01-31 09:58:15 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.005944448154836857" P_Z="0.18014191847256503" STUDIES="4" TAU2="0.26563862757307427" TOTAL_1="259" TOTAL_2="362" WEIGHT="51.49265491874178" Z="1.3403181953213161">
<NAME>Open-label studies</NAME>
<DICH_DATA CI_END="1.1806591625625122" CI_START="0.5662422515797703" EFFECT_SIZE="0.8176424050632911" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="64" LOG_CI_END="0.0721245418283099" LOG_CI_START="-0.24699772779442827" LOG_EFFECT_SIZE="-0.08743659298305917" MODIFIED="2012-04-14 09:46:53 +0100" MODIFIED_BY="[Empty name]" ORDER="51966" O_E="0.0" SE="0.1874540008571078" STUDY_ID="STD-Loprinzi-1999a" TOTAL_1="79" TOTAL_2="159" VAR="0.03513900243733657" WEIGHT="18.178133081810824"/>
<DICH_DATA CI_END="2.0217938657680343" CI_START="0.879307138021432" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="39" LOG_CI_END="0.3057368745373635" LOG_CI_START="-0.05585940132076362" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2012-04-14 09:46:54 +0100" MODIFIED_BY="[Empty name]" ORDER="51967" O_E="0.0" SE="0.21240344236949693" STUDY_ID="STD-Loprinzi-1999b" TOTAL_1="79" TOTAL_2="158" VAR="0.0451152223304122" WEIGHT="17.417089090826508"/>
<DICH_DATA CI_END="43.86715397607745" CI_START="0.8942259357832195" EFFECT_SIZE="6.2631578947368425" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="1" LOG_CI_END="1.6421394590555214" LOG_CI_START="-0.04855273817611772" LOG_EFFECT_SIZE="0.7967933604397018" MODIFIED="2012-04-14 09:45:33 +0100" MODIFIED_BY="[Empty name]" ORDER="219" O_E="0.0" SE="0.9931209657152156" STUDY_ID="STD-Schmoll-1991" TOTAL_1="38" TOTAL_2="17" VAR="0.9862892525431224" WEIGHT="3.5188152130114383"/>
<DICH_DATA CI_END="5.737800103182554" CI_START="1.309153277018078" EFFECT_SIZE="2.740740740740741" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="6" LOG_CI_END="0.7587454139697585" LOG_CI_START="0.11699049717421948" LOG_EFFECT_SIZE="0.43786795557198893" MODIFIED="2012-04-14 09:45:33 +0100" MODIFIED_BY="[Empty name]" ORDER="51924" O_E="0.0" SE="0.37697001486377146" STUDY_ID="STD-Schmoll-1992" TOTAL_1="63" TOTAL_2="28" VAR="0.1421063921063921" WEIGHT="12.378617533093"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="3.3622236950219375" CI_END="2.542626525281144" CI_START="0.3517666653001592" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="1.4471965952906518" ESTIMABLE="YES" I2="40.51555811229417" I2_Q="0.0" ID="CMP-005.10" MODIFIED="2013-01-31 10:10:48 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.18616709884865634" P_Q="0.9696979079734425" P_Z="0.009615686783642389" Q="0.00144302582162408" RANDOM="YES" SCALE="25.23" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.4163050503943871" TOTALS="YES" TOTAL_1="41" TOTAL_2="43" UNITS="" WEIGHT="100.0" Z="2.589351566597495">
<NAME>Blinded versus open-label appetite gain</NAME>
<GROUP_LABEL_1>Megestrol acetate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.2607822705785727" CI_END="3.0829915517971163" CI_START="-0.00972254713922327" DF="1" EFFECT_SIZE="1.5366345023289465" ESTIMABLE="YES" I2="69.33251235377435" ID="CMP-005.10.01" MODIFIED="2012-02-19 21:19:56 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.07095532807887173" P_Z="0.0514579426720839" STUDIES="2" TAU2="0.9097812271062273" TOTAL_1="37" TOTAL_2="38" WEIGHT="87.87516775128232" Z="1.9476409300181867">
<NAME>Blinded studies</NAME>
<CONT_DATA CI_END="4.169203641533771" CI_START="0.8907963584662286" EFFECT_SIZE="2.53" ESTIMABLE="YES" MEAN_1="3.46" MEAN_2="0.93" MODIFIED="2012-02-19 21:19:52 +0000" MODIFIED_BY="[Empty name]" ORDER="127" SD_1="1.9" SD_2="2.43" SE="0.8363437565504266" STUDY_ID="STD-Herrejon-2011" TOTAL_1="13" TOTAL_2="14" WEIGHT="27.996003257685178"/>
<CONT_DATA CI_END="1.5462088580598388" CI_START="0.27379114194016096" EFFECT_SIZE="0.9099999999999999" ESTIMABLE="YES" MEAN_1="1.16" MEAN_2="0.25" MODIFIED="2012-02-19 21:19:56 +0000" MODIFIED_BY="[Empty name]" ORDER="184" SD_1="1.02" SD_2="1.22" SE="0.3246023207967969" STUDY_ID="STD-Yeh-2000" TOTAL_1="24" TOTAL_2="24" WEIGHT="59.87916449359714"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.480547005813186" CI_START="-1.280547005813186" DF="0" EFFECT_SIZE="1.5999999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-005.10.02" MODIFIED="2013-01-31 09:58:39 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.27630293419524765" STUDIES="1" TAU2="0.0" TOTAL_1="4" TOTAL_2="5" WEIGHT="12.124832248717686" Z="1.0886621079036347">
<NAME>Open-label studies</NAME>
<CONT_DATA CI_END="4.480547005813186" CI_START="-1.280547005813186" EFFECT_SIZE="1.5999999999999999" ESTIMABLE="YES" MEAN_1="3.3" MEAN_2="1.7" MODIFIED="2012-02-19 21:19:46 +0000" MODIFIED_BY="[Empty name]" ORDER="373" SD_1="2.8" SD_2="1.0" SE="1.4696938456699067" STUDY_ID="STD-Batterham-2001" TOTAL_1="4" TOTAL_2="5" WEIGHT="12.124832248717686"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="58.32253192052498" CI_END="1.9445561481394842" CI_START="1.0081187608313458" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4001226854920077" ESTIMABLE="YES" EVENTS_1="351" EVENTS_2="219" I2="72.5663487624253" I2_Q="0.0" ID="CMP-005.11" LOG_CI_END="0.2888204877123773" LOG_CI_START="0.0035116969265613102" LOG_EFFECT_SIZE="0.14616609231946928" METHOD="MH" MODIFIED="2013-01-31 10:10:57 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.000718004129375E-6" P_Q="0.40938927953129" P_Z="0.044620762400524476" Q="0.6805746408515837" RANDOM="YES" SCALE="54.23" SORT_BY="STUDY" STUDIES="17" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.30844196169465604" TOTALS="YES" TOTAL_1="1199" TOTAL_2="1038" WEIGHT="100.0" Z="2.0082120562641896">
<NAME>Blinded versus open-label weight Improvement</NAME>
<GROUP_LABEL_1>Megestrol acetate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="24.815388368545577" CI_END="2.318336999106426" CI_START="1.1487290552282012" DF="9" EFFECT_SIZE="1.6319133159221746" ESTIMABLE="YES" EVENTS_1="289" EVENTS_2="108" I2="63.73218155470082" ID="CMP-005.11.01" LOG_CI_END="0.36517656631887035" LOG_CI_START="0.06021760597698213" LOG_EFFECT_SIZE="0.2126970861479262" MODIFIED="2012-04-14 09:59:49 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0031823354780151636" P_Z="0.006257038130610416" STUDIES="10" TAU2="0.18623076473536285" TOTAL_1="909" TOTAL_2="643" WEIGHT="62.548703920407" Z="2.733998227165962">
<NAME>Blinded studies</NAME>
<DICH_DATA CI_END="10.274845018517457" CI_START="1.6276445030275961" EFFECT_SIZE="4.089473684210526" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="5" LOG_CI_END="1.0117752798804394" LOG_CI_START="0.2115595558157313" LOG_EFFECT_SIZE="0.6116674178480853" MODIFIED="2012-02-19 19:33:45 +0000" MODIFIED_BY="[Empty name]" ORDER="51938" O_E="0.0" SE="0.47005067744732804" STUDY_ID="STD-Feliu-1992" TOTAL_1="76" TOTAL_2="74" VAR="0.22094763936869202" WEIGHT="5.305546242892873"/>
<DICH_DATA CI_END="5.09648598079" CI_START="1.0004649042928742" EFFECT_SIZE="2.2580645161290325" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" LOG_CI_END="0.7072708339097552" LOG_CI_START="2.0185845021324637E-4" LOG_EFFECT_SIZE="0.3537363461799842" MODIFIED="2012-02-19 19:33:45 +0000" MODIFIED_BY="[Empty name]" ORDER="130" O_E="0.0" SE="0.41533581623281146" STUDY_ID="STD-Fietkau-1996" TOTAL_1="31" TOTAL_2="30" VAR="0.17250384024577572" WEIGHT="5.839953270443722"/>
<DICH_DATA CI_END="8.144860274151203" CI_START="1.1489714717071373" EFFECT_SIZE="3.059119496855346" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="5" LOG_CI_END="0.9108836383454965" LOG_CI_START="0.0603092455429576" LOG_EFFECT_SIZE="0.4855964419442271" MODIFIED="2012-02-19 19:40:47 +0000" MODIFIED_BY="[Empty name]" ORDER="332" O_E="0.0" SE="0.4996316087433604" STUDY_ID="STD-Jatoi-2002" TOTAL_1="159" TOTAL_2="152" VAR="0.24963174445547834" WEIGHT="5.032849564484946"/>
<DICH_DATA CI_END="6.736736556469645" CI_START="1.4703903131304714" EFFECT_SIZE="3.1473214285714284" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="8" LOG_CI_END="0.8284495643767887" LOG_CI_START="0.16743263293768296" LOG_EFFECT_SIZE="0.49794109865723585" MODIFIED="2012-02-19 19:40:57 +0000" MODIFIED_BY="[Empty name]" ORDER="333" O_E="0.0" SE="0.3882846176139129" STUDY_ID="STD-Jatoi-2004" TOTAL_1="140" TOTAL_2="141" VAR="0.15076494427558257" WEIGHT="6.11641718021165"/>
<DICH_DATA CI_END="1.4019742832668287" CI_START="0.6921468047426783" EFFECT_SIZE="0.9850746268656716" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="32" LOG_CI_END="0.1467400473412371" LOG_CI_START="-0.15980178165915268" LOG_EFFECT_SIZE="-0.00653086715895778" MODIFIED="2012-02-19 19:33:45 +0000" MODIFIED_BY="[Empty name]" ORDER="51940" O_E="0.0" SE="0.18006418776135494" STUDY_ID="STD-Loprinzi-1990b" TOTAL_1="67" TOTAL_2="66" VAR="0.03242311171415649" WEIGHT="8.23992021493977"/>
<DICH_DATA CI_END="1.7903122675350842" CI_START="0.20108223941047487" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.2529287875383019" LOG_CI_START="-0.6966262867710147" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2012-02-19 19:33:45 +0000" MODIFIED_BY="[Empty name]" ORDER="162" O_E="0.0" SE="0.5577733510227171" STUDY_ID="STD-McMillan-1994" TOTAL_1="20" TOTAL_2="18" VAR="0.3111111111111111" WEIGHT="4.533430842701581"/>
<DICH_DATA CI_END="2.1734264488318" CI_START="0.873112966324461" EFFECT_SIZE="1.3775510204081634" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="16" LOG_CI_END="0.33714494776726445" LOG_CI_START="-0.05892956216224188" LOG_EFFECT_SIZE="0.13910769280251128" MODIFIED="2012-02-19 19:33:45 +0000" MODIFIED_BY="[Empty name]" ORDER="51943" O_E="0.0" SE="0.23265612773303632" STUDY_ID="STD-Tchekmedyian-1992" TOTAL_1="49" TOTAL_2="40" VAR="0.054128873771730916" WEIGHT="7.746626960040174"/>
<DICH_DATA CI_END="2.5620676643452334" CI_START="0.8850337986238072" EFFECT_SIZE="1.505827505827506" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="13" LOG_CI_END="0.4085905953008247" LOG_CI_START="-0.05304014368010501" LOG_EFFECT_SIZE="0.17777522581035987" MODIFIED="2012-02-19 19:33:45 +0000" MODIFIED_BY="[Empty name]" ORDER="51944" O_E="0.0" SE="0.2711641811864099" STUDY_ID="STD-Vadell-1998" TOTAL_1="99" TOTAL_2="51" VAR="0.07353001315849614" WEIGHT="7.353159901398523">
<FOOTNOTE>Esta bien. Ha sumado los dos</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="4.04356192770385" CI_START="1.1429460967682334" EFFECT_SIZE="2.1497844827586206" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="8" LOG_CI_END="0.606764098776945" LOG_CI_START="0.058025748830864796" LOG_EFFECT_SIZE="0.33239492380390495" MODIFIED="2012-02-19 19:38:16 +0000" MODIFIED_BY="[Empty name]" ORDER="51945" O_E="0.0" SE="0.32233162305696766" STUDY_ID="STD-Von-Roenn-1994" TOTAL_1="232" TOTAL_2="38" VAR="0.1038976752225391" WEIGHT="6.811620221492892"/>
<DICH_DATA CI_END="1.6974685611582485" CI_START="0.2994554351039547" EFFECT_SIZE="0.7129629629629629" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.22980173945213891" LOG_CI_START="-0.5236678000810746" LOG_EFFECT_SIZE="-0.14693303031446786" MODIFIED="2012-04-14 09:59:49 +0100" MODIFIED_BY="[Empty name]" ORDER="51947" O_E="0.0" SE="0.44259173725618267" STUDY_ID="STD-Yeh-2000" TOTAL_1="36" TOTAL_2="33" VAR="0.19588744588744586" WEIGHT="5.569179521800864"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="37.79634422042023" CI_END="2.466278791392469" CI_START="0.530164429882602" DF="6" EFFECT_SIZE="1.1434742189354954" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="111" I2="84.12544883968334" ID="CMP-005.11.02" LOG_CI_END="0.39204216825310706" LOG_CI_START="-0.27558941357749195" LOG_EFFECT_SIZE="0.05822637733780759" MODIFIED="2013-01-31 09:59:00 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.231179518224046E-6" P_Z="0.7324487322615806" STUDIES="7" TAU2="0.8258157941253637" TOTAL_1="290" TOTAL_2="395" WEIGHT="37.451296079593" Z="0.34186999428465803">
<NAME>Open-label studies</NAME>
<DICH_DATA CI_END="1.8600503184319712" CI_START="0.7053928072271484" EFFECT_SIZE="1.1454545454545455" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.26952469299305315" LOG_CI_START="-0.1515689730743774" LOG_EFFECT_SIZE="0.05897785995933788" MODIFIED="2012-02-19 19:41:13 +0000" MODIFIED_BY="[Empty name]" ORDER="336" O_E="0.0" SE="0.24735250389527325" STUDY_ID="STD-Batterham-2001" TOTAL_1="4" TOTAL_2="6" VAR="0.06118326118326117" WEIGHT="7.598780697592933"/>
<DICH_DATA CI_END="0.3265771783915999" CI_START="0.06805917755032036" EFFECT_SIZE="0.1490857946554149" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="81" LOG_CI_END="-0.4860141675628994" LOG_CI_START="-1.1671133033670926" LOG_EFFECT_SIZE="-0.8265637354649961" MODIFIED="2012-02-19 19:41:44 +0000" MODIFIED_BY="[Empty name]" ORDER="334" O_E="0.0" SE="0.40008100386648004" STUDY_ID="STD-Loprinzi-1999a" TOTAL_1="79" TOTAL_2="159" VAR="0.16006480965481043" WEIGHT="5.995006221272198"/>
<DICH_DATA CI_END="6.705706743584816" CI_START="0.5965068490098677" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.8264445567832687" LOG_CI_START="-0.22438456545530627" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2012-02-19 19:41:58 +0000" MODIFIED_BY="[Empty name]" ORDER="335" O_E="0.0" SE="0.6172622280909857" STUDY_ID="STD-Loprinzi-1999b" TOTAL_1="79" TOTAL_2="158" VAR="0.38101265822784813" WEIGHT="4.073801128874741"/>
<DICH_DATA CI_END="1.7527020355825875" CI_START="0.6696010430095779" EFFECT_SIZE="1.0833333333333333" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.24370809105031782" LOG_CI_START="-0.174183878531894" LOG_EFFECT_SIZE="0.03476210625921191" MODIFIED="2012-02-19 19:42:14 +0000" MODIFIED_BY="[Empty name]" ORDER="337" O_E="0.0" SE="0.24547181153120257" STUDY_ID="STD-Mwamburi-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.06025641025641024" WEIGHT="7.617882862040342"/>
<DICH_DATA CI_END="38.04338372729278" CI_START="0.7575547118765404" EFFECT_SIZE="5.368421052631579" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="1" LOG_CI_END="1.5802791378325827" LOG_CI_START="-0.12058599621440545" LOG_EFFECT_SIZE="0.7298465708090885" MODIFIED="2012-02-19 19:37:59 +0000" MODIFIED_BY="[Empty name]" ORDER="218" O_E="0.0" SE="0.9990965991574009" STUDY_ID="STD-Schmoll-1991" TOTAL_1="38" TOTAL_2="17" VAR="0.9981940144478842" WEIGHT="2.1495665665352863"/>
<DICH_DATA CI_END="5.104141833207412" CI_START="0.6990207856990239" EFFECT_SIZE="1.8888888888888888" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="4" LOG_CI_END="0.7079227339974891" LOG_CI_START="-0.15550991011959098" LOG_EFFECT_SIZE="0.27620641193894907" MODIFIED="2012-02-19 19:37:59 +0000" MODIFIED_BY="[Empty name]" ORDER="51942" O_E="0.0" SE="0.5071846092148924" STUDY_ID="STD-Schmoll-1992" TOTAL_1="63" TOTAL_2="28" VAR="0.25723622782446315" WEIGHT="4.965192331943837"/>
<DICH_DATA CI_END="4.4199565732614685" CI_START="0.6284626854892529" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.6454180023614081" LOG_CI_START="-0.20172050312869536" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2012-02-24 14:45:50 +0000" MODIFIED_BY="[Empty name]" ORDER="449" O_E="0.0" SE="0.4976133515281193" STUDY_ID="STD-Summerbell-1992" TOTAL_1="7" TOTAL_2="7" VAR="0.24761904761904763" WEIGHT="5.0510662713336645"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="58.322531920524966" CI_END="1.9445561481394842" CI_START="1.008118760831346" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4001226854920077" ESTIMABLE="YES" EVENTS_1="351" EVENTS_2="219" I2="72.56634876242529" I2_Q="0.0" ID="CMP-005.12" LOG_CI_END="0.2888204877123773" LOG_CI_START="0.003511696926561406" LOG_EFFECT_SIZE="0.14616609231946928" METHOD="MH" MODIFIED="2013-01-31 10:11:07 +0000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0007180039073305E-6" P_Q="0.5971842769472541" P_Z="0.04462076240052439" Q="0.2792637070403292" RANDOM="YES" SCALE="145.34" SORT_BY="STUDY" STUDIES="17" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.3084419616946559" TOTALS="YES" TOTAL_1="1199" TOTAL_2="1038" WEIGHT="100.0" Z="2.0082120562641905">
<NAME>Sensitivity number patients weight improvement</NAME>
<GROUP_LABEL_1>Megestrol acetate</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="9.589469316868364" CI_END="1.6453227938693777" CI_START="0.9755045115103549" DF="8" EFFECT_SIZE="1.266893763624401" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="62" I2="16.575154102348566" ID="CMP-005.12.01" LOG_CI_END="0.21625111434906114" LOG_CI_START="-0.010770717740994204" LOG_EFFECT_SIZE="0.1027401983040335" MODIFIED="2012-04-14 10:41:24 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2950295894291859" P_Z="0.07606501064454492" STUDIES="9" TAU2="0.025966455419110378" TOTAL_1="268" TOTAL_2="199" WEIGHT="51.07167932443241" Z="1.7739887532977903">
<NAME>n &lt; 100 patients</NAME>
<DICH_DATA CI_END="1.8600503184319712" CI_START="0.7053928072271484" EFFECT_SIZE="1.1454545454545455" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.26952469299305315" LOG_CI_START="-0.1515689730743774" LOG_EFFECT_SIZE="0.05897785995933788" MODIFIED="2012-02-20 11:31:57 +0000" MODIFIED_BY="[Empty name]" ORDER="336" O_E="0.0" SE="0.24735250389527325" STUDY_ID="STD-Batterham-2001" TOTAL_1="4" TOTAL_2="6" VAR="0.06118326118326117" WEIGHT="7.598780697592935"/>
<DICH_DATA CI_END="5.09648598079" CI_START="1.0004649042928742" EFFECT_SIZE="2.2580645161290325" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" LOG_CI_END="0.7072708339097552" LOG_CI_START="2.0185845021324637E-4" LOG_EFFECT_SIZE="0.3537363461799842" MODIFIED="2012-02-20 11:29:48 +0000" MODIFIED_BY="[Empty name]" ORDER="130" O_E="0.0" SE="0.41533581623281146" STUDY_ID="STD-Fietkau-1996" TOTAL_1="31" TOTAL_2="30" VAR="0.17250384024577572" WEIGHT="5.839953270443722"/>
<DICH_DATA CI_END="1.7903122675350842" CI_START="0.20108223941047487" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.2529287875383019" LOG_CI_START="-0.6966262867710147" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2012-02-20 11:29:48 +0000" MODIFIED_BY="[Empty name]" ORDER="162" O_E="0.0" SE="0.5577733510227171" STUDY_ID="STD-McMillan-1994" TOTAL_1="20" TOTAL_2="18" VAR="0.3111111111111111" WEIGHT="4.5334308427015815"/>
<DICH_DATA CI_END="1.7527020355825875" CI_START="0.6696010430095779" EFFECT_SIZE="1.0833333333333333" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.24370809105031782" LOG_CI_START="-0.174183878531894" LOG_EFFECT_SIZE="0.03476210625921191" MODIFIED="2012-02-20 11:33:41 +0000" MODIFIED_BY="[Empty name]" ORDER="337" O_E="0.0" SE="0.24547181153120257" STUDY_ID="STD-Mwamburi-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.06025641025641024" WEIGHT="7.617882862040342"/>
<DICH_DATA CI_END="38.04338372729278" CI_START="0.7575547118765404" EFFECT_SIZE="5.368421052631579" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="1" LOG_CI_END="1.5802791378325827" LOG_CI_START="-0.12058599621440545" LOG_EFFECT_SIZE="0.7298465708090885" MODIFIED="2012-02-20 11:33:53 +0000" MODIFIED_BY="[Empty name]" ORDER="218" O_E="0.0" SE="0.9990965991574009" STUDY_ID="STD-Schmoll-1991" TOTAL_1="38" TOTAL_2="17" VAR="0.9981940144478842" WEIGHT="2.1495665665352863"/>
<DICH_DATA CI_END="5.104141833207412" CI_START="0.6990207856990239" EFFECT_SIZE="1.8888888888888888" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="4" LOG_CI_END="0.7079227339974891" LOG_CI_START="-0.15550991011959098" LOG_EFFECT_SIZE="0.27620641193894907" MODIFIED="2012-02-20 11:33:58 +0000" MODIFIED_BY="[Empty name]" ORDER="51942" O_E="0.0" SE="0.5071846092148924" STUDY_ID="STD-Schmoll-1992" TOTAL_1="63" TOTAL_2="28" VAR="0.25723622782446315" WEIGHT="4.965192331943837"/>
<DICH_DATA CI_END="4.4199565732614685" CI_START="0.6284626854892529" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.6454180023614081" LOG_CI_START="-0.20172050312869536" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2012-02-24 14:47:14 +0000" MODIFIED_BY="[Empty name]" ORDER="449" O_E="0.0" SE="0.4976133515281193" STUDY_ID="STD-Summerbell-1992" TOTAL_1="7" TOTAL_2="7" VAR="0.24761904761904763" WEIGHT="5.0510662713336645"/>
<DICH_DATA CI_END="2.1734264488318" CI_START="0.873112966324461" EFFECT_SIZE="1.3775510204081634" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="16" LOG_CI_END="0.33714494776726445" LOG_CI_START="-0.05892956216224188" LOG_EFFECT_SIZE="0.13910769280251128" MODIFIED="2012-02-20 11:29:48 +0000" MODIFIED_BY="[Empty name]" ORDER="51943" O_E="0.0" SE="0.23265612773303632" STUDY_ID="STD-Tchekmedyian-1992" TOTAL_1="49" TOTAL_2="40" VAR="0.054128873771730916" WEIGHT="7.746626960040175"/>
<DICH_DATA CI_END="1.6974685611582485" CI_START="0.2994554351039547" EFFECT_SIZE="0.7129629629629629" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.22980173945213891" LOG_CI_START="-0.5236678000810746" LOG_EFFECT_SIZE="-0.14693303031446786" MODIFIED="2012-04-14 10:41:24 +0100" MODIFIED_BY="[Empty name]" ORDER="51947" O_E="0.0" SE="0.44259173725618267" STUDY_ID="STD-Yeh-2000" TOTAL_1="36" TOTAL_2="33" VAR="0.19588744588744586" WEIGHT="5.569179521800863"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="49.75902258826301" CI_END="2.9094657501705337" CI_START="0.8024843795585632" DF="7" EFFECT_SIZE="1.5280055030570048" ESTIMABLE="YES" EVENTS_1="248" EVENTS_2="157" I2="85.93219955720927" ID="CMP-005.12.02" LOG_CI_END="0.4638132491047885" LOG_CI_START="-0.09556341242781909" LOG_EFFECT_SIZE="0.18412491833848468" MODIFIED="2012-02-20 22:43:58 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.6106847522401324E-8" P_Z="0.1969510395735207" STUDIES="8" TAU2="0.7038364369648047" TOTAL_1="931" TOTAL_2="839" WEIGHT="48.9283206755676" Z="1.2902869691097114">
<NAME>n &gt; 100 patients</NAME>
<DICH_DATA CI_END="10.274845018517457" CI_START="1.6276445030275961" EFFECT_SIZE="4.089473684210526" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="5" LOG_CI_END="1.0117752798804394" LOG_CI_START="0.2115595558157313" LOG_EFFECT_SIZE="0.6116674178480853" MODIFIED="2012-02-20 11:32:07 +0000" MODIFIED_BY="[Empty name]" ORDER="51938" O_E="0.0" SE="0.47005067744732804" STUDY_ID="STD-Feliu-1992" TOTAL_1="76" TOTAL_2="74" VAR="0.22094763936869202" WEIGHT="5.3055462428928735"/>
<DICH_DATA CI_END="8.144860274151203" CI_START="1.1489714717071373" EFFECT_SIZE="3.059119496855346" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="5" LOG_CI_END="0.9108836383454965" LOG_CI_START="0.0603092455429576" LOG_EFFECT_SIZE="0.4855964419442271" MODIFIED="2012-02-20 11:32:20 +0000" MODIFIED_BY="[Empty name]" ORDER="332" O_E="0.0" SE="0.4996316087433604" STUDY_ID="STD-Jatoi-2002" TOTAL_1="159" TOTAL_2="152" VAR="0.24963174445547834" WEIGHT="5.032849564484946"/>
<DICH_DATA CI_END="6.736736556469645" CI_START="1.4703903131304714" EFFECT_SIZE="3.1473214285714284" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="8" LOG_CI_END="0.8284495643767887" LOG_CI_START="0.16743263293768296" LOG_EFFECT_SIZE="0.49794109865723585" MODIFIED="2012-02-20 11:32:24 +0000" MODIFIED_BY="[Empty name]" ORDER="333" O_E="0.0" SE="0.3882846176139129" STUDY_ID="STD-Jatoi-2004" TOTAL_1="140" TOTAL_2="141" VAR="0.15076494427558257" WEIGHT="6.11641718021165"/>
<DICH_DATA CI_END="1.4019742832668287" CI_START="0.6921468047426783" EFFECT_SIZE="0.9850746268656716" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="32" LOG_CI_END="0.1467400473412371" LOG_CI_START="-0.15980178165915268" LOG_EFFECT_SIZE="-0.00653086715895778" MODIFIED="2012-02-20 11:32:33 +0000" MODIFIED_BY="[Empty name]" ORDER="51940" O_E="0.0" SE="0.18006418776135494" STUDY_ID="STD-Loprinzi-1990b" TOTAL_1="67" TOTAL_2="66" VAR="0.03242311171415649" WEIGHT="8.239920214939772"/>
<DICH_DATA CI_END="0.3265771783915999" CI_START="0.06805917755032036" EFFECT_SIZE="0.1490857946554149" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="81" LOG_CI_END="-0.4860141675628994" LOG_CI_START="-1.1671133033670926" LOG_EFFECT_SIZE="-0.8265637354649961" MODIFIED="2012-02-20 11:29:48 +0000" MODIFIED_BY="[Empty name]" ORDER="334" O_E="0.0" SE="0.40008100386648004" STUDY_ID="STD-Loprinzi-1999a" TOTAL_1="79" TOTAL_2="159" VAR="0.16006480965481043" WEIGHT="5.9950062212722"/>
<DICH_DATA CI_END="6.705706743584816" CI_START="0.5965068490098677" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.8264445567832687" LOG_CI_START="-0.22438456545530627" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2012-02-20 11:29:48 +0000" MODIFIED_BY="[Empty name]" ORDER="335" O_E="0.0" SE="0.6172622280909857" STUDY_ID="STD-Loprinzi-1999b" TOTAL_1="79" TOTAL_2="158" VAR="0.38101265822784813" WEIGHT="4.073801128874741"/>
<DICH_DATA CI_END="2.5620676643452334" CI_START="0.8850337986238072" EFFECT_SIZE="1.505827505827506" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="13" LOG_CI_END="0.4085905953008247" LOG_CI_START="-0.05304014368010501" LOG_EFFECT_SIZE="0.17777522581035987" MODIFIED="2012-02-20 11:32:58 +0000" MODIFIED_BY="[Empty name]" ORDER="51944" O_E="0.0" SE="0.2711641811864099" STUDY_ID="STD-Vadell-1998" TOTAL_1="99" TOTAL_2="51" VAR="0.07353001315849614" WEIGHT="7.353159901398522">
<FOOTNOTE>Esta bien. Ha sumado los dos</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="4.04356192770385" CI_START="1.1429460967682334" EFFECT_SIZE="2.1497844827586206" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="8" LOG_CI_END="0.606764098776945" LOG_CI_START="0.058025748830864796" LOG_EFFECT_SIZE="0.33239492380390495" MODIFIED="2012-02-20 11:33:10 +0000" MODIFIED_BY="[Empty name]" ORDER="51945" O_E="0.0" SE="0.32233162305696766" STUDY_ID="STD-Von-Roenn-1994" TOTAL_1="232" TOTAL_2="38" VAR="0.1038976752225391" WEIGHT="6.811620221492892"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="24.082929744996758" CI_END="2.5393122612422356" CI_START="1.142607460008368" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7033605411028212" ESTIMABLE="YES" EVENTS_1="346" EVENTS_2="155" I2="75.08608768313788" I2_Q="0.0" ID="CMP-005.13" LOG_CI_END="0.4047161096944523" LOG_CI_START="0.057897055213671465" LOG_EFFECT_SIZE="0.23130658245406188" METHOD="MH" MODIFIED="2013-01-31 10:11:16 +0000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="5.042299425687125E-4" P_Q="0.383322455556213" P_Z="0.008939835084533622" Q="0.7600195021117377" RANDOM="YES" SCALE="202.55" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.19317462033056848" TOTALS="YES" TOTAL_1="634" TOTAL_2="540" WEIGHT="99.99999999999997" Z="2.614346386911844">
<NAME>Appetite improvement, study quality</NAME>
<GROUP_LABEL_1>Megestrol acetate</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.953138240738394" CI_END="5.72262374514387" CI_START="0.9296697931648455" DF="1" EFFECT_SIZE="2.306545129302294" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="26" I2="79.81077952205663" ID="CMP-005.13.01" LOG_CI_END="0.7575951925658183" LOG_CI_START="-0.03167127991009493" LOG_EFFECT_SIZE="0.3629619563278617" MODIFIED="2012-04-14 00:20:42 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.02604350592328064" P_Z="0.07144050783273118" STUDIES="2" TAU2="0.3433975750268599" TOTAL_1="143" TOTAL_2="140" WEIGHT="29.70252962831738" Z="1.8026671269316312">
<NAME>Study quality (Jadad score 3, 4 or 5)</NAME>
<DICH_DATA CI_END="6.869043147371471" CI_START="1.9929995643190366" EFFECT_SIZE="3.7" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="10" LOG_CI_END="0.8368962443727193" LOG_CI_START="0.2995072037612709" LOG_EFFECT_SIZE="0.568201724066995" MODIFIED="2012-04-14 00:19:10 +0100" MODIFIED_BY="[Empty name]" ORDER="51920" O_E="0.0" SE="0.31566498257381764" STUDY_ID="STD-Feliu-1992" TOTAL_1="76" TOTAL_2="74" VAR="0.0996443812233286" WEIGHT="14.173654704923281"/>
<DICH_DATA CI_END="2.5191420940586524" CI_START="0.8666986476316989" EFFECT_SIZE="1.4776119402985075" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="16" LOG_CI_END="0.4012526648880033" LOG_CI_START="-0.062131881094556314" LOG_EFFECT_SIZE="0.1695603918967235" MODIFIED="2012-04-14 00:19:17 +0100" MODIFIED_BY="[Empty name]" ORDER="51923" O_E="0.0" SE="0.2721943761006519" STUDY_ID="STD-Loprinzi-1990b" TOTAL_1="67" TOTAL_2="66" VAR="0.07408977838082315" WEIGHT="15.528874923394097"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="13.935040609757348" CI_END="2.2705264627378714" CI_START="0.9574588282887251" DF="4" EFFECT_SIZE="1.4744272130598872" ESTIMABLE="YES" EVENTS_1="284" EVENTS_2="129" I2="71.29538325708796" ID="CMP-005.13.02" LOG_CI_END="0.3561265679212227" LOG_CI_START="-0.018879892065819835" LOG_EFFECT_SIZE="0.16862333792770146" MODIFIED="2012-04-14 00:20:42 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.007505317465971384" P_Z="0.07796574828975769" STUDIES="5" TAU2="0.14854889095586762" TOTAL_1="491" TOTAL_2="400" WEIGHT="70.29747037168259" Z="1.7626132056639305">
<NAME>Study quality (Jadad score 2 or low)</NAME>
<DICH_DATA CI_END="1.1806591625625122" CI_START="0.5662422515797703" EFFECT_SIZE="0.8176424050632911" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="64" LOG_CI_END="0.0721245418283099" LOG_CI_START="-0.24699772779442827" LOG_EFFECT_SIZE="-0.08743659298305917" MODIFIED="2012-04-14 00:20:03 +0100" MODIFIED_BY="[Empty name]" ORDER="51966" O_E="0.0" SE="0.1874540008571078" STUDY_ID="STD-Loprinzi-1999a" TOTAL_1="79" TOTAL_2="159" VAR="0.03513900243733657" WEIGHT="18.17813308181082"/>
<DICH_DATA CI_END="2.0217938657680343" CI_START="0.879307138021432" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="39" LOG_CI_END="0.3057368745373635" LOG_CI_START="-0.05585940132076362" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2012-04-14 00:20:03 +0100" MODIFIED_BY="[Empty name]" ORDER="51967" O_E="0.0" SE="0.21240344236949693" STUDY_ID="STD-Loprinzi-1999b" TOTAL_1="79" TOTAL_2="158" VAR="0.0451152223304122" WEIGHT="17.417089090826504"/>
<DICH_DATA CI_END="43.86715397607745" CI_START="0.8942259357832195" EFFECT_SIZE="6.2631578947368425" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="1" LOG_CI_END="1.6421394590555214" LOG_CI_START="-0.04855273817611772" LOG_EFFECT_SIZE="0.7967933604397018" MODIFIED="2012-04-14 00:20:34 +0100" MODIFIED_BY="[Empty name]" ORDER="219" O_E="0.0" SE="0.9931209657152156" STUDY_ID="STD-Schmoll-1991" TOTAL_1="38" TOTAL_2="17" VAR="0.9862892525431224" WEIGHT="3.518815213011437"/>
<DICH_DATA CI_END="5.737800103182554" CI_START="1.309153277018078" EFFECT_SIZE="2.740740740740741" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="6" LOG_CI_END="0.7587454139697585" LOG_CI_START="0.11699049717421948" LOG_EFFECT_SIZE="0.43786795557198893" MODIFIED="2012-04-14 00:20:34 +0100" MODIFIED_BY="[Empty name]" ORDER="51924" O_E="0.0" SE="0.37697001486377146" STUDY_ID="STD-Schmoll-1992" TOTAL_1="63" TOTAL_2="28" VAR="0.1421063921063921" WEIGHT="12.378617533092996"/>
<DICH_DATA CI_END="2.160001993545509" CI_START="1.1271637657049847" EFFECT_SIZE="1.5603448275862069" ESTIMABLE="YES" EVENTS_1="181" EVENTS_2="19" LOG_CI_END="0.3344541519775116" LOG_CI_START="0.05198701930702044" LOG_EFFECT_SIZE="0.19322058564226602" MODIFIED="2012-04-14 00:20:42 +0100" MODIFIED_BY="[Empty name]" ORDER="51926" O_E="0.0" SE="0.1659225919655037" STUDY_ID="STD-Von-Roenn-1994" TOTAL_1="232" TOTAL_2="38" VAR="0.02753030652455104" WEIGHT="18.804815452940847"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="31.026641394512115" CI_END="1.9798538243061832" CI_START="1.2145531232665754" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5506894098826975" ESTIMABLE="YES" EVENTS_1="351" EVENTS_2="146" I2="48.431414807179145" I2_Q="0.0" ID="CMP-005.14" LOG_CI_END="0.2966331268066368" LOG_CI_START="0.08441651513701051" LOG_EFFECT_SIZE="0.1905248209718237" METHOD="MH" MODIFIED="2013-01-31 10:11:24 +0000" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.01335125073480703" P_Q="0.7734698267762458" P_Z="4.327666637900871E-4" Q="0.0828514152996396" RANDOM="YES" SCALE="196.11" SORT_BY="STUDY" STUDIES="17" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.11168924968808414" TOTALS="YES" TOTAL_1="1199" TOTAL_2="1038" WEIGHT="100.0" Z="3.5192512436024574">
<NAME>Weight improvement, study quality</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="24.36433407903759" CI_END="2.0986906319015457" CI_START="1.0699142471678398" DF="9" EFFECT_SIZE="1.4984722244570101" ESTIMABLE="YES" EVENTS_1="197" EVENTS_2="112" I2="63.06075934271745" ID="CMP-005.14.01" LOG_CI_END="0.3219484239276482" LOG_CI_START="0.029348970699944712" LOG_EFFECT_SIZE="0.17564869731379645" MODIFIED="2012-04-14 09:57:31 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0037609945910692666" P_Z="0.01861515085568402" STUDIES="10" TAU2="0.16828921549371148" TOTAL_1="697" TOTAL_2="625" WEIGHT="66.66982698463079" Z="2.3531494462397937">
<NAME>Study quality (Jadad score 3,4 or 5)</NAME>
<DICH_DATA CI_END="10.274845018517457" CI_START="1.6276445030275961" EFFECT_SIZE="4.089473684210526" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="5" LOG_CI_END="1.0117752798804394" LOG_CI_START="0.2115595558157313" LOG_EFFECT_SIZE="0.6116674178480853" MODIFIED="2012-04-14 00:25:27 +0100" MODIFIED_BY="[Empty name]" ORDER="51938" O_E="0.0" SE="0.47005067744732804" STUDY_ID="STD-Feliu-1992" TOTAL_1="76" TOTAL_2="74" VAR="0.22094763936869202" WEIGHT="4.671577370313354"/>
<DICH_DATA CI_END="5.09648598079" CI_START="1.0004649042928742" EFFECT_SIZE="2.2580645161290325" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" LOG_CI_END="0.7072708339097552" LOG_CI_START="2.0185845021324637E-4" LOG_EFFECT_SIZE="0.3537363461799842" MODIFIED="2012-04-14 00:25:27 +0100" MODIFIED_BY="[Empty name]" ORDER="130" O_E="0.0" SE="0.41533581623281146" STUDY_ID="STD-Fietkau-1996" TOTAL_1="31" TOTAL_2="30" VAR="0.17250384024577572" WEIGHT="5.4678984763870115"/>
<DICH_DATA CI_END="8.144860274151203" CI_START="1.1489714717071373" EFFECT_SIZE="3.059119496855346" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="5" LOG_CI_END="0.9108836383454965" LOG_CI_START="0.0603092455429576" LOG_EFFECT_SIZE="0.4855964419442271" MODIFIED="2012-04-14 00:25:27 +0100" MODIFIED_BY="[Empty name]" ORDER="198" O_E="0.0" SE="0.4996316087433604" STUDY_ID="STD-Jatoi-2002" TOTAL_1="159" TOTAL_2="152" VAR="0.24963174445547834" WEIGHT="4.300715952396742"/>
<DICH_DATA CI_END="6.736736556469645" CI_START="1.4703903131304714" EFFECT_SIZE="3.1473214285714284" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="8" LOG_CI_END="0.8284495643767887" LOG_CI_START="0.16743263293768296" LOG_EFFECT_SIZE="0.49794109865723585" MODIFIED="2012-04-14 00:25:27 +0100" MODIFIED_BY="[Empty name]" ORDER="208" O_E="0.0" SE="0.3882846176139129" STUDY_ID="STD-Jatoi-2004" TOTAL_1="140" TOTAL_2="141" VAR="0.15076494427558257" WEIGHT="5.920800654700877"/>
<DICH_DATA CI_END="1.4019742832668287" CI_START="0.6921468047426783" EFFECT_SIZE="0.9850746268656716" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="32" LOG_CI_END="0.1467400473412371" LOG_CI_START="-0.15980178165915268" LOG_EFFECT_SIZE="-0.00653086715895778" MODIFIED="2012-04-14 00:25:49 +0100" MODIFIED_BY="[Empty name]" ORDER="51940" O_E="0.0" SE="0.18006418776135494" STUDY_ID="STD-Loprinzi-1990b" TOTAL_1="67" TOTAL_2="66" VAR="0.03242311171415649" WEIGHT="10.782829094804553"/>
<DICH_DATA CI_END="1.7903122675350842" CI_START="0.20108223941047487" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.2529287875383019" LOG_CI_START="-0.6966262867710147" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2012-04-14 00:25:27 +0100" MODIFIED_BY="[Empty name]" ORDER="162" O_E="0.0" SE="0.5577733510227171" STUDY_ID="STD-McMillan-1994" TOTAL_1="20" TOTAL_2="18" VAR="0.3111111111111111" WEIGHT="3.6753491896547756"/>
<DICH_DATA CI_END="1.7527020355825875" CI_START="0.6696010430095779" EFFECT_SIZE="1.0833333333333333" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.24370809105031782" LOG_CI_START="-0.174183878531894" LOG_EFFECT_SIZE="0.03476210625921191" MODIFIED="2012-04-14 00:25:27 +0100" MODIFIED_BY="[Empty name]" ORDER="167" O_E="0.0" SE="0.24547181153120257" STUDY_ID="STD-Mwamburi-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.06025641025641024" WEIGHT="9.037384043020886"/>
<DICH_DATA CI_END="2.1734264488318" CI_START="0.873112966324461" EFFECT_SIZE="1.3775510204081634" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="16" LOG_CI_END="0.33714494776726445" LOG_CI_START="-0.05892956216224188" LOG_EFFECT_SIZE="0.13910769280251128" MODIFIED="2012-04-14 00:25:27 +0100" MODIFIED_BY="[Empty name]" ORDER="51943" O_E="0.0" SE="0.23265612773303632" STUDY_ID="STD-Tchekmedyian-1992" TOTAL_1="49" TOTAL_2="40" VAR="0.054128873771730916" WEIGHT="9.371345731250276">
<FOOTNOTE>Data at one month</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.5620676643452334" CI_START="0.8850337986238072" EFFECT_SIZE="1.505827505827506" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="13" LOG_CI_END="0.4085905953008247" LOG_CI_START="-0.05304014368010501" LOG_EFFECT_SIZE="0.17777522581035987" MODIFIED="2012-04-14 00:25:27 +0100" MODIFIED_BY="[Empty name]" ORDER="51944" O_E="0.0" SE="0.2711641811864099" STUDY_ID="STD-Vadell-1998" TOTAL_1="99" TOTAL_2="51" VAR="0.07353001315849614" WEIGHT="8.389726530421507">
<FOOTNOTE>Esta bien. Ha sumado los dos</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.6974685611582485" CI_START="0.2994554351039547" EFFECT_SIZE="0.7129629629629629" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.22980173945213891" LOG_CI_START="-0.5236678000810746" LOG_EFFECT_SIZE="-0.14693303031446786" MODIFIED="2012-04-14 09:57:31 +0100" MODIFIED_BY="[Empty name]" ORDER="51947" O_E="0.0" SE="0.44259173725618267" STUDY_ID="STD-Yeh-2000" TOTAL_1="36" TOTAL_2="33" VAR="0.19588744588744586" WEIGHT="5.05219994168081"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.190123046425888" CI_END="2.195777855173298" CI_START="1.1708170850640007" DF="6" EFFECT_SIZE="1.6033883583967063" ESTIMABLE="YES" EVENTS_1="154" EVENTS_2="34" I2="3.071393654051237" ID="CMP-005.14.02" LOG_CI_END="0.34158840082702363" LOG_CI_START="0.06848905121894659" LOG_EFFECT_SIZE="0.20503872602298515" MODIFIED="2012-04-14 00:27:04 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.40223326036603213" P_Z="0.0032502669304615675" STUDIES="7" TAU2="0.006099064570533291" TOTAL_1="502" TOTAL_2="413" WEIGHT="33.330173015369205" Z="2.9430206920503124">
<NAME>Study quality (Jadad score 2 or low)</NAME>
<DICH_DATA CI_END="1.8600503184319712" CI_START="0.7053928072271484" EFFECT_SIZE="1.1454545454545455" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.26952469299305315" LOG_CI_START="-0.1515689730743774" LOG_EFFECT_SIZE="0.05897785995933788" MODIFIED="2012-04-14 00:26:11 +0100" MODIFIED_BY="[Empty name]" ORDER="51976" O_E="0.0" SE="0.24735250389527325" STUDY_ID="STD-Batterham-2001" TOTAL_1="4" TOTAL_2="6" VAR="0.06118326118326117" WEIGHT="8.988930371963747"/>
<DICH_DATA CI_END="4.200975696245815" CI_START="0.5423909365820319" EFFECT_SIZE="1.509493670886076" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.6233501690369533" LOG_CI_START="-0.26568757619353306" LOG_EFFECT_SIZE="0.1788312964217101" MODIFIED="2012-04-14 00:26:28 +0100" MODIFIED_BY="[Empty name]" ORDER="51974" O_E="0.0" SE="0.5222251723562018" STUDY_ID="STD-Loprinzi-1999a" TOTAL_1="79" TOTAL_2="159" VAR="0.2727191306424647" WEIGHT="4.042416978820422"/>
<DICH_DATA CI_END="6.705706743584816" CI_START="0.5965068490098677" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.8264445567832687" LOG_CI_START="-0.22438456545530627" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2012-04-14 00:26:28 +0100" MODIFIED_BY="[Empty name]" ORDER="51975" O_E="0.0" SE="0.6172622280909857" STUDY_ID="STD-Loprinzi-1999b" TOTAL_1="79" TOTAL_2="158" VAR="0.38101265822784813" WEIGHT="3.153913022220753"/>
<DICH_DATA CI_END="38.04338372729278" CI_START="0.7575547118765404" EFFECT_SIZE="5.368421052631579" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="1" LOG_CI_END="1.5802791378325827" LOG_CI_START="-0.12058599621440545" LOG_EFFECT_SIZE="0.7298465708090885" MODIFIED="2012-04-14 00:26:47 +0100" MODIFIED_BY="[Empty name]" ORDER="218" O_E="0.0" SE="0.9990965991574009" STUDY_ID="STD-Schmoll-1991" TOTAL_1="38" TOTAL_2="17" VAR="0.9981940144478842" WEIGHT="1.4000922562417344"/>
<DICH_DATA CI_END="5.104141833207412" CI_START="0.6990207856990239" EFFECT_SIZE="1.8888888888888888" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="4" LOG_CI_END="0.7079227339974891" LOG_CI_START="-0.15550991011959098" LOG_EFFECT_SIZE="0.27620641193894907" MODIFIED="2012-04-14 00:26:47 +0100" MODIFIED_BY="[Empty name]" ORDER="51942" O_E="0.0" SE="0.5071846092148924" STUDY_ID="STD-Schmoll-1992" TOTAL_1="63" TOTAL_2="28" VAR="0.25723622782446315" WEIGHT="4.212067363648582"/>
<DICH_DATA CI_END="4.4199565732614685" CI_START="0.6284626854892529" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.6454180023614081" LOG_CI_START="-0.20172050312869536" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2012-04-14 00:26:57 +0100" MODIFIED_BY="[Empty name]" ORDER="449" O_E="0.0" SE="0.4976133515281193" STUDY_ID="STD-Summerbell-1992" TOTAL_1="7" TOTAL_2="7" VAR="0.24761904761904763" WEIGHT="4.324806788752734"/>
<DICH_DATA CI_END="4.04356192770385" CI_START="1.1429460967682334" EFFECT_SIZE="2.1497844827586206" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="8" LOG_CI_END="0.606764098776945" LOG_CI_START="0.058025748830864796" LOG_EFFECT_SIZE="0.33239492380390495" MODIFIED="2012-04-14 00:27:04 +0100" MODIFIED_BY="[Empty name]" ORDER="51945" O_E="0.0" SE="0.32233162305696766" STUDY_ID="STD-Von-Roenn-1994" TOTAL_1="232" TOTAL_2="38" VAR="0.1038976752225391" WEIGHT="7.207946233721233"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="56.0508516498319" CI_END="2.8103781913621932" CI_START="1.107856212525368" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="MD" EFFECT_SIZE="1.9591172019437806" ESTIMABLE="YES" I2="78.59086945731362" I2_Q="0.0" ID="CMP-005.15" MODIFIED="2013-01-31 10:11:31 +0000" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="1.172004209237798E-7" P_Q="0.7338380677644631" P_Z="6.460824649310606E-6" Q="0.1156167137436311" RANDOM="YES" SCALE="13.47" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="1.5859107052011465" TOTALS="YES" TOTAL_1="482" TOTAL_2="611" UNITS="" WEIGHT="100.0" Z="4.5107190450793135">
<NAME>Weight gain, study quality</NAME>
<GROUP_LABEL_1>Megestrol acetate</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="33.78599688226899" CI_END="2.9149142228539278" CI_START="0.8858333198044854" DF="8" EFFECT_SIZE="1.9003737713292066" ESTIMABLE="YES" I2="76.32155112108465" ID="CMP-005.15.01" MODIFIED="2012-04-14 00:32:40 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="4.441855655701321E-5" P_Z="2.4133683041720574E-4" STUDIES="9" TAU2="1.5390461076310853" TOTAL_1="267" TOTAL_2="261" WEIGHT="68.95243322609215" Z="3.6712820502840673">
<NAME>Study quality (Jadad score 3,4 or 5)</NAME>
<CONT_DATA CI_END="2.450790635597685" CI_START="0.3492093644023153" EFFECT_SIZE="1.4000000000000001" ESTIMABLE="YES" MEAN_1="1.06" MEAN_2="-0.34" MODIFIED="2012-04-14 00:30:18 +0100" MODIFIED_BY="[Empty name]" ORDER="51929" SD_1="1.95" SD_2="1.01" SE="0.5361275226923491" STUDY_ID="STD-De-Conno-1998" TOTAL_1="17" TOTAL_2="16" WEIGHT="10.069592145129038"/>
<CONT_DATA CI_END="6.3265405202233715" CI_START="1.2734594797766285" EFFECT_SIZE="3.8" ESTIMABLE="YES" MEAN_1="5.3" MEAN_2="1.5" MODIFIED="2012-04-14 00:30:48 +0100" MODIFIED_BY="[Empty name]" ORDER="51935" SD_1="3.6" SD_2="1.6" SE="1.2890749728833797" STUDY_ID="STD-Eubanks-2002" TOTAL_1="10" TOTAL_2="7" WEIGHT="5.808492143712874"/>
<CONT_DATA CI_END="4.007979966871202" CI_START="0.5920200331287977" EFFECT_SIZE="2.3000000000000003" ESTIMABLE="YES" MEAN_1="-0.9" MEAN_2="-3.2" MODIFIED="2012-04-14 00:30:18 +0100" MODIFIED_BY="[Empty name]" ORDER="51931" SD_1="3.6" SD_2="3.2" SE="0.8714343632554121" STUDY_ID="STD-Fietkau-1996" TOTAL_1="31" TOTAL_2="30" WEIGHT="8.043207878958308"/>
<CONT_DATA CI_END="4.000770353465514" CI_START="0.3992296465344851" EFFECT_SIZE="2.1999999999999997" ESTIMABLE="YES" MEAN_1="2.3" MEAN_2="0.1" MODIFIED="2012-04-14 00:30:48 +0100" MODIFIED_BY="[Empty name]" ORDER="129" SD_1="3.37" SD_2="1.18" SE="0.9187772671690712" STUDY_ID="STD-Herrejon-2011" TOTAL_1="15" TOTAL_2="16" WEIGHT="7.762683157370416"/>
<CONT_DATA CI_END="2.9782080386276055" CI_START="0.1817919613723944" EFFECT_SIZE="1.58" ESTIMABLE="YES" MEAN_1="1.36" MEAN_2="-0.22" MODIFIED="2012-04-14 00:30:18 +0100" MODIFIED_BY="[Empty name]" ORDER="51932" SD_1="4.99" SD_2="3.01" SE="0.7133845568880307" STUDY_ID="STD-Loprinzi-1990b" TOTAL_1="67" TOTAL_2="66" WEIGHT="9.004940817789441"/>
<CONT_DATA CI_END="2.628336756896459" CI_START="-2.028336756896459" EFFECT_SIZE="0.2999999999999998" ESTIMABLE="YES" MEAN_1="2.8" MEAN_2="2.5" MODIFIED="2012-04-14 00:31:30 +0100" MODIFIED_BY="[Empty name]" ORDER="168" SD_1="4.3" SD_2="2.4" SE="1.18794874562088" STUDY_ID="STD-Mwamburi-2004" TOTAL_1="18" TOTAL_2="15" WEIGHT="6.2939498187940135"/>
<CONT_DATA CI_END="11.836072310194206" CI_START="5.163927689805794" EFFECT_SIZE="8.5" ESTIMABLE="YES" MEAN_1="6.5" MEAN_2="-2.0" MODIFIED="2012-04-14 00:31:30 +0100" MODIFIED_BY="[Empty name]" ORDER="51972" SD_1="3.81" SD_2="4.5" SE="1.702108985934802" STUDY_ID="STD-Timpone-1997" TOTAL_1="12" TOTAL_2="12" WEIGHT="4.207772388462849"/>
<CONT_DATA CI_END="1.0101786698446733" CI_START="0.18982133015532654" EFFECT_SIZE="0.6" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="0.6" MODIFIED="2012-04-14 00:30:48 +0100" MODIFIED_BY="[Empty name]" ORDER="51936" SD_1="1.4" SD_2="1.1" SE="0.20927867709820713" STUDY_ID="STD-Weisberg-2002" TOTAL_1="72" TOTAL_2="73" WEIGHT="11.574957674321238">
<FOOTNOTE>Values at 2 weeks. Values at 8 weeks were written without SD</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="2.5107557286828244" CI_START="-2.230755728682824" EFFECT_SIZE="0.14" ESTIMABLE="YES" MEAN_1="1.05" MEAN_2="0.91" MODIFIED="2012-04-14 00:30:48 +0100" MODIFIED_BY="[Empty name]" ORDER="51937" SD_1="5.0" SD_2="3.47" SE="1.2095914758551907" STUDY_ID="STD-Yeh-2000" TOTAL_1="25" TOTAL_2="26" WEIGHT="6.186837201553979"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="21.039722670356703" CI_END="4.3474832569251545" CI_START="0.24697257130757944" DF="3" EFFECT_SIZE="2.297227914116367" ESTIMABLE="YES" I2="85.74125692147662" ID="CMP-005.15.02" MODIFIED="2013-01-31 09:59:27 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0329560401844962E-4" P_Z="0.028087641172171322" STUDIES="4" TAU2="3.3291787741814094" TOTAL_1="215" TOTAL_2="350" WEIGHT="31.04756677390784" Z="2.1960601111176166">
<NAME>Study quality (Jadad score 0 or low)</NAME>
<CONT_DATA CI_END="10.848577123414998" CI_START="1.5314228765850002" EFFECT_SIZE="6.1899999999999995" ESTIMABLE="YES" MEAN_1="10.2" MEAN_2="4.01" MODIFIED="2012-04-14 00:31:59 +0100" MODIFIED_BY="[Empty name]" ORDER="51971" SD_1="4.51" SD_2="1.68" SE="2.3768687384876768" STUDY_ID="STD-Batterham-2001" TOTAL_1="4" TOTAL_2="5" WEIGHT="2.6071486441197456"/>
<CONT_DATA CI_END="1.592969098374519" CI_START="-0.6129690983745186" EFFECT_SIZE="0.4900000000000002" ESTIMABLE="YES" MEAN_1="2.5" MEAN_2="2.01" MODIFIED="2012-04-14 00:32:22 +0100" MODIFIED_BY="[Empty name]" ORDER="51969" SD_1="4.45" SD_2="3.24" SE="0.5627496765627319" STUDY_ID="STD-Loprinzi-1999a" TOTAL_1="79" TOTAL_2="159" WEIGHT="9.91476139495627"/>
<CONT_DATA CI_END="1.7905445910798514" CI_START="-0.33054459107985146" EFFECT_SIZE="0.73" ESTIMABLE="YES" MEAN_1="2.5" MEAN_2="1.77" MODIFIED="2012-04-14 00:32:22 +0100" MODIFIED_BY="[Empty name]" ORDER="51970" SD_1="4.45" SD_2="2.58" SE="0.5411041220375945" STUDY_ID="STD-Loprinzi-1999b" TOTAL_1="79" TOTAL_2="158" WEIGHT="10.04085820289913">
<FOOTNOTE>SD were available from the previous review of Bernstein</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="5.824705003771884" CI_START="2.695294996228116" EFFECT_SIZE="4.26" ESTIMABLE="YES" MEAN_1="3.54" MEAN_2="-0.72" MODIFIED="2012-04-14 00:32:40 +0100" MODIFIED_BY="[Empty name]" ORDER="51934" SD_1="4.29" SD_2="2.85" SE="0.7983335490417564" STUDY_ID="STD-Von-Roenn-1994" TOTAL_1="53" TOTAL_2="28" WEIGHT="8.484798531932693">
<FOOTNOTE>MA 800 mg/d versus placebo</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="12.570803115845079" CI_END="1.7197261084366382" CI_START="1.1247080223433092" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="RR" EFFECT_SIZE="1.390751505622743" ESTIMABLE="YES" EVENTS_1="173" EVENTS_2="109" I2="0.0" I2_Q="38.17328065482587" ID="CMP-005.16" LOG_CI_END="0.23545928465967836" LOG_CI_START="0.05103979289795316" LOG_EFFECT_SIZE="0.14324953877881577" METHOD="MH" MODIFIED="2013-01-31 10:11:38 +0000" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.48148314339884046" P_Q="0.19840935798422676" P_Z="0.0023280400545894597" Q="3.234847362406767" RANDOM="NO" SCALE="87.06" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1239" TOTAL_2="997" WEIGHT="100.0" Z="3.044840153569094">
<NAME>Sensitivity duration oedema</NAME>
<GROUP_LABEL_1>Megestrol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours megestrol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.8113536112087703" CI_END="3.080589706683515" CI_START="1.067661800374512" DF="3" EFFECT_SIZE="1.8135677413465732" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="17" I2="0.0" ID="CMP-005.16.01" LOG_CI_END="0.4886338599563691" LOG_CI_START="0.028433704479301592" LOG_EFFECT_SIZE="0.2585337822178353" MODIFIED="2013-01-31 09:59:46 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6124675371107131" P_Z="0.027654095991114812" STUDIES="4" TAU2="0.0" TOTAL_1="385" TOTAL_2="253" WEIGHT="17.00558160063445" Z="2.202158760283729">
<NAME>1 to 4 weeks</NAME>
<DICH_DATA CI_END="81.5401396001865" CI_START="0.2422498479473772" EFFECT_SIZE="4.444444444444445" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.911371450647396" LOG_CI_START="-0.6157364868701207" LOG_EFFECT_SIZE="0.6478174818886375" MODIFIED="2012-02-20 11:10:41 +0000" MODIFIED_BY="[Empty name]" ORDER="109" O_E="0.0" SE="1.4844357118838287" STUDY_ID="STD-Beller-1997" TOTAL_1="161" TOTAL_2="79" VAR="2.2035493827160493" WEIGHT="0.6161834759780783"/>
<DICH_DATA CI_END="2.648913122911793" CI_START="0.5281432800850032" EFFECT_SIZE="1.1827956989247312" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.42306771486245204" LOG_CI_START="-0.2772482416538721" LOG_EFFECT_SIZE="0.07290973660428994" MODIFIED="2012-02-20 11:12:48 +0000" MODIFIED_BY="[Empty name]" ORDER="138" O_E="0.0" SE="0.4113690594775825" STUDY_ID="STD-Gebbia-1996" TOTAL_1="62" TOTAL_2="60" VAR="0.16922450309547082" WEIGHT="8.42005179742722"/>
<DICH_DATA CI_END="4.792262977570249" CI_START="1.0563902740092879" EFFECT_SIZE="2.25" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="8" LOG_CI_END="0.6805406421387491" LOG_CI_START="0.02382439408397598" LOG_EFFECT_SIZE="0.3521825181113625" MODIFIED="2012-02-20 11:04:14 +0000" MODIFIED_BY="[Empty name]" ORDER="250" O_E="0.0" SE="0.3857583749052298" STUDY_ID="STD-Loprinzi-1990b" TOTAL_1="63" TOTAL_2="63" VAR="0.1488095238095238" WEIGHT="7.363772898108393"/>
<DICH_DATA CI_END="53.16111846915853" CI_START="0.12716060524425982" EFFECT_SIZE="2.6" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7255941095896155" LOG_CI_START="-0.8956474136479796" LOG_EFFECT_SIZE="0.414973347970818" MODIFIED="2012-04-14 10:56:34 +0100" MODIFIED_BY="[Empty name]" ORDER="349" O_E="0.0" SE="1.5397302461045672" STUDY_ID="STD-Vadell-1998" TOTAL_1="99" TOTAL_2="51" VAR="2.370769230769231" WEIGHT="0.6055734291207561"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.842282910462251" CI_END="1.9687554798240785" CI_START="1.0379775754889287" DF="6" EFFECT_SIZE="1.4295188140344077" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="67" I2="0.0" ID="CMP-005.16.02" LOG_CI_END="0.29419177994842977" LOG_CI_START="0.01618797109758734" LOG_EFFECT_SIZE="0.15518987552300859" MODIFIED="2013-01-31 09:59:52 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.564195074985917" P_Z="0.028653675496548296" STUDIES="7" TAU2="0.0" TOTAL_1="552" TOTAL_2="673" WEIGHT="51.80915184322635" Z="2.188218701374308">
<NAME>&gt; 5 to 8 weeks</NAME>
<DICH_DATA CI_END="8.454599871089044" CI_START="0.610515601735595" EFFECT_SIZE="2.2719298245614037" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.9270930586646785" LOG_CI_START="-0.2143032331751198" LOG_EFFECT_SIZE="0.35639491274477925" MODIFIED="2012-04-14 11:07:12 +0100" MODIFIED_BY="[Empty name]" ORDER="279" O_E="0.0" SE="0.6704618318294641" STUDY_ID="STD-Feliu-1992" TOTAL_1="76" TOTAL_2="74" VAR="0.44951906794012053" WEIGHT="2.7982337012811893"/>
<DICH_DATA CI_END="2.8432163806372266" CI_START="0.9353651130956683" EFFECT_SIZE="1.6307806141324455" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="17" LOG_CI_END="0.4538099125714769" LOG_CI_START="-0.029018832281470428" LOG_EFFECT_SIZE="0.21239554014500323" MODIFIED="2012-04-14 11:07:12 +0100" MODIFIED_BY="[Empty name]" ORDER="213" O_E="0.0" SE="0.28361599476745436" STUDY_ID="STD-Jatoi-2002" TOTAL_1="159" TOTAL_2="152" VAR="0.08043803248793269" WEIGHT="16.00022358809243"/>
<DICH_DATA CI_END="1.666271152948541" CI_START="0.4220577767556478" EFFECT_SIZE="0.8386075949367089" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="24" LOG_CI_END="0.22174567573055243" LOG_CI_START="-0.37462809309374434" LOG_EFFECT_SIZE="-0.07644120868159596" MODIFIED="2012-04-14 11:07:12 +0100" MODIFIED_BY="[Empty name]" ORDER="268" O_E="0.0" SE="0.3503129039051584" STUDY_ID="STD-Loprinzi-1999a" TOTAL_1="79" TOTAL_2="159" VAR="0.12271913064246476" WEIGHT="14.665665351694868">
<FOOTNOTE>We have split events and total patients</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="3.0995830674633513" CI_START="0.6185218210275557" EFFECT_SIZE="1.3846153846153846" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" LOG_CI_END="0.4913032797447138" LOG_CI_START="-0.20864497415177521" LOG_EFFECT_SIZE="0.1413291527964693" MODIFIED="2012-04-14 11:07:12 +0100" MODIFIED_BY="[Empty name]" ORDER="269" O_E="0.0" SE="0.411153069138534" STUDY_ID="STD-Loprinzi-1999b" TOTAL_1="79" TOTAL_2="158" VAR="0.16904684626203612" WEIGHT="7.977420639617425">
<FOOTNOTE>We have split events and total patients</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="45.64099187213433" CI_START="0.11668115806733034" EFFECT_SIZE="2.3076923076923075" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.6593550739563865" LOG_CI_START="-0.9329992691307355" LOG_EFFECT_SIZE="0.3631779024128256" MODIFIED="2012-04-14 11:07:12 +0100" MODIFIED_BY="[Empty name]" ORDER="223" O_E="0.0" SE="1.5227617734903314" STUDY_ID="STD-Schmoll-1991" TOTAL_1="38" TOTAL_2="17" VAR="2.318803418803419" WEIGHT="0.6297963662855862"/>
<DICH_DATA CI_END="2.8787678644278736" CI_START="0.41152729900149687" EFFECT_SIZE="1.08843537414966" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.4592066460303423" LOG_CI_START="-0.3856013502148449" LOG_EFFECT_SIZE="0.036802647907748724" MODIFIED="2012-04-14 11:11:18 +0100" MODIFIED_BY="[Empty name]" ORDER="458" O_E="0.0" SE="0.4962443988614486" STUDY_ID="STD-Tchekmedyian-1992" TOTAL_1="49" TOTAL_2="40" VAR="0.2462585034013605" WEIGHT="6.0813180675389535"/>
<DICH_DATA CI_END="8.351880446698283" CI_START="0.930811726729654" EFFECT_SIZE="2.7881944444444446" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" LOG_CI_END="0.9217842689782489" LOG_CI_START="-0.031138153939348854" LOG_EFFECT_SIZE="0.4453230575194501" MODIFIED="2012-04-14 11:07:12 +0100" MODIFIED_BY="[Empty name]" ORDER="237" O_E="0.0" SE="0.559751348263866" STUDY_ID="STD-Weisberg-2002" TOTAL_1="72" TOTAL_2="73" VAR="0.31332157188321574" WEIGHT="3.6564941287158916"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.423226537667652" CI_END="1.4573510213098193" CI_START="0.8239166369975098" DF="2" EFFECT_SIZE="1.0957808870401384" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="25" I2="54.784138163210805" ID="CMP-005.16.03" LOG_CI_END="0.1635641696540456" LOG_CI_START="-0.08411672753038447" LOG_EFFECT_SIZE="0.03972372106183057" MODIFIED="2013-01-31 09:59:56 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.10952391307743115" P_Z="0.5295530291836799" STUDIES="2" TAU2="0.0" TOTAL_1="302" TOTAL_2="71" WEIGHT="31.185266556139204" Z="0.628688473743121">
<NAME>9 to 12 weeks</NAME>
<DICH_DATA CI_END="1.6755022190767384" CI_START="0.9432444465135759" EFFECT_SIZE="1.2571428571428571" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="21" LOG_CI_END="0.2241450073620657" LOG_CI_START="-0.02537574309024209" LOG_EFFECT_SIZE="0.09938463213591178" MODIFIED="2012-04-14 11:03:56 +0100" MODIFIED_BY="[Empty name]" ORDER="150" O_E="0.0" SE="0.14656972396332055" STUDY_ID="STD-Casado-2008" TOTAL_1="60" TOTAL_2="33" VAR="0.02148268398268398" WEIGHT="24.941811429076814"/>
<DICH_DATA CI_END="1.3243001827858807" CI_START="0.01211541359957555" EFFECT_SIZE="0.12666666666666668" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.12198643899412455" LOG_CI_START="-1.916661755199829" LOG_EFFECT_SIZE="-0.8973376581028523" MODIFIED="2012-04-14 11:10:16 +0100" MODIFIED_BY="[Empty name]" ORDER="194" O_E="0.0" SE="1.1975120407408428" STUDY_ID="STD-Von-Roenn-1994" TOTAL_1="75" TOTAL_2="19" VAR="1.4340350877192982" WEIGHT="2.9376753582879225"/>
<DICH_DATA CI_END="3.0322048441667704" CI_START="0.18036091740217222" EFFECT_SIZE="0.7395209580838323" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="2" LOG_CI_END="0.48175853722592" LOG_CI_START="-0.7438575643297174" LOG_EFFECT_SIZE="-0.13104951355189876" MODIFIED="2012-04-14 11:10:16 +0100" MODIFIED_BY="[Empty name]" ORDER="195" O_E="0.0" SE="0.7199329649513297" STUDY_ID="STD-Von-Roenn-1994" TOTAL_1="167" TOTAL_2="19" VAR="0.5183034740236125" WEIGHT="3.3057797687744666"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.16.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-04-14 11:01:57 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>&gt; 12 weeks</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.2160117855543415" CI_END="3.174587017550965" CI_START="1.1087185826567132" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8760926465981118" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="18" I2="0.0" I2_Q="11.863746112558166" ID="CMP-005.17" LOG_CI_END="0.50168723587541" LOG_CI_START="0.04482132657404073" LOG_EFFECT_SIZE="0.27325428122472534" METHOD="MH" MODIFIED="2013-01-31 10:11:47 +0000" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.9370765830491934" P_Q="0.2867948529971702" P_Z="0.01905093588744898" Q="1.1346068795675077" RANDOM="NO" SCALE="323.08" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="761" TOTAL_2="843" WEIGHT="100.0" Z="2.3445327782973457">
<NAME>Sensitivity duration thromboembolic phenomena</NAME>
<GROUP_LABEL_1>Megestrol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours megestrol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.8712954674789954" CI_END="5.7619594891088655" CI_START="1.1621082666271891" DF="6" EFFECT_SIZE="2.5876670485718187" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="7" I2="0.0" ID="CMP-005.17.01" LOG_CI_END="0.7605702005396172" LOG_CI_START="0.0652465905400504" LOG_EFFECT_SIZE="0.4129083955398338" MODIFIED="2013-01-31 10:00:03 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8248186864834943" P_Z="0.01992296530506768" STUDIES="7" TAU2="0.0" TOTAL_1="395" TOTAL_2="539" WEIGHT="37.65680675574203" Z="2.3277954970428736">
<NAME>&lt; 12 weeks</NAME>
<DICH_DATA CI_END="129.75780650166408" CI_START="0.3582644047330511" EFFECT_SIZE="6.818181818181818" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.113133495372975" LOG_CI_START="-0.44579633890602527" LOG_EFFECT_SIZE="0.8336685782334751" MODIFIED="2012-02-20 11:17:46 +0000" MODIFIED_BY="[Empty name]" ORDER="282" O_E="0.0" SE="1.5031280515624539" STUDY_ID="STD-Feliu-1992" TOTAL_1="76" TOTAL_2="74" VAR="2.2593939393939393" WEIGHT="2.5640787035469748"/>
<DICH_DATA CI_END="8.030017184192781" CI_START="0.013836970527265503" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9047164746674874" LOG_CI_START="-1.8589589841068126" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2012-02-20 11:15:25 +0000" MODIFIED_BY="[Empty name]" ORDER="252" O_E="0.0" SE="1.6233966448981796" STUDY_ID="STD-Loprinzi-1990b" TOTAL_1="63" TOTAL_2="63" VAR="2.6354166666666665" WEIGHT="7.59233694037286"/>
<DICH_DATA CI_END="21.507553852360854" CI_START="0.7533712424818613" EFFECT_SIZE="4.025316455696203" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.3325910189959207" LOG_CI_START="-0.12299096160793822" LOG_EFFECT_SIZE="0.6048000286939913" MODIFIED="2012-02-20 11:15:25 +0000" MODIFIED_BY="[Empty name]" ORDER="262" O_E="0.0" SE="0.8550160606537155" STUDY_ID="STD-Loprinzi-1999a" TOTAL_1="79" TOTAL_2="159" VAR="0.7310524639757982" WEIGHT="6.720387879993904"/>
<DICH_DATA CI_END="11.62563201676808" CI_START="0.6116752277084367" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="1.0654165722229592" LOG_CI_START="-0.213479107678397" LOG_EFFECT_SIZE="0.4259687322722811" MODIFIED="2012-02-20 11:15:25 +0000" MODIFIED_BY="[Empty name]" ORDER="263" O_E="0.0" SE="0.7512296530097713" STUDY_ID="STD-Loprinzi-1999b" TOTAL_1="79" TOTAL_2="158" VAR="0.5643459915611814" WEIGHT="10.123115920497147"/>
<DICH_DATA CI_END="59.29601510215695" CI_START="0.11151246650499884" EFFECT_SIZE="2.5714285714285716" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.773025508249681" LOG_CI_START="-0.9526765780715827" LOG_EFFECT_SIZE="0.41017446508904926" MODIFIED="2012-02-20 11:18:05 +0000" MODIFIED_BY="[Empty name]" ORDER="224" O_E="0.0" SE="1.601090897948041" STUDY_ID="STD-Schmoll-1991" TOTAL_1="20" TOTAL_2="17" VAR="2.5634920634920637" WEIGHT="2.725454286287693"/>
<DICH_DATA CI_END="14.696930580691841" CI_START="0.06342981197893298" EFFECT_SIZE="0.9655172413793104" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.167226642839416" LOG_CI_START="-1.1977065759528895" LOG_EFFECT_SIZE="-0.015239966556736846" MODIFIED="2012-02-20 11:15:25 +0000" MODIFIED_BY="[Empty name]" ORDER="228" O_E="0.0" SE="1.389173479326835" STUDY_ID="STD-Schmoll-1992" TOTAL_1="29" TOTAL_2="28" VAR="1.9298029556650245" WEIGHT="5.150357222709075"/>
<DICH_DATA CI_END="83.0247600695134" CI_START="0.20246972091127569" EFFECT_SIZE="4.1" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9192076292190898" LOG_CI_START="-0.6936399157796186" LOG_EFFECT_SIZE="0.6127838567197355" MODIFIED="2012-02-20 11:15:25 +0000" MODIFIED_BY="[Empty name]" ORDER="461" O_E="0.0" SE="1.5347995817361826" STUDY_ID="STD-Tchekmedyian-1992" TOTAL_1="49" TOTAL_2="40" VAR="2.355609756097561" WEIGHT="2.7810758023343816"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.23367803897417644" CI_END="2.9436777332813384" CI_START="0.7105867900092437" DF="3" EFFECT_SIZE="1.446284381203805" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="11" I2="0.0" ID="CMP-005.17.02" LOG_CI_END="0.4688902627583607" LOG_CI_START="-0.14838287041750076" LOG_EFFECT_SIZE="0.16025369617043003" MODIFIED="2013-01-31 10:00:07 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9719777033385615" P_Z="0.30883282329620965" STUDIES="5" TAU2="0.0" TOTAL_1="366" TOTAL_2="304" WEIGHT="62.34319324425797" Z="1.0176742061248354">
<NAME>&gt; 12 weeks</NAME>
<DICH_DATA CI_END="58.07278205442537" CI_START="0.1417241285924793" EFFECT_SIZE="2.8688524590163933" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7639726319906837" LOG_CI_START="-0.8485562046396291" LOG_EFFECT_SIZE="0.4577082136755274" MODIFIED="2012-03-10 16:22:12 +0000" MODIFIED_BY="[Empty name]" ORDER="144" O_E="0.0" SE="1.5346123708629553" STUDY_ID="STD-Casado-2008" TOTAL_1="60" TOTAL_2="34" VAR="2.355035128805621" WEIGHT="3.216198287241281"/>
<DICH_DATA CI_END="5.524267745677316" CI_START="0.3013851679121783" EFFECT_SIZE="1.2903225806451613" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7422747194453831" LOG_CI_START="-0.5208781244580037" LOG_EFFECT_SIZE="0.1106982974936897" MODIFIED="2012-02-20 11:15:25 +0000" MODIFIED_BY="[Empty name]" ORDER="139" O_E="0.0" SE="0.7419822332162692" STUDY_ID="STD-Gebbia-1996" TOTAL_1="62" TOTAL_2="60" VAR="0.550537634408602" WEIGHT="15.433602960757945">
<FOOTNOTE>Both arms were MA. First MA 160 mg and second MA 320 mg daily</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="3.3392773430618368" CI_START="0.5742950321317771" EFFECT_SIZE="1.3848214285714286" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.5236524908001913" LOG_CI_START="-0.2408649405133445" LOG_EFFECT_SIZE="0.14139377514342336" MODIFIED="2012-02-20 11:15:25 +0000" MODIFIED_BY="[Empty name]" ORDER="214" O_E="0.0" SE="0.4490813235758903" STUDY_ID="STD-Jatoi-2004" TOTAL_1="140" TOTAL_2="141" VAR="0.20167403518467347" WEIGHT="40.34836238774664"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-06-19 11:03:28 +0100" MODIFIED_BY="[Empty name]" ORDER="519" O_E="0.0" SE="0.0" STUDY_ID="STD-Madeddu-2012" TOTAL_1="29" TOTAL_2="31" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="36.917263636388" CI_START="0.06419704471381053" EFFECT_SIZE="1.5394736842105263" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.567229502980672" LOG_CI_START="-1.1924849640499313" LOG_EFFECT_SIZE="0.1873722694653703" MODIFIED="2012-02-20 11:15:25 +0000" MODIFIED_BY="[Empty name]" ORDER="191" O_E="0.0" SE="1.6210699387407068" STUDY_ID="STD-Von-Roenn-1994" TOTAL_1="75" TOTAL_2="38" VAR="2.627867746288799" WEIGHT="3.3450296085121005"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="270.4441811723028" CI_END="3.4261881811225408" CI_START="1.4080885176718947" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="MD" EFFECT_SIZE="2.417138349397218" ESTIMABLE="YES" I2="95.19309310200408" I2_Q="0.0" ID="CMP-005.18" MODIFIED="2013-01-31 10:11:54 +0000" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="-4.440892098500626E-16" P_Q="0.485485887147602" P_Z="2.6658714211169597E-6" Q="0.4865153846761296" RANDOM="YES" SCALE="17.91" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="2.9286990966632" TOTALS="YES" TOTAL_1="544" TOTAL_2="670" UNITS="" WEIGHT="100.0" Z="4.695015014638794">
<NAME>Sensitivity blinded versus open-label weight gain</NAME>
<GROUP_LABEL_1>Megestrol acetate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="32.3016984151985" CI_END="2.279006503253616" CI_START="1.1109454023513874" DF="8" EFFECT_SIZE="1.6949759528025017" ESTIMABLE="YES" I2="75.23350042722255" ID="CMP-005.18.01" MODIFIED="2012-02-19 21:08:41 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="8.223562728360001E-5" P_Z="1.2837351263204345E-8" STUDIES="9" TAU2="0.37157295838964904" TOTAL_1="352" TOTAL_2="321" WEIGHT="66.04807725188927" Z="5.688215829785497">
<NAME>Blinded studies</NAME>
<CONT_DATA CI_END="2.450790635597685" CI_START="0.3492093644023153" EFFECT_SIZE="1.4000000000000001" ESTIMABLE="YES" MEAN_1="1.06" MEAN_2="-0.34" MODIFIED="2012-02-19 19:46:26 +0000" MODIFIED_BY="[Empty name]" ORDER="51929" SD_1="1.95" SD_2="1.01" SE="0.5361275226923491" STUDY_ID="STD-De-Conno-1998" TOTAL_1="17" TOTAL_2="16" WEIGHT="8.241290178013395"/>
<CONT_DATA CI_END="6.3265405202233715" CI_START="1.2734594797766285" EFFECT_SIZE="3.8" ESTIMABLE="YES" MEAN_1="5.3" MEAN_2="1.5" MODIFIED="2012-02-19 19:46:26 +0000" MODIFIED_BY="[Empty name]" ORDER="51935" SD_1="3.6" SD_2="1.6" SE="1.2890749728833797" STUDY_ID="STD-Eubanks-2002" TOTAL_1="10" TOTAL_2="7" WEIGHT="5.774006249298403"/>
<CONT_DATA CI_END="1.054293157887498" CI_START="0.9457068421125022" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="-0.8" MEAN_2="-1.8" MODIFIED="2012-02-19 19:46:26 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Pendiente de Marta Roque para ver si la MD y la SD calculada es correcta ponerla&lt;/p&gt;" NOTES_MODIFIED="2012-02-19 19:46:26 +0000" NOTES_MODIFIED_BY="[Empty name]" ORDER="276" SD_1="0.2" SD_2="0.1" SE="0.027701099773136287" STUDY_ID="STD-Feliu-1992" TOTAL_1="66" TOTAL_2="62" WEIGHT="9.04774846576551"/>
<CONT_DATA CI_END="4.007979966871202" CI_START="0.5920200331287977" EFFECT_SIZE="2.3000000000000003" ESTIMABLE="YES" MEAN_1="-0.9" MEAN_2="-3.2" MODIFIED="2012-02-19 19:46:26 +0000" MODIFIED_BY="[Empty name]" ORDER="51931" SD_1="3.6" SD_2="3.2" SE="0.8714343632554121" STUDY_ID="STD-Fietkau-1996" TOTAL_1="31" TOTAL_2="30" WEIGHT="7.186653698069093"/>
<CONT_DATA CI_END="4.000770353465514" CI_START="0.3992296465344851" EFFECT_SIZE="2.1999999999999997" ESTIMABLE="YES" MEAN_1="2.3" MEAN_2="0.1" MODIFIED="2012-02-19 19:46:26 +0000" MODIFIED_BY="[Empty name]" ORDER="129" SD_1="3.37" SD_2="1.18" SE="0.9187772671690712" STUDY_ID="STD-Herrejon-2011" TOTAL_1="15" TOTAL_2="16" WEIGHT="7.025211761442057"/>
<CONT_DATA CI_END="2.9782080386276055" CI_START="0.1817919613723944" EFFECT_SIZE="1.58" ESTIMABLE="YES" MEAN_1="1.36" MEAN_2="-0.22" MODIFIED="2012-02-19 19:46:26 +0000" MODIFIED_BY="[Empty name]" ORDER="51932" SD_1="4.99" SD_2="3.01" SE="0.7133845568880307" STUDY_ID="STD-Loprinzi-1990b" TOTAL_1="67" TOTAL_2="66" WEIGHT="7.7103058502572965"/>
<CONT_DATA CI_END="5.824705003771884" CI_START="2.695294996228116" EFFECT_SIZE="4.26" ESTIMABLE="YES" MEAN_1="3.54" MEAN_2="-0.72" MODIFIED="2012-02-19 19:48:25 +0000" MODIFIED_BY="[Empty name]" ORDER="51934" SD_1="4.29" SD_2="2.85" SE="0.7983335490417564" STUDY_ID="STD-Von-Roenn-1994" TOTAL_1="53" TOTAL_2="28" WEIGHT="7.432644786853569">
<FOOTNOTE>MA 800 mg/d versus placebo</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="1.0101786698446733" CI_START="0.18982133015532654" EFFECT_SIZE="0.6" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="0.6" MODIFIED="2012-02-19 19:46:26 +0000" MODIFIED_BY="[Empty name]" ORDER="51936" SD_1="1.4" SD_2="1.1" SE="0.20927867709820713" STUDY_ID="STD-Weisberg-2002" TOTAL_1="72" TOTAL_2="73" WEIGHT="8.916772187277243">
<FOOTNOTE>Values at 2 weeks. Values at 8 weeks were written without SD</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="6.607323465695768" CI_START="0.17267653430423202" EFFECT_SIZE="3.39" ESTIMABLE="YES" MEAN_1="2.94" MEAN_2="-0.45" MODIFIED="2012-02-19 19:46:26 +0000" MODIFIED_BY="[Empty name]" ORDER="51937" SD_1="6.41" SD_2="4.12" SE="1.641521727477446" STUDY_ID="STD-Yeh-2000" TOTAL_1="21" TOTAL_2="23" WEIGHT="4.713444074912703"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="166.79966177007236" CI_END="7.186731160261775" CI_START="-0.8918870700560722" DF="4" EFFECT_SIZE="3.1474220451028514" ESTIMABLE="YES" I2="97.60191360249047" ID="CMP-005.18.02" MODIFIED="2013-01-31 10:00:28 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="5.551115123125783E-16" P_Z="0.12671122650654576" STUDIES="5" TAU2="19.83330013706259" TOTAL_1="192" TOTAL_2="349" WEIGHT="33.951922748110725" Z="1.5272002406050775">
<NAME>Open-label studies</NAME>
<CONT_DATA CI_END="10.848577123414998" CI_START="1.5314228765850002" EFFECT_SIZE="6.1899999999999995" ESTIMABLE="YES" MEAN_1="10.2" MEAN_2="4.01" MODIFIED="2012-02-19 19:46:26 +0000" MODIFIED_BY="[Empty name]" ORDER="312" SD_1="4.51" SD_2="1.68" SE="2.3768687384876768" STUDY_ID="STD-Batterham-2001" TOTAL_1="4" TOTAL_2="5" WEIGHT="3.089816383247482"/>
<CONT_DATA CI_END="1.592969098374519" CI_START="-0.6129690983745186" EFFECT_SIZE="0.4900000000000002" ESTIMABLE="YES" MEAN_1="2.5" MEAN_2="2.01" MODIFIED="2012-02-19 19:46:26 +0000" MODIFIED_BY="[Empty name]" ORDER="310" SD_1="4.45" SD_2="3.24" SE="0.5627496765627319" STUDY_ID="STD-Loprinzi-1999a" TOTAL_1="79" TOTAL_2="159" WEIGHT="8.16700175151595"/>
<CONT_DATA CI_END="1.7905445910798514" CI_START="-0.33054459107985146" EFFECT_SIZE="0.73" ESTIMABLE="YES" MEAN_1="2.5" MEAN_2="1.77" MODIFIED="2012-02-19 19:46:26 +0000" MODIFIED_BY="[Empty name]" ORDER="311" SD_1="4.45" SD_2="2.58" SE="0.5411041220375945" STUDY_ID="STD-Loprinzi-1999b" TOTAL_1="79" TOTAL_2="158" WEIGHT="8.227575682832944"/>
<CONT_DATA CI_END="2.628336756896459" CI_START="-2.028336756896459" EFFECT_SIZE="0.2999999999999998" ESTIMABLE="YES" MEAN_1="2.8" MEAN_2="2.5" MODIFIED="2012-02-19 19:48:50 +0000" MODIFIED_BY="[Empty name]" ORDER="313" SD_1="4.3" SD_2="2.4" SE="1.18794874562088" STUDY_ID="STD-Mwamburi-2004" TOTAL_1="18" TOTAL_2="15" WEIGHT="6.107270987004358"/>
<CONT_DATA CI_END="9.463510533587678" CI_START="7.536489466412321" EFFECT_SIZE="8.5" ESTIMABLE="YES" MEAN_1="6.5" MEAN_2="-2.0" MODIFIED="2012-02-19 19:49:02 +0000" MODIFIED_BY="[Empty name]" ORDER="314" SD_1="1.1" SD_2="1.3" SE="0.49159604012508756" STUDY_ID="STD-Timpone-1997" TOTAL_1="12" TOTAL_2="12" WEIGHT="8.360257943509987"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="24.08292974499677" CI_END="2.5393122612422356" CI_START="1.1426074600083678" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7033605411028212" ESTIMABLE="YES" EVENTS_1="346" EVENTS_2="155" I2="75.08608768313788" I2_Q="66.26548810887246" ID="CMP-005.19" LOG_CI_END="0.4047161096944523" LOG_CI_START="0.05789705521367138" LOG_EFFECT_SIZE="0.23130658245406188" METHOD="MH" MODIFIED="2013-01-31 10:12:00 +0000" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="5.042299425692676E-4" P_Q="0.08512023917365885" P_Z="0.008939835084533632" Q="2.964323311472037" RANDOM="YES" SCALE="92.93" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.19317462033056856" TOTALS="YES" TOTAL_1="634" TOTAL_2="540" WEIGHT="100.0" Z="2.6143463869118437">
<NAME>Sensitivity number of patients in trial appetite improvement</NAME>
<GROUP_LABEL_1>Megestrol acetate</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.6385054831830531" CI_END="6.068236623160438" CI_START="1.5243235028077886" DF="1" EFFECT_SIZE="3.04137398313368" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="7" I2="0.0" ID="CMP-005.19.01" LOG_CI_END="0.7830625072052111" LOG_CI_START="0.18307714585841836" LOG_EFFECT_SIZE="0.48306982653181474" MODIFIED="2013-01-31 10:00:37 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4242527446077736" P_Z="0.0015990762300017317" STUDIES="2" TAU2="0.0" TOTAL_1="101" TOTAL_2="45" WEIGHT="15.897432746104439" Z="3.1560752078853356">
<NAME>n &lt; 100 patients</NAME>
<DICH_DATA CI_END="43.86715397607745" CI_START="0.8942259357832195" EFFECT_SIZE="6.2631578947368425" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="1" LOG_CI_END="1.6421394590555214" LOG_CI_START="-0.04855273817611772" LOG_EFFECT_SIZE="0.7967933604397018" MODIFIED="2012-02-20 11:37:55 +0000" MODIFIED_BY="[Empty name]" ORDER="219" O_E="0.0" SE="0.9931209657152156" STUDY_ID="STD-Schmoll-1991" TOTAL_1="38" TOTAL_2="17" VAR="0.9862892525431224" WEIGHT="3.5188152130114387"/>
<DICH_DATA CI_END="5.737800103182554" CI_START="1.309153277018078" EFFECT_SIZE="2.740740740740741" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="6" LOG_CI_END="0.7587454139697585" LOG_CI_START="0.11699049717421948" LOG_EFFECT_SIZE="0.43786795557198893" MODIFIED="2012-02-20 11:37:59 +0000" MODIFIED_BY="[Empty name]" ORDER="51924" O_E="0.0" SE="0.37697001486377146" STUDY_ID="STD-Schmoll-1992" TOTAL_1="63" TOTAL_2="28" VAR="0.1421063921063921" WEIGHT="12.378617533093001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="18.33904303504309" CI_END="2.2685476352054543" CI_START="0.9902330005552216" DF="4" EFFECT_SIZE="1.4987964277085628" ESTIMABLE="YES" EVENTS_1="295" EVENTS_2="148" I2="78.1886110831595" ID="CMP-005.19.02" LOG_CI_END="0.3557479030596816" LOG_CI_START="-0.004262604443419778" LOG_EFFECT_SIZE="0.1757426493081309" MODIFIED="2012-02-20 11:37:59 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0010593252376452922" P_Z="0.055677529878389476" STUDIES="5" TAU2="0.17029787384184325" TOTAL_1="533" TOTAL_2="495" WEIGHT="84.10256725389556" Z="1.9135511659399127">
<NAME>n &gt; 100 patients</NAME>
<DICH_DATA CI_END="6.869043147371471" CI_START="1.9929995643190366" EFFECT_SIZE="3.7" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="10" LOG_CI_END="0.8368962443727193" LOG_CI_START="0.2995072037612709" LOG_EFFECT_SIZE="0.568201724066995" MODIFIED="2012-02-20 11:37:27 +0000" MODIFIED_BY="[Empty name]" ORDER="51920" O_E="0.0" SE="0.31566498257381764" STUDY_ID="STD-Feliu-1992" TOTAL_1="76" TOTAL_2="74" VAR="0.0996443812233286" WEIGHT="14.173654704923285"/>
<DICH_DATA CI_END="2.5191420940586524" CI_START="0.8666986476316989" EFFECT_SIZE="1.4776119402985075" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="16" LOG_CI_END="0.4012526648880033" LOG_CI_START="-0.062131881094556314" LOG_EFFECT_SIZE="0.1695603918967235" MODIFIED="2012-02-20 11:37:37 +0000" MODIFIED_BY="[Empty name]" ORDER="51923" O_E="0.0" SE="0.2721943761006519" STUDY_ID="STD-Loprinzi-1990b" TOTAL_1="67" TOTAL_2="66" VAR="0.07408977838082315" WEIGHT="15.528874923394099"/>
<DICH_DATA CI_END="1.1806591625625122" CI_START="0.5662422515797703" EFFECT_SIZE="0.8176424050632911" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="64" LOG_CI_END="0.0721245418283099" LOG_CI_START="-0.24699772779442827" LOG_EFFECT_SIZE="-0.08743659298305917" MODIFIED="2012-02-20 11:35:34 +0000" MODIFIED_BY="[Empty name]" ORDER="369" O_E="0.0" SE="0.1874540008571078" STUDY_ID="STD-Loprinzi-1999a" TOTAL_1="79" TOTAL_2="159" VAR="0.03513900243733657" WEIGHT="18.178133081810827"/>
<DICH_DATA CI_END="2.0217938657680343" CI_START="0.879307138021432" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="39" LOG_CI_END="0.3057368745373635" LOG_CI_START="-0.05585940132076362" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2012-02-20 11:35:34 +0000" MODIFIED_BY="[Empty name]" ORDER="370" O_E="0.0" SE="0.21240344236949693" STUDY_ID="STD-Loprinzi-1999b" TOTAL_1="79" TOTAL_2="158" VAR="0.0451152223304122" WEIGHT="17.41708909082651"/>
<DICH_DATA CI_END="2.160001993545509" CI_START="1.1271637657049847" EFFECT_SIZE="1.5603448275862069" ESTIMABLE="YES" EVENTS_1="181" EVENTS_2="19" LOG_CI_END="0.3344541519775116" LOG_CI_START="0.05198701930702044" LOG_EFFECT_SIZE="0.19322058564226602" MODIFIED="2012-02-20 11:37:40 +0000" MODIFIED_BY="[Empty name]" ORDER="51926" O_E="0.0" SE="0.1659225919655037" STUDY_ID="STD-Von-Roenn-1994" TOTAL_1="232" TOTAL_2="38" VAR="0.02753030652455104" WEIGHT="18.80481545294085"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="270.4441811723028" CI_END="3.426188181122543" CI_START="1.4080885176718945" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="MD" EFFECT_SIZE="2.4171383493972187" ESTIMABLE="YES" I2="95.19309310200408" I2_Q="65.20497250290089" ID="CMP-005.20" MODIFIED="2013-01-31 10:12:11 +0000" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="-4.440892098500626E-16" P_Q="0.09002246629669208" P_Z="2.6658714211169945E-6" Q="2.873973874811195" RANDOM="YES" SCALE="12.09" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="2.9286990966632076" TOTALS="YES" TOTAL_1="544" TOTAL_2="670" UNITS="" WEIGHT="100.0" Z="4.695015014638791">
<NAME>Sensitivity number of patients weight gain</NAME>
<GROUP_LABEL_1>Megestrol acetate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="125.09283972019782" CI_END="6.0802638095413695" CI_START="0.8248179580970256" DF="7" EFFECT_SIZE="3.4525408838191973" ESTIMABLE="YES" I2="94.40415613263133" ID="CMP-005.20.01" MODIFIED="2012-02-20 11:43:10 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="-2.220446049250313E-16" P_Z="0.010018834424839746" STUDIES="8" TAU2="12.852203675893971" TOTAL_1="128" TOTAL_2="124" WEIGHT="50.497951275497485" Z="2.575178578075538">
<NAME>n &lt; 100 patients</NAME>
<CONT_DATA CI_END="10.848577123414998" CI_START="1.5314228765850002" EFFECT_SIZE="6.1899999999999995" ESTIMABLE="YES" MEAN_1="10.2" MEAN_2="4.01" MODIFIED="2012-02-20 11:43:10 +0000" MODIFIED_BY="[Empty name]" ORDER="312" SD_1="4.51" SD_2="1.68" SE="2.3768687384876768" STUDY_ID="STD-Batterham-2001" TOTAL_1="4" TOTAL_2="5" WEIGHT="3.0898163832474865"/>
<CONT_DATA CI_END="2.450790635597685" CI_START="0.3492093644023153" EFFECT_SIZE="1.4000000000000001" ESTIMABLE="YES" MEAN_1="1.06" MEAN_2="-0.34" MODIFIED="2012-02-20 11:40:37 +0000" MODIFIED_BY="[Empty name]" ORDER="51929" SD_1="1.95" SD_2="1.01" SE="0.5361275226923491" STUDY_ID="STD-De-Conno-1998" TOTAL_1="17" TOTAL_2="16" WEIGHT="8.241290178013392"/>
<CONT_DATA CI_END="6.3265405202233715" CI_START="1.2734594797766285" EFFECT_SIZE="3.8" ESTIMABLE="YES" MEAN_1="5.3" MEAN_2="1.5" MODIFIED="2012-02-20 11:40:37 +0000" MODIFIED_BY="[Empty name]" ORDER="51935" SD_1="3.6" SD_2="1.6" SE="1.2890749728833797" STUDY_ID="STD-Eubanks-2002" TOTAL_1="10" TOTAL_2="7" WEIGHT="5.774006249298406"/>
<CONT_DATA CI_END="4.007979966871202" CI_START="0.5920200331287977" EFFECT_SIZE="2.3000000000000003" ESTIMABLE="YES" MEAN_1="-0.9" MEAN_2="-3.2" MODIFIED="2012-02-20 11:40:37 +0000" MODIFIED_BY="[Empty name]" ORDER="51931" SD_1="3.6" SD_2="3.2" SE="0.8714343632554121" STUDY_ID="STD-Fietkau-1996" TOTAL_1="31" TOTAL_2="30" WEIGHT="7.186653698069094"/>
<CONT_DATA CI_END="4.000770353465514" CI_START="0.3992296465344851" EFFECT_SIZE="2.1999999999999997" ESTIMABLE="YES" MEAN_1="2.3" MEAN_2="0.1" MODIFIED="2012-02-20 11:40:37 +0000" MODIFIED_BY="[Empty name]" ORDER="129" SD_1="3.37" SD_2="1.18" SE="0.9187772671690712" STUDY_ID="STD-Herrejon-2011" TOTAL_1="15" TOTAL_2="16" WEIGHT="7.025211761442058"/>
<CONT_DATA CI_END="2.628336756896459" CI_START="-2.028336756896459" EFFECT_SIZE="0.2999999999999998" ESTIMABLE="YES" MEAN_1="2.8" MEAN_2="2.5" MODIFIED="2012-02-20 11:40:37 +0000" MODIFIED_BY="[Empty name]" ORDER="313" SD_1="4.3" SD_2="2.4" SE="1.18794874562088" STUDY_ID="STD-Mwamburi-2004" TOTAL_1="18" TOTAL_2="15" WEIGHT="6.107270987004359"/>
<CONT_DATA CI_END="9.463510533587678" CI_START="7.536489466412321" EFFECT_SIZE="8.5" ESTIMABLE="YES" MEAN_1="6.5" MEAN_2="-2.0" MODIFIED="2012-02-20 11:40:37 +0000" MODIFIED_BY="[Empty name]" ORDER="314" SD_1="1.1" SD_2="1.3" SE="0.49159604012508756" STUDY_ID="STD-Timpone-1997" TOTAL_1="12" TOTAL_2="12" WEIGHT="8.360257943509986"/>
<CONT_DATA CI_END="6.607323465695768" CI_START="0.17267653430423202" EFFECT_SIZE="3.39" ESTIMABLE="YES" MEAN_1="2.94" MEAN_2="-0.45" MODIFIED="2012-02-20 11:40:37 +0000" MODIFIED_BY="[Empty name]" ORDER="51937" SD_1="6.41" SD_2="4.12" SE="1.641521727477446" STUDY_ID="STD-Yeh-2000" TOTAL_1="21" TOTAL_2="23" WEIGHT="4.713444074912706"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="22.0375892497778" CI_END="1.6757792742895823" CI_START="0.5870653075990024" DF="5" EFFECT_SIZE="1.1314222909442924" ESTIMABLE="YES" I2="77.31149290728153" ID="CMP-005.20.02" MODIFIED="2012-05-10 12:01:48 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="5.150541412187737E-4" P_Z="4.627211620367319E-5" STUDIES="6" TAU2="0.2635130058862656" TOTAL_1="416" TOTAL_2="546" WEIGHT="49.50204872450251" Z="4.073699813546811">
<NAME>n &gt; 100 patients</NAME>
<CONT_DATA CI_END="1.054293157887498" CI_START="0.9457068421125022" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="-0.8" MEAN_2="-1.8" MODIFIED="2012-02-20 11:42:42 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Pendiente de Marta Roque para ver si la MD y la SD calculada es correcta ponerla&lt;/p&gt;" NOTES_MODIFIED="2012-02-20 11:42:42 +0000" NOTES_MODIFIED_BY="[Empty name]" ORDER="276" SD_1="0.2" SD_2="0.1" SE="0.027701099773136287" STUDY_ID="STD-Feliu-1992" TOTAL_1="66" TOTAL_2="62" WEIGHT="9.047748465765507"/>
<CONT_DATA CI_END="2.9782080386276055" CI_START="0.1817919613723944" EFFECT_SIZE="1.58" ESTIMABLE="YES" MEAN_1="1.36" MEAN_2="-0.22" MODIFIED="2012-02-20 11:42:53 +0000" MODIFIED_BY="[Empty name]" ORDER="51932" SD_1="4.99" SD_2="3.01" SE="0.7133845568880307" STUDY_ID="STD-Loprinzi-1990b" TOTAL_1="67" TOTAL_2="66" WEIGHT="7.710305850257296"/>
<CONT_DATA CI_END="1.592969098374519" CI_START="-0.6129690983745186" EFFECT_SIZE="0.4900000000000002" ESTIMABLE="YES" MEAN_1="2.5" MEAN_2="2.01" MODIFIED="2012-02-20 11:40:37 +0000" MODIFIED_BY="[Empty name]" ORDER="310" SD_1="4.45" SD_2="3.24" SE="0.5627496765627319" STUDY_ID="STD-Loprinzi-1999a" TOTAL_1="79" TOTAL_2="159" WEIGHT="8.167001751515949"/>
<CONT_DATA CI_END="1.7905445910798514" CI_START="-0.33054459107985146" EFFECT_SIZE="0.73" ESTIMABLE="YES" MEAN_1="2.5" MEAN_2="1.77" MODIFIED="2012-02-20 11:40:37 +0000" MODIFIED_BY="[Empty name]" ORDER="311" SD_1="4.45" SD_2="2.58" SE="0.5411041220375945" STUDY_ID="STD-Loprinzi-1999b" TOTAL_1="79" TOTAL_2="158" WEIGHT="8.227575682832942"/>
<CONT_DATA CI_END="5.824705003771884" CI_START="2.695294996228116" EFFECT_SIZE="4.26" ESTIMABLE="YES" MEAN_1="3.54" MEAN_2="-0.72" MODIFIED="2012-02-20 11:40:37 +0000" MODIFIED_BY="[Empty name]" ORDER="51934" SD_1="4.29" SD_2="2.85" SE="0.7983335490417564" STUDY_ID="STD-Von-Roenn-1994" TOTAL_1="53" TOTAL_2="28" WEIGHT="7.43264478685357">
<FOOTNOTE>MA 800 mg/d versus placebo</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="1.0101786698446733" CI_START="0.18982133015532654" EFFECT_SIZE="0.6" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="0.6" MODIFIED="2012-02-20 11:43:03 +0000" MODIFIED_BY="[Empty name]" ORDER="51936" SD_1="1.4" SD_2="1.1" SE="0.20927867709820713" STUDY_ID="STD-Weisberg-2002" TOTAL_1="72" TOTAL_2="73" WEIGHT="8.916772187277239">
<FOOTNOTE>Values at 2 weeks. Values at 8 weeks were written without SD</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="24.063000925053394" CI_END="3.044014835633744" CI_START="1.0631368627296254" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7989453528270656" ESTIMABLE="YES" EVENTS_1="165" EVENTS_2="136" I2="79.22121178662215" I2_Q="0.0" ID="CMP-005.21" LOG_CI_END="0.48344676472736897" LOG_CI_START="0.026589176943027166" LOG_EFFECT_SIZE="0.25501797083519806" METHOD="MH" MODIFIED="2013-01-31 10:00:49 +0000" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="2.1114434832103512E-4" P_Q="1.0" P_Z="0.02866200191684754" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.30587187299563984" TOTALS="YES" TOTAL_1="402" TOTAL_2="502" WEIGHT="100.00000000000001" Z="2.1881043529189035">
<NAME>Sensitivity appetite improvement cancer</NAME>
<GROUP_LABEL_1>Megestrol acetate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="24.063000925053394" CI_END="3.044014835633744" CI_START="1.0631368627296254" DF="5" EFFECT_SIZE="1.7989453528270656" ESTIMABLE="YES" EVENTS_1="165" EVENTS_2="136" I2="79.22121178662215" ID="CMP-005.21.01" LOG_CI_END="0.48344676472736897" LOG_CI_START="0.026589176943027166" LOG_EFFECT_SIZE="0.25501797083519806" MODIFIED="2012-05-10 11:33:49 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="2.1114434832103512E-4" P_Z="0.02866200191684754" STUDIES="6" TAU2="0.30587187299563984" TOTAL_1="402" TOTAL_2="502" WEIGHT="100.00000000000001" Z="2.1881043529189035">
<NAME>Cancer</NAME>
<DICH_DATA CI_END="6.869043147371471" CI_START="1.9929995643190366" EFFECT_SIZE="3.7" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="10" LOG_CI_END="0.8368962443727193" LOG_CI_START="0.2995072037612709" LOG_EFFECT_SIZE="0.568201724066995" MODIFIED="2012-04-19 23:04:58 +0100" MODIFIED_BY="[Empty name]" ORDER="51920" O_E="0.0" SE="0.31566498257381764" STUDY_ID="STD-Feliu-1992" TOTAL_1="76" TOTAL_2="74" VAR="0.0996443812233286" WEIGHT="17.75941361800946"/>
<DICH_DATA CI_END="2.5191420940586524" CI_START="0.8666986476316989" EFFECT_SIZE="1.4776119402985075" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="16" LOG_CI_END="0.4012526648880033" LOG_CI_START="-0.062131881094556314" LOG_EFFECT_SIZE="0.1695603918967235" MODIFIED="2012-04-19 23:12:21 +0100" MODIFIED_BY="[Empty name]" ORDER="51923" O_E="0.0" SE="0.2721943761006519" STUDY_ID="STD-Loprinzi-1990b" TOTAL_1="67" TOTAL_2="66" VAR="0.07408977838082315" WEIGHT="18.953836160600105"/>
<DICH_DATA CI_END="1.1806591625625122" CI_START="0.5662422515797703" EFFECT_SIZE="0.8176424050632911" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="64" LOG_CI_END="0.0721245418283099" LOG_CI_START="-0.24699772779442827" LOG_EFFECT_SIZE="-0.08743659298305917" MODIFIED="2012-05-10 11:33:49 +0100" MODIFIED_BY="[Empty name]" ORDER="51966" O_E="0.0" SE="0.1874540008571078" STUDY_ID="STD-Loprinzi-1999a" TOTAL_1="79" TOTAL_2="159" VAR="0.03513900243733657" WEIGHT="21.11877188185451"/>
<DICH_DATA CI_END="2.0217938657680343" CI_START="0.879307138021432" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="39" LOG_CI_END="0.3057368745373635" LOG_CI_START="-0.05585940132076362" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2012-04-19 23:11:43 +0100" MODIFIED_BY="[Empty name]" ORDER="51967" O_E="0.0" SE="0.21240344236949693" STUDY_ID="STD-Loprinzi-1999b" TOTAL_1="79" TOTAL_2="158" VAR="0.0451152223304122" WEIGHT="20.51850618841252"/>
<DICH_DATA CI_END="43.86715397607745" CI_START="0.8942259357832195" EFFECT_SIZE="6.2631578947368425" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="1" LOG_CI_END="1.6421394590555214" LOG_CI_START="-0.04855273817611772" LOG_EFFECT_SIZE="0.7967933604397018" MODIFIED="2012-04-19 23:08:27 +0100" MODIFIED_BY="[Empty name]" ORDER="219" O_E="0.0" SE="0.9931209657152156" STUDY_ID="STD-Schmoll-1991" TOTAL_1="38" TOTAL_2="17" VAR="0.9862892525431224" WEIGHT="5.573400054500012"/>
<DICH_DATA CI_END="5.737800103182554" CI_START="1.309153277018078" EFFECT_SIZE="2.740740740740741" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="6" LOG_CI_END="0.7587454139697585" LOG_CI_START="0.11699049717421948" LOG_EFFECT_SIZE="0.43786795557198893" MODIFIED="2012-04-19 23:04:58 +0100" MODIFIED_BY="[Empty name]" ORDER="51924" O_E="0.0" SE="0.37697001486377146" STUDY_ID="STD-Schmoll-1992" TOTAL_1="63" TOTAL_2="28" VAR="0.1421063921063921" WEIGHT="16.0760720966234"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="24.082929744996765" CI_END="2.5393122612422356" CI_START="1.142607460008368" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7033605411028212" ESTIMABLE="YES" EVENTS_1="346" EVENTS_2="155" I2="75.08608768313789" I2_Q="71.82429264908504" ID="CMP-005.22" LOG_CI_END="0.4047161096944523" LOG_CI_START="0.057897055213671465" LOG_EFFECT_SIZE="0.23130658245406188" METHOD="MH" MODIFIED="2013-01-31 10:12:22 +0000" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="5.042299425692676E-4" P_Q="0.02874891787053635" P_Z="0.008939835084533622" Q="7.098313362965325" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.19317462033056854" TOTALS="YES" TOTAL_1="634" TOTAL_2="540" WEIGHT="100.00000000000001" Z="2.614346386911844">
<NAME>Appetite improvement doses</NAME>
<GROUP_LABEL_1>Megestrol acetate</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.743949938417393" CI_END="3.2714062321175557" CI_START="1.1712570233535726" DF="2" EFFECT_SIZE="1.9574620112815306" ESTIMABLE="YES" EVENTS_1="243" EVENTS_2="45" I2="70.34378934803686" ID="CMP-005.22.01" LOG_CI_END="0.5147344766877097" LOG_CI_START="0.06865220811744055" LOG_EFFECT_SIZE="0.2916933424025751" MODIFIED="2013-01-31 10:00:58 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.03432189744213221" P_Z="0.010369968342203873" STUDIES="3" TAU2="0.14337584354226368" TOTAL_1="375" TOTAL_2="178" WEIGHT="48.50734508125824" Z="2.563242190600988">
<NAME>&#8804; 400 mg of MA/d</NAME>
<DICH_DATA CI_END="6.869043147371471" CI_START="1.9929995643190366" EFFECT_SIZE="3.7" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="10" LOG_CI_END="0.8368962443727193" LOG_CI_START="0.2995072037612709" LOG_EFFECT_SIZE="0.568201724066995" MODIFIED="2012-04-21 08:24:24 +0100" MODIFIED_BY="[Empty name]" ORDER="51920" O_E="0.0" SE="0.31566498257381764" STUDY_ID="STD-Feliu-1992" TOTAL_1="76" TOTAL_2="74" VAR="0.0996443812233286" WEIGHT="14.173654704923285"/>
<DICH_DATA CI_END="2.5191420940586524" CI_START="0.8666986476316989" EFFECT_SIZE="1.4776119402985075" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="16" LOG_CI_END="0.4012526648880033" LOG_CI_START="-0.062131881094556314" LOG_EFFECT_SIZE="0.1695603918967235" MODIFIED="2012-04-21 08:15:38 +0100" MODIFIED_BY="[Empty name]" ORDER="51923" O_E="0.0" SE="0.2721943761006519" STUDY_ID="STD-Loprinzi-1990b" TOTAL_1="67" TOTAL_2="66" VAR="0.07408977838082315" WEIGHT="15.5288749233941"/>
<DICH_DATA CI_END="2.160001993545509" CI_START="1.1271637657049847" EFFECT_SIZE="1.5603448275862069" ESTIMABLE="YES" EVENTS_1="181" EVENTS_2="19" LOG_CI_END="0.3344541519775116" LOG_CI_START="0.05198701930702044" LOG_EFFECT_SIZE="0.19322058564226602" MODIFIED="2012-04-21 08:25:15 +0100" MODIFIED_BY="[Empty name]" ORDER="51926" O_E="0.0" SE="0.1659225919655037" STUDY_ID="STD-Von-Roenn-1994" TOTAL_1="232" TOTAL_2="38" VAR="0.02753030652455104" WEIGHT="18.804815452940847"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6385054831830531" CI_END="6.068236623160438" CI_START="1.5243235028077886" DF="1" EFFECT_SIZE="3.04137398313368" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="7" I2="0.0" ID="CMP-005.22.02" LOG_CI_END="0.7830625072052111" LOG_CI_START="0.18307714585841836" LOG_EFFECT_SIZE="0.48306982653181474" MODIFIED="2013-01-31 10:01:04 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4242527446077736" P_Z="0.0015990762300017317" STUDIES="2" TAU2="0.0" TOTAL_1="101" TOTAL_2="45" WEIGHT="15.897432746104437" Z="3.1560752078853356">
<NAME>480 to 800 mg of MA/d</NAME>
<DICH_DATA CI_END="43.86715397607745" CI_START="0.8942259357832195" EFFECT_SIZE="6.2631578947368425" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="1" LOG_CI_END="1.6421394590555214" LOG_CI_START="-0.04855273817611772" LOG_EFFECT_SIZE="0.7967933604397018" MODIFIED="2012-04-21 08:15:38 +0100" MODIFIED_BY="[Empty name]" ORDER="219" O_E="0.0" SE="0.9931209657152156" STUDY_ID="STD-Schmoll-1991" TOTAL_1="38" TOTAL_2="17" VAR="0.9862892525431224" WEIGHT="3.5188152130114383"/>
<DICH_DATA CI_END="5.737800103182554" CI_START="1.309153277018078" EFFECT_SIZE="2.740740740740741" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="6" LOG_CI_END="0.7587454139697585" LOG_CI_START="0.11699049717421948" LOG_EFFECT_SIZE="0.43786795557198893" MODIFIED="2012-04-21 08:15:38 +0100" MODIFIED_BY="[Empty name]" ORDER="51924" O_E="0.0" SE="0.37697001486377146" STUDY_ID="STD-Schmoll-1992" TOTAL_1="63" TOTAL_2="28" VAR="0.1421063921063921" WEIGHT="12.378617533093"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.97970856169791" CI_END="1.6682627757622985" CI_START="0.6402915833654829" DF="1" EFFECT_SIZE="1.033525333101486" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="103" I2="66.43967088411574" ID="CMP-005.22.03" LOG_CI_END="0.22226445941630385" LOG_CI_START="-0.19362220694039797" LOG_EFFECT_SIZE="0.014321126237952914" MODIFIED="2013-01-31 10:01:09 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0843146361092203" P_Z="0.892625023734617" STUDIES="2" TAU2="0.07943998794257037" TOTAL_1="158" TOTAL_2="317" WEIGHT="35.595222172637335" Z="0.13498336886023143">
<NAME>&#8805; 800 mg of MA/d</NAME>
<DICH_DATA CI_END="1.1806591625625122" CI_START="0.5662422515797703" EFFECT_SIZE="0.8176424050632911" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="64" LOG_CI_END="0.0721245418283099" LOG_CI_START="-0.24699772779442827" LOG_EFFECT_SIZE="-0.08743659298305917" MODIFIED="2012-04-21 08:26:11 +0100" MODIFIED_BY="[Empty name]" ORDER="51966" O_E="0.0" SE="0.1874540008571078" STUDY_ID="STD-Loprinzi-1999a" TOTAL_1="79" TOTAL_2="159" VAR="0.03513900243733657" WEIGHT="18.178133081810824"/>
<DICH_DATA CI_END="2.0217938657680343" CI_START="0.879307138021432" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="39" LOG_CI_END="0.3057368745373635" LOG_CI_START="-0.05585940132076362" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2012-04-21 08:26:11 +0100" MODIFIED_BY="[Empty name]" ORDER="51967" O_E="0.0" SE="0.21240344236949693" STUDY_ID="STD-Loprinzi-1999b" TOTAL_1="79" TOTAL_2="158" VAR="0.0451152223304122" WEIGHT="17.417089090826508"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="32.56939541082797" CI_END="1.9701149789906227" CI_START="1.213546937873036" CI_STUDY="95" CI_TOTAL="95" DF="17" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5462299311589691" ESTIMABLE="YES" EVENTS_1="351" EVENTS_2="146" I2="47.80375937114201" I2_Q="0.0" ID="CMP-005.23" LOG_CI_END="0.29449157300626255" LOG_CI_START="0.08405657874378489" LOG_EFFECT_SIZE="0.18927407587502368" METHOD="MH" MODIFIED="2013-01-31 10:12:29 +0000" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="0.012774011653494344" P_Q="0.6841821103054273" P_Z="4.2228870968080554E-4" Q="0.7590627797345096" RANDOM="YES" SCALE="17.78" SORT_BY="STUDY" STUDIES="17" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.11556026980820758" TOTALS="YES" TOTAL_1="1199" TOTAL_2="1038" WEIGHT="100.0" Z="3.525747922509819">
<NAME>Weight improvement doses</NAME>
<GROUP_LABEL_1>Megestrol acetate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="10.504007958811158" CI_END="2.599078513062163" CI_START="1.1925383457052718" DF="6" EFFECT_SIZE="1.760539914436838" ESTIMABLE="YES" EVENTS_1="168" EVENTS_2="39" I2="42.87894655518636" ID="CMP-005.23.01" LOG_CI_END="0.4148193988833273" LOG_CI_START="0.076472352542726" LOG_EFFECT_SIZE="0.24564587571302662" MODIFIED="2013-01-31 10:01:47 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.1049695626096957" P_Z="0.004428105292364043" STUDIES="7" TAU2="0.11349052459472676" TOTAL_1="479" TOTAL_2="339" WEIGHT="38.366722530167294" Z="2.8459362926648386">
<NAME>&#8804; 400 mg MA/d</NAME>
<DICH_DATA CI_END="1.8600503184319712" CI_START="0.7053928072271484" EFFECT_SIZE="1.1454545454545455" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.26952469299305315" LOG_CI_START="-0.1515689730743774" LOG_EFFECT_SIZE="0.05897785995933788" MODIFIED="2012-04-21 08:37:51 +0100" MODIFIED_BY="[Empty name]" ORDER="51976" O_E="0.0" SE="0.24735250389527325" STUDY_ID="STD-Batterham-2001" TOTAL_1="4" TOTAL_2="6" VAR="0.06118326118326117" WEIGHT="8.645051838816586"/>
<DICH_DATA CI_END="10.274845018517457" CI_START="1.6276445030275961" EFFECT_SIZE="4.089473684210526" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="5" LOG_CI_END="1.0117752798804394" LOG_CI_START="0.2115595558157313" LOG_EFFECT_SIZE="0.6116674178480853" MODIFIED="2012-04-21 08:37:11 +0100" MODIFIED_BY="[Empty name]" ORDER="51938" O_E="0.0" SE="0.47005067744732804" STUDY_ID="STD-Feliu-1992" TOTAL_1="76" TOTAL_2="74" VAR="0.22094763936869202" WEIGHT="4.540627265891389"/>
<DICH_DATA CI_END="5.09648598079" CI_START="1.0004649042928742" EFFECT_SIZE="2.2580645161290325" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" LOG_CI_END="0.7072708339097552" LOG_CI_START="2.0185845021324637E-4" LOG_EFFECT_SIZE="0.3537363461799842" MODIFIED="2012-04-21 08:38:07 +0100" MODIFIED_BY="[Empty name]" ORDER="130" O_E="0.0" SE="0.41533581623281146" STUDY_ID="STD-Fietkau-1996" TOTAL_1="31" TOTAL_2="30" VAR="0.17250384024577572" WEIGHT="5.304225463249808"/>
<DICH_DATA CI_END="6.705706743584816" CI_START="0.5965068490098677" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.8264445567832687" LOG_CI_START="-0.22438456545530627" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2012-04-21 08:37:11 +0100" MODIFIED_BY="[Empty name]" ORDER="51975" O_E="0.0" SE="0.6172622280909857" STUDY_ID="STD-Loprinzi-1999b" TOTAL_1="79" TOTAL_2="158" VAR="0.38101265822784813" WEIGHT="3.077004204880436"/>
<DICH_DATA CI_END="4.4199565732614685" CI_START="0.6284626854892529" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.6454180023614081" LOG_CI_START="-0.20172050312869536" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2012-04-21 08:38:36 +0100" MODIFIED_BY="[Empty name]" ORDER="449" O_E="0.0" SE="0.4976133515281193" STUDY_ID="STD-Summerbell-1992" TOTAL_1="7" TOTAL_2="7" VAR="0.24761904761904763" WEIGHT="4.207169610925829"/>
<DICH_DATA CI_END="2.254454616409926" CI_START="0.4797612655970775" EFFECT_SIZE="1.04" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="7" LOG_CI_END="0.35304149710937915" LOG_CI_START="-0.3189748185118184" LOG_EFFECT_SIZE="0.01703333929878037" MODIFIED="2012-04-21 09:09:31 +0100" MODIFIED_BY="[Empty name]" ORDER="51944" O_E="0.0" SE="0.3947457103303034" STUDY_ID="STD-Vadell-1998" TOTAL_1="50" TOTAL_2="26" VAR="0.15582417582417582" WEIGHT="5.630230516845831">
<FOOTNOTE>We include the events of the arm of 160 mg of MA and split the events in placebo group</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="4.04356192770385" CI_START="1.1429460967682334" EFFECT_SIZE="2.1497844827586206" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="8" LOG_CI_END="0.606764098776945" LOG_CI_START="0.058025748830864796" LOG_EFFECT_SIZE="0.33239492380390495" MODIFIED="2012-04-21 08:37:21 +0100" MODIFIED_BY="[Empty name]" ORDER="51945" O_E="0.0" SE="0.32233162305696766" STUDY_ID="STD-Von-Roenn-1994" TOTAL_1="232" TOTAL_2="38" VAR="0.1038976752225391" WEIGHT="6.962413629557419"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="20.575453879706238" CI_END="2.124621905350089" CI_START="1.0044785044157842" DF="9" EFFECT_SIZE="1.4608685888659088" ESTIMABLE="YES" EVENTS_1="156" EVENTS_2="91" I2="56.258559093674315" ID="CMP-005.23.02" LOG_CI_END="0.3272816548427926" LOG_CI_START="0.0019406473923842195" LOG_EFFECT_SIZE="0.16461115111758842" MODIFIED="2013-01-31 10:01:53 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.01467488667011796" P_Z="0.047328770638184664" STUDIES="10" TAU2="0.17918937192471243" TOTAL_1="671" TOTAL_2="659" WEIGHT="52.62882995267653" Z="1.9833462137006035">
<NAME>480 to 800 mg MA/d</NAME>
<DICH_DATA CI_END="8.144860274151203" CI_START="1.1489714717071373" EFFECT_SIZE="3.059119496855346" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="5" LOG_CI_END="0.9108836383454965" LOG_CI_START="0.0603092455429576" LOG_EFFECT_SIZE="0.4855964419442271" MODIFIED="2012-04-21 08:34:25 +0100" MODIFIED_BY="[Empty name]" ORDER="198" O_E="0.0" SE="0.4996316087433604" STUDY_ID="STD-Jatoi-2002" TOTAL_1="159" TOTAL_2="152" VAR="0.24963174445547834" WEIGHT="4.1839824747467675"/>
<DICH_DATA CI_END="6.736736556469645" CI_START="1.4703903131304714" EFFECT_SIZE="3.1473214285714284" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="8" LOG_CI_END="0.8284495643767887" LOG_CI_START="0.16743263293768296" LOG_EFFECT_SIZE="0.49794109865723585" MODIFIED="2012-04-21 08:34:25 +0100" MODIFIED_BY="[Empty name]" ORDER="208" O_E="0.0" SE="0.3882846176139129" STUDY_ID="STD-Jatoi-2004" TOTAL_1="140" TOTAL_2="141" VAR="0.15076494427558257" WEIGHT="5.737184865703378"/>
<DICH_DATA CI_END="1.4019742832668287" CI_START="0.6921468047426783" EFFECT_SIZE="0.9850746268656716" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="32" LOG_CI_END="0.1467400473412371" LOG_CI_START="-0.15980178165915268" LOG_EFFECT_SIZE="-0.00653086715895778" MODIFIED="2012-04-21 08:36:39 +0100" MODIFIED_BY="[Empty name]" ORDER="51940" O_E="0.0" SE="0.18006418776135494" STUDY_ID="STD-Loprinzi-1990b" TOTAL_1="67" TOTAL_2="66" VAR="0.03242311171415649" WEIGHT="10.325193085048"/>
<DICH_DATA CI_END="4.200975696245815" CI_START="0.5423909365820319" EFFECT_SIZE="1.509493670886076" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.6233501690369533" LOG_CI_START="-0.26568757619353306" LOG_EFFECT_SIZE="0.1788312964217101" MODIFIED="2012-04-21 08:34:25 +0100" MODIFIED_BY="[Empty name]" ORDER="51974" O_E="0.0" SE="0.5222251723562018" STUDY_ID="STD-Loprinzi-1999a" TOTAL_1="79" TOTAL_2="159" VAR="0.2727191306424647" WEIGHT="3.9351997191281534"/>
<DICH_DATA CI_END="1.7903122675350842" CI_START="0.20108223941047487" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.2529287875383019" LOG_CI_START="-0.6966262867710147" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2012-04-21 08:34:25 +0100" MODIFIED_BY="[Empty name]" ORDER="162" O_E="0.0" SE="0.5577733510227171" STUDY_ID="STD-McMillan-1994" TOTAL_1="20" TOTAL_2="18" VAR="0.3111111111111111" WEIGHT="3.5811096218934404"/>
<DICH_DATA CI_END="1.7527020355825875" CI_START="0.6696010430095779" EFFECT_SIZE="1.0833333333333333" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.24370809105031782" LOG_CI_START="-0.174183878531894" LOG_EFFECT_SIZE="0.03476210625921191" MODIFIED="2012-04-21 08:34:25 +0100" MODIFIED_BY="[Empty name]" ORDER="167" O_E="0.0" SE="0.24547181153120257" STUDY_ID="STD-Mwamburi-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.06025641025641024" WEIGHT="8.690625866869764"/>
<DICH_DATA CI_END="38.04338372729278" CI_START="0.7575547118765404" EFFECT_SIZE="5.368421052631579" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="1" LOG_CI_END="1.5802791378325827" LOG_CI_START="-0.12058599621440545" LOG_EFFECT_SIZE="0.7298465708090885" MODIFIED="2012-04-21 08:34:25 +0100" MODIFIED_BY="[Empty name]" ORDER="218" O_E="0.0" SE="0.9990965991574009" STUDY_ID="STD-Schmoll-1991" TOTAL_1="38" TOTAL_2="17" VAR="0.9981940144478842" WEIGHT="1.3718977418949272"/>
<DICH_DATA CI_END="5.104141833207412" CI_START="0.6990207856990239" EFFECT_SIZE="1.8888888888888888" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="4" LOG_CI_END="0.7079227339974891" LOG_CI_START="-0.15550991011959098" LOG_EFFECT_SIZE="0.27620641193894907" MODIFIED="2012-04-21 08:34:25 +0100" MODIFIED_BY="[Empty name]" ORDER="51942" O_E="0.0" SE="0.5071846092148924" STUDY_ID="STD-Schmoll-1992" TOTAL_1="63" TOTAL_2="28" VAR="0.25723622782446315" WEIGHT="4.0986355754400945"/>
<DICH_DATA CI_END="4.336954814319346" CI_START="0.9603354097401541" EFFECT_SIZE="2.0408163265306123" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="6" LOG_CI_END="0.6371848973634271" LOG_CI_START="-0.017577057420454394" LOG_EFFECT_SIZE="0.3098039199714864" MODIFIED="2012-04-21 09:10:32 +0100" MODIFIED_BY="[Empty name]" ORDER="517" O_E="0.0" SE="0.3846104133640003" STUDY_ID="STD-Vadell-1998" TOTAL_1="49" TOTAL_2="25" VAR="0.1479251700680272" WEIGHT="5.799018679417164">
<FOOTNOTE>Events in arm of 480 mg of MA. We also split the events and the Total of placebo</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.6974685611582485" CI_START="0.2994554351039547" EFFECT_SIZE="0.7129629629629629" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.22980173945213891" LOG_CI_START="-0.5236678000810746" LOG_EFFECT_SIZE="-0.14693303031446786" MODIFIED="2012-04-21 08:34:25 +0100" MODIFIED_BY="[Empty name]" ORDER="51947" O_E="0.0" SE="0.44259173725618267" STUDY_ID="STD-Yeh-2000" TOTAL_1="36" TOTAL_2="33" VAR="0.19588744588744586" WEIGHT="4.905982322534843"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1734264488318" CI_START="0.873112966324461" DF="0" EFFECT_SIZE="1.3775510204081634" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="16" I2="0.0" ID="CMP-005.23.03" LOG_CI_END="0.33714494776726445" LOG_CI_START="-0.05892956216224188" LOG_EFFECT_SIZE="0.13910769280251128" MODIFIED="2013-01-31 10:01:40 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.16859224499621875" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="40" WEIGHT="9.004447517156166" Z="1.3767413000847222">
<NAME>&#8805; 800 mg MA/d</NAME>
<DICH_DATA CI_END="2.1734264488318" CI_START="0.873112966324461" EFFECT_SIZE="1.3775510204081634" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="16" LOG_CI_END="0.33714494776726445" LOG_CI_START="-0.05892956216224188" LOG_EFFECT_SIZE="0.13910769280251128" MODIFIED="2012-04-21 08:41:24 +0100" MODIFIED_BY="[Empty name]" ORDER="51943" O_E="0.0" SE="0.23265612773303632" STUDY_ID="STD-Tchekmedyian-1992" TOTAL_1="49" TOTAL_2="40" VAR="0.054128873771730916" WEIGHT="9.004447517156166">
<FOOTNOTE>Data at one month</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.216011785554341" CI_END="3.174587017550964" CI_START="1.108718582656713" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8760926465981116" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-005.24" LOG_CI_END="0.5016872358754099" LOG_CI_START="0.04482132657404065" LOG_EFFECT_SIZE="0.2732542812247253" METHOD="MH" MODIFIED="2013-01-31 10:12:38 +0000" MODIFIED_BY="[Empty name]" NO="24" P_CHI2="0.9370765830491934" P_Q="0.9012594498095141" P_Z="0.019050935887449005" Q="0.015393491744932129" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="761" TOTAL_2="843" WEIGHT="99.99999999999999" Z="2.3445327782973453">
<NAME>Sensitivity (cancer/other patients) thromboembolic phenomena</NAME>
<GROUP_LABEL_1>Megestrol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours megestrol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.205466290881593" CI_END="3.2178856862675023" CI_START="1.1074262652629234" DF="9" EFFECT_SIZE="1.8877423361217067" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="18" I2="0.0" ID="CMP-005.24.01" LOG_CI_END="0.5075706119491387" LOG_CI_START="0.04431481963056678" LOG_EFFECT_SIZE="0.2759427157898527" MODIFIED="2013-01-31 10:02:01 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8973761053755824" P_Z="0.01954643245800779" STUDIES="11" TAU2="0.0" TOTAL_1="686" TOTAL_2="805" WEIGHT="96.65497039148788" Z="2.3349423524201076">
<NAME>Cancer patients</NAME>
<DICH_DATA CI_END="58.07278205442537" CI_START="0.1417241285924793" EFFECT_SIZE="2.8688524590163933" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7639726319906837" LOG_CI_START="-0.8485562046396291" LOG_EFFECT_SIZE="0.4577082136755274" MODIFIED="2012-04-22 22:47:20 +0100" MODIFIED_BY="[Empty name]" ORDER="144" O_E="0.0" SE="1.5346123708629553" STUDY_ID="STD-Casado-2008" TOTAL_1="60" TOTAL_2="34" VAR="2.355035128805621" WEIGHT="3.2161982872412804"/>
<DICH_DATA CI_END="129.75780650166408" CI_START="0.3582644047330511" EFFECT_SIZE="6.818181818181818" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.113133495372975" LOG_CI_START="-0.44579633890602527" LOG_EFFECT_SIZE="0.8336685782334751" MODIFIED="2012-04-22 22:45:45 +0100" MODIFIED_BY="[Empty name]" ORDER="282" O_E="0.0" SE="1.5031280515624539" STUDY_ID="STD-Feliu-1992" TOTAL_1="76" TOTAL_2="74" VAR="2.2593939393939393" WEIGHT="2.5640787035469743"/>
<DICH_DATA CI_END="5.524267745677316" CI_START="0.3013851679121783" EFFECT_SIZE="1.2903225806451613" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7422747194453831" LOG_CI_START="-0.5208781244580037" LOG_EFFECT_SIZE="0.1106982974936897" MODIFIED="2012-04-22 22:47:20 +0100" MODIFIED_BY="[Empty name]" ORDER="139" O_E="0.0" SE="0.7419822332162692" STUDY_ID="STD-Gebbia-1996" TOTAL_1="62" TOTAL_2="60" VAR="0.550537634408602" WEIGHT="15.433602960757943">
<FOOTNOTE>Both arms were MA. First MA 160 mg and second MA 320 mg daily</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="3.3392773430618368" CI_START="0.5742950321317771" EFFECT_SIZE="1.3848214285714286" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.5236524908001913" LOG_CI_START="-0.2408649405133445" LOG_EFFECT_SIZE="0.14139377514342336" MODIFIED="2012-04-22 22:47:20 +0100" MODIFIED_BY="[Empty name]" ORDER="214" O_E="0.0" SE="0.4490813235758903" STUDY_ID="STD-Jatoi-2004" TOTAL_1="140" TOTAL_2="141" VAR="0.20167403518467347" WEIGHT="40.34836238774663"/>
<DICH_DATA CI_END="8.030017184192781" CI_START="0.013836970527265503" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9047164746674874" LOG_CI_START="-1.8589589841068126" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2012-04-22 22:45:45 +0100" MODIFIED_BY="[Empty name]" ORDER="252" O_E="0.0" SE="1.6233966448981796" STUDY_ID="STD-Loprinzi-1990b" TOTAL_1="63" TOTAL_2="63" VAR="2.6354166666666665" WEIGHT="7.592336940372859"/>
<DICH_DATA CI_END="21.507553852360854" CI_START="0.7533712424818613" EFFECT_SIZE="4.025316455696203" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.3325910189959207" LOG_CI_START="-0.12299096160793822" LOG_EFFECT_SIZE="0.6048000286939913" MODIFIED="2012-04-22 22:45:45 +0100" MODIFIED_BY="[Empty name]" ORDER="262" O_E="0.0" SE="0.8550160606537155" STUDY_ID="STD-Loprinzi-1999a" TOTAL_1="79" TOTAL_2="159" VAR="0.7310524639757982" WEIGHT="6.720387879993903"/>
<DICH_DATA CI_END="11.62563201676808" CI_START="0.6116752277084367" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="1.0654165722229592" LOG_CI_START="-0.213479107678397" LOG_EFFECT_SIZE="0.4259687322722811" MODIFIED="2012-04-22 22:45:45 +0100" MODIFIED_BY="[Empty name]" ORDER="263" O_E="0.0" SE="0.7512296530097713" STUDY_ID="STD-Loprinzi-1999b" TOTAL_1="79" TOTAL_2="158" VAR="0.5643459915611814" WEIGHT="10.123115920497145"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-06-19 11:05:02 +0100" MODIFIED_BY="[Empty name]" ORDER="520" O_E="0.0" SE="0.0" STUDY_ID="STD-Madeddu-2012" TOTAL_1="29" TOTAL_2="31" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="59.29601510215695" CI_START="0.11151246650499884" EFFECT_SIZE="2.5714285714285716" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.773025508249681" LOG_CI_START="-0.9526765780715827" LOG_EFFECT_SIZE="0.41017446508904926" MODIFIED="2012-04-22 22:45:45 +0100" MODIFIED_BY="[Empty name]" ORDER="224" O_E="0.0" SE="1.601090897948041" STUDY_ID="STD-Schmoll-1991" TOTAL_1="20" TOTAL_2="17" VAR="2.5634920634920637" WEIGHT="2.7254542862876927"/>
<DICH_DATA CI_END="14.696930580691841" CI_START="0.06342981197893298" EFFECT_SIZE="0.9655172413793104" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.167226642839416" LOG_CI_START="-1.1977065759528895" LOG_EFFECT_SIZE="-0.015239966556736846" MODIFIED="2012-04-22 22:45:45 +0100" MODIFIED_BY="[Empty name]" ORDER="228" O_E="0.0" SE="1.389173479326835" STUDY_ID="STD-Schmoll-1992" TOTAL_1="29" TOTAL_2="28" VAR="1.9298029556650245" WEIGHT="5.150357222709074"/>
<DICH_DATA CI_END="83.0247600695134" CI_START="0.20246972091127569" EFFECT_SIZE="4.1" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9192076292190898" LOG_CI_START="-0.6936399157796186" LOG_EFFECT_SIZE="0.6127838567197355" MODIFIED="2012-04-22 22:45:45 +0100" MODIFIED_BY="[Empty name]" ORDER="461" O_E="0.0" SE="1.5347995817361826" STUDY_ID="STD-Tchekmedyian-1992" TOTAL_1="49" TOTAL_2="40" VAR="2.355609756097561" WEIGHT="2.7810758023343807"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="36.917263636388" CI_START="0.06419704471381048" DF="0" EFFECT_SIZE="1.5394736842105263" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-005.24.02" LOG_CI_END="1.567229502980672" LOG_CI_START="-1.1924849640499318" LOG_EFFECT_SIZE="0.1873722694653703" MODIFIED="2013-01-31 10:02:06 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7901270951366783" STUDIES="1" TAU2="0.0" TOTAL_1="75" TOTAL_2="38" WEIGHT="3.3450296085121" Z="0.26614557718995163">
<NAME>Other patients</NAME>
<DICH_DATA CI_END="36.917263636388" CI_START="0.06419704471381053" EFFECT_SIZE="1.5394736842105263" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.567229502980672" LOG_CI_START="-1.1924849640499313" LOG_EFFECT_SIZE="0.1873722694653703" MODIFIED="2012-04-22 22:45:45 +0100" MODIFIED_BY="[Empty name]" ORDER="191" O_E="0.0" SE="1.6210699387407068" STUDY_ID="STD-Von-Roenn-1994" TOTAL_1="75" TOTAL_2="38" VAR="2.627867746288799" WEIGHT="3.3450296085121"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.85272037956149" CI_END="1.8909562060158642" CI_START="1.0098683071352326" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3818888315042215" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="56" I2="0.0" I2_Q="0.0" ID="CMP-005.25" LOG_CI_END="0.27668147083028993" LOG_CI_START="0.004264742878188526" LOG_EFFECT_SIZE="0.1404731068542392" METHOD="MH" MODIFIED="2013-01-31 10:12:44 +0000" MODIFIED_BY="[Empty name]" NO="25" P_CHI2="0.7392722003703711" P_Q="0.8144791258666537" P_Z="0.043245480521424885" Q="0.05506139295993432" RANDOM="YES" SCALE="700.45" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="807" TOTAL_2="560" WEIGHT="99.99999999999999" Z="2.0213313059039826">
<NAME>Deaths sensitivity 6 weeks</NAME>
<GROUP_LABEL_1>Megestrol acetate</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.9354967373191687" CI_END="2.855805637539516" CI_START="0.558300739399842" DF="2" EFFECT_SIZE="1.2626948954599242" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" I2="0.0" ID="CMP-005.25.01" LOG_CI_END="0.4557286465857724" LOG_CI_START="-0.2531317969802016" LOG_EFFECT_SIZE="0.10129842480278536" MODIFIED="2012-12-26 10:10:38 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6264111660389509" P_Z="0.5753633228917866" STUDIES="3" TAU2="0.0" TOTAL_1="103" TOTAL_2="102" WEIGHT="14.76882893494744" Z="0.5601702453738904">
<NAME>&lt; 6 weeks</NAME>
<DICH_DATA CI_END="14.954425656523698" CI_START="0.06686983659340748" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1747697380632693" LOG_CI_START="-1.1747697380632693" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-12-26 10:09:36 +0000" MODIFIED_BY="[Empty name]" ORDER="527" O_E="0.0" SE="1.3801311186847085" STUDY_ID="STD-De-Conno-1998" TOTAL_1="21" TOTAL_2="21" VAR="1.9047619047619047" WEIGHT="1.3443181181467658"/>
<DICH_DATA CI_END="2.7514307510854565" CI_START="0.363447271789593" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.4395585868182921" LOG_CI_START="-0.4395585868182921" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-12-26 10:10:38 +0000" MODIFIED_BY="[Empty name]" ORDER="528" O_E="0.0" SE="0.5163977794943223" STUDY_ID="STD-Giacosa-1997" TOTAL_1="15" TOTAL_2="15" VAR="0.2666666666666667" WEIGHT="9.602272272476895"/>
<DICH_DATA CI_END="12.249197952852823" CI_START="0.49512018267925834" EFFECT_SIZE="2.462686567164179" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0881076531043297" LOG_CI_START="-0.30528937007817014" LOG_EFFECT_SIZE="0.3914091415130798" MODIFIED="2012-12-26 10:06:47 +0000" MODIFIED_BY="[Empty name]" ORDER="51923" O_E="0.0" SE="0.8184883088439054" STUDY_ID="STD-Loprinzi-1990b" TOTAL_1="67" TOTAL_2="66" VAR="0.6699231117141564" WEIGHT="3.8222385443237776"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.867506474397439" CI_END="1.9715123677425688" CI_START="0.9993625243909593" DF="7" EFFECT_SIZE="1.4036579272369785" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="48" I2="0.0" ID="CMP-005.25.02" LOG_CI_END="0.2947995058452063" LOG_CI_START="-2.7694042011725006E-4" LOG_EFFECT_SIZE="0.14726128271254452" MODIFIED="2012-12-26 10:10:38 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5553027216618227" P_Z="0.05043159212645692" STUDIES="8" TAU2="0.0" TOTAL_1="704" TOTAL_2="458" WEIGHT="85.23117106505255" Z="1.9562849836834075">
<NAME>&gt; 6 weeks</NAME>
<DICH_DATA CI_END="1.7625727840986332" CI_START="0.37353104506494894" EFFECT_SIZE="0.8114035087719298" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.24614705989308047" LOG_CI_START="-0.42767329708796054" LOG_EFFECT_SIZE="-0.09076311859744" MODIFIED="2012-12-26 10:06:41 +0000" MODIFIED_BY="[Empty name]" ORDER="51920" O_E="0.0" SE="0.3958054131552242" STUDY_ID="STD-Feliu-1992" TOTAL_1="76" TOTAL_2="74" VAR="0.15666192508297774" WEIGHT="16.344787911746387"/>
<DICH_DATA CI_END="2.343475769883212" CI_START="0.9030522444829295" EFFECT_SIZE="1.4547443259502324" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="23" LOG_CI_END="0.3698604675381503" LOG_CI_START="-0.04428712362414266" LOG_EFFECT_SIZE="0.1627866719570038" MODIFIED="2012-12-26 10:06:41 +0000" MODIFIED_BY="[Empty name]" ORDER="526" O_E="0.0" SE="0.24327234511237011" STUDY_ID="STD-Jatoi-2002" TOTAL_1="159" TOTAL_2="152" VAR="0.0591814338964721" WEIGHT="43.26704796991771"/>
<DICH_DATA CI_END="4.2749448044003024" CI_START="0.8870860188439328" EFFECT_SIZE="1.9473684210526316" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="7" LOG_CI_END="0.6309305117427589" LOG_CI_START="-0.05203426551442686" LOG_EFFECT_SIZE="0.28944812311416607" MODIFIED="2012-12-26 10:06:41 +0000" MODIFIED_BY="[Empty name]" ORDER="529" O_E="0.0" SE="0.401176890891042" STUDY_ID="STD-Macbeth-1994" TOTAL_1="38" TOTAL_2="37" VAR="0.16094289778500304" WEIGHT="15.910027559885124"/>
<DICH_DATA CI_END="7.1001879173392695" CI_START="0.1609376104343082" EFFECT_SIZE="1.0689655172413792" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.851269843139287" LOG_CI_START="-0.7933424512686539" LOG_EFFECT_SIZE="0.028963695935316558" MODIFIED="2012-12-26 10:06:41 +0000" MODIFIED_BY="[Empty name]" ORDER="530" O_E="0.0" SE="0.9660534026973775" STUDY_ID="STD-Madeddu-2012" TOTAL_1="29" TOTAL_2="31" VAR="0.9332591768631814" WEIGHT="2.7437243616866844"/>
<DICH_DATA CI_END="31.88561370954489" CI_START="0.4275638605818494" EFFECT_SIZE="3.6923076923076925" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5035947803668315" LOG_CI_START="-0.3689990102293305" LOG_EFFECT_SIZE="0.5672978850687505" MODIFIED="2012-12-26 10:00:16 +0000" MODIFIED_BY="[Empty name]" ORDER="531" O_E="0.0" SE="1.0999708620849453" STUDY_ID="STD-Oster-1994" TOTAL_1="52" TOTAL_2="48" VAR="1.2099358974358976" WEIGHT="2.116315372371067"/>
<DICH_DATA CI_END="7.016577384170804" CI_START="0.015835514243992307" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8461253193035242" LOG_CI_START="-1.8003678287428493" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2012-12-26 10:00:16 +0000" MODIFIED_BY="[Empty name]" ORDER="532" O_E="0.0" SE="1.5545631755148024" STUDY_ID="STD-Summerbell-1992" TOTAL_1="7" TOTAL_2="7" VAR="2.4166666666666665" WEIGHT="1.0595610783422784"/>
<DICH_DATA CI_END="34.58652933695328" CI_START="0.6396621472063648" EFFECT_SIZE="4.703583061889251" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="1" LOG_CI_END="1.53890698394459" LOG_CI_START="-0.19404934843172214" LOG_EFFECT_SIZE="0.6724288177564338" MODIFIED="2012-12-26 10:00:16 +0000" MODIFIED_BY="[Empty name]" ORDER="51926" O_E="0.0" SE="1.0179471279100396" STUDY_ID="STD-Von-Roenn-1994" TOTAL_1="307" TOTAL_2="76" VAR="1.0362163552202983" WEIGHT="2.471111294882806"/>
<DICH_DATA CI_END="14.072922267905014" CI_START="0.05970883387128004" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1483842888383442" LOG_CI_START="-1.2239614106171437" LOG_EFFECT_SIZE="-0.0377885608893998" MODIFIED="2012-12-26 10:06:01 +0000" MODIFIED_BY="[Empty name]" ORDER="533" O_E="0.0" SE="1.3935276071607594" STUDY_ID="STD-Yeh-2000" TOTAL_1="36" TOTAL_2="33" VAR="1.941919191919192" WEIGHT="1.3185955162204945"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.852720379561491" CI_END="1.8909562060158642" CI_START="1.0098683071352326" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3818888315042215" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="56" I2="0.0" I2_Q="0.0" ID="CMP-005.26" LOG_CI_END="0.27668147083028993" LOG_CI_START="0.004264742878188526" LOG_EFFECT_SIZE="0.1404731068542392" METHOD="MH" MODIFIED="2013-01-31 10:12:50 +0000" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="0.7392722003703709" P_Q="0.6502829082072403" P_Z="0.043245480521424885" Q="0.8606955960438618" RANDOM="YES" SCALE="526.14" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="807" TOTAL_2="560" WEIGHT="100.0" Z="2.0213313059039826">
<NAME>Deaths sensitivity/pathology</NAME>
<GROUP_LABEL_1>Megestrol acetate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.56359169297094" CI_END="1.8510155294530468" CI_START="0.966004900829725" DF="6" EFFECT_SIZE="1.3371948522797907" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="52" I2="0.0" ID="CMP-005.26.01" LOG_CI_END="0.2674100623658018" LOG_CI_START="-0.015020670274043616" LOG_EFFECT_SIZE="0.12619469604587907" MODIFIED="2012-12-26 09:49:31 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7354908335056969" P_Z="0.07986183807137846" STUDIES="7" TAU2="0.0" TOTAL_1="405" TOTAL_2="396" WEIGHT="93.03441673818335" Z="1.7514882815908386">
<NAME>Cancer</NAME>
<DICH_DATA CI_END="14.954425656523698" CI_START="0.06686983659340748" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1747697380632693" LOG_CI_START="-1.1747697380632693" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-12-26 09:47:19 +0000" MODIFIED_BY="[Empty name]" ORDER="527" O_E="0.0" SE="1.3801311186847085" STUDY_ID="STD-De-Conno-1998" TOTAL_1="21" TOTAL_2="21" VAR="1.9047619047619047" WEIGHT="1.3443181181467658"/>
<DICH_DATA CI_END="1.7625727840986332" CI_START="0.37353104506494894" EFFECT_SIZE="0.8114035087719298" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.24614705989308047" LOG_CI_START="-0.42767329708796054" LOG_EFFECT_SIZE="-0.09076311859744" MODIFIED="2012-12-26 09:47:28 +0000" MODIFIED_BY="[Empty name]" ORDER="51920" O_E="0.0" SE="0.3958054131552242" STUDY_ID="STD-Feliu-1992" TOTAL_1="76" TOTAL_2="74" VAR="0.15666192508297774" WEIGHT="16.344787911746387"/>
<DICH_DATA CI_END="2.7514307510854565" CI_START="0.363447271789593" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.4395585868182921" LOG_CI_START="-0.4395585868182921" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-12-26 09:47:45 +0000" MODIFIED_BY="[Empty name]" ORDER="528" O_E="0.0" SE="0.5163977794943223" STUDY_ID="STD-Giacosa-1997" TOTAL_1="15" TOTAL_2="15" VAR="0.2666666666666667" WEIGHT="9.602272272476895"/>
<DICH_DATA CI_END="2.343475769883212" CI_START="0.9030522444829295" EFFECT_SIZE="1.4547443259502324" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="23" LOG_CI_END="0.3698604675381503" LOG_CI_START="-0.04428712362414266" LOG_EFFECT_SIZE="0.1627866719570038" MODIFIED="2012-12-26 09:48:01 +0000" MODIFIED_BY="[Empty name]" ORDER="526" O_E="0.0" SE="0.24327234511237011" STUDY_ID="STD-Jatoi-2002" TOTAL_1="159" TOTAL_2="152" VAR="0.0591814338964721" WEIGHT="43.26704796991771"/>
<DICH_DATA CI_END="12.249197952852823" CI_START="0.49512018267925834" EFFECT_SIZE="2.462686567164179" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0881076531043297" LOG_CI_START="-0.30528937007817014" LOG_EFFECT_SIZE="0.3914091415130798" MODIFIED="2012-12-26 09:48:44 +0000" MODIFIED_BY="[Empty name]" ORDER="51923" O_E="0.0" SE="0.8184883088439054" STUDY_ID="STD-Loprinzi-1990b" TOTAL_1="67" TOTAL_2="66" VAR="0.6699231117141564" WEIGHT="3.8222385443237776"/>
<DICH_DATA CI_END="4.2749448044003024" CI_START="0.8870860188439328" EFFECT_SIZE="1.9473684210526316" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="7" LOG_CI_END="0.6309305117427589" LOG_CI_START="-0.05203426551442686" LOG_EFFECT_SIZE="0.28944812311416607" MODIFIED="2012-12-26 09:49:04 +0000" MODIFIED_BY="[Empty name]" ORDER="529" O_E="0.0" SE="0.401176890891042" STUDY_ID="STD-Macbeth-1994" TOTAL_1="38" TOTAL_2="37" VAR="0.16094289778500304" WEIGHT="15.910027559885124"/>
<DICH_DATA CI_END="7.1001879173392695" CI_START="0.1609376104343082" EFFECT_SIZE="1.0689655172413792" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.851269843139287" LOG_CI_START="-0.7933424512686539" LOG_EFFECT_SIZE="0.028963695935316558" MODIFIED="2012-12-26 09:49:31 +0000" MODIFIED_BY="[Empty name]" ORDER="530" O_E="0.0" SE="0.9660534026973775" STUDY_ID="STD-Madeddu-2012" TOTAL_1="29" TOTAL_2="31" VAR="0.9332591768631814" WEIGHT="2.7437243616866844"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.205588511841248" CI_END="10.27888376570927" CI_START="0.6303327166184847" DF="2" EFFECT_SIZE="2.5454109153229396" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="3" I2="9.321254202109564" ID="CMP-005.26.02" LOG_CI_END="1.0119459550567245" LOG_CI_START="-0.20043015078628856" LOG_EFFECT_SIZE="0.40575790213521795" MODIFIED="2012-12-26 09:59:36 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.331942525201933" P_Z="0.1895467699628572" STUDIES="3" TAU2="0.1473071918703238" TOTAL_1="366" TOTAL_2="131" WEIGHT="5.646987745596151" Z="1.3119210627704871">
<NAME>AIDS</NAME>
<DICH_DATA CI_END="31.88561370954489" CI_START="0.4275638605818494" EFFECT_SIZE="3.6923076923076925" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5035947803668315" LOG_CI_START="-0.3689990102293305" LOG_EFFECT_SIZE="0.5672978850687505" MODIFIED="2012-12-26 09:54:28 +0000" MODIFIED_BY="[Empty name]" ORDER="531" O_E="0.0" SE="1.0999708620849453" STUDY_ID="STD-Oster-1994" TOTAL_1="52" TOTAL_2="48" VAR="1.2099358974358976" WEIGHT="2.116315372371067"/>
<DICH_DATA CI_END="7.016577384170804" CI_START="0.015835514243992307" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8461253193035242" LOG_CI_START="-1.8003678287428493" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2012-12-26 09:54:49 +0000" MODIFIED_BY="[Empty name]" ORDER="532" O_E="0.0" SE="1.5545631755148024" STUDY_ID="STD-Summerbell-1992" TOTAL_1="7" TOTAL_2="7" VAR="2.4166666666666665" WEIGHT="1.0595610783422784"/>
<DICH_DATA CI_END="34.58652933695328" CI_START="0.6396621472063648" EFFECT_SIZE="4.703583061889251" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="1" LOG_CI_END="1.53890698394459" LOG_CI_START="-0.19404934843172214" LOG_EFFECT_SIZE="0.6724288177564338" MODIFIED="2012-12-26 09:59:36 +0000" MODIFIED_BY="[Empty name]" ORDER="51926" O_E="0.0" SE="1.0179471279100396" STUDY_ID="STD-Von-Roenn-1994" TOTAL_1="307" TOTAL_2="76" VAR="1.0362163552202983" WEIGHT="2.471111294882806"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="14.072922267905021" CI_START="0.05970883387128001" DF="0" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-005.26.03" LOG_CI_END="1.1483842888383444" LOG_CI_START="-1.2239614106171437" LOG_EFFECT_SIZE="-0.0377885608893998" MODIFIED="2012-12-26 09:58:46 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.950212719875196" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="33" WEIGHT="1.3185955162204945" Z="0.062439650669649086">
<NAME>Other underlying pathology</NAME>
<DICH_DATA CI_END="14.072922267905014" CI_START="0.05970883387128004" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1483842888383442" LOG_CI_START="-1.2239614106171437" LOG_EFFECT_SIZE="-0.0377885608893998" MODIFIED="2012-12-26 09:58:46 +0000" MODIFIED_BY="[Empty name]" ORDER="533" O_E="0.0" SE="1.3935276071607594" STUDY_ID="STD-Yeh-2000" TOTAL_1="36" TOTAL_2="33" VAR="1.941919191919192" WEIGHT="1.3185955162204945"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-02-11 09:25:54 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-02-08 08:05:31 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZIAAAS3CAYAAADM2/zYAAB9GUlEQVR42uydD4RVTfz/vySPJIm1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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-02-11 09:25:54 +0000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEZCAMAAABxStv9AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Methodological quality summary wight improvement vs placebo.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2013-02-07 13:21:31 +0000" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAOECAYAAAB97U88AACAAElEQVR42uydBZQc1fb1TzwQx53g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</FILE>
</FIGURE>
<FIGURE FILENAME="Methodological quality summary appetitte improvement vs placebo.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2013-02-07 13:21:31 +0000" MODIFIED_BY="[Empty name]" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAOECAYAAAB97U88AACAAElEQVR42uydBZQdVdb9T4hCbJDg
hODu7gSXCYEJ7vrhMMAgg31I8A93GSYw6KCDM1j4E2SAwR0Ggg7urv/a6+5a73Z1vX7V3XVfV73a
e62zurveS6fvq6p7f3XuEfvtt99MJpPJZDKZTJaf6UOQyWQymUwmE2DJZDKZTCaTCbBkMplMJpPJ
BFgymUwmk8lkMgGWTCaTyWQymQBLJpPJZDKZTIAlk8lkMplMJhNgyWQymUwmkwmwZDKZTCaTyQRY
MplMJpPJZDIBlkwmk8lkMpkASyaTyWQymUyAJZPJZDKZTCbAkslkMplMJpMJsGQymUwmk8kEWDKZ
TCaTyWQCrCz/2OzIyB6O7AGZTCZLsf9Hm6CxFM7ub7HrTPeMzk0om0Ab2UzAujWySyJbN7INZDKZ
jLYu54f7IlunBcZyXWT/aoGxrBfZtpG9F9lBkf2+5GPZIrK3+bD/+5KfG/z9F0T2HL9fv8RjGR3Z
JpH9J7LjSs4IOA9jInspsm2aCVj/iGw3kyRJaq9jIzu/RcZycGRXtshYBkf2WGTLtMBY+nEXZfUW
OTfbRHZ7C80B4wlXrSCcl62bDVh/1DoiSVKK/i+yv7TIWP43sr+3yFimiezfka3cAmP5nTnP4u9b
5Nz8T2T/bJGxTGpue/APLTCWSXheBFiSJAmwBFgCLAGWAEuAJUmSAEuAJcASYAmwBFgCLEmSBFgC
LAGWAEuAJcCSJEmAJcASYAmwBFgCLEmSBFgCLAGWAEuAJcCSJEkSYAmwBFgCLAGWAEuSJAGWAEuA
JcASYAmwJEkSYAmwBFgCLAGWAEuSJAGWAEuAJcASYAmwBFiSJAmwBFgCLAGWAEuAJUmSAEuAJcAS
YAmwBFiSJAmwBFgCLAGWAEuAJcCSJEmAJcASYAmwBFgCLEmSBFgCLAGWAEuAJcCSJEmAJcASYAmw
BFgCLAGWJEkCLAGWAEuAJcASYEmSJMASYAmwBFgCLAGWJEkCLAGWAEuAJcASYEmSJAmwBFgCLAGW
AEuAJUmSAEuAJcASYAmwBFiSJAmwBFgCLAGWAEuAJUmSAEuAJcASYAmwBFgCLEmSBFgCLAGWAEuA
JcCSJEmAJcASYAmwBFgCLEmSBFgCLAGWAEuAJcASYEmSJMASYAmwBFgCLAGWJEkCLAGWAEuAJcAS
YEmSJMASYAmwBFgCLAGWAEuSJAGWAEuAJcASYBUfsJaP7KjIxkV2cWRHRraS1ipJEmAJsARYAiwB
lgCr8xoW2ZWR/RzZbwn7JbK/8maSJEmAJcASYAmwBFgCrAzqx9/1WwO7OrI+WrckSYAlwBJgCbAE
WAKsxhpFgHotsjv4e2/i19sjmxDZO3zP2lq3JEmAJcASYAmwBFgCrMY6lzZtymu9zHm4hpvzYJ2i
dUuSBFgCLAGWAEuAJcBqrBvMBbc30oaRXaB1S5IEWAIsAZYAS4AlwGqsMyJ7JLJ1I5s7sqkiG+LZ
TJGtGdlTkY3VuiVJAiwBlgBLgCXAEmA11ipWC2T/KrJPIvvQs8+915fUuiVJAiwBlgBLgCXAEmBl
01hrnEV4hNYsSRJgCbAEWAIsAZYAq3PaKbLnU8DqJV54kiQJsARYAiwBlgBLgNUFIf4KpRh2IHAh
LmtqrVWSJMASYAmwBFgCLAGWJEkCLAGWAEuAJcASYBUCsHCzbBLZsZGdH9mJkW0T2fRaqyRJgCXA
EmAJsARYAqzOawVzZRjSgtvfimwfrVeSJMASYAmwBFgCLAFWds0W2bvWOItQNbAkSYAlwBJgCbAE
WAKsjDrKg6iJkT1qrv/gA5E9Htkbkf3E1xfTuiVJAiwBlgBLgCXAEmA1Fn7Px5FtzBumv7n+g30j
G2Cumju2EJ+I7DitW5LU0oCF/qPrRHZCZHtGNrMAS4AlwBJgCbC6ppMiuyrD+3Ci1ItQkloXsPBw
hQSXX63m1YYHey0BlgBLgCXAEmB1Xug1iIbP83Twnj6RncNJW5Kk1gSsbS09/vKDBvODAEuAJcAS
YFUesBaM7DoC1fW0y81Va381smu947Fdy5voo8gW17olSS0LWP8gUCHmEn1IP7Za/OW9nLSTWiCy
7SIbLsASYAmwBFhVBqw1rHG2YD27WWuWJLUsYCHeEqVa7otsqchmMOfdxvdnmGsEfylBqj//DZq/
v8f54emAkCXAEmAJsARYhQesVbsBWLD1tW5JUksC1uDI7jLnkUrTXObiNfE7N+SxgxPzwwYCLAGW
AEuAVVXAQm/B8ZEdEtmhnbRjzGUXSZLUeoDVO7K/mfNYIXN4e84XvRLvg6drIL9fxFxpF0xIj0U2
owBLgCXAEmBVFbAWjmwOrT2SJMBK0Zbm4jFfIjQhm3DVBv8G8wk8WiGbwguwBFgCLAFW6Zs946Qg
EH4+72lVQCZJ1QCsXvx38Zbf5+Y8Wj0tAZYAS4AlwCotYKGw6N68Wb6N7HYeRzDrEbTeWrMkqaUB
KxYKC+8a2TIFGYsAS4AlwBJglRKwAFHjrG2w6j+tFnsxgP/XRdY+HkOSpNYDrKJJgCXAEmAJsEoJ
WFsQqlAHC6UYUO/mVg4q1sZ8z2patyRJgJUQvNvzBXwAE2AJsARYAqxSAtaV5jIEf8efEYOFAqN9
vffsRcA6UeuWJLUsYM3Kh6iVO2HLR3aYuRpZoSTAEmAJsARYpQQs9CHczPt5zsiu9n5e1Fw/Mvyn
Z2vdkqSWBawjrVbJPav9yH+Dhba/AEuAJcASYAmw2l5UX5jzTqGp61aR3cMTc2pkn1gtNmtfrVuS
1LKAdbR1vQjxZ1bLPhZgCbAEWAIsAZa5Cs7/8ibKHyL7OWUCfSeymbVuSVLLAtZxkX0d2QuRvWyu
HtaTkX0X2feRvcjjseF9H3HOQKuc5QRYAiwBlgBLgNVWs5nrQVbv6fT1yFbSmiVJLQtYCFCHhxrd
GlDJfcrIhprzagMI1vCOT+m9Pi/nom1MQe4CLAGWAEuAlarJzG0PXm5uixAn57rIDrRwLTAkSSoG
YGESm93a1rvD93eYa5vTkZAY83hkswiwBFgCLAGWAKtjIYOwv0mSVBXAStNM5kIDGs0z65nbQhwj
wBJgCbAEWAKsthoW2f7mtggmS7y2YmTbar2SpMoBFrYEEYOFTMFLItsjsk0i2yiyTc2Vb8Hxr8yF
EqwrwBJgCbAEWAKsmiY3V1w0jrf6n8TrQ/n6AVqzJKlSgGW877NkEb4S2bQCLAGWAEuAJcCqaZfE
RLl1ynu24VPsfCZJUpUAayB/T0dwhUzC9QKORYAlwBJgCbBKCVgIakecxV/NBbP2SXnPtpxID9O6
JUmVAiwI2YGbcZJ7K7LPI/vUXKmGiyNbOPBYBFgCLAGWAKuUgHVtg6dPZBA+RsA6V+uWJFUOsHwh
Lgue7AX4fTMkwBJgCbAEWKUErLHmeg/OYS57EB6sAebq2+xqrrhgvBUwVuuWJFUSsABTqIm1Z2RL
8dgMFi6wXYAlwBJgCbBKD1jzm0ux/jiyRyObwAngI2sbZ4Hq7kto3ZKkygHW6Mie8uaCOFQACTJo
p3WGuVgtAZYAS4AlwBJgJbQJIaujQNYDtWZJUuUAC16rnxJzwUHe6/0JDGcIsARYAiwBlgArXXD7
32Cups2vnEjRg+zBFjlJkiTA6pz6RXZXZK9Gdnxku0V2U2RHJd73Fz6gzSvAEmAJsARYAqz6QruL
1c31JEMwa1+tVZJUScBCXOZDkQ1PLEIneD9PZrVm8aFKNQiwBFgCLAFWy7TKSWoIJwZJkqoDWOjw
MCExSWMROoLfzxzZpVbbOhwlwBJgCbAEWAKs9kLF9nloc9Pw/VyRrR3ZAxaumaskScUDLOgEwtMt
kR0b2Z3mvFqom/eWB1efcK4QYAmwBFgCLAGWp40je9pc8cBPEobsws9MZRokqYqANbXV6uB1ZP8b
cCwCLAGWAEuAVUrAQumFryxbv7GztG5JUqUACxphruPDdylzwnuRHRxZbwGWAEuAJcASYLXV8VbL
GARo/RLZt5F9Gdk3/B6vPxnZklq3JKlygBVrUXOFRk+M7JjItrC2AfACLAGWAEuAJcDydHNkV5uL
uUJl5u34u2fkkysyif4W2UZasySpcoAFENi4g9eRZTy/AEuAJcASYAmw2gtZQMsljiGQ9QDv560i
e8Fc5WZJkqoDWAgLeLDB5Id5aF8BlgBLgCXAEmC1FUDq0MhWjOwScxmD+B7Vm882V+UdGYT4T3fW
uiVJLQ1YgyKbwlx9K8RVnRbZPeYqtk/K476hd+nykX0Q2WICLAGWAEuAJcCqCVuDH5rrNYhf/AYH
dL61D2g9V+uWJLU0YC3FB6pn+fXdyD43V5rh4cgeSRjqZL3N+WF9AZYAS4AlwBJgtdV+HkSN54BQ
ZPDRBGDtqHVLkloasHDvL01w+q0ThuSYZQVYAiwBlgBLgNVeaI1zSGSzJyaD4yK7NrK9OVBJkloX
sGINjuyyjHCFDOQjA84PAiwBlgBLgNWyrXJi9dG6JUmVACxoMs4zL3MRHW1uG9C3DczV0gspAZYA
S4AlwGppwFrUwsVYSJJUPMCCRnDh6UkJsARYAiwBVuEBa0Fz2303RHZdRovfj2BXZRFKUrUAK4um
sLDhAwIsAZYAS4BVeMBawzoXuJq07bVuSVIlAQvbhUh8mSphQyLbI7LTLVwIgQBLgCXAEmAVHrBW
FWBJkgCrk9qDUDAxstcT9qq5JvGYH5YXYAmwBFgCrKoCFm4E1LM5gP92n4yGDMJ7I9tN65YkVQqw
tu3EA1ioyVyAJcASYAmwCg9YCFSft4uDnD6ykVq3JKkygDXAal0cfqLFZRl+9H5GDaz7zPUyFWAJ
sARYAqxKApYkSQKsrJrZXGeHEyJbknZlZMebS5hBeYYx5lrpzBpwLAIsAVaZAAtAcLRlK8w9nPcq
Esn2IhgJsFoQsBCguq65YqMXmWuVgx6Fa5nqX0lSFQFrlsjuMFd0NNYCkT0e2RzesavM9SwUYAmw
BFiuh+e/uI6igPcFkZ1k7evFIUEk2THhMssnI1eAVSDAQpPWh6x+bMWDfGKVJKk6gNWf8LRcZKPM
ebKmjuwMc/0Ht4xsvcjeiuwLc31NBVgCrKoD1iR8MEED9J+8dfRT3kex1vRem0AYw7WxoQCrdQBr
Nk6QjQJYkS00ndYtSaoMYEFIcPnKXJwV5gF4qqayWoPnX705YrQAS4AlwLJekd1SZx19jZ9bfG/F
x/fhsW0iO1eA1TqAdYx3kgFaj5kLWIU9EtkrHoXvp3VLkioFWEPNZRDHc8RJPI4WOd9Z236EoVrm
CLAEWGUCLBTefZH3zcGR7cu1E2E3X0e2Gd93hHf/xF6rOc3FY/UTYLUGYOH3fBTZVuY8VJPy5Pbj
97iJUKD0zcgu1rolSZUCLGjyyA431/h9mHccMZvYCkGm4ZYBxyLAEmCVCbBQb/L6Oq8d4j2kHO4B
1hgemymyuyMbJMBqDcACWV+d4X3IHjo6cQzBfFNqLZOklgasjoQ5oH/g/0OAJcAqE2CN4ucyPOVe
OctcFm4MW8kacrMIsFoLsJAhhODVVcztHadpmcjutPYxWAiO31hrmSS1JGBhPtiOE/UfO5gfQkuA
JcAqE2Bhmw9b5gi5uSmyS+mgeJAwdTrfN9YDrE14DOvwbYQxAVYLANbchKfP+PWmhOH/+TCylyK7
JnEcrTJ211omSS0JWNOaq4OFCed763qRYgGWACsPDaUVHbD6moujSgtyfzmyUyK70WqJIr9x7V3B
XE05Bbm3EGCtZt3rT7iL1jJJaknAGsCnadznKNcwRIAlwAoMWPDcYFdlUIqtTHCZquCAFTsuXkms
leh+AE8VguCf9Y7Dw3WX93MeHVMEWAUBrJUFWJIkwKojeK3gvd6gwfuwAE4uwBJgdUNImng4svfo
3Unah1xzQu2a5N0qB50QTubv/BudGbGQLPJnczHQSCibP7KbzZVuyEMCrIIAVnxRH8YTfnBGQ8Po
O03teiSplQELk/+SfMre2Vx8yTQJw1bigeYKkgqwBFhdEeJ8v8z4UH90SQArVu8eODcCrIIA1lLW
vQbQy2stk6SWBSwUQHzV8x4gVhMlWxCbNZH2jrlSLwsJsARYXdQ5HkDFRW1/4Pd+MdvnCPxlAqyO
tEhkkwmwWhewepkkSQKsdB2d0auANiALCLAEWF0Qet2iKOe15mpIIdj7RHPV0JfmsbXNxSmtHnA8
eQMW/vbtzW0D7pOwvThG7AINCjAWAVbBmj1LkiTASuooqwXo1jN4GbC9M78AS4DVBSHrDrUYF/eO
IcEC3UTW8o7tSSAZUALAAlR9neHB5AkCpgBLgCVJUsUAC620joxsUXPhBEnDorhSZJdHtqwAS4DV
RaG6Ofrwobbiqea8ofj5G3Pxvvg/xhNKQpWFyAuw5jDX/DyL5/cxAqYAS4AlSVKFAAsT2yIZFwC0
+BheQMBClfmNzG3LjCzAeRFgpQufB+L4viJ4YDuwHxfWZFPxsQUHrFX4dwKybuK1e23C4LGbYM6D
FcIjJ8ASYEmSVGDASgr1e5DtNZv380xNGEtXAWs4Fxk/eBr9VAcLsAoHWIgFPtc7V7fy+IKR/dfa
en22LjhgIfkLMYkHNngfwGqTQNejAEuAJUlSCQBrRGTnm6tF9LO5ci4xwIyzsI2euwpYWLAvt/Rt
mfMEWIUDrHghRY0r9OvzM9vhRUWrmUciO8jCbKnlCVgQWkxdRNDpSMiIHCjAqiZgYTKYUWuVJFUW
sGa39hWpD0rA1wtcnIoEWPi7P7Zauv+n/BqPYds6/w6xZstwUhdgNQ+w+mQAjYGBx5MXYAHu1zdX
ymQ87xfUjjzEMzyknGH5NHYWYBUYsEDQYyLblNaPFzv2uV/jUyueHubSmiVJlQOsywgkmKwRO4I6
RIcl3jMusvfNbY0UBbAQbwVvG7adkPaPDMfl6SH5F4FrfS7acSHI3cxlfgHEjrIwJWwEWOlC+YWb
G3h8trBwxWzzBCxcT/dYtiD3f5uyCFsasDbgiUbj5p147DRLb1I5lUmSVBXAwhYgspxGeRACQDk+
8b5bOEesUyDAwt98R53XUNhxR3N97bAdtQjH97g3370VaL4TYNU/X280eA92U+60cOVA8gKsSXjt
KYtQgGWbc2KZlT9vmrgAXuMEh4t/X61bklQZwBoR2QPmttti7UTvTqw9Ivuec8X6BQIsbPNdwu8x
tyFOLBmQj4VtOnNerF5Wq/kFuzCQZ0GA5TQdrx3EKm3B6/Vdc4U5t0wxvAceRnQSOKjggNWXgIXt
v3Hm+hAmDcfRSP1RaxynJcAqMWBhC2Bj7wnhbW+SQdpsXPwNmRvnmSRJVQEs6ErOCVjU4O0+21yK
OTxAt3hzBbbVQrUw6QpgoTzDNeYqhL/JvxGTdEcp8X0IiXjInCzQWARYTkN5jX6f0dPj25EFByxc
OxtmuIZ6832KwWphwMIkNIYXw82JC3ln733YGjhN65YkVQqwFrZsRROvtnDZXV0t04CtpDe8v3GC
hasCLsDqmhArN7ETcIUYuVBxWD3Ri3AaPgwIsFoUsNATCdk2TyQu5CuslkmDWIQnW+RkSZIAq3NC
H7hXOlj04MmaNuBYulNodJi5IqOoSD9PAc6LACsd4mMQfoKfzxMJe5qL7LoBx9MdwJo+8YCBGnEz
mNsKTbOpI1vC3Fb0UAFW6wIWipxdk5gw7+TEhIGtEdlTPL6w1i1JqhxgGQEK88219ATdz9+PLY4+
gceiVjmtDVgQvFIP8fMZxHXJtyFNuM66AljIuj/BXGzYrfz7jdfrJ+aya9MMxVO/peNCQe4tDFgQ
AjyxTYj0662sVm9kysj+FNmx5va9l9e6JUmVBCxf2Gbr38Sx5AVYCIM4M7LVOnjPvJwLBVjNBSxo
7iZAVN6ANUfCObE9j99p2bY8HxVgtTZgoe3F5FqPJEmA1Q3NaOGKEucFWFjInrGOW61gMkcByJ0E
WE0HrCzXWNG2CBE+8wJhCY2pV+DxuIfiDx0Y+is+IcBqbcCK68UsrTVJkgRYKZrZXGYdMgd3SBjS
7JEAc7sVK4sQ6kWQQX2uFc0Vs0ShVBRRxpbUSglbkYaQCYRFhMgkFGDVF7xXyFTdOeU62yay48zF
Cy9TIMCC5ovsUF5fxusG9dVGm6uxtkSK4ThiGxHrrBisFgasNc3tCcNViZINiKkYYJIkCbBcltdr
1nir46vIFigYYEGooRSXafieXoMfzcW/fJdicdmAV83FoQqwmgNYgJJxlm1b7eiCAVZSWD9nyfje
OU11sFoasDCBrmIu6wHuV9S5uY5PpcNMkqSqAhYm6fEZFz0E+YaqsN3dLcI5rbZlk9XQKFqtcpoH
WDt34tzsVnDAwnVzsnW8FY3tzs0CnhsBVkEAKy2oEOmlCG5/iE8L6kMoSdUDLMwDE+n1QUuP2znR
+YbwAmQUIitq0YICFoRtmBu4QKOu1wfmCin79gm/YtsmVF9FAVY6kFxvzoOI6uco+wGv6UuR3chr
DKCP7cFj+P8WGbCgR6x9z86kDs/wHgFWyQErGWCHtFNsG6KC8y+ckD7nBLes1i1Jqgxg9SM8YYHr
zYmuT8J68ysW2XkLDFgxEGA8e5sLTp6+jvUKeF4EWOlr0D8JOLFWIdAP8hbZkxLvKRJgLc51cxka
yi+cH9li3rHYEO+8lLlG5OiSMKUAq3UBayQvjBl5gT1o6W5ZND/dWOuWJFUGsIwPVTeZa/zckWbK
8J6eBiwIfQnn7MHzIsBKX0AvIozE1xIET+JV5mpgQSgVBC/WLIHG0x3AQoul5+mU+JZfEeuH2MRv
6hjWVXhNZxdgtS5goZDofwlQaWCFZq9IWVY8liRVD7Dm4+T2cmQHRLYn553Y0AniQHNbOEXLIuyO
MN+p2XNzAAvalzB1irnt2/3NVd5HaxxkdGJH5XOuSXsVELCMToorrHOxfvAOq0xDCwPWyJST/j2f
WpFmqoxCSaouYI3NuFAUNYswTagMjq4UKNWwbMKwdbOJuVpYIYqpCrDqw8m73vX0NI//OeVaG1tQ
wDJC+TlW807hweQ/CXudX1EOJJTXV4BVEMBa2btwEeCJfWPVxJIkAVYMN2XPIvQ1ios3/t60bZuv
OJ67Ao1FgFVfq5oLbEew+6E8hgf8C6wWD4ySG6GSKfIKcodHCkH7aKGDWL8ZEgaYDB3rJ8AqUB0s
TDYnWs/GJkiSVDzAOtF72r4hxbCQ3Gwu23CxggMWsqE/yAiMtwmwmg5YEJogY2uwt3cMIIKdFhQc
nSXgePLMIkTW6qw9eG4EWAXaItxI65EkCbASwsKGwsNzZ3gvqqUX3YO1iQdQn9cxPGz+FNk9Aqwe
Aays12WRAQtwg3jFv5nbhhZgVRiw+pokSQKs7i9woRa+vABrRcIVstH87RrfpjOXSo8G94rBKhZg
odr7IRamtUyegLW8B/LP9tAaK8AqCGBJkiTAaqSV+TvvNNcXDsKW21GRTRt4LHkBFuJ5kI22e4b3
ov9iPwFWEMBCLz5sOSPj7vKMdqm5GmYIEJ+64ICFsgufErCOsrCxVgIsAZYkSSUFrH78XT97T+Vx
9WlkTKEBNEq5hIzfzAuwsNChqfMT5rZw4Klajh6H2HBsi8jOE2AFA6wNrHOlDHz7juepyIAF7Wqu
9NEUGT5DlWkQYEmSVEHA+mNicQNoHZR4Dypu32dhttTyBCyUZxjvjSet4XNcAFJZhOEAa1QdePo1
I2SFquaeJ2BBiPlDyYa1zHl5AewDaPgenrhjM0CYAEuAJUlSiwEWgAQ9CLE9s4K5IHZkFR6TeN84
LnyhWmnlBViDCATKIuxZwELiBHoO7k9Yh+1jrkTDvxLHD+LP6ImLbNYLI1uk4IAFIEAdNfQjRN9L
lJhAb8XHzXlPn+D38bEQnlIBVkEAqzeJuqPA1Um0XklS5QBrLk7Sk3nHdo7sOO9nbA2+SShZv+CA
BWB81Fx18Hciey/FcByFluXBCgdYgPVkSY+1+ZlP1cG/W81ctfcpA40nT8C6OyPI4wFGW4QtDFi4
2NF/cLoOBjfGXDkHSZKqA1gDOUmfHdkIPmn/kYCF/nCbRvait1isUXDAwjbNEebKTuD76Tnv+Y2e
p+Hif4yF6WIhwHJAkaxzhW3mwzL8WwDJvgUHrF78PVkAC02hQ7RkEmAVqJL7+9bxPvBgPl0spXVL
kioDWNB2Vmv7ATB4g56eNxILBUArVL/SvACrj2XfjpnUwnjuBVjpCyjWF7SVWYXrTR8eB4jBgzqb
uXglbLedUHDAApj/jSCIz2b9FEMcGvp63sLxCrBaBLAmj2x7/LE80Udy8tzFnKdq44T9ge//hJO2
JEnVASwscGdb4zY5owKOJUSzZ8ST7WbOozUDj63ThIdIAVa6DuO19CNB6z4uqgAvtDb62Lvetis4
YAEIs7bzWdycp1iA1SKAhZN/OCfFzqbInql1S5IqBVjxBIc2JQ+Zq3b+Kz0J/zXXLmf5wGPJE7Cw
mJ3KccQL+mIedGE8Owqwmg5Y0xKkGq1B+P+KHoNV77pDfFn/Jp0bAVYPbxGCnJ/vBFz9YC4QUZKk
agGW/3C2UGSrm9vKma1JY8kLsOCNOy8xr8Ezv6D3nqXpLVlLgNVUwILmMNfb8oeU9QdAj+20svQi
jLVeZJeZix3DevuwuUzIFQRYrQ1Y0IjInuIFjBM/nifFNxQRRMryZlqzJKlygAXQ2CvjezGZIzh8
W8s3riQvwIKnCp57VBHfw1yYxOOEqliIRX2PE3qICtwCrMYQDI8oSjNcZK4EyMHmkqxCt5zJE7AQ
63dmBw4L1GD7kwCrtQELQufyR/m1H0+Mb5NZ24wPSZKqA1inm6vnMyMXoD9a+xR744LoLyB3WH49
4/ICLMSZXpI4Bq/Iit7Pa9Nb8oqFCdoXYBVXeQLWfpZtZ2hTAVZrAxY0wpq3NyxJUnkA62h6dJ71
FgX0WdvSew/iZ163WsA7PA4o/XJowQBrNB8m5/CO3RzZkuay1kZ543jOXEKQAEuA1ZXPZaK5mLJT
eR8cTjvMuzff4cNLCAeGAKtkldzhLh+udUuSKgVYh9Z58v7SarFL2GKL42Zu4jHEeKLYYh61pPIC
LHjUnjEX4I5twpPNVQfH755gznMVj+/KQOdFgNX6gIX4xHsyADp2jR5OAL8AqwUBCwS9MJ/gcEI2
SBie/M6ysNk1kiQVD7AuNueVujay0yI7JbLrzFU7j1vmrOqByXk8NpDvm7dAgAWtabV+g/XsPc6H
AiwBVle0PtfnRhrIh5CFBFitC1h4qkOWw1eW3mzTP7aD1i1JqgxgoRltvQLDm/EpHRrpzRHneu+5
IieQyLsOFlquPJQy38GDdb+1DXoXYAmwOqsRkX3Ea3ZnQs4qfBDB17X4f+H+eZEwJMBqUcA6wLKX
athe65YkVQawZucCukAdT9D9/H7lOoD1d8unxVaIQqPwHqDcBALfD4xsVy6AAwKfFwFW6wMWwmku
TjgpsIX+I+0n77XDA41FgFUQwLqWJ/oDc4GpD6UYjn/FyUiSpGoA1iBzZVzeiuz8yA4xF8B+PueL
J/i+5b0F4xweG8on9PkLCliN1N/UKqenAAvlGBCfNLcHCzOWCLDi83xXA4fFpbzHBFgtDFhjzcVY
LMCTMpAnPbaBfKrDE+s6WrckqTKABR1XZ3HAdhq2ABGHdYN3HNmGKAa5F0FisoICVn8CwhQJG8rF
/c+mZs/NBqy4mTh+JwrAXuKB/onmWhuVBbAg1IJDrSvUWkPc3/f8ej/H0ifgWARYBQGsGSx7I+fZ
tW5JUqUACyUYHk0BrCsIJP/0jr1B2PqUP5+S01jyBKwFuXADBF81l0XoG459xDkxhARY6QKIX564
xvxMzqkIJkeXCLDMA0SsnXPzazNKIgmwCgJYSCU9PrI3I9vHXOGzzT3bjF//wgtQkqTqAFb8EIaq
1C+Zq+1ztNVS0NEX7hhCC+pJITB+AifEGQoGWPh7XrRs8aa3CbCaCli78nPHdjQaPaOcxlUp70EM
0+IlAyyoL8GqT5POjQCrIICFwM4fMk46yiKUpOoBVqx4Cy3L5J7nU3pegDUmMZ/9ZLXA42QAsjxY
zQMsQMeNkR1FYEfZIJQMuj7xvkN4bg4sCWAN4xp9p7kCtm+b6xCA8iVIGJss4LkRYBUEsEaasggl
SYBVXOUFWH/gPAbPyAac+3xbmYa4mUstTO87AVY6YGE9WzOxLvnnfBlz3i2cv2NLAFio//Z0g/UU
/9e0AqzWBixc1KhsjGxBuPYfTDGcKHSY31XrliQJsEoKWMhEezMjEExnYbZzBFjpOjKy98318ENW
6p70/KCUxgmRfeiByU4FByzAzfiMTosLBFitDVi40TcylzEzKb/G38eGJ7kVzFV0lyRJgFVGwIIQ
U3o9AWqSOoZt0E1NWYTNBCycjzcIHci2Q9jKT9a2ZhTsdQtXsiEvwFraGwd6XSLGGVmDO/PrsbwG
0W7qXXNxiwKsFgWszjyl9TZJkgRY5QUslJ15ILLXzNXpui9h95qr/XWHqQ5WMwELWsLaNhVPGrI8
Vww4nrwAa1kC4nYN3geIh9cuRHa+AKtgzZ6xF4wYq4vMuWvjk7S7ubowkiQJsMoMWEiXv86ybd3c
HmgsAqyOhcDw/ejhwef0JNc6NB0fHng8eQEWgtevznCO16lznc0X2RABVusAFvojvexNLniS68XX
kGU4nl8lSao2YGGyiz3ZzUo5zwuw1rDsCT13CrB6BLB8ATKGNnE8eQa5L8trdnWC4WyezWzOE4f6
cluZ6104G78uaq5+3OQCrNYALGQ7fJmYXO7wAAva31yQ4fRatySpkoCFheI0TtpxuZa5zNXECt3G
JC/A2oTz22ORHWGu2vye/Bp/D0PgMQqmKouwZwErTYCVxQoOWHgAQRbqz+ZKf7zP9TM2/PyduR6F
yIz8gMfx9Wtz2YfdvfYEWAUBLEzEr3CCwRMeAvFuTDydbsSJaT+tW5JUKcBC+5JTEw9gh3oLCWAL
GcghwwjyAiz0RUSrknUzvrefAKupgIUwlS0iO8hc8dqxngHkUSfrAQtXjzEvwIqB4Lcu2r8FWK0D
WIApf/tvTnNxCnGAJzxZcQuD87RuSVKlAOtP3sT/KZ/I/5x4z22czEO1AMkzyB2L91nWeHtzhUDj
EWClCy2MslbZ36TggNXLA6xPeN9kMbwXWZPyYLUQYJ3OyWsuDgRbhldwcsFFf5F3YZ+kdUuSKgNY
iIF5nL8HhR/hpUJNomShx0s4P6xQcMDCorW3uZCImzifnZYwfG4IUL7ZVAermYB1USc8PBsXHLAG
EuLXM+cJXSij4b2Ih76An60AqwUAC0F1v5jbA0aKMlyw7/Drx4kLe12TJKkqgIWHrvGcrGMhhOB4
7+cFzLUA+S3gZJ4XYA0m3GRZxO8INBYBVnthq/kufu5YdxC/9NcUu5xrU9G3CFE/rTsZj8MT95wA
q+RZhH/MMOGcY6qDJUlVAqzJOEnj3odnG15tBIEjJgbFEbeJ7FVvjli94IA1kECgMg3FAizoXHOF
RhsVd0WtrGULDljJ8w3I2cVqySBLmfNYhZQAq2B1sHAi0BbHb/yMLAgUd0PcQj+TJKlKgGWEqDiW
5Dlzlaf/G9nEBJC8ENlUBQcspL7fb2777+w6dha9KXeaCo02E7DgCX3CXA2ojtTPwtXDyhuw9uT6
Gd8jI3kcDytXWtjevgKsggFWfFIWjmxDcy0lljNX+E2SpGoCFgJ2T2vg7QF8rR1wLHkB1hTmMqUb
gRM8deuZgtybCVjxQ/4jBA9kE27pWfwztgq3CzSePAFr/8Q9gjAcP0YRIImyDOsLsKoDWFmeACVJ
qg5gxYInCx7uz8x5udFnDZ4s1ItaOvBY8swi7AxYyoPVPMAaxnPcClmEM5iLacZnczyvX5zzNRPX
F7IFUZMtRDKFAKtggIWKuagmm8xsgEcL7ttdMUCtW5JUScCCEIM5D+Fg+chmatJYmg1YWCD/bN0P
NBZgZddYa50swtHmSpf4pRbGRbaB9zMSSJDN+lFkswiwWhewsKd9IGkaLsvPU+wzXtg7ad2SpMoB
FuaIFQkeSQG0piwgYCFY+szI7o7s1k4Yyje8ZC4Oq5cAqymAhQX0Dq4x8IpOMJfRnmzCDQ8qCsVu
U3DAWoGfy4gEYK3F7xfkGOPxzirAal3A2roTTw7bmyRJVQIshAVcZS6G5PEUyMJD1y0WNlazK4CF
xs5PWderad8WaCwCrPYCyKL22If07Awg1Pf3LP55PQ9UigpYgBv0GURCyIWRHWAugP8yc8HtH3rX
GT6/EC2ZBFgFAayrvJMNl2Wy8uwnVutVKA+WJFULsI5NgMcyKe+538I0lu4OYE1m2WteqdlzzwKW
8XdgF2VwhvdOUXDAglaythn5aYaq7WMCjUWAVRDAQlbGF+b6DaJNzuwJQ1zWHOb6EG6rdUuSKgNY
Q7jowXuFfqVjLT2z7uLIvjWXfl4UwMIijC2/I/lguGtGw3vRe1HNnpsLWJNxLbqBEI8C2IsnDE2e
0Qdz8xIAFgRP25N14Ar147YIeG4EWAUBrHXMFXgbmHHClSSpGoCFByxsbaCA6NA670Htq+e5aIwq
EGDh712xG/8nMr4GBBiLAKs+jMSxvt/wof/LFPutRIAFwSOHUgzwBKPG2okEq2kCnxsBVoGyCDGB
odbN1ISo3yUM8QzokbSB1i1JqgxgIXgdAcbL1Zn0luMkHrqVVrOzCAcF/N0CrHSNttbJIozP80I9
eG6aBViI0Qzd4aX0gIUb5CtznixUZH4pYS/y9f/RuiVJlQEs6HR6FFDlHMG6+/Mp/B5z24LxoocM
5FkDjSUEYA0gSPk2kHaehWv7I8BK1wa8jtD/9i1zPQd9w7E4ODzU1lpegIVK80/x/jjVwtRTaxZg
DaZzZSTPUVxpH42przEXOoBM3U0FWOnCB/e1KYtQkgRY7TWduezBRnPDAQHHkidgYcFA8ceHCQeP
ePYw7UdzafTaImweYI3iNYQ44JkIKb7hGLas0bat6FuEK3j3BWKw+vTAuckTsOISGjcSrFC36/WU
OWBbAVZ7/cXal/RPWvzajlq3JKlSgGVc3JBtnJYV9X5k+1iYmlF5AxZS/S/I+DAJb/7UAqymAdbA
Trw31BZuXoCFsTzItXOxHjo3eQEW4BAeqhMJOr34Gfn3yj9oz3XyPFYCsK7khYAPcB3e+Kt4hp/h
LscWgco0SFL1AMs4saKoKLK4xkV2fmS70eMQWnkBFjLTfk6BqeQxbO2cZSo02kzASvvduLaw7TxZ
k8aTZwwW6sVdznumI61g2UpT9BRgLcbPJI6z2jtxr1xJCIPB07WUAKutAE1vWbZ94um0bklSJQGr
J5UXYCF2BzE+e5rLEkRFcGzhbM2HyzUJjhdauLgZAVbHWtJcuYaXzXlHUazzmchOtraV0YsMWADz
lQgj2F5HrNIe5kJsYkPDanh+byo4YK3CvxFa1lx2p19qImYCABgKDi8swGp/Ii7jpNORZrO23cAl
SRJg+U+6obxZeQEWQhzOSRxDPNbZ3s9TE7qWEGA1HbA2NNeard62LQKqQ2bm5QVYgI17LNtW9BNW
7GbPyCR+ieN5z/u7Eafol2XZNrKHLEztuFID1tzmqhb/QALFRHZtwv7Oi3sXrVuSVDnAQjmGgyM7
xVxWlG/wLJxrriDp4gUHLEDNJeZSy3cwV0Ub8WVv0muyiLltz18ju0KA1VTAmifhHalnz1i43pd5
ARaA4PaMgPWYFb9Vzmbmqs77cPUnvoY6ePvzOO7RENvqpQas1U29CCVJgJUubKt9lWFuwOI4f8EB
ayCfxF/1/m5A1TZWaxUWJ/W8HGghF2Cl6xhzrdlO5IP89oTg7Qm9h/B6xkJf9CzC3vw9r0X2AD07
SXuA1yE8WP0KDljQ0pGdwAeqNbzj+P4ic15gPIQNFWC1f6oTYEmSACupoVwAsswNZQAsIwz4T+PL
cwK/JjGeB7lICbDCAxY8OGiRk6WQ9eHmPKlFBqzB9OrAOzrAavXVfMNxxC8dwc+x6IDVkyo1YKH6
Mjp/H20uKG+fhOH/QO2R8eZ6dUmSVA3Amt7c9hk8WJdxYTs9YdgmROkDbN2EilvKu9Do2pFdx/kt
jn+ZnE/nKBCJtPRlA41FgJUOWOgbuVmG9x5lrutIkQGrj2UvVzDIih2DlVV7WLhODqWPwRqR4X3Y
a11Q65YkVQawEE+B4oI3ZXgvttpmKwlgdSQsjP0C/n4BVv3rFSCPxuF/Nrc9uGVkW/Hrfubi4uB9
LHol9yIob8DaknMBPp87EgY4/q+5YHhtEWaYVPt4A5vEJEmqImBBs3OuaZRBvDjfWxbAwvbMRuYy
C6fiMYxxlsDnRYCVrgWs4wzC2FDMsuhB7q0GWLtatjCB7wI5YVoCsJD+Cvfr/eZqwUAo8HZIi0wG
kiTA6rxQB+cxLn5/M9en70LPzudx9DANVbU6T8DqRw/JW96isAhfQw0mbB2uL8BqOmBBaPj8TgcL
+LMWdhdFgJV+jl/PAFfIvEXwviq5pwju2E+9D+teq6VborkjMh621ZolSZUDrGOttYLcj0/83Z8n
Fu3VzBW4XD7QWARYHWsOc3F9iIX7xFxhWPSJPIKfXUgJsNoLldm/5FyCmEXEYz/P+eWPPHYJP7ep
A42l1IC1rDfZfGZuH/x2a1vPAmmz30Q2l9YtSaoUYP1vRsD6sgSAtSDnt/9H0BprLjh/qQQ0oHr4
zQKsHgGsWIjlGRHZzBau96AAq7FWNZfh6QvJcMmCvfjcVhRgtdfZPBGjCFCj+IH6mQ2bcxI9VOuW
JFUKsAAi482FDxybYmP5f/3bwvQhyxOwdrb2xRABUit5PyMOC4UUVQer+YAFKMA24ciU11a3cJmd
zQCsSb01tX+JAAsxiUguQKYnCg6jndQU5rZrESIAj+My5jyNCC/qLcBqqxsSNzsg61rvZ9T0uIOA
da7WLUmqDGD14tyQBTQQw1n0IPeNI7svsmHeMWRILsnvUWbiac51yIgKseUhwEoX4n2vslqz7TUS
ryMI/qGU40UGrKGE+msIO3GnA3xeKMo5MOBY8gKs3vz7J5jzUqMx+qocA87Vh1arwI/t9nkEWG2F
p9AH+aHhgliEH+j0pNUYrmDHaN2SpMoAVpqmsFoq9gAL0+YjFGABrFBdGxW0z4zsQHPxJBfw9/tx
qLdYmLYfAqx07WJtt5zTamIdyfM3VQkAa1ZCiT+m+JwP5Fr6DwtTZDRPwILg4f3VG8eOPH55Yny4
f2YWYLUVGrR+xQ8Qkw3SYBFciN6DfsVjvK5mz5JUPcAayCfxuwkne/A4PFbnWLgCo3kDFrShZYsn
GxloLAKsdOGh/uvI7uL5HlQHgHB+il4HCw8dcS/C7+nZ+drabkVjfMiYPLEEgAUhdOi2yC61mmd3
cj6oICnkjch2CjSW0mcRbsRJpaNJR/FXklQ9wJqSc40/FxzsvQ4QwbbaqiUBLGgTc1uA9eos/T7g
WARY7dWPi/emHbxniLlYQJyjowoOWChX8nZku0c2r7k4JcT6rZcYM5wY6JQQojhniEru9Wpijohs
hoDXWUvUwUIcwtWRfRDZD+YCPb/kRb2p1itJqiRgneB5dRD4jW2AQxLvQe2o5wMtFCEAC5qCoHWS
OS/ciXzQ/F3g8yLAaq9evFaPSlnEsQ29BmEhhuCDCg5YY8zFk/m6lF6gWGgwjl2hjyxMdn5P9CJc
0VTJvaHQoBJxWHD7z84LXJKk6gEWtgIeNxerNAsXVBTpPD7xviu58IXyYjWzVU6/wL9fgJWuOGga
RW2RTHUKryt4FP1QFTz4h8omzAuwsG7+J7J9IxtuLlHsajoq5iJIfsPxYGstRLZqVwEL9/z2Vkv8
gOClRozcjnVsO0LvPQKs9lrGwtWvkCSpvIA1JyfpoYlFaKz3MxJhPuZisUEJAAtxI/BaIZ5svcRr
05qrTL+4AKvpgNWL12yj+LhjA44nzyD3s/j3okcfuhwgDgv11T5KjOfSQGPpCmAhk/NOq9XEjIvt
3mDZauHBwx2iBEWpAQud5T8gVc9ukiQJsJwQrHsHJ11s0yAz6jAuHnjCRVbXJ5xcfwkIDXkBFsbz
V29BeCjlPVtzoZhJgNVUwIoX0j0tPT4O2YP7BB5PnoCFz+b2BkAC7/DwAgEW4qj8bMEDePzqjIAF
kAyx41VqwPo9J9Fx5gIN8QSHdhF9tEZJUqUBC1rXm0Df45P4VzR/cn3Y3FZIkQFrUYJgnBV9Usp7
pqTX4SwBVtMBKxYaca9H2IKhN+SMTRhP3nWwkCl4ED8jeIR+5n3zpLlt9ukCjqUrgIUHkDPMbcmi
VVEcG3Ydofc2skLSbuMYAViTCbDaaiHvaQ03P1JgL+OT3nqmGCxJqjJgQfuZK/5Y78n1FcJLKOUF
WFuay9ra31y8WNp2xjwc69OBFgsBVrrQ83Zf67iuGiqJT1ECwErWT8ODB9pIIXYM8c2TN+HcdDUG
C58/vNPT8ucBPC+zcFy9UwwAhCzPwy1MjbKWCnKPtTmfWB/nU8T0WrMkqZKABSEeY5y5oGNUb0bt
GxQoHmvhttPyBqztGnwmKJJ4i9XiSUI0FxZgpQsZnG81eKBfy1xrt1CZnnkB1kDCfL8ePDd5VnLP
+qCB94XY+So1YE2TuBCWNpfF8U7iKRWBrFtr3ZKkSgJWLGyhjTAXOzJZk8aSF2ChJhGytlDTD4Hs
2HZCID+2QRFPNtGb7+4PtFgIsJz609sxGWEAD/Sv8fqatI7hmns9sh0KDli4bu7hA8ja1pxuB6EA
Kzku1PhCMssYskIzdrhKDVjrcAJDCumNVksf9Q1PrBeb6wclSVJ1Aaujp9dQWx95ZhGezjntaz5E
IsHnl5Q5L9QiLsBygtcTxTfhtUJ3AOyW/MDv4T18JWEvew/9oTIJ8wIsQMc4c2E2V3Nd3dWauwuU
N2DhIQRJIX7sJVgB8WR7WNgG1qUGrFWsbeZAMu3yf/mUJ0lS9QALC+HyfFpNs6XMlXk5h98XHbAG
W9tMwqQhEPkYq1+1WoCVD2BBCPI+07JlqPm2VcEBCw8bi3g/w1uKgr3Xmwt6b8Z6midgob3U9w3O
yXUWLsml1IA1kpOK/2E9QuKeVuuUJFUasBC4+qPVMgeT9iUnX3wfysOdd6HRSbhoYA590Vzg+/Nc
JNYNfF4EWO21T8oalGZIPjjLwm1N551FmNRskd1qLtwGDcYRtB8qWz8vwELw+nPeOUCGITKJv+BX
3/t7uACrvVa2WoXcm8ztrQ7S+iRJAixzsUlZvAoArAVLAlj+xD3MXGzPVE06LwKsdB1M8EBJBhSv
XTth+D+WDjyevAALMc1+dXZcX/vys/o6cd9gHQ+RGZkXYCGjEDtcL/PzwXWLjOHF+BUlnRCbjVp5
/yGQCbA8oT/SY/ygJjFJkgRYNY3lUysmzzcShniZb/g6vN5zlwywOhKKLoYIThZgpQvZajtYz9Zf
zDOL8DhzmYT/x3sl+UACzw8C4beyMNmGeQEWypag/2ijNlgDCFkhILjUgLVAwIlRkqTyAhbq3uzF
SXp6Pon7hhiaZQgM2wccS96ABW8VahKtzgdL3xCTinIOyKQOEbgrwOq+QkFYXoAVA0E9T+9lBJaQ
MJlnDNbZ1jjurS/HvJgAq75GmOvyfYi5pq74flatVZJUWcDKAhkIK0BhzqlLAFiot4TtDnjefkyx
H7gQ3hVoLAKsdPWmF6QjAzRsEtnoEgDWbQmwQh/Ck80V9m6GugpYaIm1Oz8L2E6RHWEuDmtv/vw/
CduZn9sEC+P1LT1gwUV5tLkWEUniRkHBQ3kDSJJUHcCChtOzMzLFVqLH52LOFesUHLBQLfwTyxZT
dpsAq6mAhWssLsfwUh3Da0io2LIEgBU3TX6WzooRTT43XQWsm6zzWZ2xrR1oLKUGLDylnpXhw/s/
rVmSVDnAAtwgyPW7OvaDN0eMKjhgbWq1+BfUX3ozxRAvg22cewVYTQWs9TuxkG9ScMCC1xc1vg63
cFXnQwHWNd0ArFMsTBx3qQFrJavtDaNZI1z9z9CQujzRajUwltW6JUmVAqwjMk6umC9CNa/NC7CW
Jyz+maAzfYrh+GL8PxWD1TzAGp3xOgPQb15wwMJ2ZtaacCg5EWJ3qKuAhVIlz/IBY3wnDP8XSlCE
KO1UasA6lR8MUi6RWopqzFPwK4JB0U4CgawPmOsALklSdQDrWHqqEIPxYsKwbYNKzteaa2YbSnkB
Vj9+JlnmzVksTHaXACtd8C6iNhS2meEJXc8zHNuS19tJFq7hc3cAK81z04vH0wyvoUTIkRamA0JX
AAvxU3twze9njWPikvFx6kWYousJUI00hjeAJEnVACwsAntykcPD19QJm9bCtccJAViYqJE5CG/b
UeaaB6+bsLW50F4owGoqYE2b4fNGx4DHCABFAqztCTMnWK0I6onmgr7vrWN3m9sxesLCeEq7Ali9
rHn9RSsDWBeZ65eEIoFDeJH39QwnH01SbzPFYUlS1QCrCBNuXoCFVh5owOvXIvo1xZRF2HzAwrWG
AtdDuQ4lbRD/H5ybvQsEWDNb2/58Y3j8Hsu25fmYhcm8C9HsWYDVBW3AE41iYnD7w+X/OCcBfEVM
1kd8zxpatySpMoDVXY0wl4VYFMAaRCBQFmHxAAvZqHG24Isp9oIHMscVCLDgTfvYu27W4/E7M15n
8GCF2FYTYBUEsOCx+luGC+EvpkrvklQlwMIkjewuxMds2AnDU/wWhKJlchhLnh6sx7ggoiTAaymG
UgCf0QMhwGoeYHUmi3D9AgGWEaquiGw/cwHrWFOvNNc0HPfBNimG40i2uMPCNEkWYBWoDhZK+2P/
OK1GzOd8bVKtWZJUKcDCQnGpdT1tGx6HPAor5gVYiPM5KLLZzQUYT5NiSOxBd4vDzAXvCrCaA1h+
FuEvKYYisO/zvIR60M8rixDb6vNlfC/iykL0/hVgFbCSOyYW7G8jUwNVZ/ex5lWelSSpWIBlBI4X
uwhY8ATl0QA6L8DqY9m3Y/oHWsgFWOlChf1zzBUcXSNhaP6MckIjAo8nL8BCPBn6Ko5sAPshyx4J
sAoEWCjRMLPWJEkSYCWEGE20lcH22cPmmjrH9jBhAWUcHjIXQB4fx1Yc2oPk0ZssRLNngNaSkW0W
2Y70oMzZhPMiwKr/ufT0LklegAUhfvmIBgB0mrnt96IDFna4erJlXqkBa5fIvozs9cgW17okSQIs
Clsd48210ZqOEy22MwbTBvIrvN3oX9qXPw+i/TGnp/S8AQsFR5Em72d/wdAq7ExzJSkEWM0FrLTP
aRFzuypTNGk83QGsmQkhuE+m50PG8fzbk8Vs8R6UOUGl9xes2FuEKMOC9jnv8z7sJcDqnK72Jpht
tC5JkgCLmstcuYJG9YnmMLeNOHfK5DxVwQALcPWRdby1eXvARV2A1bFWMBcg/qq5zHacK3QUOYfX
WVEBa0veA2jBhAQKeHU/5rFXE/YKDR1SEPc8e4EBa3HvvnjbwsQltjRgrckP76Ye+vAkSSomYCEQ
/EkuPB3FIyFz8AcLF++RF2DB4zbBagH4H0T2off128h+5uuHCbCaDlibWXuvom/YZVmioIDVi+f0
WetcnOKTvC6LCljwrsW14zbqoeus9DFY25pzjf+uwQetLURJqg5gQRdycr3PXNuc3SPbiYa09Ou8
RfH3gcaSF2AtF9k7XEjhncO2DlrijOBXeOCWjuwSc7Fk6kXYPMCarwFcxQZv1lSBxpNHDBa2/u62
Wjbkj4T2pP1krubXCoHGkmcMFu4N1PVassH75g8Ei6UGLFwQ63MixY1/NIELDTW3pG3O13fRuiVJ
lQKsuejhabTwYbGYNtBY8gKs3fkg2UiDOaHPJsBqGmAdx+tsbGRb0VuyCb9uHdmfIjvf3NbbVgUG
LCj2/F5sLsljmYQtS5CfOuC5yROwsDW7GX/fqTwvyJBclYYisaN5j4bYWi81YK3m0XajSXQHrVuS
VCnAghBG8FoH88LbgYEhL8DakAvfAvRO9aqzMG1HcAjRZ1GA1V7I6Lwh4+85hIt8kQELWsjyKbJb
BMC6yly82PfePf99wnAMcWUhwoxKDVgjLft+8fZatySpcoAFzcTF7YHI/hPZm+bafMAjNF/gseQF
WMPpJUHwNMpK3BzZZZFdzq/Y7nycc90VgcYiwEoHrFssW5IVMvNOLgFgQVPTu5MEdXhI17awGXl5
AtbfM/LBCwKs9kJ3eVRrv99cl+/7EhYfw6S0s9YtSaokYPmT3XSElaFNGkueWYR/zLBQIHNtEQFW
0wALQnFrJBmgbdtxPE+7mtvW3c1cTalreX62KAFgIV45LtALgO+dAEp44c4KCFl5AtZ1XP/Rl/jZ
FMPx98y1mRJgJbSOuUJ7/Wj9UwwXxLoBL2xJkooNWDPz/j+RD2XQCHMxmn0CjyVPwMKCtjcXhDS4
AvwsH3AsAqx0zWONy2fE5ycU2OcFWICbh7y/OW3rbGpegzsVHLDABOipiJgxeOIQXzYVbRgNcVco
0nu2hUlAKDVgDbbsLSGGaN2SpMoBFoKK3/AWjLiEwSBOvvA6hCzOGaKSOwLYETiNXouou3SRuara
vwt8XgRY9bVm4jpLGrZv5w44nrwAa2FzmYIARuz+jEl5Dzxaz0X2jLkCvUUFrD6duLensMY18yoH
WMmnO1SaRTomXJzTaZ2SpEoD1piUhe6gxJyBp/VLSgZYPSUBVseCpxRxVqhXhuQJFO68J7I/W7jy
DHkD1voEqxEdAAeSy1CqAfXXQrShCdGLEFnCyOrc12rFUbGVvnTg89ISgIU0zLt4UaN1zhf8/g6+
JklStQBrACfpxwhVmFwRDH504n34f37gk3vRAQsLD5rYw+uWrEE0g7kt0NkCnhcBVjahTdNMPCf9
mjSevAALpRnGW3oZBmxvIhs/3qJ+h2MsOmAhFu517yFrFI8DDi8ldAmwUgRX5dnWeO/7JK1ZklQp
wJqTk/Qw7xgSXU7wfkZcxlOcIzYoOGDB23aqN6eNT3nPXgSgYQKsHgWsnlBegIW4ZVQ/h/ftjMj2
j+xgc17eFxPr6h2WPUSnpwBrrxQeWMt7HSCMXoXbCbDaa2PLXqZhTa1bklQZwJqcC8UOnhdhJwIP
tGBkt3rzw7oFByzUv/Jr+VyY8p5hXCyOE2AJsLoh1MD6tMF6il6FywYaS16AhW1ZlGRBZwN4rvfl
98m4Mmzpos+isggTupInG/VtDjQX6DmaBvhCimycHnuG1i1JqgxgxXDzG0HrfE7aj0Z2IxeIeLEA
lITaWssLsBDq8BHnsW0sPaAdWx5o2fJkoMVCgFUNwILQmun+OnCFz22lgGPJC7BW4Wfib9NiHtjS
+3kEYfIbC1MTr9SANY4nYtIG77vNXOl/SZKqA1iIGbnLGnu39wo4lrwACwvoRQ3GeonVUutDJPkI
sKoDWEZIX5WeH2xPH2quNFLojPy8AAsV6ZG9uUACsDbk9/Bij+c985kAq72W5ETcu4P3IHbhJnOZ
D75Q4mEprWWS1LKABQ2j1ydZp+hXc9Wb/yfwWPICrEXNbWPswKduNKadknMgYsse88b2sIUJrhZg
VQuwYiHgvY8HXaGVZ5kGPGChGPnVkR1O4EJrI+xsfejdM8+YtgjbCZCEzBm0hkBmAILX1qbhe8Rd
wXN1LwErfm0Nc+m0agAtSa0NWLGQmo3YC2Th7UZImLIJY8kLsPAQeZnVsrdQhRrVp7+09h65fQKN
RYCVXb28BbaMgIX75RRzSSBoLxWXM8Daebq5bghFBywI2cGfWccebPQy3jTQWEoNWLjRv0p8UL79
bLXmjj8lXsPxXbWWSVIlACtt4uvVhLHkWaYBnoTbGiwWf7HGIRMCrDCAhcxVbKddb7VkCvw/B0Q2
V4kACzs7byauq5U8cNyZnqBQkJV3mQYE7T9Q537BdvpWgeeZ0gLWKpY9izDN5MGSpNYELGyRoRk8
YkY2sVrdKBQcvMDcdtsTXPwmDTiWvAuNYmtwT3PbgAjO/TqyT8xlQu0QGBoFWPWFRfq/3tpyrQck
a3GBD/m55dkq5wmOAZXp4cH6kGttLFRvf82cR7UMgBX/TrTJQhwZPHDHmvNaTduEB7nSAhYC8L7n
yX6pE4Z6Ht9xopIkqfUACxPbKVbLelqVi+rdKQ9ap5UIsGKh1c8c5rZAsJ0zWRPOiwArXSt61xKK
1iK+74rEe8bSKzRNwQFrRa6Ra/FvxeeE+KXRCcifSKAMUaE+BGBlUYiHk1IDFuKu9iWFTs0LIosh
9gKpmttrLZOklgQs6LzIrrNag90zE2CFNPSzzFWmXrRkgNUTEmClC9mbSDJAQ3FsR+3P687XTrzm
diw4YKHg7jUp41vH+/lwjgWJIyH6KzYbsAaSBUL08iw1YCFDqKvZMqDVKbSWSVJLAhZaeKCnWtwr
DYVEf7S2tXyGeQvI1gIsAVYXhMrntxKsYmE77foEMMTlQk4oOGDhvoGnDeUM4PVFKQNk3e3Ne+hK
axu/NLTggAXP7h48H6g8f3vCENOI2njPE7QEWF2EqeEmSVJVAAuFQ+8nFAznYhAvDOhV6pdoGWcu
TkuAJcDqytryFy7g85rL9lyT5xyggC23G71r74CCAxZ0MP9WJImhIC/CcBDr96u19QCfHGgseQEW
4Cbpta5nCBtSmYY6QiExuDDhot2SX31DkbSdtG5JUmUAqy+fTp+19j3U/OauCH5/zlwGmABLgNUV
xTFYgJGHeT0hMBzB4t961x08qMuUALCwK3ROAyDxt96LCli4pz/PCFh4AOsvwGorbPEhk+GzFLpO
2g5atySpMoAFIa7qbWsf0D4JJ3G0nEEdqRcCTa4CrGoAFrR/hkX88IDjCVFoFHXjriYwovYagt/h
jdsu4P2SJ2Dh/ocXDpmQ2CbckZ+Tb+CCQyK7JxAwlhqw/mTZSzIooF2SqgVY0EycQM9PTNhL8hj+
H6RtF70XoQCr2IAFbWSu7+U33roDD9ZjTVh/QlZyhyNjRqvFLMbqZWEy7/ICLPweFOPdL8N74e0K
kYlbasC6nhcx6sE8wxvmUc/wMxqfYg9ZRUUlqXqA1dPqCcBCoHIfAVbTAAuLaF9+j0DpBfl7Udpg
YQu3ldYswKoHL+gYMHmBAQtCB5ebeE/UEyBxfZMHq52QYo1978V5otE6Z4hn8c+j+QFKkiTAKjNg
YaFYzlwR1ZUTtiI9JWgKHWILR4CVLmQNIruuoyDpzSJbpGCAhcUfAe0oinpZJwxZtyic+piFCQzv
KmDtmzIWeKkRJoBYzHEpY7k0sjv5+iABVlshEwgVmWfM8N6pTJIkAVZ5AWtzc0WVse30fYqheDIm
2LsDjUWAlS48wL/Z4D1olXOzueKwRQEsZDzea13vhALA6lsgwLqpG2N50RTknipkDV7Ppzd4spZI
2GLmAty2MkmSBFjlBKz5rXHT2thuE2AFBaxpuJ5gVwTZ60fSS/IH/r6krUsPFnZb9i+YB+uObkAJ
roUQW9FdBazrujGWlwVY7dWL8PQTn94+r2P4T1WmQZIEWGUFrE05j/3ExeAFPnX79hwhTB6ssICF
TiDoEvBjFxbyowsEWCjHgCKiFxH8/pzRUMvrbHOFfEMU5+wKYIEFLuO84Y/lIFq9sRwY2YnmauYp
BqvOpKMsQkkSYLUyYCHuCinnyJxGuENaazAcX4gLSojYGAFWW6GtzPudWIPQp3CVAgEWQGadbvyf
8OANKQhgYbtzqW78n8gqVgxWQld4F+9Xlu69+tLkwZKkqgMWFlSEEIzgz0g9n6FEgIWtmAsJT400
h3W9hZgAq/Pg+67VtplgryTsP+YKkG4WcDyhsggBO+iEEJcwmJIwE1J5ZhGiZtcaHbyOh5JlAo6l
1IA1zlzNEeyHz8uJZc6EIbhw58AXtyRJxQQsJMCgk8NLnCtiQJnZXDbUxiUBLEzUaMGCIPfjuWjg
57U8Wz2y3SP7qwCraYBlPA+o2j6LtfUoTkubzlxGe0jlDVhYO1EfDtl1EyNbnsdxnZ3D+6cMgDU+
spM6eB33ybEWrhdpqQEL2RuvWrZAu6EmSVKVAGuEufp4/jaN7wHCwxdimbYtAWAN5mLht135KWFx
TNBdgcYiwKqvRXt4PHkC1rKRvZW4b1byXt+ZQBkKsroDWDPT0QLv9PTm4hHRj3AYjyUN1/TehMgp
BVjtdTZJG08Kk/ND8m0on+xGa92SpEoB1jguDtieQYo8tm8OS7wHXqx3OX8UGbAQH/KIKYuwqIAF
YbsJHtFTrFbYGlvRu5iLmSsDYE1KePqNDycP8v7wY8fg0MDW5xUFBKyNeZ+/Z25rFiVNPqcj5vUU
w3u+4/sWEmC1FUowPMWL4SV+/0zCcOwLXuSSJFUDsNAi5/HINrRawPee5rbXfMW1c9YuOGAN4Xje
MFd/6N8p9igXQ/RVC9HCRIBVX/DwPO1B7g3eAovtJ5RDmKcEgIVyR88RqCYn7FyRcFAMpMfnvxam
vmR3AAvX/TK8FzqT3fkqrwkBlqfVTFmEkiTAaq9ZOEnPnFiEjvJ+3olPrpgfQnV6yAuw4AH5E8c1
hItf0oZwEVcWYXMBa0GrlQOK7fLEe86mZ2hIoPHkBVgAqesTx1Dt3M82PJpj/CiyuQsGWLEAfrfz
7/zF0rfUY3s14ANWqQFrpHdB/1rH4td31LolSZUBLOhqc1sAiLFAIPLpXPhQER0tNX62Wvr8UoHG
kmcW4SQZ39u3E+8VYHVfZ/M6Q1Px9SIba67opa/teK1tWnDAQkA+qtJfQqhawNz2OtbrMVbr/xtn
TYaIbc4ryB3bs4/ynkeboiVTDPd9yGziUgPWuvzwsA2wqrlYK99WJZmeJ8CSpMoBFgKPv/YewH5J
PHTFBtjqF2gsIZo9Y9LGNgi88vDCIUN6ziacFwFWe+G6uTXxmayS8AL14jX2G+GryIAFHeDdG6g+
jzZM36TcN8cGGkueWYTw6K7Rg9dZqQELWQKDOjE5SJJUHcCCsOXxutUPHbgz8BNs3oCFWJ/xKQve
B5Gda2GDqQVY7dWLD/lnWi2GB6ErV/P7WfmAH5+nQ0oAWIDGs63jkJvLLExhzrwBy1d/ng8Es2Or
fUATrrPSZxFmvWDmNkmSqgZY0AhzbTFuMZeJ9xAXxa0sTP+xUICFkIhG/QiRlj5loLEIsNK1Lj97
lPy42NyWGrLs4LV61zs3vxC+ig5Y/sPJVeaC9xGnhJpYN/K+6Rvw3OQNWAPJG7jvEZj/ibksQ2QX
7xYYtEoFWPPzCS6eFBHYuQov2lXr2Gqk8V21bklSpQALmYRzJSa7wda2f9qgwGPJC7AGEgji4GIs
eIj7eY1fPzQXsPsb/8+iAxbOw2QZ34v4s7yDw/MELHixzrDGiVZnW5jYuFCAFQuxTFN34nwVCbCG
EAo7Oi9XWpieiqUCLMRUvc9J5GQew42OGhbIEPihjsXF93bQuiVJlQKsE8xlEnU0kR8U0KuQJ2Ah
fR7FHxFLiq4V2Nac0TMcQ7VtNO591IqdRYgH5MvoPYgBqp7wkHwfvSgXmAsLKRpgQdgl2Zeeq+QC
jqDxIyystzQvwOrLa6c3gWqAd4424725o4Xdis4TsI6wbFUGjqg6YJ3lfRhv84SvaCrTIEkCrHSd
lGHRAZSErEqdF2ChBc6ZGT1DGPPsBQYsLKCo5XV+ZAeb26rB1mYyw26Etd1iQ7D1nTl5UkIUGjWC
7xpcbwA9SLKapQn3TF6ABYC9hvcECtYuw8/774n19MnIZis4YOEcw9OLJIS4J+GanuF6Q4YxOh/A
E1zpZs9IGUX8AbKAzuaxkfRQxfvDz9UxeL3U7FmSWhuwFqeX4zRztXoQb4UA9+PozToxYcjoiguN
jio4YP2Bc9yi9JYkG+72oodkZ4JDiKKJeXqwAFTfJRbtnxMPwlta26DqeenN2rLAgNWREBs3f8EB
axLCzb+t1v7n5MR5QmbhtwSxIgMWwoluscZFdwfwswtRqqVUMVgLEaom5c+4OfbijY/CYsMShmNT
kFS30bolSS0NWKjJgxTzr6xzVZx/4xNtkQEL24AI0P3S3HbZA1w8buPX+whgMYyEUJ6AdX8CrH7h
937boiO892zFY5vR89VTgIU6URuYq3fVkY2ixd/j3/yNnpQiAxYg9mHvHKxttXpxMHRGmY+eLXQW
GF5gwFousgnWOOljGt5PIfpJljqLEPCUNZshVGaNJEnFACzfk/VCJ+AKcVqTFxywoF0zjAUQtkDB
AQvNeNHa7FRzOxPL0duAGKZ3zLWWia+DeFxxJfGFzWXpdbduWVcBa3QX4N23TQoOWKgp+Vd+P3Xi
PgLcL+29F+2AFikwYCHAfaK5XSwkIRzCewi2C50zCCN43twuWIi4xUqUaZAkqTqABc3FSRPbGQgp
ODdhqE2E7cRDzXm7QynvOliIxXq7zuKN4PYlAo4lL8ACZFxc5zV4IOMClid6Y1uXxwCP6LXY3Tis
rgLWqG4C1sYFB6xFCb/Y8bkj8bcflPAOwdM1uMCABe2f8byE4hEBliRJLQdYEDLQzurhsYSo5D47
588L+LvxdL65hYm7CgFYWDiRbYdwD+xCDORCje0pBLEfzPcda+23cOHBujsHb0NXAQt/O4q8YpsW
gd5PZbD4fYg52zLQuckLsJA8dlkKgCDeqj+BYUGevwsDjSVPwMIOF2LIvq8DVojPPsE6zmQVYEmS
JMBKUaPMoN4lBKwsINQn0O/NA7DQ1udrAsdz9IQgnucDLnpIUsAW4DhvIYwzDBHDhDY0vbr5N3Rn
ixBbTHHD7SkyGN6H+EBsS21dcMCKP5tTInuG9n8evP+B5+sNc7FwIbbVQlRyR5mnK8x5eV/i9YaY
uLUD34sCLEmSWhawGgkL7GYFBCwAxIxWK0yJnxF4PMJcYPFM1rYOFn6envBzqtUSgYoIWBjLRVY/
Hg5V95+1tu2AEKy8rbmaUgfnBBFdAawh1vX4rz4ErqIDVqwprX3sMoL8Z+G1OL2FqegeqlVOfP6m
szBNqgVYkiRVCrCWIHCgWvNlCUMwL+oxIU5rngIBFuKLEDf2Fj8HeOH603ODY6/XMdTyQfr83YHG
kmcl9+n5d/pw9bK5GKt4rDiGYtF/stq21aeWT9uzUGUa+vJawvbnigTiZihkJfdmKyRgNVstB1i9
vIFJklRdwFrWXFZdliDXUJN5VwBrBWtfQmISwmCWsdxWAsAygiOCqU+PbE9znrhYgCzE0C3nAdlx
PJaH8gYsbJWhaCW2zz4kGGIL9B0usJsKsARYZQUsPCXswYnsJO8G3c/C1LaQJKnYgDWJ5wVpZPBg
LVwgwJrLA0N4bFD/r7cHWHELsKT9wNdDLbRq9pyugda+0nkz27EIsARYwQALhdwmehfxeKt5seCi
xd79aK1ZklQpwEKcBbbNHqTn43hzmV9Xm6vyjp/HmYv1WTbgWLoag4UWPtjaXM2DG2xpomAl6nwt
mWKLmSvIeYWF6XvXbMDqy0U2RJPhPAFrrxSYQnHOnxLHUEx1pQIC1rwWrtlxswEL27ODCzSWUgMW
njrjdgs/8qK+w9pmmOD/QYud4SZJUlUAaw7Cld9jEA9a11nb8IFLrVYlvEiAldRQjimL0I6lX4Cx
5AlYWETR1udsguPFCUMJAPSIuz/QWPICLFxLt3MNupGwBQhenYbvsf0Ze1OPKBhgHcT1EXXhehfk
/u8qYGEXCx7fvwW6ZioHWEjnRRrpNnzi24YXuZ+ivDEv7AO1bklSZQALqfHwVk3Hh6tV+ZR+J+eI
2fgaFlmknE9VcMAaQOjoCAgQIL5DwPOSZ7Pnv1q27dsJFiaeNi/A6kVozxL3hof/kwoEWNMRrvA5
v2nh66iFBCw8gMSNwbHlP60Aq/vCRDky8dTqP6H248+/kdAlSaoGYEEnc4F+jnPAbuZae8DTjeDj
V6x9K5aiAhbmNGxxNipUiW3F/QsOWAhc/zUjYD1o3a95FRKwoBW4vnRUewwB/bea28b1BbBfpocA
C0COLfIrEtcVvHCrZ/j3C1mYrcWuANasHAuyhXf0jsNLum7Gz2JQgLGUGrD+j08Oi/LiXpAfMPZg
EVdxlXejHq91S5IqBVgIFv/UmwPiJshjUxbyNQoIWIA+FKbENhPay7xozms/mouPb3jP+ub69D0f
aOHLC7DWsVrjYJyLw81tnfl2mDkvFxanEPFkeQIWakWdQVCJz8UfEt/fwHPze+81nK8zLZ/io10B
LAAS2kahrhXqqMGriy4Bz3A8w/lz0mblmnuOhenh2RXAwt9+If++Gfkz/s5HzNVcqzeW2fg5YKs6
RMusUgMWYg2QOfOVuQqtT5irBoyvXycm0NW0bklSpQAr9i7cS0/I4jzWnw9cn3L+OD/Q02t3AWtD
QlVn+929YmG2PPMCLGzfYFt224zerhBFU/MELCRaZfHI/VLneB6FbrsCWIDwh7hmor/lO/yKe+IL
c9uG76QY3vM519miFBrFbhVi9j4yVysu/ju/Jx90NJZPzFV3V7PnFCHm4KcGFza2CnqZJElVAyzj
xDmwjodrocBzQ3e3CFH/6apOAlaocIg8g9zh2bmR3pOOFs0xVvwswvWsew2g86iR1dUg98268Xc/
ZsWq5L5uN8byggCrvtYyVxX4c+9JAhWNEbOwp6noqCRVGbCyKFQGVR4xWJj4L+a8hqdzbK09lzBs
CyIGBVuIkwcaS16AhXCO/ek5mGhua+3KhGE790EutCEW8TwB6w/0+rzIc/BcBovfh3+XRwPo7pRp
2J4enG/o7fnZ82J9lWJf8loskgfLB0Z8tl97Y/mxwVjADC8LsDoWnnbmI2yNMrcdMKXWKkmqLGD1
5qTZv4714+uYlItUaLTeooMYnt3N9VMblrCpLVwmZN6Ahc/8IWuNLEJoNCFlqpTz0pFNQbjauIcB
Kz638OYuSlA8n+vpIimGWGc0Sb7KwmQedrfQ6DCOBfakubIN9caC9yDD+OpAvFD6OljnN5hYcAPN
Y5IkVQ2wsOihdcn4OobYLATBvmfhOj7kBVjQDNa2rlezlRdg9ePn3ypZhEO7AYGTWD4NoPOs5H5Y
xs8FpZFCFPXMs5I7+liOyfC+ZSxMA+hSAxYC1z/j01s9oXTDtda8ppuSJBUDsI7JuIgjtGD+EgBW
FmFhLPoWIRZleOPOimwfc9uFScNxZLKhblnRswg7M+5ZA/1utcoppkoFWCBM1OdAZgm2AFHXBj27
0Ax1iciWShjegywiFCAbq3VLkioFWEda9l6EC5UEsLDVsXlkW/BrbAiURikHBOueUgLAWiLjexcv
CWD1oUdnTMq52YznB10DtisRYKGFDvr5opYkiqReyTV3phICFhwtqO91DaH9av48a+CxlAqwcGOi
bgfa43xDQ4AaAtoQxPZlwvBk+j0n0XO1bklSpQALD1UXcKLeNGHIYjucD2i7W7j+ZXkCFuJe3rNs
ZRpCxJP0RLNn1C8qcqscI3Dc4q01oTMGmwFYSA77sM4YXjNXw6ssgLW91aq8J+1NQrAAy9MWHZz8
eraF1i1JqgxgIW5nbmscv4NebJdbuN5leQEW2pr8x7Knzxep0Cg8UKhgPsQ7NyiRsTQ9VGm2CL1B
lwQaS56AdXIn1qGNA11neQLWxhnGgQy8FUsAWChq+3ODsQCM1xJgtdVyHpWiYCDc/J8kDPFZb/FJ
tSiNLCVJao4HK17cB9QxzAk7cQJeoeCAFdf4QTmGuwkHmONQXPE+HnvfXNB+qLF0BbAGEWCx23CP
uSKjWHRu5bHP61hcgf9hK3YWIa6hO/m3xp8/zsf9nt1H6EW5gG0KDlioOYYyB1/ymsK24NU0ZA3e
wbH8ynGHSEDIC7D68vr5jufgqsRYbuc18CPfF4IRSh3kvoq5isCYUFD2fs6E4Ql2uNYrSaokYKEP
2ZNcEJL2KL9+xcUxVEBtXoC1C2EqbueBLc2bzBW5jL1CqxNm+gYaS1cAa/GEtyDejhmf0ePz/6z4
ZRpQs+sdrkGDCO+TejaA52sjc/HCRQYstJh73JzHsU8doBzM6+7JQOtrXoC1IK/X5ercE715vpAs
9wx5QYCV0PKWrZXCAJMkqUqANTbjIg5PStHLNCBQOu6nimQfbGmi3t/LVmsBNCu9WvsWCLCGccH+
jRCyAGHwAXoWJpqLg0naRJ6Xh0oAWPg8nrNsvexC1WbMC7A2JKRn0W3etVdEwEJ/0esyvhddBUJs
ebZModGOhHpZ65skSVUCrCxZhOjDtnPAseQFWMiCwhbb7vQc3E3gQQkabOegMfLDHNMjgR4ouxqD
BfBDS7NFPMg4gwsaPCAjUgzHsTNxsYVJQMg7i3DHyK6PbCV6TJZPGDxDqC8VKhY4L8BClirimw/h
WABQc9G7MxcBGcfRMeAVK2ah0VgzE+rH8ppdIjGW+XiNHUuon6bKgDWET3B/9542FySh3kQCTdoN
/Pp64ElUkqTiARbqYJ1uLvtudMLwwIW4ptBFiPPMIjw9AYeoQI1efl8kjv8nozelWYCVtoBmXcwQ
s1X0LML+HsyjxQw8b9+mmL9FWlTAipsmx2NBPNx7nn3E43j9wkBjyQuwJiH04m+N2+X4YwFIxpmf
oWrVlQawDvAmkEf4h69i2bM3tte6JUmVAaw4U62nk1vyBKwp+UD5k7WNf0H9qw+8ue74QGNpdpkG
/H+zB/rdeQLWXtZaWYQouvtGg3FgDZ6+4IAFzWZuG72jsTxr4ToklAaw/HiK5/iHLy/AkiQBVqBJ
Po+tqbwLjSJYF1sdMySOY9sDRSA3sGIFuQN0UY4B3sI1O2FIm0e2V6idh7wAC+O71VtnkP34bsJT
8q7VsiKL7sGKhS1plMj4MrGOwutzroXZTgsBWEZ4Qku9zxJjQbwitqBnDDiW0gAWaBnZGvfyZjV+
RSYQ9lBRiuGIhGFyw743UmV31bolSZUBLGRAoWXMEIJSVkNWEYLI9ycYFA2welJdASy/7+AvnbBf
+W9OLIEHC9tQnxMKASazJmwWHseat0lJACsW4pTW5+/H1vrsTbjOQrXKwUPIKI4FDyJzNWEspQty
9/fjF8lIn1Nbc6sPS5LUs4CFej5oi/GqudpRWQ3e8Zf4pL5YwQAL8HcQx7Vq4jV4tE4LvGh0FbDu
t84VhS5bmQbUtnq2E/9vmQCrJ6RehAXJIkSLgq2tY1f+/JxsJUmqDmBByFL7uIsLO7Z0FiwQYGGi
PisBHknBS/+0hdu+6Qpg9SdgvU2AfZEQ+6zVSjc8x+Mveq9/y3N3fSAoyROw+vB6RQ9I7LQgMH+6
hOEhf4uA0CDAEmDlDljYq8c+akderLX5ZDdI65YkVQqwsDVTrwfZr9733yZ+hiHjKI8G0HkBFmDv
R+/vOyflPVOZ6614UoEACyCDbE4Ufh7G34Gt26O5DszOv3sazxDMj62cWzjuEIkKeQIWyha8zvOC
rwiqfiXFUPdrKwGWAKuogNWH3qo+/MPX4gQ6nDdh0ibh+/HktLvWLUmqDGAh+BgFE5HthLgXVDlf
w2pB1KvzK1poHElv15re+8aZq11UFMBCcDRasSBDcENL99oDVtD4/ikrTh2sAQRdX4iFQRbkDA3+
7R7mAt2LDlgbWGtlEQqwKgpYeNK5NLInInvQnCsZNTlQKXiCuaq/vk3gjYz/9DytW5JUGcAaYS64
eqYM3gdMgMkwgvnodSkKYO3U4DPB3Hgl5zp4S6YtCGClCYCIekrzd/AeZEKeTqicKcBY8gSs0R5A
NQra31SAJcAq8hYhnoYutM7HVBykdUuSKgVY/2qwiMfeFMRbrRNoLHkBFrYrUUAUcVbISMM2G2J7
UDUcdZie8eY6PHyGKM6ZF2AtReh4y1zcEuJoN6EhTulAc1Xr4y23EEVT8wQsACPKAKxm6VXccWwV
rlvbCbAEWGWIwdqPN2kWuLqDT3iSJFUDsLCtdKe5LEIsPtgCnIveEIQUILYH224TOEdsUHDAwpbn
xVZr7/Mi4ePblPluj0BjybOS++0Z5+6LA40lT8ACAPbP8D68Z9pA4wkBWIhbHsn7JC4qirZzcwa+
/0MA1mScA7awWoFePHzNK8CqLzzpfMcJZRNeCL5tySfTwSZJUpUAy6xtbAzmCRR9nEjzswu/5cJR
ZMCCEPx9YwMgOSfjYt+TgAXNSsDpaCwTLMz2YN6AlQbDg6y52et5AxaC8RFe85PV2jLFgHV1YO9S
3oC1UWSPWq3Fz2geR5usK8gJAqw62tNcMUFJkgRYSR2TwUtyaMCx5F1odFIupuPNlTgAKGKr7R4u
FL0CjiXvVjnYVUDoBuJl3+ZY3uXPBxMoQykEYM3Ade0mwgmKYF8V2baRDSwRYO2SuD9+NtcUOdYS
fFhZrQSAtWXK/b6W9/o8vObWF2A1vmGWtFpqNZ7iFjRJkqoMWBBifBCX9H1iokV28d6BxxKqkjtA
CrWVsN0xLDBYhQKsWICPEeYSC2a15pTUyRuwFuf1VA/ib7NwvfvyBKxpCByoU4bEMJTTQHzfmolr
72mCcIgMz7wACx0ZECKAshkXRXYU/+7k732I4w3RYqr0gDUZn4KQWfgtL2RcAAjyPCKy4yycy1yS
pOIDlnHyRGV2pMlvxQVjiiaMJRRgIZ4M2zYoKYFA6mmbMJZmN3uGpgy08OUJWPjsX7HGnlL0LBwQ
6HPKC7B+z98z1DuGzH0/RhGJZmgNBI9jiCbJeQEWMoRRhsWPv77A2m4J4ppGpuo35rxZAqzEibgq
cRHf5T3N9eP/damFabcgSVI5AAuLILK54qLEkwdaHEID1kL8fR9Y2y0cLPCo5xUy3jRvwML8Da8V
sgqXSNhiXOzPsDAerTwB6088DzebK2qN3rjH8yt+RvmMuF3Q7wOdm7wAa2XCjZ+5Oc5qHizUWruT
YwGYzFZgwMI1BM+1X2/tPO/34v6/wWqFhRcQYLXVVvxwUFjvOsLVrQmY2tDa77tKklQNwMKWE7YH
4krbh/E4Jl1kqG1bIsBa1FzcVUdekr9buC22PAEL3oWHzfV8/JILnG+fczwPW7F7EWKLDL0hG201
wwt3PsGryICFHSHEj71mrtH29uaK9Z5FOHnLu9YeszDexbwAC3/bBP7Np3IsD5grl3GmNyfAXrQw
SQmlBixkMxzhPbXNS9DyT/q+/ABPMkmSqgRY2EZ7yerXwxsR2QtcnIoOWP35ABl7rJAR9SPtBx6L
x7hfwQELcWNvWGs0e8Zag5Y+WQK+/8iFvciABa2b4bygcOpmgcaSZ5D7yta2xVQ92ynQWEoNWNge
3Nr7eQ4ei7WsR9znat2SpEoB1uXeIo1tGni6D0+8B16sD6xx25aeBixso6HP4KGc15AuvwgN3y8T
2XrmtqkQtNunwIA1ylvYPjPXT/bThCG+5yd6T4oMWBDielAEdhdCAWpHIS5uBRrGewDHuWsJAAtC
2aNX68DIOxxrKOVdpmEUH6TSxvJ+wAeS0gPWjuYC2082l2YZpy8jiO0MXtDxB7mv1i1JqgxgzcQF
dF2rebR3i+yExPvigpdFr+SOXqpnZ3jf5JzQZy0wYC3JzxzbNnPR5k4YHpZX5NweYusmT8Bawdo2
C0e26jdcm77xjqO0wYwlASwIWY/b8368mNffHoGurZCABU1NZ8yJnFvOJYOELppaasBCrMED3gWM
J5606u5vWriCdZIkFQ+wZuYkPUdiETqS3/fiHBQXHyx6JXd4FBCwO0uD9/2BHqwQnSvyAiwkHyHx
aP+MoBwiCzzvMg17W/syIL59QNgPpZCtcia3mhexXxPu/5CtcnDe49ISfZswltKXaRhhrhVOvQv7
RWtbJE2SpNYHLAjhAhMjO8RcOYMzubBva64YZDxHIEZjiYIDFrK1sJ2GkAdsA15mLlj3In4dx3kQ
Y7kh0FjyDHLHlieqayMmbmlz256+4dj69DQU3YMVC4lUtxOmfqXhfCFWePHA90zegAXvFbaj747s
OZ4vCNmE8AIPCziWvAFrGGEe9wdiMkfyOBItTraw9claotAoaosgW/CvvMCRRnqtuSaoM5gkSVUE
LJQ0+MJqQbm/WNutnNjQLqNPoLHkmUV4uDUO1v3KXDmKIgMWPFK3en9zvJ3m29dWjizCNGGLc1Uu
5LM16Z7JE7DmJVT511V8znGfoEXdvea23YoOWLMS5P2xxJ5EeLL24DUWauu2ZSq5S5IkwEoKT9wv
dgAkNwZcKPIGLGxpHO1BY9JetbDbUHkC1nhrjSzCJNCnARU6ioQOUckLsPrzM8dnjxIaqIL+SeKc
w6Ex0VzfyyIDFgDqFo7lY47li5RzDq/WZQKsjgU34CrmYhU25hNEMyo1S5JUXMCCpjPnzcZWDUod
wMs9LrIxFj6mJEQl9yX4GWEexRYO6jDt04RFPE/AwgKKmCUEfv83xXAcDbrLkEUIr87xXLyxJbhU
4vUVuMjOE/Dc5AVY2Jp9jesoioqiQO/15jJUfQBC1uQ7gdbYvABrfnMFeLcxF4s5DeeAzb33IBYT
bXKw/R5iq7D0gIVgzuNIp34tmJ9JpsfxZpIkqZqAlZzwmqlQrXI60uQWpkdcXoCFRflogsgsXMiT
huPINkS8T4hGyXkC1qbW1uu2dcp7EP/3mIVr+pwXYG2Qcr1emvic/shxfmRuO7SogIXaZDcmjl3A
8xULlQgQOoAt6UUFWO1vkn9aYzfzDTxpkiRVG7CSwvbgRgHBqyuAhafqQZzfhtSxwXzPIH4/hIs3
4meOCTTf5QVY2OrMGrg+qYWJj8sTsK60Wn0oxPNNl/Ke7fiePwS6zvICLGTfvkHHBOqrTUuvD7qm
LEtQjAt3vk6YLypgDaOTBe2KFuf1+zdzNbyW4jzzHcfyX74uwPK0RwKk4OZ7l4Y9V9+jtbnWLUlq
WcBand6OozthaJuD7cI7CubBmpSLNrYunuqEAX6wtXZXoLE0u9lzHy7sRe5F2JfXD+oszlAH1HHs
Oq5DRxQcsKDjvfUU24VfEUC+Tqy3ZwcaS55B7gfzb/2SY8HXD/jVH8slgcZSasDC3jCygtDjabS5
qsaxi3l+Trq4oJGlokruktS6gHWCZQuaTrOnAj2JdxWw4Il6shvjua1ggIV0eJSS2Ig/Y/sSDZIv
4iKdZigUjQDl8RYmTi4vwJqEXqt6rVbm4bUcn5vDSgBYANqrGlxj+L/KkEWIgPyLG4xlgoWrNlBq
wMJNeGuG9yEINJnx0MuaU2hMkqTwgHVUN4AEMRhLFQyw/t2N8YQqONkVwEIs1Xv8u7Adszzn3ocz
jmUC319UwIJQ7fwnghbarqAdzlg6AN5LjCdUx4C862DBe7gjfyeyUxFvNZHA+ycLG9ccotAourvA
W41YbWRHvsn/AzXyQtb0KjVgzURw6qiGxdT8YOdLHMfe8kitZZLUEoCFuCNUMB9nLuUasRaoi/cF
oSA+Hht+Rr28z7kwLlggwJrSXNwo4nbghV8zoyGodx8+UIZ4eOwKYC2UAIx40byvhQALXpJrM4wF
5yVU1mqoSu6TcJ2dn7Bc5kruveipAgugPlb/Joyl1ICFiQju5Ec5sSB4bTfarrzocIM+wMkqfm1H
3hB7ai2TpNIDFibObc11dfCFY8giqtc2BltVx5ornBhKXQEsBKx3p/L3koEWj64AFjwhR5hrtotQ
jsEEkjt4bs6w+luE/yCIFXmLMNZQcwHgX6WA1fcc++QBr7O8AAtwcwo/91E9dP/nBVh4yIAncby5
0k09oVIDFp7YfrGuu9J3NUmSWgGwhiY8HVjIn8ywSODpfKIVa4uwu1qTEFMEwIrlQy7KNIzJeF4R
t1X0Mg2+FjO37QQP6mU8/0s34ZznBVgreuvjC9YzYTR5Adai3ljeCnRPtDRgjewGXMF21lomSaUH
rDQh3fw9/p5pOwCGYzgXjAk0lq4AVl8+ce/Jh8CstiO9PzdbmNIGzc4ihGYPtDCGbJXTE8oLsPDA
8V/eEwf00FjyLNPwH47lKAuz1dzSgIUGrh9yADdxYmlkN/H/R82SvbWWSVJLAha2le7i5IpqzjcQ
Ps7kV8wBL3sPWysVCLCQxfV0Nx4cQ5Wd6ApgYVGbl16cxT1bLPFz0hYhZF5RMg9WR0IbnVBNxfOM
wdqY98b0Ga6HENu3ecZgrcP7f5YMMBZiW730gLU+B9EZg+AK3VBrmSS1JGAZF8/vMwDJ7RauwnZX
AAtFOB/tBmDdXiDA6kfgQwPnzzthn1q5mj0DnpBBeHJkp5qLY0oatqy3LwFgYbsddSMv5xoJQB5u
zis8M71c83FMRW6VAw3m77mCY5o/MRZ8PzfP21QCrPYnojtqRhaBJEk9A1gQ0rNf7wBG7uREG0pd
DXJ/mIsMPO63ZLSbCED/tDDbIV0FrP/XDVgsQ7NneNteyzieTQoOWPiskX2LCuhxlfMPeA9NpOH7
j3gtFN2DdTbH8o3V2vv4Y0HV+vfNNYQP0f2gZZo9z0CPFvoMbcTvpzZJkqoMWBC2BxAOcA29O7fx
929k2Vu2NBOw8CS9WxcnfPzbfaw4rXKwACOT+2suZm9mtDe4KBbdgwWQbVTI0rdQ2Wx5AtZdGceC
3oohguDzBKzrMo4FAf0hYv1KD1jDOCGnPUFgH/l4U7NnSaoyYDVSHwvXq7QrgNW7m56BoVacZs/4
W7CVtIw5T+GsGQ3vXc5cncPBBQasSQjtvxLc0THkgoShRMOF9JIUfYswBgKsnyie+nOK/cTXnywB
YF2bcSyvCLDSb96szZ57IkVTkqTiA9bW1jplGgAjBxTMg9WdJrozBFrE89wiPNyc162Rp22ugNdZ
XoAFjy5aGG1mrp7a0imG4xsSXoYUGLD6EHi3bTAWlHKBpytEnbKWavaMIm+f0r6wts2et9S6JUkC
LE8IIUDNItTIWbQFAAvZd4jFuteKE4PVGc3N3z2iCZ9VnoCF34WA8C0avG82614B2WYAFqBk3ozv
XcDCbLHnBVi9OjEWBO2HSHQpNWChEjBcs3DDrmuu3cU8tPl5s6L+Bfbyz9O6JUkCLE66AJ+X+PD1
OeeLMgIWPESrRHYpx1G0LEJf6EN4XGQnWts2ZShLgcw7BFN/T+A9wcJt2+YNWHNGdiXXGRQXPYnj
iQ1bpKeZ2yLcoWCANQ2BdlY+ZMxVgPu/q4A1FceCmMtFOgFXIVVqwDqVT2yN9PcUwALdKotQkqoB
WL0JBhdzIfc93x/zabxMgIXYU7T/grfqh8R4bisgYKGEgd9GBt9vyteOtfTQjuNLAlhjrJxB7rgn
UHH+XXMxzBdwLJP08P3fVcA6n2N5g/f5Ztac3oktC1hxs+fhHbxnWk4486YcX1VrmSS1NGAN5UR7
u9WvifWllceDBQ/DoZE9bx2XnigSYC1Z57N/nmD7VgfnJVQT7jwBa1RJAQuL/z38u7axMIkRzQSs
f3AsyMDtU5CxlBqwUOQMQWyPmwvs3Iu/F4a07N3NpQg/yAtwb762G/+GPbSWSVJLAha2CfYlENRb
7PAatqJutXCxMXkB1tKc696rMxZsT11vbivqKitWq5xTvb/Tz9yKE5Din9/jXD7Re32fEgAWals9
E9np5rYDT7X2W4Sn8j1FyiIEUN1nbT2e89LxgGD8hWioPo8tXRTnbkayWFcBC7tZD3g/Y+t2NY5l
YY5lcV6/sIFNGEvpmz3/nOGp4VdTs2dJqgJgYQI9owOvCOwpc1lQQ/lvUDOvSK1yYmEBwJYNWnx9
XWcsgJNLrG12Gh4sBxUIsDDf/xLZ0eZKLyxrbsvwC47hM87Fs/OcjODr3xMWiw5YiPeZO8P75rBi
BbkDwu9NQCyCvQ8zV+LoC54bAC/i5tB2phlbbl0FrFv5t8eCt/egyJ77/+ydB5gUVfa3iygIQ5AR
MAAigllAUVSUYICRpIiCigFzxBzAgGBADJhdA7ooYk6IiGME066u+W9c1ywqQQQkCKLUd0/NKb5D
UdVhEtPN+3ue3zPMrVvVVdXTfV/OPfeUVxINlWuZqbDb36vYHL+8ACwe9owQgOXpl798kS1N+KzP
1UiCVHYeE9m3iVcxj8koLWA1MgNDKkg8W+HLwpXklraoQhEsGZDf1MhaVCfqtYxM2PdqhaCqVGh0
/TIMzBVZb620gPWSV5LLF5UkvMtzfv/QQEbSPayIacWyRLCGxbTLorfvNRjTP2Hfiqodl/PPIpSE
VQlxSqh5coZ+Uv+He6aHEMoHwOqv/xu3Ee0/vZJq05eaCMMJCYN9Ram0D3sW6PgiAlXz9LtOnqkW
1uyRVWuVlUtaGsASIJFpqL1itkke7DcpjreTAkBFRE1KC1gyVVva1WltdcyqaoB1VMJ2ifQ8kGJ/
iQJXpWcRCmAlpf2MUu5I0gEezyJcQ72cB5Ry3y4eD3tGKF8Ay36upWq2rAycH/MZPyMHACuUQNSR
CigrFSBbm+0SrXqkigOWFD6VgpRbJgzwMgW4bcK+Utbh5SoGWDJle4FCcEEWlv5Sc60qlWkIAesk
r2RFvT3funqdw/X+223ra1ToXq9inpJSWsCSaO65Mecrx5Np88tirrOefqbk+YtNAKw1/3eUzZsW
FWUaEMovwAolg7ZMBX6ig/QQHVCO0f+ZRweaWhV0LeWR5C7fU0UKU5Ibc7dGUjwd5KKAVdurOoVG
5Xu3WCFLVnzfqZayOVIW4H8KWbdFtklfeT7cm17VmiKU/9BLbtiHei/ez9DSXyKqh1UhwJIpMVld
K7M5/4mcryw2mKmO2/ajV/UelSN/Yz/FnO87eo0/J1zLd/q54lE5pZR8GR3KuIXQOgNYoaSEy4U6
GMxwftUrKQQZ/X7YuQoDlpUkiE9UMJmig0eXSJ/DvIpZIVXaHCy576XNk32tigFWP69seb+DqxBg
yX19tgzX8p8qBliPluFaPgWwspfcsIOVTk9h3EJonQOsUDLdJtMzMt32tfM4r2T110ZeyfL6LjkC
WKFkiuZKr6Q6+Ns6wEpye2e9d1XpWYTTASwAC8DKH8CSKsfH6ZsU3sBjPITQugpY9gtPcjfl4a6S
YC1THfLs0lyr5G6/6ySx999eSQVrWVpflQqNCmBJbSKZunlTB+VMLNcjC5j+VcUAS5KhZYrwHd0/
k2t5yyuZIpSSGlVpijAc/H/S+/yfLK5Hptver2KAJQvd5pTiWn7wmCLMSLJSaKT+ry5KqAAWQgCW
laxSk7yNiqwYXlkPe5bBQaqEf+mVJMNXFcBq4JXkVG2vA2emSeHSV2pGyXRoRdT0Ki1gyaAvidT1
vMwT3evr653nxZdEWFuAJfd4nP7tZ/PeyLXLSso7vaqT5C55lFLWY+dSXMsW+jdKknuCZLXJ3d6a
zxizPtZDCAFYq0uSwW/S75BcBqxQktw/oYL+N14awJKp2YFleM2jKmgQLy1g7VEGGBco6VOFAEsA
Y4BX+gUREo2rKmUa6ui1lLaWlfznZEMAa/U/DnkDJNHzjwSo+kkp+0kACyEAK0Hyxdo0TwDL0/+R
V8TUTWkASwa8BqUcxKspoFWlKcJ6Xunz2+rqvagqgCX3tWEZAKuxV3UKjYbXUr0M11IRxXlzDrBk
VZCU9n/XS45WyTys1PBoo/ts4lVcciFCKLcBqyK1NgCrolTaR+VURZXno3KqgkoDWFVVpc3BqorK
GcCSVTP/9EqSUuOgSqJYEqmSJ80/E9lX6si0YNxCCMACsAAsAAvAArBWl+QWSNn+XyNg9ZVXMg0Y
PqxVHkcw1aOIKEIAFoAFYAFYABaAlbHaeSXPFQqf0yXVmm1F9w5eyfO66ngIIQALwAKwACwAC8DK
+sN+vL4RUo9DnvPUXAFMpgijEayaHkIIwAKwACwAC8ACsDKS1BiR5aJS+0WeXSXFxl70Vl8ZIeDV
i3ELIQALwAKwACwAC8DKTrJcdF+v5IGoUmVWCgj2VACTJ2mfyLiFEIAFYAFYABaABWCVXlII7hav
pKK7lMCXRxscz7iFEIAFYAFYABaABWCVXa2cL3de7BHBQgjAArAALAALwFoHAOvUSrzIoR6V3BHK
FV3lfFeeXMuFzg/lybUIlMhDjnfPg2uRVebyQOl8yc2VZxw+lyfXIvnTM5z75cn1PFfZgCUFQW9w
3tF5lwq2PPyxs1fyDKhdMMZV2vKdcK/zY15JceEdctjy7LmbvZKyMbl+Lds5d3X+WAYLvbZcvRZ5
8PSuzh96JTMb2+TB39lIjfpsm+PXIu/NThpdHJYHf2ftnd9wPqIyAUsS0ec7f+D8SSX4I6+klMMn
GOMqbflOmOPV8f7wNnA/G3u/5qzl/NfzljZs4C3bcktv9uabe7/mqtu08eZutpk3r3Zt7y+vgfvu
zu33Zq7XyJvn1cyLaxHP8ep6i+vX85a3a+fNyfG/s+BnnTreio039ha0bZu716PXMq9uXfd35nkD
KxOwpJSC5EbJ42s2xxhjtXwnXOvt6vneJc7n5rAvdN7Z84cc5PmzZnn+Dz/krn/6yfM/+T/P32Yb
d02H67Xl6vtyvvMw52bOQ3L8WsTDnbt7ftE+nv/LL57/44+5+3c2c6bnf/WV53fu7Pn33JPbn5vw
fdhrr6Ag+oGVnYN1GqkmCKEYDfe6uS+lG5yvyGFf67yH5x9/ZJm+LquMf1/g+R3au2s6Wa8tV9+X
MQrvmzifmOPXIr7GeT/PP6Bvfvyd/fWX53dzn/+nn86P6+nTZ+0AVopVhA1L6UxVkMH+RV7JE3mK
KnFckXNo6dwjy3Mv8LK7l5meQ7pjI1QhutjbUwe+UTnsq5x39/xjD8+PgeLXOZ6/ww7umk7Qa8vV
9+Uy5xHOGzsfl+PXMkqBsZfn9++dH39nS5d6/p7u8//EE/lxPfvtVyUAq7bCTLHzglK6OA0QFSo0
zU6x/yj9aZ8nXVxBoNXQgFx43VJRYmXMa6Y699m6rTACiMUprnOEcxPt20R/j55D0rERArAALAAL
wAKwcgCwZFXmpRGoKYtDOAkjNk0VEuaW03HLKgs/6V5zWhbnPlf7TsvwegSexunPTI8NaCEAC8AC
sAAsACtHAKtBFCC2de7u3MF5G/19W/19J+cd9d/ba7v8bLwmFIQRm9+jwFBdj9FRj9/euVmkz67O
xzu3igetUWlclAKsEkGmrvNu+jNVP7n2I5z7O2+Spm8t5721fw/nemn6b+a8n3Nf53aAFgKwACwA
C8ACsHIWsKR+3Z92IBfoOdL5U+fZxv9z/tj5E+dvnN1o7y9y/s356CyiUdWcHe34n+tx5ztfGoEr
OaZc6dvODUsf8equTglWAodDnF91/ikFNAkE3q334B7nmc5fOQ9L6L+L88t63EnOfzi/oaAV19+9
J/53et3iX5xHK6QBWgjAArAALAALwMotwJKiujPiBvybzGAvPs55c42sSBSnn/MU3XZaKSDoYXPs
60z7CZHXbVf6acWV6ljIk+NeqCAZvtYs541i+jdwfkH7jNC2Q8x+wyP92+uxZFtnbRuvv8/XCKHt
f0Hkmq0vSj112BckQAAWgAVgAVgAVtVMcpcoz7LoAH5JZKDfJ2aQr+n8lPO5pQCg28yxx0amyd50
Xu58p3Pt8ssPW+UCjbodplGm8Dx+SgCsYbr9b+cuJvL1X21folOeIbw9oe0fOTfS9n2dV5jIXANt
30kjeRIdO9H5Xn2d8Jxk26bJ17Jco1m1QQMEYAFYABaABWBVLcBazysp7r7a4D0qAlj7xcCV/NzL
+eRSQM4dCYAlru+8XQWAlY1ghf/ukwawaji/otsFkDqZbU+ZfW/SNonyzTMgVaDtG+m0X9j/AG0/
P2aK9dLIve+e/pqeca4PHiAAC8ACsAAsAKvqAFbDuFV1qQCrpQGEAo3C2H3X1+jQDQoQ7TIErIY6
vdZCgaSFyUFq7by1Rri2cN7AAE1ce6bumwaw5PevDWB1Nqwpj4sAAGnFSURBVNvuNPu+qeDWy3ml
tr1rIlWOYv3PTP+rtb15zDlJxOpH85odM7uWUeABArAALAALwAKwcgywisy2Q50vTxjot9dk7u80
X+kDTQgfmAFgNTMJ5D9oEvlWuq235kt9r/lNF5sI1Gfa/ouedzaA1T8NYAnsfGv69DPbrjXtM3WV
YJEBrG8UEsMVhW+Z/k+lOKcmupjA1/tXP7NrWeTcDURAABaABWABWABWjgDWSpODtZ0O/pfFDPIb
O3+p+wzRtn30998i035JU4SSQL/YRG+2S0iMH2faH0poLw/Akhyw/5g+p5tt15j2HzUCt7U5/6Ua
kQunVP9t+j+Z4py202R46XdOdtczHURAABaABWABWABWDkWwXtNVg+HAf0HMAH+Vbpun04hhNOa3
GJBKAqw2zj+b5PFtzbbxZp9rTPtdMVNv5QVYnp5f2KfY5HDdYtplOrCOAtmbpv18c5yPTfvNKc7p
KO3zjsnhysL9wQQEYAFYABaABWDlCGCN0Omxe/T3C2MS0z/SbV9pFKbQua3Wy/I1ElQzDWC1M8ng
UcC6JwGw7qlgwNowstpwkq6c/CrSFvbf3eRQyWrIMXpeS0z/YxPOp6YC2m8xuW0ZOlxZSJ0sBGAB
WAAWgAVgVXXA6hGJJF0VU4V8gfb93flZ58c06vW+Rm8mawJ8rgGWp2UZLtEI1ksavfrB7Dsk0l/O
+3Zdgfi0lmFYrn1/TVHfS6Yg/4rJWSuFKUiKACwAC8ACsACsXFpF2C0y9eXpCr5FpnZTJ83J2lQj
WRtqTahqOQpYXswjc37X/T4x9a6SfIZ5nbsT+nTSKdhhMaUiapYNtChIigAsAAvAArAArEoGrIJs
Aaupc9dI/000MuNrBKZHmhpUpQGsfyYA1vi1AFi20v1hafrWMdOns8zKSOtCrRZ/UqR9PV2x2bJs
0azlQBYCsAAsAAvAArAqF7BkCmmhl6bYZVEGDzZ+0fR/JlKFvbHmLdWNAayrShHBurKcIlh9I6UW
MgGsIn22YFyR1Dhfrn3dTfb3T+hzv5aauEBXaF6ukPu83tf1yj5lKJDVFYRAABaABWABWABW5QCW
5Oms8cy+6KNy9spgEB8S2UegYU+tRD4lUvH9lgRYamUAa6kmyYfbLjb7SGmG6pp4PzfhWNkC1iwF
wVT9+ykoLdN7lKpvDXPO32q0LK7fOSmeRZgpxGXoVz0eq4MALAALwAKwAKwKB6wWzvO8SBX2LSOl
BnytWr5JmkhKzZiHRIfP8BsXgaj3zfbXNV+rhj42xo/UnaoZ8xDlcFWiJJy/Z9qezaCaezUtfyDV
4R+JvN4pWvA0jL5V1xWSe2g5iDnO01I8vqam7n+gRp9ma7J7mzQlGVJ5YPkBlq9/AggBWAAWgAVg
AVgVCFh7RQfgnZ1P0BynK9RXahTlCE1mTzWAV1cgmKSA8ZB5rE4INwP0+Feqr9Vpt2Y6RTZWX1em
DkcqCIX7y6NqHtB8pZsV+nrrMa7UKcJdMogsdVOYC88jfL3RzoPNA5ab6NSmvNbwyKNyvIQioVcp
aJ6c5n5V1+T368y9th6j59a8/J/HuB8ogQAsAAvAArAArIoDLDfGB9W/Vxv0q6UAgurl/LBl21Y9
xeuW9fhxkJXqOquZf9fJ4rVrlk++VEV7LCiBACwAC8ACsACsis3B6uFVfSDA5etRoAQCsAAsAAvA
ArAqFrC8aBQLA1gIwAKwACwAC8ACsMoOWESx1i1fBkogAAvAArAALACr4gGLKNa65eGgBAKwACwA
C8ACsCoHsIhi5b+LnYuc64ASCMACsAAsAAvAqhzACjcDIvkLVggBWAAWgAVgAVhrAbCkyvczAAlg
hQAsAAvAArAALACr/AALyAKsEIAFYAFYABaABWBVAGABWYAVArAALAALwAKwAKwKACwgC7BCABaA
BWABWAAWgFUBgAVkAVYIwAKwACwAC8ACsCoAsIAswAoBWAAWgAVgAVgAVgUAVhJkzXW+Qj23ioKI
nNco52kVdPyF6kz7LwCsEIAFYAFYABaABWDFQdYChZZCs61Q22YngMGPzq+UASyy3X9uzDkWKaCU
FYYW6HFG6PHDa4+DzN8j/Rs675vleQBWCMACsAAsAAvAymPACtUwxbYCBYFRxgIWGzhXi9kW+izn
/gnbUu3fX/eN9i9McY5J5xA9RghDtr0oxfUX6n72GE1T9M/kPEYBVgjAArAALAALwFo3AAshBGAB
WAAWgAVgAVgAFkIIwAKwACwAC8ACsBBCABaABWABWAAWgIUQArAALAALwAKwACyEEAKwACwAC8AC
sAAshBCABWABWAAWgAVgIYQALAALwAKwACwACyEEYAFYABaABWABWAAWQgjAArAALAALwAKwEEIA
FoAFYAFYABaAhRACsAAsAAvAArAALAALIQRgAVgAFoAFYAFYCCEAC8ACsAAsAAvAQggBWAAWgAVg
AVgAlgGskxlHEEIxOtfr4b6UbnW+Ood9k3NXzz/56PwYKJa5gW/HHd01DXO+IYffFwH30c6bOp/q
fGOO/53Je9HX8w/snx9/Z+Ie7vM/bVp+XEv//pUPWE84P+w8xHkoxhir5TvhcW8L96V0gHPvHLZ8
sbb2/O5dPH/SJM+/917PnzAhNz1xouff6oC3RQt3Td2dBzkfmKMe6NzPuVEeXIv4YOftPb+zg9+n
H/X8Jx/y/CcezE0/9bDnP3yf52+zleeffkbJ5yZXPzPh5719+8oHrEedv3V+2fk1jDFWy3fCt61b
en7ffT2/Z/fcde+9PX+LzTy/aVPP33vvkmmPXHW3bp6/226eX6+eGyyaO7vr8lrmqFs5CyjWzoNr
Ca9nA+c6+u9Nc9yblLw37Xfw/L32yt3PTNeuJT8bN658wJrsfI5zNef1MMZYLd8JF591VsnXxZ8r
nP/MTcv5jxrl+YMGef7KlZ6/fHnueoV7H2b/ov8bD3OwRueoL3e+UAfy453H5vC1jNYcLInItdNr
GZXj+XHuvanuoPe5Kbn9uZHvAPnZu/faycE6nVQThFCMLgwBK9c9enQJYOXDtfz2qwLWiTqQX5aj
vsL5IgWsEzSP6bIc9lidjt7S+ZocvxZ5by4uAawXpubH52ZtAVbCKsJC5xHOo1J4hPbLFRWZ8266
ll432/tV4NzQeT89RmGKfk3NexZeY0GK/kWR97JpmvOw/YtSHBvliS4+88z8+HKVCNbBB7OKkFWE
FbyKsJ8C1tV5EsFq5fnFU1hFWI6AVVsH0LnOfgaem2bgrypgVRw579+1raiSXzeT+xWC0hjn2c4L
YvZvon2b6O+z9Zqi1zg7RX8/g3tSmKL/7Bx47xGABWABWAAWgLXWAauO85QMwSpb0AojMaGzUbhP
QTkATpyTQKsiXzfufoX7/Z7BOQvcjEsAn/LoPy0L0J4LaAFYABaABWABWABWMmA1cv7LDp47OQ90
PtC5r/FBzgN0e8xg2z8CDTYSE7rYTJmlmo4sNvvYiEm6KcxYwNna+Vbnc5zrxoNWhbzuds63OZ/l
XCceTqalgphqzr2d904DO9s4n+d8nfMRzhul6d/D+Qrny5z7OK+X5hz2c77K2Z2wvxugBWABWAAW
gAVgAVgZAVaDaMSijQ7s/5VXMn7OuZvzFvGD8RyFrGkZRD8WqrOJlpVmH7+e85vmGs7IPkpXqtct
cH7bvO4pWezb2Plg5ym6780p4MdRn/+r8+0KWCucP1MQjvZv6jzJeabzRc6T9fiODv12Cecxwdld
vD/S+R/Oi/Xf1ZNBqxaIAmABWAAWgAVgAVglK7NlYFwZHWAviwBWv9RgsLKU04wV6ibO35lruLqS
XreZgkz4updnsM8mCmJvRe77VQn9h+n2r0xkbpK2CRR1MX1rOz+m2+7Wtg2cv9e2d/V3e/y7dNsE
0/aOtg1Lvo4XnHuCKQAWgAVgAVgAFknuJdM7a0RpRkYG+p5VEKAy8UAFiMkKMZX1uoP1dZ/MYNpO
3MF5XwXZH9IA1kYGjh437Yeb/V40U5NFziu1/VTT/z7T/xLTLnC2XNtHmfaHtG22c4vka/lTob02
uAJgAVgAFoAFYK3LgFUQWbUWeFQEsPbLUcDKRU9OA1gHme2PmvbOOo0n7X8776ztN5r+J5n+Z5n2
D50bavv1pv1c0/92035M+ut4hilDAAvAArAALABrXQashhUBWIXOpyksSD7RODPgh95QIzb7qvfS
qEsv56c0+nNoZJ+6Gk2TqMw++u+NdVs/3Udyk9zI7u+uCfrd9fhbab/19Xp6arskftdw3tX5n3q+
p2qbnWbb07m/As5B+nr7mPPoqv32iLxuuyzv3TNpAOtcs32y5mNJ+5bOc8y2k2OOd3pCxOt3jaJ5
kWnK403/O0z73ZldC1OGABaABWABWAAWgFVegLWFTo/Jfpdq0rwkXy9yviCSI3WFRlvCQf4GzSV6
x7z2tQYi1lMwWGi2H+J8bOR8d9Ck/K9N263mGHJef2n7An2NN5znm/6jInlVAi+fOj+gOUpvRF7z
DoUyAa5vTfv15QxYp5vt/1JglPbNnH80267U9idM23UJkTBfVyw2jpz7iQmA9bLCZAbXI1OGfUEX
AAvAArAALAALwCoDYMnKvRkmedrmQoXHOiwCWQvMtpt0lVp9509SJNnbVXr36H4P6O8/mKjW7ZFj
2zym38y2VzWvqI/JP/qfAof0b+38mq6yDFfx2am8WQo44fHviQBieQJWH7N9jrnWlpHk+hAQx0Qi
XnHvyUqNvG0XeT+SAOtzjUBmeE3LgSwAC8ACsAAsAAvAKgNg2WmnR0y7RJSWavtbCmJh+YC52i5g
s6PZ5+pIrlEYxarp/LrZ9rFzA40eHWimujyNWoX9bjTtLczr/qVwIe2tnOdp+1ytMxUC1mCz/1GR
+3Na5D7cbbZdU86AJSv+3jN9ztT27SPQOFTbdzP3/jfN1ZL240zfuQqIu5i+qQBLVi82z+66gCwA
C8ACsAAsAAvAKi1gTTL7/CNSEHORAan22t5cazlJ+zLnTmafk8yxZIqxkQEsOz03NsX53JYAWC0N
YC3RyI20tzWQMk+hxVN4q2Hyy2ydsLfMNF1cBKu8ActTEArPQepfPez8ilktuDwCmieayNRPuoLw
U/M6/9H7ahPlyzGCBWQBWAAWgAVgAVgAVraAVUPzruTnCwlAs60BLF+nucLcJgtYNhH+iMgUXDvz
ehawji0jYC01MGIB61cDXl5CjbAVmpTvVTJghdG2M3Tqc7hOh4b5bK/EVGnfTXPPbtGaW6/F1Ora
XAEsHWBNT1MFPg1kdQVlACwAC8ACsAAsACsNYG2reT7Vtf5SXM7TNhHA6pUBYB1p+v9iqshHAevo
SgSsbSOJ8BMTXrcyACtV9PCQDKrNf2eus51ZLfmBOc4JCYA1oWylKF6lThaABWABWAAWgEUdrDSA
NdJAxD0JQNNep+Kk/Q+T25TpFOFHCgVxU4THVCJgPWyO96u5jvBa1ltLgNXJAOzkNZ9/uIYvMK9x
TmTbnQm5Zf9IAK9S+mlwBsACsAAsAAvAWucrue+TMFBuqtN3Z+nvA8w+95l+3UxZhOnm8S4WsGxu
lqclHMJj3RuZknw9Q8CySe43ZABYWxjAmqsRK89URF9hjjciUp9rrCnWeXcZHtHzdEyphVRuampX
vZpB5fg9TZmL6yP1vjyt57UiplTFBHNfWpRPUdUeIA2ABWABWAAWgJWvgOXG0DWfJXhFBLBO1SnA
0DIodzSRpIN0vzqm7tJHZvA+wSSU7xuJ+vxqXucuPUYtAw1/atHOpDINR5YigtUsAnbbmhykMBl8
vilOKtGz9yP1p+oYuJIo1UvmesuyinB6Qt2qpOnZsGbYgxms7Bug17dEH/pcLaHf3TFTgeH7cV75
Va2f4VwHrAGwACwAC8ACsPINsFo4z/Mi4NE1ssIsnA6bbvyGifT8rQnUNqIy2dSoOlnrM/0UqYEV
BSyJqkxzLjYRqkWR6uM1NJK0KFLCYdOEabPPTL8PFEiqKzD+HYlGCTCdH7nuc7R/tP0VTRi/zxRV
fdi87pem77uRqcSknKi2mnxuyyR8rQsCWup5eFqbq6uC25f6fhyU4thybw5QAPtBc7V2SXM+jfR6
Fuo9uE6ncMfqFG05AZY7pNcIrAGwACwAC8ACsPINsPaKDno7aoK0RIUGGQ/Rukmhj9G2Q7T2VP2Y
R9rs73yzTu+dk/DIGAtYS3SKsLeuiLs8Am6e1s86UOttDdZzkyT3nWJWNhZpvaqw31CdqpRjHKyw
N0iv4VCdWhuo/x6sPw9W+Omu1zvIHOtUzRM7Ws+ns0JQkW63r9vdAFKcN1aQOlLPK9z3SH3dLiY6
1k1XMp6siwJSHbeaHmO0HrdtFgBUS89hvOZf7V3+z11coIssEIAFYAFYABaAlVeA5cZmb7pX/gNn
xk6V5J6LrlYJr1G9gvtXogEsAAvAArAALAArb3OweqzNQTZVmQac9wawACwAC8ACsACsvAUsb21G
sRqbXK4VkVWEGMBCABaABWABWABWLgPWWoli1dfn6Nnk8YszKDOA88Z/kuQOYAFYABaABWDlM2Ct
lShWU028DpO6D9Fk8W0Bj3XFkynTAGABWAAWgAVg5Ttg9WDAx5XkYucicAbAArAALAALwFoXACvc
DABgwArAArAALAALwAKwyhGw5AG8zwACGLACsAAsAAvAArAArPIDLCALA1YAFoAFYAFYABaAVQGA
BWRhwArAArAALAALwAKwKgCwgCwMWAFYABaABWABWABWBQAWkIUBKwALwAKwACwAC8CqAMACstad
elSTASsEYAFYABaABWBVHmBlA1kLgJW0nut8hXpuOR97tvMo52mlBKQibQOsACwAC8ACsAAsAKsS
ACuErKcVoqIOB3Z5rty+OgDb7b+XAzy84vx9wuuH5xCCy+wU/daWw3tUaO5pobZlcr7f6z2Ithfr
MQR4CmJgKVX/JKXaF7ACsAAsAAvAArAArHIErFANY1yQpl9THdRLE7EJB/VqzvUSXj96DgUp+q0t
F6S4p5mcbz29B9H2bN+vsrzXCMACsAAsAAvAArAqCLDKosIsQItoCUIAFoAFYAFYABaAlSVojVDY
ijNghRCABWABWAAWgAVgIYQALAALwAKwACwACyGEACwAC8ACsAAsAAshBGABWAAWgAVgAVgIIQAL
wAKwACwAC8BCCAFYABaABWABWAAWgIUQArAALAALwAKwACyEEIAFYAFYABaABWAhhAAsAAvAArAA
LAALwEIIAVgAFoAFYAFYABZCCMACsAAsAAvAArAQQgAWgAVgAVgAFoBlAGsY4whCKEYjzj47P75c
L3MDxqBB+XEt8+d5fvv2brA4SQfyy3LUVzhf5LyJwmIuX4t4rHN/Baxrc/xa5L252AHWZp7/4rP5
8bnp06fyAWuy83Dn9Z0bYYyxWr4TRg0b5vlLl7pBfX7ueskSz7/IDeQDB+b+tfz+u+d//41GsI7T
gXBkjnq083CNYB3jfLnzJTlsARMZxNs6X5nj13Kp8wUlEaynHy/5DOXqZ2bBghL36lX5gPWo80/O
/3J+B2OM1fKdMHOjjTx/9909v1On3PVuu3n+xm4Qb9Ik96+lc2fP79jR8+vW9fwaTZ1buEFw0xy2
wFVt5w01krVxDlvOv6FzHedN8+Bampe8N1tvVfIZytXPzM47l/xs0KDyAetJ53uc+zj3xxhjtXwn
TDzgAM+fOtX9L/bp3LWc/2GHef4ee+T+tUyZ4vkTH/D8LVp7/k3u63+680s56pedpzpvU80NfH2d
j3Y+PIc91LmzwskxOX4tRzgf4gC4medfNjL3PzdiAa21kYN1MqkmCKEYnXfeefmRfzFmjOcfemh+
XMuiP9xg0dHz/y1f/znuv513r+EGvjOcr9dE91z1OOcBzls735jj16JJ+tUdyM94IT8+N/36VelV
hA2dmzpfpG6qbeL91dmowOxvXVWVdL5JLijFa2Syb0GWr1Xae1yW60CsImQVYUV51q+ev+MOJdGr
XAes3507C2CdwipCVhGuk2UaipyLnRc4u49DcI6+/nuBOmwr1v6pVCi5s86zzf7WmRyjMpXufJM8
W/crTAMxRdqvOM2+qc4jrn9R5Jjp7nFBFueCACwAC8ACsAAsAKsUgFXbDNB+KRwO4NWc65nolwzU
c7M8RrYRoIIU0ZhsolTZnm+S56aBn3T7XqGem8VrTcviHvfXhaSzS3EdCMACsAAsAAvAArCyAKxL
4wbZmjJd7ny887H671q6rYlz4zX3ecX5+5joV2DZt61zS+dN1HXWPIac4gYKa2GEJc7FJuIyRsHh
rEg0JgnainQfGx1a43xrOG/pvJmeq5x3Q3P9W5vr2FTvV7bwU915K+f10sDR5s77Oe9qziGVO2r/
7Z2rZQGIci7117yOvqAHgAVgAVgAFoAFYGUHWBs6/xodaDs4v+j8f853Od+qvzti8Q9z/odz+yyj
OwJYZzt/7fw/9d7xfX9UWPPLyQJa3dUZR+kEsA52/sj5S+fvnEfotubOtzt/pdfxiQJYpscWoOrp
/KTz584bJfRr4HyV8wfOk51nOb/tfFAKQHrY+Q19r+bra2yfBvL2cJ7g/HP8+7ocyAKwACwAC8AC
sACs7ADr7OiAK4OxIxz/U+dWpr2u86nOi52XazQqW9jZwPkb83nbv/wgKp1XqrPed5o53xtN+27O
K7R9hUaZ0h1LQOpk5zd1QY3s+5Nzs5i+cr+f0j6jNRJ1qv7+l0YVbf925t7uoYD4uP7+o0Jz9L04
QldQL9d+fybDGJAFYAFYABaABWABWBkCVh3nF6LRjEf0s3BmAiQc6bxQoyXZwopEbt43n7d+lQdY
pfYEc77XmvZtnH/V9iXOrdMcR6b2TnQ+QyOD4TG/TwCsE3X7Sp2elbaNtb+0z3HeQtsFvh7U9g80
8uXp/f1L259TaAujiUc5n+b8ujkXgeftkq8ByAKwACwAC8ACsACsDABLnpCxzA6iG2tExdeppZox
A60M5o86dyoFrKzv/GGOAdbEBMASEJmXBWBVN/dzYBrAquH9/+/TPzWnKrz3z5t9rzQ5WnO07Q29
z57mj80yoLaPOU4tE4lbmhlgAVkAFoAFYAFYABaAlQFgNYwmdwskzDWfhwkJU1+9EiJYEjk50Pks
5yHO26YBrH0UJno7H61TW9FjNnXe0LmRTmtV1/Y9nYc6H+BcEIksHaGvnyovakMFnbM1mtO6ggHL
+oA0gCWJ898awNrJbLvf7PuKtu1nphxl+rGeud9fmP6jYs5FEucXZQ5YQBaABWABWAAWgAVgpQGs
BtFyALKq77XIZ0KSu0dqNCQakbG/d3N+Vwf4exQMZivAxAGW5C2drnlCfxtQOT9y3EHO7+nU4sfO
FzrfYKBA/Ixzoe4707RLAvkOMZDQX48lcHONV1IkWfKUhsdE7SoCsA5MA1it9XzCyFOR2Xaz2fcb
vaf7m7YvNAk/bkr24Zhz2V3BKgvAArIALAALwAKwACwAKwVgVdNSAqslfw/UQT362ZDB/GItURAd
cHdQmFpkQONdAwi9YgDrL43SHKer9X4zg3zbyOrDVyKfUUn67uH8jml/R/OQ9laQCNvvjQGKhbpt
qJlKC1//8ioAWOtH8rRONNtuisBvQ51CXGruz5bat7Z5H3yF2XICLCALwAKwACwAC8ACsFKsIpSa
Uwujg+eZZtCN+n2dVrI5WU/qtmdN+11mnzMSpghPM/3t98eAFJBjgeky0/4fk3s0yLTPMFGpWvq7
r0CyiznWv0z7DmsZsMR3mj6PmfbbI1BZN+a+Hmf6f2zaby5fwAKyACwAC8ACsAAsACsbwAqn/F5I
+JzM1FwnT3OxwujJI2b/Ns6TnO8wU1ZREOhlIO0l0z40ci6TzLZLTPtw0z7RtPc0047vmuKZu+rU
pa/J31uYfaaaY11QBQCrVSSKNVZzy740bQ+Y/rJgYIG2/6rlIC6ITKUeU/6ABWQBWAAWgAVgAVgA
ViZThF6kmvvgyBRd6Pu0z6GmbXIpVxEKYL1s2o9MAVh2Cm+EaX/ItBcZwPrIVD8/PjK91tzs82zM
ta1NwAoh63bNQftA78MvZt+jIv27a+2sT7X8wuMGKH/T6vMVAFhAFoAFYAFYABaABWClSnKX3Ke9
EqqwH2VqMPlakb22rv4L294z03RVBbA+NIB1RgRsNk6IYD1WRQDLLj6opasJw/yx/2lif1z/cBXh
KSaf7t6Ex+aUE2ABWQAWgAVgAVgAFoCVVKaho5YB8FI84y6MoMzWsgy9zefnD/n8VGHAOjjDCNYN
VQywQl9n9js2Td+aZhHAvBSPNipHwAohqz+oAmABWAAWgAVgreuAtSAawZqdEMUKPV4/K9O1htWm
JvcnmgsVRr9alhGw7k8ArOEJgNUrAbA2NtXXfzFQVEujb+GxDqtgwBoQAb2mGeyzp4le3ab3PlX/
Cwz0Hp6i327lC1j2+Y9FIAuABWABWAAWgAVgabmCxTr9lPSswWL9rAxMKB2wUh9QvKVGTSaapPUa
EZDpZY5hE+oPjbzmfWbbSNN+vmm/PwJYKxOmLceaMhG7G8D60iTF28Kl/zSvcZVp3zICWJuWstDo
D1pENVX/Lgq+0n+cqcKe5NO071xNjE/VdxezSGFJJPEf0AKwACwAC8ACsACscgAsWfk3X6etPtWB
up1WUN9Sp6hW6NSc3a9JZBVgGA1ZqKsI65ioz6+mz8VasLRNJL/rOlNaYUNNVLcgVVv9oGl/U3OS
qisI+WYq00ZlCsxDkB/RxO9z9ff/Rh6KvGGk1pZMIzbWiNvgyPUOThNVqqaFP5tGomIhUBZE9q+t
5321XsPbOrWYdOz6WhvsEV05+FjMA569yHMhG0fuVVhSo1HCY5LKYPnTqw3CAFgAFoAFYAFY6+Sz
CLfS59s108evTFRwmuL8qv7cN2EQbaJTdjM0ajRV61HZnKATFZDGa2Toen0szOGaZzVeq8DfZiIp
fTWCJdvu1vpQ2ysY3alt4zWJez893o16nPF6DSdHoj71FB5f0qnJNxU0WkeeBzhYjzvenLO8xkZ6
n+417WNjqt1Hc6L20nvwT3PeEzTn61A9d09B8Ty9hhv1NWunOPYOWpFezufSDJ4TWU2jd0drvbK7
zXX8Qxc0lHMkS+z+fIIHjCMAC8ACsAAsACuvAUsGuxnRfKlqMeC0ZYoVa3GDd62E9rgIT42Yx+54
pm/SPtkeq1rCOdVLcb41E0Ap7njVMsiLWi8FKK1n9q+p0aXaGd7zOiaylinw1NbXTHcu5eg/FeoR
gAVgAVgAFoCV94VGe3jlP5BiHOcFOi2NACwAC8ACsACsvAcs0XQGfwxgIQALwAKwACwAq3wBiygW
rgwvBrAALAALwAKwAKx1CbCIYuHK8I9eydMDEIAFYAFYABaAtc4AFlEsXFGWxzGNct7QK3n+JQKw
ACwAC8ACsNYZwCKKhSsKrApBFwALwAKwACwAa10GrG66lB44wIAVgAVgAVgAFoAFYJUTYIl6Oo9x
XgQoYMAKwAKwACwAC8ACsMoHsEKNAhgwYAVgAVgAFoAFYAFY5QtY9Z2fAR4wYAVgAVgAFoAFYAFY
5QdYInk476uABAasACwAC8ACsAAsAKv8AEvU1Xk5UIEBKwALwAKwACwAC8AqP8AS9U1YXbhQDXzE
F9V8pYKOne19n+08Tn8CVgjAArAALAALwKoigBWuLnzJeaUO1OGAW6j/nltOMBB9tEp5gsm0NOcq
nqwua5RnA6+kqGaRc3E5XPOCLO7779pfXneEcxN9D5tkcP2AFYAFYAFYABaABWBVImCJCrySiu8F
MdsKdTAfZTzCwEB0Wzpf4NxCf2a6z1nO/RO2FaU512ifoizP115vnIrKcM2yb8MM77v8u6mX+pl/
mbwfIwArAAvAArAALAALwKocwEIIAVgAFoAFYAFYABaAhRACsAAsAAvAArAALIQQgAVgAVgAFoAF
YCGEACwAC8ACsAAsAItxBCEEYAFYABaABWABWAghAAvAArAALAALwEIIAVgAFoAFYAFYABZCCMAC
sAAsAAvAArAALIQQgAVgAVgAFoAFYCGEACwAC8ACsAAsAAshBGABWAAWgAVgAVgAFkIIwAKwACwA
C8ACsBBCABaABWABWABW7gPWGYwjCKEYXQRgVT3PnlcCWDPyALAW5RNgXWUA65ocv5bL/z9gPf8M
gFUWwDqVcQQhFKPzzzsvP75cr7zS8w89ND+uZcFiz+/U0fP/lQeAtcJ5dwGs053HaRQoV32d8wHO
WzvfkOPXMrYEtKq39vxXns+Pz03fvpUPWI87/8f5JufbMcZYfbPz2x06eP4ZZ3j+SSflrk93g3en
Tp7frl3uX8upp3r+0GM8v7CJ5x/kvv6HOZ+Uoz7F+TjnZtXcwLetc2fnTjnsXZxbOTdy3jXHr0W8
o3N9zz+gX8lnKFc/MyefXPKzRYvKB6zHnN91vsX5TowxVt/q/Fb79p5/2mmef8IJuWuBkp139vy2
bXP/WmSgOGqo529Y6PkD3Nf/qc4n5KgFso4JAWt7590VsnLVuzm3VsDK9WtR2K1W4Pn9+uT25+bE
E0t+tmq1dqYIT2EmBCEUo3PPPz8/pgfGjvX8ww7Lj2tZuMTzO++UP1OEe8gU4dnON2vuUq76RueB
zts435Lj1yLTnVd4fo02nj/jhfz43Oy/f06sImyotqqmRmVXpveygTqb9y1TZXtslKdiFWEVTnKf
TpJ71V1FOJZVhCS5ZwxYRc6jnIudF6iLtU08XV2U4fd2ofMIs791URUcZ1Kdb5JH6H6ZgE9Tc/xU
9zLsN8Z5rnpMiteKvm/FKc6tMMtjIwALwKJMA2UaKNMAYJUSsIp0UPazcHEKSCrUAX5uGY5R2WCV
yfkmea7unwQzIfj8nuI+dFcXp+hnX0uAbd8M3jfpf4lzC/05txTXgQAsAAvAArAALAArC8DaNWmA
ruXc1nkL59qmvYZui8BBf+ezdHAeEx3Eq6mzBK2GMW4aiTAV6TRbPRPFSRVVKoj0SzzfGgnnWr38
YCZ6X1aq1+jXKPIeqBcknV+j+NdbHNd/Pee6gBaABWABWAAWgAVglStgzYgOuI5UfEdK/ivO05wn
Oz/r7IjFb+V8ovO2WUZ4BA5Oc37Y+T7n+507JoNWdIrSOi6y407V+z5NNCaMUM3O5HwFIIc4T9Tz
fcj5UN3W2nms8yTdfo9z0wxhJvQGumr54fh9V3lvvVfyPrzq7EjQb5HiHh/l/KTzS87FuoCnTkL/
Ns7XO7/m/KbzbfHvK6AFYAFYABaABWABWFkCVq/ooNvQ2fXzf3M+0rlQ22Sgf8L5J+dfnLcuxTTa
9s4LzOftwNJNxZXGC9VZ7SfX/r4531u0vabz4Mh3R5sMjieRqg7Olzh/pPv96tw8of85zn85P673
e4Lu84Vzp0jfAoU1X1dzC7x+rr8/pUBn+3d2/iHmO1De3y6ppw5rgyIAFoAFYAFYABaAlQxYMq12
Q3QgHaOfhZEJg/4/dLVt21KAjoDJu+bz1q/yAKvU/qc532tN+1bO87R9iUa1Uh1nfefjne/V75nw
mN9LaZiEyNVf2mdfbdvSvOZ7zg1M/1Ha/rVzY20bal7n+sh046fOczR6NSvyPfi6RjETruUZolkA
FoAFYAFYABaAlQxYDaLTZRLl+DIGJqwb6HRS+1LAikDGhzkGWBMTAGu7UgBWW53GOz0DwHpUt/+p
Ua9wCvANs++JJtL2tYGj9bV9B+f55rttB20/2/kxjbrV1GuxxxWw2yl9nlk/kATAArAALAALwAKw
1gSsRtE8oTY6NSivtFAjIHEDrDz1YMeEbZs47+zcTgfvVIDVW9ubae5PgyzAp4Hu0zImSralvn66
Y2zqvGuaaFx5AZZ13zSAZUF3eSRX7RGz71Pa1l1BzFdQqmemDb82/Ydpey8T5Qq9h16H9FspjwxL
fx2/64IBBGABWAAWgAVgAVipIljh1JH9TDwWk5PTIGYKSaDgOue3dBpQcoueU4CJA6y/NYIlyfTf
6OD+tnO3yHEHKuTcrcnmvbRNcpiWOn/nPNzkFb2k9ezmafJ5owQIvF1zmV7XYz2VABUVAVgHpgEs
Ad2Z5j51i0zRhvt+risAB5g2ub9NzOpAC7QTUpzThs7/1X6/6D3K4FqmONcHTQAsAAvAArAALAAr
TQ7WxTGfiz+cH4zAUhSuXtG+B2h05GuTNL11DGCt0ARyAZi7NGoS5hDZVXXNTbK2r0D1jPPVznNN
xOVGr+Q7SCDo/0z/0ZFzbW4S169TCAkjSjKd1r8KAFZjhb+wzxCz7WbT/oPC7p4a6ZI2R8z+5gaw
3jP9n0hxThLF+1n7jc9uGnW0R2V/AAvAArAALAALwFpN+zj/EV2N9lTC52OxJktHo0JXmfyfsO0J
s9/Z2lY3ElH5h+n/tmnvGTn+JLPtNV3V6ClUhe0zFXqk/VjT/lKkntV4A3hdzOq+D7T928iqvrUB
WOIpps8NCYD1iUYSNzQRL4HNItP/A9P/7hTn1Fv3XWBytTL0HNAEwAKwACwAC8ACsFb/TpXpnTWK
VdbXyM/chM/JVAM5zcwqtMciA7ZEoz7WnKy4HKx9Tf8XTftRkfO532y7yLRfaNonmvb9TETsbZP0
3VanD8PyCLbm03PmWMdVAcDa25zrPIXOtloLK9x3iil6elFkFeA2mlc127SflcFqyVOyXwiwXKNY
rCwEsAAsAAvAArAALJ3WGeUlVA73dKXgPw1IWI/SPvtH8rXs/i0j031JqwglgvSyaT8yRQTrctM+
3LQ/ZNp7ae6Sr/lVYcRtSGSqcSOzz1Sz7fYqAFjig3S6c4WWVHjZLELwtfCrTe4fqZGslZpP9abu
GybLJ9S3CqZ+JUn+zvTV9kvzqCAEYAFYABaABWCtc0nuc6P5SVvEDJ4dtX7TX+az8pFOvR0bmb6r
WYoyDaUFrBEJgFVkAOtDE207KwI2G5t9njXbnqwigBUmn++heVZdNafN16m8uJWS8v710DILx5j3
bHpCRff6eo+mxT8upyygRUFSAAvAArAALABrnQSshl7ksTOdtNCol6I8wzL9rMzVBOuDzednjkmw
roqAdUyKCNYzZttdVQiwrE9IyMtK8qOm/8CEPjfo9Gz9mCnKZmUDrWeALAALwAKwACwAa10FrNXy
r7bSFXupYCFMgP9YC19uZ2owiS9IeK5fVQCs9roiUtp/1DpY4fTam+ZYZ1RBwJKp1s9MFfd0++xr
YPjWhAdXH6uJ8ntqzlZ7vS7JgXvelHsog58GWwAsAAvAArAArHUesFprbamHEgZkT2tR+fo8PU/7
2QT1uZFVbENNmYH1Is/2652Q5H54ilIJtuzCBab9AdPe0wDWB7oy0tOE8KlmRWRHA1ifmjIH9rmC
95rXuNq0b6OJ8iFgtcwCPGze2rcZgExDE2F7J02UMATJH000br2YPp20LMUKLSq7TP1H6Uo1pHJ/
0AXAArAALAALwFrnAWuRSVjfNjJY9lKYeC5SdX1HnR4MP0cCacWa9/MvE91pHKksfrgp3/BeQgSp
egS+xplt15v2pxOm0r6MAMzWGjWySeJdNAonsHF05JqnJpQ52DUSueuUBXTYFX/L9CHYXsLDobvp
Ssi/NPm+eYrj1tNp0F/UZ5pVhtabm6KiST62/ABLVhnyWB0AC8ACsAAsAGudelTOMjsYbqvwNFDr
Lb2hj2aRPJ3HdfpwXEJ19D0VqH43j9qRqb0WBpRO0YH9c/35gD5H70id/vpcC2wKLLUyJRc+MNte
0KnMLbTG1Re67R2dFivUcw3bxadGku+306Tu73TK8xPd/7AI2A1Q8AuPI7C4jxZWvUnhLbyW2yNJ
81HX0ErzR2kZhfCYX2qF9X5m2q9Ac9tu14UDd6Qo8urpVOdpGnl8TYvFtk5xHjfrtX8e4/9qNG/7
8n2mo+T6bQjCAFgAFoAFYAFY6wJg1XGe4UUeldMsMnAfpFGRQ9I8sy+cAtxZIaRtzDMCW+sjWJqr
N9fXbKGvZds30P1a6PRbuK21rqxrov8O21vqMRpE2jfR49WMiQ51UJjsFpPkXUOnClvocZop9LXU
SFw78xrN9fcNUtyb6gqF25pjhm6j0NfQTAn2VahaPwOA2Vwr6G+TYmrXXlcLTfBvHuOwvXr5Pzh7
BAgDYAFYABaABWCtK4VGe3jlP5BiHOfLQBgAC8ACsAAsAGtdASzRdAZ/XAkeBcIAWAAWgAVgAVjr
EmARxcJEsBCABWABWAAWgFXOgEUUC1eGLwRhACwAC8ACsACsdQ2wiGLhinL46JwGIAyABWABWAAW
gLWuARZRLFxRYMXDnwEsAAvAArAArHUasLo5/wkYYMAKwAKwACwAC8ACsMoPsEQ9nccCCRiwArAA
LAALwAKwAKzyA6xQkwEGDFgBWAAWgAVgAVgAVvkCVoFX8ngTAAIDVgAWgAVgAVgAFoBVToAlkgf0
LgckMGAFYAFYABaABWABWOUHWKK+QBYGrAAsAAvAArAALACrfAErFWStVAMf8V5QQcfN9r4vBqwQ
gAVgAVgAFoBV9QArhKywhIPkZhU7d1cXryXQyNY/Or+SJrdsobosryP3Y1/nhgomc8vp/Gc7j8nw
vv+u/S9xbqE/5wJWCMACsAAsAAvAqlqAJeqlA27TmG1Fui3qEDRGJGyvLMvrb+BcTc9/REKfQnVp
z7co5t5kc7z+zmclHLcgw/s+Qq+xoAznMQKwArAALAALwAKwAKzKASyEEIAFYAFYABaABWABWAgh
AAvAArAALAALwEIIAVgAFoAFYAFYABZCCMACsAAsAAvAArAYRxBCABaABWABWAAWgIUQArAALAAL
wAKwACyEEIAFYAFYABaABWAhhAAsAAvAArAALAALwEIIAVgAFoAFYAFYABZCCMACsAAsAAvAArAQ
QgAWgAVgAVgAFoAFYCGEACwAC8ACsAAsAAshBGABWAAWgAVgAVgIIQALwAKwACwAC8CKANYpjCMI
oRidd955+fHlepUbvA89ND+u5felnr9zR8//dx4A1l/OuwtgOZD3blDIylWPcx7gvLXzjTl+LQKI
ox1gtfb8GS/kx+emX7/KB6wnne927uW8P8YYq+U7YeIAN2A8/7znP/107vq55zx/yBDP79rV/W+8
OLevZepUz5/0oOdv4Qa+a9zX/3POT+eon3F+1Hmr6m7g6+M81HlIDvso512cN3U+Osev5XDnwZ5f
rannXzEqtz83U6aUuFOnygcs9/ftzXJ+x/kDjDFWv+v8S7Nmnr/zzp7foUPueqedPL95c89v3Dj3
r2XHHT1/u+09v24dz9/Sff3v5NwhR93ReQfn9au5ga/QeSPnZjlsOf8GzuvlwbU015+1PL9t2xI4
ydXPTMeOJT8LCiofsCY7X+Bcx7kexhir5Tvh0mHDPP+PPzx/8eLctZz/xRd7/sCBuX8tS5d6/ncz
3aDhIOt59/X/h/PiHPVS59nOu0gE60TnK51H5rAvd+7t3E7zsXL5WiQPa7jnV2/p+VOeyO3PzZIl
JT+LitZODtbppJoghGJ04dln50f+xWWXef6gQflxLXPne/5O7T3/tTzIwVrivKvkYJ3mfI0mV+eq
JW+pv/NWztfl+LUI7Lr/lFTfzPNfnJofn5vevavUKsIi51EpPMK5ifZtor/H9SlcS2NDuvO3lr4N
nQvW4bG0oblnRSn6NY281yO0LU4FMe9DURb3udC8VhG4wypCVhGyipBVhKwizOUyDZLbWuzsZ+DZ
zuP0Z1KfuTpAFlYiWGV6/tYL9DpGrUUorExZ+CnW67f3ozgCNeF9/T3m3v1u+ldz3kCPOzvF302q
+1yo2+emOScEYAFYABaABWDlBGBt6LyoFHCSiUPQaqrRkqSIUYHZbvvY9jj1LCVYZQOFDSPOJCqU
dK0FCcdKdZ2lvTdx8DI7w3sxWZ3pvXvF+cdS3udaCWDlx4BWT/AHwAKwACwAC8DKFcAabQey2s4D
nI9zPtT4SOchzm0iA9/uzsfo9sOdT3JuGR/tWGAiRmOc91U4CAf+Bca/aJTsF9MWjWT0d/4zOhBv
6jzY+djI+cs5nqqWbfs4t9PrjQGA4Xr84sh5hecRnQYNp7Wi/eW6LnFuoT+j1zkt5vqLy+HepIsK
reb2zqc4N0zRxx3IP9H5NucrnfdKA1JbO1/k/A/n8/X3BNCKBeShun/91dvl/e4LAgFYABaABWAB
WLkAWH3swFbNeQ/n9yKfiamy8MN5g8hA6MjBH+g8S/td7Nwouym6bCNN0xR+5sRtb+C8o/MtkfN/
3/lqbX/debmzG+H9lxS2ShnxukKdLvqyuJTTl9nuE4WzxPOq5byb853O85xnOjdP6Nvd+UPnt51P
c/7C2ZGOPz7hvT5T7+29zhdoTusvum8m1+EIyl/h/LPzRmtuXw5kAVgAFoAFYAFYuZKDNT06yHXT
grvhZ+LuNIPicwovXuV5Zartm+vnODz/MWZbDeezzDZHMn5R5Z57RTsRzuo693K+z3mZuQf/dW4a
07+dgo6vkU1P79UKbbvLubrpf4S2z3dupm1jzOsMTnPumzl/q30/TzgnIAvAArAALAALwMoVwOru
vMwOYjW9kpIr4WdCohytEgZFiTK8qdGsqgIZrfWcw/O/PqbPW2b7W2tOR+Wlm2jETmr+/TMDwLpJ
t0sJm04mSviltgto7a3tBRrpkvZ/OdczEbDl2v5ZTBTUwt9L5pxSABaQBWABWAAWgAVg5QRgSX3B
P6KD2KGRz8XIhMHuLJ1+q0ogIRGs39IA1nizfanmInnrkA9PA1gCPJ+aKN9OZpsFobu0rYdOHUrb
G1Ks2UTBfjH9D0o4H8ntekffiwwAC8gCsAAsAAvAArByArDWSDaWiMQn5nPxP+fGMYPwi87bpBgI
D3Ce5PyU82POR2sUxPaRwXt/ja700mhZoQ66k3WKcttyBqx7IrXvtk+YIrtCH6Ml53+dPukh6XW7
aGRIzvl+E90JvadzH3OdjfVab9Z9btZE/WgOlN1ng8g+N8Xsk4mPSQNYrQwYLdGcrXCbjX69rdOE
B5q2/5j3uDDydzQu5lyO1r+NPibalQFgAVkAFoAFYAFYAFaVBizRhXED2IWRz8bhke2SUzMhYfCr
qRAg+01XQLhWf39V823CvrvptNNK3f6k+uMIBLQqJWCNiwFDe+xXtc322df5e50ek1WS/RQ4JIH7
hJjXvEDh4FHd9y19qsXQSAL3bH3NvzXJ/FmF1/BcZkSSx/fX1/T1/kjEaIrzV5F9GpQzYG2sye9h
n75m262m/Qu9d/1N2w8mQb2BRqbCbRNi4Po9XX3aXe9LFoAFZAFYABaABWABWFUasEbEJY5vZgZ3
8QuaJB6uOHxKoypxA98ws9/epgxECDbPR8ok3G76z9ek6vW91b9TjiojYFXXgf9Gs22WTm9Fyz18
p9sfMu0jtG1ZJDo1yEw1huA4UNvkPNqavi9GQETgckPnb0x7NOnePiFjpu7TNAJZe5UzYAkgv2v6
DDPb7CrNj/V96qCRrvD+hFOu9SPHsQsmGun7O1B/3690gAVkAVgAFoAFYAFYVRawpBhobMHRu8xn
Y7mWcQinu57WgTi6T1OzGmxJpA7SM+Z4Fs7uNO3jE9pHlRKwZLB+RKHuS5NXdIuCQXT/y82+15j2
w0z7E6bkQZgw/2YkMhOu1DvfAF6xOcY5pv/rCSBZPQKZ55ltb5v248oZsMRnRKYCwyniJ037y/o3
UCPy3t5iYPWbhFy+OzWq6SUA1obZXdNyb92pyg9gAVgAFoAFYOUIYNX3Eip972GSly383KVFO5Nq
GdkyCM3Mtslm23UJIDc2Id/n8lIC1r2atL8isjKyfcLUpl1heKbZZvOMvtXpr+1MSQiJ1PTUqa7T
TN9HTdTPrs4cYkpHvGnaj44A1gyz7Rhznnbq7fgKACyZ+rvD9PvI+UGNMIZtV0dWb1pQlPId0yIl
P/YxxUQnxeSbhYD1ieYBlrJGmYBWbXAJwAKwACwAC8Ba24Alz5O7Km7Aig7wP+h01NQURUWPjkz3
NTHbnjbbHkoArOsSAOuyUgLW2JiIjPjfMblLMqX1k+lzitl2UOR7op1O54VtP2uNqXvNz4dM1CkK
WEMTAGtoivt/QgJgVUQEyzO1ryTyNFrvR5j8/qfWTLN9G2qu3pUaoRttAP0Tvb91dIXic1od/m6d
Ip5q8vB+UwDrVPqVks8AWQAWgAVgAVgA1toGLNGYpMHKTo39rZB1VorBLQpYhQkRrImVBFjXG8B5
MvJ5j64wrKfJ7eH2U822gab9N43Y7GfaPklTT6t6jgJWdFVoCEHPxD9uKLaWlq+A6+lKyJ8z/D4e
WrZyFEAWgAVgAVgAFoC11gGrKFpw1EZ1vowkhm+UYmDb20wLRQHr2YScqsoArLD8wA9m25+6Us8C
zUsJEawhkdVz6+mjeZaYwptdYs5nwzwBLHnNV3SfuZHaWF7CMwlnmZWOBaYEyIOavD9D/bIWKl1p
ipv+O2YBQik8RUuRIAALwAKwACwAa60AluMFb2HSQHVhQuJ3nOvp8//CJPfNDSyEOToCYJ0Tktmv
TahXNTrDQXWzSCX36yLbB0bygr6K1JI6MwHqTjXtd2rbelr3KWwvjjw4uW9kirA4Jpm9hhbnzCTJ
/fgEwDo2S/AYGlkEUJjBPiNN9K5vmr4F5lrf1WifF3nuZXX9GbrIvC+fZreKMF3yO1EsAAvAArAA
LABrrQFWg6RE9zDys0BrO22fwcB2oMm9OcjUVgqnhm6O9L89AYgmlCKCJblRi8x+t8b0iT4QepJ5
rl4jjZ6ED7qOTndJqYStTPuRkWO9oiB0mQLllqbvCwkgZVcEHhk511cTQOq9MgDWSWbf79Ks2Gus
yexhonv3NMfeUiNSvhYQzfQxSkWRqFph+QCWRGX7gU4AFoAFYAFYANbaAixJdL861WD1uEYlMh3c
jtcpou80Z2ualnq4zTxKxdOVeJ9qftdKhY3W2v6NWVn2rzTFRgu07MIEEyWTfb/WWlUtI9Dwb9PP
1/NqZqYZp+u0300KS4t1GqtLTDRmRGR1XVj9fs/IKrlZ5nqmKkTsrRG3sP1x88y+blqc9G+T97SB
7vObOfcnMwCSmhrd66FRt5Vm/+v03tUzkbmOGs2T6cv/02KqSVGlRnquV2su2gwtRFs9i7+X3uY6
v4ysPi2HKFY//RtHABaABWABWABWpQKW6IJUA9VuEWDIxFvpIC3FPi9JyFHaSQGoj3qQwlVHjX71
0Smpg9I8MqeZDtKDtX94PJkSPDgmZ6iVJm330UrkQyLRlnqan3WVTosO8ZIfVuzp+QpIXqqJ/lEY
6arnEl7PID2HrlpY1ba3MM/4O9BsG6z7dIm0D4pUx49zLZ2W3d+cRx+tUj9I712hecSNlJo4Xc8h
3cOwt1cAO07vQ2lAaEM9n/CxSbXLD7B8nf5uAEIBWAAWgAVgAVhrA7DcGOf96pXvwIZxVbD7avca
glAAFoAFYAFYANbaACxPizQyION88wIAC8ACsAAsAAvAWpuA1YQoFgawACwAC8ACsAAsAKt8AYso
Fs5H/+ncCIQCsAAsAAvAArDWJmARxcL55skeBUcBLAALwAKwAKy1DFhEsXC+uNgreUoBArAALAAL
wAKwqgRgEcXCgBWABWABWAAWgAVglTNgEcXCgBWABWABWAAWgAVgVQBgEcXCgBWABWABWAAWgAVg
lTNgEcXCgBWABWABWAAWgAVgVQBgEcXCgBWABWABWAAWgAVglTNgEcXCgBWABWABWAAWgAVgVQBg
pYpiyYDX33m481wAACd4tvM451+8kqrqvwNWABaABWABWADWug5YotEZDHiFGu2qDNCaVomvFfVc
fe1pVTjKU1HQm+21z9b+TfRvpMAreWRN0wzfP8AKwAKwACwAC8DKa8Cq7/y88/QMBrwQtGZrtMJa
BsyzFACKY7anc3TATfVaUUufK9SzUxx/VMK5hbBQaF5fzmVMzPFmK+CU9joXlMO9yfb+iF9x/j7m
WuQaR8Rce3GKe1ikQFWavxXACsACsAAsAAvAWicAS1TduVoW/cNohXVUDbN0Nq8VdUEG/VOdW0EW
r19QxutsWI73JtP701Df33pZXLeX5Xlken4IwAKwACwAC8BaZwALIQRgAVgAFoAFYAFYABZCCMAC
sAAsAAvAArAQQgAWgAVgAVgAFoCFEAKwACwAC8ACsAAsxhGEEIAFYAFYABaABWAhhAAsAAvAArAA
LAALIQRgAVgAFoAFYAFYCCEAC8ACsAAsAAvAArAQQgAWgAVgAVgAFoCFEAKwACwAC8ACsAAshBCA
BWABWAAWgAVgAVgIIQALwAKwACwAC8BCCAFYABaABWABWLkPWMMYRxBCMRpx9tn58eV6+eWeP2hQ
flzLrws8f6f2nv9aHgDWUuddBbBOc77G+fIctkBVf+etnK/L8Wu50vkSB1ibef6Lz+bH56ZPn8oH
rCnOlzg3cN4QY4zVDZ3HnHqq5y9Z4vm//Za7XrzY84cP9/wDD8z9a1m40PO//Mbz22/n+c+5r//F
zr/lqBc4/+jcqbob+I5zvtR5RA57pHOR8xbOo3P8Wi5yPsfzq7Xw/KceLfkM5epnZv78kp/77hsA
1sDKBKwHnGc5v+P8AcYYq991/qFZM2/Jzjt7Szt0yF3vtJO3tHlzb+kGG3hLc/1aOnb0lm63vbe0
bl1v6VaeuzbnDjnqjs47OK9fzVvqNXHeyLlZDtv9jXkNnNfLk2uRn7W8pW3blnyGcvlz0769t7Sg
wFvuvtMOqEzA2sa5l3MRxhhHvLdzV4wxzgP3kOh8ZQIWQgghhNA6IQALIYQQQgjAQgghhBACsAAs
hBBCCAFYABZCCCGEEICFEEIIIQRgIYQQQggBWAAWQgghhBCAhRBCCCEEYCGEEEIIAVgAFkIIIYQQ
gIUQQgghBGAhhBBCCAFYABZCCCGEACwACyGEEEIIwEIIIYQQArAQQgghhAAsAAshhBBCCMBCCCGE
EAKwEEIIIYQALAALIYQQQgjAQgghhBACsBBCCCGEACwACyGEEEIIwEIIIYQQArAQQgghhAAsAAsh
hBBCABaAhRBCCCEEYCGEEEIIAVgIIYQQQgAWgIUQQgghBGAhhBBCCAFYCCGEEEIAFoCFEEIIIQRg
IYQQQggBWAghhBBCABaAhRBCCCEEYCGEEEIIAVgIIYQQQgAWgIUQQgghAAvAQgghhBACsBBCCCGE
ACyEEEIIIQALwEIIIYQQArAQQgghhAAshBBCCCEAC8BCCCGEEAKwEEIIIYQALIQQQgghAAvAQggh
hBACsBBCCCGEACyEEEIIIQBrFWC1du7k3AFjjDHGOE8trNO2MgFrQtOmTZe0bdt2/uabb45xTrpN
mzbBzzp16sxv3tybv8UWnvsdY4wxLhkT3Niw2DHPlMoErEdvuOEGf/78+f7s2bMxzknPmTPH/+WX
2f4ee3TxH33U83/7zXPtGGOMsefPm+f5kyZ5Aj0vVyZgPTRhwgQfoXxQjx7d/RdfLNNHAmOMcR76
2WcDwHqhUgHr7rvvZmRGOa8VK/72u3Xr6j/3HF8kGGOMV/fTTwNYCAFYGGOMASyEACyMMcYAVikB
a8WKFf6SJUvWaJc22Wb1559/rtb377//Dn6XnxWt77//3n/xxRf95cuXQx0AFsYYY1y1AeuHH37w
H3zwQf+MM87wjznmGP/YY4/1hw0b5k+aNMn/8ccfV+v7v//9z7/vvvv8U045xT/iiCP8888/33/y
ySf9pUuXVtgA+3//93/+6aef7rdu3drfbrvt/AULFkAdABbGGGNctQHrr7/+CqJQY8aMkR0DX3bZ
Zf7ixYuDbdFo18KFCwMYq1Gjhj916lT/jz/+8FeuXFlhA+znn3/uX3311cF5dezY0V+0aBHUAWBh
jDHGuZGD9cUXX/i1atXy69atG0SNUun555/399xzzzUArKL066+/+o0bN/Z32GEHAAvAwhhjjHMH
sCRSVLt2bX/99df333///ZR9n3nmmQCw4nK3KkIyVbnBBhsAWAAWxhhjnFuA9dlnn60CrPfeey8t
YO2xxx6JgGWT3jNNShdwSjpepoAl05fpomoyzfnbb7+l7We3V0YSPwKwMMYYA1irAZbAiCTA3377
7f6gQYP8WbNm+d98841/0kkn+bvttpt/+OGHB1OQcfrwww/9s88+O0iu79evn3/CCSf4n3zySVaA
9dhjjwV5YfI6PXv29K+66qrgMUFWklMm7dJHEvR79+7tjxo1Kph+DCXgJSsVZfv999/v//LLL8G/
99tvP3/69OnQDoCFMcYYwKo8wHrnnXf8gQMHBonoAkICWgIwAwYMcINjt6C9U6dOQYTJ6pFHHvG3
3357/4EHHgieO/fqq6/6BQUF/qabbuq/++67GQHWBRdc4B922GFB/59//tkfO3Zs8Ho9evRYBVm/
//6736tXr2AVolzb3LlzVyXOy3lLVEtWJ0qi/8Ybbxy0n3feeQHsyevK74MHD4Z2ACyMMcYAVuUB
1rJly4JI0NZbbx0kyguYSERLJLWzQsiSVYehJEolr3X99devduwQ1I4//vi0gPXwww8H0CSvYXXI
IYcExxBgEj377LPB73JeVttss41fr149/+uvvw6mASXKdfnllwd927VrF0SzZJuUpZDEfgRgYYwx
BrAqNQdLokBdunQJgCWEq1CXXHJJAC133nnnqjaZPqxevbo/c+bM1fq+8cYbwTSjvEYqwBIgEnDb
dddd/YkTJwbHFsvUXt++fYPXk20yfSkwJ/uOHz9+tbwqSdSvU6eO/9FHH61qv/XWW9cAPARgYYwx
BrAqHLAkEhUFLIlide7c2W/YsOEagBVGhULAkojTtttu62+yySZrTBvGKQ6w5s2b5zdq1Mjv2rWr
f+ONN/rXXnvtKt9www3+TTfdFBRQDaNbEp0K97v33nsDgJJjyjE+/vjjVa8l+8m5XnHFFdANgIUx
xhjAKh/AkjpYmUSwBGxsBfcQsBo0aOD/97//Xa3/6NGjA2i56667gt8FqqQyu8CNTTLPBrAE4qTY
6XHHHZfxNUp0qqioKCik+sEHHwQRMIm4xQGWJMAjAAtjjDGAVSbAkiRzSTAXuCguLk7Zd8KECcHK
OlvBPRvAksjXlltuGbTNmDEj9jUEwkKAiwMsecSPwKDkSiWVdwifkyhJ7gcffHCQI2aLqApgScQO
wAKwMMYYA1gVAlhSr0qSvgUu0u0rzyo8+uijV2vLBrAEemRVn7RJQvqag+oKf9y4ccF0XhJgyett
tdVWa+R2hZKpwTvuuCP4KceSfi+88MJqfWSlIYAFYGGMMQawKgywRBdffHEAF5IkniSpb9W2bVs3
4D23BtBIzau4HCzJZ4qCm0TBwmcfSskEAaYwV+rCCy8M2kL99NNPfpMmTfwOHTqsFq269NJLg/1l
qlHyqsJjSJ/hw4cHuVkiSZqXfo8//vhqx5SIVv369VetIgynEcnBArAwxhgDWOUGWJIPtfPOOweA
MXLkyKDwZiiZrpNyBxI1ksKg0Qc8C9S0adMmKNMQLRR6/vnnB8e87rrrVjvegQceuAqyBM4OOOCA
oOyC/NsWChWok9V+rVq1WhXVCs9XVgqGx9h9992D2lsS6ZLolEwNisIk+8033zwo7SB1ug499FB/
o402ClYySs2r2267Leh7zTXXBH2zye1CABbGGGMAK6WkbILAhUzJScRIIEiKbEpJA5lClFV6UUmB
T2kXgGnZsqV/+umnB5XbZapvypQpwb4CR/vss09QTyp8DI0U9zz55JNXFfMUOJNok+RXhZJo2Lnn
nhvsL8cW8LPb5d8CS/IwaDlGzZo1g3OWacVQs2fPDnLGqlWrFoCaROjk/CQCJonyApWS9C51r/ba
ay9/s802C65VgFAiXQjAwhhjDGCVCbBCybSZrBaUPCbJcRL4kArocZJI16effhqAljxeRh4cLf8W
kBKQ+e6771Y9PufLL79c49l+0vb666/HPk5HjicrHOWnHFNeJ27loRxDKsEnPZJHImb//ve/gxWS
YfRNIlzSFka65BjffvttcK4CmpIQb6N4CMDCGGMMYDE6IwALY4wxgAVgIQRgYYwxrsKAJavqEMoH
9ejR3X/pJb5IMMYYr+5p09YCYMmDjiWfSGpSYZyLlpy4zz//r9+58y7+xHs9f+Z3nv/tVxhjjLHn
/+jGhLvvWguAJc/5k3IFUusJ49z1NkEx2KbNPX+zNp7fojXGGGPs+a3cmFDYdC0AllRPlxV3H330
Eca56w8/KqnNtp/7EJ3lfCrGGGPsfKZzn7UAWPfddx/JOygv1L17d98b4j5E1zpfiTHGGOuYcASr
CBEqlf7+62+/a9euvneI+xCNcR6FMcYY65hwKICFEICFMcYYwEIIwMIYYwxglRKw5LEx8szAOEl7
9KHOuazFixcHj8ZZuHBhqfaXRQNS+mJtSR7pM336dP+FF14IyhikkjzmR57BmKk+/PDD4LmPABbG
GGMAqxwAa/ny5cFzBuXBxueff75/0UUX+eecc45//fXXB88iFCjJFw0fPjx4ILRcZ6aS+zN16lT/
iCOO8Bs1auRffvnla+Xc5TmLp556qj9q1Ch/++23D85F3it5xqIFyIceesg/4IADgu2PP/54Rsf+
z3/+EzwEu127dsEzHwEsjDHGAFY5RLAkMvLKK68E9YYEQNq3b++//fbbwYOO5YHN+SIpvlq3bt0A
UjLVggULAsAKSgW4e3PNNddU+nlL5KxVq1b+888/H/wuBTg33njj4Hxee+21Vf3kYdwCWC1btgy2
Pf300xlHr5o2bRpcY9IDvQEsjDHGAFYpc7B69eoVDMzjxo3Ly3wemfL85JNPgqhUtvrHP/4R3Jur
r7660s9bomdNmjTx582bt6pNpgpHjhzp//rrr2v0P+WUU7ICLNFXX31V5aJXABbGGOO8AKz99tsv
GJivvfZasqsjuvXWW9cKYC1btszfbLPNgum7+fPnZ7TPySefnDVgkeSOMcYYwKogwCoqKirzNFg+
TSla3XLLLRUCWH///XfaxHaZvttyyy39P/74I6NjnnTSSaUGrKRFDZm+r+X9/gNYGGOM12nAkkT5
c889N4ieHHbYYf6NN94Y5C+FktV3V155ZTCtJTlQd955ZwAMP/zwQ5BQf/HFFwftV111lf/uu++u
2u/ll18O2mV7qpVzkjv02GOPBa8vryv7DRkyxL/sssuCRHAZ+N9///0ggV/6RaHijjvu8I899tgg
kXzs2LHB+cl0YirA+vrrr4PfL7jgguDapkyZEuStpZNEom666Sb/jDPO8I888kj/xBNPDKb8omB1
2223Bfe0Xr16wRSh3INLLrkkyLPKBLBktaHciwsvvNDff//9/dNOO221exvqxx9/9G+//fbgvYlC
nOTinXXWWcG0o7yvcs72voSS6UVZRHDCCSf4Z555ZnDud91112rTmgAWxhhjACsLyco6ibDIqjUB
KYEVWcUmSdPh0n+Z6pJzkuOHg79Eb6RdYEggQtpvuOGG1VYuCrDssssuweBtV8xZSemF/v37B/s3
bNjQv/fee4MHBYevNW3atOC4zZo1C36X5zRanXfeeX7fvn2D1XQCD/J7jRo1/JdeeiklYElO13bb
bRcknD/55JPBuSaVvAj1zTffBPfluOOOC5LL33nnHX/w4MF+9erVV1uhKNcqyfXjx4/3Gzdu7MvD
uydMmODff//9qyW2pwIsOdd99tknSHqXVYLSVlhY6BcXF6/qK1C45557Btt22mmn1QBLQFTu5xVX
XBG8r3If5X1t0aKF/8UXX6zqN2fOnACCRowYEeRyzZgxw9933339tm3bZgScABbGGGMAK6KHH344
2EcgyUqiLNK+6667rgZGBx10UNAeLSEgURZpv+eee1Zr//nnn4NIVBJcheUJBFxkQJeVkIcccoj/
2WefBVE0ibrMnDkzGOglGiSvIREqu0KvoKAgAD4r2U/KVCQBlkTEzj777AAkJJKVacmHLl26+Hvs
scca04TB8/bc8QUOo9cmYLjVVlsFMJpNDlanTp38Rx55xF+0aJH/8ccfr7r3bdq08WfNmhX0lZpg
AkQ1a9b0d99991WA9eeffwZ5XwJmdmWhRASjoHnzzTcHkLlkyZJVbd99913w9yTvH4CFMcYYwMoC
sGQw3mabbYIk7OjgL9Cw4447BsebNGnSqvannnoqaOvdu/dq+Uf/+te/VkGBHagFuKIRpyQJzEkk
6I033ojdLlNWUcAKX1ciYBYkZGrMTqeFgCVTewJKRx11lD9w4MCsyho88cQTq6J0UQlwyjapcSXT
g6GkWKjkYAnsZBoNCiNYAr/RkhNSgkO22WlSAVCJTO22226rAEsicXJPunXrttr5yEPEZX+pwRVK
phbjFkdIVA/AwhhjDGBlCVgCMtJ/7733jk2OloKesv3www9fLbdIojG1a9cOoip2mrF58+ZBf5ka
C3OjBGRk6i6dJOIiU1z169f3f/rpp9g+khcUBSzJEdphhx1W1f+S+xZX6T0ErGHDhvl9+vQJnK2O
OeaY4BhxOVSSwyQgJVOTr7/+erkAVngfrS699NJgm0yD2mlLmQq0gBUCmUS/RB999FHwdyF9ZH85
TiipoVarVq2gXXK97NQqSe4YY4wBrCwB65///GfQX/J84lbDhbWjevbsuRqASUTKRkE+//xzf+jQ
of6jjz66apAWCYBJEni6vCYLWJLLJdNTmQKW6IMPPlgVbRN37NhxDQiSaTDZJlOCAodS+FPyp7Kp
wSW5ZEmAJVGxbbfdNtgu96E8ACtuFaFErmSbJNanA6ywPpa8NzK9+MADDwRTg7K/RK2sZFHAhhtu
uOoeSjV5yTEDsDDGGANYGQKWwIxYBlzpL4O/ndYLJcnusl1yoqwkP0oiTa1btw7AQgZrmUYUCJEo
kgCMDOwylSZJ3pmoLIAVRtZkJZ1Njpffo4Al9bBk2jK87qTXiivHEIBCwhShXHsIeTafrbwBK5yi
tRGoJMCS/SWqKCAcFmedOHFiLGCJpMK85KU1aNAg6LPRRhsF8ApgYYwxBrAyACwBj/feey9YSSZJ
0DI9ZFeVRYFG8paiOvDAA1fBjkwDhnk+Ah/SfvzxxwdTaknTfeUFWBI9k+mvUFIZXUo5SD9ZGRkW
9wynCOWZjSIpRxDmksXBZZykxIHsI9cbd/5bbLFFsFowTECvCMCSkhiyzZaFiAMsKZ8heVkSfbSK
AyyZKrYlOeR+Su6W9JOEewALY4zxOg1YkleUFGGxQCIlDcI8pXCfuOf7CSTJCr3vv/9+jW2TJ09e
FSmSSFgo6RvmYgmQZFPgVBLkBbCkrlOcwoiaBUiBkNNPP32NvjLtKVNeUoLAwlm4r+QmCXxIm9TO
yjRnTVbrCTBJ2QMrARqJ3EWvWYBPVhEK7FmISaUQ/mw5hlBSkkFWMdpVmQKkAlOyijBcrBC+PzLV
ZyV1yqRdVhOGeXJSB0xWK1rJMSVKOWjQIAALY4zxugtYAihhsrfkPUlURqIqMuDK9JAAhayskz4W
SCRPSpboy0OU33rrrdWiGAIoAiZxkuNvvvnmwTShXaUmkhpRch6ywi9TybmGOUw2ed5KVrnFRV8E
LuyqOrnezp07B1ObYe6Y1IKK1tASiAgfrBw37RinsByFlIGwKy8FrCT5P7rqTupyyb2VCJOs9stE
kl8lryHgYyurS/RKXkOmaK2kVtl6660XTM+G4CX5U/K6Ep2UCKS8t3LtEiWUYws4yYpC2VcKoEqE
Lax5Fr7/AtdStwvAwhhjvM4BloCJgJNEoKRauBSilAiLPJdQyhAMGDAgmM6TiM6mm24a5NdEa17J
Kj9J4JZyDbJyUKqay/42hylOAgBxYPL8888HdaEyrfsk02iSfC2RHinKKQnZAk4hXEh+k6zMk+iN
bJcBW+peCTy9+eabQXRIcq+OPvro4EHXsr8U/5TpSYE/yVuS65N9ZepLVsnJvlKiQVZQSrvcN1lh
KPcyXS6WRH/kHksETKYcBYgE5iygCOQJ1MiDngUABbCkorpUzE9X+kAAU6YhJQdK3ge5N1JdXd5H
qfsVLXwq2+Qa5P7J+YSlJyRPS6JqAlTy3ko+nLz3Al4SnRLgkr8feQ9lelPgK3z/5R4LlJb10TkA
FsYY45wFLAEkARIZfCW6IVETAQUZ4ENLH4lqSK6V7BMXkZLBV15X6i8lTdNZyUAejV6FcCEDf6aS
EgcCUHLecv5yvpIjFg7ucr5S00raZLv8lD4COzIFJyAl0SipRSUQYYuOyrScHFses2P3lWPL64bt
AjVSYT3V43yiq/NkNaHcL7lv0TIXcg/knstryfsiln9LSQSbo5VKAmwydSevIfvFwY4USRXIDN93
uQYBVhvhk/pdksAe6tVXX10tWinTm5IfJvdCIlayCMDmtQFYGGOM1+kcLISqmgAsjDHGABZCABbG
GON8BqzoM/0QykWt/Hvl/wesq5xHpzFfOhhjnB9O930vY8JhlQ9YD997771S/nxBBv6DYRytJcnf
3vx0f6Pdu3Vf4R3uLfHGeQvc/1jSeVnwvxqMMca57JXOC1N+31/nfLj3Z2UD1uM77bTTp4ceeuiD
Bx100ONJHjhw4EPHH3/8B7Ja7JJLLsG40iyrVt3f3kfub/CBpL/PQYMGPTbwwIGPN2nSZI7X2nvd
29F72OvgPZ7CD3t7ev/1ityHsyfGGOOcdC/nfdx/ljt6k933+qOJ3/kyJmzmfeiY58VKnSLcZZdd
/jrssMOWHXzwwSntBrIVUtMI48q2/u0l/m0G25ybNW36936e9+cJnrfs2PT+y9nHGGOc017pvDzV
972MCT09b0Wl52BJEUiE8kH77LWXP10+EhhjjLFxsUeSO0Kl0l8rV/rdunYNPkR8mWCMMbaesjYA
izINKB+04u+/A8B6ji8SjDHGET8NYCEEYGGMMQawEAKwMMYYA1ilBSx5hqA8F+/bb78Nnq0n/v77
74Nnz8nz5UJJuzzbbubMmcG/5YHDsp88w0+e6SeSZ9jJA4/lIc/RZ+tlXBjpjz+CZx6OGDEieC5e
RUqes3fccccFP7PR0qVLg2cbnnfeecFz/NaG5PmKkydPDh6YPWTIEP/6669f7f2KO9dMr1Pe/1NO
OcWfOHFiqd9HAAtjjPE6DVjz5s3zn3vuOf/www/3t9hiC79t27b+Xnvt5T/wwAMBPIWSh/fedNNN
focOHfx27doF/S688MLgQcgrVqwI+jz22GPy4n6zZs2Chyhnqzlz5vgjR470GzZsGBxHBviK1NCh
Q4PXGTx4cMb7CFyOHj3aLygoCPaVB1tXthYtWuQfddRR/pgxY4L7L+cv59KlS5fVHtQsECzvUb16
9YLt8p5mIvnbkf6bbbZZLLQBWBhjjAGsDPXpp5/6NWvWDAbW8ePHx/aRaMaxxx4b9Nltt92C6IjV
rFmz/GOOOSYAsTCqlW30SiDrgAMOCF7jkUceqdDBe8aMGVKLKfiZTfRK4PHggw8OzvGJJ56odOgQ
CBXIXbZs2apz6t69u19YWOh/8cUXq52r3M9+/foF5yoAnIkErI888kj/rrvuKtX7CGBhjDEGsMxU
4QYbbBAMxMXFxYn9pOq79BEwqSjJtNfaig5le46VDVgLFy4MIks9e/ZcrV0iVzKFG6ezzz47K8Ai
BwtjjDGAVU6AtWDBAr9x48bBQPzMM88k9rvooouCPgMGDKiwQTUEgqoMWOE5VjZgff75536tWrWC
qFSmkrw4AAvj/9fevYVKVe9xAD8mdDHoRQy7YFQPFV2gSIuoEx66WZKQECn1EHRRkjIKTw8JQkl3
hIyol5KK5IgYbSxO3sKXLg8ZZAQ9JJT05EMgvQTBOn7/nf+w9tozs2efU2nbz4IPtdfMrFmzJpov
///v/1uAgPUXDlipDzpw4MDA4uivv/662blzZ/PNN9+MHLAyFfbVV1+Nm/4aZfvll196ozq//vpr
s3///jIC1N5+/PHHUlfV73qkyD4F4j///HN5XXtKtF/A+umnn8qUXOraDh48WI5d69Mm2/LaTz/9
tNm7d2/f88lxcuxcuxkzZjQ33nhjeV7eI+c6SsDaunVr+TtTnF9++WVZsDBspCwLH/pt3333XbNn
z57m888/L5910JbX7969u3xv+S7+l7o8AQuAaROwtm/fPvB5Tz75ZN+AlSCzfv365oorrmhuv/32
CQErj2daccWKFWXFWwrpFy1a1LzzzjulqDq39qlBoYaXBL38iC9YsKCEitSIZTXcZKEl4ebll19u
/n7kh/nqq68uNUV5rxNOOKEUgicUfPLJJ81DDz3UnHHGGaVmrFublfN75JFHynNuvfXWcqysrBwW
sBIac66Zwst55jiZep1se+WVV5pbbrmlefzxx5tly5Y1Z511Vvn3dhj84YcfyrVLfVquxbx580q9
W2rBJlsMUANWvteE1rlz55a/Z8+eXQJzat/q9u233zZPP/10c8kll0wo/k+Yu+eee8r1yOtS93Xu
uec2r7322oT3fOmll8pnSpF9CvIXLlzYPPDAAwIWAMdvwPrwww+HFlh3A1bCVOq27rrrrvJYfli7
9UEpym6/JqMnCSJ5fkJQQlldtVjDy7333tvcf//9pe3Dpk2byirHyQJgtow8JYzkuRdffHGzZs2a
UrQ9Z86csvov02xvv/12c+mll5bnbNy4cdzKu/POO2/cirt8ttNPP728bljA2rdvX3P22WeXoJk2
CqNsa9eubc4555zSmqJuCSw5doJMDVkpNk9YSzCcOXNmeSwja5HRoWHbww8/XI6XacUEx9TRpbVD
glr2P/bYY73v8YMPPijfRfYvXbq0d4yMIt58881lhWiuUR11u+yyy0pw/eyzz3rPzUjZ+eef3/s+
M3qYsJpzFrAAOO4CVi1yz8hEWhjkR7gt+zKyMWiKMKMfeSw/xO3thRdeKPvfe++9cfufeeaZsv+N
N94YN+KVH/zsz/u1R4ASsrJ/9erVk36eBIKEovz41/syZpqxvWLw+eefnxCwMsKTfR999NG44yWk
ZVqtG7DqZ3r//febyy+/vNmyZcvI1zw9tHKMF198ccJjtfXCs88+O25/ziGfafHixSO/Tw1YGUHK
FG7d3nzzzTIqeOKJJ5Zw2B7B6wasTPel9isjdAlM3UUPCax1S5hNaGxPXSZsZTRwqqsSBSwApk3A
Sn+l1PokZLTt2rWrTPcMCliZIusXsGq/qW5tV9owZH9+ePvVYKWRZnvLOWR/psZG/TwZSTl8+HDf
5/QLWDt27Cj70ucrI3ntJqoZsemeY56TUJbgMdXGqPVatkd/2qNAeSyBth1UvvjiixKwbrvttikX
ufcb+bvjjjvKYxs2bBgasDItm7DXno7MVGwdtcxUb90yPZp9mb5M3VvdMsU61calAhYA02aKMCFj
0JYmm4MCVgrY+wWsOsrx6quv9g1YqecZZRVhGqJmf3pxjVI0ns9zwQUXDAxYzz333ISAlUL2jA79
7bcvrUxr9ZsyreeYgJKptgcffHDKbTHStDXHSA+y7pbGrqeddloJU+2pyf8nYPVbRVinI5944one
vhSwdwNWe0sgzChjRsSuueaaCU1MM1KYqdLsT9PYdIVvBy0BCwCrCKewinBQwMrIRZpgpgC+HXYy
7ZhRprxulICVoDPVgJXar+7KwWEBq742xfyZYqxBK9Ne/UawnnrqqTLaldCTQv1RtzRlzejaoBGs
do1ae8Xl7x2w3n333ZEDVv4bybGuvfbaEqgSElNv1h3BqiErixpqnVe+iyw8ELAAELB+p4CVLe0H
UiCdVXCpucoISLrB51Yvo/bB+jMCVu2OXtsR5FxSo9QdaavnmDYEKTw/5ZRTSgF9PucoW1buzZ8/
v1eD1t2yYi+jQFnxV4vK/4iAVevaspBgWMDK9UyBfBYatNs71FWlNWBlCrBddJ/rkVHAPCfnnesl
YAFw3ASshJBRAtagNg3DAlbqdzLSkULoFGmPjY2VUZtBBc9HM2Bt27Ztwk2RU8ie+/llSq/2wqrn
mOdny+hMvX9fboI9leCTWqx+1zIF6Klxam8pRp9qkXu3D1b3WueztVtQ9AtYtSYs0739pozrFGEC
VqaCM0LXXmWaRQJ53qOPPipgAXD8BKysLhulTUMNWKk9GrSKsLscP32e8iOeUJVmmVVGzfrdTLj+
GHe7pKfwPvtHqXeqt/5JwGr3eer2asrx2n2cct26oSbbRRddVEZw6gq6WsidsNhdrZeeT4NCXTdE
5RxnzZpVptTaW84j02vdEb7UZiVgTaXlQW1Z0b2eCUFnnnlmaRXRbXOR59955529fbk/ZfZl5Kz2
IUvtWPqK1TCc7zKfO4saur2x8vnyvFxzAQuAaR+wMoqUnk2bN2/u1Rtl+i4BpT3ClH/PVFXqb/Kc
TF/lx77+2ObxWs+T5pPff/99b8VYfsDrsRMmIsXP6TeVKaeMhtU6rISuBJk8N6+r/aQSbDLSlP1X
XXVVc+jQoaGfKVNT9T0zItdtTpqpwPTZqiNIdWQqIzHZl8LsFJenZiz7EkTSIypb3jutLPK8devW
9Y6d/bVuKyNMKexuTzn223LshM8EuHRyz/tltWZWD3ZrljL1VkfdEobTZT7vPVnrgzR2TSi78sor
yxRdRvfSdyvd4LOCs31tcp1r4XvOqXaVTx1Y6uiyP99PatISdGs7iZxvgnGCcwLWySefXG4Wndcn
yOW5GQFsj2wJWABM24CVWp/U4axataq5++67S9hI8Eh38/bKr0wbpcN3CtPznHQcT2F0po7yA506
pDSTzDHynLR6yLHraFJGPhI60sQyIzxx/fXXlyajCQtpc5Bl/znvHD8dw/OjnP5SCRAJHfUc81jC
x6DbtCT4pRN6nrt8+fJm5cqVvXBUQ0TaDaSJaY6Vz5saouxPi4KEppzDkiVLyj8zVVZrq9LPKX29
8rrIMXKO2RJ47rvvvhI+0qIgI1oJTaP0w8poUUJbziVtKDJa162RS9+qes65/hlNzHfX79Y63cCZ
65fXXXfddeW65DgJ1d0tK0hz3nluvseEs7SoyJY2DznHBK9MOyYMZmoxx0xBe50aTd+xTCXm+uU8
89nyHQy7NY+ABcC0ClgJR5ke7PYn6nYIzwhPd6oto0t5Xl6bx9oNKPN3HRl5/fXXSw1Wuyan/eOf
IJYAlhDTfY+8b56ff7ZHavJ3+/26o1PtUZm8rn0fwRyvewub/N29BtnXDXH5zO1j1XOpj3Wv7agd
3ev79ZsyrZ8h17p7Lgk5g67DoOL6fKZBr+le1/zdvpa5Rt3PNGwELcFwsnslClgATNsarD9qy2hS
7q037ObO+UHPCEfut2ezCVgACFiTbHV1XYris4IwozQJVBn1yEhT9mU6arIbFtsELP8zAeCoB6xj
JbAkUKXjd+5jl35SufnyTTfdVKQLeOp3Jrt5s+343v6xcGHzsf+RANDx76MQsLYl1KSxZILW0ZRC
6twSJwXquW1NXdmX28DccMMNZWVg+kylR9bRPleOLVl48NaR/y4uvPDCZs2R/2b+dcRbAPDf34TV
v2WKvX9mwPpnEt0RY8eKk046aWzWrFljM2bM6P196qmnjh1L5wgA/KUk66z/0wIWAAACFgCAgAUA
IGABAAhYLgIAgIAFACBgAQAIWAAACFgAAAIWAICABQCAgAUAIGABAAhYAAAIWAAAAhYAgIAFACBg
AQAgYAEACFgAAAIWAAACFgCAgAUAIGABACBgAQAIWAAAAhYAAAIWAICABQAgYAEACFgAAAhYAAAC
FgCAgAUAgIAFACBgAQAIWAAACFgAAAIWAICABQCAgAUAIGABAAhYAAACFgAAAhYAgIAFACBgAQAg
YAEACFgAAAIWAAACFgCAgAUAIGABAAhYLgIAgIAFACBgAQAIWAAACFgAAAIWAICABQCAgAUAIGAB
AAhYAAAIWAAAAhYAgIAFACBgAQAgYAEACFgAAAIWAAACFgCAgAUAIGABACBgAQAIWAAAAhYAAAIW
AICABQAgYAEACFgAAAhYAAACFgCAgAUAgIAFACBgAQAIWAAACFgAAAIWAICABQCAgAUAIGABAAhY
AAACFgAAAhYAgIAFACBgAQAgYAEACFgAAAIWAAACFgCAgAUAIGABABz3/gO2gWPkjyA/RgAAAABJ
RU5ErkJggg==
</FILE>
</FIGURE>
<FIGURE FILENAME="Methodological quality summary wight improvement vs other drugs.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2013-02-07 13:20:14 +0000" MODIFIED_BY="[Empty name]" NO="5" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAOECAYAAAB97U88AACAAElEQVR42uy9BZgcVdr+/YQEQowQ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</FILE>
</FIGURE>
<FIGURE FILENAME="Methodological quality summary deaths.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2013-02-07 13:20:14 +0000" MODIFIED_BY="[Empty name]" NO="6" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAOECAYAAAB97U88AACAAElEQVR42uydBbgcRfbFbzyBCJAE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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2012-01-15 16:39:21 +0000" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2013-02-08 09:37:14 +0000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2013-01-31 11:37:26 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-09-25 13:42:01 +0100" MODIFIED_BY="Jessica R Thomas">Cochrane Pain, Palliative and Supportive Care Group's Trial Register</TITLE>
<APPENDIX_BODY MODIFIED="2012-06-11 21:49:48 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="1" ROWS="13">
<TR>
<TD VALIGN="TOP">
<P>#1       MeSH descriptor Cachexia, this term only</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#2       MeSH descriptor Anorexia, this term only</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#3       anorexi*</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#4       cachex* or cachectic</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#5       MeSH descriptor Weight Loss explode all trees</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#6       MeSH descriptor Appetite, this term only</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#7       weight or wasting or appetite</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#8       (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#9       MeSH descriptor Megestrol explode all trees</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#10     megestrol</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#11     (#9 OR #10)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#12     (#8 AND #11)</P>
</TD>
</TR>
<TR>
<TD>
<P>Issue 3 2011; we have rerun the searches from Issue 3 to Issue 5, 2012</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2013-02-08 09:37:09 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2011-08-11 00:04:14 +0100" MODIFIED_BY="[Empty name]">MEDLINE search strategy in OVID</TITLE>
<APPENDIX_BODY MODIFIED="2013-02-08 09:37:09 +0000" MODIFIED_BY="[Empty name]">
<TABLE COLS="1" ROWS="22">
<TR>
<TD VALIGN="TOP">
<P>1 Cachexia/</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>2 Anorexia/</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3 anorexi*.mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>4 (cachex* or cachectic).mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5 exp Weight Loss/</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>6 Appetite/</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>7 (weight or wasting or appetite).mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>8 1 or 2 or 3 or 4 or 5 or 6 or 7</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>9 exp Megestrol/</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>10 megestrol.mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>11 9 or 10</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>12 randomised controlled trial.pt.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>13 controlled clinical trial.pt.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>14 randomized.ab.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>15 placebo.ab.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>16 drug therapy.fs.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>17 randomly.ab.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>18 trial.ab.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>19 groups.ab.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>20 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>21 8 and 11 and 20</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Key: mp = protocol supplementary concept, rare disease supplementary concept, title, original title, abstract, name of substance word, subject heading word, unique identifier; pt = publication type; ab = abstract: fs = floating subheading; MEDLINE 1948 to July week 3, 2011; we have rerun the searches from 2011 to May week 2 2012</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2013-02-08 09:37:14 +0000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2011-08-11 00:05:14 +0100" MODIFIED_BY="[Empty name]">EMBASE search strategy in OVID</TITLE>
<APPENDIX_BODY MODIFIED="2013-02-08 09:37:14 +0000" MODIFIED_BY="[Empty name]">
<TABLE COLS="1" ROWS="27">
<TR>
<TD VALIGN="TOP">
<P>1   cachexia/</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>2   anorexia/</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3   anorexi*.mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>4   (cachex* or cachectic).mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5   weight reduction/</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>6   appetite/</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>7   (weight or wasting or appetite).mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>8   1 or 2 or 3 or 4 or 5 or 6 or 7</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>9   megestrol/</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>10 megestrol acetate/</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>11 megestrol.mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>12 9 or 10 or 11</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>13 crossover procedure/</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>14 randomised controlled trial/</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>15 single blind procedure/</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>16 random*.mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>17 factorial*.mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>18 (crossover* or cross over* or cross-over).mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>19 placebo*.mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>20 (doubl* adj blind*).mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>21 (singl* adj blind*).mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>22 assign*.mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>23 allocat*.mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>24 volunteer*.mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>25 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>26 8 and 12 and 25</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Key: mp = title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]: 1980 to 2011 week 29; we have rerun the searches from 2011 to 2012 week 19</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2012-01-15 16:39:21 +0000" MODIFIED_BY="[Empty name]">
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;35 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;2 studies included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;35 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;371 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;371 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;923 records identified through database searching: CENTRAL (164); EMBASE (437); MEDLINE (375)&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;1 additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;336 records excluded:&lt;/p&gt;&lt;p&gt; - 50 studies were reviews&lt;/p&gt;&lt;p&gt; - 8 prospective studies&lt;/p&gt;&lt;p&gt; - 3 cross-over studies&lt;/p&gt;&lt;p&gt; - 10 systematic reviews&lt;/p&gt;&lt;p&gt; - 4 studies were guidelines&lt;/p&gt;&lt;p&gt; - 261 non-relevant studies&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;22 full-text articles excluded, with reasons&lt;/p&gt;&lt;p&gt;(n = 22) trials did not meet criteria for review (no weight loss, no outcome of interest, comparator is another drug)&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>